Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use

Abstract

Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids, polypeptides, or antibodies, or fragments thereof.

Description

FIELD OF THE INVENTION

[0002] The present invention relates to novel antibodies that bind immunospecifically to antigenic polypeptides, wherein the polypeptides have characteristic properties related to biochemical or physiological responses in a cell, a tissue, an organ or an organism. The novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use of the antibodies encompass procedures for diagnostic and prognostic assay of the polypeptides, as well as methods of treating diverse pathological conditions.

BACKGROUND OF THE INVENTION

[0003] Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways are constituted of extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells.

[0004] Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells and receptor cells in close proximity to each other, for example two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding biochemical or physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect.

[0005] Signaling processes may elicit a variety of effects on cells and tissues including by way of nonlimiting example induction of cell or tissue proliferation, suppression of growth or proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue.

[0006] Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as elevated or excessive synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by elevated or excessive levels of a protein effector of interest.

[0007] Antibodies are multichain proteins that bind specifically to a given antigen, and poorly or not at all to substances deemed not to be a cognate antigen. Antibodies are comprised of two short chains termed light chains and two long chains termed heavy chains. These chains are constituted of immunoglobulin domains, of which generally there are two classes: one variable domain per chain and one constant domain in light chains and three or more constant domains in heavy chains. The antigen-specific portion of the immunoglobulin molecules resides in the variable domains; the variable domains of one light chain and one heavy chain associate with each other to generate the antigen-binding moiety. Antibodies that bind immunospecifically to a cognate or target antigen bind with high affinities. Accordingly, they are useful in assaying specifically for the presence of the antigen in a sample. In addition, they have the potential of inactivating the activity of the antigen.

[0008] Therefore there is a need to assay for the level of the protein effector of interest in a biological sample from such a subject, and to compare the level with that characteristic of a nonpathological condition. In particular, there is a need for such an assay based on the use of an antibody that binds immunospecifically to the antigen. There further is a need to inhibit the activity of the protein effector in cases where a pathological condition arises from elevated or excessive levels of the effector based on the use of an antibody that binds immunospecifically to the effector. Thus there is a need for the antibody as a product of manufacture. There further is a need for a method of treatment of a pathological condition brought on by an elevated or excessive level of the protein effector of interest based on administering the antibody to the subject.

SUMMARY OF THE INVENTION

[0009] The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, etc. nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as “NOVX” nucleic acid or polypeptide sequences.

[0010] In one aspect, the invention provides an isolated polypeptide comprising a mature form of a NOVX amino acid. The polypeptide can be, for example, a NOVX amino acid sequence or a variant of a NOVX amino acid sequence, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also includes fragments of any of NOVX polypeptides. In another aspect, the invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof.

[0011] Also included in the invention is a NOVX polypeptide that is a naturally occurring variant of a NOVX sequence. In one embodiment, the variant includes an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a NOVX nucleic acid sequence. In another embodiment, the NOVX polypeptide is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution.

[0012] In another aspect, invention provides a method for determining the presence or amount of the NOVX polypeptide in a sample by providing a sample; introducing the sample to an antibody that binds immunospecifically to the polypeptide; and determining the presence or amount of antibody bound to the NOVX polypeptide, thereby determining the presence or amount of the NOVX polypeptide in the sample.

[0013] In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide in a mammalian subject by measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and comparing the amount of the polypeptide in the sample of the first step to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease. An alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

[0014] In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, e.g., a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.

[0015] In still another aspect, the invention provides the use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease that is associated with a NOVX polypeptide.

[0016] In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample expressing the NOVX polypeptide with antibody that binds the NOVX polypeptide in an amount sufficient to modulate the activity of the polypeptide.

[0017] The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. In a preferred embodiment, the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant. In another embodiment, the nucleic acid encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence. In one embodiment, the NOVX nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 101, or a complement of the nucleotide sequence. In one embodiment, the invention provides a nucleic acid molecule wherein the nucleic acid includes the nucleotide sequence of a naturally occurring allelic nucleic acid variant.

[0018] Also included in the invention is a vector containing one or more of the nucleic acids described herein, and a cell containing the vectors or nucleic acids described herein. The invention is also directed to host cells transformed with a vector comprising any of the nucleic acid molecules described above.

[0019] In yet another aspect, the invention provides for a method for determining the presence or amount of a nucleic acid molecule in a sample by contacting a sample with a probe that binds a NOVX nucleic acid and determining the amount of the probe that is bound to the NOVX nucleic acid. For example the NOVX nucleic may be a marker for cell or tissue type such as a cell or tissue type that is cancerous.

[0020] In yet a further aspect, the invention provides a method for determining the presence of or predisposition to a disease associated with altered levels of a nucleic acid molecule in a first mammalian subject, wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

[0021] The invention further provides an antibody that binds immunospecifically to a NOVX polypeptide. The NOVX antibody may be monoclonal, humanized, or a fully human antibody. Preferably, the antibody has a dissociation constant for the binding of the NOVX polypeptide to the antibody less than 1×10−9 M. More preferably, the NOVX antibody neutralizes the activity of the NOVX polypeptide.

[0022] In a further aspect, the invention provides for the use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, associated with a NOVX polypeptide. Preferably the therapeutic is a NOVX antibody.

[0023] In yet a further aspect, the invention provides a method of treating or preventing a NOVX-associated disorder, a method of treating a pathological state in a mammal, and a method of treating or preventing a pathology associated with a polypeptide by administering a NOVX antibody to a subject in an amount sufficient to treat or prevent the disorder.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0025] Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

[0026] The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as “NOVX nucleic acids” or “NOVX polynucleotides” and the corresponding encoded polypeptides are referred to as “NOVX polypeptides” or “NOVX proteins.” Unless indicated otherwise, “NOVX” is meant to refer to any of the novel sequences disclosed herein. Table 1 provides a summary of the NOVX nucleic acids and their encoded polypeptides.

TABLE 1
NOVX Polynucleotide and Polypeptide Sequences and Corresponding
SEQ ID Numbers
		SEQ ID	SEQ ID
NOVX		NO	NO
Assign-	Internal	(nucleic	(poly-
ment	Identification	acid)	peptide)	Homology
1a	CG58546-01	1	2	Adlican
1b	174307918	3	4	Adlican
1c	174307924	5	6	Adlican
1d	169679197	7	8	Adlican
1e	169679219	9	10	Adlican
1f	207704655	11	12	Adlican
2a	CG58598-01	13	14	Brain Specific Trans-
				membrane-like
2b	CG58598-02	15	16	Brain Specific Trans-
				membrane-like
2c	209770459	17	18	Brain Specific Trans-
				membrane-like
3a	CG57833-01	19	20	Amino Acid Transporter-like
4a	CG57853-01	21	22	Heal Na(+)/Bile Cotrans-
				porter-like
4b	CG57853-02	23	24	Heal Na(+)/Bile Cotrans-
				porter-like
4c	CG57853-03	25	26	Heal Na(+)/Bile Cotrans-
				porter-like
5a	CG57829-01	27	28	ADAM-TS 1 Precursor-like
5b	CG57829-05	29	30	ADAM-TS 1 Precursor-like
5c	175070495	31	32	ADAM-TS 1 Precursor-like
5d	175070504	33	34	ADAM-TS 1 Prccursor-like
5e	175070512	35	36	ADAM-TS 1 Precursor-like
5f	175070519	37	38	ADAM-TS 1 Precursor-like
6a	CG59197-01	39	40	TULIP 2-like (Tuberin)
6b	188822075	41	42	TULIP 2-like (Tuberin)
7a	CG58524-01	43	44	T cell receptor beta chain
				precursor V region-like
8a	CG56512-01	45	46	Oncofetal Antigen
				Precursor -like
9a	CG58180-01	47	48	Prohibitin-like
10a	CG59199-01	49	50	Natriuretic Peptide Receptor
11a	CG59249-01	51	52	Metalloproteinase Disintegrin
				beta (ADAM)
11b	CG59249-02	53	54	Metalloproteinase Disintegrin
				beta (ADAM)
12a	CG58577-01	55	56	CASPR4
12b	174307971	57	58	CASPR4
12c	174307975	59	60	CASPR4
12d	174307979	61	62	CASPR4
12e	174307983	63	64	CASPR4
12f	174307987	65	66	CASPR4
12g	174307996	67	68	CASPR4
12h	169894929	69	70	CASPR4
13a	CG59237-01	71	72	1 g, ring finger and
				fibronectin domains
13b	CG59237-02	73	74	1 g, ring finger and
				fibronectin domains
14a	CG58575-01	75	76	phosphatidylserine synthase
				2-like
15a	CG59256-01	77	78	MHC class 1-like
16a	CG59239-01	79	80	MHC class 1-like
17a	CG59295-01	81	82	Otogelin-like
18a	CG59293-01	83	84	renal organic anion transport
				protein 1-like
19a	CG59284-01	85	86	solute carrier family 22-like
20a	CG59278-01	87	88	GPCR P2-like
21a	CG59274-01	89	90	lipoma HMGIC fusion
				partner-like
21b	CG59274-02	91	92	lipoma HMGIC fusion
				partner-like
22a	172885510	93	94	lipoma HMGIC fusion
				partner-like
23a	CG57734-01	95	96	lipid associated protein-like
23b	CG57734-02	97	98	lipid associated protein-like
23c	198363601	99	100	lipid associated protein-like
24a	CG59389-01	101	102	galactose binding lectin-like
24b	CG59389-02	103	104	galactose binding lectin-like
24c	CG59389-04	105	106	galactose binding lectin-like
24d	174308481	107	108	galactose binding lectin-like
24e	174308497	109	110	galactose binding lectin-like
24f	174308507	111	112	galactose binding lectin-like
24g	174308517	113	114	galactose binding lectin-like
24h	174308525	115	116	galactose binding lectin-like
25a	CG59885-01	117	118	HGFR
26a	CG93443-01	119	120	LIV-1
27a	CG50838-01	121	122	Leucine-rich repeat trans-
				membrane protein FLRT3
28a	CG58567-01	123	124	Protocadherin
28b	CG58567-05	125	126	Protocadherin
28c	CG58567-06	127	128	Protocadherin
29a	CG59243-01	129	130	Mitochondrial carrier-like
29b	188822080	131	132	Mitochondrial carrier-like
29c	CG59243-02	133	134	Mitochondrial carrier like
30a	CG59534-01	135	136	membrane glycoprotein-like
31a	CG59289-01	137	138	Crumbs-like
31b	CG59289-02	139	140	Crumbs-like
32a	CG57111-01	141	142	Protocadherin 13-like
33a	CG59363-01	143	144	BAB26184-like
33b	CG59363-02	145	146	BAB26184-like
33c	CG59363-03	147	148	BAB26184-like
34a	CG59301-01	149	150	androgen receptor like
35a	CG59525-01	151	152	carcinoembryonic antigen
				cgml-like
36a	CG59484-01	153	154	wd-repeat protein-like
37a	CG57245-02	155	156	CD40L Receptor Precursor-
				like
37b	CG57245-04	157	158	CD40L Receptor Precursor-
				like
37c	174308232	159	160	CD40L Receptor Precursor-
				like
38a	CG59454-01	161	162	Butyrophilin-like
38b	CG59454-03	163	164	Butyrophilin-like
38c	CG59454-04	165	166	Butyrophilin-like
39a	CG59307-01	167	168	DNA-binding protein-like
40a	CG59713-01	169	170	Van Gogh-like
40b	170645777	171	172	Van Gogh-like
41a	CG59570-01	173	174	Aquaporin-like
42a	CG56162-02	175	176	Lysophospholipase-like
42b	174228465	177	178	Lysophospholipase-like
43a	CG59681-01	179	180	immunoglobulin domain
				containing protein
43b	174308213	181	182	immunoglobulin domain
				containing protein
43c	174308218	183	184	immunoglobulin domain
				containing protein
43d	174308224	185	186	immunoglobulin domain
				containing protein
44a	CG59869-01	187	188	Leucine rich repeat membrane
				protein-like
44b	CG59869-02	189	190	Leucine rich repeat membrane
				protein-like
44c	CG59869-03	191	192	Leucine rich repeat membrane
				protein-like
45a	CG59859-01	193	194	Testis expressed protein 261
				(TEG-261)-like
45b	CG59859-02	195	196	Testis expressed protein 261
				(TEG-261)-like
46a	CG59913-01	197	198	ATP-binding cassette trans-
				porter (ABC transporter)-like
47a	CG59909-01	199	200	ATP-binding cassette trans-
				porter (ABC transporter)-like
48a	CG59945-01	201	202	Steroid Hormone Receptor-
				like

[0027] Table 1 indicates homology of NOVX nucleic acids to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table 1 will be useful in therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table 1.

[0028] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

[0029] Consistent with other known members of the family of proteins, identified in Column 5 of Table 1, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A.

[0030] The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit diseases associated with the protein families listed in Table 1.

[0031] The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example B. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g. a variety of cancers.

[0032] Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

[0033] NOVX Clones

[0034] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

[0035] The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders.

[0036] The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

[0037] In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 101; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 101, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 101; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1 and 101 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d).

[0038] In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO: 2n, wherein n is an integer between 1 and 101; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 101 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 101; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 101, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 101 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules.

[0039] In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 101; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 101 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein n is an integer between 1 and 101; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n−1, wherein i is an integer between 1 and 101 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

[0040] NOVX Nucleic Acids and Polypeptides

[0041] One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNA's) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

[0042] A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a “mature” form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

[0043] The term “probes”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

[0044] The term “isolated” nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′- and 3′-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

[0045] A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993.)

[0046] A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

[0047] As used herein, the term “oligonucleotide” refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NO:2n−1, wherein n is an integer between 1-101, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.

[0048] In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence SEQ ID NO:2n−1, wherein n is an integer between 1-101, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of a NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101, is one that is sufficiently complementary to the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101, that it can hydrogen bond with little or no mismatches to the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101, thereby forming a stable duplex.

[0049] As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

[0050] Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

[0051] A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5′ direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3′ direction of the disclosed sequence.

[0052] Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to all aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993, and below.

[0053] A “homologous nucleic acid sequence” or “homologous amino acid sequence,” or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO:2n−1, wherein n is an integer between 1-101, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

[0054] A NOVX polypeptide is encoded by the open reading frame (“ORF”) of a NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG “start” codon and terminates with one of the three “stop” codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bona fide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.

[0055] The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101; or an anti-sense strand nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101; or of a naturally occurring mutant of SEQ ID NO:2n−1, wherein n is an integer between 1-101.

[0056] Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express a NOVX protein, such as by measuring a level of a NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

[0057] “A polypeptide having a biologically-active portion of a NOVX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a “biologically-active portion of NOVX” can be prepared by isolating a portion of SEQ ID NO:2n−1, wherein n is an integer between 1-101, that encodes a polypeptide having a NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX.

[0058] NOVX Nucleic Acid and Polypeptide Variants

[0059] The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1-101, due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1-101. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1-101.

[0060] In addition to the human NOVX nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1-101, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame (ORF) encoding a NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

[0061] Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from any one of the human SEQ ID NO:2n−1, wherein n is an integer between 1-101, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

[0062] Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

[0063] Homologs (i.e., nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

[0064] As used herein, the phrase “stringent hybridization conditions” refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60° C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

[0065] Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6× SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65° C., followed by one or more washes in 0.2× SSC, 0.01% BSA at 50° C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to any one of the sequences of SEQ ID NO:2n−1, wherein n is an integer between 1-101, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

[0066] In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6× SSC, 5× Reinhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55° C., followed by one or more washes in 1× SSC, 0.1% SDS at 37° C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, and Krieger, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, New York.

[0067] In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1-101, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5× SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/volt) dextran sulfate at 40° C., followed by one or more washes in 2× SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50° C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, New York; Shilo and Weinberg, 1981. Proc Natl Acad Sci USA 78: 6789-6792.

[0068] Conservative Mutations

[0069] In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO:2n−1, wherein n is an integer between 1-101, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence of SEQ ID NO:2n, wherein n is an integer between 1-101. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an “essential” amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

[0070] Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from any one of SEQ ID NO:2n−1, wherein n is an integer between 1-101, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences of SEQ ID NO:2n, wherein n is an integer between 1-101. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NO:2n, wherein n is an integer between 1-101; more preferably at least about 70% homologous to SEQ ID NO:2n, wherein n is an integer between 1-101; still more preferably at least about 80% homologous to SEQ ID NO:2n, wherein n is an integer between 1-101; even more preferably at least about 90% homologous to SEQ ID NO:2n, wherein n is an integer between 1-101; and most preferably at least about 95% homologous to SEQ ID NO:2n, wherein n is an integer between 1-101.

[0071] An isolated nucleic acid molecule encoding a NOVX protein homologous to the protein of SEQ ID NO:2n, wherein n is an integer between 1-101, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

[0072] Mutations can be introduced into any of SEQ ID NO:2n−1, wherein n is an integer between 1-101, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis of any one of SEQ ID NO:2n−1, wherein n is an integer between 1-101, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

[0073] The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved “strong” residues or fully conserved “weak” residues. The “strong” group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the “weak” group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

[0074] In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and a NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

[0075] In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

[0076] Antisense Nucleic Acids

[0077] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a NOVX protein of SEQ ID NO:2n, wherein n is an integer between 1-101, or antisense nucleic acids complementary to a NOVX nucleic acid sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101, are additionally provided.

[0078] In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding a NOVX protein. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence encoding the NOVX protein. The term “noncoding region” refers to 5′ and 3′ sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).

[0079] Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).

[0080] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyl adenine, 1-methylguanine, 1-methylinosine 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminoethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0081] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOVX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

[0082] In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other. See, e.g., Gaultier, el al., 1987. Nucl. Acids Res. 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (See, e.g., Inoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148) or a chimeric RNA-DNA analogue (See. e.g., Inoue, et al., 1987. FEBS Lett. 215: 327-330.

[0083] Ribozymes and PNA Moieties

[0084] Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

[0085] In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988. Nature 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for a NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOVX cDNA disclosed herein (i.e., any one of SEQ ID NO:2n−1, wherein n is an integer between 1-101). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide any of whose residues may be changed from the corresponding residues shown in any one of SEQ ID NO:2n, wherein n is an integer between 1-101, while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

[0086] In general, a NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

[0087] One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

[0088] An “isolated” or “purified” polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language “substantially free of cellular material” includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a “contaminating protein”), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA. See, e.g., U.S. Pat. No. 4,987,071 to Cech, et al. and U.S. Pat. No. 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418.

[0089] Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. N.Y. Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15.

[0090] In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996. Bioorg Med Chem 4: 5-23. As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleotide bases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomer can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Perry-O'Keefe, et al., 1996. Proc. Natl. Acad. Sci. USA 93: 14670-14675.

[0091] PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (See, Hyrup, et al., 1996.supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra).

[0092] In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleotide bases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996. Nucl Acids Res 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5′ end of DNA. See, e.g., Mag, et al., 1989. Nucl Acid Res 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment. See, e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment. See, e.g., Petersen, et al., 1975. Bioorg. Med. Chem. Lett. 5: 1119-11124.

[0093] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989. Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaitre, et al., 1987. Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e.g., Krol, et al., 1988. BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988. Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

[0094] NOVX Polypeptides

[0095] A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in any one of SEQ ID NO:2n, wherein n is an integer between 1-101. The invention also includes a mutant or variant protein about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

[0096] The language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

[0097] Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1-101) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of a NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of a NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

[0098] Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

[0099] In an embodiment, the NOVX protein has an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1-101. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NO:2n, wherein n is an integer between 1-1 01, and retains the functional activity of the protein of SEQ ID NO:2n, wherein n is an integer between 1-101, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1-101, and retains the functional activity of the NOVX proteins of SEQ ID NO:2n, wherein n is an integer between 1-101.

[0100] Determining Homology Between Two or More Sequences

[0101] To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid “identity”).

[0102] The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. J Mol Biol 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence of SEQ ID NO:2n−1, wherein n is an integer between 1-101.

[0103] The term “sequence identity” refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term “substantial identity” as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

[0104] Chimeric and Fusion Proteins

[0105] The invention also provides NOVX chimeric or fusion proteins. As used herein, a NOVX “chimeric protein” or “fusion protein” comprises a NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An “NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a NOVX protein of SEQ ID NO:2n, wherein n is an integer between 1-101, whereas a “non-NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within a NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of a NOVX protein. In one embodiment, a NOVX fusion protein comprises at least one biologically-active portion of a NOVX protein. In another embodiment, a NOVX fusion protein comprises at least two biologically-active portions of a NOVX protein. In yet another embodiment, a NOVX fusion protein comprises at least three biologically-active portions of a NOVX protein. Within the fusion protein, the term “operatively-linked” is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

[0106] In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

[0107] In another embodiment, the fusion protein is a NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

[0108] In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOVX ligand and a NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with a NOVX ligand.

[0109] A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

[0110] NOVX Agonists and Antagonists

[0111] The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

[0112] Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOVX sequences thereini. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983. Tetrahedron 39: 3; Itakura, et al., 1984. Annu. Rev. Biochem. 53: 323; Itakura, et al., 1984. Science 198: 1056; Ike, et al., 1983. Nucl. Acids Res. 11: 477.

[0113] Polypeptide Libraries

[0114] In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of a NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.

[0115] Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. Proc. Natl. Acad. Sci. USA 89: 7811-7815; Delgrave, et al., 1993. Protein Engineering 6:327-331.

[0116] NOVX Antibodies

[0117] The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab, Fab′ and F(ab′)2 fragments, and an Fab expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG1, IgG2, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

[0118] An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1-101, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

[0119] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore, encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

[0120] The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. A NOVX polypeptide or a fragment thereof comprises at least one antigenic epitope. An anti-NOVX antibody of the present invention is said to specifically bind to antigen NOVX when the equilibrium binding constant (KD) is ≦1 μM, preferably ≦100 nM, more preferably ≦10 nM, and most preferably ≦100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.

[0121] A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

[0122] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, incorporated herein by reference). Some of these antibodies are discussed below.

[0123] Polyclonal Antibodies

[0124] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

[0125] The polygonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).

[0126] Monoclonal Antibodies

[0127] The term “monoclonal antibody” (MAb) or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

[0128] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

[0129] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.

[0130] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

[0131] The culture medium in which the hybridoma cells arc cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, Such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.

[0132] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding, 1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.

[0133] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

[0134] The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

[0135] Humanized Antibodies

[0136] The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Pat. No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

[0137] Human Antibodies

[0138] Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed “human antibodies”, or “fully human antibodies” herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).

[0139] In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Techology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al, (Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).

[0140] Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

[0141] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

[0142] A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

[0143] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

[0144] Fab Fragments and Single Chain Antibodies

[0145] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F(ab′)2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab′)2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments.

[0146] Bispecific Antibodies

[0147] Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

[0148] Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published May 13, 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

[0149] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

[0150] According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

[0151] Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab′)2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab′)2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab′ fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives is then reconverted to the Fab′-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab′-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

[0152] Additionally, Fab′ fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab′)2 molecule. Each Fab′ fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

[0153] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab′ portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary VL and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).

[0154] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).

[0155] Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

[0156] Heteroconjugate Antibodies

[0157] Heteroconjugate antibodies arc also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxinis can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Pat. No. 4,676,980.

[0158] Effector Function Engineering

[0159] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Designs 3: 219-230 (1989).

[0160] Immunoconjugates

[0161] The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

[0162] Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas acruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 212Bi, 131I, 131In, 90Y, and 186Re.

[0163] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as gluitareldehlyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepenitaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

[0164] In another embodiment, the antibody can be conjugated to a “receptor” (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

[0165] Immunoliposomes

[0166] The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77:4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.

[0167] Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab′ fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al ., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon ct al., J. National Cancer Inst., 81(19): 1484 (1989).

[0168] Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention

[0169] Antibodies directed against a protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of the protein (e.g., for use in measuring levels of the protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies against the proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antigen binding domain, are utilized as pharmacologically-active compounds (see below).

[0170] An antibody specific for a protein of the invention can be used to isolate the protein by standard techniques, such as immunoaffinity chromatography or immunoprecipitation. Such an antibody can facilitate the purification of the natural protein antigen from cells and of recombinantly produced antigen expressed in host cells. Moreover, such an antibody can be used to detect the antigenic protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic protein. Antibodies directed against the protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, 131I, 35S or 3H.

[0171] Antibody Therapeutics

[0172] Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thius the receptor mediates a signal transduction pathway for which ligand is responsible.

[0173] Alteratively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

[0174] A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

[0175] Pharmaceutical Compositions of Antibodies

[0176] Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.

[0177] If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

[0178] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

[0179] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

[0180] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

[0181] ELISA Assay

[0182] An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polygonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab)2) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labelinig of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term “biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in “ELISA: Theory and Practice: Methods in Molecular Biology”, Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, N.J., 1995; “Immunoassay”, E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, Calif., 1996; and “Practice and Thory of Enzyme Immunloassays”, P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0183] NOVX Recombinant Expression Vectors and Host Cells

[0184] Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors”. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0185] The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably-linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

[0186] The term “regulatory sequence” is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylationl signals). Such regulatory sequences are described, for example, in Coeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

[0187] The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

[0188] Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathionc S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

[0189] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

[0190] One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e.g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

[0191] In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSec1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

[0192] Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF89 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

[0193] In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO. J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

[0194] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO. J. 8: 729-733) and immunoglobulins (Banerji, et al., 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. Science 230: 912-916), and mammary gland-specific promoters (e g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. Science 249: 374-379) and the α-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546).

[0195] The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genies see, e.g., Weintraub, et al., “Antisense RNA as a molecular tool for genetic analysis,” Reviews-Trends in Genetics, Vol. 1(1) 1986.

[0196] Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0197] A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0198] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

[0199] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0200] A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

[0201] Transgenic NOVX Animals

[0202] The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human, animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

[0203] A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences, i.e., any one of SEQ ID NO:2n−1, wherein n is an integer between 1-101, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191 ; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods arc used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

[0204] To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of any one of SEQ ID NO:2n−1, wherein n is an integer between 1-101), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NO:2n−1, wherein n is an integer between 1-101, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector).

[0205] Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5′- and 3′-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′- and 3′-termini) are included in the vector. See, e.g., Thomas, et al., 1987. Cell 51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e.g., Li, et al., 1992. Cell 69: 915.

[0206] The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. Curr. Opin. Biotechnol. 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

[0207] In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage PI. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae. See, O'Gorman, et al., 1991. Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

[0208] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997. Nature 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G0 phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.

[0209] Pharmaceutical Compositions

[0210] The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as “active compounds”) of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compound(s can also be incorporated into the compositions.

[0211] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabeins; anitioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0212] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0213] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0214] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0215] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0216] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0217] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0218] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

[0219] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

[0220] The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

[0221] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0222] Screening and Detection Methods

[0223] The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in a NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses antimicrobial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

[0224] The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.

[0225] Screening Assays

[0226] The invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e.g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

[0227] In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. Anticancer Drug Design 12: 145.

[0228] A “small molecule” as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomlimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

[0229] Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993. Proc. Natl. Acad. Sci. USA. 90: 6909; Erb, et al., 1994. Proc. Natl. Acad. Sci. USA. 91: 11422; Zuckermann, et al., 1994.,J. Med. Chem. 37: 2678; Cho, et al., 1993. Science 261: 1303; Carrell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2059; Carell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2061; and Gallop, et al., 1994. J. Med. Chem. 37: 1233.

[0230] Libraries of compounds may be presented in solution (e.g., Houghten, 1992. Biotechniques 13: 412-421), or on beads (Lam, 1991. Nature 354: 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner, U.S. Pat. No. 5,233,409), plasmids (Cull, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990. Science 249: 404-406; Cwirla, et al., 1990. Proc. Natl. Acad. Sci. U.S.A. 87: 6378-6382; Felici, 1991. J. Mol. Biol. 222: 301-310; Ladner, U.S. Pat. No. 5,233,409.).

[0231] In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with i test compound and the ability of the test compound to bind to a NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with 125I, 35S, 14C, or 3H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

[0232] In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule. As used herein, a “target molecule” is a molecule with which a NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOVX target molecule can be a non-NOVX molecule or a NOVX protein or polypeptide of the invention. In one embodiment, a NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

[0233] Determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e. intracellular Ca2+, diacylglycerol, IP3, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

[0234] In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

[0235] In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to a NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate a NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra.

[0236] In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of a NOVX target molecule.

[0237] The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)n, N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1 1-propane sulfonate (CHAPSO).

[0238] In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

[0239] Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NFIS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

[0240] In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

[0241] In yet another aspect of the invention, the NOVX proteins can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos, et al., 1993. Cell 72: 223-232; Madura, et al., 1993. J. Biol. Chem. 268: 12046-12054; Bartel, et al., 1993. Biotechniques 14: 920-924; Iwabuchii, et al., 1993. Oncogene 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX (“NOVX-binding proteins” or “NOVX-bp”) and modulate NOVX activity. Such NOVX-binding proteins are also involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

[0242] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

[0243] The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

[0244] Detection Assays

[0245] Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

[0246] Chromosome Mapping

[0247] Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences of SEQ ID NO:2n−1, wherein n is an integer between 1-101, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

[0248] Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

[0249] Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, et al., 1983. Science 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

[0250] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

[0251] Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

[0252] Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

[0253] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, el al., 1987. Nature, 325: 783-787.

[0254] Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected inindividuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or delectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

[0255] Tissue Typing

[0256] The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP (“restriction fragment length polymorphisms,” described in U.S. Pat. No. 5,272,057).

[0257] Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5′- and 3′-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

[0258] Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

[0259] Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If coding sequences, such as those of SEQ ID NO:2n−1, wherein n is an integer between 1-101, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

[0260] Predictive Medicine

[0261] The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in a NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

[0262] Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as “pharmacogenomics”). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

[0263] Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials.

[0264] These and other agents are described in further detail in the following sections.

[0265] Diagnostic Assays

[0266] An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NO:2n−1, wherein n is an integer between 1-101, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

[0267] An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′)2) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genome DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0268] In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

[0269] In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

[0270] The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

[0271] Prognostic Assays

[0272] The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a “test sample” refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

[0273] Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

[0274] The methods of the invention can also be used to detect genetic lesions in a NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOVX gene; (ii) an addition of one or more nucleotides to a NOVX gene; (iii) a substitution of one or more nucleotides of a NOVX gene, (iv) a chromosomal rearrangement of a NOVX gene; (v) an alteration in the level of a messenger RNA transcript of a NOVX gene, (vi) aberrant modification of a NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOVX gene, (viii) a non-wild-type level of a NOVX protein, (ix) allelic loss of a NOVX gene, and (x) inappropriate post-translational modification of a NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

[0275] In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g, Landegran, et al., 1988. Science 241:1077-1080; and Nakazawa, et al., 1994. Proc. Natl. Acad Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995. Nucl. Acids Res. 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

[0276] Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989. Proc. Natl. Acad. Sci. USA 86:1173-1177); Qβ Replicase (see, Lizardi, et al, 1988. BioTechnology 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

[0277] In an alternative embodiment, mutations in a NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

[0278] In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996. Human Mutation 7: 244-255; Kozal, et al., 1996. Nat. Med. 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

[0279] In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. Proc. Natl. Acad. .Sci. USA 74: 560 or Sanger, 1977. Proc. Natl. Acad. Sci. USA 74: 5463. It is also contemplate(d that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996. Adv. Chromatography 36: 127-162; and Griffin, et al., 1993. Appl. Biochem. Biotechnol. 38: 147-159).

[0280] Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985. Science 230: 1242. In general, the art technique of “mismatch cleavage” starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988. Proc. Natl. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. Methods Enzymol. 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

[0281] In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called “DNA mismatch repair” enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994. Carcinogenesis 15: 1657-1662. According to an exemplary embodiment, a probe based on a NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.

[0282] In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation. polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Appl. 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. Trends Genet. 7:5.

[0283] In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylanide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. Nature 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.

[0284] Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. Nature 324: 163; Saiki, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

[0285] Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3′-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. Tibtech. 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992. Mol. Cell Probes 6:1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3′-terminus of the 5′ sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

[0286] The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOVX gene.

[0287] Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

[0288] Pharmacogenomics

[0289] Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

[0290] Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol., 23: 983-985; Linder, 1997. Clin. Chem., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

[0291] As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochhrome PREGNANCY ZONE PROTEIN PRECURSOR enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard closes. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

[0292] Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

[0293] Monitoring of Effects During Clinical Trials

[0294] Monitoring the influence of agents (e.g., drugs, compounds) oil the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a “read out” or markets of the immune responsiveness of a particular cell.

[0295] By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

[0296] In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOVX protein, mRNA, or genomic DNA in the preadministrational sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent.

[0297] Methods of Treatment

[0298] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Osteodystrophy, and other diseases, disorders and conditions of the like.

[0299] These methods of treatment will be discussed more fully, below.

[0300] Disease and Disorders

[0301] Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are “dysfunctional” (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to “knockout” endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244:1288-1292); or (v) modulators ( i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

[0302] Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

[0303] Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).

[0304] Prophylactic Methods

[0305] In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, a NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

[0306] Therapeutic Methods

[0307] Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOVX protein, a peptide, a NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering a NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

[0308] Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity has a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

[0309] Determination of the Biological Effect of the Therapeutic

[0310] In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

[0311] In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.

[0312] Prophylactic and Therapeutic Uses of the Compositions of the Invention

[0313] The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.

[0314] As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

[0315] Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

EXAMPLES

Example A

[0316] Polynucleotide and Polypeptide Sequences, and Homology Data

Example 1

[0317] The NOV1 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 1A.

TABLE 1A
NOV1 Sequence Analysis
	SEQ ID NO: 1	8554bp
NOV1a	GCACCCCGACAAGATGCCCAAGCGCGCGCACTGGGGGGCCCTCTCTGTGGTGCTGATC
CG58546-01 DNA
Sequence	CTGCTTTGGGGTCTCCGCGAGTGGCGCTGGCCTGCCCTCATCCTTGTGCCTGCTACG
	TCCCCAGCGAGGTCCACTGCACGTTCCGATCCCTGGCTTCTGTGCCCGCTGGCATTGC
	TAAACACTGTGGAAAGAATCAATTTGGGGTTTGGAAATAGCATACAGGCCCTGTCAGAA
	ACCTCATTTGCAGGACTGACCAAGTTGGAGCTACTTATGATTCACGGCAATGAGATCC
	CAAGCATCCCCGATGGAGCTTTAAGAGACCTCAGCTCTCTTCAGGTTTTCAAGTTCAG
	CTACAACAAGCTGACAGTGATCACAGGACAGACCCTCCAGCGTCTCTCTAACTTAATG
	AGGCTGCACATTGACCACAACAAGATCGAGTTTATCCACCCTCAAGCTTTCAACGGCT
	TAACCTCTCTGAGGCTACTCCATTTGGAAGGAAATCTCCTCCACCAGCTGCACCCCAG
	CACCTTCTCCACGTTCACATTTTTGGATTATTTCAGACTCTCCACCATAAGGCACCTC
	TACTTAGCAGAGAACATGGTTAGAACTCTTCCTGCCAGCATGCTTCGGAACATGCCGC
	TTCTGGAGAATCTTTACTTGCAGGGAAATCCGTGGACCTGCGATTGTGAGATGAGATG
	GTTTTTGGAATGGGATGCAAAATCCAGAGGAATTCTGAAGTGTAAAAGGACAAAGCT
	TATGAAGGCGGTCAGTTGTGTGCAATGTGCTTCAGTCCAAAGAAGTTGTACAAACATG
	AGATTCACAAGCTGAAGGACCTGACTTGTCTGAAGCCTTCCATAGAGTCTCCTCTGAG
	ACAGAACAGGAGCACGAGTATTGAGGAGGAGCAACAAGAAGAGAATGGTGACAGC
	CAGCTCATCCTGGAGAAAATCCAACTTCCCCAGTGGAGCATCTCTTTGATATGACTG
	ATGAGCACGGGAACCTGGTGAACTTGGTGTGTGACATCAAGAAACCAATGGATGTGTA
	CAAATTCACTTGAACCAAACAGATCCTCCAGATATTGACATAAATGCAATGGTTGCC
	TTGGACTTTGAGTATCCAATGACCCAGGAAAACTATGAAAATCTATGGAAATTGATAG
	CATACTACAGTGAAGTTCCCATGAAGCTACACAGAGAGCTCATGCTCAGCAAACACCC
	CAGAGTCAGCTACCAGTACAGGCAAGATGCCGATCAAGAAGCTCTTTACTACACAGGT
	GTGAGAGCCCAGATTCTTGCAGAACCAGAATGGATCATGCAGCCATCCATAGATATCC
	AGCTGAACCGACCTCAGAGTACCCCCAGAJGGTGCTACTTTCCTACTACAACCAGTA
	TTCTCAAACAATAGCCACCAAGATACAGGCAGGCTCGGGGCAGAAGCTGGGTAATG
	ATTGAGCCTAGTAGAGCTGTGCAAAAAGATCAGACTGTCCTGGAAGGGGGTCGATGCC
	AGTTGAGCTGCAATGTGAAACCTTCTGAGAGTCCATCTATCTTCTGGGTGCTTCCAGA
	TGGCTCCATCCTGAAAGTGCCTGTCGATGACCCAGACAGCAAGTTCTCCATTCTCAGC
	AGTGGCTGCCTGAGGATCAAGTCCATGCAAGCCATCTGACTCGGGCTTCTACCAGTGCA
	TTGCTCAAGTGAGGGATGAAATGGACCGCATGGTATATAGGGTACTTGTGCAGTCTCC
	CTCCACTCAGCCAGCCGAGAAGACACAGTGACAAATTGGCAAGAACCCAGGGGAGCCA
	GTGATGTTGCCTTGCAATGCTTTAGCTATACCCGAAGCCCACCTTAGCTGGATTCTTC
	CAACAGAAGGATAATTAATGATTTGGCTAACACATCACATGTATACATGCTGCCAAA
	TGGAACTCTTTCCATCCCAAAGGTCCAAGTCAGTGACAGTGGTTACCACAGATGTGTG
	GCTGTCAACCAGCATGGGGCAGACCATATCACGGTGGGAATCACAGTCACCAAGAAAG
	GTTCTGGCTCGCCATCCAAAAGAGGCAGATGGCCAGGTCCAAAGGCTCTTTCCAGATC
	CAAAGGCTCTTTCCAGATGAGAGAAGACATCGTGGACCATGAAGGGGTCTCAGCCACG
	CGAGATGAAGAGAACACTTCAAGGAGACTTCTACATCCAAAGCACCAAGAGGCGTTCC
	TCAAAACAAAGGATGATGCCATCAATGGAGATAAGAGCCAAGAAAGGGAGAAGAAA
	GCTCAAACTCTGGAAGCATTCACAAAAGAACCAGAGACCACTGTTCCAGAAGATCTC
	ACTGGGCTGATATTTT AGAGTGTTTGAATCAAGACGAAGGATAAACGTGGCAAACAAACAGATTAATCCGGAGC
	ATCCCCAATTATTAAAAGCCAAAGTCTTTGGGAAAAATCTCCCTACAGGCACAGAAGT
	TTGCCTGCTGTTTCTCACCACAAGTTCTCCATTCTTGAGCCTAGTAGTCACACCACCT
	AATCCTCAGCAGATGTCCCCCTTGGCATCTCCAATACAGACAGCAAACAAGTGCTGAAC
	CTCAGCCAGCATGGGAACCTCTACTCAGCGAAGGAAAGCACATTTTGAGTACCATTTC
	GAACAAGCACACCTCTCTAGAACACCACAACAITGGAGTTATTCTTGTTGAACCTGAAX
	TCACTTCCACTGAAGGCGAAGAAGTTGTTGATGAGTATTCCAAGAAGACTGAGGAGA
	TTATGAACAATCTCCTCGACCTGAAGGGCACTGCAGCCTCTACACTTATATCTGAGCC
	GAAGAGACGGAAACAGACTCTACACACCTTAGACACAGTCTATGAAGAGCCCACCCAT
	CATCCAGTGAGTATGAAGGGTTGGTCTGCAGCAGATGTTGGATCCTCACCAGATCCCA
	GCAATACTTTGACCCAGCTTCCATTGGTTGTTGTCTCCTTCCCTGAGTCTAGCCTGT
	GAATACAGTTTTGCACGATTTGGAGACTAATTCACAACCACATGAGGATAACATAAAA
	CATCACTGTCATTTGAACCTTACTCCAACCGCCATCATCTGGTTTAATGACTCTAGTA
	TCTACAAGGACCGACAGGATTCTACTGTAGGGGAACAAGGTGTCCCAGGCAAATCACA
	ACCTTATTGATTAAAAGAGAACATCCAGCTTGTGAAAAGTAGTTTTAGCACTCAAGAC
	TGCTAGAGGGAGACCCAACGTATGAAAGAGATGTCTCAGACACTACAGGGACGATA
	ATCCATCACTTTACCTTACACACTCCAGAAGTTCTGAGATGAGGGCCAAGAGAGCAA
	AAGCCTGCGGAAACCAGACTCCACACTGGGTATAACCAGCAGTACGTCTCCAGTTAAG
	CTCCAAGGCAAAAAGTCAGTTGTCACCTGCTACACAAAGACACCACAACAGAAACAA
	ACCCAATGGGAGAAAAGGCTTCATCATCCACCATGAGCACTCACCCTTCTCGAAGAAA
	CCCACAACTTTTGCTCTTACACCCTCACAAATTCCACCACCCGACAAGCAAACCCCA
	TTAAGATTTCAAATCACATTAGAGACTTTTTCTACTCACCACTCAACCAACTGACA
	AGTTAATACCCCCAAAAATGGAGAGTTCTCTGGTTCCTACATCTTGGGACATTAACAC
	ACTCCACGGAGAAAACCAGCTGGMATGGAGAAGAATGTACAGCTCATATCAAAAGCAA
	TGAGTTCAAGAGCATCACGGGAAGAGGCCAAACAAACATCGATATACCCCTTCTACAG
	CATTGTTACTCCCAGTTGCATCCAAGCCCAGCCCTTCTCCAGATAACATAGAA
	GAGGGCGTTTATGATTTCAGAAACTACACTTTTGCCTAGAAATGTTTCTCTGAAAACT
	ACCATAAAGTCCAAGACCTTAGATTACACGACAACCACCAGAAAAATACATTCATCTC
	AATTCAGGATGATGTTCACACTTCCAGTCATGTATAAACCCACATCAGATGGAAAAGA
	GGTGAGTCAATTACAAGCCACAAATGTTGACAAACATAAAAGTGACATTTTAGTCCCT
	AATTTAAGGAAGAATCATGTCACACkACTTCTCGCTCCTTGGTCTCCACTATGGGAG
	AAGGAAAGCTCAGCCTCTCTCCTGTGGGCTTTCCAGGAATTCCAACCTGGAATCCCTC
	ACCCCTACAGACCCTCGGGAGGCTACAGACAGACATACATGTTACCACTTCTGGGGAA
	TTTTGTCCTCTGTGACCCCTTGTTAACGAGCTTGAGGATGTGGATTTTACTTCTGAGT
	AATTCTCTCAAGCATAAGTCTCCACACCATTTCACCAGGAAGAAGCTGGTTTTTCCAC
	GGTCAAGATCATCATGAAAGTGGAGATGGCTTCAAGTCACGTAGAAACTACCACCCTT
	ATCACATCCTTACTGCAAACCACTGTGGCTATTCTCCACTCTGAAACTAGACCACAGA
	TCTCCTGTCTTTGGGATGCCTGGATGAAGGAGCCAGCATCTTTGTCCCCTCCCATGAT
	TCTCAAATATGTAAAGCAAACCACCACCACTAAGCCAGAACTTCTCAGTCCAAGAACA
	AAACAGAAGCAACCCCATTCCAAGGAAAATGTTTTCTTGAATTACATGGGGAAACCAG
	ATTATCAACACCATCTAGTGAAAATGAAGGAACACAGCGTATGTCAGGGCCAAATGA
	GAAAAGCAAGTATTTGTCTGACCACGATGCATTTAACTTGTCTACAAAGCTAGAATTG
	ATGGAAGAGTTCATGCATAGTAGGAGTCTAACACGTGGCCCACATAGCCACCACCAGG
	AACAGGAACAGTGAGGTTCTCATCAACTAACCAGAATCCCTGCCAAACCCATCCTACC
	ACTTTCCAGCCACCTCCTGCCTGAAATGTCCACACAAAGCACTTCCAGATACTTTGTA
	GGGCTTTGCCAGAGAGATCACGGGACCAACAAACCAGAAATAACTACATATCCTTCTA
	CCTATCACACATGTCCCAACAGTTTACAACTCCAAGAGTAGCAAGTACACTCCTCT
	CAATCCAATGGCTCCTAACCCAGCATTTCTAGTAAGTTTCCTGACCTAAGAACTGAC
	CAGTTGGAAAGCCTCTACAAAGTGTTTGGAAATAGCAACATCCCTGAGGCAAGAAACT
	CTTTACCAACAGGACTCAGTCCAAGAATTTATCATTATTCCAATGGAAGACTCCCTTT
	CCCTCTTCTCCTGTCCCTTTCTTTTTCACAGTTGGGAGTCACCCGGAGACCCCAGATA
	GGATATATTCCCATAGCAGTAATGAGAGAGAGAAAAGTTAATCCAGGTTCCTACAATA
	GCACACTCCATGGACCCACCTTCCATCTGGACTTTGGCCTTCCAGCACCTCCACTGTT
	TCATCCACCCAGAGTTATGGTATCACCCCCAACTAACTTACAGAATATCCCTATGGTC
	TCCACCAAAGCGGCTCCTGTCTCCTTTATAACATCTTCTGTCCAGTCCTCAGGAAGCA
	TCTTGGGCAAAAGCCCAAAGTTCTTTGCAGGAGGACCGCCTGCATCCAAATTCTGGCC
	CAAATCCTCACCAAGTCCCCACAGACTGTGTCTGTCACTGCT
	GAAACGGACGCTGTGTTCCCGTGTGAGGCAATAGGAACCAAAAGCCTTTCGTTACTT
	GGACAAAAGTTTCCACATCTCCAGGAGTTCTTATGACTCCGAATACCAGGATACAACG
	GTTTGAGGTTCTCAAGAACCGTACCTTAGTGATAAGGAAGTTTCAAGTGCAAGATCGA
	GGCCAGTATATGTGCACCGCCAGCAACCTGTACGGCCTGGACAGGATGGTGGTCTTTC
	TCTGGGTCACCGTGCAGCAACCTCAAATCCTAGCCTCCCACTACCAGGACGTCACCGT
	CTACCTGGGAGACACCATTACAATGGAGTGTCTGGCGAAAGGGACCCCAGCCCCCCAAA
	ATTTCCTGGATCTTCCGTGACAGGAGGGTGTGGCAAACTCTGTCCTCCGTGGAGGGCC
	GGATCACCCTGCACCAAAACCGGACCCTTTCCATCAAGGAGGCGTCCTTCTCAGACAG
	AGGCGTCTATAAGTGCGTGGCCAGCAACGCAACCCGGGCGGACAGCGTGTCCATCCGC
	CTACACGTGGCGGCACTGCCCCCCATTATCCACCAGGAGAAGCTGGAGAACATCTCGC
	TGCCCCCGGGGCTCAGCATTCACATTCACTGCACTGCCAAAGCTGCGCCCCTGCCCAG
	CGTGCTCTGGGTGCTCGGGGATGCATACCCAAATCCGCCCCTCGCATTTCCTCCACCGG
	AACTTGTTTGTTTTCCCCAACGGGACGCTCTACATCTGCAACCTCGCGCCCAAGAAAA
	GCGGGCGCTATGAGTGCGTGGCCGCCAACCTGATCGGCTCCGCGCGCAGTACGGTGCA
	GCTGAACGTGCAGCGCGCAGCAGCGAACGTGCAGCGCGCAGCAGCGAACGTGCAGCGC
	GCCAACGCGCGCATCACGGGCACCTCCTCGCAGAGGACGGACGTCAGCTACGGAGGGA
	CCCTCAAGCTGGACTGCAGCGCCTCGGGGGATCCCTGGCCGCGCATCCTCTGGAGGCT
	GCCGTCCAAGAGGACGATCGACGCGCTTTTCAGTTTTGATAGTAGAATCAAGGTGTTT
	GCCAACAGGACCCTGGTGGTGAAATCAATGACAGACAAAGACGCCGGAGATTACCTGT
	GTGTAGCTCGAATAAGCTTCGTGATGACTGCGTGGTGCTCAGGTGGATGTGATGAT
	GAAACCGGCCAAGATTGAACACAAGGAGGAGAACGACCACAPAAGTCTTCTACAGGGGT
	GACCTCAAAGTGGACTGTGTGGCCACTGCACTTCCCAITCCCGAGATCTCCTGGAGCC
	TCCTGGATGCGAGTCTGGTGAACTCCTTCATCCAGTCAGATGACAGTGGTGGACCCAC
	CAAGCACTATGTGGTCTTCAACAATGGGACACTCTACTTCAGTGAAGTGGGGATGAGG
	GAGGAAGGAGACTACACCTGCTTTGCTGAAAATCAGGTTGGGAAGGATGAGATGAGAG
	TCAGAGTCAAGATGGTGACACCTGCCACCATCTGGAACAAGACTTACTTGGCAGTTCA
	GGTACCCTATGGAGATCTGGTCACTGTAACCTGTGAGGCCAAACGAGAACCCATGCCC
	AAGGTGACTTGGTTGTCCCCAGCCAACAGGGTGATCCCCACCTCCTCTGAGAAAGTATC
	AGATATACCAATATGGCACTCTCCTTATTCAGAAAGCCCAGTGCTCTGACAGCGGCPA
	CTACACCTGCCTGGTCAGGAACAGTGCCGGAGAGGATACGAAGACAGTGTGGATTCAC
	GTCAACCTCCAGCCACCCAAGATCAATGGTAACCCCAACCCCATCACCACCGTGTGGG
	AGATAGCAGCCGCGGCCAGTCGGAAACTGATTGACTGCAAAGCTGAAGGCATCCCCAC
	CCCGAGGGTGTTATGGGCTTTTCCCCAGGGTGTGGTTCTGCCAGATCCATACTATGGA
	AACCGGATCACTGTCCATGGCAACGGTTCCCTGCACATCAGGAGTTTGAGGAAGAGCG
	ACTCCGTCCAGCTGGTATGCATGGCACGCAACGAGGGAGCGGAGGCGAGGTTGATCGT
	GCAGCTCACTGTCCTGGAGCCCATGGAGAAACCCATCTTCCACCACCCGATCAGCGAG
	AAGATCACGGCCATGGCGGGCCACACCATCACCCTCAACTGCTCTGCCGCGGGGACCC
	TGACACCCAGCCTGGTGTGGGTCCTTCCCAATGGCACCGATCTGCAGAGTGGACAGCA
	GCTGCAGCGCTTCTACCACAAGGCTGACGGCATGCTACACATTAGCGGTCTCTCCTCG
	GTGGACGCCGGGGCCTACCGCTGCGTGGCCCGCAATGCCGCGGCCCACACGGAGAGGC
	TGGTCTCCCTGAAGGTGGGACTGAAGCCAGAAGCAAACAAGCAGTATCATAACCTGGT
	CAGCATCATCAATGGTGAGACCCTGAAGCTCCCCTGCACCCCTCCTGCAGCTGGGCAG
	GGACATTTCTCCTGGACACTCCCCAATGGCATGCATCTOGAGGGCCCCCAAACCCTGG
	GACGCGTTTCTCTTCTCGACAATGGCACCCTCACGGTTCGTGAGGCCTCGGTGTTTGA
	CAGCGGTACCTATGTATGCAGCATGGAGACGGCGTACGGCCCTTCCGTCACCAGCATC
	CCCGTGATTGTCATCGCCTATCCTCCCCGGATCACCAGCGAGCCTACCCCAGTCATCT
	ACACCCGTCCCCGGAACACCGTGAACTGAACTGCATGGCTATGGGGATTCCCAAAGG
	TGACATCACGTGGGAGTTACCGGATAAGTTGCATCTGAACGCAGGGGTTCAGGCTCGT
	CTGTATGGAAACAGATTTCTTCACCCCCAGGGATCACTGACCATCCAGCAGGCCAGAC
	CGAGACACGCTGGCTTCTACAAGTGCACGGCAAAAAACATTCTCAGCAGTGACTCCAA
	AACAACTTATATCCATGTCTTCTGAAAT
	ORE Start: ATG at 14	ORE Stop: TGA at 8549
	SEQ ID NO: 2	2845 aa	MW at 31 5664.5kD
NOV 1a,	MPKRAHWGALSVVLILLWGHPRVALACPHPCACYVPSEVHCTFRSLASVPAGIAKHVE
CG58546-01 Protein
Sequence	RINLGFGNSIQALSETSFAGLTKLELLMIHGNEIPSIPDGALRDLSSLQVFKSYNKL
	RVITGQTLQGLSNLMRLHIDHNKIEFIHPQAFNGLTSLRLLHLEGNLLHQLHPSTFST
	FTFLDYFRLSTIRHLYLAENMVRTLPASMLRNMPLLENLYLQGNPWTCDCEMRWFLEW
	DAKSRGILKCKKDKAYEGGQLCAMCFSPKKLYKHETHKLKDLTCLKPSIESPLRQNRS
	RSIEEEQKQEENGDSQLILEKIQLPQWSISLNMTDEHGNLVNLVCDIKKPMDVYKIHL
	NQTDPPDIDINAMVALDFEYPMTQENYENLWKLIAYYSEVPMKLHRELMLSKIPRVSY
	QYRQDADEEALYYTGVRAQILAEPEWIMQPSIDIQLNRPQSTAKKVLLSYYNQYSQTI
	ATKDTRQARGRSWVMIEPSRAVQKDTVLEGGRCQLSCVKASESPSIFWVLPDGSIL
	KVPVDDPDSKFSILSSGWLRIKSMEPSDGLYQCIAQVRDEMDRVYRVLVQSPSTQP
	AEKDTVTIGKNPGEPVMLPCNALAIPEAHLWILPNRRIINDLANTSHVYMLPNGTLS
	IPKVQVSDSYHRCVAVNQHGADHITVGITVTKKGSGSPSKRGRWPGPKALSRSKGSF
	QMREDIVEDEGVSGTGDEENTSRRLLHPHQEAFLKTKDDAINGDKKAKKGRRKLKLW
	KHSEKEPETSVAEDLRVFESRRRINVANKQINPEHWADILAKVFGKNLPTGTEVSPII
	KTTSSPFLSLVVTPPLPAVSPPLASPIQTATSAEESSADVPLLSEGKHILSTISSASM
	GLEHHNNGVILVEPEVTSTPLEEVVDEYSKKTEEMTSTEGDLKGTAASTLISEPYEQS
	PTLHTLDTVYEEPTHEETETEGWSAADVGSSPDPTSSEYELPLVVVSLAESKPVQYFD
	PDLETNSQPHEDNIKEYSFAHLTPTAIIWFNDSSTSLSFEDSTVGEQGVPGKSHLQGP
	TENIQLVKSSFSTQDTLLIKKGMKEMSQTLQGGNMLEGDPTHSRSSENEGQESKSITL
	PDSTLGITSSTSPVKKPAETTVVTLLHKDTTTETTPRQKVASSSTMSTHPSRRRPNGR
	KLHPHKFHHRHKQTPPTTFAPLETFSTQPTQATDIKISNQMESSLVPTWEINTVNTP
	KQLEMEKNVELISKGTPPPKHGKRPNKHRYTPSTVSSRASASKPSPSPENKHRNIVTP
	SSETTLLPRNVSLKTEGVYDSLDYTTTTRKIHSSHHKVQDTLPVMYKPTSDGKEIQDD
	VATNVDKHKSDILVPGESITNVTQTSRSLVSTMGEFKEESSPVGFGIPTWNPSRKAQ
	PGRLQTDIHVTTSGETPTDPPLVNELEDVDFTSEFLSSVTVSTPFHQEEAGFSTILSS
	IKVEMASSQVETTTLGQDHHETTVAILHSETRPQNHILTAAWMKEPASLSPPMILLSL
	GQTTTTKPELLSRTSQICKDSKENVFLNYMGNPETEATPVKEGTQRMSGPNELSTP
HVF
	SEQ ID NO: 3	762 bp
NOV1b,	CGGCCGTGCCCTCATCCTTGTGCCTGCTACGTCCCCAGCOAGGTCCACTGCACGTTCC
174307918 DNA
Sequence	GATCCCTGGCTTCCGTGCCCGCTGGCATTGCTAACACGTGGAAAAGAATCAATTTGGG
	GTTTAATAGCATACAGGCCCTGTCAGAAACCTCATTTGCAGGACTGACCAAGTTGCAG
	CTACTTATGATTCACGGCAATGAGATCCCAAGCATCCCCGATGGAGCTTTAAGAGACC
	TCAGCTCTCTTCAGGTTTTCAAGTTCAGCTACAACAAGCTGAGAGTGATCACAGGACA
GACCCTCCAGGGTCTCTCTAACTTAATGAGGCTGCACATTGACCACAACAAGATCGAG
	TTTATCCACCCTCAAGCTTTCACGGCTTAACGTCTCTGAGGCTACTCCATTTGGAAG
	GAAATCTCCTCCACCAGCTGCACCCCAGCACCTTCTCCACGTTCACATTTTTGGATTA
	TTTCAGACTCTCCACCATAAGGCACCTCTACTTCGCAGAGAAACATGGTTAGAACTCTT
	CCTGCCAGCATGCTTCGGAACATGCCGCTTCTGGAGAATCTTTACTTGCAGGGAAATC
	CGTGGACCTGCGATTGTGAGATGAGATGGTTTTTGGAATGGGATGCAAAATCCAGAGG
	AATTCTGAAGTGTAAAAAGGACAAAGCTTATGAAGGCGGTCAGTTGTGTGCAATGTGC
	TTCAGTCCAAAGAAGTTGTACAAACATGAGATTCACAAGCTGAAGGACCTGACTTGTC
	TGCTCGAG
	ORF Start: CGG at 1	ORF Stop: it at 763
	SEQ ID NO: 4	1254 aa	MW at 29088.6kD
NOV 1b,	RPCPHPCACYVPSEVIICTFRSLASVPAGIAKHVERINLGFNSIQALSETSFAGLTKLE
174307918 Protein
Sequence LLMTHGNEIPSIPDGALRDLSSLQVFKFSYNKLRVITGQTLQGLSNLMRLHIDHNKIE
	FIHPQAFNGLTSLRLLHLEGNLLHQLHPSTFSTFTFLDYFRLSTIRHLYFAENMVRTL
	PASMLRNMPLLENLYLQGNPWTCDCEMRWFLEWDAKSRIGILKCKKDKAYEGGQLCAMC
	FSPKKLYKHEIHKLKDLTCLLE
	SEQ ID NO: 5	762 bp
NOV 1c,	CGGCCGTGCCCTCATCCTTGTGCCTGCTACGTCCCCAGCGAGGTCCACTGCACGTTCC
174307924 DNA
Sequence	GATCCCTGCCTTCCGTGCCCGCTGGCATTGCTAAACACGTGGAAAGAATCAATTTGGG
	GTTTAATAGCATACAGGCCCTGTCAGAAACCTCATTTGCAGGACTGACCAAGTTGGAG
	CTACTTATGATTCACGGCAATGAGATCCCAAGCATCCCCGATGGACCTTTAAGAGACC
	TCAGCTCTCTTCAGGTTTTCAAGTTCAGCTACAACAAGCTGAGAGTGATCACAGGACA
	GACCCTCCAGGGTCTCTCTAACTTAATGAGGCTGCACATTGACCACAACAAGATCAAA
	TTTATCCACCCTCAAGCTTTCAACGGCTTAACGTCTCTGAGGCTACTCCATTTGGAAG
	GAAATCTCCTCCACCAGCTGCACCCCAGCACCTTCTCCACGTTCACATTTTTGGATTA
	TTTCAGACTCTCCACCATAAGGCACCTCTACTTAGCAGAGAACATGGTTAGAACTCTT
	CCTGCCAGCATGCTTCCGAACATGCCGCTTCTGGAGAATCTTTACTTGCAGGGAAATC
	CGTGGACCTGCGATTGTGAGATGAGATGGTTTTTGGAATGGGATGCAAAGTCCAGAGG
	AATTCTGAAGTGTAAAAAGGGCAAAGCTTATGAAGGCGGTCAGTTGTGTGCATGTGC
	TTCAGTCCAAAGAAGTTGTACAAACATGAGATTCACAAGCTGAAGGACCTGACTTGTC
	TGCTCGAG
	ORF Start: CCC at 1	AORF Stop: it at 763
SEQ ID NO:6	254 aa	MW at 28996.5kD
NOV 1c,	RPCPHPCACYVPSEVHCTFRSLASVPAGIAKHVERINLGFNSIQALSETSFAGLTKLE
174307924 Protein
Sequence	LLMIHGNEIPSIPDGALRDLSSLQVFKFSYNKLRVITGQTLQGLSNLMRLHIDHNKIE
	FIHPQAFNGLTSLRLLHLEGNLLHQLHPSTFSTFTFLDYFRLSTIRHLYLAENMVRTL
	PASMLRNNPLLENLYLQGNPWTCDCEMRWFLEWDAKSRGILKCKKGAYEGGQLCAMC
	FSPKKLYKHEIHKLKDLTCLLE
	SEQ ID NO:7	762bp
NOV 1d,	CGGCCGTGCCCTCATCCTTGTGCCTGCTACGTCCCCAGCGAGGTCCACTGCACGTTCC
169679197 DNA
Sequence CTACTTATGATTCACGGCAATGAGATCCCAAGCATCCCCGATCGAGCTTTAAGAGACC
	GATCCCTCGCTTCCGTGCCCGCTGGCATTGCTAAACACGTGGAAAGAATCATTTGGG
	GTTTAATAGCATACAGGCCCTGTCAGAAACCTCATTTGCAGGACTGACCAAGTTGGAG
	TCAGCTCTCTTCAGGTTTTCAAGTTCAGCTACAACAAGCTGAGAGTGATCACAGGACA
	GACCCTCCAGGGTCTCTCTAACTTAATGAGGCTGCACATTGACCACAACAAGATCGAG
	TTTATCCACCCTCAGCTTTCAACGGCTTAACGTCTCTGAGGCTACTCCATTTGGAG
	GAAATCTCCTCCACCAGCTGCACCCCAGCACCTTCTCCACCTTCACATTTTTGGATTA
	TTTCAGACTCTCCACCATAAGGCACCTCTACTTAGCAGAGAACATGGTTAGAACTCTT
	CCTGCCAGCATGCTTCGGAACATGCCGCTTCTGGAGAATCTTTACTTGCAGGGAAATC
	CGTGGACCTGCGATTGTGAGATGAGATGGTTTTTGGAATGGGATGCAAAATCCAGAGG
	AATTCTGAAGTGTAAAAAGGACAAAGCTTATGAAGGCGGTCACTTGTGTACATGTGC
	TTCAGTCCAAAGAAGTTGTACAACATGAGATTCACAAAGCTGAGGACCTGACTTGTC
	TTGCTCGAG
	ORF Start: CGG at 1	ORF Stop: it at 763
	SEQ ID NO: 8	254 aa	MW at 29084.6kD
NOV 1d,	RPCPHPCACYVPSEVHCTFRSLASVPAGIAKHVERINLGFNSIQALSETSFAGLTKLE
169679197 Protein
Sequence	LLMIHGNEIPSIPDGALRDLSSLQVFKFSYNKLRVITGQTLQGLSNLMRLHIDHNKIE
	FIHPQAFNGLTSLRLLHLEGNLLHQLHPSTFSTFTFLDYFRLSTIRHLYLAENMAARTL
	PASMLRNNPLLENLYLQGNPWTCDCEMRWFLEWDAKSRGILKCKKDKAYEGGQLCTMC
	FSPKKLYKHEIHKLKDLTCLLE
	SEQ ID NO: 9	762 bp
NOV 1c,	CGGCCGTGCCCTCATCCTTCTGCCTGCTACGTCCCCAGCGAGGTCCACTGCACGTTCC
169679219 DNA
Sequence	GATCCCTGGCTTCCGTGCCCGCTGGCATTGCTAACACGTGGAAAGAATCAATTTGGG
	GTTTAATAGCATACAGGCCCTGTCAGAAACCTCATTTGCAGGACTGACCAAGTTGGAG
	CTACTTATGATTCACGGCAATGAGATCCCAAGCATCCCCGATGGAGCTTTAAGAGACC
	TCAGCTCTCTTCAGGTTTTCAAGTTCAGCTACAACAAGCTGAGAGTGATCACAGGACA
	GACCCTCCAGGGTCTCTCTAACTTAATGAGGCTGCACATTGACCACMA.CIAGATCGAG
	TTTATCCACCCTCAAGCTTTCAACGGCTTAACGTCTCTGAGGCTACTCCATTTGGAAG
	GAAATCTCCTCCACCAGCTGCACCCCAGCACCTTCTCCACGTTCACATTTTTGGATTA
	TTTCAGACTCTCCACCATAAGGCACCTCTACTTAGCAGAGAACATGGTTAGAACTCTT
	CCTGCCAGCATGCTTCGGAACATGCCGCTTCTGGAGAATCTTTACTTGCAGGGAAATC
	CGTGGACCTGCGATTGTGAGATGAGATGGTTTTTGGAATGGGATGCAAAATCCAGAGG
	AATTCTGAAGTGTAAAAAGGACAAAAGCTTATGAAGGCGGTCAGTTGTGTGCPATGTGC
	TTCAGTCCAAAGAAGTTGTACAACATGAGATTCACAIGCTGAAGGACCTGACTTGTC
	TGCTCGAG
	ORE Start: COG at 1	ORF Stop: it at 763
SEQ ID NO: 10	254aa	MW at 29054.6kD
NOV 1e,	RPCPHPCACYVPSEVHICTFRSLASVPAGIAKIVERINLGFNSIQALSETSFAGLTKLE
169679219 Protein
Sequence	LLMIHCNEIPSIPDGALRDLSSLQVFKFSYNKLRVITGQTLQGLSNLMRLHIDHNKIE
	FIHPQAFNGLTSLRLLHLEGNLLHQLHPSTFSTFTFLDYFRLSTIRHLYLAENNVRTL
	PASMLRNNPLLENLYLQGNPWTCDCEMRWFLEWDAKSRG ILKCKKDKAYEGGQLCAMC
	FSPKKLYKHEIHKLKDLTCLLE
	SEQ ID NO: 11	762 bp
NOV 1f	GGATCCTGCCCTCATCCTTGTGCCTGCTACGTCCCCAGCGAGGTCCACTGCACGTTCC
207704655 DNA
Sequence	GATCCCTGGCTTCCGTGCCCGCTGGCATTGCTAAACACGTGGAAAGAATCAATTTGGG
	GTTTAATAGCATACAGGCCCTGTCAGAAACCTCATTTGCAGGACTGACCAAGTTGGAG
	CTACTTATGATTCACGGCATGAGATCCCAAGCATCCCCGATCGAGCTTTAAGAGACC
	TCAGCTCTCTTCAGGTTTTCAAGTTCAGCTACAACAAGCTGAGAGTGATCACAGGACA
	GACCCTCCAGGGTCTCTCTAACTTAATGAGGCTGCACATTGACCACAACAAGATCGAG
	TTTATCCACCCTCAGCTTTCIVAACGGCTTIAACGTCTCTGAGGCTACTCCATTTGGAAG
	GAAATCTCCTCCACCAGCTGCACCCCAGCACCTTCTCCACGTTCACATTTTTGGATTA
	TTTCAGACTCTCCACCATAAGGCACCTCTACTTAGCAGAGAACATGGTTAGAACTCTT
	CCTGCCAGCATGCTTCGGAACATGCCGCTTCTGGAGAATCTTTACTTGCAGGGAAIATC
	CGTGGACCTGCCATTGTGAGATGAGATGGTTTTTGGAATGGGATGCAAAATCCAGAGG
	AATTCTGAAGTGTAAAAAGGACAAAGCTTATGAAGGCGGTCAGTTGTGTACAATGTGC
	TTCAGTCCAAGAAGTTGTACAAACATGAGATTCACAAGCTGAAGGACCTGACTTGTC
	TGCTCGAG
	ORF Start: OGA at 1	ORE Stop: it at 763
	SEQ ID NO: 12	254 aa	AMW at 28975.4kD
NOV 1f,	GSCPHPCACYTPSEVHCTFRSLASVPAGIAKHVERINLGFNSIQALSETSFAGLTKLE
207704655 Protein
Sequence	LLMIHGNEIPSIPDGALRDLSSLQVFKFSYNKLRVITGQTLQGLSNLMRLHIDHNKIE
	FIHPQAFNGLTSLRLLNLEGNLLHQLHPSTFSTFTFLDYFRLSTIRHLYLAENMVRTL
	PASMLRNMPLLENLYLQGNPWTCDCEMRWFLEWDAKSRGILKCKKDKAYEGGQLCTMC
	FSPKKLYKHEIEHKLKDLTCLLE

[0318] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 1B.

TABLE 1B
Comparison of NOV1a against NOV1b through NOV1f.
Protein	NOV1a Residues/	Identities/
Sequence	Match Residues	Similarities for the Matched Region
NOV1b	27 . . . 277	234/251 (93%)
	3 . . . 252	234/251 (93%)
NOV1c	27 . . . 277	234/251 (93%)
	3 . . . 252	234/251 (93%)
NOV1d	27 . . . 277	234/251 (93%)
	3 . . . 252	234/251 (93%)
NOV1e	27 . . . 277	235/251 (93%)
	3 . . . 252	235/251 (93%)
NOV1f	26 . . . 277	234/252 (92%)
	2 . . . 252	235/252 (92%)

[0319] Further analysis of the NOV1a protein yielded the following properties in Table 1C.

TABLE 1C
Protein Sequence Properties NOV1a
PSort     0.4371 probability located in outside; 0.1900 probability
analysis: located in lysosome (lumen); 0.1800 probability located in
          nucleus; 0.1000 probability located in endoplasmic reticulum
          (membrane)
SignalP   Cleavage site between residues 27 and 28
analysis:

[0320] A search of the NOV1 a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1D.

TABLE 1D
Geneseq Results for NOV1a
		NOV1a	Identities/
	Protein/Organism/	Residues/	Similarities for
Geneseq	Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAM41498	Human polypeptide SEQ ID NO 6429 -	2211 . . . 2845	605/636 (95%)	0.0
	Homo sapiens, 666 aa.	31 . . . 666	612/636 (96%)
	[WO200153312-A1, 26 JUL. 2001]
AAM39712	Human polypeptide SEQ ID NO 2857 -	2258 . . . 2845	561/589 (95%)	0.0
	Homo sapiens, 589 aa.	1 . . . 589	567/589 (96%)
	[WO200153312-A1, 26 JUL. 2001]
AAB42539	Human ORFX ORF2303 polypeptide	2263 . . . 2845	556/584 (95%)	0.0
	sequence SEQ ID NO: 4606 - Homo	1 . . . 584	562/584 (96%)
	sapiens, 584 aa. [WO200058473-A2,
	05 OCT. 2000]
ABB19814	Protein #1813 encoded by probe for	841 . . . 1349	509/509 (100%)	0.0
	measuring heart cell gene expression -	1 . . . 509	509/509 (100%)
	Homo sapiens, 509 aa.
	[WO200157274-A2, 09 AUG. 2001]
AAM67586	Human bone marrow expressed probe	841 . . . 1349	509/509 (100%)	0.0
	encoded protein SEQ ID NO: 27892 -	1 . . . 509	509/509 (100%)
	Homo sapiens, 509 aa.
	[WO200157276-A2, 09 AUG. 2001]

[0321] In a BLAST search of public sequence databases, the NOV1a protein was found to have homology to the proteins shown in the BLASTP data in Table 1E.

TABLE 1E
Public BLASTP Results for NOV1a
		NOV1a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9NR99	ADLICAN - Homo sapiens (Human),	1 . . . 2845	2568/2849 (90%)	0.0
	2828 aa.	1 . . . 2828	2641/2849 (92%)
Q9Y3Y8	HYPOTHETICAL 63.9 KDA	2263 . . . 2845	554/584 (94%)	0.0
	PROTEIN - Homo sapiens (Human),	1 . . . 584	562/584 (95%)
	584 aa (fragment).
Q96SC3	FIBULIN-6 - Homo sapiens	1787 . . . 2844	284/1075 (26%)	8e−81
	(Human), 2673 aa (fragment).	28 . . . 1022	443/1075 (40%)
Q96RW7	HEMICENTIN - Homo sapiens	1861 . . . 2844	268/991 (27%)	1e−80
	(Human), 5636 aa.	3064 . . . 3985	416/991 (41%)
Q96DN3	CDNA FLJ31995 FIS, CLONE	1854 . . . 2831	263/988 (26%)	4e−73
	NT2RP7009236, WEAKLY	147 . . . 1066	416/988 (41%)
	SIMILAR TO BASEMENT
	MEMBRANE-PROTEOGLYCAN
	CORE PROTEIN PRECURSOR -
	Homo sapiens (Human),
	1252 aa (fragment).

[0322] PFam analysis indicated that the NOV1 a protein contains the domains shown in the Table 1F.

TABLE 1F
Domain Analysis of NOV1a
		Identities/
		Similarities
		for the
	NOV1a	Matched	Expected
Pfam Domain	Match Region	Region	Value
LRRNT: domain 1 of 1	26 . . . 54	11/31 (35%)	0.078
		22/31 (71%)
LRR: domain 1 of 6	56 . . . 80	6/26 (23%)	2.4e+02
		20/26 (77%)
LRR: domain 2 of 6	81 . . . 104	7/25 (28%)	0.36
		20/25 (80%)
LRR: domain 3 of 6	105 . . . 128	5/25 (20%)	4.2
		18/25 (72%)
LRR: domain 4 of 6	129 . . . 152	7/25 (28%)	0.015
		21/25 (84%)
LRR: domain 5 of 6	153 . . . 176	8/25 (32%)	0.84
		18/25 (72%)
LRR: domain 6 of 6	185 . . . 208	7/25 (28%)	3.3
		17/25 (68%)
LRRCT: domain 1 of 1	218 . . . 277	18/64 (28%)	4.1e−05
		40/64 (62%)
ig: domain 1 of 13	495 . . . 558	15/67 (22%)	3.7e−06
		46/67 (69%)
ig: domain 2 of 13	593 . . . 654	15/65 (23%)	1.8e−06
		44/65 (68%)
ig: domain 3 of 13	1011 . . . 1295	5/286 (2%)	5.9e+04
		221/286
		(77%)
ig: domain 4 of 13	1872 . . . 1936	13/68 (19%)	2.5e−06
		45/68 (66%)
ig: domains 5 of 13	1971 . . . 2033	14/66 (21%)	1.1e−06
		43/66 (65%)
IF3: domain 1 of 1	2110 . . . 2122		3.5
		11/13 (85%)
ig: domain 6 of 13	2073 . . . 2130	14/61 (23%)	0.00026
		38/61 (62%)
ig: domain 7 of 13	2179 . . . 2241	18/66 (27%)	1.8e−08
		44/66 (67%)
ig: domain 8 of 13	2276 . . . 2344	12/72 (17%)	0.00089
		43/72 (60%)
ig: domain 9 of 13	2378 . . . 2437	21/63 (33%)	2.4e−11
		45/63 (71%)
ig: domain 10 of 13	2476 . . . 2537	14/65 (22%)	0.11
		39/65 (60%)
ig: domain 11 of 13	2574 . . . 2635	14/65 (22%)	2.1e−06
		45/65 (69%)
ig: domain 12 of 13	2669 . . . 2730	12/65 (18%)	7.3e−05
		44/65 (68%)
ig: domain 13 of 13	2765 . . . 2829	17/68 (25%)	8.9e−09
		47/68 (69%)

Example 2

[0323] The NOV2 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 2A.

TABLE 2A
NOV2 Sequence Analysis
	SEQ ID NO: 13	1055 bp
NOV2a,	CCAAGAAACAGAATCAAGGCTCGATGCCTGTCCTGCACGTCCATGGTTCTGAAGGGC
	ATCTGGGGACTCTTGATCATCTTGTCAGTATCATCATCTTGGTCTATTATTCTGGTCA
	TCTAGCCACTGCTCAAGAAAAGCAATCTCCAATGAAAAAATTCAGGGAATGCAGTCGG
	ATTTTTGGTGAAGATGGTCTGACGCTGAAACTCTTTCTTAAAAGAACTGCTCCCTTTT
	CTATTCTATGGACTTTGACTAATTACCTTTATTTACTGGCTTTAAAGAAGCTGACGGC
	CACGGATGTCTCCGCTCTGTTCTGTTGTAACAAAGCCTTTGTCTTCTTGCTGTCATGG
	ATTGTGCTGAAAGACAGGTTCATGGGAGTGAGGATAGTTGCTGCAATAATGGCAATTA
	CCGGCATTGTCATGATGGCATATGCAGATAATTTCCACGCTGATTCCATCATAGGAGT
	GGCATTTGCGGTGGGCTCAGCCTCTACATCTGCATTATATAAGGTATTGTTTAAAATG
	TTTCTTGGAAGTGCCAACTTTGGGGAAGCTGCACACTTTGTCTCCACCTTGGGTTTCT
	TCAATTTGATCTTCATCTCCTTCACCCCAGTCATCTTGTATTTCACCAAGGTGGAGCA
	CTGGTCCTCTTTTGCTGCTCTGCCATGGGGCTGTCTCTGTGGGATGGCAGGGCTGTGG
	CTGGCCTTCAACATCCTGGTGAATGTTGGGGTGGTGCTGACATACCCAATCCTAATCT
	CCATTGGGACAGTGCTCAGCGTTCCTGGAAATGCAGCTGTGGATCTCCTAAAGCAGGA
	GGTGATATTCAATGTTGTCCGCCTGGCTGCTACCATCATCATCTGCATTGGGTTTCTG
	CTGATGCTGTTGCCTGAGGAATGGGATGAAATCACCCTGAGGTTCATCAACAGCCTGA
	AGGAAAAGAAGAGTGAGGAGCATGTGGATGATGTGACTGATCCCAGCATACACCTGCG
	GGGCAGAGGCAGAGCCAATGGGACAGTGTCTATACCACTGGCTTAGAGAGGGACATAT
	TTTGAATGCAC
	ORF Start: ATG at 25	ORF Stop: TAG at 1030
	SEQ ID NO: 14	335 aa	MW at 36928.2kD
NOV 2a	MPVLHVHGSEGHLGTLDHLVSIIILVYYSGHLATAQEKQSPMKKFRECSRIFGEDGLT
CG58598-01 Protein
Sequence	LKLFLKRTAPFSILWTLTNYLYLLALKKLTATDVSALFCCNKAFVFLLSWIVLKDRFM
	GVRIVAAIMAIGIVMMAYADNFHADSIIGVAFAVGSASTSALYKVLFKMFLGSANFG
	EAAHFVSTLGFFNLIFISFTPVILYFTKVEHWSSFAALPWGCLCGMAGLWLAFNILVN
	VGVVLTYPILISIGTVLSVPGNAAVDLLKQEVIFNVVRLAATIIICIGFLLMLLPEEW
	DEITLRFINSLKEKKSEEHVDDVTDPSIHLRGRGRANGTVSIPLA
	SEQ ID NO: 15	1154 bp
NOV2b,	CCAAGAAAACAGAATCAAGGCTCGCTGCCATGGTTCTGAAGGGC
CG58598-02 DNA
	ATCTGGGACCCTTGATCATCTTGTCAGTATCATCATCTTGGGTTGGAACTACACAGA
	TTGTAAAAAATTACTTATAAGAACTTCTATTGCCCATTTTTCATGACTTGGTTTTCAAC
	AAACTGAACATTATGTTTTTCCCAGTCTATTATTCTGGTCATCTAGCCACTGCTCAA
	GAAAAGCAATCTCCAATGAAAAAATTCAGGGAATGCAGTCGGATTTTTGGTGAAGATG
	GTCTGACGCTGAAACTTTCTTAAAAGAACTGCTCCCTTTTCTATTCTATGGACTTT
	GACTAATTACCTTTATTTACTCCCTTTAAACAACCTGACGGCCACGGATGTCTCCGCT
	CTGTTCTGTTGTAACAAGCCTTTGTCTTCTTGCTGTCATGGATTGTCCTGAAAGACA
	GGTTCATGGGAGTGAGGATAGTTGCTGCAATAATGGCAATTACCCCCAAGACAAAAA
	GGCATATGCAGATAATTTCCACGCTGATTCCATCATAGGACTGGCATTTGCGGTGGGC
	TCAGCCTCTACATCTGCATTATATAAGGTCTTGTTTAAAATGTTTCTTGGAGTGCCA
	ACTTTGGGGAAGCTGCACACTTTGTCTCCACCTTGGGTTTCTTCAATTTGATCTTCAT
	CTCCTTCACCCCAGTCATCTTGTATTTCACCAAGGTGGAGCACTGGTCCTCTTTTGCT
	GCTCTGCCATGCGGCTGTCTCTGTGGGATGGCAGGGCTGTGGCTGGCCTTCACATCC
	TGGTGAATGTTGGGGTGGTGCTGACATACCCAATCCTAAACTCCATTGGGACAATAAA
	CAGCGTTCCTGGAAATGCAGCTGTGGATCTCCTAAAGCAGGAGGTGATATTCAATGTT
	GTCCGCCTGGCTGCTACCATCATCATCTGCATTGGGTTTCTGCTGATGCTGTTGCCTG
	AGGAATGGGATGAAATCACCCTGAGGTTCATCAACAGCCTGAAGGAAACAAAGTAA
	GGAGCATGTGGATGATGTGACTGATCCCAGCATACACCTGCGGGGCAGAGCCAGAGCC
	AATGGGACAGTGTCTATACCACTGGCTTAGAGAGGGACATATTTTGAATGCA
	ORF Start: ATG at 44	ORF Stop: TAG at 1130
	SEQ ID NO: 16	362 aa	MW at 40382.4kD
NOV2b,	MVLKGIWGPLIILSVSSSWVGTTQIVKITYKNFYCPFFMTWFSTNWNIMFFPVYYSGH
CG58598-02 Protein
Sequence	LATAQEKQSPMKKFRECSRIFGEDGLTLKLFLKRTAPFSILWTLTNYLYLLALKKLTA
	TDVSALFCCNKAFVFLLSWIVLKDRFMGVRIVAIMAITGIVMMAYADNFAASIIGV
	AFAVGSASTSALYKVLFKNFLGSANFGEAAAAFVSTLGFFNLIFISFTPVILYFTKVEH
	WSSFAALPWGCLCGMAGLWLAFNILVNVGVVLTYPILISIGTVLSVPGNAAVDLLKQE
	VIFNVVRLAATIIICIGFLLMLLPEEWDEITLRFINSLKEKKSEEHVATDDVTDPS IHLR
	GRGRANGTVSIPLA
	SEQ ID NO: 17	324 bp
NOV2c,	GGATCCTGGGTTGGAACTACACAGATTGTMAAAATTACTTATAAGAAIACTTCTATTGCC
209770459 DNA
Sequence	CATTTTTCATGACTTGGTTTTCAACIAAACTGGAACATTATGTTTTTCCCAGTCTATTA
	TTCTGGTCATCTAGCCACTGCTCAAGAAAAGCAATCTCCAATGAAAAAATTCAGGGAA
	TGCAGTCGGATTTTTGGTGAAGATGGTCTGACGCTGAAACTCTTTCTTAAAAGAACTG
	CTCCCTTTTCTATTCTATGGACTTTGACTAATTACCTTATTTACTGGCTTTAAAGAA
	GCTGACGGCCACGGATGTCTCCGCTCTGCTCGAG
	ORF Start: GGA at 1	ORF Stop: 32 at 325
	SEQ ID NO: 18	108 aa	MW at 12629.7kD
NOV2c,	GSWVGTTQIVKITYKNFYCPFFMTWFSTNWNIMFFPVYYSGHLATAQEKQSPMKKFRE
209770459 Protein
Sequence	CSRIFGEDGLTLKLFLKRTAPFSILWTLTNYLYLLALKKLTATDVSALLE

[0324] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 2B.

TABLE 2B
Comparison of NOV2a against NOV2b through NOV2c.
Protein	NOV2a Residues/	Identities/
Sequence	Match Residues	Similarities for the Matched Region
NOV2b	26 . . . 335	291/310 (93%)
	53 . . . 362	291/310 (93%)
NOV2c	26 . . . 95	51/70 (72%)
	37 . . . 106	51/70 (72%)

[0325] Further analysis of the NOV2a protein yielded the following properties shown in Table 2C.

TABLE 2C
Protein Sequence Properties NOV2a
PSort     0.6850 probability located in endoplasmic reticulum
analysis: (membrane); 0.6400 probability located in plasma membrane;
          0.4600 probability located in Golgi body; 0.1000 probability
          located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 36 and 37
analysis:

[0326] A search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2D.

TABLE 2D
Geneseq Results for NOV2a
		NOV2a	Identities/
	Protein/Organism/	Residues/	Similarities for
Geneseq	Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAG28842	Arabidopsis thaliana protein fragment	73 . . . 289	55/231 (23%)	4e−09
	SEQ ID NO: 34212 - Arabidopsis	14 . . . 240	104/231 (44%)
	thaliana, 278 aa. [EP1033405-A2,
	06 SEP. 2000]
AAG28841	Arabidopsis thaliana protein fragment	73 . . . 289	55/231 (23%)	4e−09
	SEQ ID NO: 34211 - Arabidopsis	94 . . . 320	104/231 (44%)
	thaliana, 358 aa. [EP1033405-A2,
	06 SEP. 2000]
AAG28840	Arabidopsis thaliana protein fragment	73 . . . 289	55/231 (23%)	4e−09
	SEQ ID NO: 34210 - Arabidopsis	174 . . . 400	104/231 (44%)
	thaliana, 438 aa. [EP1033405-A2,
	06 SEP. 2000]
AAG38623	Arabidopsis thaliana protein fragment	73 . . . 289	55/231 (23%)	6e−09
	SEQ ID NO: 47675 - Arabidopsis	14 . . . 240	103/231 (43%)
	thaliana, 305 aa. [EP1033405-A2,
	06 SEP. 2000]
AAG38622	Arabidopsis thaliana protein fragment	73 . . . 289	55/231 (23%)	6e−09
	SEQ ID NO: 47674 - Arabidopsis	94 . . . 320	103/231 (43%)
	thaliana, 385 aa. [EP1033405-A2,
	06 SEP. 2000]

[0327] In a BLAST search of public sequence databases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2E.

TABLE 2E
Public BLASTP Results for NOV2a
		NOV2a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9JJG8	BRAIN CDNA, CLONE MNCB-	1 . . . 335	323/335 (96%)	0.0
	0335 - Mus musculus (Mouse), 335	1 . . . 335	330/335 (98%)
	aa.
AAL39312	GH20388P - Drosophila	26 . . . 301	97/278 (34%)	5e−41
	melanogaster (Fruit fly), 578 aa.	265 . . . 539	157/278 (55%)
Q95XC7	HYPOTHETICAL 37.3 KDA	47 . . . 287	84/242 (34%)	4e−34
	PROTEIN - Caenorhabditis elegans,	87 . . . 326	138/242 (56%)
	339 aa.
Q9VDJ2	CG15688 PROTEIN - Drosophila	26 . . . 127	45/103 (43%)	7e−13
	melanogaster (Fruit fly), 365 aa.	265 . . . 365	62/103 (59%)
Q9VDJ0	CG15689 PROTEIN - Drosophila	143 . . . 298	42/169 (24%)	5e−12
	melanogaster (Fruit fly), 195 aa.	9 . . . 176	82/169 (47%)

[0328] PFam analysis indicates that the NOV2a protein contains the domains shown in the Table 2F.

TABLE 2F
Domain Analysis of NOV2a
	NOV2a	Identities/
	Match	Similarities	Expect
Pfam Domain	Region	for the Matched Region	Value
DUF6: domain 1 of 1	25 . . . 135	18/127 (14%)	0.89
		78/127 (61%)

Example 3

[0329] The NOV3 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 3A.

TABLE 3A
NOV3 Sequence Analysis
	SEQ ID NO: 19	1681 bp
NOV3a,	AAAGCGCTGACAGCTCAAATGGATCCCATGGAACTGAGAAATGTCAACATCGAACCAG
CG57833-01 DNA
Sequence	ATGATGAGAGCAGCAGTGGACAAAGTGCTCCAGATAGCTACATCGGGATAGGAAATTC
	AGAAAGGCAGCAATGAGTCAATTTGCTPATGAAGACACTGIAAAGTCAGAATTCCTG
	ACAAATGGATTTTTGGGGAAAAAGAAGCTGGCAGATTATGCTGATGAACACCATCCCG
	GAACCACTTCCTTTGGAATGTCTTCATTTAACCTGAGTAATGCCATCATCCCCACTCC
	GATCCTGGGCTTGTCCTATGCCATGGCCAACACAGGGATCATACTTTTTATGATCATG
	CTGCTTGCTGTGGCAATATTATCACTGTATTCAGTTCACCTTTTATTAAAAACAGCCA
	AGGAAGGAGGTTCTTTGATTTATGAAAAATTAGGAGAAAAGGCATTTGGATGGCCCGG
	AAAAATTGGAGCTTTTGTTTCCATTACAATGCAGAACATTGGAGCAATGTCAAGCTAC
	CTCTTTATCATTAAATATGAACTACCTGAAGTAATCAGAGCATTCATGGGACTTGAAG
	AAAATACTGGGGAATGGTACCTCAATGGCAACTACCTCATCATATTTGTGTCTGTTCG
	AATTATTCTTCCACTTTCGCTCCTTAAAAATTTAGGTTATCTTGGCTATACCAGTGGA
	TTTTCTCTTACCTGCATGGTGTTTTTTGTTAGTGTGGTAATTTACAAGATTCCAAAAA
	TACCCTGCCCTCTACCTGTTTTGGATCACAGTGTTGGAATCTGTCATTCAACAACAC
	GCTTCCAATGCATGTGGTAATGTTACCCAACAACTCTGACAGTTCTGATGTGAACTTC
	ATGATGGATTACACCCACCGCAATCCTGCAGGGCTGGATGAGAACCAGGCCAGGGCT
	CTCTTCATGACAGTGGAGTAGAATATGAAGCTCATAGTGATGACAAGTGTGAACCCAA
	ATACTTTGTATTCAACTCCCGGACGGCCTATGCAATTCCTATCCTAGTATTTGCTTTT
	GTATGCCACCCTGAGCTCCTTCCCATCTACAGTGAACTTAAAAGAGCGGTCCCGGAGAA
	AAATGCAAACGGTGTCAAAATATTTCCATCACGGGGATGCTTGTCATGTACCTGCTTGC
	CGCCCTCTTTGGTTACCTACCTTCTATGGTGAGTTGIAGATGAATTACTTCATGCC
	TACAGCAAAGTGTATACATTAGACATCCCCCTTCTCATGGTTCGCCTGGCACTCCTTG
	TGGCAGTAACACTAACTCTCCCCATTGTCCTCTTCCCAATTCGTACATCAGTGATCAC
	ACTGTTATTTCCCAAACGACCCTTCAGCTGGATACGACATTTCCTGATTGCAGCTGTG
	CTTATTGCACTTAATAATGTTCTGGTCATCCTTGTGCCAACTATAAAATACATCTTCG
	GATTCATAGGTGCTTCTTCTGCCACTATGCTGATTTTTATTCTTCCAGCAGTTTTTTA
	TCTTAAACTTGTCAAGAAAGAAACTTTTAGGTCACCCCAAAAGGTCGGGGCTTTAATT
	TTCCTTGTGGTTGGAIATATTCTTCATGATTGGAAGCATGGCACTCATTATAAAAATTGACT
	GGATTTATGATCCTCCAAATTCCAACCATCACTAACACAAGGAAAATACTTTCTTT
	ORF Start: ATG at 19	ORF Stop: TAA at 1657
	SEQ ID NO: 20	546 aa	MW at 60708.4kD
NOV3a,	MDPMELRNVNIEPDDESSSGESAPDSYIGIGNSEKAAMSQFANEDTESQKFLTNGFLG
CG57833-01 Protein
Sequence	KKKLADYADEHHPGTTSFCMSSFNLSNAIMGSGILGLSYAIVIANTGIILFMIMLLAVAI
	LSLYSVHLLLKTAKEGGSLIYEKLGEKAFGWPGKIGAFVSITMQNIGAMSSYLFIIKY
	ELPEVIRAFMGLEENTGEWYLNGNYLIIFVSVGIILPLSLLKNLGYLGYTSCFSLTCM
	VFFVSVVIYKKFQIPCPLPVLDHSVGNLSFNNTLPMHVATMLPNSESSDVNFAAVIDYTH
	RNPAGLDENQAKGSLHDSGVEYEAHSDDKCEPKYFVFNSRTAYAIPILVFAFVCHPEV
	LPIYSELKERSRRKMQTVSNISITGMLVMYLLALFGYLTFYCEVEDELLHAYSKVYT
	LDIPLLMRLAVLVAVTLTVPIVLFPIRTSVITLLFPKRPFSWIRHFLIAAVLIALNN
	VLVILVPTIKYIFGFIGASSATMLIFILPAVFYLKLVKKETFRSPQKGALIFLVVGI
	FFMIGSMALIIIDWIYDPPNSKHH

[0330] Further analysis of the NOV3a protein yielded the following properties shown in Table 3B.

TABLE 3B
Protein Sequence Properties NOV3a
PSort     0.6000 probability located in plasma membrane; 0.4000
analysis: probability located in Golgi body; 0.3000 probability
          located in endoplasmic reticulum (membrane); 0.0300
          probability located in mitochondrial inner membrane
SignalP   No Known Signal Sequence Indicated
analysis:

[0331] A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3C.

TABLE 3C
Geneseq Results for NOV3a
		NOV3a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAY79188	Haematopoietic stem cell specific	1 . . . 546	474/547 (86%)	0.0
	protein - Mus musculus, 547 aa.	1 . . . 547	509/547 (92%)
	[WO200011168-A2, 02-MAR-2000]
AAB93237	Human protein sequence SEQ ID	108 . . . 545	255/438 (58%)	e−140
	NO: 12239 - Homo sapiens, 406 aa.	5 . . . 406	310/438 (70%)
	[EP1074617-A2, 07-FEB-2001]
AAB81002	Rat neuronal glutamine transporter	5 . . . 546	258/542 (47%)	e−134
	(NGT) amino acid sequence - Rattus	12 . . . 485	347/542 (63%)
	norvegicus, 485 aa. [CN1272545-A,
	08-NOV-2000]
AAB92592	Human protein sequence SEQ ID	1 . . . 243	241/244 (98%)	e−133
	NO: 10833 - Homo sapiens, 259 aa.	1 . . . 244	242/244 (98%)
	[EP1074617-A2, 07-FEB-2001]
AAM93430	Human polypeptide, SEQ ID NO:	5 . . . 546	256/542 (47%)	e−133
	3060 - Homo sapiens, 487 aa.	12 . . . 487	346/542 (63%)
	[EP1130094-A2, 05-SEP-2001]

[0332] In a BLAST search of public sequence databases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3D.

TABLE 3D
Public BLASTP Results for NOV3a
		Residues/	Similarities for
Accession		Match	the Matched
Number	Protein/Organism/Length	Residues	Portion	Value
Q96916	AMINO ACID TRANSPORTER	1 . . . 546	544/547 (99%)	0.0
	HNAT3 (AMINO ACID	1 . . . 547	546/547 (99%)
	TRANSPORTER SYSTEM A3) -
	Homo sapiens (Human), 547 aa.
Q9EQ25	AMINO ACID TRANSPORT	1 . . . 546	481/547 (87%)	0.0
	SYSTEM A3 - Rattus norvegicus (Rat),	1 . . . 547	511/547 (92%)
	547 aa.
BAB84091	SYSTEM A AMINO ACID	1 . . . 546	473/547 (86%)	0.0
	TRANSPORTER 3 - Mus musculus	1 . . . 547	508/547 (92%)
	(Mouse), 547 aa.
Q9HAV3	AMINO ACID TRANSPORTER	1 . . . 545	313/545 (57%)	e−170
	SYSTEM A (AMINO ACID	1 . . . 506	379/545 (69%)
	TRANSPORTER SYSTEM A2) -
	Homo sapiens (Human), 506 aa.
Q96QD8	PUTATIVE 40-9-1 PROTEIN - Homo	1 . . . 545	312/545 (57%)	e−170
	sapiens (Human), 506 aa.	1 . . . 506	379/545 (69%)

[0333] PFam analysis indicates that the NOV3a protein contains the domains shown in the Table 3E.

TABLE 3E
Domain Analysis of NOV3a
	NOV3a	Identities/Similarities
	Match	for	Expect
Pfam Domain	Region	the Matched Region	Value
sec Y: domain 1 of 1	112 . . . 475	61/479 (13%)	7.5
		224/479 (47%)
Aa_trans: domain 1 of 1	98 . . . 528	107/510 (21%)	2.3e−51
		318/510 (62%)

Example 4

[0334] The NOV4 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 4A.

TABLE 4A
NOV4 Sequence Analysis
	SEQ ID NO: 21	1152 bp
NOV4a,	ATCCTAAATACTACAATGGTGAATGTGGCCAAGAAGATCTCATCAGATGCTACA
CG57853-01 DNA
Sequence	CTTTACCATAATCTGGTGACTGATGAAGAAGGAGACATGTGACTATTCACTC
	TGGGATTCTGAAGGTAGGCAAGAAAGACTCATTGAAGAAATCAAGAATGTGAAAGTCA
	AAGTGCTCAAACAAAAAGACAGTCTACTCCAGGCACCAATGCATATTGATAGACAT
	CCTAATGCTTATTTTACCACTAATACTATTGATAAGTGTGCATTTGGTTGTA.AGATT
	GAATTACAGCTGTTTCAAZACAGTATGGAAGAGACCTTTGCCAGTIAAATTCTTGGGGCAG
	TTACACAGTTTTTTCTGATGCCATTTTGCGGGTTTCTTTTGTCTCAGATTOTCCCATT
	GCCTGAGGCGCAAGCTTTTGGAGTTGTAATGACCTGCACGTGCCCAGGAGGGGGTGGG
	GGCTATCTCTTTGCTCTGCTTCTAGATGGAGATTTCACATTGGCCATTTTGATGACTT
	GCACATCAACATTATTGGCTCTGATCATGATGCCTGTCAATTCTTATATATACAGTAG
	GATATTAGGGTTGTCAGGTACATTCCATATTCCTGTTTCTAAATTGTGTCAACACTC
	CTTTTCATACTTGTGCCAGTATCAATTGGAATAGTCATCAAGCATAGAATACCTGAAA
	AAGCAAGCTTCTTAGAGAGAATAATTAGACCTCTGAGTTTTATTTTAAATGTTCGTAGG
	AATTTATTTGACTTTCACAGTGGGATTAGTGTTCTTAAAAACAGATAATCTAGAGGTG
	ATTCTGTTGGGTCTCTTAGTTCCTGCTTTGGGTTTGCTGTTTGGGTACTCCTTTGCTA
	AAGTTTGTACGCTGCCTCTTCCTGTTTGTAAAACTGTTGCTATTGAAAGTGGGATGTT
	AATAGTTTCTTAGCTCTTGCCGTTATTCAGCTGTCTTTTCCACAGTCCAAGGCCAAT
	TTAGCTTCTGTGGCTCCTTTTACAGTAGCCATGTGTTCTGGATGTGAAATGTTACTGA
	TCATTCTAGTTTACAAGGCTAAGAAAAGATGTATCTTTTTCTTACAAGATAAAAGGAA
	AAGAATTTCCTAATCTAACAATTAAAGCATTACTGAATTCCTACTCTGG
	ORF Start: ATG at 18	ORF Stop: TAA at 1119
	SEQ ID NO: 22	367 aa	MW at 40588.5kD
NOV4a,	MVNVAKKISSDATNFTINLVTDEEGETNVTIQLWDSEGRQERLIEEIKNVKVKVLKQK
CG57853-01 Protein
Sequence	DSLLQAPMHIDRNILMLILPLILLNKCAFGCKIELQLFQTVWKRPLPVILGAVTQFFL
	MPFCGFLLSQIVALPEAQAFGVVNTCTCPGGGGGYLFALLLDGDFTLAILMTCTSTLL
	ALIMNPVNSYIYSRILGLSGTFHIPVSKIVSTLLFILVPVSIGIVIKHRIPEAFLA
	RIIRPLSFILMFVGIYLTFTVGLVFLKTDILEVILLGLLVPALGLLFGYSFAKVCTLP
	LPVCKTVAIESGMLNSFLALAVIQLSFPQSKANLASVAFTVANCGCEMLLIILVYK
	AKKRCIFFLQDKRKRNFLI
	SEQ ID NO:23	11355 bp
NOV4b,	TTTCAAATTTCAAAATGATTAGAAAACTTTTTATTGTTCTACTTTTGTTGCTTGTGACTATAGAA
CG57853-02 DNA
Sequence	GAAGCAAGGATGTCATCGCTCAGTTTTCTGAATATAGAGAAGACTGATACTATTTT
	TCACAAAGACTGAAGAAACCATCCTTGTAAGTTCAAGCTACGAAATAAAACGGCCTAA
	GCCAAGAAGATCTCATCAGATGCTACAAACTTTACCATA3AATCTGGTGACTGATGAAC
	AAGCAGAACAAATGTGACTATTCAACTCTGGGATTCTGAAGGTAGGCAAGAAAAGACT
	CATTGAAGAAATCAAGAATGTGAAAGTCAAAGTGCTCAAACAAAAAACACAGTCTACTC
	CAGGCACCAATGCATATTGATAGAACATCCTAATGCTTATTTTACCACTATACTAT
	TGAATAAGTGTGCATTTGGTTGTAGATTGATTACAGCTGTTTCAACAGTATGGA
	GAGACCTTTGCCAGTAATTCTTGGGGCAGTTACACAGTTTTTTCTGATGCCATTTTGC
	GGGTTTCTTTTGTCTCAGATTGTGGCATTGCCTGAGGCGCAAGCTTTTGGAGTTGTAA
	TGACCTGCACGTGCCCAGGAGGCGGTGGOGGCTATCTCTTTGCTCTGCTTCTAGATCG
	AGATTTCACATTGGCCATTTTGATGACTTGCACATCAACATTATTGGCTCTGATCATG
	ATGCCTGTCAATTCTTATATATACAGTAGGATATTAGGGTTGTCACGTACATTCCATA
	TTCCTGTTTCTAAAATTGTGTCAACACTCCTTTTCATACTTCTGCCAGTATCATTGG
	AATAGTCATCAAGCATAGAATACCTGAGCAAAGCTTCTTAGAGAGAAATTAGA
	CCTCTGAGTTTTATTTTAATGTTCGTAGGAATTTATTTGACTTTCACAGTGGGATTAC
	TGTTCTTAAAAACAGATAATCTAGAGGTGATTCTGTTCGGTCTCTTAGTTCCTGCTTT
	GCGTTTGCTGTTTGGGTACTCCTTTGCTAAAGTTTGTACGCTGCCTCTTCCTGTTTGT
	AAAACTGTTGCTATTGAAAGTGGGATGTTAAATAGTTTCTTAGCTCTTGCCGTTATTC
	AGCTGTCTTTTCCACAGTCCAACGCCAATTTAGCTTCTGTGGCTCCTTTTACAGTAGC
	CATGTGTTCTGGATGTGAAATCTTACTGATCATTCTAGTTTACICGCTAGAAAAGA
	TGTATCTTTTTCTTACAAGATAAAGGAAAAGAAATTTCCTAATCTAACAATTAAAGC
	ATTACTGAATTCCTACTCTGG
	ORF Start: ATG at 8	ORF Stop: TAA at 1322
	SEQ ID NO: 24	438 aa	MW at 48870.2kD
NOV4b,	MIRKLFIVLLLLLVTIEEARMSSLSFLNIEKTEILFFTKTEETILVSSSYENKRPNSS
CG57853-02 Protein
Sequence	HLFVKIEDPKILQMVNVAKKISSDATNFTINLVTDEEGETNVTIQLWDSEGRQERLIE
	EIKNVKVKVLKQKDSLLQAPMHIDRNILMLILPLILLNKCAFGCKIELQLFQTVWKRP
	LPVILGAVTQFFLMPFCGFLLSQIVALPEAQAFGWAMTCTCPGGGGGYLFALLLDGDF
	TLAILMTCTSTLLALIMMPVNSYIYSRILGLSGTFHIPVSKIVSTLLFILVPVSIGIV
	IKHRIPEKASFLERIIRPLSFILMFVGIYLTFTVGLVFLKTDNLEVILLGLLVPALGL
	LFGYSFAKVCTLPLPVCKTVAIESGMLNSFLALAVIQLSFPQSKANLASVAPFTVAMC
	SGCEMLLIILVYKAKKRCIFFLQDKRKRNFLI
	SEQ ID NO: 25	1152 bp
NOV4e,	ATCCTAAAATACTACAAATGGTGAATGTGGCCAAGAAGATCTCATCAGATGCTACAAAA
CG57853-03
Sequence	DNACTTTACCATAAATCTGGTGACTGATGAAGAAGGAGAAACAAIAGTGACTATTCAACTC
	TGGGATTCTGAAGGTAGGCAGAGACTCATTGAAGATCAAGAATGTGAAAGTCA
	AGTGCTCAAACAAAAAGACAGTCTACTCCAGGCACCAATGCATATTGATAGAAACAT
	CCTAATGCTTATTTTACCACTAATACTATTGAATAAGTGTGCATTTGGTTGTAGATT
	GAATTACAGCTGTTTCAAACAGTATGGAAGAGACCTTTGCCAGTAATTCTTGGGGCAG
	TTACACAGTTTTTTCTGATGCCATTTTGCGGGTTTCTTTTGTCTCAGATTGTGGCATT
	GCCTGAGGCGCAAGCTTTTGGAGTTGTAATGACCTGCACGTGCCCAGGAGGGGGTGGG
	GGCTATCTCTTTGCTCTGCTTCTAGATGGAGATTTCACATTGGCCATTTTGATGACTT
	GCACATCAACATTATTGGCTCTGATCATGATGCCTGTCAATTCTTATATATACAGTAG
	GATATTAGGGTTGTCAGGTACATTCCATATTCCTGTTTCTAAAITTGTGTCAACACTC
	CTTTTCATACTTGTGCCAGTATCAATTGGAATAGTCATCATGCATAGAATACCTGAAA
	AAGCAAGCTTCTTAGAGAGAATAATTAGACCTCTGAGTTTTATTTTAATGTTCGTACG
	AATTTATTTGACTTTCACAGTGGGATTAGTGTTCTTAIAAACAGATAATCTAGAGGTG
	ATTCTGTTGGGTCTCTTAGTTCCTGCTTTGGGTTTGCTGTTTGGGTACCCTTGCTA
	AAGTTTGTACGCTGCCTCTTCCTGTTTGTAAAACTGTTGCTATTGAAAGTGGGATGTT
	AATAGTTTCTTAGCTCTTGCCGTTATTCAGCTGTCTTTTCCACAGTCCAAGACCAT
	TTAGCTTCTGTGGCTCCTTTTACAGTAGCCATGTGTTCTGGATGTGAAATGTTACTGA
	TCATTCTAGTTTACAAGGCTAAGAAAAGATGTATCTTTTTCTTACAAGATAAAAGGAA
	AAGAAATTTCCTAATCTACAATTAAAGCATTACTGAATTCCTACTCTGG
	ORF Start: ATG at 18	ORF Stop: TAA at 1119
	SEQ ID NO: 26	367 aa	MW at 40588.5kD
NOV4c,	MVNVAKKISSDATNFTINLVTDEEGETNVTIQLWDSEGRQERLIEEIKNVKVKVLKQK
CG5 7853-03 Protein
Sequence	DSLLQAPMHIDRNILMLILPLILLNKCAFGCKIELQLFQTVWKRPLPVILGAVTQFFL
	MPFCGFLLSQIVALPEAQAFGVVMTCTCPGGGGGYLFALLLDGDFTLAILMTCTSTL
	ALIMMPVNSYIYSRILGLSGTFHIPVSKIVSTLLFILVPVSIGIVIKIRIPEKASFLE
	RIIRPLSFILMFVGIYLTFTVGLVFLKTDNLEVILLGLLVPALGLLFGYSFAKVCTLP
	LPVCKTVAIESGMLNSFLALAVIQLSFPQSKANLASVAPFTVAiAICsGCEMLLIILVYK
	AKKRCIFFLQDKRKRNFLI

[0335] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 4B.

TABLE 4B
Comparison of NOV4a against NOV4b through NOV4c.
	NOV4a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV4b	1 . . . 367	324/367 (88%)
	72 . . . 438	324/367 (88%)
NOV4c	1 . . . 367	324/367 (88%)
	1 . . . 367	324/367 (88%)

[0336] Further analysis of the NOV4a protein yielded the following properties shown in Table 4C.

TABLE 4C
Protein Sequence Properties NOV4a
PSort     0.6000 probability located in plasma membrane; 0.4318
analysis: probability located in mitochondrial inner membrane; 0.4000
          probability located in Golgi body; 0.3000
          probability located in endoplasmic reticulum (membrane)
SignalP   No Known Signal Sequence Indicated
analysis:

[0337] A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4D.

TABLE 4D
Geneseq Results for NOV4a
		NOV4a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAR77224	Hamster ileal/renal bile acid	72 . . . 353	90/284 (31%)	2e−37
	cotransporter - Cricetulus griseus, 348	37 . . . 314	155/284 (53%)
	aa. [WO9517905-A1, 06-JUL-1995]
AAR77225	Human ileal/renal bile acid	72 . . . 353	93/285 (32%)	2e−36
	cotransporter - Homo sapiens, 348 aa.	37 . . . 314	155/285 (53%)
	[WO9517905-A1, 06-JUL-1995]
AAG91138	C glutamicum protein fragment SEQ ID	71 . . . 309	79/249 (31%)	1e−19
	NO: 4892 - Corynebacterium	44 . . . 278	127/249 (50%)
	glutamicum, 335 aa. [EP1108790-A2,
	20-JUN-2001]
AAG42824	Arabidopsis thaliana protein fragment	80 . . . 317	63/246 (25%)	5e−19
	SEQ ID NO: 53452 - Arabidopsis	18 . . . 251	114/246 (45%)
	thaliana, 288 aa. [EP1033405-A2,
	06-SEP-2000]
AAG42823	Arabidopsis thaliana protein fragment	80 . . . 317	63/246 (25%)	5e−19
	SEQ ID NO: 53451 - Arabidopsis	131 . . . 364	114/246 (45%)
	thaliana, 401 aa. [EP1033405-A2,
	06-SEP-2000]

[0338] In a BLAST search of public sequence databases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4E.

TABLE 4E
Public BLASTP Results for NOV4a
		NOV4a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
P09131	P3 protein - Homo sapiens (Human),	15 . . . 345	142/335 (42%)	3e−74
	477 aa.	131 . . . 465	225/335 (66%)
Q9BSL2	SIMILAR TO PROTEIN P3 - Homo	20 . . . 345	141/330 (42%)	4e−73
	sapiens (Human), 448 aa.	107 . . . 436	220/330 (65%)
Q60414	Ileal sodium/bile acid cotransporter (Ileal	72 . . . 353	90/284 (31%)	7e−37
	Na(+)/bile acid cotransporter) (Na+	37 . . . 314	155/284 (53%)
	dependent ileal bile acid transporter) (Ileal
	sodium-dependent bile acid transporter)
	(ISBT) (Sodium/taurocholate
	cotransporting polypeptide, ileal) -
	Cricetulus griseus (Chinese hamster),
	348 aa.
Q62633	Ileal sodium/bile acid cotransporter (Ileal	72 . . . 353	93/285 (32%)	2e−36
	Na(+)/bile acid cotransporter) (Na+	37 . . . 314	154/285 (53%)
	dependent ileal bile acid transporter) (Ileal
	sodium-dependent bile acid transporter)
	(ISBT) (Sodium/taurocholate
	cotransporting polypeptide, ileal) - Rattus
	norvegicus (Rat), 348 aa.
CAC39447	BA11L8.1 (SOLUTE CARRIER FAMILY	72 . . . 353	93/285 (32%)	8e−36
	10 (SODIUM/BILE ACID	37 . . . 314	155/285 (53%)
	COTRANSPORTER FAMILY),
	MEMBER 2) - Homo sapiens (Human),
	348 aa.

[0339] PFam analysis indicates that the NOV4a protein contains the domains shown in the Table 4F.

TABLE 4F
Domain Analysis of NOV4a
	NOV4a	Identities/
	Match	Similarities	Expect
Pfam Domain	Region	for the Matched Region	Value
SBF: domain 1 of 1	77 . . . 261	48/208 (23%)	1.5e−37
		145/208 (70%)
ABC-3: domain 1 of 1	126 . . . 323	32/283 (11%)	9.2
		125/283 (44%)

Example 5

[0340] The NOV5 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 5A.

TABLE 5A
NOV5 Sequence Analysis
	SEQ ID NO: 27	2804 bp
NOV5a,	CGCGGCGGTGCGCTGCCCGGCGCCATGCTTCTGCTGGGCATCCTAACCCTGGCTTTCG
CG57829-01 DNA
Sequence	CCGGGCGAACCGCTGGAGGCTCTGAGCCAGAGCGGGAGGTAGTCGTTCCCATCCGACT
	GGACCCGGACATTAACGGCCGCCGCTACTACTGGCGGGGTCCCGACGACTCCGGGGAT
	CAGGGACTCATTTTTCAGATCACAGCATTTCAGGAGGACTTTTACCTACACCTGACGC
	CGGATGCTCAGTTCTTGGCTCCCGCCTTCTCCACTGAGCATCTGGGCGTCCCCCTCCA
	GGGCTCACCGGGGGCTCTTCAGACCTGCGACGCTGCTTCTATTCTGGGGACGTGAAC
	GCCGAGCCGGACTCGTTCGCTGCTCTGAGCCTGTGCGGGGGGCTCCGCGGACCCTTTG
	GCTACCGAGGCGCCGAGTATGTCATTAGCCCGCTGCCCAATGCTAGCCCGCCCGCGGC
	GCACCGCAACAGCCAGGGCGCACACCTTCTCCAGCGCCGGGGTGTTCCGGGCGGGCCT
	TCCGGAGACCCCACCTCTCGCTCCGCGGTGGCCTCGGGCTGGAACCCCGCCATCCTAC
	GGGCCCTGGACCCTTACAAGCCGCGGCGGGCGGGCTTCGGGGAGAGTCGTACCCGGCG
	CAGGTCTGGGCGCGCCAAGCGTTTCGTGTCTATCCCGCGGTACGTGGAGACGCTGGTG
	GTCGCGGACGAGTCAATGGTCAAGTTCCACGGCGCGGACCTGGAACATTATCTGCTGA
	CGCTGCTGGCAACGGCGGCGCGACTCTACCGCCATCCCAGCATCCTCAACCCCATCAA
	CATCGTTGTGGTCAAGGTGCTGCTTCTTAGAGATCGTGACTCCGGGCCCAAGGTCACC
	GGCAATGCGGCCCTGACGCTGCGCAACTTCTGTGCCTGGCAGAAGAAGCTGAACAAAG
	TGAGTGACAAGCACCCCGAGTACTGGGACACTGCCATCCTCTTCACCAGGCAGGACCT
	GTGTGGACCCACCACCTGTGACACCCTGGGCATGGCTGATGTGGGTACCATGTGTGAC
	CCCAAGAGAAGCTGCTCTGTCATTGAGGACGATGGGCTTCCATCAGCCTTCACCACTG
	CCCACGAGCTGGGTCACGTGTTCAACATGCCCCATGACAATGTGAAAGTCTGTGAGGA
	GGTGTTTGGGAAGCTCCGAGCCAACCACATGATGTCCCCGACCCTCATCCAGATCGAC
	CGTGCCAACCCCTGGTCAGCCTGCAGTGCTGCCATCATCACCGACTTCCTGGACAGCG
	GGCACGGTGACTGCCTCCTGGACCAACCCAGCAAGCCCATCTCCCTGCCCGAGGATCT
	GCCGGCCGCCAGCTACACCCTGAGCCAGCAGTGCGAGCTGGCTTTTGGCGTGGGCTCC
	AAGCCCTGTCCTTACATGCACTACTGCACCAAGCTGTGGTGCACCGGGAAGGCCAAGG
	GACAGATGGTGTGCCAGACCCGCCACTTCCCCTGGGCCGATCGCACCAGCTGTCGCGA
	GGGCAAGCTCTGCCTCAAAGGGGCCTGCGTGGAGAGACACAACCTCAACAAGCACTCT
	TCCTCACAGGTGGATGGTTCCTGGGCCAAATGGGATCCCTATGGCCCCTGCTCGCGCA
	CATGTGGTCGGGGCGTGCAGCTGGCCAGGAGGCAGTGCACCAACCCCACCCCTGCCAA
	CGGGGGCAAGTACTGCGAGGGAGTGAGGGTGAAATACCGATCCTGCAATCTGGAGCCC
	TGCCCCAGCTCCGGAAAGAGCTTCCGGGAGGAGCAGTGTGAGGCTTTCAACGGCTACA
	ACCACAGCACCAACCGGCTCACTCTCGCCGTGGCATGGGTGCCCAAGTACTCCGGCGT
	GTCTCCCCGGGACAAGTGCAAGCTCATCTGCCGAGCCAATGGCACTGGCTACTTCTAT
	GTGCTGGCACCCAAGGTGGTGGACGCCACGCTGTGCTCTCCTGACTCCACCTCCGTCT
	GTGTCCAAGGCAAGTGCATCAAGGCTGGCTGTGATGGGAACCTGGGCTCCAAGAAGAG
	ATTCGACAAGTGTGGGGTGTGTGGGGGAGACAATAAGAGCTGCAAGAAGGTGACTGGA
	CTCCTTTCCCCCGCCAGGCATGGCTACAATTTCGTGGTGGCCATCCCCGCACGCGCCT
	CAAGCATCGACATCCGCCAGCGCGGTTACAAAGGGCTGATCGGGCATGACAACTACCT
	GGCTCTGAAGAACAGCCAAGGCAAGTACCTGCTCAACGGGCATTTCGTGGTGTCGGCG
	GTCGAGCGGCACCTGGTGGTGAAGGGCAGTCTGCTGCGGTACAGCGGCACGGGCACAG
	CGGTGGAGAGCCTGCAGGCTTCCCCGCCCATCCTCGAGCCGCTGACCGTGGAGGTCCT
	CTCCGTGGGGAAGATGACACCGCCCCCGGTCCGCTACTCCTTCTATCTGCCCAAAGAG
	CCTCGGGAGGACAAGTCCTCTCATCCCCCGGCACGCTGGGTGGCTGGCAGCTGGGGGC
	CGTGCTCCGCGAGCTGCGGCAGTGGCCTGCAGAAGCGGGCGGTGGACTGGCGGCGCTC
	CGCCGGGCAGCGCACGGTCCCTGCCTGTGATGCAGCCCATCGGCCCGTGGAGACACAA
	GCCTGCGGGGAGCCCTGCCCCACCTGGGAGCTCAGCGCCTGGTCACCCTGCTCCAAGA
	GCTGCGGCCGGGGATTTCAGAGGCGCTCACTCAAGTGTGTGGGCCACGGAGGCCCCCT
	GCTGGCCCGGGACCAGTGCAACTTGCACCGCAAGCCCCAGGAGCTGGACTTCTCCGTC
	CTGAGGCCGTGCTGAGTGGG
	ORF Start: ATG at 25	ORF Stop: TGA at 2797
	SEQ ID NO: 28	924aa	MW at 100396.3kD
NOV5a,	MLLLGILTLAFAGRTAGGSEPEREVVVPIRLDPDINGRRYYWRGPEDSGDQGLIFQIT
CG57829-01 Protein
Sequence	AFQEDFYLHLTPDAQFLAPAFSTEHLGVPLQGLTGGSSDLRRCFYSGDVNAEPDSFAA
	VSLCGGLRGAFGYRGAEYVISPLPNASAPAAQRNSQGAHLLQRRGVPGGPSGDPTSRC
	GVASGWNPAILRALDPYKPRRAGFGESRSRRRSGRAKRFVSIPRYVETLVVADESMVK
	FHGADLEIIYLLTLLATAARLYRHPSILNPINIVVVKVLLLRDRDSGPKVTGNAALTLR
	NFCAWQKKLNKVSDKAIPEYWDTAILFTRQDLCCATTCDTLGMADVGTMCDPKRSCSVI
	EDDCLPSAFTTAHELGHVFNMPHDNVKVCEEVFGKLRANHMMSPTLIQIDRANPWSAC
	SAAIITDFLDSGHGDCLLDQPSKPISLPEDLPGASYTLSQQCELAFGVGSKPCPYMQY
	CTKLWCTGKAKGQMVCQTRHFPWADGTSCGEGKLCLKGACVERHNLNKHSSSQVDGSW
	AKWDPYGPCSRTCGGGVQLARRQCTNPTPANGGKYCEGVRVKYRSCNLEPCPSSGKSF
	REEQCEAFNGYNHSTNRLTLAVAWVPKYSGVSPRDKCKLICRANGTGYFYVLAPKVVD
	GTLCSPDSTSVCVQGKCIKAGCDGNLGSKKRFDKCGVCGGDNKSCKKVTGLLSPARHO
	YNFVVAIPAGASS IDIRQRGYKGLIGDDNYLALKNSQGKYLLNGHFVVSAVERDLVVK
	GSLLRYSGTGTAVESLQASRPILEPLTVEVLSVGKMTPPRVRYSFYLPKEPREDKSSH
	PPARWVACSWCPCSASCGSGLQKRAVDWRGSAGQRTVPACDAAHRPVETQACGEPCPT
	WELSAWSPCSKSCGRGFQRRSLKCVGHGGRLLARDQCNLHRKPQELDFCVLRPC
	SEQ ID NO: 29	2297bp
NOV5b,	CGCGGCGGTGCGCTGCCCGGCGCCATGCTTCTGCTGGGCATCCTAACCCTGGCTTTCG
CG57829-05 DNA
Sequence	CCGGGCGAACCGCTGGAGGCTCTGAGCCAGAGCGGGAGGTAGTCGTTCCCATCCGACT
	GGACCCGGACATTAACGGCCGCCGCTACTACTGGCGGGGTCCCGAGGACTCCGGGGAT
	CAGGGACTCATTTTTCAGATCACAGCATTTCAGGAGGACTTTTACCTACACCTGACGC
	CGGATGCTCAGTTCTTGGCTCCCGCCTTCTCCACTGAGCATCTGCGCGTCCCCCTCCA
	GGGGCTCACCGGCGGCTCTTCAGACCTGCGACGCTGCTTCTATTCTGGGGACGTGAAC
	GCCGAGCCGGACTCGTTCGCTGCTGTGAGCCTGTGCGGGGGGCTCCGCGGAGCCTTTG
	GCTACCGAGGCGCCGAGTATGTCATTAGCCCGCTGCCCAATGCTAGCGCGCCGGCGGC
	GCAGCGCAACAGCCAGCGCGCACACCTTCTCCAGCGCCGGGGTGTTCCGGGCGGCCCT
	TCCGGAGACCCCACCTCTCGCTGCGGGGTGGCCTCGGGCTGGAACCCCGCCATCCTAC
	GGGCCCTGGACCCTTACAAGCCGCGGCGGGCGGGCTTCGGGGAGAGTCGTAGCCGGCG
	CAGGTCTGGGCGCGCCAAGCGTTTCGTGTCTATCCCGCGGTACGTGGAGACGCTGGTG
	GTCGCGGACGAGTCAATGGTCAAGTTCCACGGCGCGGACCTGGAACATTATCTGCTGA
	CGCTGCTGGCAACGGCGGCGCGACTCTACCGCCATCCCAGCATCCTCAACCCCATCAA
	CATCGTTGTGGTCAAGGTGCTGCTTCTTAGAGATCGTGACTCCGGGCCCAAGGTCACC
	GGCAATGCGGCCCTGACGCTGCGCAACTTCTGTGCCTGGCAGAAGAAGCTGAACAAAG
	TGAGTGACAAGCACCCCGAGTACTGGGACACTGCCATCCTCTTCACCAGGCAGGTGGA
	TGGTTCCTGGGCCAAATGGGATCCCTATGGCCCCTGCTCGCGCACATGTGGTGGGGGC
	GTGCAGCTGGCCAGGAGGCAGTGCACCAACCCCACCCCTGCCAACGGGGGCAAGTACT
	GCGAGGGAGTGAGGGTGAAATACCGATCCTGCAATCTGGAGCCCTGCCCCAGCTCAGC
	CTCCGGAAAGAGCTTCCGGGAGGAGCAGTGTGAGGCTTTCAACGGCTACAACCACAGC
	ACCAACCGGCTCACTCTCGCCGTGGCATGGGTGCCCAAGTACTCCGGCGTGTCTCCCC
	GGGACAAGTCCAAGCTCATCTGCCCAGCCAATGGCACTGGCTACTTCTATGTGCTGGC
	ACCCAAGGTGGTGGACGCCACGCTGTGCTCTCCTGACTCCACCTCCGTCTGTCTCCAA
	GGCAAGTGCATCAAGGCTGGCTGTGATGGGAACCTGGGCTCCAAGAAGAGATTCGACA
	AGTGTGGGGTGTGTGGGGGAGACAATAAGAGCTGCAAGAAGGTGACTGGACTCTTCAC
	CAAGCCCATGCATGGCTACAATTTCGTGGTGGCCATCCCCGCAGGCGCCTCAAGCATC
	GACATCCGCCAGCGCGGTTACAAAGGGCTGATCGGGGATGACAACTACCTGGCTCTGA
	AGAACAGCCAAGGCAAGTACCTGCTCAACGGGCATTTCCTGGTGTCGGCGGTGGAGCG
	GGACCTGGTGGTGAAGGGCAGTCTGCTGCGGTACAGCGGCACGGGCACAGCGGTGGAG
	AGCCTCCAGGCTTCCCGGCCCATCCTGGAGCCGCTGACCGTGGAGGTCCTCTCCGTGG
	GGAAGATGACACCGCCCCGGGTCCGCTACTCCTTCTATCTGCCCAAAGAGCCTCGGGA
	GGACAAGTCCTCTCATCCCAAGGACCCCCGGGGACCCTCTGTCTTGCACAACACCGTC
	CTCAGCCTCTCCAACCAGGTGGAGCAGCCGGACGACAGGCCCCCTGCACGCTGGGTGG
	CTGGCAGCTGGGGGCCGTGCTCCGCGAGCTGCGGCAGTGGCCTGCAGAAGCGGGCGGT
	GGACTGCCGGGGCTCCGCCGGGCAGCGCACGGTCCCTGCCTGTGATCCAGCCCATCCG
	CCCGTGGAGACACAAGCCTGCGGGGAGCCCTGCCCCACCTGGGAGCTCAGCGCCTGCT
	CACCCTGCTCCAAGAGCTGCGGCCGGGGATTTCAGAGGCGCTCACTCAAGTGTGTGGG
	CCACGGAGGCCGGCTGCTGGCCCGGGACCAGTGCAACTTGCACCGCAAGCCCCAGGAG
	CTGGACTTCTGCGTCCTCAGCCCGTGCTGAGTGGG
	ORF Start: ATG at 25	ORF Stop: TGA at 2290
	SEQ ID NO: 30	755 aa	MW at 82147.6kD
NOV5b,	MLLLGILTLAFAGRTAGGSEPEREVVVPIRLDPDINGRRYYWRGPEDSGDQGLIFQIT
CG57829-05 Protein
Sequence	AFQEDFYLHLTPDAQFLAPAFSTEHLGVPLQGLTGGSSDLRRCFYSGDVNAEPDSFAA
	VSLCGGLRGAFGYRGAEYVISPLPNASAPAAQRNSQGAHLLQRRGVPGGPSGDPTSRC
	GVASGWNPATLRALDPYKPRRAGFGESRSRRRSGRAKRFVSIPRYVETLVVADESMVK
	FHGADLEHYLLTLLATAARLYRHPSILNPINIVVVKVLLLRDRDSGPKVTGNAALTLR
	NFCAWQKKLNKVSDKHPEYWDTAILFTRQVDGSWAKWDPYGPCSRTCGGGVQLARRQC
	TNPTPANGGKYCECVRVKYRSCNLEPCPSSASGKSFREEQCEAFNGYNHSTNRLTLAV
	AWVPKYSGVSPRDKCKLICRANGTGYFYVLAPKVVDGTLCSPDSTSVCVQGKCIKAGC
	DGNLGSKKRFDKCGVCGGDNKSCKKVTGLFTKPMHGYNFVVAIPAGASSIDIRQRGYK
	GLIGDDNYLALKNSQGKYLLNGHFVVSAVERDLVVKGSLLRYSGTGTAVESLQASRPI
	LEPLTVEVLSVGKNTPPRVRYSFYLPKEPREDKSSHPKDPRGPSVLHNSVLSLSNQVE
	QPDDRPPARWVAGSWGPCSASCGSGLQKRAVDCRGSAGQRTVPACDAAHRPVETQACG
	EPCPTWELSAWSPCSKSCCRGFQRRSLKCVGHGGRLLARDQCNLHRKPQELDFCvLRp
	C
	SEQ ID NO: 31	555 bp
NOV5c,	AGATCTCGGTACGTGGAGACGCTGGTGGTCGCGGACGAGTCAATGGTCAGTTCCACG
175070495 DNA
Sequence	GCGCGGACCTGGAACATTATCTGCTGACGCTGCTGGCAACGGCGGCGCGACTCTACCG
	CCATCCCAGCATCCTCAACCCCATCAACATCGTTGTGGTCAAGGTGCTGCTTCTTAGA
	GATCGTGACTCCGGGCCCAAGGTCACCGGCAATACGGCCCTGACGCrGCGCAACTTCT
	GTGCCTGGCAGAAGAAGCTGAACAAAGTGAGTGACAAGCACCCCGAGTACTGGGACAC
	TGCCATCCTCTTCACCAGGCAGGACCTGTGTGGAGCCACCACCTGTGACACCCTGGGC
	ATGGCTGATGTCGGTACCATGTGTGACCCCAAGAGAAGCTGCTCTGTCATTGAGGACC
	ATGGGCTTCCATCAGCCTTCACCACTGCCCACGAGCTGGGCCACGTGTTCPACATGCC
	CCATGACAATGTGAAAGTCTGTGAGGAGGTGTTTGGGAAGCTCCGAGCCAACCACATG
	ATGTCCCCGACCCTCATCCAGATCGACCTCGAG
	ORF Start: AGA at 1	ORF Stop: ig at 556
	SEQ ID NO: 32	185 aa	MW at 20725.7kD
NOV5c,	RSRYVETLVVADESMVKFHGADLEHYLLTLLATAARLYRHPS ELNPINIVVVKVLLLR
175070495 Protein
Sequence	DRDSGPKATTGNTALTLRNFCAWQKKLNKVSDKHPEYWDTAILFTRQDLCGATTCDTLG
	MADVGTMCDPKRSCSVIEDDGLPSAFTTA1IELGHVFNMPHDNVKVCEEVFGKLRANHM
	MSPTLIQIDLE
	SEQ ID NO: 33	555 bp
NOV5d,	AGATCTCGGTACGTGGAGACGCTGGTGGTCGCGGACGAGTCAATGGTCAAGTTCCACG
175070504
Sequence	DNAGCGCGGACCTGGAACATTATCTGCTGACGCTGCCGGCAACGGCGGCGCGACTCTACCG
	CCATCCCAGCATCCTCAACCCCATCAACATCGTTGTGGTCAAGGTGCTGCTTCTTAGA
	GATCGTGACTCCGGGCCCAACGTCACCGGCAATGCGGCCCTGACGCTGCGCAACTTCT
	GTGCCTGGCAGAAGAAGCTGAACAAAGTGAGTCACAAGCACCCCGAGTACTGGGACAC
	TGCCATCCTCTTCACCAGGCAGGACCTGTGTGGAGCCACCACCTGTGACACCCTGGGC
	ATGGCTGATGTGGGTACCATGTGTGACCCCAAGAGAAGCTGCTCTGTCATTGAGGACG
	ATGGGCTTCCATCAGCCTTCACCACTGCCCACGAGCTGGGCCACGTGTTCAACATGCC
	CATGACAATGTGAAAGTCTGTGAGGAGGTGTTTGGGAAGCTCCGAGCCAACCACATG
	ATGTCCCCGACCCTCATCCAGATCGACCTCGAG
	ORF Start: AGA at 1	ORF Slop: ig at 556
	SEQ ID NO: 34	185 aa	MW at 20679.6kD
NOV5d,	RSRYVETLVVADESMVKFHGADLEHYLLTLPATAARLYRHPSILNPINIVVVKVLLLR
175070504 Protein
Sequence	DRDSGPKVTGNAALTLRNFCAWQKKLNKVSDKHPEYWDTAILFTRQDLCGATTCDTLG
	MADVGTMCDPKRSCSVIEDDGLPSAFTTAHELGHVFNMPHDNVKVCEEVFGKLRAIIHM
	MSPTLIQIDLE
	SEQ ID NO:35	556 bp
NOV5e,	AGATCTCGGTACGTGGAGACGCTGGTGGTCGCGGACGAGTCAATGGTCAAGTTCCACG
175070512 DNA
Sequence	GCGCGGACCTGGAACATTATCTGCTGACGCTGCTGGCAACGGCGGCGCGACTCTACCG
	CCATCCCAGCATCCTCAACCCCATCAACATCGTTGTGGTCAAGGTGCTGCTTCTTACA
	GATCGTGACTCCGGGCCCAAGGTCACCGGCAATGCGGCCCTGACGCTGCGCAACTTCT
	GTGCCTGGCAGAAGAAGCTGAACAAAGTGAGTGACAAGCACCCCGAGTACTGGGACAC
	TGTUCCTGGCAGAAGAAACTGAACAAAGTGAGTGACAAGCACCCCGAGTACTGGGACAC
	ATGGCTGATGTGGGTACCATGTGTGACCCCAAGAGAAGCTGCTCTGTCATTGAGGACG
	ATGGGCTTCCATCAGCCTTCACCACTGCCCACGAGCTGGGCCACGTGTTCAACATGCC
	CCATGACAATGTGAAAGTCTGTGAGGAGGTGTTTGGGAAGCTCCGAGCCAACCACATG
	ATGTCCCCGACCCTCATCCAGATCGACCTCGAG
	ORF Start: AGA at 1	ORF Stop: ig at 556
	SEQ ID NO: 36	185 aa	MW at 20695.6kD
NOV5e,	RSRYVETLVVADESMVKFHGADLEHYLLTLLATAARLYRHPSILNPINIVVVKVLLLR
175070512 Protein
Sequence	DRDSGPKVTGNAALTLRNFCAWQKKLNKVSDKHPEYWDTAILFTRQDLCGATTCDTLG
	MADVGTMCDPKRSCSVIEDDGLPSAFTTAHELGHVFNMPHDNVKVCEEVFGKLRANIM
	MSPTLIQIDLE
	SEQ ID NO: 37	555 bp
NOV5f,	AGATCTCGGTACGTGGAGACGCTGGTGGTCGCGGACCAGTCAATGGTCAAGCTCCACG
175070519 DNA
Sequence	GCGCGGACCTGGAACATTATCTGCTGACGCTGCTGGCAACGGCGGCGCGACTCTACCG
	CCATCCCAGCATCCTCAACCCCATCAACATCGTTGTGGTCAAGGTGCTGCTTCTTAGA
	CATCGTGACTCCGGGCCCAAGGTCACCGGCAATGCGGCCCTGACGCTGCGCAACTTCT
	CTGCCTGGCAGAAAGAAGCTGAACAAAGTGAGTGACAAGCACCCCGAGTACTGGGACAC
	TGCCATCCTCTTCACCAGGCAGGACCTGTGTGGAGCCACCACCTGTGACACCCTGGGC
	ATGGCTGATGTGGGTACCATGTGTGACCCCAAGAGAAGCTGCTCTGTCATTGAGGACG
	ATGGGCTTCCATCAGCCTTCACCACTGCCCACGAGCTGGGCCACGTGTTCAACATGCC
	CCATGACAATGTGAAAGTCTGTCACGAGGTGTTTGGGAAGCTCCGAGCCAACCACATG
	ATGTCCCCGACCCTCATCCAGATCGACCTCGAG
	ORF Start: AGA at 1	ORF Stop: ig at 556
	SEQ ID NO: 38	185aa	MW at 20661.6kD
NOV5f,	RSRYVETLVVADESMVKLHGADLEHYLLTLLATAARLYRHPSILNPINIVVVKVLLLR
175070519 Protein
Sequence	DRDSGPKVTGNAALTLRNFCAWQKKLNKVSDKHPEYWDTAILFTRQDLCGATTCDTLG
	MADVGTMCDPKRSCSVIEDDGLPSAFTTAHELGHVFNMPHDNVKVCEEVFGKLRANHM
	MSPTLIQIDLE

[0341] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 5B.

TABLE 5B
Comparison of NOV5a against NOV5b through NOV5f.
	NOV5a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV5b	494 . . . 924	410/473 (86%)
	283 . . . 755	413/473 (86%)
NOV5c	218 . . . 398	158/181 (87%)
	3 . . . 183	158/181 (87%)
NOV5d	218 . . . 398	172/181 (95%)
	3 . . . 183	172/181 (95%)
NOV5e	218 . . . 398	159/181 (87%)
	3 . . . 183	159/181 (87%)
NOV5f	218 . . . 398	158/181 (87%)
	3 . . . 183	158/181 (87%)

[0342] Further analysis of the NOV5a protein yielded the following properties shown in Table 5C.

TABLE 5C
Protein Sequence Properties NOV5a
PSort     0.5469 probability located in outside; 0.1900
analysis: probability located in lysosome (lumen); 0.1000 probability
          located in endoplasmic reticulum (membrane); 0.1000
          probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 18 and 19
analysis:

[0343] A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5D.

TABLE 5D
Geneseq Results for NOV5a
		NOV5a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAG62299	Human metalloprotease MDTS6	1 . . . 924	913/953 (95%)	0.0
	protein - Homo sapiens, 950 aa.	1 . . . 950	915/953 (95%)
	[WO200134785-A1, 17-MAY-2001]
AAB21257	Rat metalloproteinase ADAMTS-5 -	89 . . . 581	459/497 (92%)	0.0
	Rattus norvegicus, 505 aa.	13 . . . 505	468/497 (93%)
	[WO200053774-A2, 14-SEP-2000]
AAB73549	Human ADAM-type metalloprotease	1 . . . 924	477/955 (49%)	0.0
	MDTS4, SEQ ID NO: 4 - Homo	19 . . . 949	631/955 (65%)
	sapiens, 950 aa. [JP2001017183-A,
	23-JAN-2001]
AAB50011	Protein; SEQ ID 125 - Homo sapiens,	1 . . . 924	477/955 (49%)	0.0
	968 aa. [WO200071577-A1,	37 . . . 967	631/955 (65%)
	30-NOV-2000]
AAB50002	Human METH1 - Homo sapiens, 950	1 . . . 924	477/955 (49%)	0.0
	aa. [WO200071577-A1, 30-NOV-2000]	19 . . . 949	631/955 (65%)

[0344] In a BLAST search of public sequence databases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5E.

TABLE 5E
Public BLASTP Results for NOV5a
		NOV5a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9UH18	ADAMTS-1 precursor (EC 3.4.24.-) (A	1 . . . 924	477/955 (49%)	0.0
	disintegrin and metalloproteinase with	36 . . . 966	631/955 (65%)
	thrombospondin motifs 1)
	(ADAM-TS 1)
	(ADAM-TS1) (METH-1) -
	Homo sapiens (Human), 967 aa.
T00017	gene ADAMTS-1 protein - mouse,	1 . . . 924	478/953 (50%)	0.0
	951 aa.	20 . . . 950	636/953 (66%)
P97857	ADAM-TS 1 precursor (EC 3.4.24.-) (A	1 . . . 924	478/953 (50%)	0.0
	disintegrin and metalloproteinase with	37 . . . 967	636/953 (66%)
	thrombospondin motifs 1)
	(ADAMTS-1)
	(ADAM-TS1) - Mus musculus (Mouse),
	968 aa.
Q9WUQ1	ADAMTS-1 precursor (EC 3.4.24.-) (A	1 . . . 924	472/952 (49%)	0.0
	disintegrin and metalloproteinase with	37 . . . 966	638/952 (66%)
	thrombospondin motifs 1)
	(ADAM-TS 1)
	(ADAM-TS 1) - Rattus
	norvegicus (Rat), 967 aa.
Q9UP79	ADAMTS-8 precursor (EC 3.4.24.-) (A	1 . . . 869	423/902 (46%)	0.0
	disintegrin and metalloproteinase with	16 . . . 889	569/902 (62%)
	thrombospondin motifs 8)
	(ADAM-TS 8)
	(ADAM-TS8) (METH-2) (METH-8) —
	Homo sapiens (Human), 890 aa.

[0345] PFam analysis indicates that the NOV5a protein contains the domains shown in the Table 5F.

TABLE 5F
Domain Analysis of NOV5a
		Identities/
		Similarities
	NOV5a Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
Pep_M12B_propep:	67 . . . 181	30/120 (25%)	2.3e−06
domain 1 of 1		69/120 (58%)
Reprolysin: domain 1 of 1	218 . . . 427	69/226 (31%)	7.4e−09
		135/226 (60%)
tsp_1: domain 1 of 3	523 . . . 573	19/54 (35%)	1.5e−07
		32/54 (59%)
tsp_1: domain 2 of 3	817 . . . 868	16/55 (29%)	0.042
		29/55 (53%)
tsp_1: domain 3 of 3	871 . . . 924	16/61 (26%)	0.0017
		36/61 (59%)

Example 6

[0346] The NOV6 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 6A.

TABLE 6A
NOV6 Sequence Analysis
	SEQ ID NO: 39	j2633 bp
NOV6a,	ATTTTCTAACACATTTCTACAATATAATGCATTGTGGATTACTTCATATTGACCAGGA
CG59197-01 DNA
Sequence	TATTGTCAATACAATCATCAAACACTGCTCACCTCAATTTTTTTCACTTGGTTTGCCT
	GGTGCCACAATGCTTATTATGGATTTTATTGTAGCAGCTGGTAGAGTGGCTTCTTCAG
	CTTTTCTCAATGCACCAAGAGTAGAAGCACAAGTTCTTCTOGGATCTTTGGTTTGCTT
	TCCCAACTTATATTGTGAACTGCCTTCTCTTCATCCCAACATTCCTGATGTTGCTGTG
	TCTCAGTTTACAGATGTTAAGGAACTTATAATCAAAACTGTATTAAGCTCGGCAAGAG
	ATGAGCCCTCTGGTCCTCCACGGTGTGTAGCACTTTGTAGTTTAGGTATTTGGATTTG
	TGAAGAACTAGTCCATGAGTCTCATCATCCTCAAATTAAGGAAGCTCTGAATGTGATT
	TGTGTTTCCTTAAAGTTTACTAATAAAAACAGTAGCCCACGTAGCTTGTAACATGCTTC
	ACATGCTGGTTCATTATGTACCTAGACTTCAGATTTACCAGCCTGATTCTCCCTTCAA
	AATTATTCAAATCCTAATAGCTACCATCACCCATCTTTTACCAAGTACAGAGGCTTCA
	TCTTATGAAATGGACAAGAGGTTGCTACTATCTTTACTTCTCTGCCTTCTGGACTGGA
	TCATGGCCTTACCTCTAAGACACTGCTCCAACCATTTCATGCTACGGGAGCAGAAAG
	CGATAAAACAGAAAAATCTGTTCTCAATTGCATTTATAAGGTATTACATGGGTGTGTT
	TATGGAGCTCAGTGTTTTAGCAATCCAAGGTATTTTCCCATCAGCCTCTCTGATTTGG
	CATCTCTACATTATGATCCTTTTATGCATTTGGAAAGTCTGAAAAGAGCCTGAGCCTCT
	GCACTCTCCTGACTCAGAACGATCTTCTAACTCCAGCCAGTAACAGAAGTGATAAACT
	CAAATGCAGCATGGATTAATCTCTATAGCAGCCCGCACTGTTATTACACATCTGGTA
	ATCACCTGGGCCATTATCCAATGAGCGGTGGTCCTGCTATGCTAACAAGTCAGGTGTG
	TGAAAATCACGACAATCATTACAGTGAGTACTCAACTTTCTCCTGAACTCTTTGAG
	AGTCCAAATATCCAGTTCTTTGTGTTAAATAATACAACCTTAGTGTCCTGTATCCAGA
	TCAGATCAGAAGAGAATATGCCTGGAGGAGGTTTATCTCCTGGCCTTGCATCAGCCAA
	TTCAAATGTCAGAATCATAGTACGTGATCTCTCTGGAAAATATTCATGGGATTCTGCT
	ATACTCTATGGCCCACCTCCTGTAAGTGGCTTGTCAGAACCTACATCTTTCATGCTTT
	CATTGTCTCACCAAGAGAAGCCAGAACAGCCTCCGACATCTAATGAATGCTTAGAAGA
	TATAACCGTAAAAGATGCACTTTCTCTCCAGTTTAAAAGATTTAGAGAAACTGTACCA
	ACTTGGGATACAATAAGAGATGAAGAAGATGTTCTTGATGAGCTCTTGCAGTATTTGG
	GTGTTACTACTCCTGAATGCTTACAGAGAACTGGAATCTCACTTAATATTCCTGCTCC
	ACAACCTGTGTGCATTTCTGAAAAACAAGAAAATGATGTTATTAATGCTATCCTTAAG
	CAACATACAGAAGAAAAAGAATTTGTTGAGAAGCACTTTAATGACTTAAACATGAAAG
	CTGTGGAACAAGATGAACCAATACCTCAAAAACCTCAGTCAGCATTTTATTATTGCAG
	ATTGCTTCTTAGTATATTGGGAATGAATTCCTGGGACAAACGGAGGAGCTTTCATCTC
	CTGAAGAAAAATGAAAAGCTACTTAGAGAACTTAGGAACTTGGATTCAAGGCAGTGGC
	GAGAGACACACAAGATTGCAGTATTTTATGTTGCTGAAGGACAAGAAGACAAACACTC
	CATTCTCACCAATACAGGAGGAAGTCAAGCATATGAAGATTTTCTAGCTGGTCTTGGT
	TGGGAGGTAAATCTTACAAACCATTGTGGTTTTATGGCACCACTACAAAAAAACAAAA
	GCACTGGATTGACCACTCCATATTTTGCTACCTCTACAGTAGAGGTAATATTTCACGT
	GTCAACAAGAATGCCTTCTGATTCTGATGATTCTTTGACCAAAAAATTGAGACATTTG
	GGAAATGATGAAGTGCACATTGTTTGGTCAGAGCATACTAGAGACTACAGGAGAGGAA
	TTATTCCCACAGAATTTGGTGATGTCCTTATTCTAATATATCCAATGAAAAATCACAT
	GTTCAGTATTCAGATAATGAAAAAACCAGAGGTACCCTTCTTTGGTCCCCTTTTTGAT
	GGTGCTATTGTGAATGCAAAGGTTCTACCCATTATGGTTAGAGCAACAGCTATAAATG
	CAAGCCGTGCTCTGAAATCTCTGATTCCATTGTATCAAAACTTGTATGAGGAGAGAGC
	ACGATACCTGCAAACAATTGTCCAGCACCACTTAGAACCACAACATTTGAAGATTTT
	GCAGCACAGGTTTTTTCTCCAGCTCCCTACCACCATTTACCATCTGATGCCGCTAAGA
	TTAAAAGCGAGTATTAGTTACTT
	ORF Start: ATG at 27	ORF Stop: TAG at 2625
	SEQ ID NO: 40	1866 aa	MW at 97197.4kD
NOV6a,	MHCGLLHIDQDIVNTIIKHCSPQFFSLGLPGATMLIMDFIVAAGRVASSAFLNAPRVE
CG59197-01 Protein
Sequence	AQVLLGSLVCFPNLYCELPSLHPNIPDVAVSQFTDVKELIIKTVLSSARDEPSGPARC
	VALCSLGIWICEELVHESHHPQIKEALNVICVSLKFTNKTVAHVACNMLHMLVHYVPR
	LQIYQPDSPLKIIQILIATITHLLPSTEASSYEMDKRLVVSLLLCLLDWIMALPLKTL
	LQPFHATGAESDKTEKSVLNCIYKVLHGCVYGAQCFSNPRYFPMSLSDLASVDYDPFM
	HLESLKEPEPLHSPDSERSSKLQPVTEVKTQMQHGLISIAARTVITHLVNHLGHYPMS
	GGPAMLTSQVCENHDNHYSESTELSPELFESPNIQFFVLNNTTLVSCIQIRSEENMPG
	GGLSAGLASANSNVRIIVRDLSCKYSWDSAILYGPPPVSGLSEPTSFMLSLSHQEKPE
	EPPTSNECLEDITVKDGLSLQFKRFRETVPTWDTIRDEEDVLDELLQYLGVTSPECLQ
	RTGISLNIPAPQPVCISEKQENDVINAILKQHTEEKEFVEKHFNDLNMKAVEQDEPIP
	QKPQSAFYYCRLLLSILGMNSWDKRRSPHLLKKNEKLLRELRNLDSRQWRETHKIAVF
	YVAEGQEDKRSILTNTGGSQAYEDFVAGLGWEVNLTNHCGFMGGLQKNKSTGLTTPYF
	ATSTVEVIFHVSTRMPSDSDDSLTKKLRHLGADEVHIVWSEHTRDYRRGIIPTEFGDV
	LIVIYPMKNHMFSIQIMKKPEVPFFGPLFDGAIVNGKVLPIMVRATAINASRALKSLI
	PLYQNLYEERARYLQTIVQHHLEPTTFEDFAAQVFSPAPYHHLPSDAGKIKSEY
	SEQ ID NO: 41	1923 bp
NOV6b,	GGATCCAAGACACTGCTCCAACCATTTCATGCTACGGGAGCAGAAAGCGATAAACAG
188822075 DNA
Sequence	AAAAATCTGTTCTCAATTGCATTTATAAGGTTTTACATGGGTGTGTTTATGGAGCTCA
	GTGTTTTAGCAATCCAAGGTATTTTCCCATGAGCCTCTCTGATTTGGCATCTGTAGAT
	TATGATCCTTTTATGCATTTGGAAAGTCTGAAAGAGCCTGAGCCTCTGCACTCTCCTG
	ACTCAGAACGATCTTCTAAACTCCAGCCAGTAACAGAAGTGAAAACTCAAATGCAGCA
	TGGATTAATCTCTATAGCAGCCCGCACTGTTATTACACATCTGGTAAATCACCTGGGC
	CATTATCCAATGAGCGGTGGTCCTGCTATGCTAACAAGTCAGGTGTGTGAAAATCACG
	ACAATCATTACAGTGAAAGTACTGAACTTTCTCCTGAACTCTTTGAGAGTCCAAATAT
	CCAGTTCTTTGTGTTAAATAATACAACCTTAGTGTCCTGTATCCAGATCAGATCAGA
	GAGAATATGCCTGGAGGAGGTTTATCTGCTGGCCTTGCATCAGCCAATTCAAATGTCA
	GAATCATAGTACGTGATCTCTCTGGAAAATATTCATGGGATTCTGCTATACTGTATGG
	CCCACCTCCTGTAAGTGGCTTGTCACAACCTACATCTTTCATGCTTTCATTGTCTCAC
	CAAGAGAAGCCAGAAGAGCCTCCGACATCTAATGAATGCTTAGAAGATATACCGTAA
	AAGATGGACTTTCTCTCCAGTTTAAAAGATTTAGAGAAACTGTACCAACTTGGGATAC
	AATAAGAGATGAAGAAGATGTTCTTGATGAGCTCTTGCAGTATTTGGGTGTTACTAGT
	CCTGATGCTTACAGAGAACTGGAATCTCACTTAATATTCCTGCTCCACAACCTGTGT
	GCATTTCTGAAAAACAAGAAAATGATGTTATTAATGCTATCCTTAAGCAACATACAGA
	AGAAAAGAATTTGTTGAGAAGCACTTTAATGACTTAACATGAAAGCTGTCCAACAA
	GATGAACCAATACCTCAAAAACCTCAGTCAGCATTTTATTATTGCAGATTGCTTCTTA
	GTATATTGGGAATGAATTCCTGGGACAAACGGAGGAGCTTTCATCTCCTGAAGAAAAAA
	TGAAAAGCTACTTAGAGAACTTAGGAACTTGGATTCAAGGCAGTGCCGAGAGACACAC
	AGATTGCAGTATTTTATGTTGCTGAGGACAACAAGACAAACACTCCATTCTCACCA
	ATACAGGAGGAAGTCAAGCATATGAAGATTTTGTAGCTGCTCTTCGTTGGGACCTA
	TCTTACAAACCATTGTGGTTTTATGGGAGGACTACAAAAAAACAAAAGCACTGGATTG
	ACCACTCCATATTTTGCTACCTCTACAGTAGAGGTAATATTTCACGTGTCAACAGAA
	TGCCTTCTGATTCTGATGATTCTTTGACCAAAAAATTGAGACATTTGGGAAATGATGA
	AGTGCACATTGTTTGGTCAGAGCATACTAGAGACTACAGGAGAGGAATTATTCCCACA
	GAATTTGGTGATGTCCTTATTGTAATATATCCAATGAAAAATCACATGTTCAGTATTC
	AGATAATGAIAAAAACCAGAGGTTCCCTTCTTTGGTCCCCTTTTTGATGGTGCTATTT
	GAATGGAAGGTTCTACCCATTATGGTTAGAGCAACAGCTATAAATGCAAGCCGTGCT
	CTGAAATCTCTGATTCCATTCATATCAAACTTCTATGAGGAGAGAGCCGATACCTGC
	AAACAATTGTCCAGCACCACTTAGAACCAACAACATTTGAAGATTTTGCAGCACAGGT
	TTTTTCTCCAGCTCCCTACCACCATTTACCATCTGATGCCGGTAAGATTAAAAGCGAG
	TATCTCGAG
	ORF Start: OGA at 1	ORF Stop: 47 at 1924
	SEQ ID NO: 42	641 aa	MW at 72273.2kD
NOV6b,	GSKTLLQPFHATGAESDKTEKSVLNCIYKVLHGCVYGAQCFSNPRYFPMSLSDLASVD
188822075 Protein
Sequence	YDPFMHLESLKEPEPLHSPDSERSSKLQPVTEVKTQMQHGLISIARTVITHLAAAHLG
	HYPMSGGPANLTSQCENDNHYSESTELSPELFESPNIQFFVLNNTTLVSCIQIRSE
	ENMPGGGLSAGLASANSNVRHVRDLSGKYSWDSAILYGPPPVSGLSEPTSFMLSLSH
	QEKPEEPPTSNECLEDITVKDGLSLQFKRFRETVPTWDTIRDEEDVLDELLQYLGVTS
	PECLQRTGISLNIPAPQPVCISEKQENDVINAILKQHTEEKEFVEKHFNDLNNKAVEQ
	DEPIPQKPQSAFYYCRLLLSILGMNSWDKRRSFHLLKKNEKLLRELRNLDSRQCRETH
	KIAVFYVAEGQEDKHSILTNTGGSQAYEDFVAGLGWEVNLTNHCGFMGOLQKNKSTGL
	TTPYFATSTVEVIFHVSTRMPSDSDDSLTKKLRHLGNDEVHIVWSEHTRDYRRGIIPT
	EFGDVLIVIYPMKNHMFSIQIMKKPEVPFPGPLFDGAIVNCKVLPIMVAATAINASRA
	LKSLIPLYQNFYEERARYLQTIVQHHLEPTTFEDFAAQVFSPAPYHHLPSDAGKIKSE
	YLE

[0347] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 6B.

TABLE 6B
Comparison of NOV6a against NOV6b and NOV6c.
	NOV6a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV6b	230 . . . 866	606/637 (95%)
	3 . . . 639	606/637 (95%)

[0348] Further analysis of the NOV6a protein yielded the following properties shown in Table 6C.

TABLE 6C
Protein Sequence Properties NOV6a
PSort     0.7900 probability located in plasma membrane; 0.3000
analysis: probability located in microbody (peroxisome); 0.3000
          probability located in Golgi body; 0.2000
          probability located in endoplasmic reticulum (membrane)
SignalP   No Known Signal Sequence Indicated
analysis:

[0349] A search of the NOV6protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6D.

TABLE 6D
Geneseq Results for NOV6a
		NOV6a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent#, Date]	Residues	Region	Value
AAB41763	Human ORFX ORF1527 polypeptide	445 . . . 859	410/415 (98%)	0.0
	sequence SEQ ID NO: 3054 - Homo	1 . . . 415	410/415 (98%)
	sapiens, 417 aa. [WO200058473-A2,
	05-OCT-2000]
AAB93704	Human protein sequence SEQ ID	177 . . . 864	389/693 (56%)	0.0
	NO: 13287 - Homo sapiens, 704 aa.	1 . . . 658	491/693 (70%)
	[EP 1074617-A2, 07-FEB-2001]
AAB95195	Human protein sequence SEQ ID	599 . . . 819	186/221 (84%)	e−107
	NO: 17282 - Homo sapiens, 227 aa.	1 . . . 221	203/221 (91%)
	[EP1074617-A2, 07-FEB-2001]
AAR77223	Tuberous sclerosis 2 TSC2 gene	610 . . . 857	70/260 (26%)	3e−20
	product - Homo sapiens, 1784 aa.	1497 . . . 1755	128/260 (48%)
	[WO9518226-A, 06-JUL-1995]
AAW95629	Homo sapiens secreted protein gene	616 . . . 781	50/172 (29%)	1e−14
	clone gm196_4 - Homo sapiens,	17 . . . 188	89/172 (51%)
	322 aa. [WO9856805-A1,
	17-DEC-1998]

[0350] In a BLAST search of public sequence databases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6E.

TABLE 6E
Public BLASTP Results for NOV6a
Protein		NOV6a	Identities/
Accession		Residues/	Similarities for	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
O55008	TULIP 2 - Rattus norvegicus (Rat),	1 . . . 865	815/865 (94%)	0.0
	866 aa.	1 . . . 865	843/865 (97%)
O55007	TULIP 1 - Rattus norvegicus (Rat),	1 . . . 723	680/723 (94%)	0.0
	747 aa.	1 . . . 723	705/723 (97%)
Q9BQT6	BA287B20.1.1 (KIAA1272 SIMILAR	11 . . . 855	483/852 (56%)	0.0
	TO RAT TULIP PROTEINS 1 AND 2,	1 . . . 817	613/852 (71%)
	ISOFORM 1) - Homo sapiens (Human),
	820 aa (fragment).
Q9ULE8	KIAA1272 PROTEIN - Homo sapiens	1 . . . 817	464/824 (56%)	0.0
	(Human), 1023 aa (fragment).	231 . . . 1019	590/824 (71%)
Q9JMC4	TULIP 1 PROTEIN - Mus musculus	131 . . . 570	407/440 (92%)	0.0
	(Mouse), 446 aa.	7 . . . 446	423/440 (95%)

[0351] PFam analysis indicates that the NOV6a protein contains the domains shown in the Table 6F.

TABLE 6F
Domain Analysis of NOV6a
	NOV6a	Identities/
	Match	Similarities for	Expect
Pfam Domain	Region	the Matched Region	Value
Rap_GAP: domain 1 of 1	650 . . . 829	52/192 (27%)	2.5e−18
		98/192 (51%)

Example 7

[0352] The NOV7 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 7A.

TABLE 7A
NOV7 Sequence Analysis
	SEQ ID NO: 43	570 bp
NOV7a,	CTCATCCCTTTGCGACGTCAATGCGACCACGGGCACCAGGCTTCTCGGCTGGGTAGCT
CG58524-11 DNA
Sequence	CTTTGTCTCCTGCCAGCAGGTGAGCTCTGAGCACAGAATAAAAACCCTTGTCCTGGGC
	TGGCCAACCCCCAGATCCAAGCTTTGCTGTTGTTGTTIAAGGTCTTTCCTGGACTCTGT
	CTACAGCATCTGTTTCTTTCTCTTACAGGCTGTTTTCATGCCAAAGTCACACAGACTC
	CAGGATATTTGGTCAAAGGAAAAGCAAAGGAACAAAGATGTATTGTACCCCCAApAAA
	CGGACATACTTTTGTTTGTTGGTATCAGCAGAATCAGAATAAAGAGTTTATGTTTTTG
	ATTTCCTTTCAGAATGAACAAGTTCTTCAAGAAATCGAGATGCACAAGAGCGATTCT
	CATCTCAATGCCCCAAGAACCCACCCTGCAGCCTGGCAAATCCTGTCCTCGGAACCGGG
	AGACACCGCACTGTATCTCTGTGCCACCAGTCCGTCCACAGCACTGAAAATGTCAGTTC
	CTGTTAGCACACAAACTTGCCACAGACCCAGCTCAGGAGCAGGTGAT
	ORF Start: AAA at 100	ORF Stop: DF at 571
	SEQ ID NO: 44	157aa	MW at 17470.1kD
NOV7a,	KPLSWAGQPPDPSFAVVVKVFPGLCLQHLFLSLTGCFHAKVTQTPGYLVKGKGRKTKM
CG58524-01 Protein
Sequence	YCTPKNGHTFVCWYQQNQNKEFMFLISFQNEQVLQEMEMHKKRFSSQCPKIAPPCSLAI
	LSSEPGDTALYLCATSPSTALKCQFLLAHKLATDPAQEAGD

[0353] Further analysis of the NOV7a protein yielded the following properties shown in Table 7B.

TABLE 7B
Protein Sequence Properties NOV7a
PSort     0.5500 probability located in endoplasmic reticulum
analysis: (membrane); 0.1900 probability located in lysosome (lumen);
          0.1421 probability located in microbody (peroxisome);
          0.1000 probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 40 and 41
analysis:

[0354] A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7C.

TABLE 7C
Geneseq Results for NOV7a
		NOV7a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
ABB25859	Protein #7858 encoded by probe for	36 . . . 155	120/120 (100%)	5e−69
	measuring heart cell gene expression -	1 . . . 120	120/120 (100%)
	Homo sapiens, 120 aa.
	[WO200157274-A2, 09-AUG-2001]
AAM76093	Human bone marrow expressed probe	36 . . . 155	120/120 (100%)	5e−69
	encoded protein SEQ ID NO: 36399 -	1 . . . 120	120/120 (100%)
	Homo sapiens, 120 aa.
	[WO200157276-A2, 09-AUG-2001]
AAM63281	Human brain expressed single exon	36 . . . 155	120/120 (100%)	5e−69
	probe encoded protein SEQ ID NO:	1 . . . 120	120/120 (100%)
	35386 - Homo sapiens, 120 aa.
	[WO200157275-A2, 09-AUG-2001]
AAM36201	Peptide #10238 encoded by probe for	36 . . . 155	120/120 (100%)	5e−69
	measuring placental gene expression -	1 . . . 120	120/120 (100%)
	Homo sapiens, 120 aa.
	[WO200157272-A2, 09-AUG-2001]
AAY80643	Canine TCR V-beta 54 protein, SEQ ID	24 . . . 135	60/112 (53%)	1e−27
	[WO200006732-A2, 10-FEB-2000]	6 . . . 117	75/112 (66%)

[0355] In a BLAST search of public sequence databases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7D.

TABLE 7D
Public BLASTP Results for NOV7a
		NOV7a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
C32578	T-cell receptor beta chain precursor V	14 . . . 132	102/119 (85%)	2e−55
	region (HBVT72) - human, 120 aa.	2 . . . 120	108/119 (90%)
AAD15201	T-CELL RECEPTOR BETA	14 . . . 132	102/119 (85%)	2e−55
	PRECURSOR - Homo sapiens	2 . . . 120	108/119 (90%)
	(Human), 143 aa (fragment).
CAB99345	BA255A11.11 (PUTATIVE NOVEL T	36 . . . 131	96/96 (100%)	3e−54
	CELL RECEPTOR BETA CHAIN V	1 . . . 96	96/96 (100%)
	REGION PROTEIN) - Homo sapiens
	(Human), 96 aa (fragment).
AAA36721	T-CELL RECEPTOR BETA CHAIN -	26 . . . 114	88/89 (98%)	5e−49
	Homo sapiens (Human), 89 aa	1 . . . 89	88/89 (98%)
	(fragment).
CAB35951	TCRBV19S1P PROTEIN - Homo	29 . . . 134	89/106 (83%)	1e−46
	sapiens (Human), 116 aa (fragment).	11 . . . 116	93/106 (86%)

[0356] PFam analysis indicates that the NOV7a protein contains the domains shown in the Table 7E.

TABLE 7E
Domain Analysis of NOV7a
		Identities/
		Similarities
	NOV7a	for the
Pfam Domain	Match Region	Matched Region	Expect Value
ig: domain 1 of 1	53 . . . 131	12/83 (14%)	0.00096
		53/83 (64%)

Example 8

[0357] The NOV8 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 8A.

TABLE 8A
NOV8 Sequence Analysis
	SEQ ID NO:45	1156 bp
NOV8a,	CTAGCGCTCGTACTCCTGGGCTGGGTCTCCTCGTCTTCTCCCACCTCCTCGGCATCCT
CG56512-02 DNA
Sequence	CCTTCTCCTCCTCGGCGCCGTTCCTGGCTTCCGCCGTGTCCGCCCAGCCCCCGCTGCC
	GGACCAGTGCCCCGCGCTGTGCGAGTGCTCCGAGGCAGCGCGCACAGTCAAGTGCGTT
	AACCGCAATCTGACCGAGGTGCCCACGGACCTGCCCGCCTACGTGCGCAACCTCTTCC
	TTACCGGCAACCAGCTGGCCGCGCTCAACCTCAGCGGCAGCCGCCTGGACGAGGTGCG
	CGCGGGCGCCTTCGAGCATCTGCCCAGCCTGCGCCAGCTCGACCTCAGCCACAACCCA
	CTGGCCGACCTCAGTCCCTTCGCTTTCTCGGGCAGCAATGCCAGCGTCTCGGCCCCCA
	GTCCCCTTGTGGAACTGATCCTGAACCACATCGTGCCCCCTGAAGATGAGCGGCAGA
	CCGGAGCTTCGAGGGCATGGTGGTGGCGGCCCTGCTGGCGGGCCGTGCACTGCAGGGG
	CTCCGCCGCTTGGAGCTGGCCAGCAACCACTTCCTTTACCTGCCGCGGGATGTGCTGG
	CCCAACTGCCCAGCCTCAGGCACCTGGACTTAAGTAATAATTCGCTGGTGAGCCTGAC
	CTACGTGTCCTTCCCCAACCTGACACATCTAGAAAGCCTCCACCTGGAGGACAATGCC
	CTCAAGGTCCTTCACAATGGCACCCTGGCTGAGTTGCAAGGTCTACCCCACATTAGGC
	TTTTCCTGGACAACAATCCCTGGGTCTGCGACTGCCACATGGCAGACATGGTGACCTG
	GCTCAAGGAAACAGAGGTAGTGCAGGGCAAAGACCGGCTCACCTGTGCATATCCGGAAA
	AAAATGAGGAATCGGGTCCTCTTGGAACTCAACAGTGCTGACCTGGACTGTGACCCGA
	TTCTTCCCCCATCCCTCACAAACCTCTTATGTCTTCCTGGGTATTGTTTTAGCCCTGAT
	AGGCGCTATTTTCCTCCTGGTTTTGTATTTGAACCGCAAGGGGATAAAAAAGTGGATG
	CATAACATCAGAGATGCCTGCAGGGATCACATGGAACCGTATCATTACAGATATGAAAA
	TCAATGCGGACCCCAGATTAACGAACCTCAGTTCTAACTCGGATGTCTGAGAAA
	ORF Start: CTA at 1	IORF Stop: TGA at 1150
	SEQ ID NO: 46	383 aa	MW at 42319.8kD
NOV8a,	LALVLLGNVSSSSPTSSASSFSSSAPFLASAVSAQPPLPDQCPALCECSEAARTVKCV
CG56512-02 Protein
Sequence	NRNLTEVPTDLPAYVRNLFLTGNQLAALNLSGSRLDEVRAGAFEHLPSLRQLDLSHNP
	LADLSPFAFSGSNASVSAPSPLVELILNHIVPPEDERQNRSFEGMVVAALLAGRALQG
	LRRLELASNIFLYLPRDVLAQLPSLRHLDLSNNSLVSLTYVSFRNLTHLESLHLEDNA
	LKVLHNGTLAELQGLPHIRVFLDNNPWVCDCHMADMVTWLKETEVVQGKDRLTCAYPE
	KNRNRVLLELNSADLDCDPILPPSLQTSYVFLGIVLALIGAIFLLVLYLNRKGIKKWM
	HNIRDACRDHMEGYHYRYEINADPRLTNLSSNSDV

[0358] Further analysis of the NOV8a protein yielded the following properties shown in Table 8B.

TABLE 8B
Protein Sequence Properties NOV8a
PSort     0.4600 probability located in plasma membrane; 0.1000 prob-
analysis: ability located in endoplasmic reticulum (membrane); 0.1000
          probability located in endoplasmic reticulum (lumen); 0.1000
          probability located in outside
SignalP   Cleavage site between residues 19 and 20
analysis:

[0359] A search of the NOV8a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8C.

TABLE 8C
Geneseq Results for NOV8a
		Nov8a	Identities/
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAM93334	Human polypeptide, SEQ ID NO: 2867 -	1 . . . 383	383/400 (95%)	0.0
	Homo sapiens, 420 aa. [EP1130094-	21 . . . 420	383/400 (95%)
	A2, 05-SEP-2001]
AAM93333	Human polypeptide, SEQ ID NO: 2865 -	1 . . . 346	346/363 (95%)	0.0
	Homo sapiens, 383 aa. [EP1130094-	21 . . . 383	346/363 (95%)
	A2, 05-SEP-2001]
AAB83839	Amino acid sequence of canine 5T4	1 . . . 383	333/400 (83%)	0.0
	protein - Canis sp, 420 aa.	21 . . . 420	345/400 (86%)
	[WO200136486-A2, 25-MAY-2001]
AAY94351	Canine 5T4 tumour-associated antigen -	146 . . . 383	215/238 (90%)	e−123
	Canis sp, 238 aa. [WO200029428-A2,	1 . . . 238	221/238 (92%)
	25-MAY-2000]
AAE13006	Human leucine-rich repeat (LRR)	28 . . . 307	94/321 (29%)	2e−20
	family member protein - Homo sapiens,	43 . . . 361	130/321 (40%)
	713 aa. [WO200175105-A2, 11-OCT-
	2001]

[0360] In a BLAST search of public sequence databases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8D.

TABLE 8D
Public BLASTP Results for NOV8a
		NOV8a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q13641	5T4 ONCOFETAL ANTIGEN	1 . . . 383	383/400 (95%)	0.0
	PRECURSOR - Homo sapiens	21 . . . 420	383/400 (95%)
	(Human), 420 aa.
Q9Z0L0	5T4 ONCOFETAL TROPHOBLAST	1 . . . 383	322/407 (79%)	e−179
	GLYCOPROTEIN PRECURSOR -	21 . . . 426	345/407 (84%)
	Mus musculus (Mouse), 426 aa.
Q9QYD9	5T4 ONCOFETAL ANTIGEN	1 . . . 383	318/407 (78%)	e−176
	HOMOLOG - Rattus norvegicus	21 . . . 426	340/407 (83%)
	(Rat), 426 aa.
CAD10322	SEQUENCE 1 FROM PATENT	28 . . . 307	94/321 (29%)	6e−20
	WO0175105 - Homo sapiens	43 . . . 361	130/321 (40%)
	(Human), 713 aa.
Q9VK54	KEK1 PROTEIN - Drosophila	9 . . . 313	83/309 (26%)	1e−19
	melanogaster (Fruit fly), 880 aa.	55 . . . 333	135/309 (42%)

[0361] PFam analysis indicates that the NOV8a protein contains the domains shown in the Table 8E.

TABLE 8E
Domain Analysis of NOV8a
		Identities/
		Similarities
Pfam Domain	NOV8a Match Region	for the Matched Region	Expect Value
LRRNT: domain 1 of 1	41 . . . 70	16/31 (52%)	3.5e−08
		25/31 (81%)
LRR: domain 1 of 5	82 . . . 105	8/25 (32%)	7.1
		19/25 (76%)
LRR: domain 2 of 5	106 . . . 129	10/25 (40%)	0.04
		18/25 (72%)
LRR: domain 3 of 5	174 . . . 197	8/25 (32%)	1.1
		18/25 (72%)
LRR: domain 4 of 5	198 . . . 221	14/25 (56%)	0.0016
		20/25 (80%)
LRR: domain 5 of 5	222 . . . 245	8/25 (32%)	0.36
		20/25 (80%)
LRRCT: domain 1 of 1	257 . . . 308	20/54 (37%)	2.8e−18
		48/54 (89%)

Example 9

[0362] The NOV9 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 9A.

TABLE 9A
NOV9 Sequence Analysis
                   SEQ ID NO:47        958 bp
NOV9a,             AAAACATGGCAGCCAAAGTGTTTGAGTCCACGGGTAAGTTTGGCTTGGCCTTACCTGT
CG58180-01 DNA     TGCACGACTTGGCCTTAGCTGTTGCAGGAGACCTGTGAACTCTGCCTTATATAATGTG
Sequence           GATGTTGGGCACAGAGCTGTCATCTTTGACAGATTCCAGGACAAACAGGACATTGTGG
                   TAGGCGACTCACTTTCTCATCCCATGGGTACAGAAACCAATTATCTTTGCCTTTCTCC
                   ACCACGTAATGTACCAATCATCACTGGTACCAAACATTTACAGAATGTCAATATCACA
                   CTGCGCATCATCTTCCAGCCTGTTGCTAGCCAGCTTCCTCGCATCTTCACCAGCATCG
                   GAGAGGACTATGATGAGCCTGTGCTGACGTACATCACGACCGAGATCCTCAAGTCAGT
                   GGTGGCTCGCTTTGATGCTGGAGAAGTTATCACTCAGAGAGAGCTGGTCTCCAGGCAG
                   CTGAGCAACGACCTTACGGAGCAAGCAGCCACATTTGGGCTCATCCTGGACGACGTGT
                   CCTTGACATATCTGACCTTTGGAAAGGAGTTCACAGAAGCAGTGGAAGCCAAACAGGT
                   GGCTCAGCAGGAAGCAGACAGGGCCAGATTTGTGAAGGAAAAGGCTGAGCAGCAGAAA
                   AAGGCTGAGCAGCAGAAAAAGGTTGAGCAGCAGAAAAAGGCAGCCGTGATCTCTGCTG
                   AGGGCGACTCCAAGGCAACCGAGCTGATTGCCAACTCACTGGCCACCGCGGGGGACGG
                   CCTGATGGAGCTGTGCAAGTTGCAAGCCGCGGAGTCTCGGAACATGACCTACCTGCCG
                   GCGGGGCAGTCCGCTCCTCCGGCTGCCCCATGAGGGCCCACCCTGCCTGCACCTCCGC
                   AGGCTGACTGGGCCACAGCCCCAATGATTCTTAACACTGCCTTACCCCCCTACCCCAG
                   AAATCACTGAAATTTCATAATTGGCTTAAA
                   ORF Start: ATG at 6 ORF Stop: TGA at 843
                   SEQ ID NO:48        279 aa MW at 30368.2 kD
NOV9a,             MAAKVFESTGKFGLALAVAGLGLSCCRRPVNSALYNVDVGHRAVIFDRFQDKQDIVVG
CG58180-01 Protein DSLSHPMGTETNYLCLSPPRNVPIITGSKDLQNVNITLRIIFQPVASQLPRIFTSIGE
Sequence           DYDEPVLTYITTEILKSVVARFDAGEVITQRELVSRQVSNDLTEQAATFGLILDDVSL
                   TYLTFGKEFTEAVEAKQVAQQEAERARFVKEKAEQQKKAEQQKKVEQQKKAAVISAEG
                   DSKATELIANSLATAGDGLMELCKLEAAESRNNTYLPAGQSAPPAAP

[0363] Further analysis of the NOV9a protein yielded the following properties shown in Table 9B.

TABLE 9B
Protein Sequence Properties NOV9a
PSort     0.3700 probability located in outside; 0.1900 probability
analysis: located in lysosome (lumen); 0.1000 probability located in
          endoplasmic reticulum (membrane); 0.1000 probability
          located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 33 and 34
analysis:

[0364] A search of the NOV9a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9C.

TABLE 9C
Geneseq Results for NOV9a
		NOV9a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAG73845	Human colon cancer antigen protein	1 . . . 273	216/284 (76%)	e−104
	SEQ ID NO:4609 - Homo sapiens, 279	8 . . . 272	230/284 (80%)
	aa. [WO200122920-A2, 05-APR-2001]
AAB43874	Human cancer associated protein	1 . . . 273	216/284 (76%)	e−104
	sequence SEQ ID NO:1319 - Homo	8 . . . 272	230/284 (80%)
	sapiens, 279 aa. [WO200055350-A1,
	21-SEP-2000]
AAW54352	Heat shock 27 kD protein and	1 . . . 273	216/284 (76%)	e−104
	prohibitin (admixture) - Homo sapiens,	200 . . . 464	230/284 (80%)
	1998]
AAR42215	Human prohibitin - Homo sapiens, 272	1 . . . 273	216/284 (76%)	e−104
	aa. [JP05271294-A, 19-OCT-1993]	1 . . . 265	230/284 (80%)
AAR13466	Prohibitin - Rattus rattus, 272 aa.	1 . . . 273	215/284 (75%)	e−104
	[US7612674-A, 16-JUL-1991]	1 . . . 265	230/284 (80%)

[0365] In a BLAST search of public sequence databases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9D.

TABLE 9D
Public BLASTP Results for NOV9a
		NOV9a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q96CH8	HYPOTHETICAL 22.1 KDA	65 . . . 262	196/198 (98%)	e−104
	PROTEIN - Homo sapiens (Human),	1 . . . 198	197/198 (98%)
	201 aa.
P35232	Prohibitin - Homo sapiens (Human),	1 . . . 273	216/284 (76%)	e−104
	272 aa.	1 . . . 265	230/284 (80%)
P24142	Prohibitin (B-cell receptor associated	1 . . . 273	215/284 (75%)	e−103
	protein 32) (BAP 32) - Mus musculus	1 . . . 265	230/284 (80%)
	(Mouse), and, 272 aa.
Q9VIZ4	LETHAL (2) 37CC PROTEIN -	1 . . . 273	159/284 (55%)	7e−75
	Drosophila melanogaster (Fruit fly),	1 . . . 265	200/284 (69%)
	276 aa.
Q9BKU4	HYPOTHETICAL 30.0 KDA	1 . . . 272	145/283 (51%)	3e−64
	PROTEIN - Caenorhabditis elegans,	1 . . . 267	188/283 (66%)
	275 aa.

[0366] PFam analysis indicates that the NOV9a protein contains the domains shown in the Table 9E.

TABLE 9E
Domain Analysis of NOV9a
		Identities/
	NOV9a	Similarities for	Expect
Pfam Domain	Match Region	the Matched Region	Value
Band_7: domain 1 of 1	12 . . . 211	46/213 (22%)	1.3e−42
		162/213 (76%)

Example 10

[0367] The NOV10 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 10A.

TABLE 10A
NOV10 Sequence Analysis
                   SEQ ID NO:49          2482 bp
NOV 10a,           CGGCCACATAAOATATTATCTACACAAAAGCTTATTTAGGAATGACCAATGAGCTCAA
CG59 199-01 DNA    CTTAAATTTATTAGAAATCTGATTAGCATTATAAATCAACTGACTTTTAGGAGCATAG
Sequence           GCTTTGGCGCTACAGGGATCTGGCTTGAACCTCATTGAGGCCACTGATTGGTGAGTGA
                   CCTTAAGCAAGTCTCTTTACCTTGTTAGGGCACAATTTCCTCTCGGAATTGTGAAATG
                   GGTTTAATTACACCAGCTTACATCCCAACCATCAGCAAGTCCTCTTGTATGTAACCAT
                   CTCCAACACAGAAAGGGGATCTGCCCATGTTCTACCATCCTCACCTTTCTCCAAGCCA
                   CTACAACCTCTCACAACAGCCTTCCAATTGGTCTCCCTAAACTCTTATCCCCCCTACA
                   CCCCGTTCTCAGTCCTCAGTCCTTGCCCTAGGCTGGTAGCCCACTCCTTGCCCGCCCC
                   CCGCCTTCCTCCCATCTCCCCCTCCTCTCCCCGGCCCCCAGCACCTTCTGCATCCCAG
                   CCTACCTAGCCTACTCCTCCTCTTCCTGGCCCTCTTCCCCAGGCTCCAGGCTGGGGGG
                   TGCTCGCGTCTCCCCTGTAGGCCAGAGCAGCCCCAAGTTCTGGGGGCGGTCGGCCTGC
                   TGCTTTATCCCCATGGCCCTGCCATCACTTCTGCTGTTGGTGGCAGCCCTGGCAGGTG
                   GGGTGCGTCCTCCCGGGGCGCGGAACCTGACGCTGGCGGTGGTGCTGCCAGAACACAA
                   CCTGAGCTATGCCTGGCCCTGCCCACCGGTGGGACCCGCTGTGGCACTAGCTGTGGAG
                   GCTCTGGGCCGGGCACTGCCCGTGGACCTGCGGTTTGTCAGCTCCGAACTGGAAGGCG
                   CCTGCTCTGAGTACCTGGCACCGCTGAGCGCTGTGGACCTCAAGCTGTACCATGACCC
                   CGACCTGCTGTTAGGTCCCGGTTGCGTGTACCCTGCTGCCTCTCTCGCCCGCTTTGCC
                   TCCCACTGGCGCCTTCCCCTGCTGACTGCGGGTGCTGTGGCCTCTGGTTTTTCGGCTA
                   AGAATGACCATTATCGTACCCTGGTTCGCACTGGCCCCTCTGCTCCCAAGCTGGGTGA
                   GTTTGTGGTGACACTACACGGGCACTTCAATTGGACTGCCCGTGCTGCCTTGCTCTAC
                   CTGGATGCTCGCACAGATGACCGGCCTCACTACTTCACCATCGAGGGCGTCTTTGAGG
                   CCCTGCAGGCCAGCAACCTCAGTGTGCAGCACCAGGTGTATGCCCGAGAGCCAGGGGG
                   CCCCGAGCAGGCCACCCACTTCATCCGCGCCAACGGGCGCATTGTGTATATCTGCGGC
                   CCTCTGGAGATGCTGCATGAGATCCTGCTTCAGGCCCAGAGGGAGAATCTGACCAATG
                   GGGATTATGTCTTCTTTTACCTGGATGTCTTTGGGGAGAGTCTCCGTGCAGGCCCCAC
                   AAGTGATACAGGCCGGCCCTGGCAGGACAATCGCACCCGGGAACAGGCCCAGGCCCTC
                   AGAGAGGCCTTTCAGACTGTATTGGTGATCACGTACCGAGAACCCCCAAATCCTGAGT
                   ATCAGGAATTCCAGAATCGTCTGCTGATAAGAGCCCGGGAAGACTTTGGTGTGGAGCT
                   GGCCCCTTCCCTGATGAACCTCATCGCTGGCTGCTTCTATGATGGGATCCTGCTATAT
                   GCTGAAGTCCTGAATGAGACAATACAGGAAGGAGGCACCCGGGAGGATGGACTTCGAA
                   TTGTGGAAAAGATGCAGGGACGAAGATATCACGGAGTAACTGGGCTGGTTGTCATGGA
                   CAAGAACAATGACCGAAATGGTCAACGCCATGCACCAGAAATTGCTCGTATGGCCCTA
                   GCATTACTAGATGCAGTTTCTTCCTTTCGCATCCGCCACCGACCCCATGACCAGCTGA
                   GGCTACGCATAGGGGTCCATACTGGGCCAGTCTGTGCTCGGGTTGTTCGCCTGAAGAT
                   GCCCCGTTATTGTCTTTTTGGAGACACAGTGAACACTGCTTCTCGAATGGAGTCTAAT
                   GGTCAAGCGCTGAAGATCCATGTCTCCTCTACCACCAAGGATGCCCTAGATGAGCTAG
                   GATGCTTCCAGCTAGAGCTTCGGGGGGATGTGGAAATGAAGGGAAAAGGAAAGATGCG
                   AACATACTGGCTCTTAGCAGAGCCGAAAGGACCTCCTGGACTCCTGTAAACCCCCATT
                   CTTTCCAAGTCAGATACTCTTCTGCTGCTGGTACCTGCCTGGGCAATCGCCACCATGT
                   CTGCACACACCAGAAATGGACATTTTCATATGCAATCGAAAACAGCCACAAAAAAACC
                   TACCTTATATGGAAGTTGTAGCCCTCTGCAGCTCAGCCCTGTACATATATCTGTCCCT
                   CTCTGGCTTGGTCCCCTTCCTCCCTACTTTCTGTAAATATCTGTATCTAAACCAGAAT
                   ATTTTGGTCAAATATAAAACAATAATAAAAAAAGTTCTGATGTCAT
                   ORF Start: ATG at 651 ORF Stop: TAA at 2193
                   SEQ ID NO:50          514 aa MW at 56836.4 kD
NOV 10a,           MALPSLLLLVAALAGGVRPPGARNLTLAVVLPEHNLSYAWAWPRVGPAVALAVEALGR
CG59199-01 Protein ALPVDLRFVSSELEGACSEYLAPLSAVDLKLYHDPDLLLGPGCVYPAASVARFASHWR
Sequence           LPLLTAGAVASGFSAKNDHYRTLVRTGPSAPKLGEFVVTLHGHFNWTARAALLYLDAR
                   TDDRPHYFTIEGVFEALQGSNLSVQHQVYAREPGGPEQATHFIRANCRIVYICGPLEM
                   LHEILLQAQRENLTNGDYVFFYLDVFCESLRAGPTSDTGRPWQDNRTREQAQALREAF
                   QTVLVITYREPPNPEYQEFQNRLLIRAREDFGVELGPSLMNLIAGCFYDGILLYAEVL
                   NETIQEGGTREDGLRIVEKMQGRRYHGVTGLVVNDKNNDRNGQRHAPEIARMALALLD
                   AVSSFRIRHRPHDQLRLRIGVHTGPVCAGVVGLKMPRYCLFGDTVNTASRMESNGQAL
                   KIHVSSTTKDALDELGCFQLELRGDVEMKCKGKMRTYWLLGERKGPPGLL

[0368] Further analysis of the NOV10a protein yielded the following properties shown in Table 10B.

TABLE 10B
Protein Sequence Properties NOV10a
PSort     0.8650 probability located in lysosome (lumen); 0.5517 prob-
analysis: ability located in outside; 0.1000 probability located in
          endoplasmic reticulum (membrane); 0.1000 probability
          located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 17 and 18
analysis:

[0369] A search of the NOV10a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 10C.

TABLE 10C
Geneseq Results for NOV10a
		NOV10a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAR10867	NPRB (Pro655, Glu656, Leu663,	1 . . . 388	386/388 (99%)	0.0
	Phe664, Ala682) - Homo sapiens, 1047	1 . . . 388	386/388 (99%)
	aa. [WO9100292-A, 10-JAN-1991]
AAR10399	Human Natriuretic Peptide Receptor B -	1 . . . 388	386/388 (99%)	0.0
	Homo sapiens, 1047 aa. [WO9100292-	1 . . . 388	386/388 (99%)
	A, 10-JAN-1991]
AAR38863	GC-B - Rattus rattus, 1025 aa.	23 . . . 388	352/366 (96%)	0.0
	[US5237051-A, 17-AUG-1993]	1 . . . 366	357/366 (97%)
AAR38862	GC-A - Rattus rattus, 1029 aa.	24 . . . 389	169/377 (44%)	7e−83
	[US5237051-A, 17-AUG-1993]	2 . . . 373	227/377 (59%)
ABB11783	Human ANP-A receptor homologue,	6 . . . 388	171/397 (43%)	2e−79
	SEQ ID NO:2153 - Homo sapiens,	30 . . . 418	227/397 (57%)
	1075 aa. [WO200157188-A2, 09-AUG-
	2001]

[0370] In a BLAST search of public sequence databases, the NOV10a protein was found to have homology to the proteins shown in the BLASTP data in Table 10D.

TABLE 10D
Public BLASTP Results for NOV10a
		NOV10a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
P20594	Atrial natriuretic peptide receptor B	1 . . . 388	386/388 (99%)	0.0
	precursor (ANP-B) (ANPRB) (GC-B)	1 . . . 388	386/388 (99%)
	(Guanylate cyclase) (EC 4.6.1.2) (NPR-B)
	(Atrial natriuretic peptide B-type receptor) -
	Homo sapiens (Human), 1047 aa.
P16067	Atrial natriuretic peptide receptor B	1 . . . 388	376/388 (96%)	0.0
	precursor (ANP-B) (ANPRB) (GC-B)	1 . . . 388	382/388 (97%)
	(Guanylate cyclase) (EC 4.6.1.2) (NPR-B)
	(Atrial natriuretic peptide B-type receptor) -
	Rattus norvegicus (Rat), 1047 aa.
P46197	Atrial natriuretic peptide receptor B	1 . . . 388	376/388 (96%)	0.0
	precursor (ANP-B) (ANPRB) (GC-B)	1 . . . 388	381/388 (97%)
	(Guanylate cyclase) (EC 4.6.1.2) (NPR-B)
	(Atrial natriuretic peptide B-type receptor) -
	Bos taurus (Bovine), 1047 aa.
Q9PWG9	GUANYLYL CYCLASE-2 - Xenopus	25 . . . 389	233/372 (62%)	e−133
	laevis (African clawed frog), 1082 aa.	59 . . . 425	291/372 (77%)
Q9Y117	C-TYPE NATRIURETIC PEPTIDE	6 . . . 389	197/395 (49%)	e−105
	RECEPTOR PRECURSOR - Squalus	8 . . . 398	258/395 (64%)
	acanthias (Spiny dogfish), 1056 aa.

[0371] PFam analysis indicates that the NOV10a protein contains the domains shown in the Table 10E.

TABLE 10E
Domain Analysis of NOV10a
		Identities/
		Similarities
	NOV10a	for the
	Match	Matched	Expect
Pfam Domain	Region	Region	Value
ANF_receptor: domain 1 of 1	21 . . . 391	121/427 (28%)	5.9e−123
		322/427 (75%)
guanylate_cyc: domain 1 of 1	376 . . . 505	65/157 (41%)	6.8e−54
		110/157 (70%)

Example 11

[0372] The NOV11 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 11A.

TABLE 11A
NOV11 Sequence Analysis
                   SEQ ID NO:51         2372 bp
NOV11a,            TCCCATTTGACTCCATTTTCTTTGGTCAAAGGCTTCCTTATTCATGGGACCTGCCTGG
CG59249-01 DNA     GTCCAGGACCCCTTGACAGGTGCTCTCTGGCTGCCTGTCCTCTGGGCACTCTTGTCCC
Sequence           AGGTCTATTGTTTTCATGACCCACCAGGATGGCGCTTCACTTCCTCAGAAATTGTGAT
                   CCCCAGGAAAGTGCCCCACAAGAGGGGTGGAGTTGAGATGCCAGACCAGCTCTcTTAC
                   AGCATGCGTTTCCGGGGCCAAAGACACGTGATTCACATGAAGCTCAAGAAGAACATGA
                   TGCCCAGACATTTACCTGTTTTTACTGATAATGACCAAGGGGCCATGCAGGAGAACTA
                   CCCTTTTGTCCCACGAGACTGTTACTATGACTGCTACCTGGAAGGGGTTCCTGGGTCT
                   AGCATGCGTTTCCGGGGCCAAAGACACGTGATTCACATGAAGCTCAAGAAGAACATGA
                   TGACTTACGAAATCAAACACCTGGAGGCTTCTTCCAAATTTGAGCATGTAGTATCTCT
                   GCTTGTGTCAGAAGAAAGACCAGGAGAGGCTAGTAGATGTAAGACTGAAGGGCAAGAG
                   ATAGATCAAGAATCTGAAAAGGTAAAACTGGCTGAAACTCCCAGAGCAGGCCACGTTT
                   ATTTGTGGACGCATCATAGAAAAAACTTGAAAATTCACTACACGGTTACTCGTGGATT
                   ATTCATGCGGAACCCTAATGTGTCACATATAATAGAGAATGTAGTGATTATTAACAGC
                   ATCATACATACCATTTTCAAACCAGTTTATTTAAATGTCTATATATGTGTTTTGTGCA
                   TATGGAATCAAAAGGATGCACTACTATTTTCTGCTAGCAGGCCAGGCCACGTTGCTGT
                   AGAACTGTTTGGTGTGTCGAAATATCACAATTTGTATTCACAAATTTCACATGATACC
                   TCAGTTGTTTTTACATCAAATCGACTTGGAAACAGTGAGTGTTATGCCAGCTTTGATG
                   GAATATGCACCCCCAACTGGGGAGCAATGTTTGTGTATATAATGAGGTATCACCTATT
                   TAGGGGGGCATGTGTTACAGCACATGCACTAGGTCATAACATGGGCTTGAGACATGAT
                   TCTGTTGGTTGTTATTGTTTTCGACGAACCAACTGTCTCATGAGCAATTGTTCTTATG
                   AGATAATTCAACGCAAGTTTAATCAATGGGATCCTTGTTTGAGTGCTCCAAATGTTCC
                   ATACACTAATTTTCCATACGTAGCTCCTCGTTGTGGAGACAAGATCAAAAATCAGAGG
                   GAAGAATGTGACTGTGGCTCCCTTAAAGATTGTGCCAGTGATAGATGTTGTGAGACCT
                   CTTGTACCCTTTCTCTTGGCAGTGTTTGCAATACAGGACTTTGCTGCCATAAGTGTAA
                   ATATGCTGCCCCTGGAGTGGTTTGCAGAGACTTGGGTGGTATATGTGATCTACCGGAA
                   TACTGTGATGGGAAAAAGGAAGAGTGTCCAAATGACATCTACATCCAGGATGGAACCC
                   CATGTTCAGCAGTATCTGTTTGTATAACAGGAAACTGCAGTGACCGTGATATGCAGTG
                   TCAAGCCCTTTTTGGCTACCAAGTGAAACACCGTTCCCCAGCGTGCTATCGAAAATTG
                   AATAGGATTGGTAACCGATTTGGAAACTGTGGGGTTATTCTACGGCGACCGGGAAGTA
                   CACCTTTTCCATGTGAAGAAGATGATGTTTTTTGTGGAATGTTGCACTGTAGCGGTGT
                   CAGCCACATTCCCGGTGGAGGTGAGCACACTACATTTTGTAATATATTAGTACACGAC
                   ATAAAAGAAGAAAAATGCTTTGGCTATGAAGCACACCAGGGGACAGACTTGCCAGAAA
                   TGGGGCTGGTAGTGGATGGTGCAACCTGTGGCCCAGGGAGCTACTGTCTTAAACGCAA
                   TTGTACTTTTTATCAAGACCTGCATTTTGAGTGTGATCTTAAAACATGCAATTACAAA
                   GGAGTATGTAACAACAAAAAACATTGTCATTGTCTGCATGAGTGGCAACCACCAACAT
                   GTGAACTGAGAGGAAAAGGAGGTAGTATAGATAGTGGCCCTCTACCTGACAAACAATA
                   TCGTATTGCAGGCAGCATACTTGTAAATACAAACCGAGCACTAGTTTTAATATGTATT
                   CGTTACATCCTTTTTGTGGTTTCGCTTCTCTTTGGTGGCTTTTCACAAGCAATACAAT
                   GTTAGGGAAGAGAAAGCAAAAGAGCCCACACAATGGAGTAAATTACATTGACACTTAC
                   TGGCAGATATAATCAATAGTCACTCTGACAATTACATCATCTTTTAGCAATTCTCATG
                   TCATCTTGAAATAAAATCACTTGGCAATTTAAAAAGGTCTGTGTGTTTAAAT
                   ORF Start: ATG at 44 ORF Stop: TAG at 2207
                   SEQ ID NO:52         721 aa MW at 81098.2 kD
NOV11a,            MGPAWVQDPLTGALWLPVLWALLSQVYCFHDPPGWRFTSSEIVIPRKVPHKRGGVEMP
CG59249-01 Protein DQLSYSMRFRGQRHVIHMKLKKNMMPRHLPVFTDNDQGANQENYPFVPRDCYYDCYLE
Sequence           GVPGSAATLDTCRGGLHGMLQVDDLTYEIKHLEASSKFEHVVSLLVSEERPGEASRCK
                   TEGEEIDQESEKVKLAETPRAGHVYLWRHHRKNLKIHYTVTRGLFMRNPNVSHIIENV
                   ISHDTSVVFTSNRLGNSECYASFDGICTPNWGANFVYIMRYHLFRGACVTAHALGHNM
                   GLRHDSVGCYCFRRTNCLMSNCSYEIIQRKFNQWDPCLSAPNVPYTNFPYVAPRCGDK
                   IKNQREECDCGSLKDCASDRCCETSCTLSLGSVCNTGLCCHKCKYAAPGVVCRDLGGI
                   CDLPEYCDGKKEECPMDTYIQDGTPCSAVSVCIRCNCSDRDMQCQALFGYQVKDGSPA
                   CYRKLNRIGNRFGNCGVILRRGGSRPFPCEEDDVFCGMLHCSGVSHIPGGGEHTTFCN
                   ILVHDIKEEKCFGYEAHQGTDLPEMGLVVDGATCGPGSYCLKRNCTFYQDLHFECDLK
                   TCNYKGVCNNKKHCHCLHEWQPPTCELRGKGGSIDSGPLPDKQYRIAGSILVNTNRAL
                   VLICIRYILFVVSLLFGGFSQAIQC
                   SEQ ID NO:53         2429 bp
NOV11b,            TCCCATTTGACTGCATTTTCTTTGGTCAAAGGCTTCCTTATTCATGGGACCTGCCTGG
CG59249-02 DNA     GTCCAGGACCCCTTGACAGGTGCTCTCTGGCTGCCTGTCCTCTGGGCACTCTTGTCCC
Sequence           AGGTCTATTGTTTTCATGACCCACCAGGATGGCGCTTCACTTCCTCAGAAATTGTGAT
                   CCCCAGGAAAGTGCCCCACAAGAGGGGTGGAGTTGAGATGCCAGACCAGCTCTCTTAC
                   AGCATGCGTTTCCGGGGCCAAAGACACGTGATTCACATGAAGCTCAAGAAGAACATGA
                   TGCCCAGACATTTACCTGTTTTTACTGATAATGACCAAGGGGCCATGCAGGAGAACTA
                   CCCTTTTGTCCCACCACACTCTTACTATGACTGCTACCTGGAAGGGGTTCCTGGGTCT
                   GCGGCCACATTGGACACCTGCCGTGGAGGTCTGCATGGCATGCTGCAGCTGGATGACT
                   TGACTTACGAAATCAAACCCCTGGAGGCTTCTTCCAAATTTGAGCATGTAGTATCTCT
                   GCTTGTGTCAGAAGAAACACCAGGAGAGGCTAGTGGATGTATGACTGAAGGGGAAGAG
                   ATAGATCAAGAATCTGAAAAGGTAAAACTGGCTGAAACTCCCAGAGCAGGCCACGTTT
                   ATTTGTGGAGGCATCATAGAAAAAACTTGAAAATTCACTACACGGTTACTCGTGGATT
                   ATTCATGCGGAACCCTAATGTGTCACATATAATAGAGAATGTAGTGATTATTAACAGC
                   ATCATACATACCATTTTCAAACCAGTTTATTTAAATGTCTATATATGTGTTTTGTGCA
                   TATGGAATCAAAAGGATGCAGTACTATTTTCTGCTAGCAGGCCGGCCCACGTTGCTGT
                   AGAACTGTTTGGTGTGTGGAAATATCACAATTTGTATTCAGAGATTTCACATGATGCC
                   TCAGTTGTTTTTACATCAAATCGACTTGGAAACAGTGAGTGTTATGCCAGCTTTGATG
                   GAATATGCACCCCCAACTGGGGAGCAATGTTTGTGTATATAATGAGGTATCACCTATT
                   TAGGGGGGCATGTCTTACAGCACATGCACTAGGTCATAACATGGGCTTGAGACATGAT
                   TCTGTTGGTTGTTATTGTTTTCGACGAACCAACTATCTCATGGCTCCTGTTCCTGATC
                   TTAATGATATGATGAGCAATTGTTCTTATGAGATAATTCAACGCAAGTTTAATCAATG
                   GGATCCTTGTTTGAGTGCTCCAAATGTTCCATACACTAATTTTCCATACGTAGCTCCT
                   CGTTGTGGAGACAAGATCAAAAATCAGAGGGAAGAATGTGACTGTGGCTCCCTTAAAG
                   ATTGTGCCAGTGATAGATGTTGTGAGACCTCTTGTACCCTTTCTCTTGGCAGTGTTTG
                   CAATACAGGACTTTGCTGCCATAAGTGTAAATATGCTGCCCCTGGAGTGGTTTGCAGA
                   GACTTGGGTGGTATATGTGATCTACCGGAATACTGTGATGGGAAAAAGGAAGAGTGTC
                   CAAATGACATCTACATCCAGGATGGAACCCCATGTTCAGCAGTATCTGTTTGTATAAG
                   AGGAAACTGCAGTGACCGTGATATGCAGTGTCAAGCCCTTTTTGGCTACCAAGTGAAA
                   GACGGTTCCCCAGCGTGCTATCGAAAATTGAATAGGATTGGTAACCGATTTGGAAACT
                   GTGGGGTTATTCTACGGCGAGGGGGAAGTAGACCTTTTCCATGTGAAGAAGATGATGT
                   TTTTTGTGGAATGTTGCACTGTAGCGGTGTCAGCCACATTCCCGGTGGAGGTGAGCAC
                   ACTACATTTTGTAATATATTAGTACACGACATAAAAGAAGAAAAATCCTTTGGCTATG
                   AAGCACACCAGGGGACAGACTTGCCAGAAATGGGGCTGGTAGTGGATGGTGCAACCTG
                   TGGCCCAGGGAGCTACTGTCTTAAACGCAATTGTACTTTTTATCAAGACCTGCATTTT
                   GAGTGTGATCTTAAAACATGCAATTACAAAGGAGTATGTAGCAACAAAAAACATTGTC
                   ATTGTCTGCATGAGTGGCAACCACCAACATGTGAACTGAGAGGAAAAGGAGGTAGTAT
                   AGATAGTCGCCCTCTACCTGACAAACAATATCGTATTGCAGGCAGCATACTTGTAAAT
                   ACAAACCGAGCACTAGTTTTAATATGTATTCGTTACATCCTTTTTGTGGTTTCGCTTC
                   TCTTTGGTGGCTTTTCACAAGCAATACAATGTTAGGGAAGAGAAAGGAAAAGAGCCCA
                   CACAATGGAGTAAATTACATTGACACTTACTGGGAGATATAATCAATAGTCACTCTGA
                   CAATTACATCATCTTTTAGCAATTCTGATGTCATCTTGAAATAAAATCACTTGGCAAT
                   TTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGG
                   ORF Start: ATG at 44 ORF Stop: TAG at 2237
                   SEQ ID NO:54         731 aa MW at 82049.3 kD
NOV11b,            MGPAWVQDPLTGALWLPVLWALLSQVYCFHDPPGWRFTSSEIVIPRKVPHKRGGVEMP
CG59249-02 Protein DQLSYSMRFRGQRHVIHMKLKKNMMPRHLPVFTDNDQGAMQENYPFVPRDCYYDCYLE
Sequence           GVPGSAATLDTCRGGLHGMLQVDDLTYEIKPLEASSKFEHVVSLLVSEERPGEASGCM
                   TEGEEIDQESEKVKLAETPRAGHVYLWRHHRKNLKIHYTVTRGLFMRNPNVSHIIENV
                   VIINSIIHTIFKPVYLNVYICVLCIWNQKDAVLFSASRPGHVAVELFGVWKYHNLYSE
                   ISHDASVVFTSNRLGNSECYASFDGICTPNWGAMFVYIMRYHLFRGACVTAHALGHNM
                   GLRHDSVGCYCFRRTNYLMAPVPDLNDMNSNCSYEIIQRKFNQWDPCLSAPNVPYTNF
                   PYVAPRCGDKIKNQREECDCGSLKDCASDRCCETSCTLSLGSVCNTGLCCHKCKYAAP
                   GVVCRDLGGICDLPEYCDGKKEECPNDIYIQDGTPCSAVSVCIRGNCSDRDMQCQALF
                   GYQVKDGSPACYRKLNRIGNRFGNCGVILRRGGSRPFPCEEDDVFCGMLHCSGVSHIP
                   GGGEHTTFCNILVHDIKEEKCFGYEAHQGTDLPEMGLVVDGATCGPGSYCLKRNCTFY
                   QDLHFECDLKTCNYKGVCSNKKHCHCLHEWQPPTCELRGKGGSIDSGPLPDKQYRIAG
                   SILVNTNRALVLICIRYILFVVSLLFGGFSQAIQC

[0373] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 11B.

TABLE 11B
Comparison of NOV11a against NOV11b and NOV11c.
Protein	NOV11a Residues/	Identities/
Sequence	Match Residues	Similarities for the Matched Region
NOV11b	1 . . . 721	698/731 (95%)
	1 . . . 731	699/731 (95%)

[0374] Further analysis of the NOV11a protein yielded the following properties shown in Table 11C.

TABLE 11C
Protein Sequence Properties NOV11a
PSort:    0.8056 probability located in plasma membrane; 0.2800 prob-
analysis: ability located in endoplasmic reticulum (membrane); 0.2000
          probability located in lysosome (membrane); 0.1000
          probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 29 and 30
analysis:

[0375] A search of the NOV11a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11D.

TABLE 11D
Geneseq Results for NOV11a
		NOV11a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAY17413	sapiens, 726 aa. [WO9923228-A1, 14-	33 . . . 714	378/704 (53%)	e−135
	MAY-1999]
AAY03223	Amino acid sequence of the novel	33 . . . 712	250/704 (35%)	e−134
	metalloprotease ADAM 16a - Homo	33 . . . 714	377/704 (53%)
	sapiens, 726 aa. [WO9907856-A1, 18-
	FEB-1999]
AAB07741	A snake venom protease (SVPH-1)	29 . . . 681	250/673 (37%)	e−132
	polypeptide variant SVPH-1c - Homo	27 . . . 671	360/673 (53%)
	sapiens, 820 aa. [WO200043525-A2,
	27-JUL-2000]
AAB07740	A snake venom protease (SVPH-1)	29 . . . 681	250/673 (37%)	e−132
	polypeptide variant SVPH-1b - Homo	27 . . . 671	360/673 (53%)
	sapiens, 787 aa. [WO200043525-A2,
	27-JUL-2000]
AAB07739	A snake venom protease (SVPH-1)	29 . . . 681	250/673 (37%)	e−132
	polypeptide variant SVPH-1a - Homo	27 . . . 671	360/673 (53%)
	sapiens, 766 aa. [WO200043525-A2,
	27-JUL-2000]

[0376] In a BLAST search of public sequence databases, the NOV11a protein was found to have homology to the proteins shown in the BLASTP data in Table 11E.

TABLE 11E
Public BLASTP Results for NOV11a
		NOV11a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q95LW7	HYPOTHETICAL 52.8 KDA PROTEIN -	271 . . . 719	390/459 (84%)	0.0
	Macaca fascicularis (Crab eating	2 . . . 460	415/459 (89%)
	macaque) (Cynomolgus monkey), 474 aa.
Q60815	ADAM 4 PROTEIN - Mus musculus	279 . . . 719	241/454 (53%)	e−151
	(Mouse), 473 aa (fragment).	1 . . . 449	309/454 (67%)
Q28484	TESTICULAR METALLOPROTEASE-	19 . . . 713	268/711 (37%)	e−137
	LIKE, DISINTEGRIN-LIKE,	19 . . . 710	378/711 (52%)
	CYSTEINE-RICH PROTEIN IVA -
	Macaca fascicularis (Crab eating
	macaque) (Cynomolgus monkey), 732 aa.
O43506	ADAM 20 precursor (EC 3.4.24.-) (A	33 . . . 712	250/704 (35%)	e−134
	disintegrin and metalloproteinase domain	33 . . . 714	377/704 (53%)
	20) - Homo sapiens (Human), 726 aa.
Q9UKF5	ADAM 29 precursor (A disintegrin and	29 . . . 681	250/673 (37%)	e−131
	metalloproteinase domain 29) - Homo	27 . . . 671	360/673 (53%)
	sapiens (Human), 820 aa.

[0377] PFam analysis indicates that the NOV11a protein contains the domains shown in the Table 11F.

TABLE 11F
Domain Analysis of NOV11a
		Identities/
	NOV11a	Similarities
	Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
Pep_M12B_propep:	75 . . . 191	34/119 (29%)	2.2e−29
domain 1 of 1		91/119 (76%)
Reprolysin: domain 1 of 1	206 . . . 392	51/210 (24%)	1.7e−06
		115/210 (55%)
disintegrin: domain 1 of 1	409 . . . 484	30/77 (39%)	3.3e−15
		50/77 (65%)
EGF: domain 1 of 1	635 . . . 663	8/47 (17%)	2.7
		20/47 (43%)

Example 12

[0378] The NOV12 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 12A.

TABLE 12A
NOV12 Sequence Analysis
                   SEQ ID NO:55        3874 bp
NOV12a,            ACAACTGTGATGATCCACTAGCATCCCTGCTCTCTCCAATGGCTTTTTCCAGTTCCTC
CG58577-01 DNA     AGACCTCACTGGCACTCACAGCCCAGCTCAACTCAACTGGAGAGTTGGAACTGGCGGT
Sequence           TGGTCCCCACCAGATTCCAATGCTCAACAGTGGCTCCAGATGGACCTGGGAAACAGAG
                   TAGAGATTACAGCAGTGGCCACGCAGGGAAGATACGGAAGCTCTGACTGGGTGACGAG
                   TTACAGCCTGATGTTCAGTGACACAGGACGCAACTGGAAACAGTACAAACAAGAAGAC
                   AGCATCTGGACCTTTGCAGGAAACATGAATGCTGACAGCGTGGTGCACCACAAGCTAT
                   TGCACTCAGTGAGAGCCCGATTTGTTCGCTTTGTGCCCCTGGAATGGAATCCCAGTGG
                   GAAGATTGGCATCAGACTCGAGGTCTACGGATGTTCCTATAATGTTGCTGACTTTGAT
                   GGCCGAAGCTCACTTCTGTACAGGTTCAATCAGAAGTTGATGAGTACTCTCAAAGATG
                   TGATCTCCCTGAAGTTCAAGAGCATGCAAGGAGATGGGGTCCTGTTCCATGGAGAAGG
                   TCAGCGTGGAGACCACATCACCTTGGAACTCCAGAAGGGGAGGCTCGCCCTACACCTC
                   AATTTGGGTGACAGCAAAGCGCGGCTCAGCAGCAGCTTGCCCTCTGCCACCCTGCGCA
                   GCCTCCTGGATGACCACCACTGGCACTCGGTCCTCATTGAGCGGGTGGGCAAGCAGGT
                   GAACTTCACGGTGGACAAGCACACACAGCACTTCCGCACCAAGGGCGAGACGGATGCC
                   TTAGACATTGACTATGAOCTTAGTTTTGGAGGAATTCCACTACCAGGAAAACcTGGGA
                   CCTTTTTAAAGAAAAACTTCCATGGATGCATCGAAAACCTTTACTACAATGGAGTAAA
                   CATAATTGACCTGGCTAAGAGACGAAAGCATCAGATCTATACTGTGGGCAATGTCACT
                   TTTTCCTGCTCCGAACCACAGATTGTGCCCATCACATTTGTCAACTCCAGCGGCAGCT
                   ATTTGCTGCTGCCCGGCACCCCCCAAATTGATGGGCTCTCAGTGAGTTTCCAGTTTCG
                   AACATGGAACAAGGATGGTCTCCTTCTGTCCACAGAGCTGTCTGAGGGCTCGGGAACC
                   CTGCTGCTGAGCCTGGAGGGTGGAATCCTGAGACTCGTGATTCAGAAAATGACAGAAC
                   GCGTAGCTGAAATCCTCACAGGCAGCAACTTGAATGATCGCCTGTGGCACTCGGTTAG
                   CATCAACGCCAGGAGGAACCGCATCACGCTCACTCTGGATGATGAAGCAGCACCCCCG
                   GCTCCAGACAGCACTTGGGTGCAGATTTATTCTGGAAATAGCTACTATTTTGGAGGTT
                   GCCCCGACAATCTCACCGATTCCCAATGTTTAAATCCCATTAAGGCTTTCCAAGGCTG
                   CATGAGGCTCATCTTTATTGATAACCAGCCCAAGGACCTCATTTCAGTTCAGCAAGGT
                   TCCCTGGGCAATTTTAGTGATTTACACATTGATCTGTGTAGCATCAAAGACAGGTGTT
                   TGCCAAACTACTGTGAACATGGAAGGAAGTTGTTCCCAGTCCTGGACTACCTTTTCTA
                   TTGTAACTGCAGTGACACAAGTTACACTGGTGCCACCTGCCACAACTCCATCTACGAG
                   CAATCCTGCGAGGTGTACAGGCACCAGGGGAATACAGCCGGCTTCTTCTACATCGACT
                   CAGATGGCAGCGGCCCACTGGGACCTCTCCAGGTGTACTGCAATATCACTCAGGACAA
                   CATCTGGACATCAGTGCAGCACAACAATACAGAGCTGACCCGAGTGCGGGGCGCTAAC
                   CCTGAGAAGCCCTATGCCATGGCCTTGGACTACGGGGGCAGCATGGAACAGCTGGAGG
                   CCGTGATCGACGGCTCTGAGCACTGTGAGCAGGAGGTGGCCTACCACTGCAGGAGGTC
                   CCGCCTGCTCAACACGCCGGATGGAACACCATTTACCTGGTGGATTGGGCGGTCCAAT
                   GAAAGGCACCCTTACTGGGGAGGTTCCCCTCCTGGGGTCCAGCAGTGTGAGTGTGGCC
                   TAGACGAGAGCTGCCTGGACATTCAGCACTTTTGCAATTGCGACGCTGACAAGGAAAA
                   TGATACTGGCTTTCTTTCCTTCAAAGACCACTTGCCTGTCACTCAGATAGTTATCACT
                   GATACCGACAGATCAAACTCAGAAGCCGCTTGGAGAATTGGTCCCTTGCGTTGCTATG
                   GTGACCCACCCTTCTGGAACGCCGTCTCATTTTATACAGAAGCCTCTTACCTCCACTT
                   TCCTACCTTCCATGCGGAATTCAGTGCCGATATTTCCTTCTTTTTTAAAACCACAGCA
                   TTATCCGGAGTTTTCCTAGAAAATCTTGGCATTAAAGACTTCATTCGACTCGAAATAA
                   GCTCTCCTTCAGAGATCACCTTTGCCATCGATGTTGGGAATGGTCCTGTGGAGCTTGT
                   AGTCCAGTCTCCTTCTCTTCTGAATGACAACCAATGGCACTATGTCCGGGCTGAGAGG
                   AACCTCAAGGAGACCTCCCTGCAGGTGGACAACCTTCCAAGGAGCACCAGGGAGACGT
                   CGGAGGAGGGCCATTTTCGACTGCAGCTGAACAGCCAGTTGTTTGTAGGCGGAACGTC
                   ATCCAGACAGAAAGGCTTCCTAGGATGCATTCGCTCCTTACACTTGAATGGACAGAAA
                   ATGGACCTGGAAGAGAGGGCAAAGGTCACATCTGGAGTCAGGCCAGGCTGCCCCGGCC
                   ACTGCAGCAGCTACGGCAGCATCTGCCACAACGGGGGCAAGTGTGTGGAGAAGCACAA
                   TGGCTACCTGTGTGATTGCACCAATTCACCTTATGAAGGGCCCTTTTGCAAAAAAGAG
                   GTTTCTCCTGTTTTTGAGGCTGGCACGTCGGTTACTTACATGTTTCAAGAACCCTATC
                   CTGTGACCAAGAATATAAGCCTCTCATCCTCAGCTATTTACACAGATTCAGCTCCATC
                   CAAGGAAAACATTGCACTTAGCTTTGTGACAACCCAGGCACCCAGTCTTTTGCTCTTT
                   ATCAATTCTTCTTCTCAGGACTTCGTGGTTGTTCTGCTCTGCAAGAATGGAAGCTTAC
                   AGGTTCCCTATCACCTAAACAAGGAAGAAACCCATGTATTCACCATTGATGCAGATAA
                   CTTTGCTAACAGAAGGATGCACCACTTGAAGATTAACCGAGAGGGAAGAGAGCTTACC
                   ATTCAGGTACCTTCCTTACTTTCTCCTGCTTCAGCCAATATGGACCAGCAACTTCGAC
                   TCAGTTATAACTTCTCTCCGGAAGTAGAGTTCAGGGTTATAAGGTCACTCACCTTGGG
                   CAAAGTCACAGAGAATCTTGGTTTGGATTCTGAAGTTGCTAAAGCAAATGCCATGGGT
                   TTTGCTGGATGCATGTCTTCCGTCCAGTACAACCACATAGCACCACTGAAGGCTGCCC
                   TGCGCCATGCCACTGTCGCGCCTCTCACTGTCCATGGGACCTTGACGGAATCCAGCTG
                   TGGCTTCATGGTGGACTCAGATGTGAATGCAGTGACCACGGTGCATTCTTCATCAGAT
                   CCTTTTGGGAAGACAGATGAGCGGGAACCACTCACAAATGCTGTTCGAAGTGATTCGG
                   CAGTCATCCGAGGGGTGATAGCAGTGGTGATATTCATCATCTTCTGTATCATCGGCAT
                   CATGACCCGGTTCCTCTACCAGCACAAGCAGTCACATCGTACGAGCCAGATGAAGGAG
                   AAGGAATATCCAGAAAATTTGGACAGTTCCTTCAGAAATGAAATTGACTTGCAAAACA
                   CAGTGAGCGAGTGTAAACGGGAATATTTCATCTGAGAAACTGCAGG
                   ORF Start: AAC at 3 ORF Stop: TGA at 3861
                   SEQ ID NO:56        1286 aa MW at 143343.7 kD
NOV12a,            NCDDPLASLLSPMAFSSSSDLTGTHSPAQLNWRVGTGGWSPADSNAQQWLQMDLGNRV
CG58577-01 Protein EITAVATQGRYGSSDWVTSYSLMFSDTGRNWKQYKQEDSIWTFAGNMNADSVVHHKLL
Sequence           HSVRARFVRFVPLEWNPSGKIGMRVEVYGCSYNVADFDGRSSLLYRFNQKLMSTLKDV
                   ISLKFKSMQGDGVLFHGEGQRGDHITLELQKGRLALHLNLGDSKARLSSSLPSATLGS
                   LLDDQHWHSVLIERVGKQVNFTVDKHTQHFRTKGETDALDIDYELSFGGIPVPGKPGT
                   FLKKNFHGCIENLYYNCVNIIDLAKRRKHQIYTVGNVTFSCSEPQIVPITFVNSSGSY
                   LLLPGTPQIDGLSVSFQFRTWNKDGLLLSTELSEGSGTLLLSLEGGILRLVIQKNTER
                   VAEILTGSNLNDGLWHSVSINARRNRITLTLDDEAAPPAPDSTWVQIYSCNSYYFGGC
                   PDNLTDSQCLNPIKAFQGCMRLIFIDNQPKDLISVQQGSLGNFSDLHIDLCSIKDRCL
                   PNYCEHGRKLFPVLDYLFYCNCSDTSYTGATCHNSIYEQSCEVYRHQGNTAGFFYIDS
                   DGSGPLGPLQVYCNITEDKIWTSVQHNNTELTRVRGANPEKPYAMALDYGGSMEQLEA
                   VIDGSEHCEQEVAYHCRRSRLLNTPDGTPFTWWIGRSNERHPYWGGSPPGVQQCECGL
                   DESCLDIQHFCNCDADKENDTGFLSFKDHLPVTQIVITDTDRSNSEAAWRIGPLRCYG
                   DRRFWNAVSFYTEASYLHFPTFHAEFSADISFFFKTTALSGVFLENLGIKDFIRLEIS
                   SPSEITFAIDVGNGPVELVVQSPSLLNDNQWHYVRAERNLKETSLQVDNLPRSTRETS
                   EEGHFRLQLNSQLFVGGTSSRQKGFLGCIRSLHLNGQKMDLEERAKVTSGVRPGCPGH
                   CSSYGSICHNGGKCVEKHNGYLCDCTNSPYEGPFCKKEVSAVFEAGTSVTYMFQEPYP
                   VTKNISLSSSAIYTDSAPSKENIALSFVTTQAPSLLLFINSSSQDFVVVLLCKNGSLQ
                   VRYHLNKEETHVFTIDADNFANRRMHHLKINREGRELTIQVPSLLSPASANMDQQLRL
                   SYNFSPEVEFRVIRSLTLGKVTENLGLDSEVAKANANGFAGCMSSVQYNHIAPLKAAL
                   RHATVAPVTVHGTLTESSCGFMVDSDVNAVTTVHSSSDPFGKTDEREPLTNAVRSDSA
                   VIGGVIAVVIFIIFCIIGIMTRFLYQHKQSHRTSQMKEKEYPENLDSSFRNEIDLQNT
                   VSECKREYFI
                   SEQ ID NO:57        429 bp
NOV12b,            GGATCCCCACTAGCATCCCTGCTCTCTCCAATGGCTTTTTCCAGTTCCTCAGACCTCA
174307971 DNA      CTGGCACTCACAGCCCAGCTCAACTCAACTGGAGAGTTGGAACTGGCGGTTGGTCCCC
Sequence           ACCAGATTCCAATGCTCAACAGTGGCTCCAGATGGACCTGGGAAACAGAGTAGAGATT
                   ACAGCAGTGGCCACGCAGGGAAGATACGGAAGCTCTGACTGGGTGACGAGTTACAGCC
                   TGATGTTCAGTGACACAGGACGCAACTGGAAACAGTACAAACAAGAAGACAGCATCTG
                   GACCTTTGCAGGAAACATGAATGCTGACAGCGTGGTGCACCACAAGCTATTGCACTCA
                   GTGAGAGCCCGATTTGTTCGCTTTGTGCCCCTGGAATCGAATCCCAGTGGGAAGATTG
                   GCATGAGAGTCGAGGTCCTCGAG
                   ORF Start: GGA at 1 ORF Stop: al at 430
                   SEQ ID NO:58        143 aa MW at 15889.6 kD
NOV12b,            GSPLASLLSPMAFSSSSDLTGTHSPAQLNWRVGTGGWSPADSNAQQWLQMDLGNRVEI
174307971 Protein  TAVATQGRYGSSDWVTSYSLMFSDTGRNWKQYKQEDSIWTFAGNMNADSVVHHKLLHS
Sequence           VRARFVRFVPLEWNPSGKIGMRVEVLE
                   SEQ ID NO:59        429 bp
NOV12c,            GGATCCCCACTAGCATCCCTGCTCTCTCCAATCGCTTTTTCCAGTTCCTCAGACCTCA
174307975 DNA      CTGGCACTCACAGCCCAGCTCAACTCAACTGGAGAGTTGGAACTGGCGGTTGGTCCCC
Sequence           AGCAGATTCCAATGCTCAACAGTGGCTCCAGATGGACCTGGGAAACAGAGTAGAGATT
                   ACAGCAGTGGCCACGCAGGGAAGGTACGGAAGCTCTGACTGGGTGACGAGTTACAGCC
                   TGATGTTCAGTGACACAGGACGCAACTGGAAACAGTACAAACAAGAAGACAGCATCTG
                   GACCTTTGCAGGAAACATGAATGCTGACAGCGTCGTGCACCACAAGCTATTGCACTCA
                   GTGAGAGCCCGATTTGTTCGCTTTGTGCCCCTGGAATGGAATCCCAGTGGGAAGATTG
                   GCATOAGAGTCGAGGTCCTCGAG
                   ORF Start: GGA at 1 ORF Stop: al at 430
                   SEQ ID NO:60        143 aa MW at 15889.6 kD
NOV12c,            GSPLASLLSPMAFSSSSDLTGTHSPAQLNWRVGTGGWSPADSNAQQWLQMDLGNRVEI
174307971 Protein  TAVATQGRYGSSDWVTSYSLMFSDTGRNWKQYKQEDSIWTFAGNMNADSVVHHKLLHS
Sequence           VRARFVRFVPLEWNPSGKIGMRVEVLE
                   SEQ ID NO:61        429 bp
NOV12d,            GGATCCCCACTAGCATCCCTGCTCTCTCCAATCGCTTTTTCCAGTTCCTCAGACCTCA
174307979 DNA      CTGGCACTCACAGCCCAGCTCAACTCAACTGGAGAGTTGGAACTGGCGGTTGGTCCCC
Sequence           AGCAGATTCCAATGCTCAACAGTGGCTCCAGATGGACCTGGGAAACAGAGTAGAGATT
                   ACAGCAGTGGCCACGCAGGGAAGATACGGAAGCTCTGACTGGGTGACGAGTTACAGCC
                   TGATGTTCAGTGACACAGGACGCAACTGGAAACAGTACAAACAAGAAGACAGCATCTG
                   GACCTTTGCAGGAAACATGAATGCTGACAGCGTGGTGCACCACAAGCTATTGCGCTCA
                   GTGAGAGCCCGATTTGTTCGCTTTGTGCCCCTGGAATGGAATCCCACTGGGAAGATTG
                   GCATGAGAGTCGAGGTCCTCGAG
                   ORF Start: GGA at 1 ORF Stop: al at 430
                   SEQ ID NO:62        143 aa MW at 15908.7 kD
NOV12d,            GSPLASLLSPMAFSSSSDLTGTHSPAQLNWRVGTGGWSPADSNAQQWLQMDLGNRVEI
174307979 Protein  TAVATQGRYGSSDWVTSYSLMFSDTGRNWKQYKQEDSIWTFAGNMNADSVVHHKLLRS
Sequence           VRARFVRFVPLEWNPSGKIGMRVEVLE
                   SEQ ID NO:63        429 bp
NOV12e,            GGATCCCCACTAGCATCCCTGCTCTCTCCAATGGCTTTTTCCAGTTCCTCAGACCTCA
174307983 DNA      CTGGCACTCACAGCCCAGCTCAACTCAACTGGAGAGTTGGAACTGGCGGTTGGTCCCC
Sequence           AGCAGATTCCAATGCTCAACAGTGGCTCCAGATGGACCTCGGAAACAGAGTAGAGATT
                   ACAGCAGTGGCCACGCAGGGAAGATACGGAAGCTCTGACTGGGTGACGAGTTACAGCC
                   TGATGTTCAGTGACACAGGACGCAACTGGAAACAGTACAAACAGGAAGACAGCATCTG
                   GACCTTTGCAGGAAACATGAATGCTGACAGCGTGGTGCACCACAAGCTATTGCACTCA
                   GTGAGAGCCCGATTTGTTCGCTTTGTGCCCCTGGAATGGAATCCCAGTGGGAAGATTG
                   GCATGAGAGTCCAGGTCCTCCAG
                   ORF Start: GGA at 1 ORF Stop: al at 430
                   SEQ ID NO:64        143 aa MW at 15889.6 kD
NOV12e,            GSPLASLLSPMAFSSSSDLTGTHSPAQLNWRVGTGGWSPADSNAQQWLQMDLGNRVEI
174307983 Protein  TAVATQGRYGSSDWVTSYSLMFSDTGRNWKQYKQEDSIWTFAGNMNADSVVHHKLLHS
Sequence           VRARFVRFVPLEWNPSGKIGMRVEVLE
                   SEQ ID NO:65        1429 bp
NOV12f,            GGATCCCCACTAGCATCCCTGCTCTCTCCAATGGCTTTTTCCAGTTCCTCAGACCTCA
174307987 DNA      CTGGCACTCACAGCCCAGCTCAACTCAACTGGAGAGTTGGAACTGGCGGTTGGTCCCC
Sequence           AGCAGATTCCAATGCTCAACAGTGGCTCCAGATGGACCTGGGAAACAGAGTAGAGATT
                   ACAGCAGTGGCCACGCGGGGAAGATACGGAAGCTCTGACTGGGTGACGAGTTACAGCC
                   TGATGTTCAGTGACACAGGACGCAACTGGAAACAGTACAAACAAGAAGACAGCATCTG
                   GACCTTTGCAGGAAACATGAATGCTGACACCGTGGTGCACCACGAGCTATTGCACTCA
                   GTGAGAGCCCGATTTGTTCGCTTTGTGCCCCTGGAATGGAATCCCAGTGGGAAGATTG
                   GCATGAGAGTCGAGGTCCTCGAG
                   ORF Start: GGA at 1 ORF Stop: al at 430
                   SEQ ID NO:66        143 aa MW at 15918.6 kD
NOV12f,            GSPLASLLSPMAFSSSSDLTGTHSPAQLNWRVGTGGWSPADSNAQQWLQMDLGNRVEI
174307987 Protein  TAVATRGRYGSSDWVTSYSLMFSDTGRNWKQYKQEDSIWTFAGNMNADSVVHHELLHS
Sequence           VRARFVRFVPLEWNPSGKIGMRVEVLE
                   SEQ ID NO:67        429 bp
NOV12g,            GGATCCCCACTAGCATCCCTGCTCTCTCCAATGGCTTTTTCCAGTTCCTCAGACCTCA
174307996 DNA      CTGGCACTCACAGCCCAGCTCAACTCAACTGGAGAGTTGGAACTGGCGGTTGGTCCCC
Sequence           AGCAGATTCCAATGCTCAACAGTGGCTCCAGATGGACCTGGGAAACAGAGTAGAGATT
                   ACAGCAGTGGCCACGCAGGGAAGATACGGAAGCTCTGACTGGGTGACGAGTTACAGCC
                   TGATGTTCAGTGACACAGGACGTAACTGGAAACAGTACAAACAAGAAGACAGCATCTG
                   GACCTTTGCAGGAAACATGAATGCTGACAGCGTGGTGCACCACAAGCTATTGCACTCA
                   GTGAGAGCCCGATTTGTTCGCTTTGTGCCCCTGGAATGGAATCCCAGTGGGAAGATTG
                   GCATGAGAGTCGAGGTCCTCGAG
                   ORF Start: GGA at 1 ORF Stop: al at 430
                   SEQ ID NO:68        143 aa MW at 15889.6 kD
NOV12g,            GSPLASLLSPMAFSSSSDLTGTHSPAQLNWRVGTGGWSPADSNAQQWLQMDLGNRVEI
174307996 Protein  TAVATQGRYGSSDWVTSYSLMFSDTGRNWKQYKQEDSIWTFAGNNNADSVVHHKLLHS
Sequence           VRARFVRFVPLEWNPSGKIGMRVEVLE
                   SEQ ID NO:69        429 bp
NOV12h,            GGATCCCCACTAGCATCCCTGCTCTCTCCAATGGCTTTTTCCAGTTCCTCAGACCTCA
169894929 DNA      CTGGCACTCACAGCCCAGCTCAACTCAACTGGAGAGTTGGAACTGGCGGTTGGTCCCC
Sequence           AGCACATTCCAATGCTCAACAGTGGCTCCAGATGGACCTGGGAAGCAGAGTAGAGATT
                   ACAGCAGTGGCCACGCAGGGAAGATACGGAAGCTCTGACTGGGTGACGAGTTACAGCC
                   TGATGTTCAGTGACACAGGACGCAACTGGAAACAGTACAAACAAGAAGACAGCATCTG
                   GACCTTTGCAGGAAACATCAACGCTGACAGCGTGGTGCACCACAAGCTATTGCACTCA
                   GTGAGAGCCCCGATTTGTTCGCTTTGTGCCCCTGGAATGGAATCCAGTGGGAAGATTG
                   GCATGAGAGTCGAGGTCCTCGAG
                   ORF Start: GGA at 1 ORF Stop: al at 430
                   SEQ ID NO:70        143 aa MW at 15862.6 kD
NOV12h,            GSPLASLLSPMAFSSSSDLTGTHSPAQLNWRVGTCGWSPADSNAQQWLQMDLGSRVEI
169894929 Protein  TAVATQGRYGSSDWVTSYSLMFSDTGRNWKQYKQEDSIWTFAGNNNADSVVHHKLLHS
Sequence           VRARFVRFVPLEWNPSGKIGMRVEVLE

[0379] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 12B.

TABLE 12B
Comparison of NOV12a against NOV12b through NOV12h.
	NOV12a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV12b	22 . . . 143	122/122 (100%)
	20 . . . 141	122/122 (100%)
NOV12c	22 . . . 143	122/122 (100%)
	20 . . . 141	122/122 (100%)
NOV12d	22 . . . 143	121/122 (99%)
	20 . . . 141	121/122 (99%)
NOV12e	22 . . . 143	122/122 (100%)
	20 . . . 141	122/122 (100%)
NOV12f	22 . . . 143	120/122 (98%)
	20 . . . 141	122/122 (99%)
NOV12g	20 . . . 141	122/122 (100%)
NOV12h	22 . . . 143	121/122 (99%)
	20 . . . 141	122/122 (99%)

[0380] Further analysis of the NOV12a protein yielded the following properties shown in Table 12C.

TABLE 12C
Protein Sequence Properties NOV12a
PSort     0.7000 probability located in plasma membrane; 0.4467 prob-
analysis: ability located in microbody (peroxisome); 0.3000 probability
          located in nucleus; 0.2000 probability located in
          endoplasmic reticulum (membrane)
SignalP   No Known Signal Sequence Indicated
analysis:

[0381] A search of the NOV12a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12D.

TABLE 12D
Geneseq Results for NOV12a
		NOV12a
		Residues/	Identities/
Geneseq	Protein/Organism/Length [Patent	Match	Similarities for the	Expect
Identifier	#, Date]	Residues	Matched Region	Value
AAE07293	Human neurexin-like protein #12 -	1 . . . 1286	1263/1291 (97%)	0.0
	Homo sapiens, 1298 aa.	20 . . . 1298	1265/1291 (97%)
	[WO200158938-A2, 16-AUG-2001]
AAE07282	Human neurexin-like protein #1 -	1 . . . 1286	1261/1291 (97%)	0.0
	Homo sapiens, 1307 aa.	29 . . . 1307	1263/1291 (97%)
	[WO200158938-A2, 16-AUG-2001]
AAE07283	Human neurexin-like protein #2 -	1 . . . 1286	1214/1291 (94%)	0.0
	Homo sapiens, 1259 aa.	29 . . . 1259	1216/1291 (94%)
	[WO200158938-A2, 16-AUG-2001]
AAE07294	Human neurexin-like protein #13 -	105 . . . 1286	1159/1187 (97%)	0.0
	Homo sapiens, 1175 aa.	1 . . . 1175	1161/1187 (97%)
	[WO200158938-A2, 16-AUG-2001]
AAE07291	Human neurexin-like protein #10 -	1 . . . 797	749/802 (93%)	0.0
	Homo sapiens, 839 aa.	29 . . . 829	755/802 (93%)
	[WO200158938-A2, 16-AUG-2001]

[0382] In a BLAST search of public sequence databases, the NOV12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12E.

TABLE 12E
Public BLASTP Results for NOV12a
		NOV12a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
BAB83897	CASPR5 - Homo sapiens (Human),	1 . . . 1286	1262/1291 (97%)	0.0
	1306 aa.	29 . . . 1306	1264/1291 (97%)
Q96MS7	CDNA FLJ31966 FIS, CLONE	1 . . . 925	912/930 (98%)	0.0
	NT2RP7007925, WEAKLY SIMILAR	29 . . . 957	914/930 (98%)
	TO HOMO SAPIENS CONTACTIN
	ASSOCIATED PROTEIN (CASPR)
	MRNA - Homo sapiens (Human), 963
	aa.
AAL68839	CELL RECOGNITION PROTEIN	1 . . . 1285	747/1293 (57%)	0.0
	CASPR4 - Homo sapiens (Human),	33 . . . 1310	961/1293 (73%)
	1311 aa.
Q9C0A0	Contactin associated protein-like 4	1 . . . 1285	747/1293 (57%)	0.0
	precursor (Cell recognition molecule	30 . . . 1307	961/1293 (73%)
	Caspr4) - Homo sapiens (Human), 1308
	aa.
Q99P47	Contactin associated protein-like 4	1 . . . 1285	725/1293 (56%)	0.0
	precursor (Cell recognition molecule	32 . . . 1309	955/1293 (73%)
	Caspr4) - Mus musculus (Mouse), 1310
	aa.

[0383] PFam analysis indicates that the NOV12a protein contains the domains shown in the Table 12F.

TABLE 12F
Domain Analysis of NOV12a
		Identities/
	NOV12a	Similarities
	Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
F5_F8_type_C:	5 . . . 143	48/167 (29%)	1e−41
domain 1 of 1		115/167 (69%)
laminin_G: domain 1 of 4	179 . . . 311	40/168 (24%)	3.6e−11
		93/168 (55%)
laminin_G: domain 2 of 4	366 . . . 495	40/161 (25%)	3.5e−12
		88/161 (55%)
EGF: domain 1 of 2	521 . . . 554	22/47 (47%)	3.5
TSPN: domain 1 of 1	729 . . . 908	35/225 (16%)	8.5
		115/225 (51%)
laminin_G: domain 3 of 4	788 . . . 910	44/164 (27%)	4.5e−15
		92/164 (56%)
EGF: domain 2 of 2	929 . . . 963	14/47 (30%)	0.0044
		27/47 (57%)
laminin_G: domain 4 of 4	1014 . . . 1085	20/87 (23%)	0.0019
		51/87 (59%)

Example 13

[0384] The NOV13 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 13A.

TABLE 13A
NOV13 Sequence Analysis
                   SEQ ID NO:71         14109 bp
NOV13a,            TGTCGCTCAACGGGATGCCCCTGTACAACGACAGCTTCCATGAGATCTCACACAAGGG
CG59237-01 DNA     CCGCCGCCACACGCTGGTACTCAAGACCATCCAGCGGGCTCATGCCGGCATAGTACGC
Sequence           GCCTCCTCCCTGAAGGTGTCGACCTCTGCCCGCCTGGAGGTCCGAGTGAAGCCCGTGG
                   TGTTCCTGAAGGCGCTGGATGACCTGTCCGCAGAGGAGCGCGGCACCCTGGCCCTGCA
                   GTGTGAAGTCTCTGACCCCGAGGCCCATGTGGTGTGGCGCAAAGATGGCGTGCAGCTG
                   GGCCCCAGTGACAAGTATGACTTCCTGCACACGGCGGGCACGCGGGGGCTCGTGGTGC
                   ATGACGTGAGCCCTGAAGACGCCGGCCTGTACACCTGCCACGTGGGCTCCGAGGAGAC
                   CCGGGCCCGGGTCCGCGTGCACGATCTGCACGTGGGCATCACCAACAGGCTGAAGACA
                   ATGGAGGTGCTGGAAGGGGAAAGCTGCAGCTTTGAGTGCGTCCTGTCCCACGAGAGTG
                   CCAGCGACCCGGCCATGTGGACAGTCGGTGGGAAGACAGTGGCCAGCTCCAGCCGCTT
                   CCAGGCCACACGTCAGGGCCGAAAATACATCCTGGTGGTCCGGGAGGCTGCACCAAGT
                   GATGCCGGGGAGGTGGTCTTCTCTGTGCGGGGCCTCACCTCCAAGGCCTCACTCATTG
                   TCAGAGAGAGGCCGGCCGCCATCATCAAGCCCCTGGAAGACCAGTGGGTGGCGCCAGG
                   GGAGGACGTGGAGCTGCGCTGTGAGCTGTCACGGGCCGGAACGCCCCTGCACTGGCTG
                   AAGGACAGGAAGGCCATCCGCAAGAGCCAGAAGTATGATGTGGTCTGCGACGGCACGA
                   TGGCCATGCTGGTCATCCGCGGGGCCTCGCTCAAGGACGCGGGCGAGTACACGTGTGA
                   GGTGCAGGCTTCCAAGAGCACAGCCAGCCTCCATGTGGAAGAAAAAGCAAACTGCTTC
                   ACAGAGGAGCTGACCAATCTGCACGTGCAGGACAAAGGCACAGCTGTGTTCACGTGCA
                   AGACGGAGCACCCCGCGGCCACAGTGACCTGGCGCAAGGGCCTCTTGGAGCTACGGGC
                   CTCAGGGAAGCACCAGCCCAGCCAGGAGGGCCTGACCCTGCGCCTCACCATCAGTGCC
                   CTGGAGAAGGCAGACAGCGACACCTATACCTGCGACATTGGCCAGGCCCAGTCCCGGG
                   CCCAGCTCCTAGTGCAAGGCCGGAGAGTGCACATCATCCAGGACCTGGAGGATGTGGA
                   TGTGCACGAGGGCTCCTCGGCCACCTTCCGTTCCCGGATCTCCCCGGCCAACTACGAG
                   CCTGTGCACTGGTTCCTGGACAAGACACCCCTGCATGCCAACGAGCTCAATGAGATCG
                   ATGCCCAGCCCGGGCGCTACCACGTGCTGACCCTGCGGCAGCTGGCGCTCAAGGACTC
                   GGGCACCATCTACTTTGAGGCGGGTGACCAGCGGGCCTCGGCCGCCCTGCGGGTCACT
                   GAGAAGCCAAGCGTCTTCTCCCGGGAGCTCACAGATGCCACCATCACAGAGGGTGAGG
                   ACTTGACCCTGGTGTGCGAGACCAGCACCTGCGACATTCCTGTGTGCTGGACCAAGGA
                   TGGGAAGACCCTGCGGGGGTCTGCCCGGTGCCAGCTGAGCCATGAGGGCCACCGGGCC
                   CAGCTGCTCATCACTGGGGCCACCCTGCAGGACAGTGGACGCTACAAGTGTGAGGCTG
                   GGGGCGCCTGCAGCAGCTCCATTGTCAGGGTCCATGCGCGGCCAGTGCGGTTCCAGGA
                   GGCCCTGAAGGACCTGGAGGTGCTGGAGGGTGGTGCTGCCACACTGCGCTGTGTGCTG
                   TCATCTGTGGCTCCCCCCGTGAAGTGGTGCTATGGAAACAACGTCCTGAGGCCAGGTG
                   ACAAATACAGCCTACGCCAGGAGGGTGCCATGCTGGAGCTGGTCGTCCGGAACCTCCG
                   GCCGCAGGACAGCGGGCGGTACTCATGCTCCTTCGGCGACCAGACTACTTCTGCCACC
                   CTCACAGTGACTGCCCTCCCTGCCCAGTTCATCGGGAAACTGAGPAACAAGGAGGCCA
                   CAGAAGGGGCCACGGCCACGCTGCGGTGTGAGCTGAGCAAGGCAGCCCCTGTGGAGTG
                   GAGAAAGGGGTCCGAGACCCTCAGAGATGGGGACAGATACTGTCTGAGGCAGGACGGG
                   GCCATGTGTGAGCTGCAGATCCGTCGCCTGGCCATGGTGGATGCCGCGGAGTACTCGT
                   GTGTGTGTGGAGAGGAGAGGACCTCACCCTCACTCACCATCAGGCCCATGCCTGCCCA
                   CTTCATAGGAAGACTGAGACACCAAGAGAGCATAGAAGGGGCCACAGCCACGCTGCGG
                   TGTGAGCTGAGCAAGGCGGCCCCCGTGGAGTGGAGGAAGGGGCGTGAGAGCCTCAGAG
                   ATGGGGACAGACATAGCCTGAGGCAGGACGGGGCTGTGTGCGAGCTGCAGATCTGTGG
                   CCTGGCTGTGGCAGATGCTGGGGAGTACTCCTGTGTGTGTGGGGACGAGAGGACCTCT
                   GCCACTCTCACCGTGAAGGCCCTGCCAGCCAAGTTCACAGAGGGTCTGAGGAATGAAG
                   AGGCCGTGGAAGGGGCCACAGCCATGTTGTGGTGTGAACTGAGCAAGGTGGCCCCTGT
                   GGAGTGGAGGAAGGGGCCCGAGAACCTCAGAGATGGGGACAGATACATCCTGAGGCAG
                   GAGGGGACCAGGTGTGAGCTGCAGATCTGTGGCCTGGCCATGGCGGACGCCGGGGAGT
                   ACTTGTGTGTGTGCGGGCAGGAGAGGACCTCAGCCACGCTCACCATCAGGCCTCTGCC
                   TGCCAGGTTCATAGAAGATGTGAAAAACCAGGAGGCCAGAGAAGGGGCCACGGCTGTG
                   CTGCAGTGTGAGCTGAACAGTGCAGCCCCTGTGGAGTGGAGAAAGGGGTCTGAGACCC
                   TTAGACATGGGCACAGATACACCCTGAGGCAGGACGGGACTAAATGTGAGCTGCAGAT
                   TCGTGGCCTGGCCATGCCAGACACTGGGGAGTACTCGTGCGTGTGCGGGCAGGAGAGG
                   ACCTCGGCTATCCTCACCGTCAGGGCTCTACCCATCAAGTTCACAGAGGGTCTGAGGA
                   ACGAAGAGGCCACAGAAGGGGCAACAGCCGTGCTGCGGTGTGAGCTGAGCAAGATGCC
                   CCCCGTGGAGTGGTGGAAGGGGCATGAGACCCTCAGAGATGGAGACAGACACAGCCTG
                   AGGCAGGACGGGGCCAGGTGTGAGCTGCAGATCCGCGGCCTCGTGGCAGAGGACGCTG
                   GGGAGTACCTGTGCATGTGCCGGAAGGAGAGGACCTCAGCCATGCTCACCGTCAGGGC
                   CATGCCTTCCAAGTTCATAGAGGGTCTGAGGAATGAAGAGGCCACAGAAGGGGACACG
                   GCCACGCTGTGGTGTGAGCTGAGCAAGGCCGCACCGGTGGAGTGGAGGAAGGGGCATG
                   AGACCCTCAGAGATGGGGACAGACACAGCCTGAGGCAGGATGGGTCCAGGTGTGAGCT
                   GCAGATCCGTGGCCTGGCTGTGGTGGATGCCGGGGAGTACTCGTGTGTGTGCGGGCAG
                   CAGAGGACCTCAGCCACACTCACTGTCAGGGCCCTGCCTGCCAGATTCATAGAAGATG
                   TGAAAAACCAGGAGGCCAGAGAAGGGGCCACGGCCGTGCTGCAATGTGAGCTGAGCAA
                   GGCGGCCCCCGTGGAGTGGAGGAAGGGGTCTGAGACCCTCAGAGGTGGGCACAGATAC
                   AGCCTGACGCAGGATGGGACCAGATGTGAGCTGCAGATTCATGGCCTGTCTGTGGCAG
                   ACACTGGCGAGTACTCGTGTGTGTGCGGGCAGGAGAGGACCTCGGCCACACTCACCGT
                   CAGGGCCCTGCCTGCACGATTCACTCAAGATCTGAAGACCAAGGAGGCCTCAGAAGGG
                   GCCACAGCTACACTGCAGTGTGAGCTGAGCAAGGTGGCCCCTGTGGAATGGAAGAAGG
                   GTCCTGAGACCCTCAGAGATGGGGGCAGATACAGCCTGAAGCAGGATGGGACGAGGTG
                   TGAGCTGCAGATCCATGACCTGTCTGTGGCGGATGCTGGGGAATACTCATGCATGTGT
                   GGACAAGAGAGGACCTCGGCCACGCTCACTGTCAGGGCCCTGCCTGCCAGGTTCACAG
                   AGGGTCTGAGGAATGAACAGGCCATGGAAGGGGCCACAGCCACACTGCAATGTGAGCT
                   GAGCAAGGCAGCCCCTGTGGAGTGGAGGAAAGGCCTTGAGGCTCTCAGAGATGGGGAC
                   AAATACAGCCTGAGACAAGACGGGGCTGTGTGTGAGCTGCAGATTCATGGCCTGGCTA
                   TGGCAGATAACGGGGTGTACTCATGTGTGTGTGGGCACGAGAGCACCTCAGCTACACT
                   CACTGTCAGGGCCCTGCCTGCCAGATTCATAGAGGATATGAGAAACCAGAAGGCCACA
                   GAAGGGCCTACAGTCACATTGCAATGTAAGCTGAGAAAGGCGGCCCCCGTGGAGTCGA
                   GAAAGGGGCCCAACACCCTCAAAGATGGGGACAGGTACAGCCTGAAGCAGGATGGGAC
                   CAGTTGTGAGCTGCAGATTCGTGGCCTGGTCATAGCAGATGCTGGAGAATACTCGTGC
                   ATATGTGAGCAGGAGAGGACCTCGGCCACGCTCACTGTCAGGGCCCTGCCGGCCAGAT
                   TCATAGAAGATGTGAGAAATCACGAGGCCACAGAAGGGGCCACAGCTGTGCTGCAGTG
                   TGAGCTGAGCAAGGCGGCCCCCGTGGACTGGCGGAAGGGGTCTCAGACCCTCAGAGAT
                   GGGCACAGATATAGCCTGAGGCAGGACGCGACCAGGTGTGAGCTGCAGATTCGTGGCC
                   TGGCTGTGGAGGACACTGCAGAGTATTTGTGTGTGTGCGGGCAGGAGAGAACCTCAGC
                   TACACTCACTGTCAGGGCCCTGCCAGCCAGATTCATAGACAACATGACAAACCAGGAA
                   GCCAGAGAAGGCGCCACGGCCACACTGCACTGTGAACTGAGCAAGGTCGCCCCTGTGG
                   AGTGGAGGAAGGGACCTGAAACCCTCCGAGATGGGGACAGACACAGCCTGAGGCAGGA
                   TGGGTCCAGGTGTGAGCTGCAGATCCGTGGCCTGGCTGTGGTGGATGCCGGGGAGTAC
                   TCGTGTGTGTGCGGGCAGGAGAGGACCTCAGCCACACTCACTGTCAGGGCCCTGCCTG
                   CCAGATTCATAGAAGATGTGAAAAACCAGGAGGCCAGAGAAGGGGCCACGGCCGTGCT
                   GCAATGTGAGCTGAGCAAGGCGGCCCCCGTGGAGTGGAGGAAGGGGTCTGAGACCCTC
                   AGAGGTGGGGACAGATACAGCCTGAGGCAGGATGGGACCAGATGTGAGCTGCAGATTC
                   ATGGCCTGTCTGTGGCAGACACTGGGGAGTACTCGTGTGTGTGCGGGCAGGAGAGGAC
                   CTCGGCCACACTCACCGTCAGGGCCCTGCCTGCACGATTCACTCAAGATCTGAAGACC
                   AAGGAGGCCTCAGAAGGGGCCACAGCTACACTGCAGTGTGAGCTGAGCAAGGTGGCCC
                   CTGTGGAATGGAAGAAGGGTCCTGAGACCCTCAGAGATGGGGGCAGATACAGCCTGAA
                   GCAGGATGGGACGAGGTGTGAGCTGCAGATCCATGACCTGTCTGTGGCGGATGCTGGG
                   GAATACTCATGCATGTGTGGACAAGAGAGGACCTCGGCCACGCTCACTGTCAGGGACT
                   GCCACACTCTTCACGTCATGCCACACTATCCCTTCCAGCTTCCTGGGCTGCTGAAGGA
                   ACCAGAAGAAACTCTCATCTACATCCAGATTCCCTCTCCTGTGATACTGTTCACAGAG
                   GGTCTGAGGAATGAAGAGGCCATGGAAGGGGCCACAGCCACACTGCAATGTGAGCTGA
                   GCAAGGCAGCCCCTGTGGAGTGGAGGAAACCCCTTGAGGCTCTCAGAGATGGGGACAA
                   ATACAGCCTGAGACAAGACGGGGCTGTGTGTGAGCTGCAGATTCATGGCCTGGCTATG
                   GCAGATAACGGGGTGTACTCATCCCTGCCTGCCAGATTCATAGAGGATATGAGAAACC
                   AGAAGGCCACAGAAGGGGCTACAGTCACATTGCAATGTAAGCTGAGAAAGGCGGCCCC
                   CGTGCAGTCCACAAAGGGGCCCAACACCCTCAAAGATGGGGACAGGTACAGCCTGAAG
                   AATACTCGTGCATATGTGAGCAGGAGAGGACCTCGGCCACGCTCACTGTCAGGGCCCT
                   GCCGGCCAGATTCATAGAAGATGTGAGAAATCACGAGGCCACAGAAGGGGCCACAGCT
                   GTGCTGCAGTGTOACCTGAGCAAGGCGGCCCCCGTGGAGTGGCGGAAGGGGTCTGAGA
                   CCCTCAGAGATGGGGACAGATATAGCCTCAGGCAGGACGGGACGAGGTGTGAGCTGCA
                   GATTCGTGGCCTGGCTGTGGAGGACACTGGAGAGTATTTGTGTGTGTGCGGGCAGGAG
                   AGAACCTCAGCTACACTCACTGTCAGGGCCCTGCCAGCCAGATTCATAGACAACATGA
                   CAAACCAGGAAGCCACAGAACGGGCCACGCCCACACTGCACTGTGAACTGAGCAAGGT
                   GGCCCCTGTGGAGTGGAGGAAGGGACCTGAAACCCTCCGAGATGGGGACAGACACAGC
                   CTGAGGCAGGATGGGACCAGGTGTGAGCTGCAGATTCGTGGCCTGTCTGTGGCAGATG
                   CCGGGGAGTACTCGTGCGTGTGTGGGCAGGAGAGGACCTCAGCCACACTCACGATCAG
                   GGCCCTGCCCGCCAAGTTCACAAAGGGTCTGAGGAATGAAGAGGCCACAGAAGGGGCC
                   ACGGCTATGTTGCAGTGTCAGCTGAGCAAGGTGGCCCCTGTTGAGTGGAGGAAGGGAC
                   CTGAAACCCTCAGAGATGGGGACAGATACAACCTGAGGCAGGATGGGACCAGATGTGA
                   GCTGCAGATTCATGGCCTGTCCGTGGCAGACACTGGGGAGTACTCATGTGTATGTGGT
                   CAGGAGAAGACGTCGGCCACTCTCACTGTCAAGGCCCCACAGCCACTGTTCCGGGAGC
                   CGCTGCAGAGTCTGCAGGCGGAGGAGGGCTCCACGGCCACCCTGCAGTGTGACCTGTC
                   TGAGCCCACTGCTACAGTGGTCTGGAGCAAGGGTGGCCTGCAGCTGCAGGCCAATGGG
                   CGCCGGGAGCCACGGCTTCAGGGCTGCACCGCGGAGCTGGTGTTACAGGACCTACAAC
                   GTGAAGACACTGGCGAATACACTTGCACCTGTGGCTCCCAGGCCACCAGTGCCACCCT
                   CACTGTCACAGCTGCGCCTGTGCGGTTCCTCCGAGAGCTGCAGCACCAGGAGGTGGAT
                   GAGGGAGGCACCGCACACTTATGCTGCGAGCTGAGCCGGGCGGGTGCGAGCGTGGAGT
                   GGCCCAAGGGCTCCCTACAGCTCTTCCCTTGTGCCAAGTACCAGATGGTGCAGGATGG
                   TGCAGCTGCAGAGCTCCTGGTACGCGGAGTGGAGCAGGAGGATGCGGGTGACTACACG
                   TGTGACACGGGCCACACGCAGAGCATGGCCAGCCTCTCTGTCCGTGGAGGGCGTGGAG
                   CTGCATGCGGGCCCCAAGTACGAGATGCGGCGCAGGGGGCCACGCGGGAGCTGCTGAT
                   CCACCAACTGGAGGCCAAGGACACGGGCGAGTATGCCTGTGTGACAGGCGGCCAGAAA
                   ACCGCTGCCTCCCTCAGGGTCACAGAGCCTGAGGTGACCATTGTACGGGGGCTGGTTG
                   ATGCGCAGGTGACGGCCGATGAGCATGTTGAGTTCAGCTCTGAGGTGTCCAGGGCTGG
                   AGCCACAGGCGTGCAGTGGTGCCTACAGGGCCTGCCACTGCAAAGCAATGAGGTGACA
                   GAGGTGGCTGTGCGGGATGGCCGCATCCACACCCTGCCGCTGAAGGGCGTGACGCCCG
                   AGGACGCTGGCACTGTCTCCTTCCATTTGGGAAACCATGCTTCCTCTGCCCAGCTCAC
                   CGTCAGAGCTCCTGAGGTGACCATCCTGGAGCCCCTGCAGGACGTGCAGCTCAGAGGG
                   GTGCCCCTGCAGGCCAACGAGATGAATGACATCACTGTGGAGCAGGGCACACTCCACC
                   TGCTCACCCTGCACAAGGTGACCCTTGAGGATCCTGGAACTGTCAGTTTCCACGTGGG
                   CACGTGTAGCTCTGAGGCCCAGCTGAAAGTCACAGAGGCAGTGCCGTGCCTGGTACGT
                   GGCTTGCAGAATGTGGATGTCTTCGCGGGGGAGGTGGCCACGTTCTCCTGTGAGGATG
                   GCCCCCAGAGCGCCATCGCTGTGCGAGATGGGATCTTTCACTCCCTCATGCTCTCGGG
                   CCTGGGGGTGGCCGACTCCGCCACTGTCATCTTCCGCGCAGGGCCCCTGGTCTCCACG
                   GCCAAGTTGTTGATCAAAGATCCCGTCGTGGAGGTGGTCAGTGCCATGCAGGACTTGG
                   CCGTGGAGGAGGGTGGCTCGGCTGAGCTCCTCTGCCAGTATTCACGGCCCGTGCAGGC
                   CACGTGGAAGATGGACGAGCGGGAGGTGCACACGGATGGGCACCGTGTCATCATAGAG
                   CAGGACTGGAACGTGGCCAGGCTGACCTTCAGGCCGGCCTTGCCCTGTGACAGTGGCA
                   TCTATTCTTGTGAGGCTGCGGGCACCCGCGTAGTGGCCCTGCTGCAAGTGCAAGCCAA
                   GAACACGGTGGTGCGAGGGCTGGAGAATGTGGAGGCGCTGGAGGGCGGCGAGGCGCTG
                   TTCGAGTGCCAGCTGTCCCAGCCCGAGGTGGCCGCCCACACCTGGCTGCTGGACGACG
                   AACCCGTGCGCACCTCGGAGAACGCCGAGGTGGTCTTCTTCGAGAACGGCCTGCGCCA
                   CCTGCTGCTGCTCAAAAACTTGCGGCCACAAGACAGCTGCCGGGTGACCTTCCTGGCT
                   GGGGATATGGTGACGTCCGCATTCCTCACGGTCCGAGGTGACTGCGCTGTGCTGGTGC
                   AGGGCTGGCGCCTGGAGATCCTGGAGCCTCTGAAAAACGCGGCGGTCCGGGCCGGCGC
                   ACAGGCACGCTTCACCTGCACGCTCAGCGAGGCGGTGCCCGTGGGAGAGGCGTCCTGG
                   TACATCAATGGCGCGGCAGTGCAGCCGGATGACAGCGACTGGACTGTCACCGCCGACG
                   GCAGTCACCACGCCCTACTGCTGCGCAGCGCCCAGCCCCACCACGCCGGGGAGGTCAC
                   CTTCGCTTGCCGCGACGCCGTGGCCTCTGCGCGGCTCACCGTGCTGGGCCTCCCTGAT
                   CCCCCAGAGGATGCTGAGGTGGTGGCTCGCAGCAGCCACACTGTGACACTGTCTTGGG
                   CAGCTCCCATGAGTGATGGAGGCGGTGGTCTCTGTGGCTACCGCGTGGAGGTGAAGGA
                   GGGGGCCACAGGCCAGTGGCGGCTGTGCCACGAGCTGGTGCCTGGACCCGAGTGTGTG
                   GTGGATGGCCTGGCCCCCGGGGAGACCTACCGCTTCCGTGTGGCAGCTGTGGGCCCTG
                   TGGGTGCTGGGGAACCGGTTCACCTGCCCCAGACAGTGCGGCTTGAGCCACCGAAGCC
                   TGTGCCTCCCCAGCCCTCAGCCCCTGAGAGCCGGCAGGTGGCAGCTGGTGAAGATGTC
                   TGTCTGCAGCTTGAGGTCGTGGCTGAGGCTGGCGAGGTCATCTGGCACAAGGGAATGG
                   AGCGCATCCAGCCCGGTGGGCGGTTCGAGGTGGTCTCCCAGGGTCGGCAACAGATGCT
                   GGTGATCAAGGGCTTCACGGCAGAAGACCAGGGCGAGTACCACTGTGGCCTGGCTCAG
                   GGCTCCATCTGCCCTGCGGCTGCCACCTTCCAGGTGGCACTCAGCCCAGCCTCTGTGG
                   ATGAGGCCCCTCAGCCCAGCTTGCCCCCCGAGGCAGCCCAGGAGGGTGACCTGCACCT
                   ACTGTGGGAGGCCCTGGCTCGGAAACGTCGCATGAGCCGTGAGCCCACGCTGGACTCC
                   ATTAGCGAGCTGCCAGAGGAGGACGGCCGCTCGCAGCGCCTGCCACAGGAGGCAGAGG
                   AGGTGGCACCTGATCTCTCTGAAGGCTACTCCACGGCCGATGAGCTGGCCCGCACTGG
                   AGATGCTGACCTCTCACACACCAGCTCTGATGATGAGTCCCGGGCAGGCACCCCTTCC
                   CTGGTCACCTACCTCAAGAAGGCTGGGAGGCCAGGCACCTCACCACTGGCCAGCAAGG
                   TGAGCCCCCCCAACTTGGCCTGCAAGGAGAGGTTCCCCACGCCCCGGGCCGGCCGCAG
                   CCTCCTGGGCTTCGTGGGGGCAGACCCAGCCTTTCCCGGCAGCGAGCGCTCGGCCAGG
                   TGCACTAGGCGCTGTGCGGCCCCCCCTCCCCGCGAGTCCCTCAAGCGGGAACCTGCCT
                   CGTGTCTCCCAGGAGCCATGGAGGCTGTGGAACTCGCCAGAAAACTGCAGGAGGAAGC
                   TACGTGCTCCATCTGTCTGGATTACTTCACAGACCCTGTGATGACCACCTGTGGCCAC
                   AACTTCTGCCGAGCGTGCATCCAGCTGAGCTGGGAAAAGGCGAGGGGCAAGAAGGGGA
                   GGCGGAAGCGGAAGGGCTCCTTCCCCTGCCCCGAGTGCAGAGACATGTCCCCCCACAG
                   GAACCTGCTGCCCAACCGGCTGCTGACCAAGGTGGCCGAGATGGCGCAGCAGCATCCT
                   CGTCTGCAGAAGCAAGACCTGTGCCAGGAGCACCACGAGCCCCTCAAGCTTTTCTGCC
                   AGAAGGACCAGAGCCCCATCTGTGTGGTGTGCAGGGAGTCCCGGGAGCACCGGCTGCA
                   CAGGGTGCTGCCCGCCGAGGAGGCAGTGCAGGGGTACAAGTTGAACCTGGAGGAGGAC
                   ATGGAGTACCTTCGGGAGCAGATCACCAGGACAGGGAATCTGCAGGCCAGGGAGGAGC
                   AGAGCTTAGCCGAGTGGCAGGGCAAGGTGAAGGAGCGGAGAGAACGCATTGTGCTGGA
                   GTTTGAGAAGATGAACCTCTACCTGGTGGAAGAAGAGCAGAGGCTCCTCCAGGCTCTG
                   GAGACCGAAGAAGAGGAGACTCCCACCAGGCTCCGGGAGAGCGTGGCCTGCCTGGACC
                   GGCAGGGTCACTCTCTGGAGCTGCTGCTGCTGCAGCTGCAGGAGCCGAGCACACAGGG
                   GCCCCTCCAGATGCTGCAGGACATGAAGCAACCCCTGACCAGGGCGGCGTTACTGGTG
                   GTTCTAATTCATGGGATGAATCTTGTTGAGTTCCCAGTGGTCTCTCTGCCCAGCCCCC
                   TGTACCTTATTGCCACCAAGGCCCACACACAATTGGGCCCGGGGACTCCCACCTTTGA
                   CCCTGAATGCCCCACACCTCTCCCCATCTCTCCACCACCACGCCCATCTACAGAGGAT
                   GTGGTGCCTGATGCCACCTCCGCGTACCCCTACCTCCTCCTGTATGAGAGCCGCCAGA
                   GGCGCTACCTCGGCTCTTCGCCGGAGGGCAGTGGGTTCTGCAGCAAGGACCGATTTGT
                   GGCTTACCCCTGTGCTGTGCGCCAGACGGCCTTCTCCTCTGGGAGGCACTACTGGGAG
                   GTGGGCATGAACATCACCGGGGACGCGTTGTGGGCCCTGGGTGTGTGCAGGGACAACG
                   TGAGCCGGAAAGACAGGGTCCCCAAGTGCCCCGAAAACGGCTTCTGGGTGGTGCAGCT
                   GTCCAAGGGGACCAAGTACTTATCCACCTTCTCTGCCCTAACCCCGGTCATGCTGATG
                   GAGCCTCCCAGCCACATGGGCATCTTCCTGGACTTCGAAGCCCGGGAAGTGTCCTTCT
                   ACAGTGTAAGCGATGGGTCCCACCTGCACACCTACTCCCAGGCCACCTTCCCAGGCCC
                   CCTGCAGCCTTTCTTCTGCCTGGGGGCTCCGAAGTCTGGTCAGATGGTCATCTCCACA
                   GTGACCATGGCAGGGGTAAAAGACCTGGCCACAAGAACCGGAGCGGTGGTGACGCCAG
                   CGCTCGGAGCCTACGCGCCCAGCGCTACCGAAACCCAGAGTCCTGCGCCCTGGAGTCC
                   CCGCGCCCCGGAGCCCGAGCACCCGGGAGTCCCGAGCCTCGCGCCCCGGAGTGCCCGA
                   GCCTGCGCCGCCGCACCCGGATACCCCGGGTCCCCGCGAGCTGCCGAGGCCGCCCGCC
                   GCCGCCCCGCGGACAGTACCGCCTTCCTCCCCTCTGTCCGCGCCATGGCCGCCCCCGA
                   CCTGTCCACCAACCTCCAGGAGCAGGCCACCTGCGCCATCTGCCTCGACTACTTCACG
                   GATCCGGTGATGACCGACTGCGGCCACAACTTCTGCCGCGAGTGCATCCGGCGCTGCT
                   GGGGCCAGCCCGAGGCCCGTACGCGTGCCCCGAGTGCCGCGAGCTGTCCCCGCAGAGG
                   AACCTGCGGCCCAACCGCCCGCTTGCTAAGATGGCCGAGATGGCGCGGCGCCTGCACC
                   CGCCGTCGCCGGTCCCGCAGGCGTGTGCCCGCGCACCGCGAGCCACTGGCCGCCTTCT
                   GTGGCGACGAGCTGCGCCTCCTGTGTGCGGCCTGCGAGCGCTCTGGGGAGCACTGGGC
                   GCACCGCGTTGGCCGCTGCAGGACGCGGCCGAAGACCTCAAGGCCCCTTGAGGCTGGG
                   ACCATGGCCGCCAATGAGACCCTGCTCTCGGGGGCGAAGCTGGAGAAGTCACTGGAGC
                   ATCTCCGGAAGCAGATGCAGGATGCGTTGCTGTTCCAAGCCCAGGCGGATGAGACCTG
                   CGTCTTGTGGCAGGCAGAAGATGGTGGAGAGCAGCGGCACAACCTGCTGCCTGAGTTC
                   GAGCGTCTTCGCCGTTTGCTGGCAGAGGGAGGGACAGCAGCTGCTGCAGAGGCTGGAG
                   AGGAGGAGCTGAAGCAGAGCGCCCACCTAGCTGAGCTCATCGCCGAGCTCGAGAGGCC
                   GCTGCCAGCTGCCTGCGCTGGGGCTGCTGCAGGAGAGTCTTTTCCCATGTGTGGGCTC
                   CACTCCCTGAGCCGGCCCCCTGGCGTGGGCTTTCCTTGGTGCACCCCCAAACCAGAAC
                   CAGTGGACGCCCTGGCCTGTGCGTGGCGGCAGGGCTGCCAGACCCAGGTGGAGCCCAC
                   AATGCTGCAGATGTGGCTGGGCGGCTTTGCACAGGGGGTGACACTGCTGCCGGCCTCT
                   GGAGCCCAGCAGAACATCAGTCCAGGCACCGGCTCCTGGTTTCGATTGTCATTTCTAT
                   TATTTAAGGGGTACAAGTGCAGTCAGAGTGTAGCCATCACCCGAATGGTGCACACTGT
                   ACCCAAGACCAAACCCCCTTGTCGAGGCCAAGGTTCTCCTCTACCCCCAAGCCCTTCT
                   CCTGCCGCCCCTGCACCCGGCCTTGTGACAGCCACCACCTGTTTCCAAATGACACCAG
                   GGGTGGGCCGCCCACCCCAGGACATCAAGGACGCCCTGCGCAGGGTCCAGGATGTGAA
                   GCTGCAGCCCCCAGAAGTTGTGCCTATGGAGCTGAGGACCGTGTGCAGGGTCCCGGGA
                   CTGGTAGAGACACTGCGCAGGTTTCGAGGGGACGTGACCTTGGACCCGGACACCGCCA
                   ACCCTGACCTGATCCTGTCTGAAGACAGGCGGAGCGTGCAGCGGGGGGACCTACGGCA
                   GGCCCTGCCGGACAGCCCAGAGCGCTTTGACCCCGGCCCCTGCGTGCTGGCCCAGGAG
                   CGCTTCACCTCAGGCCGCCACTACTGGGAGGTGGAGGTTGGGGACCGCACCAGCTGGG
                   CCCTGGGGGTGTGCAGGGAGAACGTGAACAGGAAGGAGAAGGGCGAGCTGTCCGCGGG
                   CAACGGCTTCTGGATCCTGGTCTTCCTGGGGAGCTATTACAATTCCTCGGAACGGGCC
                   TTGGCTCCACTCCGGGACCCACCCAGGCGCGTGGGGATCTTTCTGGACTACGAGGCTG
                   GACATCTCTCTTTCTACAGTGCCACCGATGGGTCACTGCTATTCATCTTTCCCGAGAT
                   CCCCTTCTCGGGGACCCTGCGGCCCCTCTTCTCACCCCTGTCCAGCAGCCCGACCCCG
                   ATGACTATCTGCCGGCCGAAAGGTGGGTCCGOGGACACCCTGGCTCCCCAGTGACTCG
                   GGCCCTCCTGGAGGA
                   ORF Start: ATG at 15 ORF Stop: TGA at 14088
                   SEQ ID NO:72         4691 aa MW at 512894.2 kD
NOV13a,            MPLYNDSFHEISHKGRRHTLVLKSIQRADAGIVRASSLKVSTSARLEVRVKPVVFLKA
CG59237-01 Protein LDDLSAEERGTLALQCEVSDPEAHVVWRKDGVQLGPSDKYDFLHTAGTRGLVVHDVSP
Sequence           EDAGLYTCHVGSEETRARVRVHDLHVGITKRLKTMEVLEGESCSFECVLSHESASDPA
                   MWTVGGKTVGSSSRFQATRQGRKYILVVREAAPSDAGEVVFSVRGLTSKASLIVRERP
                   AAIIKPLEDQWVAPGEDVELRCELSRAGTPVHWLKDRKAIRKSQKYDVVCEGTMAMLV
                   IRGASLKDAGEYTCEVEASKSTASLHVEEKANCFTEELTNLQVEEKGTAVFTCKTEHP
                   AATVTWRKGLLELRASGKHQPSQEGLTLRLTISALEKADSDTYTCDIGQAQSRAQLLV
                   QGRRVHIIEDLEDVDVQEGSSATFRCRISPANYEPVHWFLDKTPLHANELNEIDAQPG
                   GYHVLTLRQLALKDSGTIYFEAGDQRASAALRVTEKPSVFSRELTDATITEGEDLTLV
                   CETSTCDIPVCWTKDGKTLRGSARCQLSHEGHRAQLLITGATLQDSGRYKCEAGGACS
                   SSIVRVHARPVRFQEALKDLEVLEGGAATLRCVLSSVAAPVKWCYGNNVLRPGDKYSL
                   RQEGANLELVVRNLRPQDSCRYSCSFGDQTTSATLTVTALPAQFIGKLRNKEATEGAT
                   ATLRCELSKAAPVEWRKGSETLRDGDRYCLRQDGAMCELQIRGLAMVDAAEYSCVCCE
                   ERTSASLTIRPMPAHFIGRLRHQESIEGATATLRCELSKAAPVEWRKGRESLRDGDRH
                   SLRQDGAVCELQICGLAVADAGEYSCVCGEERTSATLTVKALPAKFTEGLRNEEAVEG
                   ATANLWCELSKVAPVEWRKGPENLRDGDRYILRQEGTRCELQICGLAMADAGEYLCVC
                   GQERTSATLTIRALPARFIEDVKNQEAREGATAVLQCELNSAAPVEWRKGSETLRDGD
                   RYSLRQDGTKCELQIRGLAMADTGEYSCVCGQERTSANLTVRALPIKFTEGLRNEEAT
                   EGATAVLRCELSKMAPVEWWKGHETLRDGDRHSLRQDGARCELQIRGLVAEDAGEYLC
                   MCGKERTSAMLTVRAMPSKFIEGLRNEEATEGDTATLWCELSKAAPVEWRKGHETLRD
                   GDRHSLRQDGSRCELQIRGLAVVDAGEYSCVCGQERTSATLTVRALPARFIEDVKNQE
                   AREGATAVLQCELSKAAPVEWRKGSETLRGGDRYSLRQDGTRCELQIHGLSVADTGEY
                   SCVCGQERTSATLTVRALPARFTQDLKTKEASEGATATLQCELSKVAPVEWKKGPETL
                   RDGGRYSLKQDGTRCELQIHDLSVADAGEYSCMCGQERTSATLTVRALPARFTEGLRM
                   EEANEGATATLQCELSKAAPVEWRKGLEALRDGDKYSLRQDGAVCELQIHGLAMADNG
                   VYSCVCGQERTSATLTVRALPARFIEDMRNQKATEGATVTLQCKLRKAAPVEWRKGPN
                   TLKDGDRYSLKQDGTSCELQIRGLVIADAGEYSCICEQERTSATLTVRALPARFIEDV
                   RNHEATEGATAVLQCELSKAAPVEWRKGSETLRDCDRYSLRQDGTRCELQIRGLAVED
                   TGEYLCVCGQERTSATLTVRALPARFIDNMTNQEAREGATATLHCELSKVAPVEWRKG
                   PETLRDGDRHSLRQDGSRCELQIRGLAVVDAGEYSCVCGQERTSATLTVRALPARFIE
                   DVKNQEAREGATAVLQCELSKAAPVEWRKGSETLRGGDRYSLRQDGTRCELQIHGLSV
                   ADTGEYSCVCGQERTSATLTVRALPARFTQDLKTKEASEGATATLQCELSKVAPVEWK
                   KGPETLRDGGRYSLKQDGTRCELQIHDLSVADAGEYSCMCGQERTSATLTVRDCHTLH
                   VMPHYPFQLPGLLKEPEETLIYIQIPSPVILFTEGLRNEEANEGATATLQCELSKAAP
                   VEWRKGLEALRDGDKYSLRQDGAVCELQIHGLAMADNGVYSSLPARFIEDMRNQKATE
                   GATVTLQCKLRKAAPVEWRKGPNTLKDGDRYSLKQDGTSCELQIRGLVIADAGEYSCI
                   CEQERTSATLTVRALPARFIEDVRNHEATEGATAVLQCELSKAAPVEWRKGSETLRDG
                   DRYSLRQDGTRCELQIRGLAVEDTGEYLCVCGQERTSATLTVRALPARFIDNNTNQEA
                   REGATATLHCELSKVAPVEWRKGPETLRDGDRHSLRQDGTRCELQIRGLSVADAGEYS
                   CVCGQERTSATLTIRALPAKFTKGLRNEEATEGATAMLQCELSKVAPVEWRKGPETLR
                   DGDRYNLRQDGTRCELQIHGLSVADTGEYSCVCGQEKTSATLTVKAPQPVFREPLQSL
                   QAEEGSTATLQCELSEPTATVVWSKGGLQLQANGRREPRLQGCTAELVLQDLQREDTG
                   EYTCTCGSQATSATLTVTAAPVRFLRELQHQEVDEGGTARLCCELSRAGASVEWRKGS
                   LQLFPCAKYQMVQDGAAAELLVRGVEQEDAGDYTCDTGHTQSMASLSVRGGRGARCGP
                   QVRDAAQGATRELLIHQLEAKDTGEYACVTGGQKTAASLRVTEPEVTIVRGLVDAEVT
                   ADEDVEFSCEVSRAGATGVQWCLQGLPLQSNEVTEVAVRDGRIHTLRLKGVTPEDAGT
                   VSFHLGNHASSAQLTVRAPEVTILEPLQDVQLRGVPLQANEMNDITVEQGTLHLLTLH
                   KVTLEDAGTVSFHVGTCSSEAQLKVTEAVPCLVRGLQNVDVFAGEVATFSCEDGPQSA
                   IAVRDGIFHSLMLSGLGVADSGTVIFRAGPLVSTAKLLIKDPVVEVVSAMQDLAVEEG
                   GSAELLCQYSRPVQATWKMDEREVHTDGHRVIIEQDWNVARLTFRPALPCDSGIYSCE
                   AAGTRVVALLQVQAKNTVVRGLENVEALEGGEALFECQLSQPEVAAHTWLLDDEPVRT
                   SENAEVVFFENGLRHLLLLKNLRPQDSCRVTFLAGDMVTSAFLTVRGDCAVLVQGWRL
                   EILEPLKNAAVRAGAQARFTCTLSEAVPVGEASWYINGAIWQPDDSDWTVTADGSHHA
                   LLLRSAQPHHAGEVTFACRDAVASARLTVLGLPDPPEDARVVARSSHTVTLSWAAPMS
                   DGGCGLCGYRVEVKEGATGQWRLCHELVPGPECVVDGLAPGETYRFRVAAVGPVGAGE
                   PVHLPQTVRLEPPKPVPPQPSAPESRQVAAGEDVCLELEVVAEAGEVIWHKGMERIQP
                   GGRFEVVSQGRQQMLVIKGFTAEDQGEYHCGLAQGSICPAAATFQVALSPASVDEAPQ
                   PSLPPEAAQEGDLHLLWEALARKRRMSREPTLDSISELPEEDGRSQRLPQEAEEVAPD
                   LSEGYSTADELARTGDADLSHTSSDDESRAGTPSLVTYLKKAGRPGTSPLASKVSPPN
                   LACKERFPTPRAGRSLLGFVCADPAFPGSERSARCTRRCAAPPPRESLKREPASCLPG
                   AMEAVELARKLQEEATCSICLDYFTDPVMTTCGHNFCRACIQLSWEKARGKKGRRKRK
                   GSFPCPECREMSPQRNLLPNRLLTKVAEMAQQHPGLQKQDLCQEHHEPLKLFCQKDQS
                   PICVVCRESREHRLHRVLPAEEAVQGYKLKLEEDMEYLREQITRTGNLQAREEQSLAE
                   WQGKVKERRERIVLEFEKMNLYLVEEEQRLLQALETEEEETASRLRESVACLDRQGHS
                   LELLLLQLEERSTQGPLQMLQDMKEPLSPAALLVVLIHGMNLVEFPVVSLPSPLYLIA
                   TKAHTQLGPGTPTFDPECPTPLPISPPPRPSTEDVVPDATSAYPYLLLYESRQRRYLG
                   SSPEGSGFCSKDRFVAYPCAVGQTAFSSGRHYWEVGMNITGDALWALGVCRDNVSRKD
                   RVPKCPENGFWVVQLSKGTKYLSTFSALTPVMLMEPPSHMGIFLDFEAGEVSFYSVSD
                   GSHLHTYSQATFPGPLQPFFCLGAPKSGQMVISTVTMAGVKDLATRTGAVVTPALGAY
                   APSATETQSPAPWSPRAPEPEHPGVPSLAPRSARACAAAPGYPGSPRAAEAARRRPAD
                   STAFLPSVRAMAAPDLSTNLQEEATCAICLDYFTDPVMTDCGHNFCRECIRRCWGQPE
                   ARTRAPSAASCPRRGTCGPTARLLRWPRWRGACTRRRRSRRRVPAHREPLAAFCGDEL
                   RLLCAACERSGEHWAHRVGRCRTRPKTSRPLEAGTMAANETLLSGAKLEKSLEHLRKQ
                   MQDALLFQAQADETCVLWQAEDGGEQRQNVLREFERLRRLLAEGGTAAAAEAGEEELK
                   QSAHLAELIAELERPLPAACAGAAAGESFPMCGLHSLSRPPGVGFPWCTPKPEPVDAL
                   ACAWRQGCQTQVEPTMLQMWLGGFAQGVTLLPASGAQQNISPGTGSWFRLSFLLFKGY
                   KCSQSVAITRMVHTVPKTKPPCRGQGSPLPPSPSPAAPAPGLVTATTCFQMTPGVGRP
                   PQDIKDALRRVQDVKLQPPEVVPMELRTVCRVPGLVETLRRFRGDVTLDPDTANPELI
                   LSEDRRSVQRGDLRQALPDSPERFDPGPCVLGQERFTSCRHYWEVEVGDRTSWALGVC
                   RENVNRKEKGELSAGNGFWILVFLGSYYNSSERALAPLRDPPRRVGIFLDYEAGHLSF
                   YSATDGSLLFIFPEIPFSGTLRPLFSPLSSSPTPMTICRPKGGSGDTLAPQ
                   SEQ ID NO:73         14061 bp
NOV13b,            TGTCGCTCAACGGGATGCCCCTGTACAACGACAGCTTCCATGAGATCTCACACAAGGG
CG59237-02 DNA     CCGGCGCCACACGCTGGTACTGAAGAGCATCCAGCGGGCTGATGCGCGCATAGTACGC
Sequence           GCCTCCTCCCTGAAGGTGTCGACCTCTGCCCGCCTGGAGGTCCGAGTGAAGCCGGTGG
                   TGTTCCTGAAGGCGCTGGATGACCTGTCCGCAGAGGAGCGCGGCACCCTGGCCCTGCA
                   GTGTGAAGTCTCTGACCCCGAGGCCCATGTGGTGTGGCGCAAAGATGGCGTGCAGCTG
                   GGCCCCAGTGACAAGTATGACTTCCTGCACACGGCGGGCACGCGGGGGCTCGTGGTGC
                   ATGACGTGAGCCCTGAAGACGCCGGCCTGTACACCTGCCACGTGGGCTCCGAGGAGAC
                   CCGGGCCCGCGTCCGCCTCCACGATCTGCACGTGGGCATCACCAAGAGGCTGAAGACA
                   ATGGAGGTGCTGGAAGGGGAAAGCTGCAGCTTTGAGTGCGTCCTGTCCCACGAGAGTG
                   CCAGCGACCCGGCCATGTGGACAGTCGGTGGGAAGACAGTGGGCAGCTCCAGCCGCTT
                   CCAGGCCACACGTCAGGGCCGAAAATACATCCTGGTGGTCCGGGAGGCTGCACCAAGT
                   GATGCCGGGGAGGTGGTCTTCTCTGTGCGGGGCCTCACCTCCAAGGCCTCACTCATTG
                   TCAGAGAGAGGCCGGCCGCCATCATCAAGCCCCTGGAAGACCAGTGGGTGGCGCCAGG
                   GGAGGACGTGGAGCTGCCCTGTGAGCTGTCACGGGCGGGAACGCCCGTGCACTGGCTG
                   AAGGACAGGAAGGCCATCCGCAAGAGCCAGAAGTATGATGTGGTCTGCGAGGGCACGA
                   TGGCCATGCTGGTCATCCGCGGGGCCTCGCTCAAGGACGCGGGCGAGTACACGTGTGA
                   GGTGGAGGCTTCCAAGAGCACAGCCAGCCTCCATGTGGAAGAAAAAGCAAACTGCTTC
                   ACAGAGGAGCTGACCAATCTGCAGGTGGAGGAGAAAGGCACAGCTGTGTTCACGTGCA
                   AGACGGAGCACCCCGCGGCCACAGTGACCTGGCGCAAGGGCCTCTTGGAGCTACGGGC
                   CTCAGGGAAGCACCAGCCCAGCCAGGAGGGCCTGACCCTGCGCCTCACCATCAGTGCC
                   CTGGAGAAGGCAGACAGCGACACCTATACCTGCGACATTGGCCAGGCCCAGTCCCGGG
                   CCCAGCTCCTAGTGCAAGGCCGGAGAGTGCACATCATCGAGGACCTGGACGATGTGGA
                   TGTGCAGGAGGGCTCCTCGGCCACCTTCCGTTGCCGGATCTCCCCGGCCAACTACGAG
                   CCTGTGCACTGGTTCCTGGACAAGACACCCCTGCATGCCAACGAGCTCAATGAGATCG
                   ATGCCCAGCCCGGGGGCTACCACGTGCTGACCCTGCGCCAGCTGGCGCTCAAGGACTC
                   GGGCACCATCTACTTTGAGGCGGGTGACCAGCGGGCCTCGGCCGCCCTGCGGGTCACT
                   CAGAAGCCAAGCGTCTTCTCCCGGGAGCTCACAGATGCCACCATCACAGAGGGTGAGG
                   ACTTGACCCTGGTGTGCGAGACCAGCACCTGCGACATTCCTGTGTGCTGGACCAAGGA
                   TGGCAAGACCCTGCGGGGGTCTGCCCGGTGCCAGCTGAGCCATGAGGGCCACCGGGCC
                   CAGCTGCTCATCACTGGGGCCACCCTGCAGGACAGTGGACGCTACAAGTGTGAGGCTG
                   GGGGCGCCTGCAGCACCTCCATTGTCAGCGTGCATGCGCGGCCAGTGCGGTTCCAGGA
                   GGCCCTGAAGGACCTGGAGGTGCTGGAGGCTGGTGCTGCCACACTCCGCTGTGTGCTG
                   TCATCTGTGGCTGCGCCCGTGAAGTGGTGCTATGGAAACAACGTCCTGAGGCCAGGTG
                   ACAAATACAGCCTACGCCAGGAGGGTGCCATGCTGGAGCTGGTGGTCCGGAACCTCCG
                   GCCGCAGGACAGCGGGCGGTACTCATGCTCCTTCGGGGACCAGACTACTTCTGCCACC
                   CTCACAGTGACTGCCCTGCCTGCCCAGTTCATCGGGAAACTGAGAAACAAGGAGGCCA
                   CAGAAGGGGCCACGGCCACGCTGCGGTGTGAGCTGAGCAAGGCAGCCCCTGTGGAGTG
                   GAGAAAGGGGTCCGAGACCCTCAGAGATGGGGACAGATACTGTCTGAGGCATTACGGG
                   GCCATGTGTGAGCTGCAGATCCGTGGCCTGGCCATGGTGGATGCCGCGGAGTACTCGT
                   GTGTGTGTGGAGAGGAGAGGACCTCAGCCTCACTCACCATCAGGCCCATGCCTGCCCA
                   CTTCATAGGAAGACTGAGACACCAAGAGAGCATAGAACGGGCCACAGCCACGCTGCGG
                   TGTGAGCTGAGCAAGGCGGCCCCCGTGGAGTGGAGGAAGGGGCGTGAGAGCCTCAGAG
                   ATGGGCACAGACATAGCCTGAGGCAGGACGGGGCTGTGTGCGAGCTGCAGATCTGTGG
                   CCTGGCTGTGGCAGATGCTGGGGAGTACTCCTCTGTGTGTGGGGAGGAGAGGACCTCT
                   GCCACTCTCACCGTGAAGGCCCTGCCAGCCAAGTTCACAGAGCCTCTGAGGAATGAAG
                   ACGCCGTGGAAGGGGCCACAGCCATGTTGTGGTGTGAACTGAGCAAGGTGGCCCCTGT
                   GGAGTGGAGGAAGGGGCCCGAGAACCTCAGAGATGGGGACAGATACATCCTGAGGCAG
                   GAGGGGACCAGGTGTGAGCTGCAGATCTGTGGCCTGGCCATGGCGGACGCCGGGOAGT
                   ACTTGTGTGTGTGCGGGCAGGAGAGGACCTCAGCCACGCTCACCATCAGGGCTCTGCC
                   TGCCAGGTTCATAGAAGATGTGAAAAACCAGGAGGCCAGAGAAGGGGCCACGGCTGTG
                   CTGCAGTGTGAGCTGAACAGTGCAGCCCCTGTGGAGTGGAGAAAGGGGTCTGAGACCC
                   TTAGAGATGCGGACAGATACAGCCTGAGGCAGGACGGGACTAAATGTGAGCTGCAGAT
                   TCGTGGCCTGGCCATCGCAGACACTGGGGAGTACTCGTGCGTGTGCGGGCAGGAGAGG
                   ACCTCGGCTATGCTCACCGTCAGGGCTCTACCCATCAAGTTCACAGAGGGTCTGAGGA
                   ACGAAGAGGCCACAGAAGGGGCAACAGCCGTGCTGCGGTGTGACCTGAGCAAGATGGC
                   CCCCGTGGAGTGGTGGAAGGGGCATGAGACCCTCAGAGATGGAGACACACACAGCCTC
                   AGGCAGGACGGGGCCAGGTGTGAGCTGCAGATCCGCGGCCTCGTGGCAGAGGACGCTG
                   GGGAGTACCTGTGCATGTGCGGGAAGGAGAGGACCTCAGCCATGCTCACCGTCAGGGC
                   CATGCCTTCCAAGTTCATAGAGGGTCTGAGGAATGAAGAGGCCACAGAAGGGGACACG
                   GCCACGCTGTGGTGTGAGCTGAGCAAGGCGGCACCGGTGGAGTGGAGGAAGGGGCATG
                   AGACCCTCAGAGATGGGGACAGACACAGCCTGAGGCAGGATGGGTCCAGGTGTGAGCT
                   GCAGATCCGTGGCCTGGCTGTGGTGGATGCCGGGGAGTACTCGTGTGTGTGCGCCCAG
                   GAGAGGACCTCAGCCACACTCACTGTCAGGGCCCTGCCTGCCAGATTCATAGAAGATG
                   TGAAAAACCAGGAGGCCAGAGAAGGGGCCACGGCCGTGCTGCAATGTGAGCTGAGCAA
                   GGCGGCCCCCGTGGAGTGGAGGAAGGGGTCTGAGACCCTCAGAGGTGGGGACAGATAC
                   AGCCTGAGGCAGGATGGGACCAGATGTGAGCTGCAGATTCATGGCCTGTCTGTGGCAG
                   ACACTGGGGAGTACTCGTGTGTGTGCGGGCAGGAGAGGACCTCGGCCACACTCACCGT
                   CAGGGCCCTGCCTGCACGATTCACTCAAGATCTGAAGACCAAGGAGGCCTCAGAAGGG
                   GCCACAGCTACACTGCAGTGTGAGCTGAGCAAGGTGGCCCCTGTGGAATGGAAGAAGG
                   GTCCTGAGACCCTCAGAGATGGGGGCAGATACAGCCTGAAGCAGGATGGGACGAGGTG
                   TGAGCTGCAGATCCATGACCTGTCTGTGGCGGATGCTGGGGAATACTCATGCATGTGT
                   GGACAAGAGAGGACCTCGGCCACGCTCACTGTCAGGGCCCTGCCTGCCAGGTTCACAG
                   AGGGTCTGAGGAATGAAGAGGCCATGGAAGGGGCCACAGCCACACTGCAATGTGAGCT
                   GAGCAAGGCAGCCCCTGTGGAGTGGAGGAAAGGCCTTGAGGCTCTCAGAGATGCGGAC
                   AAATACAGCCTGAGACAAGACGGGGCTGTGTGTGAGCTGCAGATTCATGGCCTGGCTA
                   TGGCAGATAACGGGGTGTACTCATGTGTGTGTGGGCAGGAGAGGACCTCAGCTACACT
                   CACTGTCAGGGCCCTGCCTGCCAGATTCATAGAGGATATGAGAAACCAGAAGGCCACA
                   GAAGGGGCTACAGTCACATTGCAATGTAAGCTGAGAAAGGCGGCCCCCGTGGAGTGGA
                   GAAAGGGGCCCAACACCCTCAAAGATGGGGACAGGTACAGCCTGAACCAGGATGGGAC
                   CAGTTGTGAGCTGCAGATTCGTGGCCTGGTCATAGCAGATGCTGGAGAATACTCGTGC
                   ATATGTGAGCAGGAGAGCACCTCGGCCACGCTCACIGTCAGGGCCCTGCCGGCCAGAT
                   TCATAGAAGATGTGAGAAATCACGAGGCCACAGAAGGGGCCACAGCTGTGCTCCAGTG
                   TGAGCTGAGCAAGGCGGCCCCCGTGGAGTGGCGGAAGGGGTCTGAGACCCTCAGAGAT
                   GGGGACAGATATAGCCTGAGGCAGGACGGGACGAGGTGTGAGCTGCACATTCGTGGCC
                   TGGCTGTGGAGGACACTGGAGAGTATTTGTGTGTGTGCGGGCAGGAGAGAACCTCAGC
                   TACACTCACTGTCAGGGCCCTGCCAGCCAGATTCATAGACAACATGACAAACCACGPA
                   GCCAGAGAAGGGGCCACGGCCACACTGCACTGTGAACTGAGCAAGGTGGCCCCTGTGC
                   AGTGGAGGAAGGGACCTGAAACCCTCCGAGATGGGGACAGACACAGCCTGAGGCAGCA
                   TGGGTCCAGGTGTGAGCTGCAGATCCGTGGCCTGGCTGTGGTGGATGCCGGGCACTAC
                   TCGTGTGTGTGCGGGCAGGAGAGGACCTCAGCCACACTCACTGTCAGGGCCCTGCCTG
                   CCAGATTCATAGAAGATGTGAAAAACCAGGAGGCCAGAGAACGGGCCACGGCCGTGCT
                   GCAATGTGAGCTGAGCAAGGCGGCCCCCGTGGAGTGGAGGAAGGGGTCTGAGACCCTC
                   AGAGGTGGGGACAGATACAGCCTGAGGCAGGATGGGACCAGATGTGAGCTGCAGATTC
                   ATGGCCTGTCTGTGGCAGACACTGGGGAGTACTCGTGTGTGTGCGGGCAGCAGAGGAC
                   CTCGGCCACACTCACCGTCAGGGCCCTGCCTCCACGATTCACTCAAGATCTGAAGACC
                   AAGCAGGCCTCAGAAGGGGCCACAGCTACACTGCAGTGTGAGCTGAGCAAGGTGGCCC
                   CTGTGGAATGGAAGAAGGGTCCTGAGACCCTCAGAGATGGGGGCAGATACAGCCTGAA
                   GCAGGATGGGACGAGGTGTGAGCTGCAGATCCATGACCTGTCTGTGGCGGATGCTGGG
                   GAATACTCATGCATGTGTGGACAAGAGAGGACCTCGGCCACGCTCACTGTCAGGGACT
                   GCCACACTCTTCACGTCATGCCACACTATCCCTTCCAGCTTCCTGGGCTGCTGAACGA
                   ACCAGAAGAAACTCTCATCTACATCCAGATTCCCTCTCCTGTGATACTGTTCACAGAG
                   GGTCTGAGGAATGAAGAGGCCATGGAAGGGGCCACAGCCACACTCCAATGTGAGCTGA
                   GCAAGGCAGCCCCTGTGGAGTGGAGGAAAGGCCTTGAGGCTCTCAGAGATGGGGACAA
                   ATACAGCCTGAGACAAGACGGGGCTGTGTGTGAGCTGCAGATTCATGGCCTGGCTATG
                   CCAGATAACGGGGTGTACTCATCCCTGCCTGCCAGATTCATAGAGGATATGAGAAACC
                   AGAAGGCCACAGAAGGGGCTACAGTCACATTGCAATGTAACCTGAGAAAGGCGGCCCC
                   CGTGGAGTGGAGAAAGGGGCCCAACACCCTCAAAGATGGGGACAGGTACAGCCTGAAG
                   CAGGATGGGACCAGTTGTGAGCTGCAGATTCGTGGCCTGGTCATAGCAGATGCTGGAG
                   AATACTCGTGCATATGTGAGCAGGAGAGGACCTCGGCCACGCTCACTGTCAGGGCCCT
                   GCCCGCCAGATTCATAGAAGATGTGAGAAATCACGAGGCCACAGAAGGGGCCACAGCT
                   GTGCTGCAGTGTOAGCTGAGCAAGGCGGCCCCCGTGGAGTGGCGGAAGGGGTCTGAGA
                   CCCTCAGAGATGGGGACAGATATAGCCTGACGCAGGACGGGACGAGGTGTGAGCTGCA
                   CAAACCAGGAAGCCAGAGAAGGGGCCACGGCCACACTGCACTGTGAACTGAGCAAGGT
                   GGCCCCTGTGGAGTGGAGGAAGGGACCTGAAACCCTCCGAGATGGGGACAGACACAGC
                   CTGAGGCAGGATGGGACCAGGTGTGAGCTGCAGATTCGTGGCCTGTCTGTGGCAGATC
                   CCGGCGAGTACTCGTGCGTGTGTGGGCAGGAGAGGACCTCAGCCACACTCACGATCAG
                   GGCCCTGCCCGCCAAGTTCACAAAGCGTCTGAGGAATGAAGAGGCCACAGAAGGGGCC
                   ACGGCTATGTTGCAGTGTGAGCTGAGCAAGGTGGCCCCTGTTGAGTGGAGGAAGGGAC
                   CTGAAACCCTCAGAGATGGGGACAGATACAACCTGAGGCAGGATGGGACCAGATGTGA
                   GCTGCAGATTCATGOCCTGTCCGTGGCAGACACTGCGGAGTACTCATGTGTATGTGGT
                   CAGGAGAAGACGTCGGCCACTCTCACTGTCAAGGCCCCACAGCCAGTGTTCCGGGAGC
                   CGCTGCAGAGTCTGCAGGCGGAGGAGGGCTCCACGGCCACCCTGCAGTGTGAGCTGTC
                   TGAGCCCACTGCTACAGTGGTCTGGAGCAAGGGTGGCCTGCAGCTGCAGCCCAATGGG
                   CGCCGGGAGCCACGGCTTCAGGGCTGCACCGCGGAGCTGGTGTTACAGGACCTACAAC
                   GTGAAGACACTGGCGAATACACTTGCACCTGTGGCTCCCAGGCCACCAGTGCCACCCT
                   CACTGTCACAGCTGCGCCTGTGCGGTTCCTCCGAGAGCTGCAGCACCAGGAGGTGGAT
                   GAGGGAGGCACCGCACACTTATGCTGCGAGCTGAGCCGGGCGGGTGCGAGCGTGGAGT
                   GGCGCAAGGGCTCCCTACAGCTCTTCCCTTGTGCCAAGTACCAGATGGTGCAGGATGG
                   TGCAGCTGCAGAGCTGCTGGTACGCGGAGTGGACCAGGAGGATGCGGGTGACTACACG
                   TGTGACACGGGCCACACGCAGAGCATGGCCAGCCTCTCTGTCCGTGGAGGGCGTGGAG
                   CTGCATGCGGGCCCCAAGTACGAGATGCGGCGCAGGGGGCCACGCGGGAGCTGCTGAT
                   CCACCAACTGGAGGCCAAGGACACGGGCGAGTATGCCTGTGTGACAGGCGGCCAGAAA
                   ACCGCTGCCTCCCTCAGGGTCACAGAGCCTGAGGTGACCATTGTACGGGGGCTGGTTG
                   ATGCGGAGGTGACGGCCGATGAGGATGTTGAGTTCAGCTGTGAGGTGTCCAGGGCTGG
                   AGCCACAGGCGTGCAGTGGTGCCTACAGGGCCTGCCACTGCAAAGCAATGAGGTGACA
                   GAGCTGGCTGTGCGGGATGGCCGCATCCACACCCTGCGGCTGAAGGGCGTGACGCCCG
                   AGGACGCTGGCACTGTCTCCTTCCATTTGGGAAACCATGCTTCCTCTGCCCAGCTCAC
                   CGTCAGAGCTCCTGAGGTGACCATCCTGGAGCCCCTGCAGGACGTGCAGCTCAGAGGG
                   GTGCCCCTGCAGGCCAACGAGATGAATGACATCACTGTGGAGCAGGGCACACTCCACC
                   TGCTCACCCTGCACAAGGTGACCCTTGAGGATGCTGGAACTGTCAGTTTCCACGTGGG
                   CACGTGTAGCTCTGAGGCCCAGCTGAAAGTCACAGAGGCAGTGCCGTGCCTGGTACGT
                   GGCTTGCAGAATGTGGATGTCTTCGCGGGGGAGGTGGCCACGTTCTCCTGTGAGGATG
                   GCCCCCAGAGCGCCATCGCTGTCCGAGATGGGATCTTTCACTCCCTCATGCTCTCGGG
                   CCTGGGGGTGGCCGACTCCGGCACTGTCATCTTCCGCGCAGGGCCCCTGGTCTCCACG
                   GCCAAGTTGTTGATCAAAGATCCCGTGGTGGAGGTGGTCAGTGCCATGCAGGACTTGG
                   CCGTGGAGGAGGGTGGCTCGGCTGAGCTCCTCTGCCAGTATTCACGGCCCGTGCAGGC
                   CACGTGGAAGATGGACGAGCGGGAGGTGCACACGGATGGGCACCGTGTCATCATAGAG
                   CAGGACTGGAACGTGGCCAGGCTGACCTTCAGGCCGGCCTTGCCCTGTGACAGTGGCA
                   TCTATTCTTGTGAGGCTGCGGGCACCCGCGTAGTGGCCCTGCTGCAAGTCCAAGCCAA
                   GAACACGGTGGTGCGAGGGCTGGAGGATGTGGAGGCGCTGGAGGGCGGCGAGGCGCTG
                   TTCGAGTGCCAGCTGTCCCAGCCCGAGGTGGCCGCCCACACCTGGCTGCTGGACGACG
                   AACCCGTGCGCACCTCGGAGAACGCCGAGGTGGTCTTCTTCGAGAACGGCCTGCGCCA
                   CCTGCTGCTGCTCAAAAACTTGCGGCCACAAGACAGCTGCCGGGTGACCTTCCTGGCT
                   GGGGATATGGTGACGTCCGCATTCCTCACGGTCCGAGGTGACTGCGCTGTGCTGGTGC
                   AGGGCTGGCGCCTGGAGATCCTGGAGCCTCTGAAAAACGCGGCGGTCCGGGCCGGCGC
                   ACAGGCACGCTTCACCTGCACGCTCAOCGAGGCGGTGCCCGTGGGAGAGGCGTCCTGG
                   TACATCAATGGCGCGGCAGTGCAGCCGGATGACAGCGACTGGACTGTCACCGCCGACG
                   GCAGTCACCACGCCCTACTGCTGCGCAGCGCCCAGCCCCACCACGCCGGGGAGGTCAC
                   CTTCGCTTGCCGCGACGCCGTGGCCTCTGCGCGGCTCACCGTGCTGGGCCTCCCTGAT
                   CCCCCAGAGGATGCTGAGGTGGTGGCTCGCAGCAGCCACACTGTGACACTGTCTTGGG
                   CAGCTCCCATGAGTGATGGAGGCGGTGGTCTCTGTGCCTACCGCGTGGAGGTGAAGGA
                   GGGGGCCACAGGCCAGTGGCGGCTGTGCCACGAGCTCGTGCCTGGACCCGAGTGTGTG
                   GTGGATGGCCTGGCCCCCGGGGAGACCTACCGCTTCCGTGTGGCAGCTGTGGGCCCTG
                   TGGGTGCTGGGGAACCGGTTCACCTGCCCCAGACAGTGCGGCTTGAGCCACCGAAGCC
                   TGTGCCTCCCCAGCCCTCAGCCCCTGAGAGCCGGCAGGTGGCAGCTGGTGAAGATGTC
                   TGTCTGGAGCTTGAGGTGGTGGCTGAGGCTGGCGAGGTCATCTGGCACAAGGGAATGG
                   AGCGCATCCAGCCCGGTGGGCGGTTCGAGGTGGTCTCCCAGGGTCGGCAACAGATGCT
                   GGCTCCATCTGCCCTGCGGCTGCCACCTTCCAGGTGGCACTGAGCCCAGCCTCTGTGG
                   ATGAGGCCCCTCAGCCCAGCTTGCCCCCCGAGGCAGCCCAGGAGGGTGACCTGCACCT
                   ACTGTGGGAGGCCCTGGCTCGGAAACGTCGCATGAGCCGTGAGCCCACGCTGGACTCC
                   ATTAGCGAGCTGCCAGAGGAGGACGGCCGCTCGCAGCGCCTGCCACAGGAGGCAGAGG
                   AGGTGGCACCTGATCTCTCTGAAGGCTACTCCACGGCCGATGAGCTGGCCCGCACTGG
                   AGATGCTCACCTCTCACACACCAGCTCTGATGATGAGTCCCGGGCAGGCACCCCTTCC
                   CTGGTCACCTACCTCAAGAAGGCTGGGAGGCCAGGCACCTCACCACTGGCCAGCAAGG
                   TGAGCCCCCCCAACTTGGCCTGCAAGGAGAGGTTCCCCACGCCCCGGGCCGGCCCCAG
                   CCTCCTGGGCTTCGTGGGGGCAGACCCAGCCTTTCCCGGCAGCGAGCGCTCGGCCAGG
                   TGCACTAGGCGCTGTGCGGCCCCCCCTCCCCGCGAGTCCCTCAAGCGGGAACCTGCCT
                   CGTGTCTCCCAGGAGCCATGGAGGCTGTGGAACTCGCCAGAAAACTGCAGGAGGAAGC
                   TACGTGCTCCATCTGTCTGGATTACTTCACAGACCCTGTGATGACCACCTGTGGCCAC
                   AACTTCTGCCGAGCGTGCATCCAGCTGAGCTGGGAAAAGGCGAGGGGCAAGAAGGGGA
                   GGCGGAAGCGGAAGGGCTCCTTCCCCTGCCCCGAGTGCAGAGAGATGTCCCCGCAGAG
                   GAACCTGCTGCCCAACCGGCTGCTGACCAAGGTGGCCGAGATGGCGCAGCAGCATCCT
                   GGTCTGCAGAAGCAAGACCTGTGCCAGGAGCACCACGAGCCCCTCAAGCTTTTCTGCC
                   AGAAGGACCAGAGCCCCATCTGTGTGGTGTGCAGGGAGTCCCGGGAGCACCGGCTGCA
                   CAGGGTGCTGCCCGCCGAGCAGGCAGTGCAGGGGTACAAGTTGAAGCTGGAGGAGGAC
                   ATGGAGTACCTTCGGGAGCAGATCACCAGGACAGGGAATCTGCAGGCCAGGGAGGAGC
                   AGAGCTTAGCCGAGTGGCAGGGCAAGGTGAAGGAGCGGAGAGAACGCATTGTGCTGGA
                   GTTTGAGAAGATGAACCTCTACCTGGTGGAAGAAGAGCAGAGGCTCCTCCACGCTCTC
                   GAGACGGAAGAAGAGGAGACTGCCAGCAGGCTCCGGGAGAGCGTGGCCTGCCTGGACC
                   GGCAGGGTCACTCTCTGGAGCTGCTGCTGCTGCAGCTGGAGGAGCGGAGCACACAGGG
                   GCCCCTCCAGATGCTGCAGGACATGAAGGAACCCCTGAGCAGGGCGGCGTTACTGGTG
                   GTTCTAATTCATGGGATGAATCTTGTTGAGTTCCCAGTGGTCTCTCTGCCCAGCCCCC
                   TGTACCTTATTGCCACCAACCCCCACACACAATTGGGCCCGGGGACTCCCACCTTTGA
                   CCCTGAATGCCCCACACCTCTCCCCATCTCTCCACCACCACGCCCATCTACAGAGGAT
                   GTGGTGCCTGATGCCACCTCCGCGTACCCCTACCTCCTCCTGTATGAGAGCCGCCAGA
                   CGCGCTACCTCGGCTCTTCGCCGGAGGGCAGTGGGTTCTGCAGCAAGGACCGATTTGT
                   GCCTTACCCCTGTGCTGTGGGCCAGACGGCCTTCTCCTCTGGGAGGCACTACTGGGAG
                   GTGGGCATGAACATCACCGGGGACGCGTTGTGGGCCCTGGGTGTGTCCAGGGACAACG
                   TGAGCCGGAAAGACAGGGTCCCCAAGTGCCCCGAAAACGGCTTCTGGGTGGTGCAGCT
                   GTCCAAGGGGACCAAGTACTTATCCACCTTCTCTGCCCTAACCCCGGTCATGCTGATG
                   GAGCCTCCCAGCCACATGGGCATCTTCCTGGACTTCGAAGCCGGGGAAGTGTCCTTCT
                   ACAGTGTAAGCGATGGGTCCCACCTGCACACCTACTCCCAGGCCACCTTCCCAGGCCC
                   CCTGCAGCCTTTCTTCTGCCTGGGGGCTCCCAAGTCTGGTCAGATGGTCATCTCCACA
                   GTGACCATGGCAGGGGTAAAAGACCTGGCCACAAGAACCGGAGCGGTCGTGACGCCAG
                   CGCTCGGAGCCTACGCGCCCAGCGCTACCGAAACCCAGAGTCCTGCGCCCTGGAGTCC
                   CCGCGCCCCGGAGCCCGAGCACCCGGCAGTCCCGACCCTCGCCCCCCGGAGTGCCCGA
                   GCCTGCGCCGCCGCACCCGGATACCCCGGGTCCCCGCGAGCTCCCCAGGCCGCCCGCC
                   GCCGCCCCGCGGACAGTACCGCCTTCCTCCCCTCTGTCCGCGCCATGGCCGCCCCCGA
                   CCTGTCCACCAACCTCCAGGAGGAGGCCACCTGCGCCATCTGCCTCGACTACTTCACG
                   GATCCGGTGATGACCGACTGCGGCCACAACTTCTGCCGCGAGTGCATCCGGCGCTGCT
                   GGGGCCAGCCCGAGGGCCCGTACGCGTGCCCCGAGTGCCGCGAGCTGTCCCCGCAGAG
                   GAACCTGCGGCCCAACCGCCCGCTTGCTAAGATGGCCGAGATGGCGCGGCGCCTGCAC
                   CCGCCGTCGCCGGTCCCGCAGGGCGTGTGCCCCGCGCACCGCGAGCCACTGGCCGCCT
                   TCTGTGGCGACGAGCTGCGCCTCCTGTGTGCGGCCTGCGAGCGCTCTGGGGAGCACTG
                   GGCGCACCGCGTGCGGCCGCTGCAGGACGCGGCCGAAGACCTCAAGGCGAAGCTGGAG
                   AAGTCACTGGAGCATCTCCGGAAGCAGATGCAGGATGCGTTGCTGTTCCAAGCCCAGG
                   CGCATGAGACCTGCGTCTTGTGGCAGAAGATGGTGGAGAGCCAGCGGCAGAACGTGCT
                   GGGTGAGTTCGAGCGTCTTCGCCGTTTGCTGGCAGAGGGAGGGACAGCAGCTGCTGCA
                   GAGGCTGGAGAGGAGGAGCTGAAGCAGAGCGCCCACCTAGCTGAGCTCATCGCCGAGC
                   TCGAGAGGCCGCTGCCAGCTGCCTGCGCTGGGGCTGCTGCAGCAGAGTCTTTTCCCAT
                   GTGTGGGCTCCACTCCCTGAGCCGGCCCCCTGGCGTGGGCTTTCCTTGGTGCACCCCC
                   TGGAGCCCACAATGCTGCAGATGTGGCTGGGCGGCTTTGCACAGGGGGTGACACTGCT
                   GCCGGCCTCTGGAGCCCACCAGAACATCAGTCCAGGCACCGGCTCCTGGTTTCGATTG
                   TCATTTCTATTATTTAAGGGGTACAAGTGCAGTCAGAGTGTAGCCATCACCCCAATGG
                   TCCACACTGTACCCAAGACCAAACCCCCTTGTCGAGGCCAAGGTTCTCCTCTACCCCC
                   AAGCCCTTCTCCTGCCGCCCCTGCACCCGGCCTTGTGACAGCCACCACCTGTTTCCAA
                   ATGACACCAGGGGTGGGCCGCCCACCCCAGGACATCAAGGACGCCCTGCGCAGGGTCC
                   AGGATGTGAAGCTGCAGCCCCCAGAAGTTGTGCCTATGGAGCTGAGGACCGTGTGCAG
                   GGTCCCGGGACTGGTAGAGACACTGCGGAGGTTTCGAGGGGACGTGACCTTGGACCCG
                   GACACCGCCAACCCTGAGCTGATCCTGTCTGAAGACAGGCGGAGCGTGCAGCGGGGGG
                   ACCTACGGCAGGCCCTGCCGGACAGCCCAGAGCGCTTTGACCCCGGCCCCTGCGTGCT
                   GGGCCAGGAGCGCTTCACCTCAGGCCGCCACTACTGGGAGGTGGAGGTTGGGGACCGC
                   ACCAGCTGGGCCCTGGGGGTGTGCAGGGAGAACGTGAACAGGAAGGAGAAGGGCGAGC
                   TGTCCGCGGGCAACGGCTTCTGGATCCTGGTCTTCCTGGGGAGCTATTACAATTCCTC
                   GGAACGGGCCTTGGCTCCACTCCGGGACCCACCCAGGCGCGTGGGGATCTTTCTGGAC
                   TACOAGGCTGGACATCTCTCTTTCTACAGTGCCACCGATCGGTCACTGCTATTCATCT
                   TTCCCGAGATCCCCTTCTCGGGGACGCTGCGGCCCCTCTTCTCACCCCTGTCCAGCAG
                   CCCGACCCCGATGACTATCTGCCGGCCGAAAGGTGGGTCCGGGGACACCCTGGCTCCC
                   CAGTGACTCGGGCCCTCCTGGAGGA
                   ORF Start: ATG at 15 ORF Stop: TGA at 14040
                   SEQ ID NO:74         4675 aa MW at 511097.3 kD
NOV13b,            MPLYNDSFHEISHKGRRHTLVLKSIQRADAGIVRASSLKVSTSARLEVRVKPVVFLKA
CG59237-02 Protein LDDLSAEERGTLALQCEVSDPEAHVVWRKDGVQLGPSDKYDFLHTAGTRGLVVHDVSP
Sequence           EDAGLYTCHVGSEETRARVRVHDLHVGITKRLKTMEVLEGESCSFECVLSHESASDPA
                   MWTVGGKTVGSSSRFQATRQGRKYILVVREAAPSDAGEVVFSVRGLTSKASLIVRERP
                   AAIIKPLEDQWVAPCEDVELRCELSRAGTPVHWLKDRKAIRKSQKYDVVCEGTMAMLV
                   IRGASLKDAGEYTCEVEASKSTASLHVEEKANCFTEELTNLQVEEKGTAVFTCKTEHP
                   AATVTWRKGLLELPASGKHQPSQEGLTLRLTISALEKADSDTYTCDIGQAQSRAQLLV
                   QGRRVHIIEDLEDVDVQEGSSATFRCRISPANYEPVHWFLDKTPLHANELNEIDAQPG
                   GYHVLTLRQLALKDSGTIYFEAGDQRASAALRVTEKPSVFSRELTDATITEGEDLTLV
                   CETSTCDIPVCWTKDGKTLRGSARCQLSHEGHRAQLLITGATLQDSGRYKCEAGGACS
                   SSIVRVHARPVRFQEALKDLEVLEGGAATLRCVLSSVAAPVKWCYGNNVLRPGDKYSL
                   RQEGAMLELVVRNLRPQDSGRYSCSFGDQTTSATLTVTALPAQFIGKLRNKEATEGAT
                   ATLRCELSKAAPVEWRKGSETLRDGDRYCLRQDGAMCELQIRGLAMVDAAEYSCVCGE
                   ERTSASLTIRPMPAHFIGRLRHQESIEGATATLRCELSKAAPVEWRKGRESLRDGDRH
                   SLRQDGAVCELQICGLAVADAGEYSCVCGEERTSATLTVKALPAKFTEGLRNEEAVEG
                   ATANLWCELSKVAPVEWRKGPENLRDGDRYILRQEGTRCELQICGLAHADAGEYLCVC
                   GQERTSATLTIRALPARFIEDVKNQEAREGATAVLQCELNSAAPVEWRKGSETLRDGD
                   RYSLRQDGTKCELQIRGLAMADTGEYSCVCGQERTSAMLTVRALPIKFTEGLRNEEAT
                   EGATAVLRCELSKMAPVEWWKGHETLRDGDRHSLRQDGARCELQIRGLVAEDAGEYLC
                   MCGKERTSAMLTVRAMPSKEIEGLRNEEATEGDTATLWCELSKAAPVEWRKGHETLRD
                   GDRHSLRQDGSRCELQIRGLAVVDAGEYSCVCGQERTSATLTVRALPARFIEDVKNQE
                   AREGATAVLQCELSKAAPVEWRKGSETLRGGDRYSLRQDGTRCELQIHGLSVADTGEY
                   SCVCGQERTSATLTVRALPARFTQDLKTKEASEGATATLQCELSKVAPVEWKKGPETL
                   RDGGRYSLKQDGTRCELQIHDLSVADAGEYSCMCGQERTSATLTVRALPARFTEGLRN
                   EEAMEGATATLQCELSKAAPVEWRKGLEALRDGDKYSLRQDGAVCELQIHGLAMADNG
                   VYSCVCGQERTSATLTVRALPARFIEDMRNQKATEGATVTLQCKLRKAAPVEWRKGPN
                   TLKDGDRYSLKQDGTSCELQIRGLVIADAGEYSCICEQERTSATLTVRALPARFIEDV
                   RNHEATEGATAVLQCELSKAAPVEWRKGSETLRDGDRYSLRQDGTRCELQIRGLAVED
                   TGEYLCVCGQERTSATLTVRALPARFIDNNTNQEAREGATATLHCELSKVAPVEWRKG
                   PETLRDGDRHSLRQDGSRCELQIRGLAVVDAGEYSCVCGQERTSATLTVRALPARFIE
                   DVKNQEAREGATAVLQCELSKAAPVEWRKGSETLRGGDRYSLRQDGTRCELQIHGLSV
                   ADTGEYSCVCGQERTSATLTVRALPARFTQDLKTKEASEGATATLQCELSKVAPVEWK
                   KGPETLRDGGRYSLKQDGTRCELQIHDLSVADAGEYSCMCGQERTSATLTVRDCHTLH
                   VMPHYPFQLPGLLKEPEETLIYIQIPSPVILFTEGLRNEEANEGATATLQCELSKAAP
                   VEWRKGLEALRDGDKYSLRQDGAVCELQIHGLAMADNGVYSSLPARFIEDMRNQKATE
                   GATVTLQCKLRKAAPVEWRKGPNTLKDGDRYSLKQDGTSCELQIRGLVIADAGEYSCI
                   CEQERTSATLTVRALPARFIEDVRNEEATEGATAVLQCELSKAAPVEWRKGSETLRDG
                   DRYSLRQDGTRCELQIRGLAVEDTGEYLCVCGQERTSATLTVRALPARFIDNNTNQEA
                   REGATATLHCELSKVAPVEWRKGPETLRDGDRHSLRQDGTRCELQIRGLSVADAGEYS
                   CVCGQERTSATLTIRALPAKFTKGLRNEEATEGATANLQCELSKVAPVEWRKGPETLR
                   DGDRYNLRQDGTRCELQIHGLSVADTGEYSCVCGQEKTSATLTVKAPQPVFREPLQSL
                   QAEEGSTATLQCELSEPTATVVWSKGGLQLQANGRREPRLQGCTAELVLQDLQREDTG
                   EYTCTCGSQATSATLTVTAAPVRFLRELQHQEVDEGGTAHLCCELSRAGASVEWRKGS
                   LQLFPCAKYQMVQDGAAAELLVRGVEQEDAGDYTCDTGHTQSMASLSVRGGRGAACGP
                   QVRDAAQGATRELLIHQLEAKDTGEYACVTGGQKTAASLRVTEPEVTIVRGLVDAEVT
                   ADEDVEFSCEVSRAGATGVQWCLQGLPLQSNEVTEVAVRDGRIHTLRLKGVTPEDAGT
                   VSFHLGNUASSAQLTVRAPEVTILEPLQDVQLRCVPLQANEMNDITVEQGTLHLLTLH
                   KVTLEDAGTVSFHVGTCSSEAQLKVTEAVPCLVRGLQNVDVFAGEVATFSCEDGPQSA
                   IAVRDGIFHSLMLSGLGVADSGTVIFRAGPLVSTAKLLIKDPVVEVVSAMQDLAVEEG
                   GSAELLCQYSRPVQATWKMDEREVHTDGHRVIIEQDWNVARLTFRPALPCDSGIYSCE
                   AAGTRVVALLQVQAKNTVVRGLENVEALEGGEALFECQLSQPEVAAHTWLLDDEPVRT
                   SENAEVVFFENGLRHLLLLKNLRPQDSCRVTFLAGDMVTSAFLTVRGDCAVLVQGWRL
                   EILEPLKNAAVRAGAQARFTCTLSEAVPVGEASWYINCAAVQPDDSDWTVTADGSHHA
                   LLLRSAQPHHAGEVTFACRDAVASARLTVLGLPDPPEDAEVVARSSHTVTLSWAAPMS
                   DGGGGLCGYRVEVKEGATGQWRLCHELVPGPECVVDGLAPGETYRFRVAAVGPVGAGE
                   PVHLPQTVRLEPPKPVPPQPSAPESRQVAAGEDVCLELEVVAEAGEVIWHKGMERIQP
                   GGRFEVVSQGRQQMLVIKGFTAEDQGEYHCGLAQGSICPAAATFQVALSPASVDEAPQ
                   PSLPPEAAQEGDLHLLWEALARKRRMSREPTLDSISELPEEDGRSQRLPQEAEEVAPD
                   LSEGYSTADELARTGDADLSHTSSDDESRAGTPSLVTYLKKAGRPGTSPLASKVSPPN
                   LACKERFPTPRAGRSLLGFVGADPAFPGSERSARCTRRCAAPPPRESLKREPASCLPG
                   AMEAVELARKLQEEATCSICLDYFTDPVNTTCGHNFCRACIQLSWEKARGKKGRRKRK
                   CSFPCPECREMSPQRNLLPNRLLTKVAEMAQQHPGLQKQDLCQEHHEPLKLFCQKDQS
                   PICVVCRESREHRLHRVLPAEEAVQGYKLKLEEDMEYLREQITRTGNLQAREEQSLAE
                   WQGKVKERRERIVLEFEKMNLYLVEEEQRLLQALETEEEETASRLRESVACLDRQGHS
                   LELLLLQLEERSTQGPLQMLQDMKEPLSRAALLVVLIHGMNLVEFPVVSLPSPLYLIA
                   TKAHTQLGPGTPTFDPECPTPLPISPPPRPSTEDVVPDATSAYPYLLLYESRQRRYLG
                   SSPEGSGFCSKDRFVAYPCAVCQTAFSSGRHYWEVGMNITGDALWALGVCRDNVSRKD
                   RVPKCPENGFWVVQLSKGTKYLSTFSALTPVMLMEPPSHMGIFLDFEAGEVSFYSVSD
                   GSHLHTYSQATFPGPLQPFFCLGAPKSGQMVISTVTMAGVKDLATRTGAVVTPALGAY
                   APSATETQSPAPWSPRAPEPEHPGVPSLAPRSARACAAAPGYPGSPRAAEAARRRPAD
                   STAFLPSVRANAAPDLSTNLQEEATCAICLDYFTDPVMTDCGHNFCRECIRRCWGQPE
                   GPYACPECRELSPQRNLRPNRPLAKMAEMARRLHPPSPVPQGVCPAHREPLAAFCGDE
                   LRLLCAACERSGEHWAHRVRPLQDAAEDLKAKLEKSLEHLRKQMQDALLFQAQADETC
                   VLWQKNVESQRQNVLGEFERLRRLLAEGGTAAAAEAGEEELKQSAHLAELIAELERPL
                   PAACAGAAAGESFPMCGLHSLSRPPGVGFPWCTPKPEPVDALACAWRQGCQTQVEPTM
                   LQMWLGGFAQGVTLLPASGAQQNISPGTGSWERLSFLLFKGYKCSQSVAITRMVHTVP
                   KTKPPCRGQGSPLPPSPSPAAPAPGLVTATTCFQMTPGVCRPPQDIKDALRRVQDVKL
                   QPPEVVPMELRTVCRVPGLVETLRRFRGDVTLDPDTANPELILSEDRRSVQRGDLRQA
                   LPDSPERFDPGPCVLGQERFTSGRHYWEVEVGDRTSWALGVCRENVNRKEKGELSAGN
                   GFWILVFLGSYYNSSERALAPLRDPPRRVGIFLDYEACHLSFYSATDGSLLFIFPEIP
                   FSGTLRPLFSPLSSSPTPMTICRPKGGSGDTLAPQ

[0385] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 13B.

TABLE 13B
Comparison of NOV13a against NOV13b and NOV13c.
	NOV13a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV13b	1 . . . 4691	4399/4696 (93%)
	1 . . . 4675	4403/4696 (93%)

[0386] Further analysis of the NOV13a protein yielded the following properties shown in Table 13C.

TABLE 13C
Protein Sequence Properties NOV13a
PSort     0.8500 probability located in endoplasmic reticulum
analysis: (membrane); 0.4400 probability located in plasma membrane;
          0.3500 probability located in nucleus; 0.3000
          probability located in microbody (peroxisome)
SignalP   No Known Signal Sequence Indicated
analysis:

[0387] A search of the NOV13a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13D.

TABLE 13D
Geneseq Results for NOV13a
		NOV13a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length/[Patent#,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAB42919	Human ORFX ORF2683 polypeptide	3482 . . . 3981	448/500 (89%)	0.0
	sequence SEQ ID NO:5366 - Homo	1 . . . 473	452/500 (89%)
	sapiens, 477 aa. [WO200058473-A2,
	05-OCT-2000]
AAY53666	from an alignment with protein 608 -	264 . . . 3443	1270/3235 (38%)	0.0
	Unidentified, 4412 aa. [WO9960164-
	A1, 25-NOV-1999]
AAU05396	Human titin (connectin) protein	9 . . . 1892	526/1918 (27%)	0.0
	sequence - Homo sapiens, 26926 aa.	4667 . . . 6570	859/1918 (44%)
	[WO200151666-A1, 19-JUL-2001]
AAB43498	Human cancer associated protein	3480 . . . 3992	193/536 (36%)	5e−84
	sequence SEQ ID NO:943 - Homo	66 . . . 570	285/536 (53%)
	sapiens, 580 aa. [WO200055350-A1,
	21-SEP-2000]
AAY53667	Sequence gi/3328186 from an	70 . . . 2452	586/2595 (22%)	3e−80
	alignment with protein 608 -	446 . . . 2900	977/2595 (37%)
	Unidentified, 3117 aa. [WO9960164-
	A1, 25-Nov-1999]

[0388] In a BLAST search of public sequence databases, the NOV13a protein was found to have homology to the proteins shown in the BLASTP data in Table 13E.

TABLE 13E
Public BLASTP Results for NOV13a
		NOV13a
Protein		Residues/	Identities/
Accession		Match	Similarities for the	Expect
Number	Protein/Organisation/Length	Residues	Matched Portion	Value
Q9HCL6	KIAA1556 PROTEIN - Homo	132 . . . 1697	1565/1566 (99%)	0.0
	sapiens (Human), 1596 aa	1 . . . 1566	1566/1566 (99%)
	(fragment).
Q96AA2	OBSCURIN - Homo sapiens	1 . . . 2368	1605/2430 (66%)	0.0
	(Human), 6620 aa.	2595 . . . 4992	1764/2430 (72%)
Q9Y577	RING FINGER PROTEIN TERF -	3482 . . . 3981	449/500 (89%)	0.0
	Homo sapiens (Human), 477 aa.	1 . . . 473	453/500 (89%)
CAD12456	TITIN - Homo sapiens (Human),	41 . . . 3323	811/3501 (23%)	0.0
	34350 aa.	5588 . . . 8921	1361/3501 (38%)
Q9WV59	RING FINGER PROTEIN TERF -	3482 . . . 3981	341/500 (68%)	0.0
	Rattus norvegicus (Rat), 477 aa.	1 . . . 473	400/500 (79%)

[0389] PFam analysis indicates that the NOV13a protein contains the domains shown in the Table 13F.

TABLE 13F
Domain Analysis of NOV13a
		Similarities
		for the Matched
Pfam Domain	Region	Region	Value
ig: domain 1 of 34	67 . . . 26	18/64 (28%)	1.3e−09
		47/64 (73%)
ig: domain 2 of 34	156 . . . 212	12/59 (20%)	30
		40/59 (68%)
PEP-utilizers: domain 1 of	178 . . . 260	22/105 (21%)	2.4
1		50/105 (48%)
ig: domain 3 of 34	247 . . . 306	18/64 (28%)	6.5e−10
		43/64 (67%)
MAM: domain 1 of 1	159 . . . 306	35/191 (18%)	4.1
		89/191 (47%)
ig: domain 4 of 34	336 . . . 395	16/64 (25%)	5.7e−07
		43/64 (67%)
ig: domain 5 of 34	425 . . . 481	13/60 (22%)	0.0025
		39/60 (65%)
ig: domain 6 of 34	516 . . . 575	18/64 (28%)	1.5e−08
		47/64 (73%)
ig: domain 7 of 34	605 . . . 664	15/64 (23%)	1.1e−07
		41/64 (64%)
ig: domain 8 of 34	694 . . . 752	13/64 (20%)	6.2e−05
		42/64 (66%)
ig: domain 9 of 34	782 . . . 840	14/64 (22%)	1e−05
		42/64 (66%)
ig: domain 10 of 34	870 . . . 928	13/64 (20%)	0.0012
		40/64 (62%)
ig: domain 11 of 34	958 . . . 1016	12/64 (19%)	0.00011
		44/64 (69%)
ig: domain 12 of 34	1046 . . . 1104	13/64 (20%)	8.5e−06
		44/64 (69%)
ig: domain 13 of 34	1134 . . . 1192	14/64 (22%)	3.3e−06
		46/64 (72%)
ig: domain 14 of 34	1222 . . . 1280	13/64 (20%)	4.5e−06
		45/64 (70%)
ig: domain 15 of 34	1310 . . . 1368	13/64 (20%)	8.5e−07
		46/64 (72%)
ig: domain 16 of 34	1398 . . . 1456	14/64 (22%)	3e−05
		41/64 (64%)
ig: domain 17 of 34	1486 . . . 1544	13/64 (20%)	0.00085
		41/64 (64%)
ig: domain 18 of 34	1574 . . . 1632	14/64 (22%)	8.6e−06
		44/64 (69%)
ig: domain 19 of 34	1662 . . . 1720	14/64 (22%)	3.6e−05
		44/64 (69%)
ig: domain 20 of 34	1750 . . . 1808	13/64 (20%)	4.5e−06
		45/64 (70%)
ig: domain 21 of 34	1838 . . . 1896	13/64 (20%)	8.5e−07
		46/64 (72%)
ig: domain 22 of 34	1958 . . . 2013	12/61 (20%)	0.014
		39/61 (64%)
ig: domain 23 of 34	2031 . . . 2089	13/64 (20%)	0.00085
		41/64 (64%)
ig: domain 24 of 34	2119 . . . 2177	14/64 (22%)	8.6e−06
		44/64 (69%)
ig: domain 25 of 34	2207 . . . 2265	14/64 (22%)	5.3e−06
		45/64 (70%)
ig: domain 26 of 34	2295 . . . 2353	13/64 (20%)	1.4e−05
		45/64 (70%)
ig: domain 27 of 34	2383 . . . 2442	16/64 (25%)	1e−09
		48/64 (75%)
ig: domain 28 of 34	2472 . . . 2531	14/64 (22%)	0.0014
		39/64 (61%)
ig: domain 29 of 34	2565 . . . 2582	7/19 (37%)	0.92
		13/19 (68%)
ig: domain 30 of 34	2612 . . . 2668	16/60 (27%)	5.5e−05
		42/60 (70%)
ig: domain 31 of 34	2842 . . . 2901	16/65 (25%)	0.00035
		46/65 (71%)
ig: domain 32 of 34	2930 . . . 2988	13/66 (20%)	0.18
		38/66 (58%)
ig: domain 33 of 34	3030 . . . 3089	13/62 (21%)	0.22
		42/62 (68%)
fn3: domain 1 of 1	3107 . . . 3192	29/89 (33%)	1.2e−14
		63/89 (71%)
ig: domain 34 of 34	3237 . . . 3280	10/47 (21%)	4.6
		29/47 (62%)
zf-C3HC4: domain 1 of 2	3497 . . . 3546	20/61 (33%)	2.1e−14
		48/61 (79%)
PHD: domain 1 of 1	3496 . . . 3549	13/59 (22%)	1.9
		37/59 (63%)
zf-B_box: domain 1 of 2	3575 . . . 3616	22/48 (46%)	3.1e−15
		38/48 (79%)
zf-UBR1: domain 1 of 1	3578 . . . 3629	13/80 (16%)	9.8
		34/80 (42%)
SPRY: domain 1 of 2	3856 . . . 3980	41/157 (26%)	1.9e−32
		95/157 (61%)
zf-C3HC4: domain 2 of 2	4086 . . . 4116	16/41 (39%)	3.8e−12
		28/41 (68%)
Flu_M1: domain 1 of 1	4178 . . . 4189	6/12 (50%)	4.7
		9/12 (75%)
zf-B_box: domain 2 of 2	4156 . . . 4197	18/48 (38%)	0.031
		26/48 (54%)
Idh_C: domain 1 of 1	4222 . . . 4242	8/21 (38%)	8.9
		17/21 (81%)
SPRY: domain 2 of 2	4562 . . . 4681	36/157 (23%)	5.6e−29
		90/157 (57%)

Example 14

[0390] The NOV14 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 14A.

TABLE 14A
NOV14 Sequence Analysis
                   SEQ ID NO:75         1617 bp
NOV14a,            CTCTCTCGCCGGTGACCCGGTGTGCGTGGGGTCGAGGCGCCGGGCGGAGTGGCTCCGG
CG58575-01 DNA     GCCGAAACGCCATGCGGAGGGGCGAGCGCAGGGACGCCGGAGGTCCGCGGCCCGAGTC
Sequence           CCCGGTGCCCGCGGGCAGGGCCTCCCTGGAGGAGCCGCCTGACCGCCCGTCTGCCGGC
                   CAAGCCACCGGGCCGGGGCGAGGCCGCAGCACCGAGTCCGAGGTCTACGACGACGGCA
                   CCAACACCTTCTTCTGGCGAGCCCACACCTTAACCGTGCTCTTCATCCTCACCTGTAC
                   GCTTGGCTATGTGACGCTGCTGGAGGAAACACCTCAGGACACGGCCTACAACACCAAG
                   AGAGGTATTGTGGCCAGTATTTTGGTTTTCTTATGTTTTGGAGTCACACAAGCTAAAG
                   ACGGGCCATTTTCCAGACCTCATCCAGCTTACTGGAGGTTTTGGCTCTGCGTGAGTGT
                   GGTCTACGAGCTGTTTCTCATCTTTATACTCTTCCAGACTGTCCACGACGGCCGGCAG
                   TTTCTAAAGTATGTTGACCCCAAGCTGGGAGTCCCACTGCCAGAGAGAGACTACGGGG
                   GAAACTGCCTCATCTACGACCCAGACAATGAGACTGACCCCTTTCACAACATCTGGGA
                   CAAGTTGGATGGCTTTGTTCCCGCGCACTTTCTTGGCTGGTACCTGAAGACCCTGATG
                   ATCCGAGACTGGTGGATGTGCATGATCATCAGCGTGATGTTCGAGTTCCTGGAGTACA
                   GCCTGGAGCACCAGCTGCCCAACTTCAGCGAGTGCTGGTGGGATCACTGGATCATGGA
                   CGTGCTCGTCTGCAACGGGCTGGGCATCTACTGCGGCATGAAGACCCTTGAGTGGCTG
                   TCCCTGAAGACGTACAAGGGCAAGATGAAGAGGATCGCCTTCCAGTTCACGCCGTACA
                   GCTGGGTTCGCTTCGAGTGGAAGCCGGCCTCCAGCCTGCGTCGCTGGCTGGCCGTGTG
                   CGGCATCATCCTGGTGTTCCTGTTGGCAGAACTGAACACGTTCTACCTGAAGTTTGTG
                   CTGTGGATGCCCCCGGAGCACTACCTGGTCCTCCTGCGGCTCGTCTTCTTCGTGAACG
                   TGGGTGGCGTGGCCATGCGTGAGATCTACGACTTCATGGATGACCCGAAGCCCCACAA
                   GAAGCTGGGCCCGCAGGCCTGGCTGGTGGCGGCCATCACGGCCACGGAGCTGCTCATC
                   GTGGTGAAGTACGACCCCCACACGCTCACCCTGTCCCTGCCCTTCTACATCTCCCAGT
                   GCTGGACCCTCGGCTCCGTCCTGGCGCTCACCTGGACCGTCTGGCGCTTCTTCCTGCG
                   GGACATCACATTGAGGTACAAGGAGACCCGGTGGCAGAAGTGGCAGAACAAGGATGAC
                   CAGGGCAGCACCGTCGGCAACGGGGACCAGCACCCACTGGGGCTGGACGAAGACCTGC
                   TGGGGCCTGGGGTGGCCGAGGGCGAGGGAGCACCAACTCCAAACTGACCTGGGCCGTG
                   GCTGCCTCGTGAGCCTCCCAGAGCCCAGGCCTCCGTGGCCTCCTCCTGTCTCGTGTGG
                   GCGCTCGTCCACAAACACTCCGTGGCTGAGAGGCAGCGGATCCAGGCAGCG
                   ORF Start: ATG at 70 ORF Stop: TCA at 1495
                   SEQ ID NO: 76        475 aa MW at 54735.7 kD
NOV14a,            MRRCERRDAGGPRPESPVPACRASLEEPPDCPSAGQATGPGRCRSTESEVYDDGTNTF
C058575-01 Protein FWRAHTLTVLFILTCTLGYVTLLEETPQDTAYNTKRGIVASILVFLCFGVTQAKDGPF
Sequence           SRPHPAYWRFWLCVSVVYELFLIFILFQTVQDGRQFLKYVDPKLGVPLPERDYGGNCL
                   IYDPDNETDPFHNIWDKLDGFVPAHFLGWYLKTLMIRDWWMCMIISVMFEFLEYSLEH
                   QLPNFSECWWDHWIMDVLVCNGLGIYCGMKTLEWLSLKTYKGKMKRIAFQFTPYSWVR
                   FEWKPASSLRRWLAVCGIILVFLLAELNTFYLKFVLWMPPEHYLVLLRLVFFVNVGGV
                   AMREIYDFMDDPKPHKKLGPQAWLVAAITATELLIVVKYDPHTLTLSLPFYISQCWTL
                   GSVLALTWTVWRFFLRDITLRYKETRWQKWQNKDDQGSTVGNGDQHPLGLDEDLLGPG
                   VAEGEGAPTPN

[0391] Further analysis of the NOV14a protein yielded the following properties shown in Table 14B.

TABLE 14B
Protein Sequence Properties NOV14a
PSort     0.6000 probability located in plasma membrane; 0.4000
analysis: probability located in Golgi body; 0.3000 probability located
          in endoplasmic reticulum (membrane); 0.0300
          probability located in mitochondrial inner membrane
SignalP   Cleavage site between residues 8 and 9
analysis:

[0392] A search of the NOV14a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14C.

TABLE 14C
Geneseq Results for NOV14a
		NOV14a	Identities/
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAM79907	Human protein SEQ ID NO 3553 -	1 . . . 475	474/487 (97%)	0.0
	Homo sapiens, 529 aa.	19 . . . 505	474/487 (97%)
	[WO200157190-A2, 09-AUG-2001]
AAM78923	Human protein SEQ ID NO 1585 -	1 . . . 475	474/487 (97%)	0.0
	Homo sapiens, 487 aa.	1 . . . 487	474/487 (97%)
	[WO200157190-A2, 09-AUG-2001]
AAB73515	Human transferase HTFS-22, SEQ ID	1 . . . 475	473/487 (97%)	0.0
	NO: 22 - Homo sapiens, 487 aa.	1 . . . 487	473/487 (97%)
	[WO200132888-A2, 10-MAY-2001]
AAG30975	Arabidopsis thaliana protein fragment	41 . . . 387	141/363 (38%)	2e−73
	SEQ ID NO: 37124 - Arabidopsis	3 . . . 363	209/363 (56%)
	thaliana, 436 aa. [EP1033405-A2,
	06-SEP-2000]
AAG30974	Arabidopsis thaliana protein fragment	41 . . . 387	141/363 (38%)	2e−73
	SEQ ID NO: 37123 - Arabidopsis	21 . . . 381	209/363 (56%)
	thaliana, 454 aa. [EP1033405-A2,
	06-SEP-2000]

[0393] In a BLAST search of public sequence databases, the NOV14a protein was found to have homology to the proteins shown in the BLASTP data in Table 14D.

TABLE 14D
Public BLASTP Results for NOV14a
		NOV14a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9BVG9	SIMILAR TO	1 . . . 475	474/487 (97%)	0.0
	PHOSPHATIDYLSERINE SYNTHASE	1 . . . 487	474/487 (97%)
	2 - Homo sapiens (Human), 487 aa.
O08888	PHOSPHATIDYLSERINE SYNTHASE	1 . . . 471	408/482 (84%)	0.0
	II - Cricetulus griseus (Chinese hamster),	1 . . . 458	422/482 (86%)
	474 aa.
Q9Z1X2	PHOSPHATIDYLSERINE SYNTHASE-	1 . . . 470	409/481 (85%)	0.0
	2 - Mus musculus (Mouse), 473 aa.	1 . . . 457	419/481 (87%)
Q922A1	SIMILAR TO	95 . . . 470	345/387 (89%)	0.0
	PHOSPHATIDYLSERINE SYNTHASE	1 . . . 384	354/387 (91%)
	2 - Mus musculus (Mouse), 400 aa
	(fragment).
Q9CY68	7 DAYS EMBRYO CDNA, RIKEN	1 . . . 273	239/273 (87%)	e−144
	FULL-LENGTH ENRICHED	1 . . . 252	243/273 (88%)
	LIBRARY, CLONE: C430041K09,
	FULL INSERT SEQUENCE - Mus
	musculus (Mouse), 300 aa.

[0394] PFam analysis that the NOV14a protein contains the domains shown in the Table 14E.

TABLE 14E
Domain Analysis of NOV14a
		Identities/
		Similarities
	NOV14a Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
Peptidase_C20: domain	302 . . . 327	8/28 (29%)	2
1 of 1		19/28 (68%)
PSS: domain 1 of 1	119 . . . 390	151/310 (49%)	3e−201
		269/310 (87%)

Example 15

[0395] The NOV15 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 15A.

TABLE 15A
NOV15 Sequence Analysis
                   SEQ ID NO:77         1210 bp
NOV15a,            TCGCTCACCCACCCGGACTCATTCTCCCCAGACGCCAAGGATGGTGGTCATGGCACCC
CG59256-01 DNA     CGAACCCTCTTCCTGCTACTCTCGGGGGCCCTGACCCTGACCGAGACCTGCGCGGGCT
Sequence           CCCACTCCATGAGGTATTTCAGCGCCGCCGTGTCCCGGCCCGGCCGCGGGGAGCCCCG
                   CTTCATCGCCATGGGCTACGTGGACGACACGCAGTTCGTGCGGTTCGACAGCGACTCG
                   GCGTGTCCGAGGATGGAGCCGCGGGCGCCGTGGGTGGAGCAGGAGGGGCCAGAGTATT
                   GGGAAGAGGAGACACGGAACACCAAGGCCCACGCACAGACTGACAGAATGAACCTGCA
                   GACCCTGCGCGGCTACTACAACCAGAGCGAGGGGGTGGGGCCAGGTTCTCATACCCTC
                   CAGTGGATGATTCGCTGCGACCTGGGGTCCGACGGACGCCTCCTCCGCGGGTATGAAC
                   AGTATGCCTACGATGGCAACGATTACCTCCCCCTGAACGAGGACCTGCGCTCCTGGAC
                   CGCAGCGGACACTGCGGCTCAGATCTCCAAGCCCAAGTGTGAGGCGGCCAATGTGGCT
                   GAACAAAGGAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCACAGATACCTCG
                   AGAACGGGAAGGAGATGCTGCAGCGCGCGGACCCCCCCAAGACACACGTGACCCACCA
                   CCCTGTCTTTGACTATCAGGCCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCG
                   GAGATCATACTGACCTGGCAGCGGGATGGGGAGGACCAGACCCAGGACGTGGAGCTCG
                   TGGAGACCAGGCCTGCAGGGGATGGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCC
                   TTCTGGAGAGGAGCAGAGATACACGTGCCATGTGCAGCATGACGGGCTGCCGGAGCCC
                   CTCATGCTGAGATGGGAGCAGTCTTCCCTGCCCACCATCCCCATCATGGGTATCGTTG
                   CTCGTCTGGTTGTCCTTGCAGCTGTAGTCACTGGAGCTGCGGTCGCTGCTGTGCTGTG
                   GAGGAAGAAGAGCTCAGGTAAGAAAGGAGGGAGCTACTCTCAGGCTGCAAGTAGTGAC
                   AGTGCCCAGGGCTCTAATGTGTCTCTCACGGCTTGTAAATGTGACACCCCGGGGGGCC
                   TGATGTGTGTGGGTTGTTGAGGGAAACAGTGGACATAGCTGTGCTATGAG
                   ORF Start: ATG at 41 ORF Stop: TGA at 1178
                   SEQ ID NO:78         379 aa MW at 42027.9 kD
NOV15a,            MVVMAPRTLFLLLSCALTLTETWAGSHSMRYFSAAVSRPGRGEPRFIAMGYVDDTQFV
CG59256-01 Protein RFDSDSACPRMEPRAPWVEQEGPEYWEEETRNTKAHAQTDRMNLQTLRGYYNQSEGVG
Sequence           PGSHTLQWMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAADTAAQISKRKC
                   EAANVAEQRRAYLEGTCVEWLHRYLENGKEMLQRADPPKTHVTHHPVFDYEATLRCWA
                   LGFYPAEIILTWQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQH
                   EGLPEPLMLRWEQSSLPTIPIMGIVAGLVVLAAVVTGAAVAAVLWRKKSSGKKGGSYS
                   QAASSDSAQGSNVSLTACKCDTPGGLMCVGC

[0396] Further analysis of the NOV15a protein yielded the following properties shown in Table 15B.

TABLE 15B
Protein Sequence Properties NOV15a
PSort     0.4600 probability located in plasma membrane; 0.1000
analysis: probability located in endoplasmic reticulum (membrane);
          0.1000 probability located in endoplasmic reticulum (lumen);
          0.1000 probability located in outside
SignalP   Cleavage site between residues 25 and 26
analysis:

[0397] A search of the NOV15a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15C.

TABLE 15C
Geneseq Results for NOV15a
		NOV15a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAB36874	MHC class I protein - Unidentified, 365	1 . . . 367	299/367 (81%)	e−179
	aa. [US6140305-A, 31-OCT-2000]	1 . . . 364	324/367 (87%)
AAB58683	HLA-A2/A28 protein #4 - Unidentified,	1 . . . 367	298/367 (81%)	e−179
	365 aa. [US6153408-A, 28-NOV-2000]	1 . . . 364	324/367 (88%)
AAY52922	HLA-A2/A28 family peptide A2 (Lee)	1 . . . 367	298/367 (81%)	e−179
	SEQ ID NO: 100 - Mammalia, 365 aa.	1 . . . 364	324/367 (88%)
	[US5976551-A, 02-NOV-1999]
AAY68268	Human leukocyte antigen A2/A28	1 . . . 367	298/367 (81%)	e−179
	family protein SEQ ID NO: 100 - Homo	1 . . . 364	324/367 (88%)
	sapiens, 365 aa. [US6011146-A,
	04-JAN-2000]
AAB58681	HLA-A2/A28 protein #2 - Unidentified,	1 . . . 367	297/367 (80%)	e−178
	365 aa. [US6153408-A, 28-NOV-2000]	1 . . . 364	323/367 (87%)

[0398] In a BLAST search of public sequence databases, the NOV15a protein was found to have homology to the proteins shown in the BLASTP data in Table 15D.

TABLE 15D
Public BLASTP Results for NOV15a
		NOV15a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
P17693	HLA class I histocompatibility antigen,	1 . . . 340	334/340 (98%)	0.0
	alpha chain G precursor (HLA G	1 . . . 337	335/340 (98%)
	antigen) - Homo sapiens (Human), 338
	aa.
Q9MYA2	MHC CLASS I ANTIGEN - Homo	1 . . . 340	332/340 (97%)	0.0
	sapiens (Human), 338 aa.	1 . . . 337	335/340 (97%)
Q30182	LYMPHOCYTE ANTIGEN - Homo	1 . . . 340	334/341 (97%)	0.0
	sapiens (Human), 339 aa.	1 . . . 338	335/341 (97%)
AAH21708	HYPOTHETICAL 38.3 KDA	1 . . . 340	331/340 (97%)	0.0
	PROTEIN - Homo sapiens (Human),	1 . . . 337	334/340 (97%)
	338 aa.
Q9TP69	DJ377H14.1 (MAJOR	4 . . . 340	331/337 (98%)	0.0
	HISTOCOMPATIBILITY	1 . . . 334	332/337 (98%)
	COMPLEX, CLASS I, G (HLA 6.0)) -
	Homo sapiens (Human), 335 aa.

[0399] PFam analysis indicates that the NOV15a protein contains the domains shown in the Table 15E.

TABLE 15E
Domain Analysis of NOV15a
		Identities/
	NOV15a	Similarities for the
Pfam Domain	Match Region	Matched Region	Expect Value
MHC_1: domain	25 . . . 206	145/183 (79%)	2e−139
1 of 1		179/183 (98%)
ig: domain 1 of 1	223 . . . 288	15/67 (22%)	4.4e−08
		45/67 (67%)

Example 16

[0400] The NOV16 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 16A.

TABLE 16A
NOV16 Sequence Analysis
                   SEQ ID NO:79         1175 bp
NOV16a,            ATTCTCCCCAAACGCCAAGGATGGGGGTCATGGCTCCCCGAACCCTCCTCCTGCTGCT
CG59239-01 DNA     CTTGGGGGCCCTGGCCCTGACCGAGACCTGGGCCGGCTCCCACTCCTTGAGGTATTTC
Sequence           AGCACCGCAGTGTCCCAGCCCGGCCGCGGGGAGCCCCGGTTCATCGCCGTGGGCTACG
                   TGGACGACACAGAGTTCGTGCGGTTCGACAGCGACTCCGTGAGTCCGAGCATCCACCG
                   GCGGGCGCCGTGGGTGGAGCAGGAGCGGCTGGAGTATTGGGACCAGGAGACACGGAAC
                   GCCAAGGGCCACGCGCAGATTTACCGAGTGAACCTGCGGACCCTGCTCCGCTATTACA
                   ACCAGAGCGAGCATGGTTCTCACACCATCCAGAGGAAGCATGGCTGCGACGTGGGCCC
                   GGACAGGCGCCTCCTCCGCAGGTATGAACAGTTCGCCTACGATGGCAAGGATTACATC
                   GCCCTGAACGACGACCTGCACTCCTGGACCCCCGCGAACACAGCGGCTCAGATCTCCC
                   AGCACAAGTGGGAAGCGGACAAATACTCAGAGCAGGTCAGGGCCTACCTGCAGCGCAA
                   GTGCATGGAGTGGCTCCGCAGACACCTGGAGAACGGGAAGGAGACGCTGCAGCACGCG
                   GATCCCCCAAAGGCACATGTGACCCAGCACCCCATCTCTGACCATGAGGCCACCCTGA
                   GGTGCTGGGCCCTGGGCCTCTACCCTGCGGAGATCACACTGACCTGGCAGCAGGATGG
                   GGAGGACCAGACCCACGACACGGAGCTTGTGGAGACCAGGCCTGCAGGGGACGGAACC
                   GCCCACCATCCCCATCGTGGGCATCGTTGCTGGCCTGTTTCTCCTTGGAGCTGTGGTC
                   ACTGCAGCTGTGGTTGCTGCTGCOATOTGGAGCAAGAAAAGCTCAGGTAGGGAAGGCG
                   TGAGAGGTTCTACCCCAGGCAGCAATTGTGCTCAGTACTCTGATGCATCTCATGATAC
                   TTGTAAAGCTTGAGACAACTGCCTTGAGTGGGACTGAGAGATACAAAATTTCTTCAGG
                   TCCTTCCTCTGACAC
                   ORF Start: ATG at 21 ORF Stop: TGA at 1113
                   SEQ ID NO:80         364 aa MW at 40983.6 kD
NOV16a,            MGVMAPRTLLLLLLGALALTETWAGSHSLRYFSTAVSQPGRGEPRFIAVGYVDDTEFV
CG59239-01 Protein RFDSDSVSPRMERRAPWVEQEGLEYWDQETRNAKGHAQIYRVNLRTLLRYYNQSEHGS
Sequence           HTIQRKHGCDVGPDRRLLRRYEQFAYDGKDYIALNEDLHSWTAANTAAQISQHKWEAD
                   KYSEQVRAYLEGKCMEWLRRHLENGKETLQHADPPKAHVTQHPISDHEATLRCWALGL
                   YPAEITLTWQQDGEDQTQDTELVETRPAGDGTFQKWVAVVVPSGEEQRYMCHVQHEGL
                   PEPLTLRWGPSSQPTIPIVGIVAGLFLLGAVVTGAVVAAAMWRKKSSGREGVRGSTPG
                   SNCAQYSDASHDTCKA

[0401] Further analysis of the NOV16a protein yielded the following properties shown in Table 16B.

TABLE 16B
Protein Sequence Properties NOV16a
PSort     0.4600 probability located in plasma membrane; 0.1357
analysis: probability located in microbody (peroxisome); 0.1000
          probability located in endoplasmic reticulum (membrane);
          0.1000 probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 25 and 26
analysis:

[0402] A search of the NOV16a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16C.

TABLE 16C
Geneseq Results for NOV16a
		NOV16a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAM24017	Human EST encoded protein SEQ ID	4 . . . 363	276/367 (75%)	e−165
	NO: 1542 - Homo sapiens, 368 aa.	1 . . . 367	307/367 (83%)
	[WO200154477-A2, 02-AUG-2001]
AAB58681	HLA-A2/A28 protein #2 -	1 . . . 363	274/364 (75%)	e−164
	Unidentified, 365 aa. [US6153408-A,	1 . . . 364	305/364 (83%)
	28-NOV-2000]
AAB58680	HLA-A2/A28 protein #1 -	1 . . . 363	274/364 (75%)	e−164
	Unidentified, 365 aa. [US6153408-A,	1 . . . 364	305/364 (83%)
	28-NOV-2000]
AAY52920	HLA-A2/A28 family peptide A2.4a	1 . . . 363	274/364 (75%)	e−164
	SEQ ID NO: 98 - Mammalia, 365 aa.	1 . . . 364	305/364 (83%)
	[US5976551-A, 02-NOV-1999]
AAY52919	HLA-A2/A28 family peptide HLA-	1 . . . 363	274/364 (75%)	e−164
	A2.1 SEQ ID NO: 97 - Mammalia,	1 . . . 364	305/364 (83%)
	365 aa. [US5976551-A,
	02-NOV-1999]

[0403] In a BLAST search of public sequence databases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16D.

TABLE 16D
Public BLASTP Results for NOV16a
		NOV16a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9TQP7	MHC CLASS I ANTIGEN - Homo	1 . . . 363	286/370 (77%)	e−168
	sapiens (Human), 371 aa.	1 . . . 370	312/370 (84%)
Q30718	MHC CLASS I ANTIGEN	1 . . . 363	282/364 (77%)	e−167
	MAMUA*07 - Macaca mulatta	1 . . . 364	312/364 (85%)
	(Rhesus macaque), 365 aa.
Q95J07	MHC CLASS I ANTIGEN HEAVY	1 . . . 363	286/366 (78%)	e−167
	CHAIN - Homo sapiens (Human),	1 . . . 364	310/366 (84%)
	365 aa.
Q9MYI5	HLA CLASS I ANTIGEN - Homo	1 . . . 363	286/366 (78%)	e−167
	sapiens (Human), 365 aa.	1 . . . 364	311/366 (84%)
Q9TQP6	sapiens (Human), 365 aa.	1 . . . 364	311/366 (84%)	e−167

[0404] PFam analysis indicates that the NOV16a protein contains the domains shown in the Table 16E.

TABLE 16E
Domain Analysis of NOV16a
	NOV16a	Identities/
	Match	Similarities for	Expect
Pfam Domain	Region	the Matched Region	Value
MHC_I: domain 1 of 1	25 . . . 203	139/180 (77%)	5.6e−131
		165/180 (92%)
ig: domain 1 of 1	220 . . . 285	12/67 (18%)	9.9e−08
		47/67 (70%)

Example 17

[0405] The NOV17 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 17A.

TABLE 17A
NOV17 Sequence Analysis
                   SEQ ID NO:81         8838 bp
NOV17a,            AGCAGAGCCCTGGGCCAGGCTCTCTGATTGCCTGGCACCCTGATGGGAGCCCGCATGC
CG59295-01 DNA     CCAGACGATGCTTGCTTCTTCTCTCTTGCTTTTGTCTACTTAGGGTTGAGTCCACTGC
Sequence           AGAGGTGCAGCACCAGGCCTCAGCACTCACATGGAAAATCAGTGCAGAGCTGCAACAG
                   GAGCCTGCTCCTGAGCCCAGCCACACATACCAGGAGATGTCCCTTGCAGTGGAGGATG
                   TCACAACAGTTATGGAAGGCAAGCAGGCTGAAGCCCCAGACTCCGTGGCCATGTCTTC
                   CTGGGAAAGGCGGCTCCATCGGGCCAAGTGTGCACCATCCTACTTGTTCTCCTGCTTC
                   AATCGAGGCGAGTGTGTGCACCCAGCCTTCTGTCACTGCAGACGCTTCAATCCCACTG
                   GACCGCGCTGCCAGATGGTGTACAATGCCGGCCCTGAGAGGGACAGCATTTGCCGGGC
                   GTGGGGGCAGCACCACGTGGAGACATTTGATGGGCTCTACTACTACCTCTCCGGAAAG
                   GGCAGCTACACCCTGGTGGGTCGCCATGAGCCCGAGGGACAGAGCTTCTCCATCCAGG
                   TACACAATGACCCGCAGTGTGGCTCTTCACCCTACACCTGCTCCAGGGCTGTCAGCCT
                   CTTCTTTGTGGGTGAGCAGGAGATCCATCTGGCCAAGGAGGTCACCCATGGAGGCATG
                   AGGGTCCAACTGCCACATGTCATGGGCAGCGCGCGTCTGCAGCAGCTTGCCGGCTATG
                   TCATCGTGCGGCATCAGTCAGCCTTCACACTGGCCTGGGATGGTGCCTCGGCTGTCTA
                   CATCAAGATGAGTCCAGAGCTTCTGGGCTGGACCCATGGGCTGTGTGGGAACAACAAT
                   GCTGACCCCAAGGATGATCTGGTGACCAGCTCTGGTGAGGGGAAGCTGACTGACGACG
                   TGGTTGAGTTTGTGCACAGCTGGCAGGAGCAGGCCCCTAACCAGCCTCCAGGGCCCAC
                   AACTTCCTCCCTGCCTCGCCCACCGTGCCTACAGCAGAACCCAGGAACCATGCAGGGC
                   GTGTACGAGCACTGTGACGCTCTACTGCGGCCCCCCTTTGACCCCTGCCACGCCTACG
                   TCAGCCCTCTGCCCTTCACAGCCAGTTGTACCAGTGATCTCTGCCAATCAATGGGTGA
                   TGTAGCCACCTGGTGCCGGGCACTGGCGGAGTATGCCCGGGCGTGTGCCCAGGCAGGG
                   CGGCCCTTGCAAGGCTGGAGGACCCAGCTCCGGCAATGCACTGTGCACTGCAAGGAGA
                   AGGCCTTTACCTACAATGAGTGCATCGCCTGCTGCCCTGCCTCCTGCCATCCCCGGGC
                   ATCCTGTGTGGACAGTGAGATCGCCTGTGTGGACGGCTGCTATTGCCCCAATGGGCTC
                   ATCTTCGAGGATGGGGGCTGCGTGGCACCAGCTGAGTGTCCCTGTGAGTTTCACGGGA
                   CTCTGTACCCACCTGGCTCTGTGGTGAAGGAAGACTGCAATACTTGCACATGCACCTC
                   AGGCAAGTGGGACTGCAGCACACCTGTCTGCCCAGCTGAGTGCTCAGTGACTGGTGAC
                   ATTCACTTCACAACCTTTGATGGCCGCCGGTACACGTTCCCCGCCACATGTCAGTACA
                   TCCTGGCCAAGAGCCGCTCTTCGGCCACCTTCACCGTGACATTGCAGAATGCCCCATG
                   TGGCCTGAACCAAGATGGAGCCTGTGTCCAGTCAGTGTCAGTGATTCTGCACCAGGAC
                   CCTCGGAGGCAGGTGACCCTGACCCAGGCAGGGGATGTCCTTCTGTTTCACCAGTACA
                   AGATCATCCCGCCATACACAGATGATGCCTTTGAGATCCGTAGGCTGTCCTCCGTGTT
                   CCTGCGGGTGAGGACGAACGTGGGCGTGCGGGTGCTCTACGACCGTGAAGGGCTCCGA
                   CTGTACCTGCAAGTGGACCAGCGATGGGTGGAGGATACCGTGGGCCTCTGCCGCACCT
                   TCAATGGCAACACGCAGGATGACTTCCTGTCTCCAGTGGGTGTACCTGAGAGCACCCC
                   ACAACTTTTTGGCAATTCCTGGAAAACACTTTCTGCTTGCTCCCCGCTGGTCTCTGGC
                   TCCCCTCTGGACCCCTGCGATCTGCACCTGCAAGCCGCCTCCTACTCAGTGCAGGCCT
                   GCAGCGTGCTCACGGGGGAGATGTTTGCGCCCTGCTCTGCGTTCCTGAGCCCCGTGCC
                   CTACTTTCAGCAGTGCCGCAGCGATGCCTGCCGCTGCGGGCAGCCCTGCCTGTGCGCC
                   ACACTGGCCCACTACGCCCACCTGTGCCGGCGCCATGGGCTCCCCGTTGATTTCCGCG
                   CCCGCCTGCCAGCCTGTGCACTGTCCTGTGAGGCCTCCAAGGAGTATAGCCCCTGCCT
                   GGCCCCGTGTGGACGTACCTGCCAGGACCTGGCCAGCCCTGAGGCCTGTGGGGTTGAT
                   GGTGGCGATGACCTGAGCAGAGACGAGTGTGTGGAGGGCTGTGCCTGCCCACCGGACA
                   CCTATCTGGACACCCAGGCTGACCTCTGTGTCCCCCGGAACCAGTGCTCCTGCCACTT
                   CCAGGGAGTGGACTATCCCCCCGGAGACAGTGACATCCCATCCCTGGGCCACTGCCAC
                   GCCAGGTCTTCGTGAACTGCAGCGACCTGCACACGGACCTGGAGCTGAGCAGGGAGAG
                   GACGTGTGAGCAGCAACTGCTGAACCTGAGCGTGTCAGCCCGTGGCCCCTGCCTCTCG
                   GGCTGCGCCTGTCCCCAGGGTCTGCTCAGACACGGGGATCCATGTTTCCTGCCAGAGG
                   AGTGCCCCTGCACTTGGAAGGGGAAGGAGTATTTCCCTGGGGACCAGGTGATGTCTCC
                   TTGCCATACCTGTGTGTGCCAGCGGGGCTCATTCCAGTGCACCCTGCACCCTTGCGCC
                   TCCACCTGCACTGCCTATGGGGACCGGCATTACCGCACGTTTGATGGGCTCCCGTTTG
                   ACTTCGTGGGGGCATGCAAAGTGCACCTGGTCAAGAGCACATCAGATGTCAGCTTCTC
                   TGTGATTGTAGAGAATGTGAACTGCTACAGCTCTGGCATGATCTGCAGGAAATTTATT
                   TCCATCAACGTTGGGAACTCACTCATTGTCTTTGATGATGACTCCGCAAATCCTAGTC
                   CAGAGAGCTTCCTGGATGACAAGCAGGAGGTCCACACATGGCGAGTGGGATTTTTCAC
                   ACTGGTGCATTTCCCACAGGAGCACATCACCCTCTTGTGGGACCAGAGAACCACAGTG
                   CACGTCCAGGCTGGGCCTCAGTGGCAGGGCCACCTGGCCGGCCTCTGTCGGAACTTTG
                   ACTTAAAAACCATCAATGAGATGAGGACCCCGGAGAACCTAGAGCTAACTAACCCCCA
                   GGAGTTTGGCAGCAGTTGGGCTGCAGTTGAGTGCCCAGACACCCTCGATCCTCGGGAT
                   ATGTGTGTCCTGAATCCTCTCCCACAACCATTTGCCAAGAAGGAGTGCAGCATCCTGC
                   TCAGTGAGGTGTTTGAGATCTGCCACCCTGTGGTTGATGTCACTTGGTTTTACTCAAA
                   CTGCCTGACAGACACATGTGGCTGCAGCCAGGGTGGTGACTGTGAGTGCTTCTGTGCC
                   AGCGTCTCCGCTTATGCCCACCAGTGTTGCCAGCATGGGGTGGCTGTTGACTGGCGAA
                   CCCCCCGCCTCTGCCCGTATGACTGTGACTTCTTTAACAAAGTGCTAGGTAAGGGCCC
                   CTATCAGCTATCCAGCTTGGCAGCCGGTGGTGCTCTGGTGGGCATGAAGGCGGTGGGC
                   GATCACATAGTCCTAGTGAGGACAGAGGATGTGGCGCCAGCAGACATTGTGAGCTTCC
                   TCCTGACAGCTGCTCTGTACAAGGCCAAGGCCCATGACCCAGATGTGGTGTCCCTGCA
                   GGCAGCAGACAGACCCAACTTCTTCCTTCACGTCACAGCCAACGGGTCTCTGGAGCTG
                   GCTAAGTGGCAGGGCCGTGACACCTTCCAACAGCATGCCTCCTTCTTGCTGCACCGGG
                   GGACACCGCAGGCAGGCCTCGTGGCCCTGGAGTCCCTGGCCAAGCCCAGCTCCTTCCT
                   CTATGTGTCGGGCGCCGTGCTGGCCCTGCGGCTGTACGAACACACAGAGGTGTTCCGC
                   CGGGGCACACTCTTCCGCCTTCTGGATGCCAAGCCCTCGGGGGCTGCCTACCCCATCT
                   GCGAGTGGCGCTACGATGCCTGTGCCAGCCCCTGCTTCCAAACCTGCCGGGACCCACG
                   GGCAGCCAGCTGCCGGGACGTACCCAGGGTAGAAGGCTGTGTCCCTGTGTGCCCCACC
                   CCCCAGGTCCTGGATGAAGTCACACAGAGATGTGTCTACTTGGAGGACTGTGTGGAGC
                   CAGCACTTTCGGTTCCCACAGAGGCCCTTGGCAATGAGACCCTCCCTCCCAGTCAAGG
                   GTTGCCCACTCCCAGTGATGAGGAGCCACAGCTGTCACAGGAAAGCCCCAGGACCCCC
                   ACCCACAGGCCAGCCCTCACCCCAGCTGCCCCACTCACCACAGCCCTGAACCCACCAG
                   TGACAGCCACTGAGGAGCCAGTGGTGTCTCCAGGCCCCACCCAGACCACCCTGCAGCA
                   GCCACTGGAGCTCACTGCATCTCAACTCCCCGCCGGCCCCACGGAGTCCCCAGCCAGC
                   AAGGGAGTGACTGCCAGCCTCCTGGCCATCCCCCATACACCAGAGTCCTCATCCCTCC
                   CTGTTGCACTGCAGACACCCACACCTGGCATGGTGTCAGGTGCCATGGAGACAACAAG
                   GGTGACTGTGATCTTTGCAGGAAGCCCTAACATCACAGTCTCCTCCCGGTCGCCCCCT
                   GCCCCTCGCTTCCCGCTCATGACCAAGGCTGTGACAGTCCGAGGCCATGGCTCCTTGC
                   CTGTTAGGACGACACCCCCACAGCCCTCCTTGACAGCAAGTCCCTCCTCCAGACCTGT
                   GGCTTCCCCTGGAGCCATCTCCAGGTCCCCCACCTCCTCGGGATCCCACAAGGCTGTG
                   CTGACACCTGCAGTAACTAAGGTCATAAGCAGGACAGGGGTCCCCCAGCCCACCCAGG
                   CCCAGAGTGCTTCAAGTCCCAGCACCCCTCTAACTGTGGCTGGAACAGCAGCAGAACA
                   GGTTCCTGTCAGTCCCCTTGCAACCAGGAGCTTGGAGATAGTGCTATCCACAGAGAAG
                   GGCGAAGCCGGGCACAGCCAGCCCATGGGCTCGCCTGCCTCCCCACAGCCACACCCAC
                   TCCCCTCTGCACCACCCCCCCCAGCCCAGCATACCACCATGGCCACCAGGTCTCCAGC
                   TCTGCCCCCACACACCCCAGCTGCCGCCAGCCTGTCAACAGCCACTGATGGGCTGGCA
                   GCCACACCCTTCATGTCCCTTGAGTCAACTCGTCCCTCCCAGCTCCTCTCTGGCCTGC
                   CTCCCGACACCAGCCTGCCCCTGGCCAAGGTGGGCACATCTGCCCCAGTGGCCACACC
                   CGGCCCCAAAGCCTCTGTCATCACCACTCCACTCCACCCACAGGCCACCACTCTGCCT
                   GCTCAGACACTTAGCCCAGTACTGCCTTTCACTCCAGCAGCAATGACCCAGGCGCACC
                   CACCCACTCACATAGCACCCCCAGCAGCAGGCACAGCTCCAGGCCTGCTGCTGGGAGC
                   CACATTGCCAACCTCTGGAGTCCTGCCTGTGGCTGAGGGCACGGCCTCCATGGTATCT
                   GTTGTCCCACGAAAGAGCACCACAGGGAAGGTGGCCATCCTATCCAAGCAAGTGTCTC
                   TGCCCACTTCCATGTATGGTTCTGCAGAGGGTGGGCCCACAGAGCTCACCCCTGCTAC
                   GAGCCACCCTCTCACGCCCTTGGTGGCTGAGCCCGAGGGAGCCCAGGCAGGCACAGCT
                   CTGCCAGTGCCCACATCCTATGCCCTGAGCCGTGTCTCAGCCAGGACGGCCCCCCAAG
                   ACAGCATGCTGGTTCTGTTGCCTCAGCTGGCTGAGGCCCATGGAACCTCGGCAGGGCC
                   TCACCTGGCAGCAGACCCGGTGGACGAGGCCACCACAGAACCATCTGGGCGCTCAGCC
                   CCAGCCCTGAGCATCGTAGAGGGTTTGGCGGAGGCTTTGGCAACTACCACTGAGGCCA
                   ATACATCCACCACCTGTGTTCCAATCGCCGAGCAGGACTGCGTCCGCCACATCTGCCT
                   GGAGGGCCAGCTGATTCGCGTGAATCAGTCCCAGCACTGTCCCCAGGGTGCTGCTCCC
                   CCTCGCTGTGGGATCCTGGGCCTCGCCCTGCGGGTGGGTGGGGACCGCTGCTGCCCAC
                   TCTGGGAGTGTGCCTGCCGGTGCTCAATCTTCCCTGACCTGAGCTTCGTGACCTTCGA
                   TGGGAGCCACGTAGCTCTGTTCAAGGAGGCCATCTACATCCTCAGCCAGAGCCCAGAT
                   GAAATGCTCACCGTCCATGTACTGGACTGCAAAAGTGCCAACCTCGGGCACCTGAACT
                   GGCCCCCGTTCTGTCTGGTGATGTTGAACATGACTCACTTGGCCCATCAGGTCACTAT
                   TGATCGCTTCAACCGAAAGGTGACTGTGGACTTGCAGCCTGTGTGGCCACCGGTGAGC
                   AGGTATGCATTCAGAATTGAGGACACAGGCCACATGTACATGATCCTGACTCCCTCAG
                   ACATCCAGATCCAGTGGCTCCACAGCTCAGGACTCATGATCGTGGAGGCCAGCAAAAC
                   CAGCAAGGCCCAGGGCCATGGCCTGTGCGGTATCTGTGATGGAGATGCAGCCAATGAC
                   CTTACCCTGAAGGATGGCTCAGTGGTGCGTGCGGCTGAGGACCCTGCTCCCTTTCTGG
                   ACAGCTGGCAGGTGCCCAGCTCCCTGACCTCAGTGGGCCAGACCCGCTTCCGCCCAGA
                   CAGCTGCGCCACAACTGACTGCTCGCCCTGCCTTCGCATGGTGTCCAACCGCACCTTC
                   AGTGCCTGCCACCGCTTTGTGCCTCCGGAGTCATTCTGTGAGCTGTGGATCCGGGACA
                   CCAAGTACGTGCAGCAGCCCTGCGTGGCCCTGACTGTGTACGTGGCCATGTGCCACAA
                   ATTTCATGTGTGCATCGAGTGGCGGCGCTCTGACTACTGCCCCTTCCTGTGCTCCAGC
                   GACTCCACATACCAGGCATGTGTGACAGCCTGTGAGCCACCCAAGACATGCCAGGATG
                   GGATACTAGGGCCTCTGGACCCAGAGCACTGCCAGGTGCTGGGCGAGGGCTGCGTCTG
                   CTCCGAGGGCACCATCTTACACCGGCGCCACTCTGCACTCTGCATCCCGGAGGCCAAG
                   TGCGCCTGCACTGACAGCATGGGGGTGCCGAGGGCCCTGGGGGAGACCTGGAACAGCT
                   CCCTCAGCGGCTGCTGCCAGCACCAGTGCCAAGCCCCAGACACCATTGTCCCGGTGGA
                   TCTGGGCTGCCCCAGTCCCCGCCCTGAGAGCTGCCTGCGATTCGGCGAGGTGGCCTTG
                   CTCCTACCCACCAAGGACCCCTGCTGCCTGGGGACTGTCTGTGTGTGTAACCAGACTC
                   TGTGTGAGGGTCTCGCCCCCACATGCCGCCCAGGCCACCGCCTCCTCACCCACTTCCA
                   GGAGGACTCCTGCTGCCCCAGCTACAGCTGTGAGTGTGACCCAGATCTCTGTGAGGCA
                   GAGCTGGTCCCCAGCTGCCGACAGGACCAGATCCTGATCACGGGCCGCCTGGGGGACT
                   CCTGCTGCACCTCCTACTTCTGCGCCTGTGGTGACTGTCCAGACTCCATCCCCGAATG
                   TCAAGAAGGGGAGGCGCTCACTGTGCACAGGAATACCACGGAACTCTGCTCCCCTCTG
                   TACCAGTGTGTGTGTGAGAACTTCCGCTGTCCCCAAGTGCAGTGTGCCCTGGGCACTG
                   CCCTGGTCGAGGTGTGGAGCCCCGACCGCTGCTGCCCCTACAAATCCTGTGAATGTGA
                   CTGTGACACAATCCCGGTGCCCCGGTGCCATCTGTGGGAGAAATCCCAGCTGGATGAG
                   GAGTTCATGCACAGCGTGGAGAATGTGTGTGGCTGCGCCAAGTACGAGTGTGTGAAGG
                   CCCCGGTGTGTCTGAGCCGCGAGCTGGGTGTGATGCAGCCCGGCCAGACAGTGGTGCA
                   GCTCTCAGCAGATGGCCTGTGCCACACCTCCCGCTGCACCACCGTGCTCGACCCTCTC
                   ACCAACTTCTACCAGATCAACACCACCTCCGTGCTCTGTGACATCCACTGTGAGGCGA
                   ACCAGGAGTACGAGCACCCGCGGGACCTCGCTGCCTGCTGCGGCTCCTGCAGGAACGT
                   GTCCTGTCTCTTCACCTTCCCCAATGGCACCACCTCCCTGTTCTTGCCCGGGCCATCC
                   TGGATCGCAGACTGCGCCCGCCACCACTGCAGCAGCACGCCCCTGGGTGCCGTGCTGG
                   TCCGCTCTCCCATAAGCTGCCCACCGCTCAATGAGACTGAGTGTGCCAAGGTTGGGGG
                   TTCCGTGGTACCTTCCTTGGAAGGATGCTGCAGGACCTGTAAGGAGGATGGGCGCTCC
                   TGCAAGAAGGTGACCATCCGCATGACCATCCGCAAGAATGAATGCAGGAGCAGCACCC
                   CTGTGAACCTAGTGTCCTGCGATGGGAGGTGCCCATCCGCCAGCATCTACAACTACAA
                   CATCAACACCTATGCCCGATTCTGCAAGTGCTGCCGTGAGGTGGGCCTGCAGCGGCGC
                   TCTGTGCAGCTCTTCTGTGCCACCAATGCCACCTGGGTGCCCTATACAGTGCACGAGC
                   CCACCGACTGTGCCTGCCAGTGGTCCTGAGGCCTGGGGCCCCCGGCTAGCTGGACCAC
                   CTCTGCCAGCCCCACTTTCTGT
                   ORF Start: ATG at 43 ORF Stop: TGA at 8785
                   SEQ ID NO:82         2914 aa MW at 314011.9 kD
NOV17a,            MGARMPRRCLLLLSCFCLLRVESTAEVQHQASALTWKTSAELQQEPAPEPSHTYQEMS
CG59295-01 Protein LAVEDVTTVMEGKQAEAPDSVAMSSWERRLHRAKCAPSYLFSCFNGGECVHPAFCDCR
Sequence           RFNATGPRCQMVYNAGPERDSICRAWGQHHVETFDGLYYYLSGKGSYTLVGRHEPEGQ
                   SFSIQVHNDPQCGSSPYTCSRAVSLFFVGEQEIHLAKEVTHGGMRVQLPHVNGSARLQ
                   QLAGYVIVRHQSAFTLAWDGASAVYIKMSPELLGWTHGLCGNNNADPKDDLVTSSGEG
                   KLTDDVVEFVHSWQEQAPNQPPGPTTSSLPRPPCLQQNPGTMQGVYEQCEALLRPPFD
                   ACHAYVSPLPFTASCTSDLCQSMGDVATWCRALAEYARACAQAGRPLQGWRTQLRQCT
                   VHCKEKAFTYNECIACCPASCHPRASCVDSEIACVDGCYCPNGLIFEDGGCVAPAECP
                   CEFHGTLYPPGSVVKEDCNTCTCTSGKWECSTAVCPAECSVTGDIHFTTFDGRRYTFP
                   ATCQYILAKSRSSGTFTVTLQNAPCGLNQDGACVQSVSVILHQDPRRQVTLTQAGDVL
                   LFDQYKIIPPYTDDAFEIRRLSSVFLRVRTNVGVRVLYDREGLRLYLQVDQRWVEDTV
                   GLCCTFNGNTQDDFLSPVGVPESTPQLFGNSWKTLSACSPLVSGSPLDPCDVHLQAAS
                   YSVQACSVLTGEMFAPCSAFLSPVPYFEQCRRDACRCGQPCLCATLAHYAHLCRRHGL
                   PVDFRARLPACALSCEASKEYSPCVAPCGRTCQDLASPEACGVDGGDDLSRDECVEGC
                   ACPPDTYLDTQADLCVPRNQCSCHFQGVDYPPGDSDIPSLCHCHCKDGVMSCDSRAPA
                   AACPAGQVFVNCSDLHTDLELSRERTCEQQLLNLSVSARGPCLSGCACPQGLLRHCDA
                   CFLPEECPCTWKGKEYFPGDQVMSPCHTCVCQRGSFQCTLHPCASTCTAYGDRHYRTF
                   DGLPFDFVGACKVHLVKSTSDVSFSVIVENVNCYSSGMICRKFISINVGNSLIVFDDD
                   SGNPSPESFLDDKQEVHTWRVGFFTLVHFPQEHITLLWDQRTTVHVQAGPQWQGQLAG
                   LCGNFDLKTINEMRTPENLELTNPQEFGSSWAAVECPDTLDPRDMCVLNPLREPFAKK
                   ECSILLSEVFEICHPVVDVTWFYSNCLTDTCGCSQGGDCECFCASVSAYAHQCCQHGV
                   AVDWRTPRLCPYDCDFFNKVLGKGPYQLSSLIAAGGALVGMKAVGDDIVLVRTEDVAPA
                   DIVSFLLTAALYKAKAHDPDVVSLEAADRPNFFLHVTANIGSLELAKWQGRDTFQQHAS
                   FLLHRGTRQAGLVALESLAKPSSFLYVSCAVLALRLYEHTEVFRRGTLFRLLDAKPSG
                   AAYPICEWRYDACASPCFQTCRDPRAASCRDVPRVEGCVPVCPTPQVLDEVTQRCVYL
                   EDCVEPAVWVPTEALGNETLPPSQGLPTPSDEEPQLSQESPRTPTHRPALTPAAPLTT
                   ALNPPVTATEEPVVSPGPTQTTLQQPLELTASQLPAGPTESPASKGVTASLLAIPHTP
                   ESSSLPVALQTPTPGMVSGAMETTRVTVIFAGSPNITVSSRSPPAPRFPLMTKAVTVR
                   GHGSLPVRTTPPQPSLTASPSSRPVASPGAISRSPTSSGSHKAVLTPAVTKVISRTGV
                   PQPTQAQSASSPSTPLTVAGTAAEQVPVSPLATRSLEIVLSTEKGEAGHSQPMGSPAS
                   PQPHPLPSAPPRPAQHTTMATRSPALPPETPAAASLSTATDGLAATPFMSLESTRPSQ
                   LLSGLPPDTSLPLAKVGTSAPVATPGPKASVITTPLQPQATTLPAQTLSPVLPFTPAA
                   MTQAHPPTHIAPPAAGTAPGLLLGATLPTSGVLPVAEGTASMVSVVPRKSTTGKVAIL
                   SKQVSLPTSMYGSAEGGPTELTPATSHPLTPLVAEPEGAQAGTALPVPTSYALSRVSA
                   RTAPQDSMLVLLPQLAEAHGTSAGPHLAAEPVDEATTEPSGRSAPALSIVEGLAEALA
                   TTTEANTSTTCVPIAEQDCVRHICLEGQLIRVNQSQHCPQGAAPPRCGILGLAVRVGG
                   DRCCPLWECACRCSIFPDLSFVTFDGSHVALFKEAIYILSQSPDEMLTVHVLDCKSAN
                   LGHLNWPPFCLVMLNNTHLAHQVTIDRFNRKVTVDLQPVWPPVSRYGFRIEDTGHMYM
                   ILTPSDIQIQWLHSSGLMIVEASKTSKAQGHGLCGICDGDAANDLTLKDGSVVGGAED
                   PAPFLDSWQVPSSLTSVGQTRFRPDSCATTDCSPCLRMVSNRTFSACHRFVPPESFCE
                   LWIRDTKYVQQPCVALTVYVANCHKFHVCIEWRRSDYCPFLCSSDSTYQACVTACEPP
                   KTCQDGILGPLDPEHCQVLGEGCVCSEGTILHRRHSALCIPEAKCACTDSMGVPRALG
                   ETWNSSLSGCCQHQCQAPDTIVPVDLGCPSPRPESCLRFGEVALLLPTKDPCCLGTVC
                   VCNQTLCEGLAPTCRPGHRLLTHFQEDSCCPSYSCECDPDLCEAELVPSCRQDQILIT
                   GRLGDSCCTSYFCACGDCPDSIPECQEGEALTVHRNTTELCCPLYQCVCENFRCPQVQ
                   CGLGTALVEVWSPDRCCPYKSCECDCDTIPVPRCHLWEKSQLDEEFMHSVENVCGCAK
                   YECVKAPVCLSRELGVMQPGQTVVELSADGVCHTSRCTTVLDPLTNFYQINTTSVLCD
                   IHCEANQEYEHPRDLAACCGSCRNVSCLFTFPNGTTSLFLPGASWIADCARHHCSSTP
                   LGAVLVRSPISCPPLNETECAKVCGSVVPSLEGCCRTCKEDGRSCKKVTIRMTIRKNE
                   CRSSTPVNLVSCDGRCPSASIYNYNINTYARFCKCCREVGLQRRSVQLFCATNATWVP
                   YTVQEPTDCACQWS

[0406] Further analysis of the NOV17a protein yielded the following properties shown in Table 17B.

TABLE 17B
Protein Sequence Properties NOV17a
PSort     0.4610 probability located in outside; 0.1900
analysis: probability located in lysosome (lumen); 0.1000
          probability located in endoplasmic reticulum (membrane);
          0.1000 probability located in endoplasmic reticulum
          (lumen)
SignalP   Cleavage site between residues 24 and 25
analysis:

[0407] A search of the NOV17a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17C.

TABLE 17C
Geneseq Results for NOV17a
		NOV17a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAU29530	Novel human secreted protein #21 -	139 . . . 1233	392/1136 (34%)	0.0
	Homo sapiens, 2814 aa.	35 . . . 1131	561/1136 (48%)
	[WO200179449-A2, 25-OCT-2001]
AAP60053	Sequence of von Willebrand factor	139 . . . 1233	392/1136 (34%)	0.0
	(vWF) - Homo sapiens, 2813 aa.	35 . . . 1131	561/1136 (48%)
	[EP197592-A, 15-OCT-1986]
AAP60462	Sequence of human von Willebrand	139 . . . 1233	393/1137 (34%)	0.0
	Factor (VWF) precursor - Homo	35 . . . 1131	559/1137 (48%)
	sapiens, 2813 aa. [WO8606096-A,
	23-OCT-1986]
AAY70557	Canine von Willebrand factor - Canis	139 . . . 1233	386/1137 (33%)	e−179
	familiaris, 2813 aa. [WO200009533-A1,	35 . . . 1131	550/1137 (47%)
	24-FEB-2000]
AAW54347	Canine von Willebrand Factor (vWF)	139 . . . 1233	386/1137 (33%)	e−179
	sequence - Canis sp, 2813 aa.	35 . . . 1131	550/1137 (47%)
	[WO9803683-A1, 29-JAN-1998]

[0408] In a BLAST search of public sequence databases, the NOV17a protein was found to have homology to the proteins shown in the BLASTP data in Table 17D.

TABLE 17D
Public BLASTP Results for NOV17a
		NOV17a	Identities/
Protein		Residues/	Similarities
Accession		Match	for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
O55225	OTOGELIN - Mus musculus	1 . . . 2914	2421/2923 (82%)	0.0
	(Mouse), 2910 aa.	1 . . . 2910	2553/2923 (86%)
CAA00831	VON WILLEBRAND FACTOR -	139 . . . 1233	392/1136 (34%)	0.0
	synthetic construct, 2324 aa	35 . . . 1131	561/1136 (48%)
	(fragment).
P04275	Von Willebrand factor precursor	139 . . . 1233	394/1137 (34%)	0.0
	(vWF) - Homo sapiens (Human),	35 . . . 1131	561/1137 (48%)
	2813 aa.
Q28295	Von Willebrand factor precursor	139 . . . 1233	390/1138 (34%)	0.0
	(vWF) - Canis familiaris (Dog),	35 . . . 1131	554/1138 (48%)
	2813 aa.
A43932	mucin 2 precursor, intestinal -	137 . . . 1236	365/1126 (32%)	e−175
	human, 3020 aa (fragment).	35 . . . 1125	554/1126 (48%)

[0409] PFam analysis indicates that the NOV17a protein contains the domains shown in the Table 17E.

TABLE 17E
Domain Analysis of NOV17a
		Identities/
	NOV17a	Similarities
	Match	for the Matched
Pfam Domain	Region	Region	Expect Value
Arthro_defensin:	87 . . . 116	10/36	(28%)	7.9
domain 1 of 1		17/36	(47%)
vwd:	139 . . . 289	58/165	(35%)	1.9e−38
domain 1 of 4		117/165	(71%)
IBR:	357 . . . 419	6/78	(8%)	7
domain 1 of 1		41/78	(53%)
EB:	409 . . . 457	15/56	(27%)	9.7
domain 1 of 1		28/56	(50%)
TIL:	409 . . . 463	19/70	(27%)	0.096
domain 1 of 5		37/70	(53%)
TILa:	462 . . . 514	15/57	(26%)	2.8
domain 1 of 1		30/57	(53%)
vwc:	465 . . . 525	18/91	(20%)	0.0087
domain 1 of 1		45/91	(49%)
vwd:	503 . . . 658	62/168	(37%)	6.1e−45
domain 2 of 4		130/168	(77%)
TIL:	769 . . . 833	19/76	(25%)	2.7e−06
domain 2 of 5		40/76	(67%)
TIL:	873 . . . 935	18/74	(24%)	0.011
domain 3 of 5		42/74	(57%)
vwd:	975 . . . 1121	45/166	(27%)	1.1e−32
domain 3 of 4		111/166	(67%)
TIL:	1398 . . . 1453	16/69	(23%)	0.05
domain 4 of 5		40/69	(58%)
vwd:	2101 . . . 2255	38/166	(23%)	3.9e−21
domain 4 of 4		111/166	(67%)
Chitin_bind_2:	2333 . . . 2381	10/61	(16%)	7
domain 1 of 1		27/61	(44%)
TIL:	2362 . . . 2423	20/71	(28%)	0.0095
domain 5 of 5		48/71	(68%)
Cys_knot:	2822 . . . 2880	12/63	(19%)	0.06
domain 1 of 1		44/63	(70%)

Example 18

[0410] The NOV18 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 18A.

TABLE 18A
NOV18 Sequence Analysis
                   SEQ ID NO:83         1882 bp
NOV18a,            CCCTCCCACGGCCCCTCCCGGCCTCTCTACATAAAGCCGGGGGTACTGGGCCTCAGGT
C059293-01 DNA     CAGGCCTATGGCCATGGCCTTCACACACCTGCTCGATGCTCTGGGCAGCATGGGCCGC
Sequence           TTCCAGCTCAACCACACAGCCCTGCTGCTGCTGCCCTGCGGCCTGCTGGCCTCCCACA
                   ACTTCCTGCAGAACTTCACCCCCGCTGTCCCCCCCCACCACTGCCGGGCCCCTGCCAA
                   CCACACTGAGGCCTCCACCAACGACTCCGGCGCCTGGCTGAGGGCCACCATACCCCTG
                   GACCAGCTTGGGGCCCCTGAGCCCTGCCGGCGCTTCACCAAGCCTCAGTGGGCCCTGC
                   TGAGCCCCAACTCCTCCATCCCGGGCGCGGCCACGGAGGGCTGCAAGGACGGCTGGGT
                   CTATAACCGCAGTGTTTTCCCGTCCACCATCGTGATGGAGTGGGATCTGGTGTGTGAG
                   GCCCGCACTCTCCGAGACCTGGCGCAGTCCGTCTACATTGCCGGGGTGCTGGTGGGGG
                   CTGCCGTGTTTGGCAGCTTGGCAGACAGGCTGGGCTGCAAGGGCCCCCTGGTCTGGTC
                   CTACCTGCAGCTGGCAGCTTCGGGGGCCGCCACAGCGTATTTCAGCTCCTTCAGTGCC
                   TATTGCGTCTTCCGGTTCCTGATGGGCATGACCTTCTCTGGCATCATCCTCAACTCCG
                   TCTCCCTGGTGATTGTGGAGTGGATGCCCACACGGGGCCGGACTGTGGCGGGTATTTT
                   GCTGGGGTATTCCTTCACCCTGGGCCAGCTCATCCTGGCTGGGGTAGCCTACCTGATT
                   CGCCCCTGGCGGTGCCTGCAGTTTGCCATCTCTGCTCCTTTCCTGATCTTTTTCCTCT
                   ATTCTTGGTGGCTTCCAGAGTCATCCCGCTGGCTCCTCCTGCATGGCAAGTCCCAGTT
                   AGCTGTACAGAATCTGCAGAAGGTGGCTGCAATGAACGGGAGGAAGCAGGAAGGGGAA
                   AGGCTGACCAAGGAGGTGATGAGCTCCTACATCCAAAGCGAGTTTGCAAGTGTCTGCA
                   CCTCCAACTCAATCTTGGACCTCTTCCGAACCCCGGCCATCCGCAAGGTCACATGCTG
                   TCTCATGGTGATTTGGTTCTCCAACTCTGTGGCTTACTATGGCCTGGCCATGGACCTG
                   CAGAAGTTTGGGCTCAGCCTATACCTGGTGCAGGCCCTGTTTGGAATCATCAACATCC
                   CGGCCATGCTGGTGGCCACCGCCACCATGATTTACGTGGGCCGCCGTGCCACGGTGGC
                   CTCCTTCCTCATCCTGGCCGGGCTCATGGTGATCCCCAACATGTTTGTGCCAGAAGGC
                   TCCACCCCCTCTCCACTACACCCTGGGCCTCCCTCTCCTCCCCTCCTCCTCAGCTGCA
                   CCCTACTCCCCTGTCTAGGCACGCAGATCCTGTGCACAGCCCAGGCAGCGCTGGGCAA
                   AGGCTGCCTGGCCAGCTCCTTCATCTGTGTGTACCTGTTTACCGGCGAGCTGTACCCC
                   ACGGAGATCAGGCAGATGGGGATGGGCTTTGCCTCTGTCCACGCCCGCCTCGGGGGCC
                   TGACGGCGCCCCTGGTTACCACACTTGGGGAATACAGCACCATCCTGCCACCCGTGAG
                   CTTTCGGGCCACCGCAATCCTGGCTGGGCTGGCCGTCTGCTTCCTGACTGAGACCCGC
                   AACATGCCCCTGGTCGAGACCATCGCAGCCATGGAGAGGAGGGTCAAAGAAGGCTCTT
                   CCAAGAAACATGTAGAAGAGAAGAGTGAAGAAATTTCTCTTCAGCAGCTGAGAGCATC
                   TCCCCTCAAAGAGACCATCTAAGCTGCCTGGAACCTGGTGCTTGCTAGCAGCACCTGA
                   GCCGATGTCCAGACGGCCCCCTGGCG
                   ORF Start: ATG at 66 ORF Stop: TAA at 1818
                   SEQ ID NO:84         584 aa MW at 63391.5 kD
NOV18a,            MAMAFTDLLDALGSMGRFQLNHTALLLLPCGLLACHNFLQNFTAAVPPHHCRGPANHT
CG59293-01 Protein EASTNDSGAWLRATIPLDQLGAPEPCRRFTKPQWALLSPNSSIPGAATEGCKDGWVYN
Sequence           RSVFPSTIVMEWDLVCEARTLRDLAQSVYIAGVLVGAAVFGSLADRLGCKGPLVWSYL
                   QLAASGAATAYFSSFSAYCVFRFLMGMTFSGIILNSVSLVIVEWMPTRGRTVAGILLG
                   YSFTLGQLILAGVAYLIRPWRCLQFAISAPFLIFFLYSWWLPESSRWLLLHGKSQLAV
                   QNLQKVAAMNGRKQEGERLTKEVMSSYIQSEFASVCTSNSILDLFRTPAIRKVTCCLM
                   VIWFSNSVAYYGLAMDLQKFGLSLYLVQALFGIINIPANLVATATMIYVGRRATVASF
                   LILAGLMVIANMFVPEGSTPSPLHPGPPSPPLLLSCTLLPCLGTQILCTAQAALGKGC
                   LASSFICVYLFTGELYPTEIRQMGMGFASVHARLGGLTAPLVTTLGEYSTILPPVSFG
                   ATAILAGLAVCFLTETRNMPLVETIAAMERRVKEGSSKKHVEEKSEEISLQQLRASPL
                   KETI

[0411] Further analysis of the NOV18a protein yielded the following properties shown in Table 18B.

TABLE 18B
Protein Sequence Properties NOV18a
PSort     0.6000 probability located in plasma membrane; 0.4000
analysis: probability located in Golgi body; 0.3142 probability
          located in mitochondrial inner membrane; 0.3000
          probability located in endoplasmic reticulum (membrane)
SignalP   Cleavage site between residues 35 and 36
analysis:

[0412] A search of the NOV18a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18C.

TABLE 18C
Geneseq Results for NOV18a
		NOV18a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAW88488	Rat organic anion transporter	3 . . . 573	249/573 (43%)	e−137
	OAT-1 - Rattus sp, 551 aa.	1 . . . 542	346/573 (59%)
	[WO9853064-A1, 26-NOV-1998]
AAB47271	hOAT1 - Homo sapiens, 550 aa.	3 . . . 573	254/573 (44%)	e−137
	[WO200104283-A2, 18-JAN-2001]	1 . . . 541	345/573 (59%)
AAY44278	Human organic anion transporter -	3 . . . 573	254/573 (44%)	e−137
	Homo sapiens, 550 aa. [WO9964459-	1 . . . 541	345/573 (59%)
	A2, 16-DEC-1999]
AAW88489	Human organic anion transporter	3 . . . 553	250/553 (45%)	e−137
	OAT-1 - Homo sapiens, 563 aa.	1 . . . 522	336/553 (60%)
	[WO9853064-A1, 26-NOV-1998]
AAY92903	Rat cerebral organic anion transporter	3 . . . 573	256/577 (44%)	e−135
	OAT3 protein - Rattus sp, 536 aa.	1 . . . 533	352/577 (60%)
	[WO200017237-A1, 30-MAR-2000]

[0413] In a BLAST search of public sequence databases, the NOV18a protein was found to have homology to the proteins shown in the BLASTP data in Table 18D.

TABLE 18D
Public BLASTP Results for NOV18a
		NOV18a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
O57379	RENAL ORGANIC ANION	3 . . . 583	262/592 (44%)	e−139
	TRANSPORTER - Pseudopleuronecta	1 . . . 561	362/592 (60%)
	americanus (Winter flounder), 562 aa.
O35956	RENAL ORGANIC ANION	3 . . . 573	250/573 (43%)	e−137
	TRANSPORT PROTEIN 1 - Rattus	1 . . . 542	348/573 (60%)
	norvegicus (Rat), 551 aa.
Q9TSY7	RENAL ORGANIC ANION	3 . . . 573	253/573 (44%)	e−136
	Oryctolagus cuniculus (Rabbit), 551	1 . . . 542	344/573 (59%)
	aa.
O95742	RENAL ORGANIC ANION	3 . . . 553	250/553 (45%)	e−136
	TRANSPORT PROTEIN 1 - Homo	1 . . . 522	336/553 (60%)
	sapiens (Human), 563 aa.
Q9R1U7	ORGANIC ANION TRANSPORTER	3 . . . 573	256/577 (44%)	e−134
	3 - Rattus norvegicus (Rat), 536 aa.	1 . . . 533	352/577 (60%)

[0414] PFam analysis indicates that the NOV18a protein contains the domains shown in the Table 18E.

TABLE 18E
Domain Analysis of NOV18a
		Identities/
	NOV18a	Similarities
	Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
Chal_stil_syntC: domain	200 . . . 212	5/13	(38%)	9.8
1 of 1		11/13	(85%)
sugar_tr: domain 1 of 1	100 . . . 548	102/528	(19%)	5.9e−07
		307/528	(58%)

Example 19

[0415] The NOV19 was analyzed, and the nucleotide and polypeptide sequences are shown in Table 19A.

TABLE 19A
NOV19 Sequence Analysis
                   SEQ ID NO:85         1802 bp
NOV19a,            TGGGGGAAACAGGCCCGTTGCCCTGGCCTCTTTCCCCTGGGCCAGCCTTTGTGAAGTG
C059284-01 DNA     GGCCCCTCTTCTGGGCCCCTTGAGTAGGTTCCATGGCATTTTCTGAACTCCTGGACCT
Sequence           CGTGGGTGGCCTGGGCAGGTTCCAGGTTCTCCAGACGATGGCTCTGATGGTCTCCATC
                   ATGTGGCTGTGTACCCAGAGCATGCTGGAGAACTTCTCGGCCGCCGTGCCCAGCCACC
                   GCTGCTGGGCACCCCTCCTGGACAACAGCACGGCTCAGGCCAGCATCCTAGGGAGCTT
                   GAGTCCTGAGGCCCTCCTGCCTATTTCCATCCCGCCGGGCCCCAACCAGAGGCCCCAC
                   CAGTGCCGCCGCTTCCGCCAGCCACAGTGGCAGCTCTTGGACCCCAATGCCACGGCCA
                   CCAGCTGGAGCGAGGCCGACACGGAGCCGTGTGTGGATGGCTGGGTCTATGACCGCAG
                   CATCTTCACCTCCACAATCGTGGCCAAGTGGAACCTCGTGTGTGACTCTCATGCTCTG
                   AAGCCCATGGCCCAGTCCATCTACCTGGCTGGCATTCTGGTGGGAGCTGCTGCGTGCG
                   GCCCTGCCTCAGACAGGTTTGGGCGCAGGCTGGTGCTAACCTGCAGCTACCTTCAGAT
                   GGCTGTGATGGGTACGGCAGCTGCCTTCGCCCCTGCCTTCCCCGTGTACTGCCTGTTC
                   CCCTTCCTGTTGGCCTTTGCCGTGGCAGGCGTCATGATGAACACGGGCACTCTCCTGA
                   TGGAGTGCACGCCGGCACGGGCCCGACCCTTGGTGATGACCTTOAACTCTCTGGGCTT
                   CAGCTTCGGCCATGGCCTGACAGCTGCAGTGGCCTACGGTGTGCGGGACTCCACACTG
                   CTGCAGCTGGTGGTCTCGGTCCCCTTCTTCCTCTGCTTTTTGTACTCCTCGTGGCTCG
                   CAGAGTCGGCACGATGGCTCCTCACCACAGGCAGGCTGGATTGGGGCCTGCAGGAGCT
                   GTGGAGGGTCGCTGCCATCAACGGAAAGGGGCCAGTGCAGGACACCCTGACCCCTGAG
                   GTCTTGCTTTCAGCCATGCGGGAGGAGCTGAGCATGGGCCAGCCTCCTGCCAGCCTGG
                   GCACCCTGCTCCGCATGCCCGGACTGCGCTTCCGGACCTGTATCTCCACGTTGTGCTG
                   GTTCGCCTTTGGCTTCACCTTCTTCGGCCTGGCCCTGGACCTGCAGGCCCTGGGCAGC
                   AACATCTTCCTGCTCCAAATGTTCATTGGTGTCGTGGACATCCCAGCCAAGATGGGCG
                   CCCTGCTGCTGCTGACCCACCTGGGCCGCCGCCCCACGCTGGCCGCATCCCTGTTGCT
                   GGCGGGGCTCTGCATTCTGGCCAACACGCTGGTGCCCCACGAAATGGGGGCTCTGCGC
                   TCAGCCTTGGCCGTGCTGGGGCTGGGCGGGGTGGGGGCTGCCTTCACCTGCATCACCA
                   TCTACAGCAGCGAGCTCTTCCCCACTGTGCTCAGGATGACGGCAGTGGGCTTGGGCCA
                   GATGGCAGCCCGTCGAGGAGCCATCCTGGGGCCTCTGGTCCGGCTGCTGGGTGTCCAT
                   GGCCCCTGGCTGCCCTTGCTGGTGTATGGGACGGTGCCAGTGCTGAGTGGCCTGGCCG
                   CACTGCTTCTGCCCGAGACCCAGAGCTTGCCGCTGCCCGACACCATCCAAGATGTGCA
                   GAACCAGGCAGTAAAGAAGGCAACACATGGCACGCTGGGGAACTCTGTCCTAAAATCC
                   ACACAGTTTTAGCCTCCTCGGGAACCTGCGATGGGACGGTCAGAGGAAGAGACTTCTT
                   CTGT
                   ORF Start: ATG at 91 ORF Stop: TAG at 1750
                   SEQ ID NO:86         553 aa MW at 59629.4 kD
NOV19a,            MAFSELLDLVGGLGRFQVLQTMALMVSIMWLCTQSMLENFSAAVPSHRCWAPLLDNST
CG59284-01 Protein AQASILGSLSPEALLAISIPPGPNQRPHQCRRFRQPQWQLLDPNATATSWSEADTEPC
Sequence           VDGWVYDRSIFTSTIVAKWNLVCDSHALKPMAQSIYLAGILVGAAACGPASDRFGRRL
                   VLTWSYLQMAVMGTAAAFAPAFPVYCLFRFLLAFAVAGVMMNTGTLLMEWTAARARPL
                   VNTLNSLGFSFGHGLTAAVAYGVRDWTLLQLVVSVPFFLCFLYSWWLAESARWLLTTG
                   RLDWGLQELWRVAAINGKGAVQDTLTPEVLLSAMREELSMGQPPASLGTLLRMPGLRF
                   RTCISTLCWFAFGFTFFGLALDLQALGSNIFLLQMFIGVVDIPAKMGALLLLSHLGRR
                   PTLAASLLLAGLCILANTLVPHEMGALRSALAVLGLGGVGAAFTCITIYSSELFPTVL
                   RMTAVGLGQMAARGGAILGPLVRLLGVHGPWLPLLVYGTVPVLSGLAALLLPETQSLP
                   LPDTIQDVQNQAVKKATHGTLGNSVLKSTQF

[0416] Further analysis of the NOV19a protein yielded the following properties shown in Table 19B.

TABLE 19B
Protein Sequence Properties NOV19a
PSort     0.6000 probability located in plasma membrane; 0.4000
analysis: probability located in Golgi body; 0.3000 probability
          located in endoplasmic reticulum (membrane);
          0.3000 probability located in microbody (peroxisome)
SignalP   Cleavage site between residues 44 and 45
analysis:

[0417] A search of the NOV19a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 19C.

TABLE 19C
Geneseq Results for NOV19a
		NOV19a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAE10332	(TRICH-9) protein - Homo sapiens,	1 . . . 553	553/553 (100%)	0.0
	553 aa. [WO200162923-A2,
	30-AUG-2001]
AAE06571	Human protein having hydrophobic	1 . . . 553	552/578 (95%)	0.0
	domain, HP03613 - Homo sapiens,	1 . . . 578	553/578 (95%)
	578 aa. [WO200149728-A2,
	12-JUL-2001]
AAE06612	Human protein having hydrophobic	1 . . . 533	284/534 (53%)	e−161
	domain, HP03882 - Homo sapiens,	1 . . . 530	372/534 (69%)
	550 aa. [WO200149728-A2,
	12-JUL-2001]
AAB69091	Human organic anion transporter OAT4	1 . . . 533	284/534 (53%)	e−161
	protein sequence SEQ ID NO:2 - Homo	1 . . . 530	372/534 (69%)
	sapiens, 550 aa. [WO200102562-A1,
	11-JAN-2001]
AAE10336	Human transporter and ion channel-13	1 . . . 533	282/549 (51%)	e−157
	(TRICH-13) protein - Homo sapiens,	1 . . . 546	370/549 (67%)
	566 aa. [WO200162923-A2,
	30-AUG-2001]

[0418] In a BLAST search of public sequence databases, the NOV19a protein was found to have homology to the proteins shown in the BLASTP data in Table 19D.

TABLE 19D
Public BLASTP Results for NOV19a
		NOV19a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q96S37	RST - Homo sapiens (Human),	1 . . . 553	553/553 (100%)	0.0
	553 aa.	1 . . . 553	553/553 (100%)
CAC51145	SEQUENCE 21 FROM PATENT	1 . . . 553	552/578 (95%)	0.0
	WO0149728 - Homo sapiens	1 . . . 578	553/578 (95%)
	(Human), 578 aa.
Q96DT2	ORGANIC ANION TRANSPORTER	1 . . . 553	507/561 (90%)	0.0
	4 LIKE PROTEIN - Homo sapiens	1 . . . 552	513/561 (91%)
	(Human), 552 aa.
O54778	RST - Mus musculus (Mouse),	1 . . . 552	409/552 (74%)	0.0
	553 aa.	1 . . . 552	462/552 (83%)
Q9NSA0	ORGANIC ANION	1 . . . 533	284/534 (53%)	e−160
	TRANSPORTER 4 (OAT4) - Homo	1 . . . 530	372/534 (69%)
	sapiens (Human), 550 aa.

[0419] PFam analysis indicates that the NOV19a protein contains the domains shown in the Table 19E.

TABLE 19E
Domain Analysis of NOV19a
	NOV19a	Identities/
	Match	Similarities for	Expect
Pfam Domain	Region	the Matched Region	Value
zf-RanBP: domain 1 of 1	26 . . . 55	7/32	(22%)	5.8
		17/32	(53%)
sugar_tr: domain 1 of 1	106 . . . 530	89/493	(18%)	4.2e−07
		277/493	(56%)

Example 20

[0420] The NOV20 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 20A.

TABLE 20A
NOV20 Sequence Analysis
                   SEQ ID NO:87         1050 bp
NOV20a,            CTTGAAGTAATTTATATTCTATCTTTATCGCTTGTTCCTAGGAATCATGGATCACGTC
CG59278-01 DNA     AGTCATAACTGGACTCAGAGTTTTATCCTTGCTGGTTTCACCACCACTGGGACCCTAC
Sequence           AACCTCTTGCCTTCTTGGGGACCCTATGCATCTATCTCCTCACACTTGCAGGGAACAT
                   TCTCATCATTGTCCTGGTACAGTTAGATTCTGGACTGTTCACGCCCATGTACTTATTT
                   ATCAGTGTCCTCTCCTTTGTAGAGGTGTGGTATGTCAGCACCACAGTGCCCATGCTGC
                   TGCACACCTTGCTCCAAGGGTGTTCACCCGTCTCATCAGCTGTATGCTTTATTCAGCT
                   ATCCTTTCATTCCTTAGGGATGACTGAGTGCTACCTGCTGGGTGTCATGGCACTGGAT
                   AGCTACCTTATCATCTGCCACCCACTCCACTACCACGCACTCATGAGCAGACAGGTAC
                   AGTTACGACTAGCTGGGGCCAGTTGGGTGGCTGGCTTCTCAGCTGCACTTGTGCCAGC
                   CACCCTCACTGCCACTCTGCCCTTCTGCTTGAAAGAGGTGGCCCATTACTTTTGTGAC
                   TTGGCACCACTAATGCGGTTGGCATGTGTGGACACAAGCTGGCATGCTAGGGCCCATG
                   GCACAGTGATTGGTGTGGCCACTGGTTGCAACTTTGTGCTCATTTTGGGACTCTATGG
                   AGGTATCCTGAATGCTGTGCTGAAGCTACCCTCAGCTGCCAGTAGTGCCAAGGCCTTC
                   TCTACCTGTTCCTCCCACGTAACTGTGGTGGCACTATTCTATGCTTCTGCCTTCACAG
                   TATATGTGGGCTCACCTGGGAGTCGACCTGAGAGCACAGACAAGCTTGTTGCCTTGGT
                   TTATGCCCTTATTACCCCTTTCCTCAATCCTATCATCTATAGCCTTCGCAACAAGGAG
                   GTGAAGAGGCTTTAAGGAGAGTCATGGCTGGGCGCGGTGGCTCACGCCTGTAACCC
                   AGCACTCTGGGAGGCCGAGGCGGGTGGATCACGAGGTCAGGAGATCGAGACCACGGTG
                   AAACCC
                   ORE Start: ATG at 47 ORF Stop: TAA at 980
                   SEQ ID NO:88         311 aa MW at 33602.3 kD
NOV20a,            MDHVSHNWTQSFILAGFTTTGTLQPLAFLGTLCIYLLTLAGNILIIVLVQLDSGLFTP
CG59278-01 Protein MYLFISVLSFVEVWYVSTTVPMLLHTLLQGCSPVSSAVCFIQLCFHSLGMTECYLLGV
Sequence           MALDSYLIICHPLHYHALMSRQVQLRLAGASWVAGFSAALVPATLTATLPFCLKEVAH
                   YFCDLAPLMRLACVDTSWHARAHGTVIGVATGCNFVLILGLYGGILNAVLKLPSAASS
                   AKAFSTCSSHVTVVALFYASAFTVYVGSPGSRPESTDKLVALVYALITPFLNPIIYSL
                   RNKEVKKALRRVMAGRGGSRL

[0421] Further analysis of the NOV20a protein yielded the following properties shown in Table 20B.

TABLE 20B
Protein Sequence Properties NOV20a
PSort     0.6400 probability located in plasma membrane; 0.5000
analysis: probability located in microbody (peroxisome); 0.4600
          probability located in Golgi body; 0.3700
          probability located in endoplasmic reticulum (membrane)
SignalP   Cleavage site between residues 41 and 42
analysis:

[0422] A search of the NOV20a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 20C.

TABLE 20C
Geneseq Results for NOV20a
		NOV20a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAG71821	Human olfactory receptor polypeptide,	1 . . . 302	300/303 (99%)	e−172
	SEQ ID NO: 1502 - Homo sapiens,	1 . . . 303	301/303 (99%)
	303 aa. [WO200127158-A2,
	19-APR-2001]
AAG72628	Murine OR-like polypeptide query	1 . . . 302	254/303 (83%)	e−148
	sequence, SEQ ID NO: 2309 - Mus	6 . . . 308	277/303 (90%)
	musculus, 333 aa. [WO200127158-A2,
	19-APR-2001]
AAG72627	Murine OR-like polypeptide query	1 . . . 266	204/267 (76%)	e−117
	sequence, SEQ ID NO: 2308 - Mus	14 . . . 280	227/267 (84%)
	musculus, 282 aa. [WO200127158-A2,
	19-APR-2001]
AAG71814	Human olfactory receptor polypeptide,	1 . . . 307	131/309 (42%)	6e−69
	SEQ ID NO: 1495 - Homo sapiens,	1 . . . 309	188/309 (60%)
	317 aa. [WO200127158-A2,
	19-APR-2001]
AAG72355	Human OR-like polypeptide query	12 . . . 303	138/294 (46%)	5e−68
	sequence, SEQ ID NO: 2036 - Homo	11 . . . 304	181/294 (60%)
	sapiens, 312 aa. [WO200127158-A2,
	19-APR-2001]

[0423] In a BLAST search of public sequence databases, the NOV20a protein was found to have homology to the proteins shown in the BLASTP data in Table 20D.

TABLE 20D
Public BLASTP Results for NOV20a
		Residues/	Similarities for
Accession		Match	the Matched
Number	Protein/Organism/Length	Residues	Portion	Value
Q96KK4	DJ994E9.5 (OLFACTORY	12 . . . 303	138/294 (46%)	2e−67
	RECEPTOR, FAMILY 10,	5 . . . 298	181/294 (60%)
	SUBFAMILY C, MEMBER 1
	(HS6M1-17)) - Homo sapiens (Human),
	306 aa.
Q96KK4	Olfactory receptor 10C1	12 . . . 303	138/294 (46%)	2e−67
	(Hs6M1-17) - Homo sapiens (Human),	11 . . . 304	181/294 (60%)
	312 aa.
Q63394	OL1 RECEPTOR - Rattus norvegicus	1 . . . 303	129/305 (42%)	1e−62
	(Rat), 313 aa.	1 . . . 305	192/305 (62%)
Q9JKA6	OLFACTORY RECEPTOR P2 - Mus	7 . . . 303	135/302 (44%)	2e−61
	musculus (Mouse), 315 aa.	5 . . . 306	178/302 (58%)
Q9H207	Olfactory receptor 10A5 (HP3)	7 . . . 301	135/302 (44%)	3e−61
	(Putative taste receptor JCG6) -	5 . . . 304	181/302 (59%)
	Homo sapiens (Human), 317 aa.

[0424] PFam analysis indicates that the NOV20a protein contains the domains shown in the Table 20E.

TABLE 20E
Domain Analysis of NOV20a
	NOV20a	Identities/
	Match	Similarities for	Expect
Pfam domain	Region	the Matched Region	Value
7tm_1: domain 1 of 1	41 . . . 288	54/268 (20%)	2.7e−18
		170/268 (63%)

Example 21

[0425] The NOV21 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 21A.

TABLE 21A
NOV21 Sequence Analysis
                   SEQ ID NO:89         793 bp
NOV21a,            ACTTACTGCATTTGGTGCTGTGATCCAACTCATCTCCCCATCCCTGCAGAGAAACCTG
CG59274-01 DNA     TGACCATGAGGAGCAGCCTGACCATGGTGGGAACCCTCTCAGGCCTTCCTGTCCCTTGT
Sequence           TACTGCTGTGACCAGTTCTACCAGTTACTTCCTACCTTACTGGCTCTTTGGATCCCAG
                   ATGGGGAAGCCAGTGTCATTCAGCACATTCCGGAGGTGCAACTACCCTGTGCGGGGAG
                   AGGGACACAGTCTGATCATGGTGGAAGAATGTGGGCGCTATGCCAGCTTCAATGCCAT
                   CCCAAGCCTGGCCTGGCAGATGTGCACAGTGGTGACAGGTGCCGGCTGTGCTCTCCTG
                   CTCCTGGTGGCACTAGCTGCTGTCCTGGGTTGCTGCATGGAGGAGCTCATCTCCAGAA
                   TGATGGGACGTTGCATGGGAGCAGCGCAGTTTGTTGGAGGGCTGCTGATAAGCTCAGG
                   CTGTGCCTTATACCCTTTAGGATGGAATAGCCCGGAGATAATGCAAACATGTGGGAAT
                   GTCTCCAATCAATTTCAGTTAGGTACCTGTCGGCTTGGCTGGGCCTATTACTGTGCTG
                   GAGGTGGAGCAGCTGCAGCCATGTTGATCTGCACCTGGCTCTCTTCCTTTGCTGGAAG
                   AAACCCCAAGCCTGTCATATTGGTGGAGAGCATCATGAGGAATACCAATTCTTATGCT
                   ATGGAGCTTGACCATTGCCTCAAACCTTGAGCTTTGAAAGAAGATTGGAGAGGGTGGG
                   AAAGGGGAGGAGGGAGCCCTGAAAAGAGGTACTAAGGAT
                   ORF Start: ATG at 64 ORF Stop: TGA at 724
                   SEQ ID NO:90         220 aa MW at 23776.7 kD
NOV21a,            MRSSLTMVGTLWAFLSLVTAVTSSTSYFLPYWLFGSQMGKPVSFSTFRRCNYPVRGEG
C059274-01 Protein HSLIMVEECGRYASFNAIPSLAWQMCTVVTGAGCALLLLVALAAVLGCCMEELISRMM
Sequence           GRCMGAAQFVGGLLISSGCALYPLGWNSPEIMQTCGNVSNQFQLGTCRLGWAYYCAGG
                   GAAAAMLICTWLSCFAGRNPKPVILVESIMRNTNSYAMELDHCLKP
                   SEQ ID NO:91         793 bp
NOV21b,            ACTTACTGCATTTGGTGCTGTGATCCAACTCATCTCCCCATCCCTGCAGAGAAACCTG
CG59274-02 DNA     TGACCATGAGGACCAGCCTGACCATGGTGGGAACCCTCTGGGCCTTCCTGTCCCTTGT
Sequence           TACTGCTGTGACCAGTTCTACCAGTTACTTCCTACCTTACTGGCTCTTTGGATCCCAG
                   ATGGGGAAGCCAGTGTCATTCAGCACATTCCGGAGGTGCAACTACCCTGTGCGGGGAG
                   AGGGACACAGTCTGATCATGGTGGAAGAATGTGGGCGCTATGCCAGCTTCAATGCCAT
                   CCCAAGCCTGGCCTGGCAGATGTGCACAGTGGTGACAGGTGCCGGCTGTGCTCTGCTG
                   CTCCTGGTGGCACTAGCTGCTGTCCTGGGTTGCTGCATGGAGGAGCTCATCTCCAGAA
                   TGATGGGACGTTGCATGGGAGCAGCGCAGTTCGTTGGAGGGCTGCTGATAAGCTCAGG
                   CTGTGCCTTATACCCTTTAGCATGGAATAGCCCGGAGATAATGCAAACATGTGGGAAT
                   GTCTCCAATCAATTTCAGTTAGGTACCTGTCGGCTTGGCTGGGCCTATTACTGTCCTG
                   GAGGTGGAGCAGCTCCAGCCATGTTGATCTGCACCTCCCTCTCTTGCTTTGCTGGAAG
                   AAACCCCAAGCCTGTCATATTGGTGGAGAGCATCATGAGGAATACCAATTCTTATGCT
                   ATGGAGCTTGACCATTGCCTCAAACCTTGAGCTTTGAAAGAAGATTGGAGAGGGTGGG
                   AAAGGGGAGGAGGGAGCCCTGAAAAGAGGTACTAGGAT
                   ORF Start: ATG at 64 ORF Stop: TGA at 724
                   SEQ ID NO:92         220 aa MW at 23776.7 kD
NOV21b,            MRSSLTMVGTLWAFLSLVTAVTSSTSYFLPYWLFGSQMGKPVSFSTFRRCNYPVRGEG
CG59274-02 Protein HSLIMVEECCRYASFNAIPSLAWQMCTVVTGAGCALLLLVALAAVLGCCMEELISRMM
Sequence           GRCMGAAQFVGGLLISSGCALYPLGWNSPEIMQTCGNVSNQFQLGTCRLGWAYYCAGG
                   GAAAAMLICTWLSCFAGRNPKPVILVESIMRNTNSYAMELDHCLKP

[0426] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 21B.

TABLE 21B
Comparison of NOV21a against NOV21b and NOV21c.
	NOV21a Residues/Match	Identities/Similarities
Protein Sequence	Residues	for the Matched Region
NOV21b	1 . . . 220	181/220 (82%)
	1 . . . 220	181/220 (82%)

[0427] Further analysis of the NOV21 a protein yielded the following properties shown in Table 21C.

TABLE 21C
Protein Sequence Properties NOV21a
PSort     0.4600 probability located in plasma membrane; 0.1000
analysis: probability located in endoplasmic
          reticulum (membrane); 0.1000 probability
          located in endoplasmic reticulum (lumen);
          0.1000 probability located in outside
SignalP   Likely cleavage site between residues 21 and 22
analysis:

[0428] A search of the NOV21 a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 21D.

TABLE 21D
Geneseq Results for NOV21a
		NOV21a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAU14297	Human novel protein #168 - Homo	1 . . . 220	216/261 (82%)	e−123
	sapiens, 261 aa. [WO200155437-A2,	1 . . . 261	219/261 (83%)
	02-AUG-2001]
AAU14533	Human novel protein #404 - Homo	1 . . . 199	199/199 (100%)	e−117
	sapiens, 239 aa. [WO200155437-A2,	1 . . . 199	199/199 (100%)
	02-AUG-2001]
AAU14532	Human novel protein #403 - Homo	1 . . . 199	199/199 (100%)	e−117
	sapiens, 239 aa. [WO200155437-A2,	1 . . . 199	199/199 (100%)
	02-AUG-2001]
AAU14296	Human novel protein #167 - Homo	1 . . . 199	195/199 (97%)	e−115
	sapiens, 269 aa. [WO200155437-A2,	1 . . . 199	196/199 (97%)
	02-AUG-2001]
AAB80378	Secreted protein encoded by gene #8 -	1 . . . 195	125/196 (63%)	5e−77
	Homo sapiens, 200 aa.	1 . . . 196	151/196 (76%)
	[WO200107459-A1, 01-FEB-2001]

[0429] In a BLAST search of public sequence databases, the NOV21a protein was found to have homology to the proteins shown in the BLASTP data in Table 21E.

TABLE 21E
Public BLASTP Results for NOV21a
		NOV21a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9Y693	PARTNER - Homo sapiens (Human),	1 . . . 196	151/196 (76%)	2e−76
	200 aa.
Q96SH5	BA183L8.1 (LIPOMA HMGIC	1 . . . 127	79/128 (61%)	3e−43
	FUSION PARTNER) - Homo sapiens	1 . . . 128	97/128 (75%)
	(Human), 128 aa (fragment).
Q92605	KIAA0206 PROTEIN - Homo sapiens	67 . . . 190	43/125 (34%)	3e−15
	(Human), 193 aa (fragment).	47 . . . 170	63/125 (50%)
Q9W068	CG12026 PROTEIN (LP10272P) -	8 . . . 197	49/195 (25%)	2e−12
	Drosophila melanogaster (Fruit fly),	25 . . . 208	85/195 (43%)
	265 aa.
Q955W9	SD01285P - Drosophila melanogaster	5 . . . 171	41/175 (23%)	1e−11
	(Fruit fly), 219 aa.	6 . . . 178	77/175 (43%)

[0430] PFam analysis indicates that the NOV21 a protein contains the domains shown in the Table 21F.

TABLE 21F
Domain Analysis of NOV21a
		Identities/
		Similarities for	Expect
Pfam Domain	NOV21a Match Region	the Matched Region	Value
No Significant Matches Found

Example 22

[0431] The NOV22 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 22A.

TABLE 22A
NOV22 Sequence Analysis
                  SEQ ID NO:93        1228 bp
NOV22a,           AGATCTGTGACCAGTTCTACCAGTTACTTCCTACCTTACTGGCTCTTTGGATCCCAGA
172885510 DNA     TGGGGAAGCCAGTGTCATTCAGCACATTCCGGAGGTGCAACTACCCTGTGCGGGGAGA
Sequence          GGGACACAGTCTGATCATGGTGGAAGAATGTGGGCGCTATGCCAGCTTCAATGCCATC
                  CCAAGCCTGGCCTGGCAGATGTGCACAGTGGTGACAGGTGCCGGCTGTCTCGAG
                  ORF Start: ATC at 3 ORF Stop: G r at 228
                  SEQ ID NO:94        75 aa MW at 8305.5 kD
NOV22a,           ICDQFYQLLPTLLALWIPDGEASVIQHIPEVQLPCAGRGTQSDHGCRMWALCQLQCHP
172885510 Protein KPGLADVHSGDRCRLSR
Sequence

[0432] Further analysis of the NOV22a protein yielded the following properties shown in Table 22B.

TABLE 22B
Protein Sequence Properties NOV22a
PSort     0.3000 probability located in microbody (peroxisome);
analysis: 0.3000 probability located in nucleus; 0.1000
          probability located in mitochondrial matrix space; 0.1000
          probability located in lysosome (lumen)
SignalP   No Known Signal Sequence Indicated
analysis:

[0433] A search of the NOV22a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 22C.

TABLE 22C
Geneseq Results for NOV22a
		NOV22a	Identities/
	Protein/Organism/	Residues/	Similarities
Geneseq	Length	Match	for the	Expect
Identifier	[Patent #, Date]	Residues	Matched Region	Value
No Significant Matches Found

[0434] In a BLAST search of public sequence databases, the NOV22a protein was found to have homology to the proteins shown in the BLASTP data in Table 22D.

TABLE 22D
Public BLASTP Results for NOV22a
		NOV22a	Identities/
Protein		Residues/	Similarities
Accession	Protein/Organism/	Match	for the	Expect
Number	Length	Residues	Matched Portion	Value
No Significant Matches Found

[0435] PFam analysis indicates that the NOV22a protein contains the domains shown in the Table 22E.

TABLE 22E
Domain Analysis of NOV22a
		Identities/
	NOV22a	Similarities
	Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
Man-6-P_recep:	156 . . . 168	9/13	(69%)	0.7
domain 1 of 1		9/13	(69%)
perilipin: domain 1 of 1	10 . . . 369	139/411	(34%)	1.4e−76
		240/411	(58%)

Example 23

[0436] The NOV23 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 23A.

TABLE 23A
NOV23 Sequence Analysis
	SEQ ID NO:95	1916 bp
NOV23a,	GCCGCTGCCGTCGCCCCTAGCCCCAGCAGCCCTGGTCTCGCAGCCTCCTGCGGCTCTG
CG57734-01 DNA	GTCGCCCGACCAGCCATGTCTCTCGGCGGAGCCTCCGAGCGCAGCGTCCCGGCCACCA
Sequence	AGATTGAAATTACCGTGTCCTGCCGGACCTTGATACCTTCTCCAAGTCCGACCCCAGT
	AGGCGGCTCCAGGACCGGGAGGGCGAACTTGGGGTCTGGGCGCGACTCAGGGGCGGGT
	GGAGTCGGGGCCAGGGGTGGGAGCCGACCTGACGTCCTTCCCTCCCCGCCCCCACCTG
	CAGTGGTGGTGCTTTACACGCAGAGCCGGGCCAGCCAGGAGTGGCGGGAGTTCGGACG
	GACCGAGGTGATTGATAACACGCTGAACCCAGACTTCGTGCGCAAATTCGTCCTCGAC
	TATTTCTTTGAGGAAAAGCAAAATCTGCGCTTCGATGTGTACAACGTGGACTCCAAAA
	CCAACATCTCCAAACCGAAGGATTTCCTGGGACAAGCGTTCCTGGCCCTGGGAGAGGT
	GATTGGAGGCCAGGGCAGCCGAGTAGAGCGAACCCTCACGGGTGTACCAGGCAAGAAG
	TGTGGGACCATATTGCTGACTGCAGAAGAGCTTAGCAATTGTCGGGACATTGCCACCA
	TGCAGCTGTGTGCAAACAAGCTGGACAAGAAGGACTTCTTTGGGAAATCAGACCCCTT
	CCTTGTGTTCTACAGGAGCAATGAGGATGGCACGTTCACCATCTGCCACAAGACAGAG
	GTTGTGAAAAACACGCTGAATCCTGTGTGGCAGCCCTTCAGCATCCCTGTGCGGGCTC
	TGTGCAATGGACACTATGACAGAACGGTGAAGATTGATGTGTACGACTGGGACCGGGA
	TGGAAGCCACGATTTCATTGGTGAGTTCACCACCAGCTACCGGGAGCTGAGCAAGGCC
	CAGAACCAGTTCACAGTATATGAGGTGCTTAACCCTCGGAAGAAATGTAAGAAGAAGA
	AATATGTCAACTCAGGAACTGTGACGCTGCTCTCCTTCTCTGTGGACTCTGAATTCAC
	TTTTGTTGATTACATCAAGGGAGGGACACAGCTGAACTTCACAGTAGCCATTGACTTC
	ACGGCTTCCAATGGTAATCCTCTGCAGCCTACCTCCCTGCACTACATGAGTCCCTACC
	AGCTCAGCGCCTATGCCATGGCCCTCAAGGCAGTGGGAGAGATCATCCAGGACTATGA
	CAGTGATAAGCTCTTCCCAGCTTATGGCTTTGGGGCCAAGCTGCCCCCAGAGGGACGG
	ATCTCCCACCAGTTCCCCCTGAACAACAATGATGAGGACCCCAACTGTGCGCGCATCG
	AGGGTGTGCTGGAGAGCTATTTCCAGAGCCTGCGCACAGTGCAGCTCTATGGGCCCAC
	CTACTTTGCTCCTGTCATCAACCAAGTGGCCAGGGCTGCAGCCAAGATCTCTGATGGC
	TCCCAGTACTATGTTCTGCTCATCATCACTGATGGGGTCATCTCTGACATGACGCAGA
	CCAAGGAGGCCATCGTCAGCGCCTCCTCATTGCCCATGTCTATCATTATCGTCGGTGT
	AGGACCAGCCATGTTTGAGGCAATGGAAGAGTTGGACGGTGATGATGTGCGCGTGTCC
	TCTAGGGGACGCTACGCAGAGCGGGACATCGTTCAGTTCGTCCCATTCCGAGACTATG
	TTGACCGGTCGGGGAACCAGGTGTTGAGCATGGCCCGACTGGCCAAGGATGTGCTGGC
	CGAGATCCCGGACCAGCTGCTGTCCTATATGCGCACCAGAGACATCCAGCCTCCGCCC
	CCACCCCCTGCCAACCCCAGCCCGATCCCAGCTCCAGAGCAGCCCTGAGCATTCCACA
	TATCCAATGCCTCACAGTCTGCAAGCCTGCTCACCCACTGCTTCTGCTTTAAGCCAGA
	GG
	ORF Start: ATG at 74	ORE Stop: TGA at 1844
	SEQ ID NO:96	590 aa MW at 65041.9 kD
NOV23a,	MSLGGASERSVPATKIEITVSCRTLIPSPSPTPVGGSRTGRGNLGSGRDSGAGGVGAR
CG57734-01 Protein	GGSRPDVLPSPPPPAVVVLYTQSRASQEWREFGRTEVIDNTLNPDFVRKFVLDYFFEE
Sequence	KQNLRFDVYNVDSKTNISKPKDFLGQAFLALGEVIGGQGSRVERTLTGVPGKKCGTIL
	LTAEELSNCRDIATMQLCANKLDKKDFFGKSDPFLVFYRSNEDGTFTICHKTEVVKNT
	LNPVWQPFSIPVRALCNGDYDRTVKIDVYDWDRDGSHDFIGEFTTSYRELSKAQNQFT
	VYEVLNPRKKCKKKKYVNSGTVTLLSFSVDSEFTFVDYIKGGTQLNFTVAIDFTASNG
	NPLQPTSLHYMSPYQLSAYAMALKAVGEIIQDYDSDKLFPAYGFGAKLPPEGRISHQF
	PLHNMDEDPNCAGIEGVLESYFQSLRTVQLYGPTYFAPVINQVARAAAKTSDGSQYYV
	LLIITDGVTSDMTQTKEAIVSASSLPMSIIIVGVGPAMFEAMEELDGDDVRVSSRGRY
	AERDIVQFVPFRDYVDRSGNQVLSMARLAKDVLAEIPEQLLSYMRTRDIQPRPPPPAN
	PSPIPAPEQP
	SEQ ID NO:97	11742 bp
NOV23b,	CCGACCAGCCATGTCTCTCGGCGGAGCCTCCGAGCGCAGCGTCCCGCCCACCAAGATT
CG5 7734-02 DNA	GAAATTACCGTGTCCTGCCGGAACCTGCTAGACCTCGATACCTTCTCCAAGTCCGACC
Sequence	CCATGGTGGTGCTTTACACGCAGAGCCGGGCCAGCCAGGAGTGGCGGGAGTTCGGACG
	GACCGACGTGATTGATAACACGCTGAACCCAGACTTCGTGCGCAAATTCGTCCTCCAC
	TATTTCTTTGAGGAAAAGCAAAATCTGCGCTTCGATGTGTACAACGTGGACTCCAAAA
	CCAACATCTCCAAACCGAAGGATTTCCTGGGACAAGCGTTCCTGGCCCTGGGAGAGGT
	GATTGGAGGCCAGGGCAGCCGAGTAGAGCGAACCCTCACGGGTGTACCAGGCAAGAAG
	TGTCGCACCATATTGCTGACTGCAGAAGAGCTTAGCAATTGTCGGGACATTGCCACCA
	TGCAGCTGTGTGCAAACAAGCTGGACAAGAAGGACTTCTTTGGGAAATCAGACCCCTT
	CCTTGTGTTCTACAGGAGCAATGAGCATCGCACGTTCACCATCTGCCACAAGACAGAG
	GTTGTGAAAAACACGCTGAATCCTGTGTGGCAGCCCTTCAGCATCCCTGTGCGGGCTC
	TGTGCAATGGAGACTATGACAGAACGGTGAAGATTGATGTGTACGACTGGGACCGGGA
	TGGAAGCCACGATTTCATTGGTGAGTTCACCACCAGCTACCGGGAGCTGAGCAAGGCC
	CAGAACCAGTTCACAGTATATGAGGTTCTTAACCCTCGGAAGAAATGTAAGAAGAAGA
	AATATGTCAACTCAGGAACTGTGACGCTGCTCTCCTTCTCTGTGGACTCTGAATTCAC
	TTTTGTTGATTACATCAAGGGAGGGACACAGCTCAACTTCACACTAGCCATTCACTTC
	ACGGCTTCCAATGGGAATCCTCTGCAGCCTACCTCCCTGCACTACATGAGTCCCTACC
	AGCTCAGCGCCTATGCCATGGCCCTCAAGGCAGTGGGAGAGATCATCCAGGACTATGA
	CAGTGATAAGCTCTTCCCAGCTTATGGCTTTGGGGCCAAGCTGCCCCCAGAGGGACGG
	ATCTCCCACCAGTTCCCCCTGAACAACAATGATGAGGACCCCAACTGTGCGGGCATCG
	AGGGTGTGCTGGAGAGCTATTTCCAGAGCCTGCGCACAGTGCAGCTCTATGGGCCCAC
	CTACTTTGCTCCTGTCATCAACCAAGCGGCCAGGGCTGCAGCCAAGATCTCTGATGGC
	TCCCAGTACTATGTTCTGCTCATCATCACTGATGGGGTCATCTCTGACATGACGCAGA
	CCAAGGAGGCCATCGTCAGCGCCTCCTCATTGCCCATGTCTATCATTATCGTCGGTGT
	AGGACCAGCCATGTTTGAGGCAATGGAAGAGTTGGACGGTGATGATGTGCGCGTGTCC
	TCTAGCGCACGCTACGCAGAGCGGGACATCGTTCAGTTCGTCCCATTCCGAGACTATG
	TTGACCGGTCGGGGAACCAGCTGTTGAGCATGGCCCGACTGGCCAAGGATGTGCTGGC
	CGAGATCCCGGAGCAGCTGCTGTCCTATATGCGCACCAGAGACATCCACCCTCGGCCC
	CCACCCCCTGCCAACCCCAGCCCGATCCCAGCTCCAGAGCAGCCCTGAGGATTCCACA
	TATCCAATGCCTCACAGTCTGCAAGCCTGCTCACCCACTGCTTCTGCTTTAAGCCAGA
	GG
	ORF Start: ATG at 11	ORF Stop: TGA at 1670
	SEQ ID NO:98	553 aa MW at 61835.3 kD
NOV23b,	MSLGGASERSVPATKIEITVSCRNLLDLDTFSKSDPMVVLYTQSRASQEWREFGRTEV
CG57734-02 Protein	IDNTLNPDFVRKFVLDYFFEEKQNLRFDVYNvDSKTNISKPKDFLGQAFLALGEVIGG
Sequence	QGSRVERTLTGVPGKKCGTILLTAEELSNCRDIATMQLCANKLDKKDFFGKSDPFLVF
	YRSNEDGTFTICHKTEVVKNTLNPVWQPFSIPVRALCNGDYDRTVKIDVYDWDRDGSH
	DFIGEFTTSYRELSKAQNQFTVYEVLNPRKKCKKKKYVNSGTVTLLSFSVDSEFTFVD
	YIKGGTQLNFTVAIDFTASNGNPLQPTSLHYMSPYQLSAYAMALKAVGEIIQDYDSDK
	LFPAYGFGAKLPPEGRISHQFPLNNDEDPNCAGIEGVLESYFQSLRTVQLYGPTYYFA
	PVINQAARAAAKISDGSQYYVLLIITDCVISDMTQTKEAIVSASSLPMSIIIVGVGPA
	MFEAMEELDGDDVRVSSRGRYAERDIVQFVPFRDYVDRSGNQVLSMARLAKDVLAEIP
	EQLLSYMRTRDIQPRPPPPANPSPIPAPEQP
	SEQ ID NO:99	1368 bp
NOV23c,	GGATCCATGTCTGTCGGCCGAGCCTCCGAGCGCAGCGTCCCGGCCACCAAGATTGAAA
198363601 DNA	TTACCGTGTCCTGCCGGAACCTGCTAGACCTTGATACCTTCTCCAAGTCCGACCCCAT
Sequence	GGTGGTGCTTTACGCGCAGAGCCGGGCCAGCCAGGAGTGGCGGGAGTTCGGACGGACC
	GAGGTGATTGATAACACGCTGAACCCAGACTTCGTGCGCAAATTCGTCCTCGACTATT
	TCTTTGAGGAAAAGCAAAATCTGCGCTTCGATGTGTACAACGTCGACTCCAAAACCAA
	CATCTCCAAACCGAAGGATTTCCTGGGACAAGCGTTCCTGGCCCTGGGAGAGGTGATT
	GGAGGCCAGGGCAGCCGAGTAGAGCGAACCCTCACGGGTGTACCAGGCAAGAAGTGTG
	GGACCATATTGCTGACTGCAGAAGAGCTTAGCAATTGTCGGGACATTGCCACCATCCA
	GCTGTGTGCAAACAAGCTGGACAAGAAGGACTTCTTTGGGAAATCAGACCCCTTCCTT
	GTGTTCTACAGGAGTAATGAGGATGGCACGTTCACCATCTGCCACAAGACAGAGGTTG
	TGAAAAACACGCTGAATCCTGTGTGGCAGCCCTTCAGCATCCCTGTGCGGGCTCTGTG
	CAATGGAGACTATGACAGAACGGTGAAGATTGATGTGTACGACTGGGACCGCGATGGA
	AGCCACGATTTCATTGGTGAGTTCACCACCAGCTACCGGGAGCTGAGCAAGGCCCAGA
	ACCAGTTCACAGTATATGAGGTTCTTAACCCTCGGAAGAAATGTAAGAAGGAGAAATA
	TGTCAACTCAGGAACTGTGACGCTGCTCTCCTTCTCTGTGGACTCTGAATTCACTTTT
	GTTGATTACATCAAGGGACGGACACAGCTGAACTTCACAGTAGCCATTGACTTCACGG
	CTTCCAATGGGAATCCTCTGCAGCCTACCTCCCTGCACTACATGAGTCCCTACCAGCT
	CAGCGCCTATGCCATGGCCCTCAAGGCAGTGGGAGAGATCATCCAGGACTATGACAGT
	GATAAGCTCTTCCCAGCTTATGGCTTTGGCGCCAAGCTGCCCCCAGAGGGACGGATCT
	CCCACCAGTTCCCCCTGAACAACAATGATGAGGACCCCAACTGTGCGGGCATCGAGGG
	TGTGCTGGAGAGCTATTTCCAGAGCCTGCGCACAGTGCAGCTCTATGGGCCCACCTAC
	TTTGCTCCTGTCATCAACCAAGTGCCCAGGGCTGCAGCCAACATCTCTGATGGCTCCC
	AGTACTATGTTCTGCTCATCATCACTdATGGGGTCATCTCTGACATGACGCAGACCAA
	GGAGGCCATCGTCAGCGCCTCCTCATTGCTCGAG
	ORF Start: GGA at 1	ORF Stop: SD at 1369
	SEQ ID NO:100	456 aa MW at 50948.9 kD
NOV23c,	GSMSVGGASERSVPATKIEITVSCRNLLDLDTFSKSDPMVVLYAQSRASQEWREFGRT
198363601	Protein	EVIDNTLNPDFVRKFVLDYFFEEKQNLRFDVYNVDSKTNISKPKDFLGQAFLALGEVI
Sequence	GGQGSRVERTLTGVPGKKCGTILLTAEELSNCRDIATMQLCANKLDKKDFFGKSDPFL
	VFYRSNEDGTFTICHKTEVVKNTLNPVWQPFSIPVRALCNGDYDRTVKIDVYDWDRDG
	SHDFIGEFTTSYRELSKAQNQFTVYEVLNPRKKCKKEKYVNSGTVTLLSFSVDSEFTF
	VDYIKGGTQLNFTVAIDFTASNGNPLQPTSLHYMSPYQLSAYAMALKAVGEIIQDYDS
	DKLFPAYGFGAKLPPEGRISHQFPLNNNDEDPNCAGIEGVLESYFQSLRTVQLYGPTY
	FAPVINQVARAAAKISDGSQYYVLLIITDGVISDMTQTKEAIVSASSLLE

[0437] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 23B.

TABLE 23B
Comparison of NOV23a against NOV23b through NOV23c.
	NOV23a Residues/Match	Identities/Similarities
Protein Sequence	Residues	for the Matched Region
NOV23b	1 . . . 572	523/572 (91%)
	1 . . . 535	525/572 (91%)
NOV23c	1 . . . 489	438/489 (89%)
	3 . . . 454	442/489 (89%)

[0438] Further analysis of the NOV23a protein yielded the following properties shown in Table 23C.

TABLE 23C
Protein Sequence Properties NOV23a
PSort     0.8500 probability located in endoplasmic reticulum
analysis: (membrane); 0.4400 probability located in plasma membrane;
          0.3388 probability located in microbody
          (peroxisome); 0.3000 probability located in nucleus
SignalP   No Known Signal Sequence Indicated
analysis:

[0439] A search of the NOV23a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 23D.

TABLE 23D
Geneseq Results for NOV23a
		NOV23a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAY97293	Lipid associated protin (LIPAP)	10 . . . 583	412/575 (71%)	0.0
	3335404CD1 - Homo sapiens, 564 aa.	20 . . . 556	475/575 (81%)
	[WO200049043-A2, 24-AUG-2000]
AAM39997	Human polypeptide SEQ ID NO 3142 -	76 . . . 579	248/511 (48%)	e−138
	Homo sapiens, 548 aa.	49 . . . 548	353/511 (68%)
	[WO2001533 12-A1, 26-JUL-2001]
AAB24231	Human vesicle associated protein 10	76 . . . 579	248/511 (48%)	e−138
	SEQ ID NO: 10 - Homo sapiens, 532	33 . . . 532	353/511 (68%)
	aa. [WO200060082-A2, 12-OCT-2000]
AAU19736	Human novel extracellular matrix	64 . . . 582	257/527 (48%)	e−137
	protein, Seq ID No 386 - Homo	25 . . . 534	351/527 (65%)
	sapiens, 540 aa. [WO200155368-A1,
	02-AUG-2001]
AAU19664	Human novel extracellular matrix	286 . . . 590	234/308 (75%)	e−133
	protein, Seq ID No 314 - Homo	20 . . . 327	268/308 (86%)
	sapiens, 335 aa. [WO200155368-A1,
	02-AUG-2001]

[0440] In a BLAST search of public sequence databases, the NOV23a protein was found to have homology to the proteins shown in the BLASTP data in Table 23E.

TABLE 23E
Public BLASTP Results for NOV23a
		NOV23a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9HCH3	Copine-like protein KIAA 1599 - Homo	10 . . . 590	422/604 (69%)	0.0
	sapiens (Human), 593 aa.	19 . . . 585	484/604 (79%)
Q9DC53	1200003E11RIK PROTEIN - Mus	10 . . . 583	411/575 (71%)	0.0
	musculus (Mouse), 577 aa.	33 . . . 569	477/575 (82%)
O75131	Copine III - Homo sapiens (Human),	64 . . . 582	257/527 (48%)	e−137
	537 aa.	22 . . . 531	352/527 (66%)
Q96A23	CDNA FLJ31613 FIS,CLONE	55 . . . 574	258/528 (48%)	e−135
	NT2R12002958, MODERATELY	30 . . . 543	347/528 (64%)
	SIMILAR TO HOMO SAPIENS
	COPINE VI PROTEIN (SIMILAR
	TO RIKEN
	CDNA 3632411M23 GENE) - Homo
	sapiens (Human), 557 aa.
Q99829	Copine I - Homo sapiens (Human),	68 . . . 588	250/528 (47%)	e−133
	537 aa.	24 . . . 536	352/528 (66%)

[0441] PFam analysis indicates that the NOV23a protein contains the domains shown in the Table 23F.

TABLE 23F
Domain Analysis of NOV23a
	NOV23a	Identities/
	Match	Similarities	Expect
Pfam Domain	Region	for the Matched Region	Value
C2: domain 1 of 1	191 . . . 276	32/99 (32%)	6.5e−07
		59/99 (60%)

Example 24

[0442] The NOV24 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 24A.

TABLE 24A
NOV24 Sequence Analysis
	SEQ ID NO: 101	1904 bp
NOV24a,	TTTTTTTTTGACACTGTAAAAGAAGTTTATTTCTTGTTCACATAACTGTCCAAGGCTG
CG59389-01 DNA	GTGTTCCTGGGCAACTTCCAGTTCTCTTCCATGCAATGATTCAAGGACACACAGTTCT
Sequence	TCCATCCTGTGACTCTACCATCCCCTAGAGCCCTCTACTGTAAGAGTTACCTAAAGCA
	TCTGTGATGGTCCAGGAGGCTTCTCAGGTGATCGGGCAGTGTCAGTCTTCAGCCACTA
	AGCCCAGAAGATCTGGGAAGAAGTCAATCAGAGAGCCTTGGGCCAGAGTTCCAGGGGC
	TCTGGGAGTGGCTGCCAGGTGAGCTGGACAGTCTGATTTTCAGTGGGGTCCACACAGA
	TGGGACGCGGCTTAGGAGGAATCCTGGGCTGCAGGCATTCCTTGGCCTGGTAGTCAGA
	TTTCTGGCACTTGTAGCAAGCTCCTGGCGGAGAAGGTTCTGGAGTAACGCCTGGCCGC
	TGCGGTTCAGGCATTTGGAAGTTCTTGTGTGCTGGACATCTGCCTGGGGTTTGTCTCA
	CAGTGGAGGTTACCTAACCAAACTCCTGTAAAACCACACCACCTATGCCTGTGATGGG
	GACTATTTGAATCTACAGTGCCCTCGGCATTCTACGATAAGTGTCCAATCGGCATTTT
	ATGGGCAAGATTACCAAATGTGTAGTTCCCAGAAGCCTGCCTCCCAGAGGGAAGACAG
	CTTAACCTGTGTGGCAGCCACCACCTTCCAGAAGGTGCTGGACGAATGCCAGAACCAG
	CGGGCCTGCCACCTCCTGGTCAATAGCCGTGTTTTTGGACCTGACCTTTGTCCAGGAA
	GCAGTAAATACCTCCTGGTCTCCTTTAAATGCCAACCTAATGAATTAAAAAACAAAAC
	CGTGTGTGAAGACCAGGAGCTGAAACTGCACTGCCATGAATCCAAGTTCCTCAACATC
	TACTCTGCGACCTACGGCAGGAGGACCCAGGAAAGGCACATCTGCTCCTCCAACGCAG
	AGCGGCTCCCCCCTTTCGATTGCTTGTCTTACTCAGCTTTGCAAGTCCTATCCCGAAG
	GTGCTATGGGAAGCAGAGATGCAAAATCATCGTCAACAATCACCATTTTGGAAGCCCC
	TGTTTGCCAGGCATGAAAAAATACCTCACTGTGACCTACGCATGTGTTCCCAAGAACA
	TACTCACACCGATTGATCCAGCCATTGCTAATCTAAAACCTTCTTTGAAGCAGAAAGA
	TGGTGAATATGGTATAAACTTTGACCCAAGCGGATCGAAGGTTCTGAGGAAAGATGGA
	ATTCTTGTTAGCAACTCTCTGGCAGCCTTTGCTTACATTAGAGCCCACCCGGAGAGAG
	CTGCCCTGCTGTTCGTCTCCAGTGTCTGCATCGGCCTGGCCCTCACACTGTGCGCCCT
	GGTCATCAGAGAGTCCTGTGCCAAGGACTTCCCCGACTTGCAGCTGGGGAGGGAGCAG
	CTGGTGCCAGGAAGTGACAAGGTCGAGCAGGACAGCGAGGATGAAGAAGACGAGGAGG
	ACCCCTCTGAGTCTGATTTCCCAGGGGAACTGTCGGGGTTCTGTAGGACTTCATATCC
	TATATACAGTTCCATAGAAGCTGCAGAGCTCGCAGAAAGGATTGAGCGCAGGGAGCAA
	ATCATTCAGGAAATATGGATGAACAGTGGTTTGGACACCTCGCTCCCAAGAAACATGG
	GCCAGTTCTACTGAAAACCACATGCATCTTGATGCGATCGCACTTTCTGAAGAAGGAA
	GGATCCCAAATGCCCCTCCAGTTCTGGTTCACCTGTACCTTCTATGAAGGAGAATTCG
	TCATGTCATTCAACACTCGTGAGGCCAGGAAGCTATTAAAGGGATGTTTCAAGCTGTT
	TCTAGCACATTCCAAATAAATGAGGAGGGAAGAAAAAAAAAAAAAAA
	ORF Start: ATG at 656	ORF Stop: TGA at 1694
	SEQ ID NO: 102	346 aa	MW at 38793.6kD
NOV24a,	MCSSQKPASQREDSLTCVAATTFQKVLDECQNQRACHLLVNSRVFGPDLCPGSSKYLL
CG59389-01 Protein	VSFKCQPNELKNKTVCEDQELKLHCHESKFLNIYSATYGRRTQERDICSSKAERLPPF
Sequence	DCLSYSALQVLSRRCYGKQRCKIIVNNHHFGSPCLPGMKKYLTVTYACVPKNILTAID
	PAIANLKPSLKQKDGEYGINFDPSGSKVLRKDGILVSNSLAAFAYIRAHPERAALLFV
	SSVCIGLALTLCALVIRESCAKDFRDLQLGREQLVPGSDKVEEDSEDEEEEEDPSESD
	FPGELSGFCRTSYPIYSSIEAAELAERIERREQIIQEIWMNSGLDTSLPRNMGQFY
	SEQ ID NO: 103	1802 bp
NOV24b,	TTTTTTTTTGACACTCTAAAAGAAGTTTATTTCTTGTTCACATAACTGTCCAAGGCTG
CG59389-02 DNA	GTGTTCCTGGGCAACTTCCAGTTCTCTTCCATGCAATGATTCAAGGACACAGAGTTCT
Sequence	TCCATCCTGTGACTCTACCATCCCCTAGAGCCCTCTACTGTAAGAGTTACCTAAAGCA
	TCTGTGATGGTCCAGGAGGCTTCTCAGGTGATCGGGCAGTGTCAGTCTTCAGCCACTA
	AGCCCAGAAGATCTGGGAAGAAGTCAATCAGAGAGCCTTGGGCCAGAGTTCCAGGGGC
	TCTGGGAGTCGCTGCCAGGTGAGCTGGACAGTCTGATTTTCAGTGGGGTCCACACACA
	TGGGACGCGGCTTAGGAGGAATCCTGGGCTGCAGGCATTCCTTGCCCTGCTAGTCAGA
	TTTCTGGCACTTGTAGCAAGCTCCTGGGGGAGAAGGTTCTGGAGTAACGCCTGGCCGC
	TGCGCTTCAGGCATTTGGAAGTTCTTGTGTGCTGGAGATGTGGCTGGGGTTTGTCTCA
	CAGTGGAGGTTACCTAACCAAACTCCTGTAAAACCACACCACCTATGCCTGTGATGGG
	GACTATTTGAATCTACAGTGCCCTCGGCATTCTACGATAAGTGTCCAATCGGCATTTT
	ATGGGCAAGATTACCAAATGTGTAGTTCCCAGAAGCCTGCCTCCCAGAGGGAAGACAG
	CTTAACCTGTGTGGCAGCCACCACCTTCCAGAAGGTGCTGGACGAATGCCAGAACCAG
	CGGGCCTGCCACCTCCTGGTCAATAGCCGTGTTTTTGGACCTGACCTTTGTCCAGGAA
	GCAGTAAATACCTCCTGGTCTCCTTTAAATGCCAACCTAATGAATTAAAAAACAAAAC
	CGTGTGTGAAGACCAGGAGCTGAAACTGCACTGCCATGAATCCAAGTTCCTCAACATC
	TACTCTGCGACCTACGGCAGGAGGACCCAGGAAAGGGACATCTGCTCCTCCAAGGCAG
	AGCGGCTCCCCCCTTTCGATTGCTTGTCTTACTCAGCTTTGCAAGTCCTATCCCGAAG
	GTGCTATGGGAAGCAGAGATGCAAAATCATCGTCAACAATCACCATTTTGGAAGCCCC
	TGTTTGCCAGGCGTGAAAAAATACCTCACTCTGACCTACGCATGTCGTATAAACTTCG
	ACCCAAGCGGATCGAAGGTTCTGAGGAAAGATGGAATTCTTGTTAGCAACTCTCTGGC
	AGCCTTTGCTTACATTAGAGCCCACCCGGAGAGAGCTGCCCTGCTGTTCGTGTCCAGT
	GTCTGCATCGGCCTGGCCCTCACACTGTGCGCCCTGGTCATCAGAGAGTCCTGTGCCA
	AGGACTTCCGCGACTTGCAGCTGGGGAGGGAGCAGCTGGTGCCAGGAAGTGACAAGGT
	CGAGGAGGACACCGAGCATGAAGAAGAGGAGGAGGACCCCTCTGAGTCTGATTTCCCA
	GGGGAACTGTCGCGGTTCTGTAGGACTTCATATCCTATATACAGTTCCATAGAAGCTG
	CAGAGCTCGCAGAAAGGATTCAGCGCAGGGAGCAAATCATTCAGGAAATATGGATGAA
	CAGTGGTTTGGACACCTCGCTCCCAAGAAACATGGGCCAGTTCTACTGAAAACCACAT
	GCATCTTGATGCGATCGCACTTTCTGAAGAAGCAAGGATCCCAAATGCCCCTCCAGTT
	CTGGTTCACCTGTACCTTCTATGAAGGAGAATTCGTCATGTCATTCAACACTCGTGAG
	GCCAGGAAGCTATTAAAGGGATGTTTCAAGCTGTTTCTAGCACAGGGGCTTCCAGCAT
	CCTG
	ORF Start: ATG at 656	ORF Stop: TGA at 1613
	SEQ ID NO: 104	319 aa	MW at 35842.2 kD
NOV24b,	MCSSQKPASQREDSLTCVAATTFQKVLDECQNQRACHLLVNSRVFGPDLCPGSSKYLL
CG59389-02 Protein	VSFKCQPNELKNKTVCEDQELKLHCHESKFLNIYSATYGRRTQERDICSSKAERLPPF
Sequence	DCLSYSALQVLSRRCYGKQRCKIIVNNHHFGSPCLPGVKKYLTVTYACGINFDPSGSK
	VLRKDGILVSNSLAAFAYIRAHPERAALLFVSSVCIGLALTLCALVIRESCAKDFRDL
	QLGREQLVPGSDKVEEDSEDEEEEEDPSESDFPGELSGFCRTSYPIYSSIEAAELAER
	IERREQIIQEIWMNSGLDTSLPRNMGQFY
	SEQ ID NO: 105	1326 bp
NOV24c,	TCCCCGCCATGTGACGCCGTCCTTAGCCCTGCGACCCCCAGCGCGTCCCGGGCCTGCG
CG59389-04 DNA	CCTCCGCCCCGCCGCGCAGCACGATGCTTCTGCCGGGACGCGCACGCCAACCGCCGAC
Sequence	GCCCCAGCCCGTGCAGCATCCCGGCCTCCGCCGGCAGGTAGAGCCGCCGGGGCAGCTC
	CTGCGCCTCTTCTACTGCACTGTCCTGGTCTGCTCCAAAGAGATCTCAGCGCTCACCG
	ACTTCTCTGGTTACCTAACCAAACTCCTGCAAAACCACACCACCTATGCCTGTGATGG
	GGACTATTTGAATCTACAGTGCCCTCGGCATTCTACGATAAGTGTCCAATCGGCATTT
	TATGGGCAAGATTACCAAATGTGTAGTTCCCAGAAGCCTGCCTCCCAGAGGGAAGACA
	GCTTAACCTGTGTGGCAGCCACCACCTTCCAGAAGGTGCTGGACGAATGCCAGAACCA
	GCGGGCCTGCCACCTCCTGGTCAATAGCCGTGTTTTTGGACCTGACCTTTGTCCAGGA
	AGCAGTAAATACCTCCTGGTCTCCTTTAAATGCCAACCTAATGAATTAAAAAACAAAA
	CCGTGTGTGAAGACCAGGAGCTGAAACTGCACTGCCATGAATCCAAGTTCCTCAACAT
	CTACTCTGCGACCTACGGCAGGAGGACCCAGGAAAGGGACATCTGCTCCTCCAAGGCA
	GAGCCGCTCCCCCCTTTCGATTGCTTGTCTTACTCAGCTTTGCAAGTCCTATCCCGAA
	GGTGCTATGGGAAGCAGAGATGCAAAATCATCGTCAACAATCACCATTTTGGAAGCCC
	CTGTTTGCCAGGCGTGAAAAAATACCTCACTGTGACCTACGCATGTGGTATAAACTTC
	GACCCAAGCGGATCGAAGGTTCTGAGGAAAGATGGAATTCTTGTTAGCAACTCTCTGG
	CAGCCTTTGCTTACATTAGAGCCCACCCGGAGAGAGCTGCCCTGCTGTTCGTGTCCAG
	TGTCTGCATCGGCCTGGCCCTCACACTGTGCGCCCTGGTCATCAGAGAGTCCTGTGCC
	AAGGACTTCCGCGACTTGCAGCTGGGGAGGGAGCAGCTGGTGCCAGGAAGTGACAAGG
	TCGAGGAGGACAGCGAGGATGAAGAAGAGGAGGAGCACCCCTCTGAGTCTGATTTCCC
	AGGGGAACTGTCGGGGTTCTGTAGGACTTCATATCCTATATACAGTTCCATAGAAGCT
	GCAGACCTCGCAGAAAGGATTGAGCGCAGGGAGCAAATCATTCAGGAAATATGGATGA
	ACAGTGGTTTGGACACCTCGCTCCCAAGAAACATGGGCCAGTTCTACTGA
	ORF Start: ATG at 82	ORF Stop: TGA at 1324
	SEQ ID NO: 106	414 aa	MW at 46563.4 kD
NOV24c,	MLLPGRARQPPTPQPVQHPGLRRQVEPPCQLLRLFYCTVLVCSKEISALTDFSGYLTK
CG59389-04 Protein	LLQNHTTYACDGDYLNLQCPRHSTISVQSAFYGQDYQMCSSQKPASQREDSLTCVAAT
Sequence	TFQKVLDECQNQRACHLLVNSRVFGPDLCPGSSKYLLVSFKCQPNELKNKTVCEDQEL
	KLHCHESKFLNIYSATYGRRTQERDICSSKAERLPPFDCLSYSALQVLSRRCYGKQRC
	KIIVNNHHFGSPCLPGVKKYLTVTYACGINFDPSGSKVLRKDGILVSNSLAAFAYIRA
	HPERAALLFVSSVCIGLALTLCALVIRESCAKDFRDLQLGREQLVPGSDKVEEDSEDE
	EEEEDPSESDFPGELSGFCRTSYPIYSSIEAAELAERIERREQIIQEIWMNSGLDTSL
	PRNMGQFY
	SEQ ID NO: 107	693 bp
NOV24d,	AAGCTTACCATGTGTAGTTCCCAGAGCCTGCCTCCCAGAGGGAAGACAGCTTAACCT
174308481 DNA	GTGTGGCAGCCACCACCTTCCAGAAGGTGCTGGACGAATGCCAGAACCAGCGGGCCTG
Sequence	CCACCTCCTGGTCAATAGCCGTGTTTTTGGACCTGACCTTTGTCCAGGAAGCAGTAAA
	TACCTCCTGGTCTCCTTTAAATGCCAACCTAATGAATTAAAAAACAAAACCGTGTGTG
	AAGACCAGGAGCTGAAACTGCACTGCCATGAATCCAAGTTCCTCAACATCTACTCTGC
	GACCTACGGCAGGAGGACCCAGGAAAGGGACATCTGCTCCTCCAAGGCAGGGCGGCTC
	CCCCCTTTCGATTGCTTGTCTTACTCAGCTTTGCAAGTCCTATCCCGAAGGTGCTATG
	GGAAGCAGAGATGCAAAATCATCGTCAACAATCACCATTTTGGAAGCCCCTGTTTGCC
	AGGCGTGAAAAAATACCTCACTGTGACCTACGCATGTGTTCCCAAGAACATACTCACA
	GCGATTGATCCAGCCATTGCTAATCTAAAACCTTCTTTGAAGCAGAAAGATGGTGAAT
	ATGGTATAAACTTCCACCCAAGCGGATCGAAGGTTCTGAGGAAAGATGGAATTCTTGT
	TAGCAACTCTCTGGCAGCCTTTGCTTACATTAGAGCCCACCCGGAGAGACTCGAG
	ORF Start: AAG at 1	ORF Stop: 37 at 694
	SEQ ID NO: 108	231 aa	MW at 25807.5 kD
NOV24d,	KLTMCSSQKPASQREDSLTCVAATTFQKVLDECQNQRACHLLVNSRVFGPDLCPCSSK
174308481 Protein	YLLVSFKCQPNELKNKTVCEDQELKLHCHESKFLNIYSATYGRRTQERDICSSKAGRL
Sequence	PPFDCLSYSALQVLSRRCYCKQRCKIIVNNHHFGSPCLPGVKKYLTVTYACVPKNILT
	AIDPAIANLKPSLKQKDGEYGINFDPSGSKVLRKDGILVSNSLAAFAYIRAHPERLE
	SEQ ID NO: 109	693 bp
NOV24e,	AAGCTTACCATGTGTAGTTCCCAGAAGCCTGCCTCCCAGAGGCAAGACAGCTTAACCT
174308497 DNA	GTGTGGCAGCCACCACCTTCCAGAAGGTGCTGGACGAATGCCTGAACCAGCGGGCCTG
Sequence	CCACCTCCTGGTCAATAGCCGTGTTTTTGGACCTGACCTTTGTCCAGGAACCAGTAAA
	TACCTCCTGGTCTCCTTTAAATGCCAACCTAATGAATTAAAAAACAAAACCGTGTGTG
	AAGACCAGGAGCTGAAACTCCACTGCCATGAATCCAAGTTCCTCAACATCTACTCTGC
	GACCTACGGCAGGAGGACCCAGGAAAGGGACATCTGCTCCTCCAAGGCAGAGCGGCTC
	CCCCCTTTCGATTGCTTGTCTTACTCAGCTTTGCAAGTCCTATCCCCAAGGTGCTATG
	GGAAGCAGAGATGCAAAATCATCGTCAACAATCACCATTTTGGAAGCCCCTGTTTGCC
	AGGCGTGAAAAAATACCTCACTGTCACCTACGCATGTGTTCCCAAGAACATACTCACA
	GCGATTGATCCAGCCATTGCTAATCTAAAACCTTCTTTGAAGCAGAAAGATGGTGAAT
	ATGGTATAAACTTCGACCCAAGCCGATCGAAGGTTCTGAGGAAAGATGGAATTCTTGT
	TAGCAACTCTCTGGCAGCCTTTGCTTACATTAGAGCCCACCCGGAGACACTCGAG
	ORF Start: AAG at 1	ORF Stop: 37 at 694
	SEQ ID NO: 110	231 aa	MW at 25864.5 kD
NOV24e,	KLTMCSSQKPASQREDSLTCVAATTFQKVLDECLNQRACHLLVNSRVFGPDLCPGSSK
174308497 Protein	YLLVSFKCQPNELKNKTVCEDQELKLHCHESKFLNIYSATYGRRTQERDICSSKAERL
Sequence	PPFDCLSYSALQVLSRRCYGKQRCKIIVNNHHFGSPCLPGVKKYLTVTYACVPKNILT
	AIDPAIANLKPSLKQKDCEYGINFDPSGSKVLRKDGILVSNSLAAFAYIRAHPERLE
	SEQ ID NO: 111	693 bp
NOV24f,	AAGCTTACCATGTGTAGTTCCCAGAAGCCTGCCTCCCAGAGGGAAGACAGCTTAACCT
174308507 DNA	GTCTGGCAGCCACCACCTTCCAGAAGGTGCTGGACGAATGCCAGAACCAGCGGGCCTG
Sequence	CCACCTCCTGGTCAATAGCCGTGTTTTTGGACCTGACCTTTGTCCAGGAAGCAGTAAA
	TACCTCCTGGTCTCCTTTAAATGCCAACCTAATGAATTAAAAAACAAAACCGTGTGTG
	AAGACCAGGAGCTGAAACTGCACTGCCATGAATCCAAGTTCCTCAACATCTACTCTGC
	GACCTACGGCAGGAGGACCCAGGAAAGGGACATCTGCTCCTCCAAGCCAGACCGGCTC
	CCCCCTTTCGATTGCTTGTCTTACTCAGCTTTGCAAGTCCTATCCCGAAGGTGCTATG
	GGAAGCAGAGATGCAAAATCATCGTCAACAATCACCATTTTGGAAGCCCCTGTTTGCC
	AGGCGTGAAAAAATACCTCACTGTGACCTACGCATGTGTTCCCAAGAACATACTCACA
	GCGATTGATCCAGCCATTGCTAATCTAAAACCTTCTTTGAAGCAGAAAGATGGTGAAT
	ATGGTATAAACTTCGACCCAAGCGGATCGAAGGTTCTGAGGAAAGATGGAATTCTTGT
	TAGCAACTCTCTGGCAGCCTTTGCTTACATTAGAGCCCACCCGGACAGACTCGAG
	ORF Start: AAG at 1	ORF Stop: 38 at 694
	SEQ ID NO: 112	231 aa	MW at 25879.5 kD
NOV24f,	KLTMCSSQKPASQREDSLTCVAATTFQKVLDECQNQRACHLLVNSRVFGPDLCPGSSK
174308507 Protein	YLLVSFKCQPNELKNKTVCEDQELKLHCHESKFLNIYSATYGRRTQERDICSSKAERL
Sequence	PPFDCLSYSALQVLSRRCYGKQRCKIIVNNHHFGSPCLPGVKKYLTVTYACVPKNILT
	AIDPAIANLKPSLKQKDGEYGINFDPSGSKVLRKDGILVSNSLAAFAYIRAHPERLE
	SEQ ID NO: 113	690 bp
NOV24g,	AAGCTTACCATGTGTAGTTCCCAGAAGCCTGCCTCCCAGAGGGAAGACACCTTAACCT
174308517 DNA	GTGTGGCAGCCACCACCTTCCAGAAGGTGCTGGACGAATGCCAGAACCAGCGGGCCTG
Sequence	CCACCTCCTGGTCAATAGCCGTGTTTTTGGACCTGACCTTTGTCCAGGAAGCAGTAAA
	TACCTCCTCGTCTCCTTTAAATGCCAACCTAAATTAAAAAACAAAACCGTGTGTGAAG
	ACCAGGAGCTGAAACTGCACTGCCATGAATCCAAGTTCCTCAACATCTACTCTGCGAC
	CTACGGCAGGAGGACCCAGGAAAGGCACATCTGCTCCTCCAAGGCAGAGCGGCTCCCC
	CCTTTCGATTGCTTGTCTTACTCAGCTTTGCAAGTCCTATCCCGAACGTGCTATGGGA
	AGCAGAGATGCAAAATCATCGTCAACAATCACCATTTTGGAAGCCCCTGTTTCCCAGG
	CGTGAAAAAATACCTCACTGTGACCTACGCATGTGTTCCCAAGAACATACTCACAGCG
	ATTGATCCAGCCATTGCTAATCTAAAACCTTCTTTGAAGCAGAAAGATGGTGAATATG
	GTATAAACTTCGACCCAAGCGGATCGAAGGTTCTGAGCAAAGATGGAATTCTTGTTAC
	CAACTCTCTGGCAGCCTTTGCTTACATTAGAGCCCACCCGGAGAGACTCGAG
	ORF Start: AAG at 1	ORF Stop: e− at 691
	SEQ ID NO: 114	230 aa	MW at 25764.5 kD
NOV24g,	KLTMCSSQKPASQREDSLTCVAATTFQKVLDECQNQRACHLLVNSRVFCPDLCPGSSK
174308517 Protein	YLLVSFKCQPKLKNKTVCEDQELKLHCRESKFLNIYSATYGRRTQERDICSSKAERLP
Sequence	PFDCLSYSALQVLSRRCYGKQRCKIIVNNHHFGSPCLPGVKKYLTVTYACVPKNILTA
	IDPAIANLKPSLKQKDGEYGINFDPSGSKVLRKDGILVSNSLAAFAYIRAHPERLE
	SEQ ID NO: 115	693 bp
NOV24h,	AAGCTTACCATGTGTAGTTCCCAGAAGCCTGCCTCCCAGAGCGAAGACAGCTTAACCT
174308525 DNA	GTGTGGCACCCACCACCCTCCAGAAGGTGCTGGACGAATGCCAGAACCAGCGGGCCTG
Sequence	CCACCTCCTGGTCAATAGCCGTGTTTTTGGACCTGACCTTTGTCCAGGAAGCAGTAAA
	TACCTCCTGGTCTCCTTTAAATGCCAACCTAATGAATTAAAAAACAAAACCGTGTGTG
	AAGACCAGGAGCTGAAACTGCACTGCCATGAATCCAAGTTCCTCAACATCTACTCTGC
	GACCTACGGCAGGAGGACCCAGGAAAGCGACGTCTGCTCCTCCAAGGCAGAGCGGCTC
	CCCCCTTTCGATTGCTTGTCTTACTCAGCTTTGCAAGTCCTATCCCGAAGGTGCTATG
	GGAAGCAGAGATGCAAAATCATCGTCAACAATCACCATTTTGGAAGCCCCTGTTTGCC
	AGGCGTGAAAAAATACCTCACTGTGACCTACGCATGTGTTCCCAAGAACATACTCACA
	GCCATTGATCCAGCCATTGCTAATCTAAAACCTTCTTTGAAGCAGAAAGATGGTGAAT
	ATGGTATAAACTTCGACCCAAGCGGATCGAAGGTTCTGAGGAAAGATGGAATTCTTGT
	TAGCAACTCTCTGGCAGCCTTTGCTTACATTAGAGCCCACCCGGAGAGACTCGAG
	ORF Start: AAG at 1	ORF Stop: 37 at 694
	SEQ ID NO: 116	231 aa	MW at 25831.5 kD
NOV24h,	KLTMCSSQKPASQREDSLTCVAATTLQKVLDECQNQRACHLLVNSRVFGPDLCPGSSK
174308525 Protein	YLLVSFKCQPNELKNKTVCEDQELKLHCHESKFLNIYSATYGRRTQERDVCSSKAERL
Sequence	PPFDCLSYSALQVLSRRCYGKQRCKIIVNNHHFGSPCLPGVKKYLTVTYACVPKNILT
	AIDPAIANLKPSLKQKDGEYGINFDPSGSKVLRKDGILVSNSLAAFAYIRAHPERLE

[0443] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 24B.

TABLE 24B
Comparison of NOV24a against NOV24b through NOV24h.
	NOV24a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV24b	1 . . . 346	281/346 (81%)
	1 . . . 319	282/346 (81%)
NOV24c	1 . . . 346	281/346 (81%)
	96 . . . 414	282/346 (81%)
NOV24d	1 . . . 226	224/226 (99%)
	4 . . . 229	225/226 (99%)
NOV24e	1 . . . 226	224/226 (99%)
	4 . . . 229	225/226 (99%)
NOV24f	1 . . . 226	225/226 (99%)
	4 . . . 229	226/226 (99%)
NOV24g	1 . . . 226	223/226 (98%)
	4 . . . 228	225/226 (98%)
NOV24h	1 . . . 226	223/226 (98%)
	4 . . . 229	225/226 (98%)

[0444] Further analysis of the NOV24a protein yielded the following properties shown in Table 24C.

TABLE 24C
Protein Sequence Properties NOV24a
PSort     0.7419 probability located in mitochondrial inner membrane;
analysis: 0.4400 probability located in plasma membrane; 0.2000
          probability located in endoplasmic reticulum
          (membrane); 0.1072 probability located in mitochondrial
          matrix space
SignalP   No Known Signal Sequence Indicated
analysis:

[0445] A search of the NOV24a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 24D.

TABLE 24D
Geneseq Results for NOV24a
		NOV24a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAU12284	Human PRO5993 polypeptide	1 . . . 346	345/346	(99%)	0.0
	sequence - Homo sapiens, 441 aa.	96 . . . 441	346/346	(99%)
	[WO200140466-A2, 07-JUN-2001]
AAB68888	Human RECAP polypeptide, SEQ ID	1 . . . 346	345/346	(99%)	0.0
	[WO200107612-A2, 01-FEB-2001]	96 . . . 441	346/346	(99%)
AAB82854	Human P2Y-like GPCR polypeptide -	50 . . . 95	46/46	(100%)	2e−21
	Homo sapiens, 158 aa.	10 . . . 55	46/46	(100%)
	[WO200168842-A2, 20-SEP-2001]
AAB95410	Human protein sequence SEQ ID	209 . . . 346	64/144	(44%)	9e−20
	NO: 17796 - Homo sapiens, 152 aa.	16 . . . 152	89/144	(61%)
	[EP1074617-A2, 07-FEB-2001]
AAB93029	Human protein sequence SEQ ID	204 . . . 329	54/133	(40%)	7e−16
	NO: 11799 - Homo sapiens, 165 aa.	5 . . . 136	78/133	(58%)
	[EP1074617-A2, 07-FEB-2001]

[0446] In a BLAST search of public sequence databases, the NOV24a protein was found to have homology to the proteins shown in the BLASTP data in Table 24E.

TABLE 24E
Public BLASTP Results for NOV24a
		NOV24a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
P58658	Protein C21 orf63 precursor (Protein	1 . . . 346	345/346 (99%)	0.0
	PRED34) (SUE21) - Homo sapiens	96 . . . 441	346/346 (99%)
	(Human), 441 aa.
Q9D4L3	4931408A02RIK PROTEIN - Mus	1 . . . 346	294/346 (84%)	e−175
	musculus (Mouse), 345 aa.	1 . . . 345	322/346 (92%)
P58659	Protein C21 orf63 homolog precursor -	1 . . . 346	294/346 (84%)	e−175
	Mus musculus (Mouse), 440 aa.	96 . . . 440	322/346 (92%)
Q9H8M9	CDNA FLJ13391 FIS, CLONE	209 . . . 346	64/144 (44%)	3e−19
	PLACE1001241 (HYPOTHETICAL	16 . . . 152	89/144 (61%)
	17.5 KDA PROTEIN) - Homo sapiens
	(Human), 152 aa.
Q9HC41	HYPOTHETICAL 17.4 KDA	209 . . . 346	64/144 (44%)	3e−19
	PROTEIN - Homo sapiens (Human),	16 . . . 152	89/144 (61%)
	152 aa.

[0447] PFam analysis indicates that the NOV24a protein contains the domains shown in the Table 24F.

TABLE 24F
Domain Analysis of NOV24a
	NOV24a	Identities/
	Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
Gal_Lectin: domain 1 of 2	2 . . . 63	23/93 (25%)	0.01
		42/93 (45%)
Gal_Lectin: domain 2 of 2	81 . . . 164	28/94 (30%)	4.6e−13
		52/94 (55%)

Example 25

[0448] The NOV25 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 25A.

TABLE 25A
NOV25 Sequence Analysis
	SEQ ID NO: 117	4517 bp
NOV25a,	GGCCCTCGCCGCCCGCGGCGCCCCGAGCGCTTTGTGAGCAGATGCGGAGCCGAGTGGA
CG59885-01 DNA	GGGCGCGAGCCAGATGCGGGGCGACAGCTGACTTGCTGAGAGGAGGCGGGGAGGCGCG
Sequence	GAGCGCGCGTGTGGTCCTTGCGCCGCTGACTTCTCCACTGGTTCCTGGGCACCGAAAG
	ATAAACCTCTCATAATGAAGGCCCCCGCTGTGCTTGCACCTGGCATCCTCCTGCTCCT
	GTTTACCTTGGTGCAGAGGAGCAATGGGGAGTGTAAAGAGGCACTAGCAAAGTCCGAG
	ATGAATGTGAATATGAAGTATCAGCTTCCCAACTTCACCGCGGAAACACCCATCCAGA
	ATGTCATTCTACATGAGCATCACATTTTCCTTGGTGCCACTAACTACATTTATGTTTT
	AAATGAGGAAGACCTTCAGAAGGTTGCTGAGTACAAGACTGGGCCTGTGCTGGAACAC
	CCAGATTGTTTCCCATGTCAGGACTGCAGCAGCAAAGCCAATTTATCAGGAGGTGTTT
	GGAAAGATAACATCAACATGGCTCTAGTTGTCGACACCTACTATGATGATCAACTCAT
	TAGCTGTGGCAGCGTCAACAGAGGGACCTGCCAGCGACATGTCTTTCCCCACAATCAT
	ACTGCTGACATACAGTCGGAGGTTCACTGCATATTCTCCCCACAGATAGAAGAGCCCA
	GCCAGTGTCCTGACTGTGTGGTGAGCGCCCTGGGAGCCAAAGTCCTTTCATCTGTAAA
	GGACCGGTTCATCAACTTCTTTGTAGGCAATACCATAAATTCTTCTTATTTCCCAGAT
	CATCCATTGCATTCGATATCAGTGAGAACGCTAAAGGAAACGAAAGATGGTTTTATGT
	TTTTGACGGACCAGTCCTACATTGATGTTTTACCTGAGTTCAGAGATTCTTACCCCAT
	TAAGTATGTCCATGCCTTTGAAAGCAACAATTTTATTTACTTCTTGACGGTCCAAAGG
	GAAACTCTAGATGCTCAGACTTTTCACACAAGAATAATCAGGTTCTGTTCCATAAACT
	CTGGATTGCATTCCTACATGGAAATGCCTCTGGAGTGTATTCTCACAGAAAAGAGAAA
	AAAGAGATCCACAAAGAAGGAAGTGTTTAATATACTTCAGGCTGCGTATGTCAGCAAG
	CCTGGGGCCCAGCTTGCTAGACAAATAGGAGCCAGCCTGAATGATGACATTCTTTTCG
	GGGTGTTCGCACAAAGCAAGCCAGATTCTGCCGAACCAATGGATCGATCTGCCATGTG
	TGCATTCCCTATCAAATATGTCAACGACTTCTTCAACAAGATCGTCAACAAAAACAAT
	GTGAGATGTCTCCAGCATTTTTACGGACCCAATCATGAGCACTGCTTTAATAGGACAC
	TTCTGAGAAATTCATCAGGCTGTGAAGCGCGCCGTGATGAATATCGAACAGAGTTTAC
	CACAGCTTTGCAGCGCGTTGACTTATTCATCGCTCAATTCAGCGAAGTCCTCTTAACA
	TCTATATCCACCTTCATTAAAGGAGACCTCACCATAGCTAATCTTGGGACATCAGAGG
	GTCGCTTCATGCAGGTTGTGGTTTCTCGATCAGGACCATCAACCCCTCATGTGAATTT
	TCTCCTGGACTCCCATCCAGTGTCTCCAGAAGTGATTGTGGAGCATACATTAAACCAA
	AATGGCTACACACTGGTTATCACTGGGAAGAAGATCACGAAGATCCCATTGAATGGCT
	TGGGCTGCAGACATTTCCAGTCCTGCAGTCAATGCCTCTCTGCCCCACCCTTTGTTCA
	GTGTGGCTGGTGCCACGACAAATGTGTOCGATCGCAGGAATGCCTGAGCGGGACATGG
	ACTCAACAGATCTGTCTGCCTGCAATCTACAAGGTTTTCCCAAATAGTGCACCCCTTG
	AAGGACGGACAAGGCTGACCATATGTGGCTGGGACTTTGGATTTCGGAGGAATAATAA
	ATTTGATTTAAAGAAAACTAGAGTTCTCCTTGGAAATGAGAGCTGCACCTTGACTTTA
	AGTGAGAGCACGATGAATACATTGAAATGCACAGTTGGTCCTGCCATGAATAACCATT
	TCAATATGTCCATAATTATTTCAAATGGCCACGGGACAACACAATACAGTACATTCTC
	CTATGTGGATCCTGTAATAACAAGTATTTCGCCGAAATACGGTCCTATGGCTGGTGGC
	ACTTTACTTACTTTAACTGGAAATTACCTAAACAGTGGGAATTCTAGACACATTTCAA
	TTGGTGGAAAAACATGTACTTTAAAAAGTGTGTCAAACAGTATTCTTGAATGTTATAC
	CCCAGCCCAAACCATTTCAACTGAGTTTGCTGTTAAATTGAAAATTGACTTAGCCAAC
	CGACAGACAAGCATCTTCAGTTACCGTGAAGATCCCATTGTCTATGAAATTCATCCAA
	CCAAATCTTTTATTAGTACTTGGTGGAAAGAACCTCTCAACATTGTCAGTTTTCTATT
	TTGCTTTGCCAGTGGTGGGAGCACAATAACAGGTGTTGGGAAAAACCTGAATTCAGTT
	AGTGTCCCGAGAATGGTCATAAATGTGCATGAAGCAGGAACGAACTTTACAGTGGCAT
	GTCAACATCGCTCTAATTCAGAGATAATCTGTTGTACCACTCCTTCCCTGCAACAGCT
	GAATCTGCAACTCCCCCTGAAAACCAAAGCCTTTTTCATGTTAGATGGGATCCTTTCC
	AAATACTTTGATCTCATTTATGTACATAATCCTGTGTTTAAGCCTTTTGAAAAGCCAG
	TGATGATCTCAATGGGCAATGAAAATGTACTGGAAATTAAGGGAAATGATATTGACCC
	TGAAGCAGTTAAAGGTGAAGTGTTAAAAGTTGGAAATAAGAGCTGTGAGAATATACAC
	TTACATTCTGAAGCCGTTTTATGCACGGTCCCCAATGACCTGCTGAAATTGAACAGCG
	AGCTAAATATAGAGTGGAAGCAAGCAATTTCTTCAACCGTCCTTGGAAAAGTAATAGT
	TCAACCAGATCAGAATTTCACAGGATTGATTGCTGGTGTTGTCTCAATATCAACAGCA
	CTGTTATTACTACTTGGGTTTTTCCTGTGGCTGAAAAAGAGAAAGCAAATTAAAGATC
	TGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCT
	TGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGAC
	TACCGAGCTACTTTTCCAGAAGATCAGTTTCCTAATTCATCTCAGAACGGTTCATGCC
	GACAAGTGCAGTATCCTCTGACAGACATGTCCCCCATCCTAACTAGTGGGGACTCTGA
	TATATCCAGTCCATTACTGCAAAATACTGTCCACATTGACCTCAGTGCTCTAAATCCA
	GAGCTGGTCCAGGCAGTGCAGCATGTAGTGATTGGGCCCAGTAGCCTGATTGTGCATT
	TCAATCAAGTCATAGGAAGAGGGCATTTTGGTTGTGTATATCATGGGACTTTGTTGGA
	CAATGATGGCAAGAAAATTCACTGTGCTGTGAAATCCTTGAACAGAATCACTGACATA
	GGAGAAGTTTCCCAATTTCTGACCGAGGGAATCATCATGAAAGATTTTAGTCATCCCA
	ATGTCCTCTCGCTCCTGGGAATCTGCCTGCGAAGTGAAGGGTCTCCGCTGGTGGTCCT
	ACCATACATGAAACATGGAGATCTTCGAAATTTCATTCGAAATGAGACTCATAATCCA
	ACTGTAAAAGATCTTATTGGCTTTGGTCTTCAAGTAGCCAAAGGCATGAAATATCTTG
	CAAGCAAAAAGTTTGTCCACAGAGACTTGGCTGCAAGAAACTGTATGCTGGATGAAAA
	ATTCACAGTCAAGGTTGCTGATTTTGGTCTTGCCAGAGACATGTATGATAAAGAATAC
	TATAGTGTACACAACAAAACAGGTGCAAAGCTGCCAGTGAAGTGGATGGCTTTGGAAA
	GTCTGCAAACTCAAAAGTTTACCACCAAGTCAGATGTGTGGTCCTTTGGCGTGCTCCT
	CTGGGAGCTGATGACAAGAGGAGCCCCACCTTATCCTGACGTAAACACCTTTGATATA
	ACTGTTTACTTGTTGCAAGGGAGAAGACTCCTACAACCCGAATACTGCCCAGACCCCT
	TATATGAAGTAATGCTAAAATGCTGGCACCCTAAAGCCGAAATGCGCCCATCCTTTTC
	TGAACTGGTGTCCCGGATATCAGCGATCTTCTCTACTTTCATTGGGGAGCACTATGTC
	CATGTGAACGCTACTTATGTGAACGTAAAATGTGTCGCTCCGTATCCTTCTCTGTTGT
	CATCAGAAGATAACGCTGATGATGAGGTGGACACACGACCAGCCTCCTTCTGGGAGAC
	ATCATAGTGCTAGTACTATGTCAAAGCAACAGTCCACACTTTGTCCAATGGTTTTTTC
	ACTGCCTGACCTTTAAAAGGCCATCGATATTCTTTGCTCTTGCCAAAATTG
	ORF Start: ATG at 189	ORF Stop: TAG at 4413
	SEQ ID NO: 118	1408 aa	MW at 157710.2 kD
NOV25a,	MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILH
CG59885-01 Protein	EHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNI
Sequence	NMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPD
	CVVSALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQ
	SYIDVLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHS
	YMEMPLECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQ
	SKPDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNS
	SGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQ
	VVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRH
	FQSCSQCLSAPPFVQCGWCHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLBGGTR
	LTICGWDFGFRRNNKFDLKKTRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSI
	IISNGHGTTQYSTFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKT
	CTLKSVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPTKSFI
	STWWKEPLNIVSFLFCFASGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQHRS
	NSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFKPFEKPVMISM
	GNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDLLKLNSELNIE
	WKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQIKDLGSEL
	VRYDAPVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGSCRQVQY
	PLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVI
	GRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSL
	LGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKF
	VHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQ
	KFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVM
	LKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDN
	ADDEVDTRPASFWETS

[0449] Further analysis of the NOV25a protein yielded the following properties shown in Table 25B.

TABLE 25B
Protein Sequence Properties NOV25a
PSort     0.4600 probability located in plasma membrane;
analysis: 0.1226 probability located in microbody (peroxisome); 0.1000
          probability located in endoplasmic reticulum
          (membrane); 0.1000 probability located in endoplasmic
          reticulum (lumen)
SignalP   Cleavage site between residues 25 and 26
analysis:

[0450] A search of the NOV25a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 25C.

TABLE 25C
Geneseq Results for NOV25a
		NOV25a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAW82791	Human RON receptor protein - Homo	7 . . . 1377	483/1424	(33%)	0.0
	sapiens, 1400 aa. [WO9855141-A1,	7 . . . 1363	710/1424	(48%)
	10-DEC-1998]
AAW94409	Human Met proto-oncogene protein	501 . . . 817	300/317	(94%)	e−175
	501-850 - Homo sapiens, 300 aa.	1 . . . 300	300/317	(94%)
	[US5871959-A, 16-FEB-1999]
AAY43976	Human protein kinase #25 - Homo	1094 . . . 1362	264/269	(98%)	e−154
	sapiens, 266 aa. [US5958784-A,	1 . . . 266	265/269	(98%)
	28-SEP-1999]
AAW94410	Mouse Met proto-oncogene protein	501 . . . 817	256/317	(80%)	e−152
	501-850 - Mus sp, 299 aa.	1 . . . 299	279/317	(87%)
	[US5871959-A, 16-FEB-1999]
AAR50089	Sequence of human Met between the	501 . . . 817	254/317	(80%)	e−143
	Ndel - PvuII sites, residues 501-850 -	1 . . . 300	255/317	(80%)
	Homo sapiens, 300 aa. [WO9406909-
	A, 31-MAR-1994]

[0451] In a BLAST search of public sequence databases, the NOV25a protein was found to have homology to the proteins shown in the BLASTP data in Table 25D.

TABLE 25D
Public BLASTP Results for NOV25a
		NOV25a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
P08581	Hepatocyte growth factor receptor	1 . . . 1408	1389/1408 (98%)	0.0
	precursor (EC 2.7.1.112) (Met proto-	1 . . . 1390	1390/1408 (98%)
	oncogene tyrosine kinase) (c-met) (HGF
	receptor) (HGF-SF receptor) - Homo
	sapiens (Human), 1390 aa.
P16056	Hepatocyte growth factor receptor	1 . . . 1399	1237/1399 (88%)	0.0
	precursor (EC 2.7.1.112) (Met proto-	1 . . . 1379	1315/1399 (93%)
	oncogene tyrosine kinase) (c-met) (HGF
	receptor) (HGF-SF receptor) - Mus
	musculus (Mouse), 1379 aa.
P97523	Hepatocyte growth factor receptor	1 . . . 1399	1220/1401 (87%)	0.0
	precursor (EC 2.7.1.112) (Met proto-	1 . . . 1382	1302/1401 (92%)
	oncogene tyrosine kinase) (c-met) (HGF
	receptor) (HGF-SF receptor) - Rattus
	norvegicus (Rat), 1382 aa.
Q90975	TYROSINE KINASE - Gallus gallus	1 . . . 1399	1010/1401 (72%)	0.0
	(Chicken), 1382 aa.	1 . . . 1382	1172/1401 (83%)
Q9W650	C-MET/HEPATOCYTE GROWTH	6 . . . 1399	869/1397 (62%)	0.0
	FACTOR RECEPTOR - Xenopus laevis	2 . . . 1375	1083/1397 (77%)
	(African clawed frog), 1375 aa.

[0452] PFam analysis indicates that the NOV25a protein contains the domains shown in the Table 25E.

TABLE 25E
Domain Analysis of NOV25a
		Identities/
		Similarities
	NOV25a Match	for the Matched	Expect
Pfam Domain/	Region	Region	Value
Sema: domain 1 of 1	55 . . . 500	117/493	(24%)	5e−172
		419/493	(85%)
integrin_B:	525 . . . 543	7/19	(37%)	0.39
domain 1 of 1		14/19	(74%)
Plexin_repeat:	519 . . . 562	22/67	(33%)	1.6e−14
domain 1 of 1		41/67	(61%)
TIG: domain 1 of 3	563 . . . 655	28/106	(26%)	2.7e−21
		80/106	(75%)
TIG: domain 2 of 3	657 . . . 739	31/104	(30%)	8e−21
		71/104	(68%)
TIG: domain 3 of 3	762 . . . 854	28/113	(25%)	5.8e−07
		67/113	(59%)
pkinase: domain 1 of 1	1096 . . . 1355	85/297	(29%)	2.1e−91
		218/297	(73%)

Example 26

[0453] The NOV26 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 26A.

TABLE 26A
NOV26 Sequence Analysis
	SEQ ID NO: 119	2317 bp
NOV26a,	AAAACTCCAGGACGCGGAGGAGGCTAGTGGCAGTACCTGGGCACCCTGACCCTCCCCA
CG93443-01 DNA	CAGGCCAGAGCCCACCCTCCTGCTCATGAGGGCAGACAGGCCTTTCCAGGGACACAGT
Sequence	CCCTCTTCTCCCCAGGACCCCAGGGCCAACTCCCCCTGCCGGCCCTCTGCCATCAAAT
	TGGCAGTGGCTCCAGGGGAGTCCCCTGGGGATGGGGCACCACTGTTGGGGACCCCTCT
	GCGTGCACCCCTGTAGTTGGGGAAGCAGGACAGGGGCCTGGGGAGACGGAAGGGCGCC
	AGGGGTTGAGAGAGGATGGTGGACGTTGTTGGACTTCAAAGGGAAACAGGCCCTCGGG
	GAAGCCCCTGGCCAGGCCTGCCTCTCCCCTCCCTGGTGGGCCCAGCGCCCCTGCTCAC
	TTGTCTCTGCCCACAGTGCCTGTCTGTGGAGGACGCCCTGGGCCTGGGCGAGCCTGAG
	GGGTCAGGGCTGCCCCCGGCCCCGGTCCTGGAGGCCAGGTACGTCGCCCCCCTCAGTG
	CCGCCGCCGTCCTGTACCTCAGCAACCCCGAGGGCACCTGTGAGGACGCTCGGGCTGG
	CCTCTCGGCCTCTCATGCAGACCACCTCCTGGCCCTGCTCGAGAGCCCCAAGGCCCTG
	ACCCCGGGCCTGAGCTGGCTGCTGCAGAGGATGCAGGCCCGGGCTGCCGGCCAGACCC
	CCAAGACGGCCTGCGTAGATATCCCTCAGCTGCTGGAGGAGCCGGTGGGGGCGGGGGC
	TCCGGGCAGTGCTGGCGGCGTCCTGGCTGCCCTGCTGGACCATGTCAGGAGCGGGTCT
	TGCTTCCACGCCTTGCCGAGCCCTCAGTACTTCGTGGACTTTGTGTTCCAGCAGCACA
	GCAGCGAGGTCCCTATGACGCTGGCCGAGCTGTCAGCCTTGATGCAGCGCCTGGGGGT
	GGGCACCGAGGCCCACAGTGACCACAGTCATCGGCACAGGGGAGCCAGCAGCCGGGAC
	CCTGTGCCCCTCATCAGCTCCAGCAACAGCTCCAGTGTGTGGGACACGGTATGCCTGA
	GTGCCAGGGACGTGATGGCTGCATATGGACTGTCGGAACAGGCTCGGGTGACCCCGGA
	GGCCTGGGCCCAACTGAGCCCTGCCCTGCTCCAACAGCAGCTGAGTGGAGCCTACACC
	TCCCAGTCCAGGCCCCCCGTCCAGGACCAGCTCAGCCAGTCACAGAGATATCTGTACG
	GCTCCCTGGCCACGCTGCTCATCTGCCTCTGCGCGGTCTTTGGCCTCCTGCTGCTGAC
	CTGCACTGGCTGCAGGGGGGTCGCCCACTACATCCTGCAGACCTTCCTGAGCCTGGCA
	GTGGGTGCACTCACTGGGGACGCTGTCCTGCATCTGACGCCCAAGGTGCTGGGGCTGC
	ATACACACAGCGAACAGGGCCTCAGCCCACAGCCCACCTGGCGCCTCCTGGCTATGCT
	GGCCGGGCTCTACGCCTTCTTCCTGTTTGAGAACCTCTTCAATCTCCTCCTGCCCAGG
	GACCCGGAGGACCTGGAGGACGCGCCCTGCGGCCACAGCAGCCATAGCCACGGCGGCC
	ACAGCCACGGTGTGTCCCTGCAGCTGGCACCCAGCGAGCTCCGGCAGCCCAAGCCCCC
	CCACGAGGGCTCCCCCCCAGACCTGGTGGCGGAGGAGAGCCCGGAGCTGCTGAACCCT
	GAGCCCAGGAGACTCAGCCCAGAGTTGAGGCTACTGCCCTATATGATCACTCTGGGCG
	ACGCCGTGCACAACTTCGCCGACGGGCTGGCCGTGGGCGCCGCCTTCGCGTCCTCCTG
	GAAGACCGGGCTGGCCACCTCGCTGGCCGTGTTCTGCCACGAGTTGCCACACGAGCTG
	GGGGACTTCGCCGCCTTGCTGCACGCGGGGCTGTCCGTGCGCCAAGCACTGCTGCTGA
	ACCTGGCCTCCGCGCTCACGGCCTTCGCTGGTCTTACGTGGCACTCGCGGTTGGAGTC
	AGCGAGGAGAGCGAGGCCTGGATCCTGGCAGTGGCCACCGGCCTGTTCCTTACGTAGC
	ACTCTGCGACATGCTCCCGGCGATGTTGAAAGTACGGGACCCGCGGCCCCTGGCTCCT
	CTTCCTGCTGCACAACGTGGGCCTGCTGGGCGGCTGGACCGTCCTGCTGCTGCTGTCC
	CTGTACGAGGATGACATCACCTTCTGATACCCTGCCCTAGTCCCCCACCTTTGACTTA
	AGATCCCACACCTCACAAACCTACAGCCCAGAAACCCAGAAGCCCCTATAGAGCCCCC
	AGTCCCAACTCCAGTAAAGACACTCTTGTCCCTTGGAAAAAAAAAAAAAAAAAAA
	ORF Start: ATG at 306	ORF Stop: TAG at 2184
	SEQ ID NO: 120	626 aa	MW at 66248.5 kD
NOV26a,	MVDVVGLERETGPRGSPWPGLPLPSLVGPAPLLTCLCPQCLSVEDALGLGEPEGSGLP
CG93443-01 Protein	PGPVLEARYVARLSAAAVLYLSNPEGTCEDARAGLWASHADHLLALLESPKALTPGLS
Sequence	WLLQRMQARAAGQTPKTACVDIPQLLEEAVGAGAPGSAGGVLAALLDHVRSGSCFHAL
	PSPQYFVDFVFQQHSSEVPMTLAELSALMQRLGVGREAHSDHSHRHRGASSRDPVPLI
	SSSNSSSVWDTVCLSARDVMAAYGLSEQAGVTPEAWAQLSPALLQQQLSGAYTSQSRP
	PVQDQLSQSERYLYGSLATLLICLCAVFGLLLLTCTGCRGVAHYILQTFLSLAVGALT
	GDAVLHLTPKVLGLHTHSEEGLSPQPTWRLLAMLAGLYAFFLFENLFNLLLPRDPEDL
	EDGPCGHSSHSHGGHSHGVSLQLAPSELRQPKPPHEGSRADLVAEESPELLNPEPRRL
	SPELRLLPYMITLGDAVHNFADGLAVGAAFASSWKTGLATSLAVFCHELPHELGDFAA
	LLHAGLSVRQALLLNLASALTAFAGLTWHSRLESARRARPGSWQWPPACSLRSTLRHA
	PGDVESTGPAAPGSSSCCTTWACWAAGPSCCCCPCTRMTSPSDTLP

[0454] Further analysis of the NOV26a protein yielded the following properties shown in Table 26B.

TABLE 26B
Protein Sequence Properties NOV26a
PSort     0.7000 probability located in plasma membrane;
analysis: 0.3048 probability located in microbody (peroxisome); 0.2000
          probability located in endoplasmic reticulum
          (membrane); 0.1000 probability located in mitochondrial
          inner membrane
SignalP   Cleavage site between residues 43 and 44
analysis:

[0455] A search of the NOV26a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 26C.

TABLE 26C
Geneseq Results for NOV26a
		NOV26a	Identities/
Geneseq	Protein/Organism/Length	Residues/	Similarities for	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAE06574	Human protein having hydrophobic	37 . . . 548	508/512 (99%)	0.0
	domain, HP10755 - Homo sapiens,	62 . . . 573	509/512 (99%)
	647 aa. [WO200149728-A2,
	12-JUL-2001]
AAE01677	Human gene 6 encoded secreted protein	37 . . . 548	508/512 (99%)	0.0
	HWLHM66, SEQ ID NO: 89 - Homo	62 . . . 573	509/512 (99%)
	sapiens, 647 aa. [WO200134767-A2,
	17-MAY-2001]
AAB74710	Human membrane associated protein	37 . . . 548	507/512 (99%)	0.0
	MEMAP-16 - Homo sapiens, 647 aa.	62 . . . 573	508/512 (99%)
	[WO200112662-A2, 22-FEB-2001]
AAE01709	Human gene 6 encoded secreted protein	37 . . . 410	365/374 (97%)	0.0
	HWLHM66, SEQ ID NO: 121 - Homo	62 . . . 435	366/374 (97%)
	sapiens, 440 aa. [WO200134767-A2,
	17-MAY-2001]
AAB59035	Breast and ovarian cancer associated	436 . . . 548	107/113 (94%)	2e−54
	antigen protein sequence SEQ ID 743 -	18 . . . 130	108/113 (94%)
	Homo sapiens, 204 aa. [WO200055173-
	A1, 21-SEP-2000]

[0456] In a BLAST search of public sequence databases, the NOV26a protein was found to have homology to the proteins shown in the BLASTP data in Table 26D.

TABLE 26D
Public BLASTP Results for NOV26a
		NOV26a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9NXC4	CDNA FLJ20327 FIS, CLONE	1 . . . 626	626/626 (100%)	0.0
	HEP10012 - Homo sapiens (Human),	1 . . . 626	626/626 (100%)
	626 aa.
Q9H6T8	CDNA: FLJ21884 FIS, CLONE	37 . . . 548	508/512 (99%)	0.0
	HEP02863 - Homo sapiens (Human),	62 . . . 573	509/512 (99%)
	647 aa.
Q9DAT9	1600025H15RIK PROTEIN - Mus	37 . . . 548	365/531 (68%)	0.0
	musculus (Mouse), 660 aa.	61 . . . 586	415/531 (77%)
Q95KA5	HYPOTHETICAL 72.8 KDA PROTEIN -	130 . . . 548	141/444 (31%)	2e−51
	Macaca fascicularis (Crab eating	177 . . . 580	217/444 (48%)
	macaque) (Cynomolgus monkey), 654 aa.
Q96NN4	CDNA FLJ30499 FIS, CLONE	174 . . . 548	127/393 (32%)	7e−49
	BRAWH2000443, WEAKLY SIMILAR	227 . . . 580	197/393 (49%)
	TO HUMAN BREAST CANCER,
	ESTROGEN REGULATED LIV-1
	PROTEIN (LIV-1) MRNA - Homo
	sapiens (Human), 654 aa.

[0457] PFam analysis indicates that the NOV26a protein contains the domains shown in the Table 26E.

TABLE 26E
Domain Analysis of NOV26a
	NOV26a	Identities/
	Match	Similarities	Expect
Pfam Domain	Region	for the Matched Region	Value
Zip: domain 1 of 1	467 . . . 618	37/184 (20%)	0.00025
		108/184 (59%)

Example 27

[0458] The NOV27 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 27A.

TABLE 27A
NOV27 Sequence Analysis
	SEQ ID NO: 121	2852 bp
NOV27a,	GTGTGCAGTAAACTGGAATGCTCTCCCTCGCTCACTCCTCAGTGTAGCAGTGATCTGA
CG50838-01 DNA	AGCAGGACAAGCTCAGCCTGCAGCTGCCGTGGGCTTTGTGTGGACTGGACGCAGAGCT
Sequence	TGGGAGACGGGGGAGGGCTATTACTCCAATTCACTGTCAATGGAATTACAGCTATAGC
	GGCAGTGTATATAGGATTGCTTTTTCTCGTCTTCCTGGAGATGCTCAGTCCCAGTATA
	TTTTAAGGAAGAGAAATATAAAGGAAATTTAGTATGCCTCCTTTTCTTTAAATGAAGA
	ATTTAGTTTCCTTTACTTCTTAAAAGAGAATACCTGTTCTTGTATAACGTGACTGCAC
	CAGACATTCTGAAAAATCAGCAAGAAGCAAAAGCTGGAAATAGCTATTTCACAGCAGG
	GTTCTGAAGTAACGGAAGCTACCTTGTATAAAGACCTCAACACTGCTGACCATGATCA
	GCGCAGCCTGGAGCATCTTCCTCATCGGGACTAAAATTGGGCTGTTCCTTCAAGTAGC
	ACCTCTATCAGTTATGGCTAAATCCTGTCCATCTGTGTGTCGCTGCGATGCGGGTTTC
	ATTTACTGTAATGATCGCTTTCTGACATCCATTCCAACAGGAATACCAGAGGATGCTA
	CAACTCTCTACCTTCAGAACAACCAAATAAATAATGCTGGGATTCCTTCAGATTTGAA
	AAACTTGCTGAAAGTAGAAAGAATATACCTATACCACAACAGTTTACATGAATTTCCT
	ACCAACCTCCCAAAGTATGTAAAAGAGTTACATTTGCAAGAAAATAACATAAGGACTA
	TCACTTATGATTCACTTTCAAAAATTCCCTATCTGGAAGAATTACATTTAGATGACAA
	CTCTGTCTCTGCAGTTAGCATAGAAGAGGGAGCATTCCCAGACAGCAACTATCTCCGA
	CTGCTTTTCCTGTCCCGTAATCACCTTAGCACAATTCCCTGGGGTTTCCCCAGGACTA
	TAGAACAACTACGCTTGGATGATAATCGCATATCCACTATTTCATCACCATCTCTTCA
	AGGTCTCACTAGTCTAAAACGCCTGGTTCTAGATGGAAACCTGTTGAACAATCATGGT
	TTAGGTGACAAAGTTTTCTTCAACCTAGTTAATTTGACAGAGCTGTCCCTGGTGCGGA
	ATTCCCTGACTGCTGCACCAGTAAACCTTCCACGCACAAACCTGAGGAAGCTTTATCT
	TCAAGATAACCACATCAATCGGGTGCCCCCAAATGCTTTTTCTTATCTAAGGCAGCTC
	TATCGACTGGATATGTCCAATAATAACCTAAGTAATTTACCTCAGGGTATCTTTGATG
	ATTTGGACAATATAACACAACTGATTCTTCGCAACAATCCCTGGTATTGCGGGTGCAA
	GATGAAATGCGTACGTGACTGGTTACAATCACTACCTGTGAAGGTCAACGTGCGTGGG
	CTCATGTGCCAAGCCCCAGAAAAGGTTCGTGGGATGGCTATTAAGGATCTCAATGCAG
	AACTGTTTGATTGTAAGGACAGTGGGATTGTAAGCACCATTCAGATAACCACTGCAAT
	ACCCAACACAGTCTATCCTGCCCAAGGACAGTGGCCAGCTCCAGTGACCAAACAGCCA
	GATATTAAGAACCCCAAGCTCACTAAGGATCAACAAACCACAGGGAGTCCCTCAAGAA
	AAACAATTACAATTACTGTGAAGTCTGTCACCTCTGATACCATTCATATCTCTTGGAA
	ACTTGCTCTACCTATGACTGCTTTGAGACTCAGCTGGCTTAAACTGGGCCATAGCCCG
	GCATTTGGATCTATAACAGAAACAATTGTAACAGGCGAACGCAGTGAGTACTTGGTCA
	CAGCCCTGGAGCCTGATTCACCCTATAAAGTATGCATGGTTCCCATGGAAACCAGCAA
	CCTCTACCTATTTGATGAAACTCCTGTTTGTATTGAGACTGAAACTGCACCCCTTCGA
	ATGTACAACCCTACAACCACCCTCAATCGAGAGCAAGAGAAAGAACCTTACAAAAACC
	CCAATTTACCTTTGGCTGCCATCATTGGTGGGGCTGTGGCCCTGGTTACCATTGCCCT
	TCTTGCTTTAGTGTGTTGGTATGTTCATAGGAATGGATCGCTCTTCTCAAGGAACTGT
	GCATATAGCAAAGGGAGGAGAAGAAAGGATGACTATGCAGPAGCTGGCACTAAGAAGG
	ACAACTCTATCCTGGAAATCAGGGAAACTTCTTTTCAGATGTTACCPATAAGCAATGA
	ACCCATCTCGAAGGAGGAGTTTGTAATACACACCATATTTCCTCCTAATGGAATGAAT
	CTGTACAAAAACAATCACAGTGAAAGCAGTAGTAACCGAAGCTACAGAGACAGTGGTA
	TTCCAGACTCAGATCACTCACACTCATGATGCTGAAGGACTCACAGCAGACTTGTGTT
	TTGGGTTTTTTAAACCTAAGGGAGGTGATGGTAGGAACCCTGTTCTACTGCAAAACAC
	TGGAAAAAGAGACTGAAAAAAAGCAATGTACTGTACATTTGCCATATAATTTATATTT
	AAGAACTTTTTATTAAAAGTTTCAAATTTCAGGTTACTGCTGCGATTGATGTAGTGGA
	CATGCCTGAACACAATTCTATATTTTAGTATTTTTTAGTAATTTGTACTGTATTTTCC
	TTGCAAATATTGGAGTTATAAACCATTTACTTTGTGTTCTACTGAGTAAGATGACTTG
	TTGACTGTGAAAGTGAATTTTCTTGCTGTGTCGAACAATCAGGACTGCATTCATATGA
	GATCCTTGTAGTATAAGCACAGGCCATTTTTCACTTTGGTATTAATAAAATGTAAAAA
	AAAAATTGGT
	ORF Start: ATG at 458	ORF Stop: TGA at 2405
	SEQ ID NO: 122	649 aa	MW at 72993.5 kD
NOV27a,	MISAAWSIFLIGTKIGLFLQVAPLSVMAKSCPSVCRCDAGFIYCNDRFLTSIPTGIPE
CG50838-01 Protein	DATTLYLQNNQINNAGIPSDLKNLLKVERIYLYHNSLDEFPTNLPKYVKELHLQENNI
Sequence	RTITYDSLSKIPYLEELHLDDNSVSAVSIEEGAFRDSNYLRLLFLSRNHLSTIPWGLP
	RTIEELRLDDNRISTTSSPSLQGLTSLKRLVLDGNLLNNHGLGDKVFFNLVNLTELSL
	VRNSLTAAPVNLPGTNLRKLYLQDNHINRVPPNAFSYLRQLYRLDMSNNNLSNLPQGI
	FDDLDNITQLILRNNPWYCGCKMKWVRDWLQSLPVKVNVRGLMCQAPEKVRGMAIKDL
	NAELFDCKDSGIVSTIQITTAIPNTVYPAQGQWPAPVTKQPDIKNPKLTKDQQTTGSP
	SRKTITITVKSVTSDTIHISWKLALPMTALRLSWLKLGHSPAFGSITETIVTGERSEY
	LVTALEPDSPYKVCMVPMETSNLYLFDETPVCIETETAPLRMYNPTTTLNREQEKEPY
	KNPNLPLAAIICGAVALVTIALLALVCWYVHRNGSLFSRNCAYSKGRRRKDDYAEAGT
	KKDNSILEIRETSFQMLPISNEPISKEEFVIHTIFPPNGMNLYKNNHSESSSNRSYRD
	SGIPDSDHSHS

[0459] Further analysis of the NOV27a protein yielded the following properties shown in Table 27B.

TABLE 27B
Protein Sequence Properties NOV27a
PSort     0.6976 probability located in plasma membrane; 0.6400
analysis: probability located in endoplasmic reticulum (membrane);
          0.1900 probability located in Golgi body;
          0.1000 probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 29 and 30
analysis:

[0460] A search of the NOV27a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 27C.

TABLE 27C
Geneseq Results for NOV27a
		NOV27a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAU29215	Human PRO polypeptide sequence	1 . . . 649	649/649 (100%)	0.0
	#192 - Homo sapiens, 649 aa.	1 . . . 649	649/649 (100%)
	[WO200168848-A2, 20-SEP-2001]
AAB87591	Human PRO1865 - Homo sapiens,	1 . . . 649	649/649 (100%)	0.0
	649 aa. [WO200116318-A2,	1 . . . 649	649/649 (100%)
	08-MAR-2001]
AAB70533	Human PRO3 protein sequence SEQ	1 . . . 649	649/649 (100%)	0.0
	ID NO: 6 - Homo sapiens, 649 aa.	1 . . . 649	649/649 (100%)
	[WO200110902-A2, 15-FEB-2001]
AAB93758	Human protein sequence SEQ ID	1 . . . 649	648/649 (99%)	0.0
	NO: 13435 - Homo sapiens, 649 aa.	1 . . . 649	649/649 (99%)
	[EP1074617-A2, 07-FEB-2001]
AAM93408	Human polypeptide, SEQ ID NO:	1 . . . 649	648/649 (99%)	0.0
	3016 - Homo sapiens, 649 aa.	1 . . . 649	648/649 (99%)
	[EP1130094-A2, 05-SEP-2001]

[0461] In a BLAST search of public sequence databases, the NOV27a protein was found to have homology to the proteins shown in the BLASTP data in Table 27D.

TABLE 27D
Public BLASTP Results for NOV27a
		NOV27a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
CAC33411	SEQUENCE 5 FROM PATENT	1 . . . 649	649/649 (100%)	0.0
	WO0110902 - Homo sapiens (Human),	1 . . . 649	649/649 (100%)
	649 aa.
Q96KB1	CDNA FLJ14391 FIS, CLONE	1 . . . 649	648/649 (99%)	0.0
	HEMBA1003077, WEAKLY	1 . . . 649	649/649 (99%)
	SIMILAR TO SLIT PROTEIN
	(Human), 649 aa.
Q9P259	KIAA1469 PROTEIN - Homo sapiens	1 . . . 649	648/649 (99%)	0.0
	(Human), 662 aa (fragment).	14 . . . 662	648/649 (99%)
Q9NZU0	LEUCINE-RICH REPEAT	1 . . . 649	648/649 (99%)	0.0
	TRANSMEMBRANE PROTEIN	1 . . . 649	648/649 (99%)
	FLRT3 (DJ581I13.1) - Homo sapiens
	(Human), 649 aa.
Q96K39	CDNA FLJ14788 FIS, CLONE	27 . . . 649	622/623 (99%)	0.0
	NT2RP4000925, WEAKLY SIMILAR	1 . . . 623	622/623 (99%)
	TO FIBROMODULIN PRECURSOR -
	Homo sapiens (Human), 623 aa.

[0462] PFam analysis indicates that the NOV27a protein contains the domains shown in the Table 27E.

TABLE 27E
Domain Analysis of NOV27a
		Identities/
		Similarities for
	NOV27a	the	Expect
Pfam Domain	Match Region	Matched Region	Value
LRRNT: domain 1 of 1	30 . . . 57	10/31 (32%)	0.00034
		19/31 (61%)
LRR: domain 1 of 10	59 . . . 83	7/26 (27%)	44
		20/26 (77%)
LRR: domain 2 of 10	84 . . . 103	8/25 (32%)	75
		16/25 (64%)
LRR: domain 3 of 10	105 . . . 128	7/25 (28%)	12
		18/25 (72%)
LRR: domain 4 of 10	129 . . . 154	9/26 (35%)	76
		20/26 (77%)
LRR: domain 5 of 10	155 . . . 174	10/25 (40%)	5.4
		16/25 (64%)
LRR: domain 6 of 10	176 . . . 199	8/25 (32%)	0.1
		20/25 (80%)
LRR: domain 7 of 10	200 . . . 225	9/26 (35%)	62
		18/26 (69%)
LRR: domain 8 of 10	226 . . . 245	11/25 (44%)	63
		16/25 (64%)
LRR: domain 9 of 10	248 . . . 271	9/25 (36%)	0.00033
		20/25 (80%)
LRR: domain 10 of 10	272 . . . 295	13/25 (52%)	0.011
		19/25 (76%)
LRRCT: domain 1 of 1	305 . . . 356	17/54 (31%)	9.4e−13
		42/54 (78%)
fn3: domain 1 of 1	405 . . . 485	18/90 (20%)	0.22
		54/90 (60%)

Example 28

[0463] The NOV28 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 28A.

TABLE 28A
NOV28 Sequence Analysis
	SEQ ID NO: 123	3373 bp
NOV28a,	TTGGATTGTCCAAGCCACAGATAAAGGGATGCCCAGGCTTTCTAATACGACTGTAATCA
CG58567-01 DNA	AGGTACAGGTGACTGATATAAATGACAATGCCCCAGCTTTTCTCCCCTCTGAAGCAGT
Sequence	GGAAATTACAGAAGTCATGACTATTTCAGAAGATTCTTTGCCTGGTGTAATTGTGACT
	CATGTGTCAGTTCATGATGTGGATTTGAATTCAGCTTTCATATTCAGTTTTGCCAAAG
	AGAGTAATCCTGGAACCAAGTTTGCTATTGATCACAACACTGGAGTGGTGGTGTTCGT
	GAAAACATTGGATTTTGAAGAAATGACTGAATATGAGCTGCTCATCCAAATTTCTGAT
	TCAGTGCACTACACAGAGGGAGCACTTGTAGTCCGTGTGCTGGATGTCPATGATAATC
	CACCAGTGTTTTCTCAACATTTCTATCAGCTCACAGTTCCTGAATCAATACCTGTGGG
	GTATTCAGTGCTGACTCTGTCAGCCACAGACTTAGAAAGCAATGAGAACATTTCTTAC
	AGAATTCTATCCTCTTCTAAGGAATTCTCCATTGATCCTAAGAATGGCACAATATTTA
	CTATCAGTCCCGTATTACTTCTGGATACAATATCAACAACTCGATTTCTTGTGGAAGC
	CAGTGATGGTGGAAATCCTGACCCGAGAGCTCTTACTTTAGTGGAGATAGGAATAGAA
	GATATGAACAATTATGCCCCTGAATTCACAGTCAAATCCTATAATCTTAGCCTAAGTG
	AGGATGCTCTGGTTGGAAGCACGCTTGTTACATTTTCAAACATCGACCATGACTGGAC
	CCGTGAAAACACATATGTTGAATATTCCATCATCAGTGGTAATTCACAGAACAATTTT
	CATGTGGAAACTAAGTTCTTTCATTCAGAATATCCTTATAAGCAAGTCGGTTATCTTG
	TGTTGCTTCACAGTCTGGACAGAGAAGCAAGTGCTAGCCATGAGCTTGTCATTCTGGC
	ATCTGACAGTGGCTGCCCTCCATTGAGTTCCACAGCTGTCATATCAATACAAGTACTT
	GATGTCAATGACAATCCCCCAAACTTCAGCAGCCTGAGCTATCACACCCATGTCAAGG
	AAAGCACCCCTCTAGGGAGTCACATCACTGTGGTCTCAGCAAATGACCGTGACACAGG
	GTCACATGCAGAAATCATCTACAACATCATCTCTGGAAATGAGAAGGGACATTTTTAC
	TTAGAAGAAAACACTGGAGTTCTTTATTTGATTAAACCTCTGGATTATGAAAAAATGA
	CAAAATTCACCTTAACTGTCCAAGCTTCAGATGCAGAAAAGAAACATTTTTCTTTTGC
	AGTTGTGTTTGTCAGTGTCCTCGATGATAACGACCATGCACCTCAGTTTATCTTCTCA
	AGCTTCAGCTGTATTGTTCCAGAAAATCTGCCTATTTCCTCTACCATATGCTCTATAA
	ATGCTCTGGATTTTGATGCTGGTCCGTATGGAGAATTGACCTATTCTATTGTATCACC
	CTGTTTTCTCACTCATGGAATGTCTTATGATCATGATCTCTTCCTCATTGACCCTTTG
	ACAGGCGATATTCATGCTAAGCAAATCCTTGACTATGAAAATGGCAATAAATACTGCC
	TCACAGTCCAAGCCAAAGACAAAGGTGATGCAACTGCCTCCTTAGTGGTCTGGGTGGA
	TATTGAAGGGATAGATGAATTTGAGCCCATTTTCACTCAAGATCAGTATTTTTTCACC
	CTCCCAGAAAAGAATAAAGACAGACAGTTGATTGGCAGAGTGGAAGCCTCAGATGCAG
	ATGCTGGTATTGATGGAGTCATTCTTTACTCCCTTGGAACCTCATCTCCTTTCTTTTC
	AGTAAATAGAACCAATGGAAATATTTATTTCATTACAGCCCTTCCCCTAATAAAAAGT
	CAACTCAACAAAGAAGACACCTTGGAAATGAAAATAATCGCTCATAGTCCCAAATCAG
	ATTCCAAGTTTGCATCTTGCACTGTTTTTGTGAATGTGTCTTTCTCCTCTGAAGGAAC
	ACCCTTGGCAGTGTTCGCCAGCAGCTTTTCAATCAGCCTGGTGGTCTCCTTTTTAGTG
	TTTCTGATACTCATCTGCATTCTAATTGTAATGATTTTAAGACATAAACAAAAAGACA
	CAATAAACAATTATGAGGAGAAGAAAACCTCATCTTTAGATGCGGACTTGAGAGTGAC
	CCGGGATGCCAGTGTGCTCAAAGCCTTCCAGAAAACTGACGACTGCAGTAACGAGGTG
	GTCCCTGTGGATGCCACTCCGGAATCGTTGAGTTTAATAAGTATCATGGAGAAGGATA
	TTGTCAATCTGTACAGATACTCAAACTCCAGTGGCCACTGTTCTGTGGAAGGAGAAAC
	TGCAGAAGATAAGGAAATCCAGAGGATAAATGAGCATCCCTACAGAAAGTGCTCAGAC
	TCAGCTCTGAGTGACCACGAGTCCAGGGTGCCAGACTCGGGTATCCCGAGGGACTCAG
	ACCAGCTCTCCTGCCTATCTGGGGAAACTGATGTGATGCTGACTGCCGAAACAGCAGA
	AGCCAGCCAAACATTTGGGGAAGGAGATCAACGGGAAGGCTCCAGCACCACCTGTGCT
	CAAAATAATGTGTTACCCCAGACAGTTCAGAAGAGAGAGGCAAAAGAGAGCATCCTGG
	CTGACGTTAGAAAAGAGTCTGTCTTTATTTCAGGTGATCAGGAAGTAAGGTGTGCAGC
	TCTTTCAACTCAGACGACCTCTGATCATGATGGAAAAGACAACTATCACTGGAATTAT
	CTTCTTAGTTGGGAGCCCAAATTCCAACCTCTTGCCTCACTATTTAATGATATTGCAA
	AACTAAAGGATGAACATTTGCATATGCCTGGCATTCCAAAAGAGAAGAAATCTTTTGT
	TTTTCCACCCCCTTTGATAACAGCAGTAGCCCAGCCTGGGATTAAAGCAGTCCCACCA
	AGAATGCCGGCAGTAAACCTGGCGCAGGTGCCTCCGAAACACCCACGCTCTCCCATCC
	CCTACCATCTTGGTTCTCTGCCAGAAGGCATGACTCCCAATTTTTCTCCATCTCTTTC
	CCTATTGACGATGCAGCCTCCTGCCTTGTCTCCACTGTTGAGAGAAGGAGAATTATTA
	GGAACACACATCAGTGGTACATGCCATGAACTTAAAGCAGAAGATGAAGTTCAAATAT
	GAAACCACTGGGATGCCAAGTACCTGCTCACCATTGGTCATGAATGAATGAACAAAAT
	TTTAGTTAGAGTTTTTAAAACTTCCCCATTAAAGTTTCTCCAATTTCAAAAAAAAAAA
	AAAAAAAAA
	ORF Start: TTG at 1	ORF Stop: TGA at 3190
	SEQ ID NO: 124	1063 aa	MW at 117200.4 kD
NOV28a,	LIVQATDKGMPRLSNTTVIKVQVTDINDNAPAFLPSEAVEITEVMTISEDSLPGVIVT
CG58567-01 Protein	HVSVHDVDLNSAFIFSFAKESNPGTKFAIDQNTGVVVLVKTLDFEEMTEYELLIQISD
Sequence	SVHYTEGALVVRVLDVNDNPPVFSQDFYQVTVPESIPVGYSVLTLSATDLESNENISY
	RILSSSKEFSIDPKNGTIFTISPVLLLDTISTTRFLVEASDGGNPDPRALTLVEIGIE
	DMNNYAPEFTVKSYNLSLSEDALVGSTLVTFSNIDHDWTRENTYVEYSIISGNSQNNF
	HVETKFFHSEYPYKQVGYLVLLHSLDREASASHELVILASDSGCPPLSSTAVISIQVL
	DVNDNPPNFSSLSYHTHVKESTPLGSHITVVSANDRDTGSHAEIIYNIISGNEKGHFY
	LEENTGVLYLIKPLDYEKNTKFTLTVQASDAEKKHFSFAVVFVSVLDDNDHAPQFMFS
	SFSCIVPENLPISSTICSINALDFDAGPYGELTYSIVSPCFLTHGMSYDHDLFLIDPL
	TGDIHAKQILDYENGNKYCLTVQAKDKGDATASLVVWVDIEGIDEFEPIFTQDQYFFT
	LPEKNKDRQLIGRVEASDADAGIDGVILYSLGTSSPFFSVNRTNGNIYLIRALPLIKS
	QLNKEDTLEMKIIAHSPKSDSKFASCTVFVNVSFSSEGTPLAVFASSFSISLVVSFLV
	FLILICILIVMILRHKQKDTINNYEEKKTSSLDADLRVTRDASVLKAFQKTDDCSNEV
	VPVDATPEWLSLISIMEKDIVNLYRYSNSSGHCSVEGETAEDKEIQRINEHPYRKCSD
	SALSDHESRVPDSGIPRDSDQLSCLSGETDVMVTAETAEASQTFGEGDQGEGCSTTCA
	QNNVLPQTVQKREAKESILADVRKESVFISGDQEVRCAALSTQTTSDHDGKDNYHWNY
	LLSWEPKFQPLASVFNDIAKLKDEHLHMPGIPKEKKSFVFPPPLITAVAQPGIKAVPP
	RMPAVNLGQVPPKHPRSPIPYHLGSLPECMTPNFSPSLSLLTMQPPALSPLLREGELL
	GTHISGTCHELKAEDEVQI
	SEQ ID NO: 125	9193 bp
NOV28b,	ATGGAGAAATGTGGGCTTAAAGAGGAAGGCAGTTACGCGGACATAGATCCAGTTGCCC
CG58567-05 DNA	ACGATCCGGACGCCGGACTGTTCAGCACTCAGGGCTACACCCTGGTGCAACCGTCCGA
Sequence	CCTGCCCAAGGACCCCGCAGGCCCGTTCTTCCAGTTGCGCTACCGGACTCCGGGGCCA
	CTACCGTCACCGCTTTTGCCAGGCTCCTCGTCACCCCTGGAGCCTCTAGATCTGGTGC
	TGCTGCGGCGCTTGGACCGAGAGGAGGCGGCGGCGCACCGGCTGCAGATCGAGGCATG
	GGACGGCGGCCGACCCCGGCGCACCGGCCTCCTGAGCGTGGAGCTGCGCGTGCTGGAT
	GAGAACGACAACCCGCCGGTCTTTGAGCAGGACGAGTACCGCGCCGCGGTGCGCGAGC
	ACGCCCAGCCGGGCGCCGAGGTCTGTCGCGTGCGCGCCACCGACCGCGACCTGGGGCC
	CAATGGCTTCGTGCGCTACAGCGTCCGCGCCCGGCAAGTGCCTGGGGCGGGTAGCGGC
	GGCGGGGCACTGGGCGACGCGGCCTACTTCGCGGTGGAGGAGCTGAGCGGCGTGGTGC
	GAGTGTGGAGACCTCTGGACCGCGAGGCACAGGCCTGGCACCAGTTGGTGGTGGAGGC
	CCGCGATGGAGGCGCCGAGCCTGAGGTTGCCACGGTCCGCGTGTCCATCGCCGTGCTG
	GACGTGAATGACAACCGGCCAGCAATTCACGTGCTCTTTCTCACAGAGGGAGGCGTCG
	CCCGTGTCTCTGAAGCCGCCCGACCGGGCGACTACGTGGCTCGCGTCTCGGTGTCTGA
	CGCGGACGGGGTAATAGGCAAAATTACAGCTATTGACATGGACTCTGGAAAGAATGGA
	CAGCTATTATATTTCCTTTTGTCTGATGGAAAATTCTTCAAGATGAATCCTAATACAG
	GAGAGTTAATCAATTGGGTGGCACTGGATCGTGAGCACCGGGCGCACCATGAGATGAC
	TGTGCTAGTGACAGACCGCGGCTCCCCACCACGAAACGCCACCATGGCGGTTTACGTC
	TCAGTTACTGACATCAATGATAACAGGCCCTTCTTCCCCCAGTGTCTCCCTGGAAAGG
	AGTTACACGTGAAGGTTCTGGAACGTCAACCAGTAAATATGTTGGTTACAACTGTGTT
	TGCAAAGGATCCTGATGAAGGAAATAATGCAGAAGTTACATACTCAGTATCTTCAGAA
	GATAGTTCTGATCACTTTAAGATTGACGCCAACAATGGTGAAATAAGAACAACCACAA
	TACTTTCGTATGATTATAGACCTTCCTACAGAATGAGTGTCATTCCCACTGACCAGGG
	AGTGCCTCCTCTTCAAGGACAGGCAGTTGTTAATATTCAGGAACTTGATTATGAGACG
	ACATCTCATTATCTTTTCAGAGTGATTACTACAGACCATAGCAAAAACCTTTCCCTGA
	GTAGCACAGTCTTCCTTAGTATCGATGTGGAAGATCAGAATGACCATTCCCCATCTTT
	CCAGGATGAGCTCATTGTGATCAGTGTAGAGGAGAATGTTCCCATAGGAACCCTGGTG
	TATGTCTTCAATGCCAAAGATGATGACGGCAGTTTTTTGAACAGTAGAATACAATACT
	ACATTGAATCCCACAACCCTGGCACGAATCCATTTCTCATCCACCCCTCATTTGGCAC
	ACTAGTCACTGTGTCCCGTCTTGACAGAGAAAGCATTCCAACTGTCATCCTGACAGTA
	ACAGCATCTGATCAGGCTGTGAATGTGACAGACCGGCGACTGAGATCACTGACAGCAC
	AAATAGTGATTTTGGATGTAAATGACCACAACCCCACTTTTATTTCTTTCCCCAATGC
	CCATGTCAAAGAGGATGTCACAGTGCGCTCCTTGGTCCACCACATAACTGCTCACGAT
	CCAGACGAAGGAAGGAATGGAAAAGTAACATACACCATCCTCTCAGGAAATGAAAACA
	TGACGTTTATGCTAGATGAGTCATCAGGCTTACTAACCACAACCTGTCCTTTGGATTA
	TGAAATGAAAACTCAGCATATTCTCACTGTTCTGGCACTGGATGATGGCACACCAGCA
	CTTTCTTCATCCCAGACTTTGACAGTTACTGTTCTTCATGTAAATGATGAAGCTCCAG
	TATTTAAGCAGCACCTGTATGAAGCCTCAGTGAAAGAAAACCAAAATCCAGGGGAGTT
	TGTTACCAGGGTTGAAGCTCTGGACAGAGATTCAGTGTTCCTTAATACTAGAGAGCTT
	AACATGTGTTTTCTAGCATTCTACGATGCAGTTTTTAAAAATGGTGGGCTAAGTGCCC
	AAGCCTTTGTTCGTGTGGACCTGGAGGACGTGAATGATAATCATCCTGTGTTTAACCC
	ATCAACCTATGTGACGAGCATCAGTGATGAGACCCAGCCAGGCACCGAGATCATCPAT
	GTTCTTGCCACTGACCAGGACTCTGGGATATATGGGACAGTCGCTTATGAGCTTATTC
	CAGGAAACGTGTCGTCCCTTTTTACCATTGACTCCACCACAGGAATTATTTACTTAAC
	ATTACCTCTTAGTCATTTGGAATCTACCACACTTTCGTTGATGGTCTCTGCTCAAGAC
	GGTGGTGGGCTCACAGCTGTCATTAATGCCGATGTCACCATACACATTTTCCAGACAA
	CTCTGGCACCTGCTGAGTTTGAAAGGCCTAAGTACACTTTCTTACTTTATGAAGATGT
	GCCTGAAGATAGTCCCATTGGAACAGTGAAAGCAAGAGAGCCCTTGAATCCACCTAGG
	AGCTCTGTAATACACCTGCAAGTTAGAGTTTTGGATGCCPATGACCACAGTCCTTCTT
	TTCCCACACTTTATTACCAGTCCTCTGTGAGAGAAGATGCTGAAGTGGGAACAGTGGT
	TCTTGTGCTTTCAGCTCTGGACAAGGATGAAGGCCTGAATGGGCAAACTGAGTATTTT
	CTGACTGATGAGGCTTGTGGTGCATTCACCATTGATCCTATGTCAGCCACATTGAAAA
	CCAGCAACACCCTCGACCGTGAAGCCAGATCTCACCATACATTTAGTGCTGTGGCCAG
	AGACTGTAGCATCCAGGGTTCACGAAGCACCACTGTAATTATAAAAGTATATGTCACT
	GATGTTAATGACAATGATCCAGTTTTGGAACAGAACCCTTTTCATGTGTTTCTTTCCC
	CCGAGTCGCCTACAAACCAGACAACTGTCATTGTGAGAGCTGATCACCTGGACTTGGG
	CCCCAATGGAACTGTGGACTCCGATGACTCCCCGCTGCTGGACGACTTCCACGTGCAC
	CCGGACACCGGCATCATCCGCACTGCCCGGCGCCTGGACCGCGAGCGCCGGGACCACT
	ACAGCTTCGTCGCCGCCACGCTGCTGGGCGCTGTGGTGCAGGTGGAGATTCGCCTCPA
	CGACGTGAATGACCACTCGCCCCGCTTTCCCCTCGACTCCCTGCAACTCGACGTCTCC
	GAGCTCAGCCCGCCAGGGACCGCCTTCCGCCTGCCAGTTGCCCACGATCCGGACGCCG
	GACTGTTCAGCACTCAGGGCTACACCCTGGTGCAACCGTCCGACCTGCCCAAGGACCC
	CGCAGGCCCGTTCTTCCAGTTGCGCTACCGGACTCCGGGGCCACTACCGTCACCGCTT
	TTGCCAGGCTCCTCGTCACCCCTGGAGCCTCTAGATCTGGTGCTGCTGCGGCGCTTGG
	ACCGAGAGGAGGCGGCGGCGCACCGGCTGCAGATCGAGGCATGGGACGCCGGCCGACC
	CCGGCGCACCGGCCTCCTGAGCGTGGAGCTGCGCGTGCTGGATGAGAACGACPACCCG
	CCGGTCTTTGAGCAGGACGAGTCCCGCGCCGCGGTGCGAGAGCACGCCCAGCCGGGCG
	CCGAGGTCTGTCGCGTGCGCGCCACCCCCCGCGACGTGGGGCCCAATGGCTTCGTGCG
	CTACAGCGTCCGCGCCCGGCAAGTGCCTGGGGCGGGTAGCGGCGGCGGGGCACTGGCC
	GACGCGGCCTACTTCGCGTTGGTGGTGGAGGCCCGCGATGGAGGCGCCGAGCATGAGG
	TTGCCGCGGTGCGTGTGTCCATCGCCGTGCTGGACGTGAATCACAACCGGCCAGCAAT
	TCACGTGCTCTTTCTCACACAGGGAGGTGTCGCCCGTGTCTCTGAAGGCGCCCCCCCG
	GGCGACTACGTGGCTCGCGTCTCGGTGTCTCACGCGGGCGGTGACTGGGAGAAGGAAG
	ATGAGGCCACAGGGGAGCTTGGTGTGACAGCCTCTGATGCAGATTCAGGACTCTATGG
	CTTTATTGAATATTCTCTTTATGATGGATTCCTGAGCTATCAAGCACCTCAGGCATTC
	CGGATCGACCCTCATGATGGGCAAATCTGTGTTTCTCAAGATATCGACAGGGAAAGGG
	ATCCAGCTACCTATGATCTCCTGGTGGAAGCTAAGGATGGGTTTGAAATCATGCCAGG
	TGCTTCATTTGAATTATTCGAGATAAATTCTGACACTGGAGAGGTAGTGACAACCACC
	ATACTTGACAGAGAAATTCAAGAAGTCTTCACCCTTCGAGTACTAGTACGAGATGGGG
	GATTCCCTTCATTGTCCAGCACCACAACAATCCTCTGCACTGTTGAAGATGAAAACGA
	TCACGCACCAGAGTTTATTGTTTCCAGTTATGACATTGAGGTTCTGGAAAACCAGGAA
	CCAGAGGTTGTCTATACGGTTTTACCCTCTGATATGGATGCTGGCAATAACAGAGCTG
	TTGAATATCACATAATTGACTCCTCAGAACCAATCTTTTACAGGATTTCTTCTGGTGA
	TCTCGGCGGAAAGTTCTCCATTCACCCGCGGCTGGGCACTATTCGCACCCGGAAGCCC
	CTGGATCACGAGACGCAGCCCGTGGTTGTGCTCACGGTGCAGGCGCAGCTCGGCAGCG
	CCCCAGCCTGCAGCAGCACCGAGGTCAACATAACAGTCATCGATGTCAATGACAACCA
	CCCACCGTTCCTCAGGACCTCGGATGAGATTAGAATATCCCAGACCACGCCCCCTGGC
	ACAGCCTTGTACCTCGCACGTGCGGAAGACAGAGACAGTGGGCGGAACGGACTCATCC
	GGTACTCCATCGCCAGCCCGCAGCCAGGCGTCTTTGCCATCGACAGAGCCCTGGGGGT
	GCTGTTCCTCAACGGCAGCCTGGGCGCGGGCGAGCAGCGGGAGCTCACGCTGACTCTC
	AGGGCCGAGGACCAAGGCGTGCATCCTCAGGCAGCCCTGCTGGTGCTGACAGTCGTTA
	TCGAGAAACGCGAACACAGCCCATCCTGGACTTTCGAACATTTGGTCTATCAAGTGGA
	AGTCAGTACTTCTATTGTGACTGTTAAAGCTTTTGCTCCTGACTCAATTCAGGACAGC
	ATGAAATATTCAATTTTTAGTGGAAATGAAGATGGAGTTCTTTCCCTGTGCTCTAAGT
	CAGGTGTGGTGAACTGCCTTGCTTCTCTCAGTCACACAGACTTTCTCTCCCTGAAATT
	TGAATCTTCGGTGAAGGGACACCAAGACAGAGACAAATTACAGCCAATTCATCTTGAT
	GACAACAACTCAAAGAAGCTGTGCTTTACATTCCCTAGAGCCACTCAGGCTCTTGTAT
	TCACTGGGCACTGTCTTTCTGATACATCTCTCCCCGGTTGGGTTTTTCCTACCGACTT
	GGACAGTGGTTTGAACGGCCTGATTGAGTATTCTATTCTGTCTGGCAACCAAGAAGAA
	GCATTCCAGATTGATGCACTGAGTGGTGTGATAACAACAAAAGCGATTCTAGATTACG
	AGCTCACCAGCTCCTACAGCTTGATTGTCCAAGCCACAGATAAAGGGATGCCCAGGCT
	TTCTAATACGACTGTAATCAAGGTACAGGTGACTGATATAAATGACAATGCCCCAGCT
	TTTCTCCCCTCTGAAGCAGTGGAAATTACAGAAGTCATGACTATTTCAGAAGATTCTT
	TGCCTGGTGTAATTGTGACTCATGTGTCAGTTCATGATGTGGATTTGAATTCAGCTTT
	CATATTCAGTTTTGCCAAAGAGAGTAATCCTGGAACCAAGTTTGCTATTGATCAGAAC
	ACTGGAGTGGTGGTGTTGGTGAAAACATTGGATTTTGAAGAAATGACTGAATATGAGC
	TGCTCATCCAAATTTCTGATTCAGTGCACTACACAGAGGGAGCACTTGTAGTCCGTGT
	GCTGGATGTCAATGATAATCCACCAGTGTTTTCTCAAGATTTCTATCAGGTCACAGTT
	CCTGAATCAATACCTGTGGCGTATTCAGTGCTGACTCTGTCAGCCACAGACTTAGAAA
	GCAATGAGAACATTTCTTACAGAATTCTATCCTCTTCTAAGGAATTCTCCATTGATCC
	TAAGAATGGCACAATATTTACTATCAGTCCCGTATTACTTCTGGATACAATATCAACA
	ACTCGATTTCTTGTGCAAGCCAGTGATGGTGGAAATCCTGACCCGAGAGCTCTTACTT
	TAGTGGAGATAGGAATAGAAGATATGAACAATTATGCCCCTGAATTCACAGTCAAATC
	CTATAATCTTAGCCTAAGTGAGCATGCTCTGGTTGGAAGCACGCTTGTTACATTTTCA
	AACATCOACCATGACTGGACCCGTGAAAACACATATGTTGAATATTCCATCATCAGTG
	GTAATTCACAGAACAATTTTCATGTGGAAACTAAGTTCTTTCATTCAGAATATCCTTA
	TAAGCAAGTCCGTTATCTTGTGTTGCTTCACAGTCTGGACAGAGAAGCAAGTGCTAGC
	CATGAGCTTGTCATTCTGGCATCTGACAGTGGCTGCCCTCCATTGAGTTCCACAGCTG
	TCATATCAATACAAGTACTTGATGTCAATGACAATCCCCCAAACTTCAGCAGCCTGAG
	CTATCACACCCATGTCAAGGAAAGCACCCCTCTAGGGAGTCACATCACTGTGGTCTCA
	GCAAATGACCGTGACACAGGGTCACATGCAGAAATCATCTACAACATCATCTCTGGAA
	ATGAGAAGGGACATTTTTACTTAGAAGAAAACACTGGAGTTCTTTATTTGATTAAACC
	TCTGGATTATGAAAAAATGACAAAATTCACCTTAACTGTCCAAGCTTCAGATGCAGAA
	AAGAAACATTTTTCTTTTGCAGTTGTGTTTGTCAGTGTCCTGGATGATAACGACCATG
	CACCTCAGTTTATGTTCTCAAGCTTCAGCTGTATTGTTCCAGAAAATCTGCCTATTTC
	CTCTACCATATGCTCTATAAATGCTCTGGATTTTGATGCTGGTCCGTATGGAGAATTG
	ACCTATTCTATTGTATCACCCTGTTTTCTCACTCATGGAATGTCTTATGATCATGATC
	TCTTCCTCATTGACCCTTTGACAGGGGATATTCATGCTAAGCAAATCCTTGACTATGA
	AAATGGCAATAAATACTGCCTCACAGTCCAAGCCAAAGACAAAGGTGATGCAACTGCC
	TCCTTAGTGGTCTGGCTGGATATTGAAGGGATAGATGAATTTGAGCCCATTTTCACTC
	AAGATCAGTATTTTTTCACCCTCCCAGAAAAGAATAAAGACAGACAGTTGATTGGCAG
	AGTGGAAGCCTCAGATGCAGATGCTGGTATTGATGGAGTCATTCTTTACTCCCTTGGA
	ACCTCATCTCCTTTCTTTTCAGTAAATAGAACCAATGGAAATATTTATTTGATTAGAG
	CCCTTCCCCTAATAAAAAGTCAACTCAACAAAGAAGACACCTTGGAAATGAAAATAAT
	CGCTCATAGTCCCAAATCAGATTCCAAGTTTGCATCTTGCACTGTTTTTGTGAATGTG
	TCTTTCTCCTCTGAAGGAACACCCTTGGCAGTGTTCGCCAGCAGCTTTTCAATCAGCC
	TGGTGGTCTCCTTTTTAGTGTTTCTGATACTCATCTGCATTCTAATTGTAATGATTTT
	AAGACATAAACAAAAAGACACAATAAACAATTATGAGGAGAAGAAAACCTCATCTTTA
	GATGCGGACTTGAGAGTGACCCGGGATGCCAGTGTGCTCAAAGCCTTCCAGPAAACTG
	ACGACTGCAGTAACGAGGTGGTCCCTGTGGATGCCACTCCCCAATCCTTCACTTTAAT
	AAGTATCATGGAGAAGGATATTGTCAATCTGTACAGATACTCAAACTCCAGTGGCCAC
	TGTTCTGTGGAAGGAGAAACTGCAGAAGATAAGGAAATCCAGAGGATAAATGAGCATC
	CCTACAGAAAGTGCTCAGACTCAGCTCTGAGTGACCACGAGTCCAGGGTGCCAGACTC
	GGGTATCCCGAGGGACTCACACCAGCTCTCCTGCCTATCTGGGGAAACTGATGTGATG
	GTGACTGCCGAAACAGCAGAAGCCAGCCAAACATTTGGGGAAGCAGATCAAGGGGAAG
	GCTGCAGCACCACCTGTGCTCAAAATAATGTGTTACCCCAGACAGTTCAGAAGAGAGA
	GGCAAAAGAGAGCATCCTGGCTGACGTTAGAAAAGAGTCTGTCTTTATTTCAGGTGAT
	CAGGAAGTAAGGTGTGCAGCTCTTTCAACTCAGACGACCTCTCATCATGATGGAAAAG
	ACAACTATCACTGGAATTATCTTCTTAGTTCGGAGCCCAAATTCCAACCTCTTGCCTC
	AGTATTTAATGATATTGCAAAACTAAAGGATGAACATTTGCATATGCCTGGCATTCCA
	AAAGAGAAGAAATCTTTTGTTTTTCCACCCCCTTTGATAACAGCAGTAGCCCAGCCTG
	GGATTAAAGCAGTCCCACCAAGAATGCCGCCAGTAAACCTGGGGCAGGTGCCTCCGAA
	ACACCCACGCTCTCCCATCCCCTACCATCTTGGTTCTCTGCCAGAAGGCATGACTCCC
	AATTTTTCTCCATCTCTTTCCCTATTGACGATGCAGCCTCCTGCCTTGTCTCCACTGT
	TGAGAGAAGGAGAATTATTAGGAACACACATCAGTGGTACATGCCATGAACTTAAAGC
	AGAAGATGAAGTTCAAATATGAAACCACTGGGATGCCAAGTACCTGCTCACCATTGGT
	CATGAATGAATGAACAAAATGTTTTCAAGCCGGCAACTCGAGATTGGGCTCATTTTTA
	TCTAAAAGCAAGTGATGTAATTTAGTTAGAGTTTTTAAAACTTCCCCATTAAAGTTTC
	TCCAATTTCAAAAAAAAAAAAAAAAAAAA
	ORF Start: ATG at 1	ORF Stop: TGA at 9010
	SEQ ID NO: 126	3003 aa	MW at 329184.0 kD
NOV28b,	MEKCGLKEEGSYADIDPVAHDPDAGLFSTQGYTLVQPSDLPKDPAGPFFQLRYRTPGP
CG58567-05 Protein	LPSPLLPGSSSPLEPLDLVLLRRLDREEAAAHRLQIEAWDGGRPRRTGLLSVELRVLD
Sequence	ENDNPPVFEQDEYRAAVREDAQPGAEVCRVRATDRDLGPNGFVRYSVRARQVPGAGSG
	GGALGDAAYFAVEELSGVVRVWRPLDREAQAWHQLVVEARDGGAEPEVATVRVSIAVL
	DVNDNRPAIHVLFLTEGGVARVSEGARPGDYVARVSVSDADGVIGKITAIDMDSGKNG
	QLLYFLLSDGKFFKMNPNTGELINWVALDREHRGHHEMTVLVTDRGSPPRNATMAVYV
	SVTDINDNRPFFPQCLPGKELHVKVLEGQPVNMLVTTVFAKDPDEGNNAEVTYSVSSE
	DSSDHFKIDANNGEIRTTTILSYDYRPSYRMSVIATDQGVPPLQGQAVVNIQELDYET
	TSHYLFRVITTDHSKNLSLSSTVFLSIDVEDQNDHSPSFQDELIVISVEENVPIGTLV
	YVFNAKDDDCSFLNSRIQYYIESHNPGTNPFLIHPSFGTLVTVSRLDRESIPTVILTV
	TASDQAVNVTDRRLRSLTAQIVILDVNDHNPTFISFPNAHVKEDVTVGSLVHHITAHD
	PDEGRNGKVTYSILSGNENMTFMLDESSGLLTTTCPLDYEMKTQHILTVLALDDGTPA
	LSSSQTLTVTVLDVNDEAPVFKQHLYEASVKENQNPGEFVTRVEALDRDSVFLNTREL
	NMCFLAFYDAVFKNGGLSAQAFVRVDLEDVNDNHPVFNPSTYVTSISDETQPGTEIIN
	VLATDQDSGIYGTVAYELIPGNVSSLFTIDSTTGIIYLTLPLSHLESTTLSLMVSAQD
	GGGLTAVINADVTIHIFQTTLAPAEFERPKYTFLVYEDVPEDSPIGTVKAREPLNPPR
	SSVIHLQVRVLDANDHSPSFPTLYYQSSVREDAEVGTVVLVLSAVDKDECLNGQTEYF
	LTDEACGAFTIDPMSGTLKTSNTLDREARSQHTFSAVARDCSIQGSRSTTVIIKVYVT
	DVNDNDPVLEQNPFDVFLSPESPTNQTTVIVRADDLDLGPNGTVDSDDSPLLDDFHVH
	PDTGIIRTARRLDRERRDHYSFVAATLLGAVVQVEIRVNDVNDHSPRFPLDSLQLDVS
	ELSPPGTAFRLPVAHDPDAGLFSTQGYTLVQPSDLPKDPAGPFFQLRYRTPGPLPSPL
	LPGSSSPLEPLDLVLLRRLDREEAAAHRLQIEAWDGGRPRRTGLLSVELRVLDENDNP
	PVFEQDESRAAVREHAQPGAEVCRVRATARDVGPNGFVRYSVRARQVPGAGSGGGALG
	DAAYFALVVEARDGGAEHEVAAVRVSIAVLDVNDNRPAIHVLFLTEGGVARVSEGARP
	GDYVARVSVSDAGGDWEKEDEATGELGVTASDADSGLYGFIEYSLYDGFLSYEAPQAF
	RIDPHDGQTCVSQDIDRERDPATYDLLVEAKDGFEIMPGASFELFEINSDTGEVVTTT
	ILDREIQEVFTLRVLVRDGGFPSLSSTTTILCTVEDENDHAPEFIVSSYDIEVLENQE
	PEVVYTVLASDMDAGNNRAVEYHIIDSSEPIFYRISSGDLCGKFSIHPRLGTIRTRKP
	LDHETQPVVVLTVQAQLGSAPACSSTEVNITVMDVNDNHPAFLRTSDEIRISQTTPPG
	TALYLAPAEDRDSGRNGLIRYSIASPQPGVFAIDRALGVLFLNGSLGAGEQRELTLTL
	RAEDQGVHPQAALLVLTVVIEKREHSPSWTFEHLVYQVEVSTSIVTVKAFAPDSIQDS
	MKYSIFSGNEDGVLSLCSKSGVVNCLASLSHTDFLSLKFESSvKGHQDRDKLQPIHLD
	DNNSKKLCFTFPRATQALVFTGHCLSDTSLPGWVFATDLDSGLNGLIEYSILSGNQEE
	AFQIDALSGVITTKAILDYELTSSYSLIVQATDKGMPRLSNTTVIKVQVTDINDNAPA
	FLPSEAVEITEVMTISEDSLPGVIVTHVSVHDVDLNSAFIFSFAKESNPGTKFAIDQN
	TGVVVLVKTLDFEEMTEYELLIQISDSVHYTEGALVVRVLDVNDNPPVFSQDFYQVTV
	PESIPVGYSVLTLSATDLESNENISYRILSSSKEFSIDPKNGTIFTISPVLLLDTIST
	TRFLVEASDGGNPDPRALTLVEIGIEDMNNYAPEFTVKSYNLSLSEDALVGSTLVTFS
	NIDHDWTRENTYVEYSIISGNSQNNFHVETKFFHSEYPYKQVGYLVLLHSLDREASAS
	HELVILASDSGCPPLSSTAVISIQVLDVNDNPPNFSSLSYHTHVKESTPLGSHITVVS
	ANDRDTGSHAEIIYNIISGNEKGHFYLEENTGVLYLIKPLDYEKMTKFTLTVQASDAE
	KKHFSFAVVFVSVLDDNDHAPQFMFSSFSCIVPENLPISSTICSINALDFDAGPYGEL
	TYSIVSPCFLTHGMSYDHDLFLIDPLTGDIHAKQILDYENGNKYCLTVQAKDKGDATA
	SLVVWVDIEGIDEFEPIFTQDQYFFTLPEKNKDRQLIGRVEASDADAGIDGVILYSLG
	TSSPFFSVNRTNGNIYLIRALPLIKSQLNKEDTLEMKIIAHSPKSDSKFASCTVFVNV
	SFSSEGTPLAVFASSFSISLVVSFLVFLILICILIVMILRHKQKDTINNYEEKKTSSL
	DADLRVTRDASVLKAFQKTDDCSNEVVPVDATPEWLSLISIMEKDIVNLYRYSNSSGH
	CSVEGETAEDKEIQRINEHPYRKCSDSALSDHESRVPDSGIPRDSDQLSCLSGETDVM
	VTAETAEASQTFGEGDQGEGCSTTCAQNNVLPQTVQKREAKESILADVRKESVFISGD
	QEVRCAALSTQTTSDHDGKDNYHWNYLLSWEPKPQPLASVFNDIAKLKDEHLHMPGIP
	KEKKSFVFPPPLITAVAQPGIKAVPPRMPAVNLGQVPPKHPRSPIPYHLGSLPEGMTP
	NFSPSLSLLTMQPPALSPLLREGELLGTHISGTCHELKAEDEVQI
	SEQ ID NO: 127	10267 bp
NOV28c,	ATGGAGAAATGTGGGCTTAAAGAGGAAGGCAGTTACGCGGACATAGATCCAGTTGCCC
CG58567-06 DNA	ACGATCCGGACGCCCCACTCTTCAGCACTCAGGGCTACACCCTGGTGCAACCGTCCGA
Sequence	CCTGCCCAAGGACCCCGCAGGCCCGTTCTTCCAGTTGCGCTACCGGACTCCGGGGCCA
	CTACCGTCACCGCTTTTGCCAGGCTCCTCGTCACCCCTGGAGCCTCTAGATCTGGTGC
	TGCTGCGGCGCTTGGACCGAGAGGAGGCGGCGGCGCACCGGCTGCAGATCGAGGCATG
	GGACGGCGGCCGACCCCGGCGCACCGGCCTCCTGAGCGTGGAGCTGCGCGTGCTGGAT
	GAGAACGACAACCCGCCGGTCTTTGAGCAGGACGAGTACCGCGCCGCGGTGCGCGAGG
	ACGCCCAGCCGGGCGCCGAGGTCTGTCGCGTGCGCGCCACCGACCGCGACCTGGGGCC
	CAATGGCTTCGTGCGCTACAGCGTCCGCGCCCGGCAAGTGCCTGGGGCGGGTAGCGGC
	GGCGGGGCACTGGGCGACGCGGCCTACTTCGCGGTGGAGGAGCTGAGCGGCGTGGTGC
	GAGTGTGGAGACCTCTGGACCGCGAGGCACAGCCCTGGCACCAGTTGGTGGTGGAGGC
	CCGCGATGGAGGCGCCGAGCCTGAGGTTGCCACGGTGCGCGTGTCCATCGCCCTGCTG
	GACGTGAATGACAACCCGCCAGCAATTCACGTGCTCTTTCTCACAGAGGGAGGCGTCG
	CCCGTGTCTCTGAAGGCGCCCGACCGGGCGACTACGTGGCTCGCGTCTCGGTGTCTGA
	CGCGGACGGTGACTGGGAGAAGGAAGATGAGGCCACAGGGGAGCTTCGTGTGGGTCTT
	GGAGACGGGAGCATCTCTCTGTCCTTGCAAGGCGGAGAGGGAGACTTCGCGTTGCTAC
	CCGGCGGCCCCCCAGGGGTATTTTTCCTTTGCCTGGAGGGGCCCCTGGACAGAGAGAG
	CCGCGATCTGTATGAGTTACTACTGGTGGCCACGCACGCGGGGTCCCCGCCGCTGAGC
	ACGGAGGAGACGCTGCTACTCCGGGTCGCTGACCTCAATGACCAACCACCTCTCTTCA
	GCCAACAGCATTACAAGGCCTCAGTGTCCGAGGCCGCCGCCCCTGGCACTGTAGTCAT
	GTGGGTCAGCGCCTCCGATGCCGACGAGGCAGGCAGTGATCACGCCTGGCTCCGCTAC
	ACTGTAGTCCAACTCTCGGCTCCCTGCAATCTCGGCTCCCTGCAATCAAAGATGGTCC
	ACACCGCAGAGTGTGGACCATCTTTTGCCATTGATTCCGAAAGCGGTGCGATCAGCAC
	TATCCGGACTCTAGACCGAGAGGTCCAGGAGGCGGTGGAGCTGAAAGTGCTGGCCCAG
	GACCTCGGAGAGCCCCCACTCTCTGCCACCTGCCTGGTGAGCATCACCGTAGATGATG
	TGAATGACAATGAGCCCATCTTCTGGAGGCAGGTGTACAATGCCACCATTGCAGAGCA
	TGCCCCGGTTGGACACTGCTTTCTGCAGCTTATATCTGCTCAAGTTGCCTCTGTCAAA
	ATCAAACACAAACACAAGGAGATACACGAGAAACACAATCTTGCCTATATTTCCTGTC
	CAGCACGCACCATCTATGTCATAACCTGGGCAGATGGTGCTGCTGCCTTTACTGGGAC
	AGACTTTGCATTCAGTTCTGATGAACTTCAAGCCTTTGTTCTCAAGTCTCTGTTCTGT
	GAATTAGGAGAAGGAGAGTTAATCAATTGGGTGGCACTGGATCGTGAGCACCGGGGGC
	ACCATGAGATGACTGTGCTAGTGACAGACCGCGGCTCCCCACCACGAAACGCCACCAT
	CGCGCTTTACGTCTCAGTTACTCACATCAATGATAACAGGCCCTTCTTCCCCCAGTGT
	CTCCCTGGAAAGGAGTTACACGTGAAGGTTCTGGAAGGTCAACCAGTAAATATGTTGG
	TTACAACTGTGTTTGCAAAGGATCCTGATGAAGGAAATAATGCAGAAGTTACATACTC
	AGTATCTTCAGAAGATAGTTCTGATCACTTTAAGATTGACGCCAACAATGGTGAAATA
	AGAACAACCACAATACTTTCGTATGATTATAGACCTTCCTACAGAATGAGTGTCATTG
	CCACTGACCAGGGAGTGCCTCCTCTTCAAGGACAGGCAGTTGTTAATATTCAGGTGAT
	CCCACTATCCAAAGGGAGAGCAATCATGTCTCAGAATATTAGACATTTAATTATACCA
	GAAAATTTGAAGCCCACAAAAATAATGAGCTTGATAAAGTCATCTGATCACCTTCAAC
	AACATTATAATGGAAAGTTACATTTTAGTATTGTTGCAGATGATAAGGATGGACACTT
	TGAAATAGACAGCTCAACCGGAGACTTGTTTCTTTCTAACGAACTTCATTATGAGACG
	ACATCTCATTATCTTTTCAGAGTGATTACTACAGACCATAGCAAAAACCTTTCCCTGA
	GTAGCACAGTCTTCCTTAGTATCGATGTGGAAGATCAGAATGACCATTCCCCATCTTT
	CCAGGATGAGCTCATTGTGATCAGTGTAGAGGAGAATGTTCCCATAGGAACCCTGGTG
	TATGTCTTCAATGCCAAAGATGATGACGGCAGTTTTTTGAACAGTAGAATACAATACT
	ACATTGAATCCCACAACCCTCGCACGAATCCATTTCTCATCCACCCCTCATTTGGCAC
	ACTAGTCACTGTCTCCCGTCTTGACAGAGAAAGCATTCCAACTGTCATCCTGACAGTA
	ACAGCATCTGATCAGGCTGTGAATGTGACAGACCGGCGACTGAGATCACTGACAGCAC
	AAATAGTGATTTTGGATGTAAATGACCACAACCCCACTTTTATTTCTTTCCCCAATGC
	CCATGTCAAAGAGGATGTCACAGTGGGCTCCTTGGTCCACCACATAACTGCTCACGAT
	CCAGACGAAGGAAGGAATGGAAAAGTAACATACAGCATCCTCTCAGGAAATGAAAACA
	TGACGTTTATGCTACATGAGTCATCAGGCTTACTAACCACAACCTGTCCTTTGGATTA
	TGAAATGAAAACTCAGCATATTCTGACTGTTCTGGCACTGGATGATGGCACACCAGCA
	CTTTCTTCATCCCAGACTTTGACAGTTACTGTTCTTGATGTAAATGATGAAGCTCCAG
	TATTTAAGCAGCACCTGTATGAAGCCTCAGTGAAAGAAAACCAAAATCCAGGGGAGTT
	TGTTACCAGGGTTGAAGCTCTGGACAGAGATTCAGGTATGAGGCTGAATGGAGATCCA
	GACAGGGAGCTGTGTGCAGGAGGGAACCCTCTTGGAAGCAGGGCCCCTCCTGGAAGCA
	GGACCCCTCCTGAAGGTGGGCTAAGTGCCCAAGCCTTTGTTCGTGTGGACCTGGAGGA
	CGTGAATGATAATCATCCTGTGTTTAACCCATCAACCTATGTGACGAGCATCAGTGAT
	GAGACCCAGCCAGGCACCGAGATCATCAATGTTCTTGCCACTGACCAGGACTCTGGGA
	TATATGGGACAGTGGCTTATGAGCTTATTCCAGCAAACGTGTCGTCCCTTTTTACCAT
	TGACTCCACCACAGGAATTATTTACTTAACATTACCTCTTAGTCATTTGGAATCTACC
	ACACTTTCGTTGATGGTCTCTGCTCAAGACGGTGGTGGGCTCACAGCTGTCATTAATG
	CCGATCTCACCATACACATTTTCCAGACAACTCTGGCACCTGCTGAGTTTGAAAGGCC
	TAAGTACACTTTCTTAGTTTATGAAGATGTGCCTGAAGATAGTCCCATTGGAACAGTG
	AAAGCAAGAGAGCCCTTGAATCCACCTAGGAGCTCTGTAATACACCTCCAAGTTAGAG
	TTTTGGATGCCAATGACCACAGTCCTTCTTTTCCCACACTTTATTACCAGTCCTCTGT
	GAGAGAAGATGCTGAAGTGGGAACAGTGGTTCTTGTGCTTTCAGCTGTGGACAAGGAT
	GAAGGCCTGAATGGGCAAACTGAGTATTTTCTGACTGATGAGGCTTGTGGTGCATTCA
	CCATTGATCCTATGTCAGGCACATTGAAAACCAGCAACACCCTCGACCGTGAAGCCAG
	ATCTCAGCATACATTTAGTGCTGTGGCCAGAGACTGTAGCATCCAGGGTTCACGAAGC
	ACCACTGTAATTATAAAAGTATATGTCACTGATGTTAATGACAATGATCCAGTTTTGG
	AACAGAACCCTTTTGATGTGTTTCTTTCCCCCCAGTCGCCTACAAACCAGACAACTGT
	CATTGTGAGAGCTGATGACCTGGACTTGGGGCCCAATGGAACTGTGGACTCCGATGAC
	TCCCCGCTGCTGGACGACTTCCACGTGCACCCGGACACCGCCATCATCCGCACTGCGC
	GGCGCCTGGACCGCGAGCGGCGGGACCACTACAGCTTCGTCGCCGCCACGCTGCTGGG
	CGCTGTGCTGCAGGTGGAGATTCGCGTCAACGACGTGAATGACCACTCCCCCCGCTTT
	CCCCTCGACTCCCTGCAACTCGACGTCTCCGAGCTCAGCCCGCCAGGGACCCCCTTCC
	GCCTGCCAGTTGCCCACGATCCGGACGCCGGACTGTTCAGCACTCAGGGCTACACCCT
	GGTGCAACCGTCCGACCTGCCCAAGGACCCCGCAGGCCCGTTCTTCCAGTTGCGCTAC
	CGGACTCCGCGGCCACTACCGTCACCGCTTTTGCCAGGCTCCTCGTCACCCCTGGAGC
	CTCTAGATCTGGTGCTGCTGCGGCCCTTGGACCCAGAGGAGGCGGCGCCCCACCGGCT
	GCAGATCGAGGCATGGGACGGCGGCCGACCCCGGCCCACCGGCCTCCTGAGCGTGGAG
	CTGCGCGTGCTGGATGAGAACGACAACCCGCCGGTCTTTGAGCACGACGAGTCCCGCG
	CCGCGGTGCGAGAGCACGCCCAGCCGGGCGCCGAGGTCTGTCGCGTCCCCGCCACCGC
	CCGCGACGTGGGGCCCAATGGCTTCGTGCGCTACAGCGTCCGCGCCCGGCAAGTGCCT
	GGGGCGGGTAGCGGCGGCGGGGCACTGGGCGACGCGGCCTACTTCGCGTTGGTGGTGG
	AGGCCCGCGATGGAGGCGCCGAGCATGAGGTTGCCGCGGTGCGTGTGTCCATCGCCGT
	GCTGGACGTGAATGACAACCGGCCAGCAATTCACGTGCTCTTTCTCACAGAGGGAGGT
	GTCGCCCGTGTCTCTGAAGGCGCCCGCCCGGGCGACTACGTGGCTCGCGTCTCGGTGT
	CTGACGCGGGCGGTGACTGGGAGAAGGAAGATGAGGCCACAGGGGACCTTCCTCTCAC
	AGCCTCTGATGCAGATTCAGGACTCTATGGCTTTATTGAATATTCTCTTTATGATGGA
	TTCCTGAGCTATGAAGCACCTCAGGCATTCCGGATCGACCCTCATGATGGGCAAATCT
	GTGTTTCTCAACATATCGACAGGGAAAGGGATCCAGCTACCTATGATCTCCTGGTGGA
	AGCTAAGGATGGGTTTGAAATCATCCCACGTGCTTCATTTGAATTATTCGAGATAAAT
	TCTGACACTGGAGAGGTAGTGACAACCACCATACTTGACAGAGAAATTCAAGAAGTCT
	TCACCCTTCGAGTACTAGTACGAGATGGGGGATTCCCTTCATTGTCCAGCACCACAAC
	AATCCTCTGCACTCTTGAAGATGAAAACGATCACGCACCAGAGTTTATTGTTTCCAGT
	TATGACATTGAGGTTCTGGAAAACCAGGAACCAGAGGTTGTCTATACGGTTTTAGCCT
	CTGATATGGATGCTGGCAATAACAGAGCTGTTGAATATCACATAATTCACTCCTCAGA
	ACCAATCTTTTACAGGATTTCTTCTGGTGATCTCGGCGGAAAGTTCTCCATTCACCCG
	CGGCTGGGCACTATTCGCACCCGGAAGCGCCTCGATCACGAGACGCAGCCCGTGGTTG
	TGCTCACGGTGCAGGCGCAGCTCGGCAGCGCCCCAGCCTGCAGCAGCACCGAGGTCAA
	CATAACAGTCATGGATGTCAATGACAACCACCCAGCGTTCCTCAGGACCTCGGATGAG
	ATTAGAATATCCCAGACCACGCCCCCTGGCACAGCCTTGTACCTCGCACGTGCGGAAG
	ACAOAGACAGTGGGCGGAACGGACTCATCCGGTACTCCATCGCCAGCCCGCAGCCAGG
	CGTCTTTGCCATCGACAGAGCCCTGGGGGTGCTGTTCCTCAACGGCAGCCTGGCCGCG
	GGCGAGCAGCGGGAGCTCACGCTGACTCTCAGCGCCGAGGACCAAGGCGTGCATCCTC
	AGGCAGCCCTGCTGGTGCTGACAGTCGTTATCGAGAAACGCGAACACAGCCCATCCTG
	GACTTTCGAACATTTGGTCTATCAAGTGGAAGTCAGTACTTCTATTGTGACTGTTAAA
	GCTTTTGCTCCTGACTCAATTCAGCACAGCATGAAATATTCAATTTTTAGTGGAAATG
	AAGATGGAGTTCTTTCCCTGTGCTCTAAGTCAGGTGTGGTGAACTGCCTTGCTTCTCT
	CAGTCACACAGACTTTCTCTCCCTGAAATTTGAATCTTCGGTGAAGCGACACCAAGAC
	AGAGACAAATTACAGCCAATTCATCTTGATGACAACAACTCAAAGAAGCTGTGCTTTA
	CATTCCCTAGAGCCACTCAGGCTCTTGTATTCACTGCGCACTGTCTTTCTGATACATC
	TCTCCCCGGTTGGGTTTTTGCTACCGACTTGGACAGTGGTTTGAACGGCCTGATTGAG
	TATTCTATTCTGTCTOGCAACCAAGAAGAAGCATTCCAGATTGATGCACTGAGTGGTG
	TGATAACAACAAAACCGATTCTAGATTACGAGCTCACCAGCTCCTACAGCTTGATTGT
	CCAAGCCACAGATAAAGGGATGCCCAGGCTTTCTAATACGACTGTAATCAAGGTACAG
	GTGACTGATATAAATGACAATGCCCCAGCTTTTCTCCCCTCTGAAGCAGTGGAAATTA
	CAGAACTCATGACTATTTCAGAAGATTCTTTGCCTGGTGTAATTGTGACTCATCTGTC
	AGTTCATGATGTGGATTTGAATTCAGCTTTCATATTCAGTTTTGCCAAAGAGAGTAAT
	CCTGGAACCAAGTTTGCTATTGATCAGAACACTGGAGTGGTGGTGTTGGTGAAAACAT
	TGGATTTTGAAGAAATGACTGAATATGAGCTGCTCATCCAAATTTCTGATTCAGTGCA
	CTACACAGAGGGAGCACTTGTAGTCCGTGTGCTGGATGTCAATGATAATCCACCAGTG
	TTTTCTCAAGATTTCTATCAGGTCACAGTTCCTGAATCAATACCTGTGGGGTATTCAG
	TGCTGACTCTGTCAGCCACAGACTTAGAAAGCAATGAGAACATTTCTTACAGAATTCT
	ATCCTCTTCTAAGGAATTCTCCATTGATCCTAAGAATGGCACAATATTTACTATCAGT
	CCCGTATTACTTCTGGATACAATATCAACAACTCGATTTCTTGTGGAAGCCAGTGATG
	GTGGAAATCCTGACCCGAGAGCTCTTACTTTAGTGGAGATAGGAATAGAAGATATGAA
	CAATTATCCCCCTGAATTCACAGTCAAATCCTATAATCTTAGCCTAAGTGAGGATGCT
	CTGGTTGGAAGCACGCTTGTTACATTTTCAAACATCGACCATGACTGGACCCGTGAAA
	ACACATATGTTGAATATTCCATCATCAGTGGTAATTCACAGAACAATTTTCATGTGGA
	AACTAAGTTCTTTCATTCAGAATATCCTTATAAGCAAGTCGGTTATCTTGTGTTCCTT
	CACAGTCTGGACAGAGAAGCAAGTGCTAGCCATGAGCTTGTCATTCTGGCATCTGACA
	GTCGCTGCCCTCCATTGAGTTCCACAGCTGTCATATCAATACAAGTACTTGATGTCAA
	TGACAATCCCCCAAACTTCAGCAGCCTGAGCTATCACACCCATGTCAAGGAAAGCACC
	CCTCTAGGGAGTCACATCACTGTGGTCTCAGCAAATGACCGTGACACAGGGTCACATG
	CAGAAATCATCTACAACATCATCTCTGGAAATGAGAAGGGACATTTTTACTTAGAAGA
	AAACACTGGAGTTCTTTATTTGATTAAACCTCTGGATTATGAAAAAATGACAAAATTC
	ACCTTAACTGTCCAAGCTTCAGATGCAGAAAAGAAACATTTTTCTTTTGCAGTTGTGT
	TTGTCAGTGTCCTGGATGATAACGACCATGCACCTCAGTTTATGTTCTCAAGCTTCAG
	CTGTATTGTTCCAGAAAATCTGCCTATTTCCTCTACCATATGCTCTATAAATGCTCTG
	GATTTTGATGCTGGTCCGTATGGAGAATTGACCTATTCTATTGTATCACCCTGTTTTC
	TCACTCATGCAATGTCTTATGATCATGATCTCTTCCTCATTGACCCTTTGACAGGGGA
	TATTCATGCTAAGCAAATCCTTGACTATGAAAATGGCAATAAATACTGCCTCACAGTC
	CAAGCCAAAGACAAACCTGATCCAACTCCCTCCTTACTCCTCTCCCTCCATATTGAAG
	GGATAGATGAATTTGAGCCCATTTTCACTCAAGATCAGTATTTTTTCACCCTCCCAGA
	AAAGAATAAAGACAGACAGTTGATTGGCAGAGTGGAAGCCTCAGATGCAGATGCTGGT
	ATTGATGCAGTCATTCTTTACTCCCTTGGAACCTCATCTCCTTTCTTTTCAGTAAATA
	GAACCAATGGAAATATTTATTTGATTAGAGCCCTTCCCCTAATAAAAAGTCAACTCAA
	CAAAGAAGACACCTTGGAAATGAAAATAATCGCTCATACTCCCAAATCAGATTCCAAG
	TTTGCATCTTGCACTGTTTTTGTGAATGTGTCTTTCTCCTCTGAAGGAACACCCTTGG
	CAGTGTTCGCCAGCAGCTTTTCAATCAGCCTGGTGGTCTCCTTTTTAGTGTTTCTCAT
	ACTCATCTGCATTCTAATTGTAATGATTTTAAGACATAAACAAAAAGACACAATAAAC
	AATTATGAGGAGAAGAAAACCTCATCTTTAGATGCGGACTTGAGAGTGACCCGGGATG
	CCAGTGTGCTCAAAGCCTTCCAGAAAACTGACGACTGCAGTAACGAGGTGGTCCCTGT
	GGATGCCACTCCGGAATGGTTGAGTTTAATAAGTATCATGGAGAAGGATATTGTCAAT
	CTGTACAGATACTCAAACTCCAGTGGCCACTGTTCTGTGGAAGGAGAAACTGCAGAAG
	ATAAGGAAATCCAGAGGATAAATGAGCATCCCTACAGAAAGTGCTCAGACTCAGCTCT
	GAGTGACCACGAGTCCAGGGTGCCAGACTCGGGTATCCCGAGGCACTCAGACCAGCTC
	TCCTGCCTATCTGCGGAAACTGATGTGATGGTGACTGCCGAAACAGCAGAACCCAGCC
	AAACATTTGGGGAAGGAGATCAAGGGGAAGGCTGCAGCACCACCTGTGCTCAAAATAA
	TGTGTTACCCCAGACAGTTCAGAAGAGAGAGGCAAAAGAGAGCATCCTGGCTGACGTT
	AGAAAAGAGTCTGTCTTTATTTCAGGTGATCAGGAAGTAAGGTGTGCAGCTCTTTCAA
	CTCAGACGACCTCTGATCATGATGGAAAAGACAACTATCACTGGAATTATCTTCTTAG
	TTGGGAGCCCAAATTCCAACCTCTTGCCTCAGTATTTAATGATATTGCAAAACTAAAG
	GATGAACATTTGCATATGCCTGGCATTCCAAAAGAGAAGAAATCTTTTGTTTTTCCAC
	CCCCTTTGATAACAGCAGTAGCCCAGCCTGGGATTAAAGCAGTCCCACCAAGAATGCC
	GGCAGTAAACCTGGGGCAGGTGCCTCCGAAACACCCACGCTCTCCCATCCCCTACCAT
	CTTGGTTCTCTGCCAGAAGGCATGACTCCCAATTTTTCTCCATCTCTTTCCCTATTGA
	CCATGCAGCCTCCTGCCTTGTCTCCACTGTTGAGAGAAGGAGAATTATTAGGAACACA
	CATCAGTGGTACATGCCATGAACTTAAAGCAGAAGATGAAGTTCAAATATGAAACCAC
	TGGGATGCCAAGTACCTGCTCACCATTGGTCATGAATGAATGAACAAAATGTTTTCAA
	GCCGGCAACTCGAGATTGGGCTCATTTTTATCTAAAAGCAAGTGATGTAATTTAGTTA
	GAGTTTTTAAAACTTCCCCATTAAAGTTTCTCCAATTTCAAAAAAAAAAAAAAAAAAA
	A
	ORF Start: ATG at 1	ORF Stop: TGA at 10084
	SEQ ID NO: 128	3361 aa	MW at 367309.1 kD
NOV28c,	MEKCGLKEEGSYADIDPVAHDPDAGLFSTQGYTLVQPSDLPKDPAGPFFQLRYRTPGP
CG58567-06 Protein	LPSPLLPGSSSPLEPLDLVLLRRLDREEAAAHRLQIEAWDGGRPRRTGLLSVELRVLD
Sequence	ENDNPPVFEQDEYRAAVREDAQPGAEVCRVRATDRDLGPNGFVRYSVRARQVPGACSG
	GGALGDAAYFAVEELSGVVRVWRPLDREAQAWHQLVVEARDGGAEPEVATVRVSIAVL
	DVNDNRPAIHVLFLTEGGVARVSEGARPGDYVARVSVSDADGDWEKEDEATGELGVGL
	GDGSISLSLEGGEGDFALLPGGPPGVFFLCVEGPLDRESRDLYELLLVATDAGSPPLS
	TEETLLLRVADLNDQPPLFSQQHYKASVSEAAAPGTVVMWVSASDADEAGSDHAWLRY
	TVVQLSAPCNLGSLQSKMVHTAECGPSFAIDSESGAISTIRTLDPEVQEAVELKVVAQ
	DLGEPPLSATCLVSITVDDVNDNEPIFWRQVYNATIAEHAPVGHCFLQLISAQVASVK
	IKHKHKEIHEKHNLAYISCPAGTIYVITWADGAAAFSGTDFAFSSDELQAFVLKSLFC
	ELGEGELINWVALDREHRGHHEMTVLVTDRGSPPRNATMAVYVSVTDINDNRPFFPQC
	LPGKELHVKVLEGQPVNMLVTTVFAKDPDEGNNAEVTYSVSSEDSSDHFKIDANNGEI
	RTTTILSYDYRPSYRMSVIATDQGVPPLQGQAVVNIQVIPLSKGRAIMSQNIRHLIIP
	ENLKPTKIMSLIKSSDHLQQHYNGKLHFSIVADDKDGHFEIDSSTGDLFLSKELDYET
	TSHYLFRVITTDHSKNLSLSSTVFLSIDVEDQNDHSPSFQDELIVISVEENVPIGTLV
	YVFNAKDDDGSFLNSRIQYYIESHNPGTNPFLIHPSFGTLVTVSRLDRESIPTVILTV
	TASDQAVNVTDRRLRSLTAQIVILDVNDHNPTFISFPNAHVKEDVTVGSLVHHITAHD
	PDEGRNGKVTYSILSGNENMTFMLDESSGLLTTTCPLDYEMKTQHILTVLALDDGTPA
	LSSSQTLTVTVLDVNDEAPVFKQHLYEASVKENQNPGEFVTRVEALDRDSGMRLNGDP
	DRELCAGGNPLGSRAPPGSRTPPEGGLSAQAFVRVDLEDVNDNHPVFNPSTYVTSISD
	ETQPGTEIINVLATDQDSGIYGTVAYELIPGNVSSLFTIDSTTGIIYLTLPLSHLEST
	TLSLMVSAQDGGGLTAVINADVTIHIFQTTLAPAEFERPKYTFLVYEDVPEDSPIGTV
	KAREPLNPPRSSVIHLQVRVLDANDHSPSFPTLYYQSSVREDAEVGTVVLVLSAVDKD
	EGLNGQTEYFLTDEACGAFTIDPMSGTLKTSNTLDREARSQHTFSAVARDCSIQGSRS
	TTVIIKVYVTDVNDNDPVLEQNPEDVELSPESPTNQTTVIVRADDLDLGPNGTVDSDD
	SPLLDDFHVHPDTGIIRTARRLDRERRDHYSFVAATLLGAVVQVEIRVNDVNDHSPRF
	PLDSLQLDVSELSPPGTAFRLPVAHDPDAGLFSTQGYTLVQPSDLPKDPAGPFFQLRY
	RTPGPLPSPLLPGSSSPLEPLDLVLLRRLDREEAAAHRLQIEAWDGGRPRRTGLLSVE
	LRVLDENDNPPVFEQDESRAAVREHAQPGAEVCRVRATARDVGPNGFVRYSVRARQVP
	GAGSGGGALGDAAYFALVVEARDGGAEHEVAAVRVSIAVLDVNDNRPAIHVLFLTEGG
	VARVSEGARPGDYVARVSVSDAGGDWEKEDEATGELGVTASDADSGLYGFIEYSLYDG
	FLSYEAPQAFRIDPHDGQICVSQDIDRERDPATYDLLVEAKDGFEIMPGASFELFEIN
	SDTGEVVTTTILDREIQEVFTLRVLVRDGGFPSLSSTTTILCTVEDENDHAPEFIVSS
	YDIEVLENQEPEVVYTVLASDMDAGNNRAVEYHIIDSSEPIFYRISSGDLGGKFSIHP
	RLGTIRTRKPLDHETQPVVVLTVQAQLGSAPACSSTEVNITVMDVNDNHPAFLRTSDE
	IRISQTTPPGTALYLARAEDRDSGRNGLIRYSIASPQPGVFAIDRALGVLFLNGSLGA
	GEQRELTLTLRAEDQGVHPQAALLVLTVVIEKREHSPSWTFEHLVYQVEVSTSIVTVK
	AFAPDSIQDSMKYSIFSGNEDGVLSLCSKSGVVNCLASLSHTDFLSLKFESSVKGHQD
	RDKLQPIHLDDNNSKKLCFTFPRATQALVFTGHCLSDTSLPGWVFATDLDSGLNGLIE
	YSILSGNQEEAFQIDALSGVITTKAILDYELTSSYSLIVQATDKGMPRLSNTTVIKVQ
	VTDINDNAPAFLPSEAVEITEVMTISEDSLPGVIVTHVSVHDVDLNSAFIFSFAKESN
	PGTKFAIDQNTGVVVLVKTLDFEEMTEYELLIQISDSVHYTEGALVVRVLDVNDNPPV
	FSQDFYQVTVPESIPVGYSVLTLSATDLESNENISYRILSSSKEFSIDPKNGTIFTIS
	PVLLLDTISTTRFLVEASDGGNPDPRALTLVEIGIEDMNNYAPEFTVKSYNLSLSEDA
	LVGSTLVTFSNIDHDWTRENTYVEYSIISGNSQNNFHVETKFFHSEYPYKQVGYLVLL
	HSLDREASASHELVILASDSGCPPLSSTAVISIQVLDVNDNPPNFSSLSYHTHVKEST
	PLGSHITVVSANDRDTGSHAEIIYNIISGNEKGHFYLEENTGVLYLIKPLDYEKMTKF
	TLTVQASDAEKKHFSFAVVFVSVLDDNDHAPQFMFSSFSCIVPENLPISSTICSINAL
	DFDAGPYGELTYSIVSPCFLTHGMSYDHDLFLIDPLTGDIHAKQILDYENGNKYCLTV
	QAKDKGDATASLVVNVDIEGIDEFEPIFTQDQYFFTLPEKNKDRQLIGRVEASDADAG
	IDGVILYSLGTSSPFFSVNRTNGNIYLIRALPLIKSQLNKEDTLEMKIIAHSPKSDSK
	FASCTVFVNVSFSSEGTPLAVFASSFSISLVVSFLVFLILICILIVMILRHKQKDTIN
	NYEEKKTSSLDADLRVTRDASVLKAFQKTDDCSNEVVPVDATPEWLSLISIMEKDIVN
	LYRYSNSSGHCSVEGETAEDKEIQRINEHPYRKCSDSALSDHESRVPDSGIPRDSDQL
	SCLSGETDVMVTAETAEASQTFGEGDQGEGCSTTCAQNNVLPQTVQKREAKESILADV
	RKESVFISGDQEVRCAALSTQTTSDHDGKDNYHWNYLLSWEPKFQPLASVFNDIAKLK
	DEHLHMPGIPKEKKSFVFPPPLITAVAQPGIKAVPPRMPAVNLGQVPPKHPRSPIPYH
	LGSLPEGMTPNFSPSLSLLTMQPPALSPLLREGELLGTHISGTCHELKAEDEVQI

[0464] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 28B.

TABLE 28B
Comparison of NOV28a against NOV28b through NOV28c.
		Identities/
	NOV28a Residues/	Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV28b	1 . . . 1063	1037/1063 (97%)
	1941 . . . 3003	1037/1063 (97%)
NOV28c	1 . . . 1063	1037/1063 (97%)
	2299 . . . 3361	1037/1063 (97%)

[0465] Further analysis of the NOV28a protein yielded the following properties shown in Table 28C.

TABLE 28C
Protein Sequence Properties NOV28a
PSort:    0.8000 probability located in mitochondrial inner membrane;
analysis: 0.7000 probability-located in plasma membrane;
          0.3000 probability located in microbody
          (peroxisome); 0.2000 probability located
          in endoplasmic reticulum (membrane)
SignalP   No Known Signal Sequence Indicated
analysis:

[0466] A search of the NOV28a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 28D.

TABLE 28D
Geneseq Results for NOV28a
		NOV28a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAU68533	Human novel cytokine encoded by	1 . . . 646	212/680	(31%)	2e−76
	cDNA 790CIP2C_4 #1 -	425 . . . 1072	338/680	(49%)
	Homo sapiens, 3014 aa.
	[WO200175093-A1,
	11-OCT-2001]
AAE08586	Human NOV7 protein - Homo sapiens,	1 . . . 646	212/680	(31%)	2e−76
	3028 aa. [WO200161009-A2,	425 . . . 1072	338/680	(49%)
	23-AUG-2001]
AAU02196	Seven-pass transmembrane receptor-	1 . . . 646	212/680	(31%)	2e−76
	like protein, MEM1 - Homo sapiens,	425 . . . 1072	338/680	(49%)
	3014 aa. [WO200144473-A2,
	21-JUN-2001]
AAU07054	Human Flamingo protein encoded by	1 . . . 611	198/627	(31%)	1e−73
	2923 aa. [WO20016003-A1,	365 . . . 960	312/627	(49%)
	23-AUG-2001]
AAU07053	Human Flamingo polypeptide - Homo	1 . . . 611	198/627	(31%)	1e−73
	sapiens, 2956 aa. [WO200161003-A1,	365 . . . 960	312/627	(49%)
	23-AUG-2001]

[0467] In a BLAST search of public sequence databases, the NOV28a protein was found to have homology to the proteins shown in the BLASTP data in Table 28E.

TABLE 28E
Public BLASTP Results for NOV28a
		NOV28a	Identities
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9NXU8	CDNA FLJ20047 FIS, CLONE	105 . . . 1063	959/959	(100%)	0.0
	COL00577 - Homo sapiens (Human),	1 . . . 959	959/959	(100%)
	959 aa.
Q9NRU0	CADHERIN-LIKE PROTEIN VR8 -	189 . . . 582	391/394	(99%)	0.0
	Homo sapiens (Human), 398 aa	5 . . . 398	393/394	(99%)
	(fragment).
Q96JQ0	KIAA1773 PROTEIN - Homo	1 . . . 1036	366/1073	(34%)	e−148
	sapiens (Human), 3298 aa.	2245 . . . 3270	543/1073	(50%)
Q24292	DACHSOUS PROTEIN	1 . . . 1037	327/1165	(28%)	e−100
	PRECURSOR (ADHERIN) -	2343 . . . 3471	528/1165	(45%)
	Drosophila melanogaster (Fruit fly),
	3503 aa.
Q9Y526	DJ439F8.2 (SUPPORTED BY	1 . . . 646	212/680	(31%)	7e−76
	GENSCAN AND GENEWISE) -	425 . . . 1072	338/680	(49%)
	Homo sapiens (Human), 1181 aa
	(fragment).

[0468] PFam analysis indicates that the NOV28a protein contains the domains shown in the Table 28F.

TABLE 28F
Domain Analysis of NOV28a
	NOV28a	Identities/
	Match	Similarities for	Expect
Pfam Domain	Region	the Matched Region	Value
cadherin: domain 1 of 6	43 . . . 130	26/108 (24%)	4.5e−15
		63/108 (58%)
cadherin: domain 2 of 6	144 . . . 232	36/108 (33%)	3.4e−12
		65/108 (60%)
cadherin: domain 3 of 6	246 . . . 348	35/113 (31%)	5.1e−15
		79/113 (70%)
cadherin: domain 4 of 6	362 . . . 452	34/107 (32%)	4e−23
		73/107 (68%)
cadherin: domain 5 of 6	466 . . . 563	33/115 (29%)	1.3e−11
		66/115 (57%)
cadherin: domain 6 of 6	577 . . . 671	27/110 (25%)	0.11
		60/110 (55%)

Example 29

[0469] The NOV29 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 29A.

TABLE 29A
NOV29 Sequence Analysis
	SEQ ID NO: 129	924 bp
NOV29a,	ATGGGGGAGCAGAACCACTCTCCCGGGAAGGAGCTTCAGCACAGGACGCGAGCAGAGG
CG59243-01 DNA	CTCCAGGAAAGAAAAGCTGGCATTCCCAGGCCTATGCCCTTGGGGCCGTTTCCAACTT
Sequence	TATGTCTACTTTTCTGACCTTTCCTATCTATAAGGTTGTGTTCCGGCAACAGATCCAT
	GCCATGGCAGTGTCAGAGGCTGTGAGACAGCTTTGGCATGAAGGTCCTCAATACTTCT
	ACCGGGGAATCTACCCTCCTCTTCTCTCCAAGACGTTGCAAGGGACTCTTCTGTTTGG
	GACTTATGATAGCCTGCTGTGCTTTCTCTCTCCTGTTGGGCCACACACCCTGGGACAC
	CGCTGGGCTGCCGGGCTCATGTCTGGCGTGGTGGAGGCCGTGGCACTCACCCCCTTTG
	AAAGGGTGCAAAATGTGCTCCAGGATGGTCGCAAGCAAGCTCGCTTCCCCAGCACCTT
	CAGCATTCTCAAGGAATTCAATTCTTATGGGCTTTGGGGGCGGCTGTCACTGGGCTAC
	TATCGTGGTTTCTGGCCTGTCCTGGCCAGGAACAGCCTGGGGAGTGCTCTATATTTTT
	CTTTCAAGGACCCCATCCAGGATGGCCTGGCAGAGCAAGGCCTGCCCCACTGGGTTCC
	TGCCTTGGTGTCTGGTAGTGTCAATGGAACAATCACCTGCCTAGTTCTGTATCCTCTG
	ATTGTGCTGGTTGCTAATATGCAGTCCCATATTGGATGGCAGAACATGCCAAGCCTGT
	GGCCCTCTGCCCAGGATGTATGGAACACTCGGGGCCGAAAGCTGCTCCTGATCTACCG
	TGGAGGCTCCCTAGTCATCCTAAGGTCCAGTGTGACATGGGGCCTCACTACGGCAATC
	CATGACTTCCTGCAGACGAAGTCGCACTCCAGGAAAGAGCTCAAGACTGACTAG
	ORF Start: ATG at 1	ORF Stop: TAG at 922
	SEQ ID NO: 130	307 aa	MW AT 34480.4 kD
NOV29a,	MGEQNHSPGKELQHRTRAEAPGKKSWHSQAYALGAVSNFMSTFLTFPIYKVVFRQQIH
CG59243-01 Protein	AMAVSEAVRQLWHEGPQYFYRGIYPPLLSKTLQGTLLFGTYDSLLCFLSPVGPHTLGH
Sequence	RWAAGLMSGVVEAVALSPFERVQNVLQDGRKQARFPSTFSILKEFNSYGLWGRLSLGY
	YRGFWPVLARNSLGSALYFSFKDPIQDGLAEQCLPHWVPALVSGSVNGTITCLVLYPL
	IVLVANNQSHIGWQNNPSLWASAQDVWNTRGRKLLLIYRGCSLVILRSSVTWGLTTAI
	HDFLQRKSHSRKELKTD
	SEQ ID NO: 131	669 bp
NOV29b,	GGATCCATGGGGGAGCAGAACCACTCTCCCGGGAAGGAGCTTCAGCACAGGACGCGAG
188822080 DNA	CAGAGGCTCCAGGAAAGAAAAGCTGGCATTCCCAGGCCCATGCCCTTGGGGCCGTTTC
Sequence	CAACTTTATGTCTACTTTTCTGACCTTTCCTATCTATAAGGTTGTGTTCCGGCAACAG
	ATCCATGCCATGGCAGTGTCAGAGGCTGTGAGACAGCTTTGGCATGAAGGTCCTCAAT
	ACTTCTACCGGGGAATCTACCCTCCTCTTCTCTCCAAGACGTTGCAAGGGACTCTTCT
	GTTTGCGACTTATGATAGCCTGCTGTGCTTTCTCTCTCCTGTTGGGCCACACACCCTG
	GGACACCGCTGGGCTGCCGGGCTCATGTCTGGCGTGGTGGAGGCCGTGGCACTCAGCC
	CCTTTGAAAGGGTGCAAAATGTGCTCCAGGATGGTCGCAAGCAAGCTCGCTTCCCCAG
	CACCTTCAGCATTCTCAAGGAATTCAATTCTTATGGGCTTTGGGGGCGGCTGTCACTG
	GGCTACTATCGTGGTTTCTGGCCTGTCCTGGCCAGGAACAGCCTGGGGAGTGCTCTAT
	ATTTTTCTTTCAAGGACCCCATCCAGGATGGCCTGGCAGAGCAAGGCCTGCCCCACTG
	GGTTCCTGCCTTGGTGTCTGGTAGTCTCGAG
	ORF Start: GGA at 1	ORF Stop: at 670
	SEQ ID NO: 132	223 aa	MW at 24883.2 kD
NOV29b,	GSMGEQNHSPGKELQHRTRAEAPGKKSWHSQAHALGAVSNFMSTFLTFPIYKVVFRQQ
188822080 Protein	IHAMAVSEAVRQLWHEGPQYFYRGIYPPLLSKTLQGTLLFGTYDSLLCFLSPVGPHTL
Sequence	CHRWAAGLMSGVVEAVALSPFERVQNVLQDGRKQARFPSTFSILKEFNSYGLWGRLSL
	GYYRGFWPVLARNSLGSALYFSFKDPIQDGLAEQGLPHWVPALVSGSLE
	SEQ ID NO: 133	924 bp
NOV29c,	ATGGGGGAGCAGAACCACTCTCCCGGGAAGGAGCTTCAGCACAGGACGCCAGCAGAGG
CG59243-02 DNA	CTCCAGGAAAGAAAAGCTGGCATTCCCAGGCCTATGCCCTTGGGGCCGTTTCCAACTT
Sequence	TATGTCTACTTTTCTGACCTTTCCTATCTATAAGCTTGTGTTCCGGCAACAGATCCAT
	GCCATGGCAGTGTCACAGGCTGTCAGACAGCTTTGGCATGAAGGTCCTCAATACTTCT
	ACCGGGGAATCTACCCTCCTCTTCTCTCCAAGACGTTGCAAGGGACTCTTCTGTTTGG
	GACTTATGATAGCCTGCTGTGCTTTCTCTCTCCTGTTGGGCCACACACCCTGGGACAC
	CGCTGGGCTCCCGGGCTCATGTCTGGCGTGGTGGAGGCCGTGGCACTCAGCCCCTTTG
	AAAGGGTGCAAAATGTGCTCCAGGATGGTCGCAAGCAAGCTCGCTTCCCCAGCACCTT
	CACCATTCTCAAGGAATTCAATTCTTATGGGCTTTGGGGGCGGCTGTCACTGGGCTAC
	TATCGTGGTTTCTGGCCTGTCCTGGCCAGGAACAGCCTGGGCAGTGCTCTATATTTTT
	CTTTCAAGGACCCCATCCAGGATGGCCTGGCAGAGCAAGGCCTGCCCCACTGGGTTCC
	TGCCTTGGTGTCTGGTAGTGTCAATGGAACAATCACCTGCCTAGTTCTGTATCCTCTG
	ATTGTGCTGGTTGCTAATATGCAGTCCCATATTGGATGGCAGAACATGCCAAGCCTGT
	GGGCCTCTGCCCAGGATGTATGGAACACTCGGGGCCGAAAGCTGCTCCTGATCTACCG
	TGGAGGCTCCCTAGTCATCCTAAGGTCCAGTGTGACATGGGGCCTCACTACGGCAATC
	CATGACTTCCTGCAGAGGAAGTCGCACTCCAGGAAAGAGCTGAAGACTGACTAG
	ORF Start: ATG at 1	ORF Stop: TAG at 922
	SEQ ID NO: 134	307 aa	MW at 34480.4 kD
NOV29c,	MGEQNHSPGKELQHRTRAEAPGKKSWHSQAYALGAVSNFMSTFLTFPIYKVVFRQQIH
CG59243-02 Protein	AMAVSEAVRQLWHEGPQYFYRGIYPPLLSKTLQGTLLFGTYDSLLCFLSPVGPHTLGH
Sequence	RWAAGLMSGVVEAVALSPFERVQNVLQDGRKQARFPSTFSILKEFNSYGLWGRLSLGY
	YRGFWPVLARNSLGSALYFSFKDPIQDGLAEQGLPHWVPALVSGSVNGTITCLVLYPL
	IVLVANMQSHIGWQNMPSLWASAQDVWNTRGRKLLLIYRGGSLVILRSSVTWGLTTAI
	HDFLQRKSHSRKELKTD

[0470] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 29B.

TABLE 29B
Comparison of NOV29a against NOV29b through NOV29c.
	NOV29a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV29b	3 . . . 222	220/220 (99%)
NOV29c	1 . . . 307	307/307 (100%)
	1 . . . 307	307/307 (100%)

[0471] Further analysis of the NOV29a protein yielded the following properties shown in Table 29C.

TABLE 29C
Protein Sequence Properties NOV29a
PSort     0.7000 probability located in plasma membrane;
analysis: 0.6400 probability located in microbody (peroxisome);
          0.2000 probability located in endoplasmic reticulum
          (membrane); 0.1000 probability located in mitochondrial
          inner membrane
SignalP   No Known Signal Sequence Indicated
analysis:

[0472] A search of the NOV29a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 29D.

TABLE 29D
Geneseq Results for NOV29a
		NOV29a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length	Match	the Matched	Expect
Identifier	[Patent #, Date]	Residues	Region	Value
AAM40554	Human polypeptide SEQ ID NO 5485 -	31 . . . 294	93/269	(34%)	3e−39
	Homo sapiens, 304 aa.	41 . . . 300	146/269	(53%)
	[WO200153312-A1, 26-JUL-2001]
AAM38768	Human polypeptide SEQ ID NO 1913 -	31 . . . 294	93/269	(34%)	3e−39
	Homo sapiens, 297 aa.	34 . . . 293	146/269	(53%)
	[WO200153312-A1, 26-JUL-2001]
AAB60090	Human transport protein TPPT-10 -	31 . . . 294	93/269	(34%)	3e−39
	Homo sapiens, 297 aa.	34 . . . 293	146/269	(53%)
	[WO200078953-A2, 28-DEC-2000]
AAY97294	Lipid associated protein (LIPAP)	31 . . . 294	93/269	(34%)	3e−39
	3735780CD1 - Homo sapiens, 297 aa.	34 . . . 293	146/269	(53%)
	[WO200049043-A2, 24-AUG-2000]
AAG03236	Human secreted protein, SEQ ID NO:	46 . . . 106	26/61	(42%)	4e−08
	7317 - Homo sapiens, 95 aa.	19 . . . 79	38/61	(61%)
	[EP1033401-A2, 06-SEP-2000]

[0473] In a BLAST search of public sequence databases, the NOV29a protein was found to have homology to the proteins shown in the BLASTP data in Table 29E.

TABLE 29E
Public BLASTP Results for NOV29a
		NOV29a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9H1U9	BA3J10.3 (CG7943 PROTEIN)	31 . . . 294	93/269 (34%)	1e−38
	(UNKNOWN) (PROTEIN FOR	34 . . . 293	146/269 (53%)
	MGC: 14836) - Homo sapiens
	(Human), 297 aa.
Q960B8	SD08549P -Drosophila melanogaster	25 . . . 296	83/275 (30%)	2e−31
	(Fruit fly), 332 aa.	51 . . . 319	146/275 (52%)
Q9VAB1	CG7943 PROTEIN - Drosophila	25 . . . 296	83/275 (30%)	2e−31
	melanogaster (Fruit fly), 349 aa.	68 . . . 336	146/275 (52%)
O01256	T20D3.5 PROTEIN - Caenorhabditis	88 . . . 296	71/221 (32%)	3e−19
	elegans, 221 aa.	2 . . . 215	103/221 (46%)
Q9V3T2	CG5254 PROTEIN - Drosophila	56 . . . 240	55/195 (28%)	5e−11
	melanogaster (Fruit fly), 306 aa.	57 . . . 242	99/195 (50%)

[0474] PFam analysis indicates that the NOV29a protein contains the domains shown in the Table 29F.

TABLE 29F
Domain Analysis of NOV29a
	NOV29a	Identities/
	Match	Similarities for	Expect
Pfam Domain	Region	the Matched Region	Value
mito_carr: domain 1 of 3	26 . . . 112	19/125 (15%)	0.0057
		62/125 (50%)
mito_carr: domain 2 of 3	113 . . . 209	23/130 (18%)	5.6e−07
		70/130 (54%)
mito_carr: domain 3 of 3	210 . . . 304	18/126 (14%)	0.037
		61/126 (48%)

Example 30

[0475] The NOV30 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 30A.

TABLE 30A
NOV30 Sequence Analysis
	SEQ ID NO: 135	5101 bp
NOV3Oa,	ATCCTCCTACCTCAGTCTACTGAGTAGCTAGGACTACAGGCATGTGCCACCACACCTG
CG59534-01 DNA	GCTAGTTTTTATTTTTTGATGAGATGGGATCTTGCTGTGTTGCCCAGACTGGTCTTGA
Sequence	TCTCCTGGGCTCAAGTGATCCTCCTGCCTTCGCCTGCGGCCGCCTGCACTTGCGCTGG
	GGACTCGCTGGACTGCGGTGGGCGCCGGCTGGCTGCGTTGCCCGGGGACCTCCCCTCC
	TCGACGCGGAGCCTAAACCTGAGTTACAACAAACTCTCTGACATTGACCCTGCTCGTT
	TTGAGGACTTGCCGAACCTACAGGAAGTGTACCTCAATAATAATGAGTTGACAGCGGT
	ACCATCCCTGGGCGCTGCTTCATCACATGTCGTCTCTCTCTTTCTGCAGCACAACAAG
	ATTCGCAGCGTGGAGGGGAGCCAGCTGAAGGCCTACCTTTCCTTAGAAGTGTTAGATC
	TGAGTTTGAACAACATCACGGAAGTGCGGAACACCTGCTTTCCACACGGACCGCCTAT
	AAAGGAGCTGAACCTGGCAGCCAATCGGATTGGCACCCTGGAGTTGGGAGCATTTGAT
	GGTCTGTCACGGTCGCTGCTAACTCTTCGCCTGAGCAAAAACAGGATCACCCAGCTTC
	CTGTAAGAGCATTCAAGCTACCCAGGCTGACACAACTGGACCTCAATCGGAACAGGAT
	TCGGCTGATAGAGGGCCTCACCTTCCAGGGGCTCAACACCTTGGAGGTGCTGAAGCTT
	CAGCGAAACAACATCACCAAACTGACAGATGGGGCCTTCTGGGGACTGTCCAAGATGC
	ATGTGCTGCACCTGGAGTACAACAGCCTGGTAGAAGTGAACAGCGGCTCGCTCTACGC
	CCTCACGGCCCTGCATCAGCTCCACCTCAGCAACAATTCCATCGCTCGCATTCACCGC
	AAGGGCTGGAGCTTCTGCCAGAAGCTGCATGAGTTGGTCCTGTCCTTCAACAACCTGA
	CACGGCTGGACGAGGAGAGCCTGGCCGAGCTGAGCAGCCTGAGTGTCCTGCGTCTCAG
	CCACAATTCCATCAGCCACATTGCGGAGGGTGCCTTCAAGGCACTCACCACCCTGCGA
	GTCTTGGATCTGGACCATAACGAGATTTCGGGCACAATAGAGGACACGAGCGGCGCCT
	TCTCAGCGCTCGACAGCCTCAGCAAGCTGACTCTGTTTGGAAACAAGATCAAGTCTGT
	GGCTAAGAGAGCATTCTCGGGGCTGGAAGGCCTGGAGCACCTGAACCTTGGAGGGAAT
	GCGATCAGATCTGTCCAGTTTGATGCCTTTGTGAAGATGAAGAATCTTAAAGAGCTCC
	ATATCAGCAGCGACAGCTTCCTGTGTGACTGCCAGCTGAAGTGGCTGCCCCCGTGGCT
	AATTGGCAGGATGCTGCAGGCCTTTGTGACAGCCACCTGTGCCCACCCAGAATCACTG
	AAGGGTCAGAGCATTTTCTCTGTGCCACCAGAGAGTTTCGTGTGCGATGACTTCCTGA
	AGCCACAGATCATCACCCAGCCAGAAACCACCATGCCTATGGTGGGCAAGGACATCCG
	GTTTACATGCTCAGCAGCCAGCAGCAGCAGCTCCCCCATGACCTTTGCCTGGAAGAAA
	GACAATGAAGTCCTGACCAATGCAGACATGGAGAACTTTGTCCACGTCCACCCGCAGG
	ACGGGGAAGTGATGGAGTACACCACCATCCTGCACCTCCGTCAGGTCACTTTCGGGCA
	CGAGGGCCGCTACCAATGTGTCATCACCAACCACTTTGGCTCCACCTATTCACATAAG
	GCCAGGCTCACCGTGAATGTGTTGCCATCATTCACCAAAACGCCCCACGACATAACCA
	TCCGGACCACCACCATGGCCCGCCTCGAATGTGCTGCCACAGGTCACCCAAACCCTCA
	GATTGCCTGGCAGAAGGATGGAGGCACGGATTTCCCCGCTGCCCGTGAGCGACGCATG
	CATGTCATGCCGGATGACGACGTGTTTTTCATCACTGATGTGAAAATAGATGACGCAG
	GGGTTTACAGCTGTACTGCTCAGAACTCAGCCGGTTCTATTTCAGCTAATGCCACCCT
	GACTGTCCTAGAGACCCCATCCTTGGTGGTCCCCTTGGAAGACCGTGTCGTATCTGTG
	GGAGAAACAGTGGCCCTCCAATGCAAAGCCACGGGGAACCCTCCGCCCCGCATCACCT
	GGTTCAAGGGGGACCGCCCGCTGAGCCTCACTGAGCGGCACCACCTGACCCCTGACAA
	CCAGCTCCTGGTGGTTCAGAACGTGGTGGCAGAGGATGCCGGCCGATATACCTGTGAG
	ATGTCCAACACCCTGGGCACGGAGCGAGCTCACAGCCAGCTGAGCGTCCTGCCCGCAG
	CAGGCTGCAGGAAGGATGGCACCACGGTAGGCATCTTCACCATTGCTGTCGTGAGCAG
	CATCGTCCTGACGTCACTGGTCTGCGTGTGCATCATCTACCAGACCAGGAAGAAGAGT
	GAAGAGTACAGTGTCACCAACACAGATGAAACCGTCGTGCCACCAGATGTTCCAAGCT
	ACCTCTCTTCTCAGGGGACCCTTTCTGACCGACAAGAAACCGTGGTCAGGACCGAGGG
	TGGCCCTCAGGCCAATGGGCACATTGAGAGCAATGGTGTGTGTCCAAGAGATGCAAGC
	CACTTTCCAGAGCCCGACACTCACAGCGTTGCCTGCAGGCAGCCAAAGCTCTGTGCTG
	GGTCTGCGTATCACAAAGAGCCGTGGAAAGCGATGGAGAAAGCTGAACGGACACCTGG
	GCCACATAAGATGGAACACGGTGGCCGGGTCGTATGCAGTGACTGCAACACCGAAGTG
	GACTGTTACTCCAGGGGACAAGCCTTCCACCCCCAGCCTCTGTCCAGAGACAGCGCAC
	AGCCAAGTGCGCCAAATGGCCCGGAGCCGGGTGGGAGTGACCAAGAGCATTCTCCACA
	TCACCAGTGCAGCAGGACTGCCGCTGGCTCCTGCCCCGAGTGCCAAGGGTCGCTCTAC
	CCCAGTAACCACGATAGAATGCTGACGGCTGTGAAGAAAAAGCCAATGGCATCTCTAG
	ATGGGAAAGGGGATTCTTCCTGGACTTTAGCAAGGTTGTATCACCCGGACTCCACAGA
	GCTACAGCCTGCATCTTCATTAACTTCAGGCAGTCCAGAGCGCGCGGAAGCCCAGTAC
	TTGCTTGTTTCCAATGGCCACCTCCCCAAAGCATGTGACGCCAGTCCCGAGTCCACGC
	CACTGACAGGACAGCTCCCCGGGAAACAGAGGGTGCCACTGCTGTTGGCACCAAAAAG
	CTAGGTTTTGTCTACCTCAGTTCTTGTCATACCAATCTCTACGGGAAAGAGAGGTAGG
	AGAGGCTGCGAGGAAGCTTGGGTTCAAGCGTCACTCATCTGTACATAGTTGTAACTCC
	CATGTGGAGTATCAGTCGCTCACAGGACTTGGATCTGAAGCACAGTAAACGCAAGAGG
	GGATTTGTGTACAAAAGGCAAAAAAAAGTATTTGATATCATTGTACATAAGAGTTTTC
	AGAGATTTCATATATATCTTTTACAGAGGCTATTTTAATCTTTAGTGCATGGTTAACA
	GAAAAAAATTATACAATTTTGACAATATTATTTTTCGTATCAGGTTGCTGTTTAATTT
	TGGAGGGGGTGGGGAAATAGTTCTGGTGCCTTAACGCATGGCTGGAATTTATAGAGGC
	TACAACCACATTTGTTCACAGGAGTTTTTGGTGCGGGGTGGGAAGGATGGAAGGCCTT
	GGATTTATATTGCACTTCATAGACCCCTAGGCTGCTGTGCGGTGGGACTCCACATGCG
	CCGGAAGGAGCTTCAGGTGAGCACTGCTCATGTGTGGATGCCCCTGCAACAGGCTTCC
	CTGTCTGTAGAGCCAGGGGTGCAAGTGCCATCCACACTTGCAGTGAATGGCTTTTCCT
	TTTAGGTTTAAGTCCTGTCTGTCTGTAAGGCGTAGAATCTGTCCGTCTGTAAGGCGTA
	GAATGAGGGTTGTTAATCCATCACAAGCAAAAGGTCAGAACAGTTAAACACTGCCTTT
	CCTCCTCCTCTTATTTTATGATAAAAGCAAATGTGGCCTTCTCAGTATCATTCGATTG
	CTATTTGAGACTTTTAAATTAAGGTAAAGGCTGCTGGTGTTGGTACCTGTGGATTTTT
	CTATACTGATGTTTTCGTTTTGCCAATATAATGAGTATTACATTGGCCTTGGGGGACA
	GAAAGGAGGAAGTTCTGACTTTTCAGGGCTACCTTATTTCTACTAAGGACCCAGAGCA
	GGCCTGTCCATGCCATTCCTTCGCACAGATGAAACTGAGCTCCCACTCGAAAGGACAG
	CCCTTGACCTGGGTTCTGGGTATAATTTGCACTTTTGAGACTGGTAGCTAACCATCTT
	ATGAGTGCCAATGTGTCATTTAGTAAAACTTAAATAGAAACAAGGTCCTTCAAATGTT
	CCTTTGGCCAAAAGCTGAAGGGAGTTACTGAGAAAATAGTTAACAATTACTGTCAGGT
	GTCATCACTGTTCAAAAGGTAAGCACATTTAGAATTTTGTTCTTGACAGTTAACTGAC
	TAATCTTACTTCCACAAAATATGTGAATTTGCTGCTTCTGAGAGGCAATGTGAAAGAG
	GGAGTATTACTTTTATGTACAAAGTTATTTATTTATAGAAATTTTGGTACAGTGTACA
	TTGAAAACCATGTAAAATATTGAAGTGTCTAACAAATGGCATTGAAGTGTCTTTAATA
	AAGGTTCATTTATAAATGTCAGTATAGTTGGTGGTCCTTCTTTTACAAACGCAGTCAT
	TCTGCCTTTAATTATCTTCCCCCAAAAAAGAAAAAAAAAATAGGCGAAGCAAAATCAC
	ATACTGTTTGTTTGCTCCAGGGCAGACAACACTGCTAGATTCCTCACATTTTGTTTTG
	AATTTTTCTACACCTGGAGCTTGTTAGTCAAGGTCTAAAATCCCTAAGTGTGGTGACC
	TTTCCATTTCATCCTGCCTTTTCAAAGCTGGCCCAGGCCCTCCTTTCAGTCTGACATG
	AGAATGGCGAGAATGGCTCACCCACCGTGCCCTCCTGCACGAAGCCAGCTGGGCC
	ORF Start: ATG at 77	ORF Stop: TAG at 3308
	SEQ ID NO: 136	1077 aa	MW at 117735.2 kD
NOV3Oa,	MRWDLAVLPRLVLISWAQVILLPWPAAACTCAGDSLDCGGRGLAALPCDLPSWTRSLN
CG59534-01 Protein	LSYNKLSEIDPAGFEDLPNLQEVYLNNNELTAVPSLGAASSHVVSLFLQHNKIRSVEG
Sequence	SQLKAYLSLEVLDLSLNNITEVRNTCFPHGPPIKELNLAGNRIGTLELGAFDGLSRSL
	LTLRLSKNRITQLPVRAFKLPRLTQLDLNRNRIRLIEGLTFQGLNSLEVLKLQRNNIS
	KLTDGAFWGLSKMHVLHLEYNSLVEVNSGSLYGLTALHQLHLSNNSIARIHRKGWSFC
	QKLHELVLSFNNLTRLDEESLAELSSLSVLRLSHNSISHIAEGAFKGLRSLRVLDLDH
	NEISGTIEDTSGAFSGLDSLSKLTLFGNKIKSVAKRAFSGLEGLEHLNLGGNAIRSVQ
	FDAFVKMKNLKELHISSDSFLCDCQLKWLPPWLIGRMLQAFVTATCAHPESLKGQSIF
	SVPPESFVCDDFLKPQIITQPETTMAMVGKDIRFTCSAASSSSSPMTFAWKKDNEVLT
	NADMENFVHVHAQDGEVMEYTTILHLRQVTFGHEGRYQCVITNHFGSTYSHKARLTVN
	VLPSFTKTPHDITIRTTTMARLECAATGHPNPQIAWQKDGGTDFPPARERRMHVMPDD
	DVFFITDVKIDDACVYSCTAQNSAGSISANATLTVLETPSLVVPLEDRVVSVGETVAL
	QCKATGNPPPRITWFKGDRPLSLTERHHLTPDNQLLVVQNVVAEDAGRYTCEMSNTLG
	TERHSQLSVLPAAGCRKDGTTVGIFTIAVXJSSIVLTSLVWVCIIYQTRKKSEEYSVT
	NTDETVVPPDVPSYLSSQGTLSDRQETVVRTEGGPQANGHIESNGVCPRDASHFPEPD
	THSVACRQPKLCAGSAYHKEPWKAMEKAEGTPGPHKMEHGGRVVCSDCNTEVDCYSRG
	QAFHPQPVSRDSAQPSAPNGPEPGGSDQEHSPHHQCSRTAAGSCPECQGSLYPSNHDR
	MLTAVKKKPMASLDGKGDSSWTLARLYHPDSTELQPASSLTSGSPERAEAQYLLVSNG
	HLPKACDASPESTPLTGQLPGKQRVPLLLAPKS

[0476] Further analysis of the NOV30a protein yielded the following properties shown in Table 30B.

TABLE 30B
Protein Sequence Properties NOV30a
PSort     0.4600 probability located in plasma membrane; 0.1000
analysis: probability located in endoplasmic reticulum (membrane);
          0.1000 probability located in endoplasmic reticulum (lumen);
          0.1000 probability located in outside
SignalP   Cleavage site between residues 29 and 30
analysis:

[0477] A search of the NOV30a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 30C.

TABLE 30C
Geneseq Results for NOV30a
		NOV30a
		Residues/	Identities/
Geneseq	Protein/Organism/Length [Patent #,	Match	Similarities for the	Expect
Identifier	Date]	Residues	Matched Region	Value
AAY08008	Human HLIG-1 protein - Homo sapiens,	29 . . . 1077	1030/1050 (98%)	0.0
	1101 aa. [EP913472-A2,	52 . . . 1101	1040/1050 (98%)
	06-MAY-1999]
AAY97833	Murine LIG-1 protein - Mus sp, 1091	9 . . . 1077	890/1088 (81%)	0.0
	aa. [JP2000093043-A, 04-APR-2000]	16 . . . 1091	950/1088 (86%)
AAY08010	Mouse LIG-1 protein - Mus sp, 1091	9 . . . 1077	890/1088 (81%)	0.0
	aa. [EP913472-A2, 06-MAY-1999]	16 . . . 1091	950/1088 (86%)
AAY08099	Murine glial cell membrane	9 . . . 1077	890/1088 (81%)	0.0
	glycoprotein LIG-1 - Mus sp, 1091	16 . . . 1091	950/1088 (86%)
	aa. [WO9914241-A2, 25-MAR-1999]
AAW41641	Sequence used in detection method -	9 . . . 1077	890/1088 (81%)	0.0
	Mus sp, 1091 aa. [JP09107971-A,	16 . . . 1091	950/1088 (86%)
	28-APR-1997]

[0478] In a BLAST search of public sequence databases, the NOV30a protein was found to have homology to the proteins shown in the BLASTP data in Table 30D.

TABLE 30D
Public BLASTP Results for NOV30a
		NOV30a
Protein		Residues/	Identities/
Accession		Match	Similarities for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
Q96JA1	MEMBRANE GLYCOPROTEIN	26 . . . 1077	1051/1052 (99%)	0.0
	LIG-1 - Homo sapiens (Human),	42 . . . 1093	1052/1052 (99%)
	1093 aa.
Q9BYB8	MEMBRANE GLYCOPROTEIN	26 . . . 1077	1051/1053 (99%)	0.0
	LIG-1 - Homo sapiens (Human),	42 . . . 1094	1052/1053 (99%)
	1094 aa.
P70193	MEMBRANE GLYCOPROTEIN -	9 . . . 1077	890/1088 (81%)	0.0
	Mus musculus (Mouse), 1091 aa.	16 . . . 1091	950/1088 (86%)
Q9UFI4	HYPOTHETICAL 51.9 KDA	595 . . . 1077	480/483 (99%)	0.0
	PROTEIN - Homo sapiens	1 . . . 483	481/483 (99%)
	(Human), 483 aa (fragment).
O94898	KIAA0806 PROTEIN - Homo	7 . . . 1002	507/1026 (49%)	0.0
	sapiens (Human), 1065 aa.	20 . . . 991	648/1026 (62%)

[0479] PFam analysis indicates that the NOV30a protein contains the domains shown in the Table 30E.

TABLE 30E
Domain Analysis of NOV30a
		Identities/
		Similarities
	NOV30a Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
LRRNT: domain 1 of 1	26 . . . 51	14/31 (45%)	0.34
		19/31 (61%)
LRR: domain 1 of 15	53 . . . 76	10/25 (40%)	0.88
		19/25 (76%)
LRR: domain 2 of 15	77 . . . 98	9/25 (36%)	0.71
		17/25 (68%)
LRR: domain 3 of 15	100 . . . 120	5/25 (20%)	1.1e+02
		17/25 (68%)
LRR: domain 4 of 15	124 . . . 147	10/25 (40%)	4.4
		18/25 (72%)
LRR: domain 5 of 15	148 . . . 171	7/25 (28%)	3.9
		18/25 (72%)
LRR: domain 6 of 15	173 . . . 195	10/25 (40%)	0.22
		18/25 (72%)
LRR: domain 7 of 15	196 . . . 219	7/25 (28%)	0.6
		19/25 (76%)
LRR: domain 8 of 15	220 . . . 243	21/25 (84%)	0.0044
LRR: domain 9 of 15	244 . . . 267	6/25 (24%)	1.8
		18/25 (72%)
LRR: domain 10 of 15	268 . . . 291	6/25 (24%)	34
		14/25 (56%)
LRR: domain 11 of 15	292 . . . 315	12/25 (48%)	0.01
		19/25 (76%)
LRR: domain 12 of 15	316 . . . 339	8/25 (32%)	0.00037
		21/25 (84%)
IGPD: domain 1 of 1	329 . . . 342	10/15 (67%)	1.1
		12/15 (80%)
LRR: domain 13 of 15	340 . . . 363	8/25 (32%)	0.1
		20/25 (80%)
LRR: domain 14 of 15	367 . . . 390	7/25 (28%)	2.5
		16/25 (64%)
LRR: domain 15 of 15	391 . . . 414	7/25 (28%)	0.49
		18/25 (72%)
LRRCT: domain 1 of 1	424 . . . 474	22/54 (41%)	2.1e−13
		43/54 (80%)
ig: domain 1 of 3	493 . . . 563	12/72 (17%)	1.4e−06
		49/72 (68%)
ig: domain 2 of 3	597 . . . 658	13/65 (20%)	1.3e−07
		46/65 (71%)
ig: domain 3 of 3	691 . . . 749	18/62 (29%)	2.9e−11
		47/62 (76%)
Adeno_E3_CR1:	687 . . . 764	23/89 (26%)	1.3
domain 1 of 1		45/89 (51%)

Example 31

[0480] The NOV31 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 31A.

TABLE 31A
NOV31 Sequence Analysis
                   SEQ ID NO:137        4200 bp
NOV31a,            TAACGAGGTCTAATTTAATTCTCCCAACACCCTATGAAGTCAGCTCTGATACCCCTAG
CG59289-01 DNA     TTTACAGAGGAGCTAAACGAGGCCCAGAGATGGCCAGTCCCAGAGCCAGGAAGCCCCA
Sequence           GAGCCAGTGCTGGGATTTCACAGTACACTGTGCTACTTCCCTAGGCAAAGTCACGTCT
                   CTTCTCTGTCTCTACAAAACGAGGACAGACTGGCTTACTCCGAGCGCTGGTATAAGGA
                   TTGGAAGAGAATGCAGTGAGCGGTTCCCCACCCCAGGAGGTAACTCCCTGGAACTGTG
                   CTCTGAGCCCAAACTCTCAAGGGTTGGTCAGTGCCAGGCACAGGGTAGGTGCTCCGTC
                   CCTGACAGCTATTGTTGCAATCGAGGTAACTCCCTGGAACTGTGCTCTGAGCCCPAAC
                   TCTCAAGGGTTCGTCAGTGCCACCCACAGGGGACGCTGCCTTCAGAGCCCCCCAGTGC
                   CTGTGCCTCAGACCCGTGCGCTCCAGGGACCGAGTGCCAGGCTACCGAGAGTGGTGGC
                   TATACCTGTGGGCCCATGGAGCCCCGGGGCTGTGCCACCCAGCCATGCCACCACGGCG
                   CTCTGTGTGTGCCCCAGGGTCCAGATCCCACCGGCTTCCGCTGCTACTCCGTGCCGGG
                   TTTCCAGGGCCCACGCTGCGAGCTGGACATCGATGAGTGTGCATCCCGGCCGTGCCAC
                   CATGGGGCCACCTGCCGCAACCTGGCCGATCGCTACGAGTGCCATTGCCCCCTTGGCT
                   ATGCAGGCGTGACCTGCGAGATGGAGGTGGACGAGTGCGCCTCAGCGCCCTGCCTOCA
                   CCGGGGCTCGTGCCTGGACGGCGTGGGCTCCTTCCGCTCTGTGTGCGCGCCAGGCTAC
                   GGGGGCACCCGTTGCCAGCTGGACCTCGACGAGTGCCAGAGCCAGCCGTGCGCACATG
                   GGGGCACGTGCCACGACCTCGTCAACGGGTTCCGGTGCGACTGCGCGGGCACCGGCTA
                   CGAGGGCACGCACTGCGAGCGGGAGGTGCTGGAGTGCCCATCGGCGCCCTGCGAGCAC
                   AACGCGTCCTGCCTCGAGGGCCTCGGGAGCTTCCGCTGCCTCTGTTGGCCAGGCTACA
                   GCGGCCAGCTGTGCGAGGTGGACGAGGACGAGTGTGCATCGAGCCCCTGCCAGCATGG
                   GGGCCGATGCCTGCAGCGCTCTGACCCGGCCCTCTACGGGGGTGTCCAGGCCGCCTTC
                   CCTGGCGCCTTCAGCTTCCGCCATGCTGCGGGTTTCCTGTGCCACTGCCCTCCTGGCT
                   TTGAGGGAGCCGACTGCGGTGTGGAGGTGGACGAGTGTGCCTCACGGCCATGCCTCAA
                   CCCAGGCCACTGCCAGGACCTGCCCAATGGCTTCCAGTGTCACTGCCCAGATGGCTAC
                   GCAGGGCCGACATGTGAGGAAGATGTGGATGAATGCCTGTCGGATCCCTGCCTGCACG
                   GCGGAACCTGCAGTGACACTGTGGCAGGCTATATCTGCAGGTGCCCAGAGACCTGGGG
                   TGGGCGCGACTGTTCTGTGCAGCTCACTGGCTGCCAGGGCCACACCTGCCCGCTGGCT
                   GCCACCTGCATCCCTATCTTCGAGTCTGGGGTCCACAGTTACGTCTGCCACTGCCCAC
                   CTGGTACCCATGGACCGTTCTGTGGCCAGAATACCACCTTCTCTGTGATGGCTGCGAG
                   CCCCATTCAGGCATCAGTGCCAGCTGGTGGCCCCCTGGGTCTGGCACTGAGGTTTCGC
                   ACCACACTGCCCGCTGGGACCTTGGCCACTCGCAATGACACCAAGGAAAGCTTGGAGC
                   TGGCATTGGTGGCAGCCACACTTCAGGCCACACTCTGGAGCTACAGCACCACTGTGCT
                   TGTCCTGAGACTGCCGGACCTGGCCCTAAACCATGGCCATTCGCACCAGGTGGAGGTT
                   GTGCTCCATCTAGCGACCCTGGAGCTACGGCTCTGGCATGAGGGCTGCCCTGCCCGGC
                   TCTGTGTGGCCTCTGGTCCTGTCGCCCTGCCTTCCACGGCTTCGGCAACTCCGCTGCC
                   TGCCGGCATCTCCTCTGCCCAGCTGGGGGACGCGACCTTTGCAGGCTGCCTCCAGGAC
                   GTGCGTGTGGATGGCCACCTCCTGCTGCCTGAGGATCTCGGTGAGAACGTCCTCCTGG
                   GCTGTGAGCGCCGAGAGCAGTGCCGGCCTCTGCCTTGTGTCCACGGAGGGTCCTGTGT
                   GGATCTGTGGACTCATTTCCGTTGCGACTGTGCCCGGCCCCATAGAGGTCCCACGTGC
                   GCTGATGAGATTCCTGCTGCCACCTTTGGCTTGGGAGGCGCCCCAAGCTCTGCCTCCT
                   TTCTGCTCCAAGAGCTGCCAGGTCCCAACCTCACACTGTCTTTCCTTCTCCCCACTCG
                   GGAGTCCGCTGGCCTGTTGCTCCAGTTTGCCAATGACTCCGCAGCTGGCCTAACAGTA
                   TTCCTGAGTGAGGGTCGGATCCGGGCTGAGGTGCCGGGCAGTCCTCCTGTAGTGCTCC
                   CTGGGCGCTGGGATGATGGGCTCCGTCACCTGGTGATGCTCAGCTTCGGCCCTGACCA
                   GCTGCAGGACCTGGGGCAGCACGTGCACGTGGGTGGGAGGCTCCTTGCTGCCGACAGC
                   CAGCCCTGGGGTGGGCCCTTCCGAGGCTGCCTCCAGGACCTGCGACTCGATGGCTGCC
                   ACCTCCCCTTCTTTCCTCTGCCACTGGATAACTCAAGCCAGCCCAGCGAGCTCGGCGG
                   CAGGCAGTCCTGGAACCTCACTGCCGGCTGCGTCTCCGAGGACATGTGCAGTCCTGAC
                   CCCTGTTTCAATGGTGGGACTTGCCTCGTCACCTGGAATGACTTCCACTGTACCTGCC
                   CTGCCAATTTCACGGGGCCTACGTGTGCCCACCAGCTGTCGTGTCCCGGCCACCCCTG
                   TCTCCCACCTGCCACGTGTGAGGAGGTCCCTGATGCCTTTGTGTGTGTGGCGGAGGCC
                   ACGTTCCGCGAGGGTCCCCCCGCCGCGTTCAGCGGGCACAACGCGTCGTCAGGGCGCT
                   TGCTCGGCGGCCTGTCGCTGGCCTTTCGCACGCGCGACTCCGAGGCCTGGCTGCTGCG
                   TGCCGCGGCGGGCGCCCTGGAAGGCGTGTGGCTGGCGGTGCGCAATGGCTCGCTGGCG
                   GGGGGCGTGCGCGGAGGCCATGGCCTCCCCGGCGCTGTGCTGCCCATACCCGGCCCGC
                   GCGTGGCCGATGGTGCCTGGCACCGCGTGCGTCTCGCCATGGAGCGCCCGGCCGCCAC
                   CACCTCGCGCTGGCTGCTGTGGCTGGATGGTGCCGCCACCCCGGTGGCGCTGCGCGGC
                   CTGGCCAGTCACCTGGGCTTCCTGCAGGGCCCGGGTGCTGTGCGCATCCTGCTGGCTG
                   AGAACTTCACCGGCTGCTTGGGCCGCGTGGCGCTGGGCGGCCTGCCCCTGCCCTTGGC
                   GCGGCCCCGGCCCGGCGCGGCCCCTGGCGCCCGAGAGCACTTCGCGTCTTGGCCTGGG
                   ACGCCGGCCCCGATCCTCGGCTGCCGCGCCCCGCCCGTGTGTGCGCCCTCGCCCTGTC
                   TGCACGACGGTGCCTGCCGTGACCTCTTCGACGCCTTTGCCTGCGCCTGCGGCCCCGG
                   GTGGGAAGGCCCGCGCTGCGAAGCCCACGTCGACCCCTGTCACTCCGCCCCCTGCGCC
                   CGTGGCCGCTGTCACACGCACCCCGACGGCCGCTTCGAGTGCCGCTGCCCGCCTGGCT
                   TCGGGGGCCCGCGCTGCAGGTTGCCTGTCCCATCCAAGGAGTGCAGCCTGAATGTCAC
                   CTGCCTCGATGGCAGCCCATGTGAGCGTGGCTCTCCCGCTGCCAACTGCAGCTGCCTG
                   GAGGGTCTTGCTGGCCAGAGGTGTCAGGTCCCCACTCTCCCCTGTGAAGCCAACCCCT
                   GCTTGAATGGGGGCACCTGCCGGGCAGCTGGAGGGGTGTCTGAATGTATCTGCAATGC
                   CAGATTCTCCGGCCAGTTCTGTGAAGTGGCGAAGGGCCTGCCCCTGCCGCTGCCATTC
                   CCACTGCTGGAGGTGGCCGTACCTGCAGCCTGTGCCTGCCTCCTCCTCCTCCTCCTGG
                   GCCTCCTTTCAGGGATCCTGGCAGCCCGAAAGCGCCGCCAGTCTGAGGGCACCTACAG
                   CCCAAGCCAGCAGGAGGTGGCTGGGGCCCGGCTGGAGATCGACAGTGTCCTCAAGGTG
                   CCACCGGAGGAGAGACTCATCTAG
                   ORF Start: TTC at 19 ORF Stop: GAG at 4183
                   SEQ ID NO:138        1388 aa MW at 145607.6 kD
NOV31a.            MKSALIPLVYRGGKRGPEMASPRARKPQSQCWDFTVHCATCLGKVTSLLCLYKTRTDW
CG59289-01 Protein LTPSAGIRIGRECSERFPTPGGNSLELCSEPKLSRVGQCQAQGRCSVPDSYCCNXGNS
Sequence           LELCSEPKLSRVGQCQAQGTVPSEPPSACASDPCAPGTECQATESGGYTCGPMEPRGC
                   ATQPCHHGALCVPQGPDPTGFRCYCVPGFQGPRCELDIDECASRPCHHGATCRNLADR
                   YECHCPLGYAGVTCEMEVDECASAPCLHGGSCLDGVGSFRCVCAPGYGGTRCQLDLDE
                   CQSQPCAHGGTCHDLVNGFRCDCAGTGYEGTHCEREVLECASAPCEHNASCLEGLGSF
                   RCLCWPGYSGELCEVDEDECASSPCQHGGRCLQRSDPALYGGVQAAFPGAFSFRHAAG
                   FLCHCPPGFEGADCGVEVDECASRPCLNGGHCQDLPNGFQCHCPDGYAGPTCEEDVDE
                   CLSDPCLHGGTCSDTVAGYICRCPETwGGRDCSVQLTGCQGHTCPLAATCIPIFESGV
                   HSYVCHCPPGTHCPFCGQNTTFSVMAGSPIQASVPAGGPLGLALRFRTTLPAGTLATR
                   NDTKESLELALVAATLQATLWSYSTTVLVLRLPDLALNDGHWHQVEVVLHLATLELRL
                   WHEGCPARLCVASGPVALASTASATPLPAGISSAQLGDATFAGCLQDVRVDGHLLLPE
                   DLGENVLLGCERREQCRPLPCVHGGSCVDLWTHFRCDCARPHRGPTCADEIPAATFGL
                   GGAPSSASFLLQELPGPNLTVSFLLRTRESAGLLLQFANDSAAGLTVFLSEGRIRAEV
                   PGSPAVVLPGRWDDGLRHLVMLSFGPDQLQDLGQHVHVGGRLLAADSQPWGGPFRGCL
                   QDLRLDGCHLPFFPLPLDNSSQPSELGGRQSWNLTAGCVSEDMCSPDPCFNGGTCLVT
                   WNDFHCTCPANFTGPTCAQQLWCPGQPCLPPATCEEVPDGFVCVAEATFREGPPAAFS
                   GHNASSGRLLGGLSLAFRTRDSEAWLLRAAAGALEGVWLAVRNGSLAGGVRGGHGLPG
                   AVLPIPGPRVADGAWHRVRLANERPAATTSRWLLWLDGAATPVALRGLASDLGFLQGP
                   GAVRILLAENFTGCLGRVALGGLPLPLARPRPGAAPGAREHFASWPGTPAPILGCRGA
                   PVCAPSPCLHDGACRDLFDAFACACGPGWEGPRCEAHVDPCHSAPCARGRCHTHPDGR
                   FECRCPPGFGGPRCRLPVPSKECSLNVTCLDGSPCEGGSPAANCSCLEGLAGQRCQVP
                   TLPCEANPCLNGGTCRAAGGVSECICNARFSGQFCEVAKGLPLPLPFPLLEVAVPAAC
                   ACLLLLLLCLLSGILAARKRRQSEGTYSPSQQEVAGARLEMDSVLKVPPEERLI
                   SEQ ID NO:139        4200 bp
NOV31b,            TAACGAGGTCTAATTTAATTCTCCCAACAGCCTATGAAGTCAGCTCTGATACCCCTAG
CG59289-02 DNA     TTTACAGAGGAGGTAAACGAGGCCCAGAGATGGCCAGTCCCAGAGCCAGGAAGCCCCA
Sequence           GAGCCAGTGCTCGGATTTCACAGTACACTGTGCTACTTGCCTAGGCAAAGTCACGTCT
                   CTTCTCTGTCTCTACAAAACGAGGACAGACTGGCTTACTCCGAGCGCTGGTATAAGGA
                   TTGGAAGAGAATGCAGTGAGCGGTTCCCCACCCCAGGAGGTAACTCCCTGGAACTGTG
                   CTCTGAGCCCAAACTCTCAAGCGTTGGTCAGTGCCAGGCACAGGGTAGGTGCTCCGTC
                   CCTGACAGCTATTGTTGCAATCGAOCTAACTCCCTGGAACTGTGCTCTGAGCCCAAAC
                   TCTCAAGGGTTGGTCAGTGCCAGGCACAGCGGACGGTGCCTTCAGAGCCCCCCACTGC
                   CTGTGCCTCAGACCCGTGCGCTCCAGGGACCGAGTGCCAGGCTACCGAGAGTGGTGGC
                   TATACCTGTCCGCCCATGGAGCCCCGGGGCTGTGCCACCCAGCCATGCCACCACGGCG
                   CTCTGTGTGTGCCCCAGGGTCCAGATCCCACCGGCTTCCGCTGCTACTGCGTGCCGGG
                   TTTCCAGGGCCCACGCTGCGAGCTGGACATCGATGAGTGTGCATCCCGGCCGTGCCAC
                   CATGGGGCCACCTGCCGCAACCTGGCCGATCGCTACGAGTGCCATCGCCCCCTTGGCT
                   ATGCAGGCGTGACCTGCGAGACGGAGGTGGACGAGTGCGCCTCAGCGCCCTGCCTGCA
                   CGGGGCCTCGTGCCTGGACGGCGTGGGCTCCTTCCGCTGTGTGTGCGCGCCAGGCTAC
                   GGGGGCACCCGTTGCCAGCTCGACCTCGACCAGTGCCAGAGCCAGCCGTGCGCACATG
                   GGGGCACGTGCCACGACCTGGTCAACGGGTTCCCCTGCGACTGCGCGGGCACCGGCTA
                   CGAGGGCACGCACTGCGAGCGGGAGGTGCTGGAGTGCGCATCGGCGCCCTGCGAGCAC
                   AACGCGTCCTGCCTCGAGGGCCTCGGGAGCTTCCGCTGCCTCTGTTGGCCAGGCTACA
                   GCGGCGAGCTGTGCGAGGTGCACGAGGACGAGTGTGCATCGAGCCCCTGCCAGCATGG
                   GGGCCGATGCCTGCAGCGCTCTGACCCGGCCCTCTACGGGGGTGTCCAGGCCGCCTTC
                   CCTCGCGCCTTCAGCTTCCGCCATGCTGCGGGTTTCCTGTGCCACTGCCCTCCTGGCT
                   TTGAGGGAGCCGACTGCGGTGTGGAGGTGGACGAGTGTGCCTCACGGCCATGCCTCAA
                   CGGAGGCCACTGCCAGGACCTGCCCAATGGCTTCCAGTGTCACTGCCCAGATGGCTAC
                   GCAGGGCCGACATGTGACCAAGATGTGGATGAATGCCTGTCGGATCCCTGCCTGCACG
                   GCGGAACCTGCAGTGACACTGTGGCAGGCTATATCTGCAGGTGCCCAGAGACCTGGGG
                   TGGGCGCGACTGTTCTGTGCAGCTCACTGGCTGCCAGGGCCACACCTGCCCGCTGGCT
                   GCCACCTGCATCCCTATCTTCGAGTCTGGGGTCCACAGTTACGTCTGCCACTGCCCAC
                   CTGGTACCCATGGACCGTTCTGTGGCCAGAATACCACCTTCTCTGTGATGGCTGGGAG
                   CCCCATTCAGGCATCAGTGCCAGCTGGTGGCCCCCTGGGTCTGGCACTGAGGTTTCGC
                   ACCACACTGCCCGCTGGGACCTTGGCCACTCGCAATGACACCAAGGAAAGCTTGGAGC
                   TGGCATTGGTGGCAGCCACACTTCAGGCCACACTCTGGAGCTACAGCACCACTGTGCT
                   TGTCCTGAGACTGCCGGACCTGGCCCTAAACGATGGCCATTGGCACCAGGTGGAGGTT
                   GTGCTCCATCTAGCGACCCTGGAGCTACGGCTCTGGCATGAGGGTGCCCTGCCCGGC
                   TCTGTGTGGCCTCTGGTCCTGTGGCCCTGGCTTCCACGGCTTCGGCAACTCCGCTGCC
                   TGCCGGGATCTCCTCTGCCCAGCTGGGGGACGCGACCTTTGCAGGCTGCCTCCAGGAC
                   GTGCGTGTGGATGGCCACCTCCTGCTGCCTGAGGATCTCGGTGAGAACGTCCTCCTGG
                   GCTGTGAGCGCCGAGAGCAGTGCCGGCCTCTGCCTTGTGTCCACGGAGGGTCCTGTGT
                   GGATCTGTGGACTCATTTCCGTTGCGACTGTGCCCGGCCCCATAGAGGTCCCACGTGC
                   GCTGATGAGATTCCTGCTGCCACCTTTGGCTTGGGAGGCGCCCCAAGCTCTGCCTCCT
                   TTCTGCTCCAAGAGCTGCCAGGTCCCAACCTCACAGTGTCTTTCCTTCTCCGCACTCG
                   GGAGTCCGCTGGCCTGTTGCTCCAGTTTGCCAATGACTCCGCAGCTGGCCTIACAGTA
                   TTCCTGAGTCACCGTCGGATCCGGGCTGAGGTGCCGGGCAGTCCTGCTGTAGTGCTCC
                   CTGGGCGCTGGGATGATGGGCTCCGTCACCTGGTGATGCTCAGCTTCGGGCCTGACCA
                   GCTGCAGGACCTGGGGCAGCACGTGCACGTGGGTGGGAGGCTCCTTGCTGCCGACAGC
                   CAGCCCTGGGGTGGGCCCTTCCGAGGCTGCCTCCAGGACCTGCGACTCGATGGCTGCC
                   ACCTCCCCTTCTTTCCTCTGCCACTGGATAACTCAAGCCAGCCCAGCGAGCTCGGCGG
                   CACGCAGTCCTGGAACCTCACTGCGGGCTGCGTCTCCGAGCACATGTGCAGTCCTGAC
                   CCCTGTTTCAATGGTGGGACTTGCCTCGTCACCTGGAATGACTTCCACTGTACCTGCC
                   CTGCCAATTTCACGGGGCCTACGTGTGCCCAGCAGCTGTGGTGTCCCGCCCAGCCCTG
                   TCTCCCACCTGCCACGTGTGAGGAGGTCCCTGATGGCTTTGTGTGTGTGGCGGAGGCC
                   ACGTTCCGCGACCGTCCCCCCGCCGCGTTCAGCGGGCACAACGCGTCGTCAGGGCGCT
                   TGCTCGGCGGCCTGTCGCTGGCCTTTCGCACGCGCGACTCCGAGGCCTGGCTGCTGCG
                   TGCCGCGGCGGGCGCCCTGGAAGGCGTGTGGCTGGCGGTGCGCAATGGCTCGCTGGCG
                   GGGGGCGTGCGCGGAGGCCATGGCCTGCCCGGCGCTGTGCTGCCCATACCGGGGCCGC
                   GCGTGGCCGATGGTGCCTGGCACCGCGTGCGTCTGGCCATGGACCGCCCGGCGGCCAC
                   CACCTCGCGCTGGCTGCTGTGCCTCGATGGTGCCGCCACCCCGGTGGCGCTGCGCGGC
                   CTGGCCAGTGACCTGGGCTTCCTGCAGGGCCCGGCTGCTGTGCGCATCCTGCTGGCTG
                   AGAACTTCACCGGCTGCTTGGGCCGCGTGGCGCTGGGCGGCCTGCCCCTGCCCTTGGC
                   GCGGCCCCGGCCCGGCGCGGCCCCTGGCGCCCGAGAGCACTTCGCGTCTTGGCCTGGG
                   ACGCCGGCCCCGATCCTCGGCTCCCGCGGCGCGCCCGTGTGTGCGCCCTCGCCCTGTC
                   TGCACGACGGTGCCTGCCGTGACCTCTTCGACGCCTTTGCCTGCGCCTGCGGCCCGGG
                   GTGGGAAGGCCCGCGCTGCGAAGCCCACGTCGACCCCTGTCACTCCGCCCCCTGCGCC
                   CGTGGCCGCTGTCACACGCACCCCGACGGCCGCTTCGAGTGCCGCTGCCCGCCTGGCT
                   TCGCGGCCCCGCGCTGCAGGTTGCCTGTCCCATCCAAGGAGTGCAGCCTGAATGTCAC
                   CTCCCTCGATGGCAGCCCATGTGAGGGTGGCTCTCCCGCTGCCAACTGCAGCTGCCTG
                   GAGGGTCTTGCTGGCCAGAGGTGTCAGGTCCCCACTCTCCCCTGTGAAGCCAACCCCT
                   GCTTGAATGGGGGCACCTGCCGGGCAGCTGGAGGGGTGTCTGAATGTATCTGCAATGC
                   CAGATTCTCCGGCCAGTTCTGTGAAGTGGCGAAGGGCCTGCCCCTGCCGCTGCCATTC
                   CCACTGCTGGAGGTGGCCGTACCTGCAGCCTGTGCCTGCCTCCTCCTCCTCCTCCTGG
                   GCCTCCTTTCAGGGATCCTCGCAGCCCGAAAGCGCCGCCAGTCTGAGGGCACCTACAG
                   CCCAAGCCACCAGGACCTCGCTGGGGCCCGGCTGGAGATGGACAGTGTCCTCAAGGTG
                   CCACCGGAGGAGAGACTCATCTAG
                   ORF Start: ATG at 34 ORF Stop: TAG at 4198
                   SEQ ID NO:140        1388 aa MW at 145800.8 kD
NOV31b,            MKSALIPLVYRGGKRGPEMASPRARKPQSQCWDFTVHCATCLGKVTSLLCLYKTRTDW
CG59289-02 Protein LTPSAGIRIGRECSERFPTPGGNSLELCSEPKLSRVGQCQAQGRCSVPDSYCCNRGNS
Sequence           LELCSEPKLSRVGQCQAQGTVPSEPPSACASDPCAPGTECQATESGGYTCGPMEPRGC
                   ATQPCHHGALCVPQGPDPTGFRCYCVPCFQGPRCELDIDECASRPCHHGATCRNLADR
                   YECHRPLGYAGVTCETEVDECASAPCLHCASCLDGVGSFRCVCAPGYGGTRCQLDLDE
                   CQSQPCAHGGTCHDLVNGFRCDCAGTGYEGTHCEREVLECASAPCEHNASCLEOLGSF
                   RCLCWPGYSGELCEVDEDECASSPCQHGGRCLQRSDPALYGGVQAAFPGAFSFRHAAG
                   FLCHCPPGFEGADCGVEVDECASRPCLNGGHCQDLPNGFQCHCPDGYAGPTCEEDVDE
                   CLSDPCLHGGTCSDTVAGYICRCPETWGGRDCSVQLTGCQGHTCPLAATCIPIFESGV
                   HSYVCHCPPGTHGPFCGQNTTFSVMAGSPIQASVPAGGPLGLALRFRTTLPAGTLATR
                   NDTKESLELALVAATLQATLWSYSTTVLVLRLPDLALNDGHWHQVEVVLHLATLELRL
                   WHEGCPARLCVASGPVALASTASATPLPAGISSAQLGDATFAGCLQDVRVDGHLLLPE
                   DLGENVLLGCERREQCRPLPCVHGGSCVDLWTHFRCDCARPHRGPTCAEEIPAATFGL
                   GGAPSSASFLLQELPGPNLTVSFLLRTRESAGLLLQFANDSAAGLTVFLSEGRIRAEV
                   PGSPAVVLPGRWDDGLRHLVMLSFGPDQLQDLGQHVHVGGRLLAADSQPWGGPFRGCL
                   QDLRLDGCHLPFFPLPLDNSSQPSELGGRQSWNLTAGCVSEDMCSPDPCFNGGTCLVT
                   WNDFHCTCPANFTGPTCAQQLWCPGQPCLPPATCEEVPDGFVCVAEATFREGPPAAFS
                   GHNASSGRLLGGLSLAFRTRDSEAWLLRAAAGALEGVWLAVRNGSLAGGVRGGHGLPG
                   AVLPIPGPRVADGAWHRVRLAMERPAATTSRWLLWLDGAATPVALRGLASDLGFLQGP
                   GAVRILLAENFTGCLGRVALGGLPLPLARPRPGAAPGAREHFASWPGTPAPILGCRGA
                   PVCAPSPCLHDGACRDLFDAFACACGPGWEGPRCEAHVDPCHSAPCARGRCHTHPDGR
                   FECRCPPGFCGPRCRLPVPSKECSLNVTCLDGSPCEGGSPAANCSCLEGLAGQRCQVP
                   TLPCEANPCLNGGTCRAAGGVSECICNARFSGQFCEVAKGLPLPLPFPLLEVAVPAAC
                   ACLLLLLLGLLSGILAARKRRQSEGTYSPSQQEVAGARLEMDSVLKVPPEERLI

[0481] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 31B.

TABLE 31B
Comparison of NOV31a against NOV31b and NOV31c.
	NOV31a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV31b	1 . . . 1388	1284/1388 (92%)
	1 . . . 1388	1284/1388 (92%)

[0482] Further analysis of the NOV31 a protein yielded the following properties shown in Table 31C.

TABLE 31C
Protein Sequence Properties NOV31a
PSort     0.7000 probability located in plasma membrane; 0.3000
analysis: probability located in microbody (peroxisome); 0.2000
          probability located in endoplasmic reticulum (membrane);
          0.1000 probability located in mitochondrial inner membrane
          No Known Signal Sequence Indicated
analysis:

[0483] A search of the NOV31a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 31D.

TABLE 31D
Geneseq Results for NOV31a
		NOV31a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAB40530	Human ORFX ORF294 polypeptide	339 . . . 586	248/248 (100%)	e−160
	sequence SEQ ID NO: 588 - Homo	1 . . . 248	248/248 (100%)
	sapiens, 248 aa. [WO200058473-A2,
	05-OCT-2000]
AAU16970	Human novel secreted protein, SEQ ID	194 . . . 743	214/581 (36%)	e−118
	211 - Homo sapiens, 604 aa.	19 . . . 557	308/581 (52%)
	[WO200155441-A2, 02-AUG-2001]
AAY06816	Human Notch2 (humN2) protein	145 . . . 541	166/434 (38%)	2e−94
	sequence - Homo sapiens, 2471 aa.	799 . . . 1225	229/434 (52%)
	[WO9904746-A2, 04-FEB-1999]
AAB40789	Human ORFX ORF553 polypeptide	842 . . . 990	147/149 (98%)	2e−92
	sequence SEQ ID NO: 1106 - Homo	1 . . . 149	148/149 (98%)
	sapiens, 149 aa. [WO200058473-A2,
	05-OCT-2000]
AAW49698	Human Notch3 protein - Homo	144 . . . 747	201/618 (32%)	3e−92
	sapiens, 2321 aa. [FR2751986-A1,	354 . . . 888	260/618 (41%)
	06-FEB-1998]

[0484] In a BLAST search of public sequence databases, the NOV31a protein was found to have homology to the proteins shown in the BLASTP data in Table 31E.

TABLE 31E
Public BLASTP Results for NOV31a
		NOV31a
Protein		Residues/	Identities/
Accession		Match	Similarities for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
AAL10682	CRB1 ISOFORM II PRECURSOR -	111 . . . 1388	448/1375 (32%)	0.0
	Homo sapiens (Human), 1406 aa.	98 . . . 1406	664/1375 (47%)
AAL65131	PRECURSOR - Mus musculus	37 . . . 1405	656/1434 (45%)	0.0
	(Mouse), 1405 aa.
P82279	Crumbs protein homolog 1	111 . . . 1313	421/1300 (32%)	0.0
	precursor - Homo sapiens (Human),	98 . . . 1334	621/1300 (47%)
	1376 aa.
Q9VC97	CRB PROTEIN - Drosophila	95 . . . 1312	430/1432 (30%)	e−174
	melanogaster (Fruit fly), 2146 aa.	552 . . . 1948	610/1432 (42%)
P10040	Crumbs protein precursor (95F) -	95 . . . 1312	430/1444 (29%)	e−172
	Drosophila melanogaster (Fruit fly),	554 . . . 1951	613/1444 (41%)
	2139 aa.

[0485] PFam analysis indicates that the NOV31a protein contains the domains shown in the Table 31F.

TABLE 31F
Domain Analysis of NOV31a
		Identities/Similarities
Pfam Domain	NOV31a Match Region	for the Matched Region	Expect Value
EGF: domain 1 of 16	86 . . . 120	8/50 (16%)	52
		20/50 (40%)
EGF: domain 2 of 16	174 . . . 208	15/47 (32%)	3.5e−05
		27/47 (57%)
EGF: domain 3 of 16	215 . . . 246	16/47 (34%)	2.2e−09
		27/47 (57%)
EGF: domain 4 of 16	253 . . . 284	16/47 (34%)	6.5e−08
		27/47 (57%)
EGF: domain 5 of 16	291 . . . 323	13/47 (28%)	0.00014
		27/47 (57%)
EGF: domain 6 of 16	330 . . . 361	13/47 (28%)	5.3e−07
		25/47 (53%)
EGF: domain 7 of 16	368 . . . 420	15/61 (25%)	1.8
		33/61 (54%)
EGF: domain 8 of 16	427 . . . 458	17/47 (36%)	5.1e−09
		29/47 (62%)
EGF: domain 9 of 16	465 . . . 496	15/47 (32%)	2.9e−08
		25/47 (53%)
EGF: domain 10 of 16	503 . . . 538	12/47 (26%)	0.19
		25/47 (53%)
laminin_G: domain 1 of 5	568 . . . 628	24/76 (32%)	0.012
		39/76 (51%)
laminin_G: domain 2 of 5	679 . . . 694	7/16 (44%)	0.2
		15/16 (94%)
EGF: domain 11 of 16	712 . . . 743	12/47 (26%)	0.00015
		25/47 (53%)
laminin_G: domain 3 of 5	865 . . . 881	6/17 (35%)	4.4
		14/17 (82%)
EGF: domain 12 of 16	914 . . . 945	16/47 (34%)	6.1e−09
		28/47 (60%)
laminin_G: domain 4 of 5	1003 . . . 1068	21/79 (27%)	0.00031
		45/79 (57%)
laminin_G: domain 5 of 5	1113 . . . 1128	7/16 (44%)	0.86
		12/16 (75%)
EGF: domain 13 of 16	1163 . . . 1194	14/47 (30%)	1.8e−07
		24/47 (51%)
EGF: domain 14 of 16	1201 . . . 1232	15/47 (32%)	0.001
		25/47 (53%)
metalthio: domain 1 of 1	1198 . . . 1266	20/75 (27%)	6.9
		41/75 (55%)
EGF: domain 15 of 16	1241 . . . 1273	11/47 (23%)	4.5
		17/47 (36%)
EB: domain 1 of 1	1223 . . . 1273	15/60 (25%)	4.8
		33/60 (55%)
EGF: domain 16 of 16	1280 . . . 1311	15/47 (32%)	0.00045
		23/47 (49%)

Example 32

[0486] The NOV32 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 32A.

TABLE 32A
NOV32 Sequence Analysis
	SEQ ID NO:141	2855 bp
NOV32a	GAGGGAATGCGCGCACCTCACAGGCCCTGGGAGTGAGCTGGTGCCCGGCGACCTGGCA
CG57111-01 DNA	CCCGCGCCTGGATATGGGGCGTCTACATCGTCCCAGGAGCAGCACCAGCTACACGAAC
Sequence	CTGCCGCATCTGTTTCTGTTTTTCCTCTTCGTGGGACCCTTCAGCTGCCTCGGGAGTT
	ACAGCCGGGCCACCGAGCTTCTGTACAGCCTAAACGAGGGACTACCCGCGGGGGTGCT
	CATCGGCAGCCTGGCCGAGGACCTGCGGCTGCTGCCCAGGTCTGCAGGGAGGCCGGAC
	CCGCAGTCGCAGCTGCCAGAGCGCACCGGTGCTCAGTGGAACCCCCCTCTCTCCTTCA
	GCCTGGCCTCCCGGGGACTGAGTGGCCAGTACGTGACCCTAGACAACCGCTCTGGGGA
	GCTGCACACTTCACCTCAGGAGATCGACAGGCAGGCCCTGTGTGTTCAAGGGGGTGGA
	GGGACTGCGTGGAGCGGCAGCGTTTCCATCTCCTCCTCTCCTTCTGACTCTTGTCTTT
	TGCTGCTGGATGTGCTTGTCCTGCCTCAGGAATACTTCAGGTTTGTGAAGGTGAAGAT
	CGCCATCAGAGACATCAATGACAACGCCCCGCAGTTCCCTGTTTCCCAGATCTCGGTG
	TCGGTCCCGGAAAATGCACCTGTAAACACCCGACTGGCCATAGAGCATCCTGCTGTGG
	ACCCAGATGTTGGCATTAATGGCGTTCAGACCTATCGCTTACTGGACTACCATGGTAT
	GTTCACCCTGGACGTGGAGGAGAATGAGAATGGGGAGCGCACCCCCTACCTAATTCTC
	ATGCGTGCTTTGGACAGGGAAACCCAGGACCAGTATGTGAGCATCATCACAGCTGAGG
	ATGGTGGCTCTCCACCACTTTTGGGCAGTGCCACTCTCACCATTGGCATCAGTGACAT
	TAATGACAATTGCCCTCTCTTCACAGACTCACAAATCAATGTCACTGTGTATGGGAAT
	GCTACAGTGGGCACCCCAATTGCAGCTGTCCAGGCTGTGGATAAAGACTTGGGGACCA
	ATGCTCAAATTACTTATTCTTACAGTCAGAAAGTTCCACAAGCATCTAAGGATTTATT
	TCACCTGGATGAAAACACTGGAGTCATTAAACTTTTCAGTAAGATTGGAGGAAGTGTT
	CTGGAGTCCCACAAGCTCACCATCCTTGCTAATGGACCAGGCTGCATCCCTGCTGTPA
	TCACTGCTCTTGTGTCCATTATTAAAGTTATTTTCAGACCCCCTGAAATTGTCCCTCG
	TTACATAGCAAACGAGATAGATGGTGTTGTTTATCTGAAAGAACTGGAACCCGTTAAC
	ACTCCCATTGCGTTTTTCACCATAAGAGATCCAGAAGGTAAATACAAGGTTAACTGCT
	ACCTGGATGGTGAAGGGCCGTTTAGGTTATCACCTTACAAACCATACAATAATGAATA
	TTTACTAGAGACCACAAAACCTATGGACTATGAGCTACAGCAGTTCTATGAAGTAGCT
	GTGGTGGCTTGGAACTCTGAGGGATTTCATGTCAAAAGGGTCATTAAAGTGCAACTTT
	TAGATGACAATGATAATGCTCCAATTTTCCTTCAACCCTTAATAGAACTAACCATCGA
	AGAGAACAACTCACCCAATGCCTTTTTGACTAAGCTGTATGCTACAGATGCCGACAGC
	GAGGAGAGAGGCCAAGTTTCATATTTTCTGGGACCTGATGCTCCATCATATTTTTCCT
	TAGACAGTGTCACAGGAATTCTGACAGTTTCTACTCACCTGGACCGAGAAGAGAAAGA
	AAAGTACAGATACACTGTCAGAGCTGTTGACTGTGGGAAGCCACCCAGAGAATCAGTA
	GCCACTGTGGCCCTCACAGTGTTGGATAAAAATGACAACAGTCCTCGGTTTATCAACA
	AGGACTTCAGCTTTTTTGTGCCTGAAAACTTTCCAGGCTATGGTGAGATTGGAGTAAT
	TAGTGTAACAGATGCTGACGCTGGACGAAATGGATGGGTCGCCCTCTCTGTGGTGAAC
	CAGAGTGATATTTTTGTCATAGATACAGGAAAGGGTATGCTGAGGGCTAAAGTCTCTT
	TGGACAGAGAGCAGCAAAGCTCCTATACTTTGTGCGTTGAAGCTGTTGATGGGGGTGA
	GCCTGCCCTCTCCTCTACAGCAAAAATCACAATTCTCCTTCTAGATATCAATGACAAC
	CCTCCTCTTGTTTTGTTTCCTCAGTCTAATATGTCTTATCTGTTAGTACTGCCTTCTA
	CTCTGCCAGGCTCCCCGGTTACAGAAGTCTATGCTGTCGACAAAGACACACGCATGAA
	TCCTGTCATAGCTTACAGCATCATAGGGAGAAGAGGTCCTAGGCCTGAGTCCTTCAGG
	ATTGACCCTAAAACTGGCAACATTACTTTGGAAGAGGCATTGCTGCAGACAGATTATG
	GGCTCCATCGCTTACTGGTGAAAGTGAGTGATCATGGTTATCCCCAGCCTCTCCACTC
	CACACTCATGGTGAACCTATTTGTCAATGACACTGTCAGTAATGAGAGTTACATTGAG
	AGTCTTTTAAGAAAAGAACCAGAGATTAATATAGAGGAGAAAGAACCACAAATCTCAA
	TAGAACCGACTCATAGGAAGGTACAATCTCTGTCTTGTATGCCCACCTTAGTAGCTCT
	GTCTGTAATAAGCTTGGGTTCCATCACACTGGTCACAGGGATCGGCATATACATCTGT
	TTAAGGAAAGGGGAAAAGCATCCCAGGGAAGATGAAAATTTGGAAGTACAGATTCCAC
	TGAAAGGAAAAATTGACTTGCATATGCGAGAGAGAAAGCCAATGGATATTTCTAATAT
	TTGATATTTCATG
	ORF Start: GGG at 3	ORF Stop: TGA at 2844
	SEQ ID NO:142	947 aa MW at 104405.1 kD
NOV32a,	GNARSSQALGVSWCPATWHPRLDMGRLHRPRSSTSYRNLPHLFLFFLPVGPFSCLGSY
CG57111-01	Protein	SRATELLYSLNEGLPAGVLIGSLAEDLRLLPRSAGRPDPQSQLPERTGAEWNPPLSFS
Sequence	LASRGLSGQYVTLDNRSGELHTSAQEIDREALCVEGGCGTAWSGSVSISSSPSDSCLL
	LLDVLVLPQEYFRFVKVKIAIRDINDNAPQFPVSQISVWVPENAPVNTRLAIEHPAVD
	PDVGILNGVQTYRLLDYHGMFTLDVEENENGERTPYLIVMGALDRETQDQYVSIITAED
	GGSPPLLGSATLTIGISDINIJNCPLFTDSQINVTVYGNATVGTPIAAVQAVDKDLGTN
	AQITYSYSQKVPQASKDLFHLDENTGVIKLFSKIGGSVLESHIKLTILANGPCCIPAVI
	TALVSIIKVIFRPPEIVPRYIANEIDGVVYLKELEPVNTPIAFFTIRDPEGKYKVNCY
	LDGEGPFRLSPYKPYNNEYLLETTKPMDYELQQFYEVAVVAWNSEGFHVKRVIKVQLL
	DDNDNAPIFLQPLIELTIEENNSPNAFLTKLYATDADSEERGQVSYFLGPDAPSYFSL
	DSVTGILTVSTQLDREEKEKYRYTVRAVDCGKPPRESVATVALTVLDKNDNSPRFINK
	DFSFFVPENFPGYGEIGVISVTDADAGRNGWVALSVVNQSDIFVIDTGKGMLRAKVSL
	DREQQSSYTLWVEAVDGGEPALSSTAKITILLLDINDNPPLVLFPQSNMSYLLVLPST
	LPGSPVTEVYAVDKDTGMNAVIAYSIIGRRGPRPESFRIDPKTGNITLEEALLQTDYG
	LHRLLVKVSDHGYPEPLHSTVMVNLFVNDTVSNESYIESLLRKEPEINIEEKEPQISI
	EPTHRKVESVSCMPTLVALSVISLGSITLVTGMGIYICLRKGEKHPREDENLEVQIPL
	KGKIDLHMRERKPMDISNI

[0487] Further analysis of the NOV32a protein yielded the following properties shown in Table 32B.

TABLE 32B
Protein Sequence Properties NOV32a
PSort     0.6400 probability located in plasma membrane; 0.4000
analysis: probability located in Golgi body; 0.3000
          probability located in endoplasmic reticulum (membrane);
          0.0300 probability located in mitochondrial inner membrane
SignalP   Cleavage site between residues 57 and 58
analysis:

[0488] A search of the NOV32a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 32C.

TABLE 32C
Geneseq Results for NOV32a
		NOV32a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAU19645	Human novel extracellular matrix	551 . . . 947	396/397 (99%)	0.0
	protein, Seq ID No 295 - Homo	1 . . . 397	397/397 (99%)
	sapiens, 397 aa. [WO200155368-A1,
	02-AUG-2001]
AAM79103	Human protein SEQ ID NO 1765 -	46 . . . 858	347/820 (42%)	0.0
	Homo sapiens, 1021 aa.	8 . . . 791	506/820 (61%)
	[WO200157190-A2, 09-AUG-2001]
AAM80087	Human protein SEQ ID NO 3733 -	127 . . . 868	325/747 (43%)	e−175
	Homo sapiens, 1090 aa.	5 . . . 728	475/747 (63%)
	[WO200157190-A2, 09-AUG-2001]
AAU19807	Human novel extracellular matrix	553 . . . 839	287/287 (100%)	e−164
	protein, Seq ID No 457 - Homo	1 . . . 287	287/287 (100%)
	sapiens, 288 aa. [WO200155368-A1,
	02-AUG-2001]
AAM31106	measuring placental gene expression -	4 . . . 611	398/612 (64%)	e−148
	Homo sapiens, 831 aa.
	[WO200157272-A2, 09-AUG-2001]

[0489] In a BLAST search of public sequence databases, the NOV32a protein was found to have homology to the proteins shown in the BLASTP data in Table 32D.

TABLE 32D
Public BLASTP Results for NOV32a
		NOV32a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9NRT9	PROTOCADHERIN 13 - Homo	1 . . . 947	947/947 (100%)	0.0
	sapiens (Human), 947 aa (fragment).	1 . . . 947	947/947 (100%)
Q9HC56	ROTOCADHERIN-9 - Homo sapiens	45 . . . 862	364/823 (44%)	0.0
	(Human), 1203 aa.	6 . . . 797	507/823 (61%)
Q95KD8	HYPOTHETICAL 113.7 KDA	45 . . . 862	363/823 (44%)	0.0
	PROTEIN - Macaca fascicularis (Crab	6 . . . 797	507/823 (61%)
	eating macaque) (Cynomolgus
	monkey), 1032 aa.
Q9H4E0	PROTOCADHERIN - Homo sapiens	46 . . . 858	347/820 (42%)	0.0
	(Human), 1025 aa.	8 . . . 791	506/820 (61%)
Q9BZA6	PROTOCADHERIN 11 - Homo	46 . . . 858	347/820 (42%)	0.0
	sapiens (Human), 1337 aa.	8 . . . 791	506/820 (61%)

[0490] PFam analysis indicates that the NOV32a protein contains the domains shown in Table 32E.

TABLE 32E
Domain Analysis of NOV32a
		ldentities/
		Similarities
Pfam Domain	NOV32a Match Region	for the Matched Region	Expect Value
cadherin: domain 1 of 5	210 . . . 307	38/111 (34%)	1.5e−08
		72/111 (65%)
cadherin: domain 2 of 5	321 . . . 413	27/110 (25%)	0.00028
		67/110 (61%)
cadherin: domain 3 of 5	536 . . . 626	32/107 (30%)	1.1e−18
		68/107 (64%)
cadherin: domain 4 of 5	640 . . . 729	70/107 (65%)	9.1e−20
cadherin: domain 5 of 5	747 . . . 840	37/112 (33%)	6.6e−11
		69/112 (62%)

Example 33

[0491] The NOV33 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 33A.

TABLE 33A
NOV33 Sequence Analysis
                   SEQ ID NO:143        1289 bp
NOV33a,            TCCCAGCCTCGCAGCCGGCCTGAGCCGCCATGCGCGGGAAGTTGCTGCCGCTGGCCGG
CG59363-01 DNA     CCTCTACCTGGTGCAGGGCCTGCCCTACGGGCTCCAGTCCGGCCTCCTGCCAGTCCTG
Sequence           CTGCGTGCCGGCGGCCTCTCGCTGACGCGCGTGGGGCTGGCCAAGGTTCTGTACGCTC
                   CGTGCCTGCTCAAGCTGGCTTGGGCCCCGCTGGTGGACGCGCAGGGCTCGGCGAGGGC
                   CTGCGTCACCCGCAGCACCGCGGGCCTCGGCCTGGTCTGTGGCCTGCTTGCCGGGCTG
                   CCCCCTCCTGGAGCTGGCCAGGCCCGGCTGCCCGCCGCTGTGGCGGGGTTGCTGCTGT
                   TGTTGAACCTGGGTGCCGCCATGCAGGATGTGGCCCTGGACGCGCTGGCTGTGCAGCT
                   GCTGGAGCCGCCCGAACTGCGGCCGGGCAATACCGTGCAGGTGGTCGCGTACAAGCTG
                   GGGGCCGCGCTAGCTGGGGGCGCGCTCCTGGCGCTGCTGCCCACCTTCTCGTGGCCGC
                   AACTCTTTCTGCTCCTGGCTGCCACCTACTGGCTGGCCGCGGCCCTGGCCTGGGCTGC
                   ACCAGCCCTGCCGCGGCTCCCACAGCAGCCCCCTTCCGAGCAGCGTCCCCACACCGCG
                   CACCTTCTGCGGGACGTGCTAGCCGTGCCGGGCACCGTGTGGACGGCAGGCTTTGTGC
                   TCACCTACAAGCTGGGTGAGCAGGGTGCCAGCAGCCTGTTTCCTCTTCTCCTGCTGGA
                   CCACGGCGTTTCTGCTCCCGAGTTGGGACTGTGGAATGGTGTGGGTGCTGTGGTCTGC
                   TCCATCGCTGGCTCCTCCCTGGGTGGGACCTTGCTGGCCAAGCACTGGAAACTGCTGC
                   CTCTGTTGAGGTCGGTGCTGCGCTTCCGCCTCGGGGGCCTAGCCTGTCAGACTGCCTT
                   GGTCTTCCACCTGGACACCCTGGGGGCCAGCATGGACGCTGGCACAATCTTGAGAGGT
                   TCAGCCTTGCTGAGCCTATGTCTGCACCACTTCTTGGCAGGCCTGGTCACCACAGTCA
                   CCTTCACTGGGATGATGCGCTGCAGCCAGCTGGCCCCCAGGGCCCTGCAGGCCACACA
                   CTACAGCCTTCTCGCCACGCTGGAGCTGCTGGGGAAGCTGCTGCTGGGCACTCTGGCC
                   GGAGGCCTGGCTGATGGGTTGGGGCCACATCCCTGCTTCTTGCTCCTGCTCATCCTCT
                   CTGCCTTTCCCGTTCTCTACCTGGACCTAGCACCCAGCACCTTTCTCTGAGCTGAGTG
                   GCTGGAGTGGTCA
                   ORF Start: ATG at 30 ORF Stop: TGA at 1266
                   SEQ ID NO:144        412 aa MW at 42695.2 kD
NOV33a,            MRGKLLPLAGLYLVQGLPYCLQSGLLPVLLRAGGLSLTRVGLAKVLYAPWLLKLAWAP
CG59363-01 Protein LVDAQGSARAWVTRSTAGLGLVCGLLAGLPPPGACQAGLPAAVAGLLLLLNLGAAMQD
Sequence           VALDALAVQLLEPAELGPGNTVQVVAYKLGAALAGGALLALLPTFSWPQLFLLLAATY
WLAAALAWAAPALRRLPQQPPSEQRPHTAHLLRDVLAVPGTVWTAGFVLTYKLGEQCA
                   SSLFPLLLLDHGVSAPELGLWNGVGAVVCSIAGSSLGGTLLAKHWKLLPLLRSVLRFR
                   LGGLACQTALVFHLDTLGASMDAGTILRGSALLSLCLQHFLGGLVTTVTFTGMMRCSQ
                   LAPRALQATHYSLLATLELLGKLLLGTLAGGLADGLGPHPCFLLLLILSAFPVLYLDL
                   APSTFL
                   SEQ ID NO:145        1256 bp
NOV33b,            CATGCGCGGGAAGTTGCTGCCGCTGGCCGGCCTCTACCTGGTGCAGGGCCCGCCCTAC
CG59363-02 DNA     GGGCTCCAGTCCGGCCTCCTGCCAGTGCTGCTGCGTGCCGGCGGCCTCTCGCTGACGC
Sequence           CCGTGGGGCTGGCCAAGGTTCTGTACGCTCCGTGGCTGCTCAAGCTGGCTTGGGCCCC
GCTGGTGGACGCGCAGGGCTCGGCGAGGGCCTGGGTGACGCGCAGCACGGCGGGCCTC
                   GGCCTGGTGTGTGGGCTGCTTGCCGGGCTGCCCCCTCCTGGAGCTGGCCAGGCCGCGC
                   TGCCCGCCGCTGTGGCGGGGTTGCTGCTGTTGTTGAACCTGGGTGCCGCCATGCAGGA
                   TGTGGCCCTGGACGCGCTGGCTGTGCAGCTGCTGGAGCCGGCCGAACTGGGGCCGGGC
                   AATACCGTGCAGGTGGTCGCGTACAAGCTCGGGGCCGCGCTAGCTGGGGGCGCGCTGC
                   TGGCGCTGCTGCCCACCTTCTCGTGGCCGCAACTCTTTCTGCTCCTGGCTGCCACCTA
                   CTGGCTGGCCGCGGCCCTGGCCTGGGCTGCACCAGCCCTGCGGCGGCTCCCACAGCAG
                   CCCCCTTCCGAGCAGCGTCCCCACACCGCGCACCTTCTGCGGGACGTGCTAGCCGTGC
                   CGGGGACCGTGTGGACGGCAGGCTTTGTGCTCACCTACAAGCTGGGTGAGCAGGGTGC
                   CAGCAGCCTGTTTCCTCTTCTCCTGCTGCACCACGGCGTTTCTGCTCCCCAGTTGGGA
                   CTGTGGAATGGTGTGGGTGCTGTGGTCTCCTCCATCGCTGGCTCCTCCCTGGGTCGCA
                   CCTTGCTGGCCAAGCACTGGAAACTGCTGCCTCTGTTGAGGTCGGTGCTGCGCTTCCG
                   CCTCGGGCGCCTAGCCTGTCAGACTGCCTTGGTCTTCCACCTGGACACCCTGGGGGCC
                   AGCATGGACGCTGGCACAATCTTGAGAGGGTCAGCCTTGCTGAGCCTATGTCTGCAGC
                   ACTTCTTGGGAGCCCTGGTCACCACAGTCACCTTCACTGGGATGATGCGCTGCAGCCA
                   GCTGGCCCCCAGGGCCCTGCAGGCCACACACTACAGCCTTCTGGCCACGCTGGAGTTG
                   CTGGGGAAGCTGCTGCTGGGCACTCTGGCCGGAGGCCTGGCTGATGGGTTGGGGCCAC
                   ATCCCTGCTTCTTGCTCCTGCTCATCCTCTCTGCCTTTCCCGTTCTGTACCTGGACCT
                   AGCACCCAGCACCTTTCTCTGAGCTGAGTGGCTGGAGT
                   ORF Start: ATG at 2  ORF Stop: TGA at 1238
                   SEQ ID NO:146        412 aa MW at 42679.2 kD
NOV33b,            MRGKLLPLAGLYLVQGPPYGLQSGLLPVLLRAGGLSLTRVGLAKVLYAPWLLKLAWAP
CG59363-02 Protein LVDAQGSARAWVTRSTAGLGLVCGLLAGLPPPGAGQAGLPAAVAGLLLLLNLGAAMQD
Sequence           VALDALAVQLLEPAELGPGNTVQVVAYKLGAALAGGALLALLPTFSWPQLFLLLAATY
                   WLAAALAWAAPALRRLPQQPPSEQRPHTAHLLRDVLAVPGTVWTAGFVLTYKLGEQGA
                   SSLFPLLLLDHGVSAPELGLWNGVGAVVCSIAGSSLGGTLLAKHWKLLPLLRSVLRFR
                   LGGLACQTALVFHLDTLGASMDAGTILRGSALLSLCLQHFLGGLVTTVTFTGMMRCSQ
                   LAPRALQATHYSLLATLELLGKLLLGTLACGLADCLGPHPCFLLLLILSAFPVLYLDL
                   APSTFL
                   SEQ ID NO:147        1186 bp
NOV33C,            TCCCAGCCTCGCAGCCGGCCTGAGCCGCCATGCGCGGGAAGTTGCTGCCGCTGGCCGG
CG59363-03 DNA     CCTCTACCTGGTGCAGGGCCTGCCCTACGGGCTCCAGTCCGGCCTCCTGCCAGTGCTG
Sequence           CTCCGTGCCGGCGGCCTCTCGCTGACGCCCGTGGGGCTGGCCAAGGTTCTGTACGCTC
                   CGTGGCTGCTCAAGCTGGCTTGCGCCCCGCTGGTGGACGCGCAGGGCTCGGCGAGGGC
                   CTGGGTGACGCGCAGCACGGCGGGCCTGGGCCTGGTGTGTGGGCTGCTTGCCGGGCTG
                   CCCCCTCCTGGAGCTGCCCAGGCCGGGCTGCCCGCCGCTGTGGCGGGGTTGCTGCTGT
                   TGTTGAACCTGGGTGCCGCCATGCAGGATGTGGCCCTGCACGCCCTGGCTGTGCAGCT
                   GCTGGAGCCGGCCGAACTGGGGCCGGGCAATACCGTGCAGGTGGTCGCGTACAAGCTG
                   GGGGCCGCGCTAGCTGGGGGCGCGCTGCTGGCGCTGCTGCCCACCTTCTCGTGGCCGC
                   AACTCTTTCTGCTCCTGGCTGCCACCTACTGGCTGGCCGCGGCCCTGGCCTGGGCTGC
                   ACCAGCCCTGCGGCGGCTCCCACAGCAGCCCCCTTCCGAGCAGCGTCCCCACACCGCG
                   CACCTTCTGCGGGACGTGCTAGCCGTGCCGGGGACCGTGTGGACGGCAGGCTTTGTGC
                   TCACCTACAAGCTGGGTGAGCAGGGTGCCAGCAGCCTGTTTCCTCTTCTCCTGCTGGA
                   CCACGGCGTTTCTGCTCCCGAGTTGGGACTGTGGAATGGTGTGGGTGCTGTGGTCTGC
                   TCCATCGCTGCCTCCTCCCTGGGTCGGACCTTGCTGGCCAAGCACTGGAAACTGCTGC
                   CTCTGTTGAGGTCGGTGCTGCGCTTCCGCCTCGGGGGCCTAGCCTGTCAGACTGCCTT
                   GGTCTTCCCCAGGGCCCTGCAGGCCACACACTACAGCCTTCTGGCCACGCTCGAGCTG
                   CTGGGGAAGCTGCTGCTGGGCACTCTGCCCGGAGGCCTGGCTGATGGCTTGCGGCCAC
                   ATCCCTGCTTCTTGCTCCTGCTCATCCTCTCTGCCTTTCCCGTTCTGTACCTGGACCT
                   AGCACCCAGCACCTTTCTCTGAGCTGAGTGGCTGGAGTGGTCAATAAAGCCACATGTC
                   CTGTGGCCCAGATGTCTCTGTGCCTG
                   ORF Start: ATG at 30 ORF Stop: TGA at 1122
                   SEQ ID NO:148        364 aa MW at 37703.4 kD
NOV33C,            MRGKLLPLAGLYLVQGLPYGLQSGLLPVLLRAGGLSLTRVGLAKVLYAPWLLKLAWAP
CG59363-03 Protein LVDAQCSARAWVTRSTAGLGLVCGLLAGLPPPGAGQAGLPAAVAGLLLLLNLGAAMQD
Sequence           VALDALAVQLLEPAELGPGNTVQVVAYKLGAALAGGALLALLPTFSWPQLFLLLAATY
                   WLAAALAWAAPALRRLPQQPPSEQRPHTAHLLRDVLAVPGTVWTAGFVLTYKLGEQGA
                   SSLFPLLLLDHGVSAPELGLWNGVGAVVCSIAGSSLGGTLLAKHWKLLPLLRSVLRFR
                   LGGLACQTALVFPRALQATHYSLLATLELLGKLLLGTLAGGLADGLGPHPCFLLLLIL
                   SAFPVLYLDLAPSTFL

[0492] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 33B.

TABLE 33B
Comparison of NOV33a against NOV33b through NOV33c.
	NOV33a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV33b	1 . . . 412	253/412 (61%)
	1 . . . 412	253/412 (61%)
NOV33c	1 . . . 412	221/412 (53%)
	1 . . . 364	221/412 (53%)

[0493] Further analysis of the NOV33a protein yielded the following properties shown in Table 33C.

TABLE 33C
Protein Sequence Properties NOV33a
PSort     0.6400 probability located in plasma membrane; 0.4600
analysis: probability located in Golgi body; 0.3700 probability located
          in endoplasmic reticulum (membrane); 0.1000
          probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 63 and 64
analysis:

[0494] A search of the NOV33a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 33D.

TABLE 33D
Geneseq Results for NOV33a
		NOV33a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAW70898	Acetyl-coenzyme A transporter (AT)	5 . . . 252	72/280 (25%)	2e−10
	protein - Homo sapiens, 549 aa.	75 . . . 347	116/280 (40%)
	[US5851788-A, 22-DEC-1998]
AAW69948	(AT-1) protein - Homo sapiens, 549 aa.	75 . . . 347	116/280 (40%)	2e−10
	[WO9833816-A1, 06-AUG-1998]

[0495] In a BLAST search of public sequences databases, the NOV33a protein was found to have homology to the proteins shown in the BLASTP data in Table 33E.

TABLE 33E
Public BLASTP Results for NOV33a
		NOV33a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q96ES6	SIMILAR TO RIKEN CDNA	1 . . . 412	412/412 (100%)	0.0
	2310010G13 GENE - Homo sapiens	1 . . . 412	412/412 (100%)
	(Human), 412 aa.
AAH19171	SIMILAR TO RIKEN CDNA	1 . . . 409	321/409 (78%)	0.0
	2310010G13 GENE - Mus musculus	1 . . . 409	351/409 (85%)
	(Mouse), 412 aa.
Q9D7F8	2310010G13RIK PROTEIN - Mus	1 . . . 409	317/409 (77%)	e−180
	musculus (Mouse), 412 aa.	1 . . . 409	351/409 (85%)
CAD13682	TRANSPORT TRANSMEMBRANE	11 . . . 404	120/403 (29%)	8e−33
	PROTEIN - Ralstonia solanacearum	21 . . . 399	187/403 (45%)
	(Pseudomonas solanacearum), 426 aa.
Q92SY4	PUTATIVE TRANSPORT PROTEIN -	8 . . . 399	115/400 (28%)	2e−25
	Rhizobium meliloti (Sinorhizobium	20 . . . 386	172/400 (42%)
	meliloti), 421 aa.

[0496] PFam analysis indicates that the NOV33a protein contains the domains shown in the Table 33F.

TABLE 33F
Domain Analysis of NOV33a
		Identities/
		Similarities
	NOV33a Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
Bac_Ubq_Cox: domain	24 . . . 55	16/32 (50%)	3.4
1 of 1		26/32 (81%)
BT1: domain 1 of 1	15 . . . 411	99/602 (16%)	8.7
		251/602 (42%)
sugar_tr: domain 1 of 1	3 . . . 411	81/522 (16%)	8.5
		243/522 (47%)

Example 34

[0497] The NOV34 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 34A.

TABLE 34A
NOV34 Sequence Analysis
                   SEQ ID NO:149       1020 bp
NOV34a,            ATGGCGGGGCAGTGGGAGGCGGGGCCCAGTCGGAGAGCGGGGCGGATTTGGGCGGGTG
CG59301-01 DNA     AGGGGAAATCGGCCTGCCCCTACGGAAATCCCGTTTCTTTATACACCCCGTCCTGGCT
Sequence           GGGCGGTGTCTTCCCCGTGGAAGAGAGGGTCCGGGAGGTCCGTGGGGCGGAACAGTCC
                   GAGGGCTTCGGGAGTCAGCCCGGGTGGATTTGTTTCGTGGCTCTCGTTGCTGGCTGGG
                   ACGGCCGTGTCCCCGTGTTGTTCCGGAGATCGAGGCCAACGGATGCCGTACTCTGTCC
                   TCGCCGGGTGCTCAGTGAGGACCCACAGCTGGGCAGGGACCCTGGGAGGCCCCTGAGC
                   AAGACTTGGAGGGACGCCCTTGTGCCCCCTGAGCACGTGGGGAAGGCCCTGTCCTGGG
                   CCCTGCACCGCTCTGTGTGTTCATTGCACGAGTGTGGAAGCCTCAGAGACGCTGCATG
                   GTGTTCCCGGGCCATCCTGGCCAAGGTGGGAGAACGCAGCCTCCGTGAGGACCCGCGG
                   GATGCCCTCCCGCCCCCCCTCCTCCTTCTCCTCTCCTCTCAAGTGCAGACGACGCTGG
                   CCCACATCCTTGTCGGGCAGAGGGGCTGCCGACTGGCCCCTGGCCATGCCTCTTGCTG
                   GGAGCCGTGTGGCCTGGGCTTGGACCCACATCCACCTCTTGCTGGCTGCCTGCTCTTG
                   CCAGTGGCTGAGCCTGGCTTCTCCCATGACAGTGGCCGCAGACAGAGGGGACCCGTGC
                   CACCAGCCAAGGATGTGATCATTGGCAGGGATGAGATTGACGGGGACGGTGTCTGGGG
                   GCGAGGTGAGAGTTCTGCCAAAGCCGGAGCCAGGGTTGGACCCCCCGAGCTCGTTGGT
                   CCGCCCCTGCACGGAGAGTGGTGTGTTCACACCACGGCCCTGGTGGCCCAGCTCTGCC
                   CATCTTCATCCCAGGTGGCAGCTGCTGCCCAGCTCTCTGGCCAGTGCCTCTTAGATGG
                   TGTCACCACCTGCAGAAGAAAACAGAAGTGCTGA
                   ORF Start: ATG at 1 ORF Stop: TGA at 1018
                   SEQ ID NO:150       339 aa MW at 36292.0 kD
NOV34a,            MAGQWEAGPSRRAGRIWAGEGKSACPYGNPVSLYTRSWLGGVFPVEERVREVRGAEQS
CG59301-01 Protein EGFGSQPGWICFVALVAGWDGRVPVLFRRSRPTDAVLCPRRVLSEDPQLGRDPGRPLS
Sequence           KTWRDALVPPEHVGKALSWALHRSVCSLHECGSLRDAAWCSRGILAKVGERSLREDPR
                   DALGGRLLVLVSSEVQTTLAHILVGQRCCRLAPGHGSCWEPCGLGLDPHPPLAGCLLL
                   PVAEPGFSHDSGRRQRGPVPPGKDVIIGRDEIDGDGVWGRGESSAKACARVGPPELVG
                   RPLEGEWCVHTTALVAQLCPSSSQVAAAAQLSGQCLLDGVTTCRRKQKC

[0498] Further analysis of the NOV34a protein yielded the following properties shown in Table 34B.

TABLE 34B
Protein Sequence Properties NOV34a
PSort     0.4500 probability located in cytoplasm; 0.1626 probability
analysis: located in lysosome (lumen); 0.1139 probability located in
          microbody (peroxisome); 0.1000 probability
          located in mitochondrial matrix space
SignalP   No Known Signal Sequence Indicated
analysis:

[0499] A search of the NOV34a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 34C.

TABLE 34C
Geneseq Results for NOV34a
		NOV34a	Identities/
	Protein/Organism/	Residues/	Similarities for
Geneseq	Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
No Significant Matches Found

[0500] In a BLAST search of public sequence databases, the NOV34a protein was found to have homology to the proteins shown in the BLASTP data in Table 34D.

TABLE 34D
Public BLASTP Results for NOV34a
		NOV34a
Protein		Residues/	Identities/
Accession	Protein/Organism/	Match	Similarities for the	Expect
Number	Length	Residues	Matched Portion	Value
No Significant Matches Found

[0501] PFam analysis indicates that the NOV34a protein contains the domains shown in the Table 34E.

TABLE 34E
Domain Analysis of NOV34a
	NOV34a Match	Identities/Similarities	Expect
Pfam Domain	Region	for the Matched Region	Value
Androgen_recep:	107 . . . 122	10/17 (59%)	7.2
domain 1 of 1		11/17 (65%)
EB: domain	298 . . . 339	10/56 (18%)	9.3
1 of 1		26/56 (46%)

Example 35

[0502] The NOV35 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 35A.

TABLE 35A
NOV35 Sequence Analysis
                   SEQ ID NO:151        781 bp
NOV35a,            CAAACAGCCCCTACCCTCAATGATCTCCATACAAAGAGCTCCAAAGAGTGCCTCTCCC
CG59525-01 DNA     CCTCCCTGCAGAGGGCGCATCCCCTGGCAGCGGTTCCTTCTCACAGCCTCAGTTTTAA
Sequence           CTTTCTGGAACCCACCCACTACTGCCATGCTCACTGTTGAAGCCATGCTGTCCAATGC
                   CACAAAGGGGAAGGAGGTTCTTCTACTCACTCACAATCTGCCCCATGATCTTATTGGC
                   TATAACTGGTACAAAGGGGAAAGGGTGGAGGCCAACCACCATATTACAGGATATGTAA
                   TAGGAACTCTAATAACTACCCCAGGGCCTGCCCACAGCATTCAAGGGACAATATACCC
                   CAATCCATCCCTGCTGATTCAGAATGTCACCCAGGACACAGGATTCTACACCCTACAC
                   GCCATAAAGATAAACCCTGAGAAAGAAGAAGTATCTGGCCAGTTCCATGTATACGAAA
                   AAAATGCCCCAGGCCTTCCTGTGGGGGCCTTCACTGGCATCGTGACCAGGGTTCTGGT
                   CGGGGTGGCACCGGTGGCCACCCTGGCATGTTTCCTGCTCCTCGTCAGGACTGGAAGG
                   GCCAGTCGCCAGCATGACTTTAGAGAGCAGCTCCCAGGCCATGGTCCCTCAAACAACT
                   CCACCTACCCTACATCCCCTCTCTCCCCTGCCCAGGCCCCGCTACCCGACCCCAGGAC
                   AGCCGCTCCCATCTATGAGGAATTGCTAAACCATGACACAAACATTTACTGCTGGGTC
                   AACCACAAAGCAGATGTGCTTTCTTAG
                   ORF Start: ATG at 20 ORF Stop: TAG at 779
                   SEQ ID NO:152        253 aa MW at 27528.2 kD
NOV35a,            MISIQRAPKSASPPPCRGRIPWQGFLLTASVLTFWNPPTTAMLTVEAMLSNATKGKEV
CG59525-01 Protein LLLTHNLPHDLIGYNWYKGERVEANHHITGYVIGTLITTPGPAHSIQGTIYPNASLLI
Sequence           QNVTQDTGFYTLHAIKINPEKEEVSGQFHVYEKNAPGLPVGAFTGIVTRVLVGVAPVA
                   TLACFLLLVRTGRASGQHDFREQLPGHGPSNNSTYPTSPLSPAQAPLPDPRTAAPIYE
                   ELLNHDTNIYCWVNHKADVVS

[0503] Further analysis of the NOV35a protein yielded the following properties shown in Table 35B.

TABLE 35B
Protein Sequence Properties NOV35a
PSort     0.8500 probability located in endoplasmic reticulum
analysis: (membrane); 0.4400 probability located in plasma membrane;
          0.1358 probability located in microbody (peroxisome); 0.1000
          probability located in mitochondrial inner membrane
SignalP   Cleavage site between residues 42 and 43
analysis:

[0504] A search of the NOV35a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 35C.

TABLE 35C
Geneseq Results for NOV35a
		NOV35a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAR22042	Carcino embryonic antigen-related	8 . . . 253	166/252 (65%)	7e−87
	antigen encoded by clone W264 -	3 . . . 252	188/252 (73%)
	Homo sapiens, 252 aa. [JP04045788-A,
	14-FEB-1992]
AAR22041	Carcino embryonic antigen-related	8 . . . 253	134/252 (53%)	4e−68
	antigen encoding clone W236 - Homo	3 . . . 244	165/252 (65%)
	sapiens, 244 aa. [JP04045788-A,
	14-FEB-1992]
AAW83138	FL-CEA protein - Homo sapiens, 526	12 . . . 155	97/145 (66%)	2e−48
	aa. [US5843761-A, 01-DEC-1998]	5 . . . 145	107/145 (72%)
AAW06873	Carcinoembryonic antigen CEA-c -	12 . . . 155	97/145 (66%)	2e−48
	Homo sapiens, 526 aa. [US5571710-A,	5 . . . 145	107/145 (72%)
	05-NOV-1996]
AAR65166	Biliary glycoprotein - Homo sapiens,	12 . . . 155	97/145 (66%)	2e−48
	464 aa. [WO9506067-A1,	5 . . . 145	107/145 (72%)
	02-MAR-1995]

[0505] In a BLAST search of public sequence databases, the NOV35a protein was found to have homology to the proteins shown in the BLASTP data in Table 35D.

TABLE 35D
Public BLASTP Results for NOV35a
		NOV35a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
P40198	Carcinoembryonic antigen-related cell	8 . . . 253	167/252 (66%)	7e−87
	adhesion molecule 3 precursor	3 . . . 252	189/252 (74%)
	(Carcinoembryonic antigen CGM1)
	(CD66d antigen) - Homo sapiens
	(Human), 252 aa.
O75871	NONSPECIFIC CROSS-REACTING	8 . . . 253	137/252 (54%)	2e−69
	ANTIGEN W236 - Homo sapiens	3 . . . 244	168/252 (66%)
	(Human), 244 aa.
Q03715	CGM7 NONSPECIFIC CROSS-	8 . . . 253	134/252 (53%)	2e−67
	REACTING ANTIGEN (NCA) - Homo	3 . . . 244	165/252 (65%)
	sapiens (Human), 244 aa.
S33324	carcinoembryonic antigen - human, 212	12 . . . 187	121/177 (68%)	7e−62
	aa.	5 . . . 181	135/177 (75%)
Q13858	BILIARY GLYCOPROTEIN - Homo	12 . . . 199	120/193 (62%)	1e−57
	sapiens (Human), 252 aa.	5 . . . 197	133/193 (68%)

[0506] PFam analysis indicates that the NOV35a protein contains the domains shown in the Table 35E.

TABLE 35E
Domain Analysis of NOV35a
	NOV35a	Identities/Similarities	Expect
Pfam Domain	Match Region	for the Matched Region	Value
No Significant Matches Found

Example 36

[0507] The NOV36 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 36A.

TABLE 36A
NOV36 Sequence Analysis
                   SEQ ID NO:153        4517 bp
NOV36a,            GTTTGAAAACACAAACACAATGGCAGGAAACAGCCTTGTTCTACCCATTGTTCTTTGG
CG59484-01 DNA     GGTCGAAAAGCGCCCACACATTGCATCTCAGCCGTACTTTTAACAGATGATGGGCCCA
Sequence           CGATCGTAACAGGATGTCACGACGGACAAATATGTCTCTGGGATCTTTCAGTAGAACT
                   GCAAGTGAATCCTCGAGCACTGTTGTTTGGTCATACAGCATCAATCACTTGTTTGTCT
                   AAAGCTTGTGCTTCCAGTGACAAACAGTATATTGTGAGTGCATCTGAAAGTGGGGAGA
                   TGTGCCTCTGGGATGTGAGTGATGGCAGATGTATTGAATTTACAAAATTAGCTTGCAC
                   ACATACTGGCATACAGTTCTACCAGTTCTCTGTTGGGAATCAGCGAGAAGGAAGGCTT
                   TTATGCCACGGACATTACCCTGAAATCCTTGTTGTGGATCCTACCAGCCTTGAAGTAT
                   TATACTCCTTAGTATCAAAGATATCACCAGACTGGATTAGCTCCATGAGTATTATTCG
                   ATCCCACCGAACACAAGAGGACACAGTGGTAGCACTCTCGGTGACTGGCATCCTGAAG
                   GTCTGGATTGTTACCTCGGAAATAAGTGACATGCAGGATACTGAGCCAATATTTCAGG
                   AGGAATCCAAACCAATTTATTGTCAGAATTGCCAAAGCATCTCTTTTTGTGCATTTAC
                   ACAAAGGTCACTTTTGGTTGTGTGTTCCAAATATTCGAGGGTATTCGATGCCGGAGAC
                   TATTCCTTGTTGTGTTCAGGTCCTAGTGAAAATGGACAGACATGGACCGGGGGGGACT
                   TTGTCTCATCAGATAAAGTCATCATTTGGACAGAAAATGGGCAAAGTTATATTTACAA
                   ACTACCTGCCAGTTGCCTTCCAGCTAGTGATTCATTCCGCAGTGATGTGGGGAAGGCA
                   GTTGAAAATTTAATTCCTCCTCTACAACATATCCTCTTGGATCGAAAAGATAAAGAGT
                   TGCTAATTTGTCCTCCTGTTACTCGGTTCTTCTATGGATGCAGAGAATATTTCCATAA
                   ACTGTTAATTCAGGGTGATTCTTCTGGAAGGTTGAATATTTGGAACATATCAGACACA
                   GCTGATAAACAGGGAAGTGAAGAAGGGCTGGCAATGACAACTTCTATTAGTTTGCAAG
                   AGGCATTTGATAAACTGAATCCTTGTCCTGCTGGAATTATAGATCAGCTGAGTGTGAT
                   TCCCAATAGTAATGAACCTCTTAAAGTAACTGCAAGTGTGTACATACCAGCACATGGA
                   CGACTTGTTTGTGGTCGTGAAGATGGAAGCATAGTTATTGTACCTGCCACACAGACGG
                   CCATAGTACAGCTGTTGCAAGGGGAACACATGCTCAGAAGAGGTTGGCCACCTCACAG
                   AACACTCCGTGGTCATCGGAACAAAGTCACATGTTTGCTATATCCTCATCAGGTCTCA
                   GCTCGGTATGATCAAAGATACCTGATATCTGGAGGTGTGGATTTTTCAGTCATAATTT
                   GGGACATATTTTCTGGAGAAATGAAACATATCTTCTGTGTTCATGGTGGTGAGATTAC
                   TCAACTTCTAGTTCCACCTGAAAACTGTAGTGCAAGAGTACAGCACTGCATCTGCTCT
                   GTAGCCAGTGACCACTCAGTAGGACTTCTAAGTTTGCGAGAGAAAAAATGCATAATGT
                   TGGCATCTCGTCACCTTTTTCCTATTCAAGTAATCAAATGGAGGCCTTCTGATGATTA
                   CCTGGTGGTGGGGTGTTCAGATGGTTCTGTGTACGTCTGGCAAATGGATACTGGTGCA
                   TTGGATCGTTGTGTGATGGGGATAACAGCAGTTGAGATTCTAAACGCTTGTGATGAAG
                   CTGTTCCTGCTGCTGTTGATTCACTTAGTCATCCAGCAGTCAACCTAAAACAAGCTAT
                   GACGAGACGTAGTCTTGCTGCTCTTAAAAATATGGCCCATCATAAGCTACAAACCCTT
                   GCAACTAACCTCTTGGCTTCTGAGGCATCTGACAAGGGAAATTTACCTAAATATTCTC
                   ATAACTCCCTGATGGTTCAAGCAATAAAGACAAACCTAACAGACCCGGACATACATGT
                   GCTATTCTTTGATGTGGAAGCGTTGATTATTCAACTCCTGACTGAAGAAGCCTCTAGG
                   CCGAATACTGCTCTTATTTCCCCAGAGAATTTGCAAAAAGCATCTGCCAGTTCAGACA
                   AAGGGGGCTCTTTTTTAACTGGAAAACGAGCAGCAGTTCTCTTCCAACAAGTGAAAGA
                   AACGATCAAAGAGAACATCAAGGAACACCTCCTTGATGATGAACAGGAGGATGAGGAG
                   ATAATGAGGCAGAGAAGGGAAGAAAGTGATCCTGAATATCGGTCCAGCAAATCAAAGC
                   CATTGACCCTATTAGAATATAATTTAACTATGGACACTGCAAAGCTGTTTATGTCCTG
                   CCTTCACGCCTGGGGTTTGAATGAAGTACTGGATGAAGTTTGCCTGGATCGCCTTGGA
                   ATGCTGAAACCCCACTGCACCGTATCGTTTGGCCTCTTGTCAAGAGGAGGCCATATGT
                   CACTGATGCTGCCGGGTTATAATCAGCCTGCTTGTAAACTGTCACATGGGAAAACAGA
                   AGTAGGAAGGAAGCTGCCAGCGTCTGAGGGAGTAGGAAAGGCAACTTACGCAGTGTCC
                   CGTGCCGTCACCACACAGCATCTCCTGTCTATCATTTCTTTGGCAAATACTTTAATGA
                   GTATGACCAATGCAACTTTTATTGGTGATCATATGAAGAAGGGTCCTACCAGGCCACC
                   TAGACCAAGCACCCCAGACCTTTCTAAGGCAAGGGGTTCCCCTCCAACTTCCAGTAAT
                   ATTGTGCAAGGACAGATTAAACAAGTTGCTGCACCTGTCGTTTCCGCTCGGTCTGATG
                   CTGATCACTCTGGCTCTGACCCTCCTTCTGCTCCTGCTTTACATACCTGTTTCTTAGT
                   AAATGAAGGTTCGAGTCAGTTAGCTGCTATGCACTGTGTTATGCTGCCAGACCTACTG
                   GGATTGGATAAATTTAGCCCTCCCCTTCTGCAGATGCTCGCCCGAAGATGGCAAGATC
                   GATGCTTGGAGGTAAGAGAAGCCGCGCAGGCCCTGCTTCTGGCGGAACTGAGAAGAAT
                   TGAGCAGGCAGGCAGGAAGGAAGCCATTGATGCCTCGGCTCCTTACTTACCTCAGTAC
                   ATAGACCACGTCATATCACGTGGAGTCACATCAGAAGCCGCGCAGACTATCACCACGG
                   CTCCTGATGCCTCAGGGCCTGAAGCAAAAGTCCAGGAGGAAGAGCATGACCTTGTTGA
                   CGATGACATCACCACTGGTTGCTTATCAAGTGTCCCACAAATGAAAAAAATTTCTACA
                   TCTTACGAGGAAAGACGGAAGCAAGCTACCGCTATTGTTTTACTTGCAGTAATAGGAG
                   CTGAATTTGGTGCTGAAATTGAACCTCCTAAACTATTGACCAGACCTCGAAGCTCTAG
                   CCAAATTCCTGAGGGATTCGGGTTGACTAGTGGTGGATCCAACTACTCGCTGGCCAGA
                   CATACTTCCAAGGCACTGACGTTTCTTCTGCTACAGCCTCCAAGCCCCAAACTTCCTC
                   CACACAGCACTATCCGAAGAACAGCCATTGATCTGATTGGACGTGGGTTCACTGTTTG
                   GGAGCCTTACATGGATGTGTCCGCTGTTCTGATGGGGCTTCTCGAACTTTCTGCCGAT
                   GCCGAGAAACAACTTGCCAACATCACAATGGGGTTGCCTCTGAGCCCAGCAGCTGACT
                   CGGCCCGCTCTGCGAGCCATGCCCTCTCGCTCATTGCCACCCCCAGACCACCCGCCTT
                   CATCACCACCATAGCCAAAGAGGTACACAGACATACGGCTCTTGCAGCAAATACCCAA
                   TCACAGCAGAATATGCACACAACAACTCTTGCACGAGCTAAAGGGGAAATTTTGAGAG
                   TCATTGAAATTCTTATTGAAAAGATGCCCACAGATGTTGTGGATCTTCTCGTGGAGGT
                   TATGGACATCATTATGTACTGCCTTGAACGATCTTTAGTTAAAAAGAAAGGTCTTCAA
                   GAATGTTTCCCAGCCATCTGCAGGTTCTACATGGTCAGCTATTATGAGCGGAATCACA
                   GAATAGCAGTTCGAGCTCGCCATGGTTCAGTGGCCCTGTACGACATCCGGACTGGAAA
                   ATGTCAGACAATCCATGGACACAAGGGACCAATCACTGCAGTGCCTTTTGCTCCTGAT
                   GGAAGATATCTTGCCACCTACTCAAACACTGACAGCCACATTTCTTTTTGGCAGATGA
                   ACACGTCACTGCTGGGAACCATCGGCATGCTGAACTCGGCACCTCAGCTGCGCTGCAT
                   TAAAACCTACCAGGTGCCCCCTGTGCAGCCCGCGTCCCCCGGCTCCCACAATGCCCTC
                   AAGCTGGCCCGGCTCATCTGGACTTCCAACCGCAACGTCATCCTCATGGCCCATGACG
                   GGAAGGAGCACCGCTTCATGGTCTAATGCTGCTGCCTGCCGCCGTGACTGC
                   ORF Start: ATG at 20 ORF Stop: TAA at 4490
                   SEQ ID NO:154        1490 aa MW at 163853.2 kD
NOV36a,            MAGNSLVLPIVLWGRKAPTHCISAVLLTDDGATIVTCCHDGQICLWDLSVELQVNPRA
CG59484-01 Protein LLFGHTASITCLSKACASSDKQYIVSASESGEMCLWDVSDGRCIEFTKLACTHTGIQF
Sequence           YQFSVGNQREGRLLCHGHYPEILVVDATSLEVLYSLVSKISPDWISSMSIIRSHRTQE
                   DTVVALSVTGILKVWIVTSEISDMQDTEPIFEEESKPIYCQNCQSISFCAFTQRSLLV
                   VCSKYWRVFDAGDYSLLCSGPSENGQTWTGGDFVSSDKVIIWTENGQSYIYKLPASCL
                   PASDSFRSDVGKAVENLIPPVQHILLDRKDKELLICPPVTRFFYGCREYFHKLLIQGD
                   SSGRLNIWNISDTADKQGSEEGLAMTTSISLQEAFDKLNPCPAGIIDQLSVIPNSNEP
                   LKVTASVYIPAHGRLVCGREDGSIVIVPATQTAIVQLLQGEHMLRRGWPPHRTLRGHR
                   NKVTCLLYPHQVSARYDQRYLISGGVDFSVIIWDIFSGEMKHIFCVHGGEITQLLVPP
                   ENCSARVQHCICSVASDHSVGLLSLREKKCIMLASRHLFPIQVIKWRPSDDYLVVGCS
                   DGSVYVWQMDTGALDRCVMGITAVEILNACDEAVPAAVDSLSHPAVNLKQAMTRRSLA
                   ALKNMAHHKLQTLATNLLASEASDKGNLPKYSHNSLMVQAIKTNLTDPDIHVLFFDVE
                   ALlIQLLTEEASRPNTALISPENLQKASGSSDKGGSFLTGKPAAVLFQQVKETIKENI
                   KEHLLDDEEEDEEIMRQRREESDPEYRSSKSKPLTLLEYNLTMDTAKLFMSCLHAWGL
                   NEVLDEVCLDRLGMLKPHCTVSFGLLSRGGHMSLMLPGYNQPACKLSHGKTEVGRKLP
                   ASEGVGKGTYGVSRAVTTQHLLSIISLANTLMSMTNATFIGDHMKKGPTRPPRPSTPD
                   LSKARGSPPTSSNIVQGQIKQVAAPVVSARSDADHSGSDPPSAPALHTCFLVNEGWSQ
                   LAAMHCVMLPDLLGLDKFRPPLLEMLARRWQDRCLEVREAAQALLLAELRRIEQAGRK
                   EAIDAWAPYLPQYIDHVISRGVTSEAAQTITTAPDASGPEAKVQEEEHDLVDDDITTG
                   CLSSVPQMKKISTSYEERRKQATAIVLLGVIGAEFGAEIEPPKLLTRPRSSSQIPEGF
                   GLTSGGSNYSLARHTCKALTFLLLQPPSPKLPPHSTIRRTAIDLIGRGFTVWEPYMDV
                   SAVLMGLLELCADAEKQLANITMGLPLSPAALSARSARHALSLIATARPPAFITTIAK
                   EVHRHTALAANTQSQQNMHTTTLARAKGEILRVIEILIEKMPTDVVDLLVEVMDIIMY
                   CLEGSLVKKKGLQECFPAICRFYMVSYYERNHRIAVGARHGSVALYDIRTGKCQTIHG
                   HKGPITAVAFAPDGRYLATYSNTDSHISFWQMNTSLLGSIGMLNSAPQLRCIKTYQVP
                   PVQPASPGSHNALKLARLIWTSNRNVILMAHDGKEHRFMV

[0508] Further analysis of the NOV36a protein yielded the following properties shown in Table 36B.

TABLE 36B
Protein Sequence Properties NOV36a
PSort     0.8110 probability located in plasma membrane; 0.6400
analysis: probability located in endoplasmic reticulum (membrane);
          0.3700 probability located in Golgi body;
          0.1000 probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 22 and 23
analysis:

[0509] A search of the NOV36a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 36C.

TABLE 36C
Geneseq Results for NOV36a
		NOV36a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAE10802	Human TGF-beta Resistance	1 . . . 1490	1489/1490 (99%)	0.0
	Associated Gene (TRAG) protein -	1 . . . 1490	1489/1490 (99%)
	Homo sapiens, 1490 aa.
	[WO200166739-A1, 13-SEP-2001]
AAE10803	Mouse TGF-beta Resistance	1 . . . 1490	1415/1490 (94%)	0.0
	Associated Gene (TRAG) protein -	1 . . . 1489	1450/1490 (96%)
	Mus sp, 1489 aa. [WO200166739-A1,
	13-SEP-2001]
AAE10801	Rat TGF-beta Resistance Associated	1 . . . 1490	1408/1490 (94%)	0.0
	Gene (TRAG) protein - Rattus sp,	1 . . . 1488	1446/1490 (96%)
	1488 aa. [WO200166739-A1,
	13-SEP-2001]
AAM40548	Human polypeptide SEQ ID NO 5479 -	454 . . . 594	38/146 (26%)	2e−07
	Homo sapiens, 277 aa.	48 . . . 181	63/146 (43%)
	[WO200153312-A1, 26-JUL-2001]
AAM40547	Homo sapiens, 277 aa.	48 . . . 181	63/146 (43%)	2e−07
	[WO200153312-A1, 26-JUL-2001]

[0510] In a BLAST search of public sequence databases, the NOV36a protein was found to have homology to the proteins shown in the BLASTP data in Table 36D.

TABLE 36D
Public BLASTP Results for NOV36a
		NOV36a
Protein		Residues/	Identities/
Accession		Match	Similarities for the	Expect
Number	Protein/Organism/Length	Residues	Matched Portion	Value
CAC88575	SEQUENCE 3 FROM PATENT	1 . . . 1490	1489/1490 (99%)	0.0
	WO0166739 - Homo sapiens	1 . . . 1490	1489/1490 (99%)
	(Human), 1490 aa.
Q96PS7	TGF-BETA RESISTANCE-	1 . . . 1490	1456/1490 (97%)	0.0
	ASSOCIATED PROTEIN TRAG -	1 . . . 1457	1456/1490 (97%)
	Homo sapiens (Human), 1457 aa
	(fragment).
CAC88576	SEQUENCES 5 FROM PATENT	1 . . . 1490	1415/1490 (94%)	0.0
	WO0166739 - unidentified, 1489 aa.	1 . . . 1489	1450/1490 (96%)
Q92019	TGF-BETA RESISTANCE-	1 . . . 1490	1414/1490 (94%)	0.0
	ASSOCIATED PROTEIN TRAG -	1 . . . 1489	1449/1490 (96%)
	Mus musculus (Mouse), 1489 aa
	(fragment).
Q9ERH3	TGF-BETA RESISTANCE-	1 . . . 1490	1408/1490 (94%)	0.0
	ASSOCIATED PROTEIN - Rattus	1 . . . 1488	1446/1490 (96%)
	norvegicus (Rat), 1488 aa.

[0511] PFam analysis indicates that the NOV36a protein contains the domains shown in Table 36E.

TABLE 36E
Domain Analysis of NOV36a
		Identities/
		Similarities
	NOV36a Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
WD40: domain 1 of 8	11 . . . 47	9/37 (24%)	0.022
		29/37 (78%)
WD40: domain 2 of 8	56 . . . 95	10/40 (25%)	14
		30/40 (75%)
WD40: domain 3 of 8	151 . . . 190	5/41 (12%)	1.5e+03
		27/41 (66%)
WD40: domain 4 of 8	209 . . . 242	6/37 (16%)	5.7e+02
		23/37 (62%)
HSF_DNA-bind:	267 . . . 282	7/16 (44%)	3.1
domain 1 of 1		14/16 (88%)
WD40: domain 5 of 8	456 . . . 498	15/43 (35%)	0.0048
		30/43 (70%)
WD40: domain 6 of 8	504 . . . 546	6/43 (14%)	2.7e+02
		27/43 (63%)
WD40: domain 7 of 8	552 . . . 588	8/37 (22%)	0.22
		26/37 (70%)
WD40: domain 8 of 8	1386 . . . 1423	11/38 (29%)	4
		29/38 (76%)

Example 37

[0512] The NOV37 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 37A.

TABLE 37A
NOV37 Sequence Analysis
                   SEQ ID NO:155        848 bp
NOV37a,            GCCTCGCTCGGGCGCCCAGTGGTCCTGCCGCCTGGTCTCACCTCGCCATGGTTCGTCT
CG57245-02 DNA     GCCTCTGCAGTGCGTCCTCTGGGGCTGCTTGCTGACCGCTGTCCATCCAGAACCACCC
Sequence           ACTGCATGCAGAGAAAAACAGTACCTAATAAACAGTCAGTGCTGTTCTTTGTCCCAGC
                   CAGGACAGAAACTGGTGAGTGACTGCACAGAGTTCACTGAAACGGPATGCCTTCCTTG
                   CGGTGAAAGCGAATTCCTAGACACCTGGAACAGAGAGACACACTGCCACCAGCACAAA
                   TACTGCGACCCCAACCTAGGGCTTCGGGTCCAGCAGAAGGGCACCTCAGAAACAGACA
                   CCATCTGCACCTGTGAAGAAGGCTGGCACTGTACGAGTGAGGCCTGTGAGAGCTGTGT
                   CCTGCACCGCTCATGCTCGCCCGGCTTTGGGGTCAAGCAGATTGGTCCCCAGGATCGG
                   CTGAGAGCCCTGGTCGTGATCCCCATCATCTTCGGGATCCTGTTTGCCATCCTCTTGG
                   TGCTGGTCTTTATCAAAAAGGTGGCCAAGAAGCCAACCAATAAGGCCCCCCACCCCAA
                   GCAGGAACCCCAGGAGATCAATTTTCCCGACGATCTTCCTGGCTCCAACACTGCTGCT
                   CCAGTGCAGGACACTTTACATGGATGCCAACCGGTCACCCAGGAGGATGGCAAAGAGA
                   GTCGCATCTCAGTGCAGGAGAGACAGTGAGGCTGCACCCACCCAGGAGTGTGGCCACG
                   TGGCCAAACAGGCAGTTGGCCAGAGAGCCTGGTGCTGCTGCTGCAGGGGTGCAGGCAG
                   AAGCGGGGAGCTATGCCCAGTCAGTGCCAGCCCCTC
                   ORF Start: ATG at 48 ORF Stop: TGA at 723
                   SEQ ID NO:156        225 aa MW at 25098.5 kD
NOV37a,            MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETE
CG57245-02 Protein CLPCCESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEAC
Sequence           ESCVLHRSCSPGFGVKQIGPQDRLRALVVIPIIFGILFAILLVLVFIKKVAKKPTNKA
                   PHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDCKESRISVQERQ
                   SEQ ID NO:157        1016 bp
NOV37b,            GCCTCGCTCGGGCGCCCAGTGGTCCTGCCGCCTGGTCTCACCTCGCCATGGTTCGTCT
CG57245-04 DNA     GCCTCTGCAGTGCGTCCTCTGGGGCTGCTTGCTGACCGCTGTCCATCCAGAACCACCC
Sequence           ACTGCATGCAGAGAAAAACAGTACCTAATAAACAGTCAGTGCTGTTCTTTGTGCCAGC
                   CAGGACACAAACTGGTGAGTGACTGCACAGAGTTCACTGAAGCGGAATGCCTTCCTTG
                   CGGTGAAACCGAATTCCTAGACACCTGGAACAGAGAGACACACTGCCACCAGCACAAA
                   TACTGCGACCCCAACCTAGGGCTTCGGGTCCAGCAGAAGGGCACCTCAGAAACAGACA
                   CCATCTGCACCTGTGAAGAAGGCTGGCACTGTACGAGTGAGGCCTGTGAGAGCTGTGT
                   CCTGCACCGCTCATGCTCGCCCGGCTTTGGGGTCAAGCAGATTGCTACAGGGGTTTCT
                   GATACCATCTGCGAGCCCTGCCCAGTCGGCTTCTTCTCCAATGTGTCATCTGCTTTCG
                   AAAAATGCCACCCTTGCACAAGCTGTGAGACCAAACACCTGGTTGTGCAACAGGCAGG
                   CACAAACAAGACTGATGTTGTCCGTGGTCCCCAGGATCGGCTGAGAGCCCTGGTGGTG
                   ATCCCCATCATCTTCGGGATCCTGTTTGCCATCCTCCTGGTGCTGGTCTTTATCAGTG
                   AGTCCTCAGAAAAGGTGGCCAAGAAGCCAACCAATAAGGCCCCCCACCCCAAGCAGGA
                   ACCCCAGGAGATCAATTTTCCCGACGATCTTCCTGGCTCCAACACTGCTGCTCCAGTG
                   CAGGAGACTTTACATGGATGCCAACCGGTCACCCAGGAGGATGGCAAAGAGAGTCGCA
                   TCTCAGTGCAGGAGAGACAGTGAGGCTGCACCCACCCAGGAGTGTGGCCACGTGGGCA
                   AACAGGCAGTTGGCCAGAGAGCCTGGTGCTGCTGCTGCAGGGGTGCAGGCAGAAGCCG
                   GGAGCTATGCCCAGTCAGTGCCAGCCCCTC
                   ORF Start: ATG at 48 ORF Stop: TGA at 891
                   SEQ ID NO:158        1281 aa MW at 31033.0 kD
NOV37b,            MVRLPLQCVLWGCLLTAVHPEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTEAE
CG57245-04 Protein CLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEAC
Sequence           ESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVV
                   QQAGTNKTDVVRCPQDRLRALVVIPIIFGILFAILLVLVFISESSEKVAKKPTNKAPH
                   PKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQERQ
                   SEQ ID NO:159        375 bp
NOV37c,            AGATCTGAACCACCCACTGCATGCAGAGAAAAACAGTACCTAATAAACAGTCAGTCCT
174308232 DNA      GTTCTTTGTGCCAGCCAGGACAGAAACTGGTGAGTGACTGCACAGAGTTCACTGAAAC
Sequence           GCAATGCCTTCCTTGCGGTGAAAGCGAATTCCTAGACACCTGGAACAGAGAGACACAC
                   TGCCACCAGCACAAATACTGCGACCCCAACCTAGGGCTTCGGGTCCAGCAGAAGGGCA
                   CCTCAGAAACAGACACCATCTGCACCTGTGAAGAAGGCTGGCACTGTACGAGTGAGGC
                   CTGTGAGAGCTGTGTCCTGCACCGCTCATGCTCGCCCGGCTTTGGGGTCAAGCAGATT
                   GGTCCCCAGGATCGGCTGAGACTCGAG
                   ORF Start: AGA at 1  ORF Stop: at 376
                   SEQ ID NO:160        125 aa MW at 14132.6 kD
NOV37c,            RSEPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETH
174308232 Protein  CHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQI
Sequence           CPQDRLRLE

[0513] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 37B.

TABLE 37B
Comparison of NOV37a against NOV37b through NOV37c.
	NOV37a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV37b	1 . . . 225	204/281 (72%)
	1 . . . 281	205/281 (72%)
NOV37c	21 . . . 141	121/121 (100%)
	3 . . . 123	121/121 (100%)

[0514] Further analysis of the NOV37a protein yielded the following properties shown in Table 37C.

TABLE 37C
Protein Sequence Properties NOV37a
PSort     0.4600 probability located in plasma membrane;
analysis: 0.1000 probability located in
          endoplasmic reticulum (membrane);
          0.1000 probability located in endoplasmic
          reticulum (lumen); 0.1000 probability located in outside
SignalP   Cleavage site between residues 21 and 22
analysis:

[0515] A search of the NOV37a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 37D.

TABLE 37D
Geneseq Results for NOV37a
		NOV37a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAB20170	Human CD40 receptor splice variant -	1 . . . 225	225/246 (91%)	e−134
	Homo sapiens, 246 aa. [WO200105967-	1 . . . 246	225/246 (91%)
	A1, 25-JAN-2001]
AAB84892	Human CD40 antigen - Homo sapiens,	1 . . . 225	225/277 (81%)	e−130
	277 aa. [WO200130974-A2, 03-MAY-2001]	1 . . . 277	225/277 (81%)
AAB37807	Human CD40 - Homo sapiens, 277 aa.	1 . . . 225	225/277 (81%)	e−130
	[WO200066155-A1, 09-NOV-2000]	1 . . . 277	225/277 (81%)
AAB50520	Human tumour necrosis factor receptor	1 . . . 225	225/277 (81%)	e−130
	CD40 protein SEQ ID NO: 10 - Homo	1 . . . 277	225/277 (81%)
	sapiens, 277 aa. [WO200071150-A1,
	30-NOV-2000]
AAY52701	Human CD40 protein - Homo sapiens,	1 . . . 225	225/277 (81%)	e−130
	277 aa. [WO9953101-A1, 21-OCT-1999]	1 . . . 277	225/277 (81%)

[0516] In a BLAST search of public sequence databases, the NOV37a protein was found to have homology to the proteins shown in the BLASTP data in Table 37E.

TABLE 37E
Public BLASTP Results for NOV37a
		NOV37a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
P25942	Tumor necrosis factor receptor	1 . . . 225	225/277 (81%)	e−130
	superfamily member 5 precursor	1 . . . 277	225/277 (81%)
	(CD40L receptor) (B-cell surface
	antigen CD40) (Bp50) (CDw40) - Homo
	sapiens (Human), 277 aa.
Q9BYU0	CD40 TYPE II ISOFORM - Homo	1 . . . 134	134/134 (100%)	1e−82
	sapiens (Human), 203 aa.	1 . . . 134	134/134 (100%)
A46476	B cell-associated surface molecule	1 . . . 225	137/281 (48%)	3e−73
	CD40, long splice form - mouse, 305 aa.	1 . . . 278	168/281 (59%)
P27512	Tumor necrosis factor receptor	1 . . . 225	137/281 (48%)	3e−73
	superfamily member 5 precursor	1 . . . 278	168/281 (59%)
	(CD40L receptor) (B-cell surface
	antigen CD40) (BP50) (CDw40) - Mus
	musculus (Mouse), 289 aa.
Q99NE0	CD40 TYPE V ISOFORM - Mus	1 . . . 225	130/252 (51%)	7e−67
	musculus (Mouse), 260 aa.	1 . . . 249	157/252 (61%)

[0517] PFam analysis indicates that the NOV37a protein contains the domains shown in the Table 37F.

TABLE 37F
Domain Analysis of NOV37a
		Identities/
		Similarities
	NOV37a	for the	Expect
Pfam Domain	Match Region	Matched Region	Value
TNFR_c6: domain	26 . . . 59	19/42 (45%)	2.7e−09
1 of 2		30/42 (71%)
EB: domain	26 . . . 77	10/60 (17%)	8.3
1 of 1		33/60 (55%)
TNFR_c6: domain	62 . . . 103	11/44 (25%)	0.9
2 of 2		29/44 (66%)
ATP-synt_B: domain	148 . . . 174	5/27 (19%)	6.8
1 of 1		23/27 (85%)

Example 38

[0518] The NOV38 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 38A.

TABLE 38A
NOV38 Sequence Analysis
                   SEQ ID NO:161         1080 bp
NOV38a,            GATTTAATTGGCATTATTGTGTTCCCGACCATGACTGCAGAGACCATGGAGCTGAAGT
CG59454-01 DNA     GGGTGAGTTTCCTGGCCTTCCTTCTGCTCAACTTTCGTGTCTGCCTCCTTTTGCTTCA
Sequence           GCTGCTCATGCCTCACTCAGCTCAGTTTTCTCTCCTTGGACCCTCTGGGCCCATCCTG
                   GCCATGGTGGGTGAAGACGCTGATCTGCCCTGTCACCTGTTCCCGACCATGAGTGCAG
                   AGACCATGGAGCTGAAGTGGGTAAGTTCCAGCCTAAGGCAGGTGGTGAACGTGTATGC
                   AGATGGAAZGGAAGTGGAAGACAGGCAGAGTGCACCGTATCGAGGGAGAACTTCGATT
                   CTGCGGGATGGCATCACTGCGGGGAAGGCTGCTCTCCGAATACACAACGTCACAGCCT
                   CTGACAGTGGAAAGTACTTGTCTTATTTCCAAGATGGTGACTTCTATCAAAAACCCCT
                   GGTGGAGCTGAAGGTTGCAGCACTGGGTTCTAATCTTCACGTCGAAGTGAAGGGTTAT
                   GAAGATGGAGGCATCCATCTGCAGTGCAGGTCCACCCCCTGGTACCCCCAACCCCAAA
                   TACAGTGGGGCAACGCCAAGGGAGAGAACATCCCAGCTGTGGAAGCACCTGTGGTTGC
                   AGATGGAGTGGGCCTATATGAAGTAGCAGCATCTGTGATCATGAAAAGCCGCTCCGGG
                   GAAGGTGTATCCTGCATCATCAGAAATTCCCTCCTCGGCCTGGAAAAGACAGCCAGCA
                   TTTCCATCGCAGACCCCTTCTTCAGGAGCGCCCAGCCCTGGATCGCAGCCCTGGCAGG
                   GACCCTGCCTATCTTGCTGCTGCTTCTCGCCGGAGCCAGTTACTTCTTGTCGAGACAA
                   CAGAAGGAAATAACTGCTCTGTCCAGTGAGATAGAAAGTGAGCAAGAGATGAAAGAAA
                   TGGGATATGCTGCAACAGAGCGGGAAATAAGCCTAAGAGAGAGCCTCCAGGAGGAACT
                   CAAGAGGAAAAAAATCCAGTACTTGACTCGTGGAGAGGAGTCTTCGTCCGATACCAAT
                   AAGTCAGCCTGATGCTCTAATGGAAAAATGGCCCTC
                   ORF Start: ATG at 31  ORF Stop: TGA at 1054
                   SEQ ID NO:162         341 aa MW at 37417.4 kD
NOV38a,            MSAETMELKWVSFLAFLLLNFRVCLLLLQLLMPHSAQFSVLGPSGPILAMVGEDADLP
CG59454-01 Protein CHLFPTMSAETMELKWVSSSLRQVVNVYADCKEVEDRQSAPYRGRTSILRDGITAGKA
Sequence           ALRIHNVTASDSGKYLCYFQDGDFYEKALVELKVAALGSNLHVEVKGYEDGGIHLECR
                   STGWYPQPQIQWGNAKGENIPAVEAPVVADGVGLYEVAASVIMKSCSGEGVSCIIRNS
                   LLCLEKTASISIADPFFRSAQPWIAALAGTLPILLLLLAGASYFLWRQQKEITALSSE
                   IESEQEMKEMGYAATEREISLRESLQEELKRKKIQYLTRGEESSSDTNKSA
                   SEQ ID NO:163         935 bp
NOV38b,            ATTTGCTTTCTCTTTTTCCTTTCTTCCGGATGAGAGGCTAAGCCATAATAGAAAGAAT
CG 59454-03 DNA    GGAGAATTATTGATTGACCGTCTTTATTCTGTGGGCTCTCATTCTCCAATGGGAATAC
Sequence           CAAGCCATGGTTTTCCATACTGGAACCCAAAGGTAAAGACACTCAAGGACAGACATTT
                   TTGGCAGAGCATAGATGAAAATGGCAAGTTCCCTCGCTTTCCTTCTGCTCAACTTTCA
                   TGTCTCCCTCCTCTTGGTCCAGCTGCTCACTCCTTGCTCAGCTCAGTTTTCTGTGCTT
                   GGACCCTCTGGGCCCATCCTGGCCATGGTGGGTGAAGACGCTGATCTGCCCTGTCACC
                   TGTTCCCGACCATCAGTGCAGAGACCATCGAGCTGAAGTGGGTAAGTTCCAGCCTAAG
                   GCAGGTGGTGAATGTGTATGCAGATGGAAAGGAAGTGGAAGACAGGCAGACTGCACCG
                   TATCGAGGGAGAACTTCGATTCTGCGGGATGGCATCACTGCAGGGAAGGCTGCTCTCC
                   GAATACACAACGTCACAGCCTCTGACAGTGGAAAGTACTTGTGTTATTTCCAAGATGG
                   TGACTTCTATGAAAAAGCCCTGGTGGAGCTGAAGGTTGCAGACCCCTTCTTCAGGAGC
                   GCCCAGCCCTGGATCGCAGCCCTGGCAGGGACCCTGCCTATCTTGCTGCTGCTTCTCG
                   CCGGAGCCAGTTACTTCTTGTGGAGACAACACAAGGAAATAACTGCTCTGTCCAGTGA
                   GATAGAAAGTGAGCAAGAGATGAAAGAAATGGGATATGCTGCAACAGAGCGGGAAATA
                   AGCCTAAGAGAGACCCTCCAGGAGGAACTCAACAGGAAAAAAATCCAGTACTTGACTC
                   GTGGAGAGGAGTCTTCGTCCGATACCAATAAGTCAGCCTGATGCTCTAATGGAAAAAT
                   GGCCCTC
                   ORF Start: ATG at 189 ORF Stop: TGA at 909
                   SEQ ID NO:164         240 aa MW at 26651.2 kD
NOV38b,            MKMASSLAFLLLNFHVSLLLVQLLTPCSAQFSVLGPSGPILAIVIVGEDADLPCHLFPTM
CG59454-03 Protein SAETMELKWVSSSLRQVVNVYADGKEVEDRQSAPYRGRTSILRDGITAGKAALRIHNV
Sequence           TASDSGKYLCYFQDGDFYEKALVELKVADPFFRSAQPWIAALAGTLPILLLLLAGASY
                   FLWRQQKEITALSSEIESEQEMKEMGYAATEREISLRESLQEELKRKKIQYLTRGEES
                   SSDTNKSA
                   SEQ ID NO:165         1689 bp
NOV38c,            ATTTGCTTTCTCTTTTTCCTTTCTTCCGGATGAGAGGCTAAGCCATAATAGAAAGAAT
CG59454-04 DNA     GGAGAATTATTCATTGACCGTCTTTATTCTGTGGGCTCTGATTCTCCAATGGGAATAC
Sequence           CAAGCGATGGTTTTCCATACTGGAACCCAAAGGTAAAGACACTCAAGGACAGACATTT
                   TTGGCAGAGCATAGATGAAAATCGCAAGTTCCCTGGCTTTCCTTCTGCTCAACTTTCA
                   TGTCTCCCTCCTCTTGGTCCAGCTGCTCACTCCTTGCTCAGCTCAGTTTTCTGTGCTT
                   GGACCCTCTGGGCCCATCCTGGCCATGGTGGGTGAAGACGCTGATCTGCCCTGTCACC
                   CGTTCCCGACCATGAGTGCAGAGACCATGGAGCTGAAGTGGGTAAGTTCCAGCCTAAG
                   TATCGAGGGAGAACTTCGATTCTGCGGGATGCCATCACTGCACGGAAGGCTGCTCTCC
                   GAATACACAACGTCACAGCCTCTGACAGTGGAAAGTACTTGTGTTATTTCCAAGATGG
                   TGACTTCTATGAAAAAGCCCTGGTGGAGCTGAAGGTTGCAGCACTGGGTTCTAATCTT
                   CACGTCGAAGTGAAGGGTTATGAGGATGGAGGGATCCATCTGGAGTGCAGGTCCACCG
                   GCTGGTACCCCCAACCCCAAATACAGTGGAGCAACGCCAAGGGAGAGAACATCCCAGC
                   TGTGGAAGCACCTCTGGTTGCAGATGGAGTGGGCCTATATGAAGTAGCAGCATCTGTG
                   ATCATGAGAGGCGGCTCCGGGGAGGGTGTATCCTGCATCATCAGAAATTCCCTCCTCG
                   GCCTGGAAAAGACAGCCAGCATTTCCATCGCAGAGAGCCTCCAGGAGGAACTCAAGAG
                   GAAAAAATCCAGTACTTGACTCGTGGAGAGGAGTCTTCGTCCGATACCAATAAGTCAG
                   CCTGATGCTCTAATGGAAAAATGGCCCTCTTCAAGCCTGCAGATGTAATTCTGTATCC
                   AGACATGGCAAATGCCATCCTCCTTGTTTCTGAGGACCAGAGGAGTGTACAGCGTGCT
                   GAGGAGCCCCATGACCTACCAGACAACCCTGAGAGATTTGAATGGCGTTACTGTGTGC
                   TTGGCTGTGAAAGCTTCATGTCAGAGAGACACTACTCGGAGGTGGAAGTGGCGGACAG
                   AAAAGAGTGGCATATTGGGCTATGTAGTAAGAACGTGGAGAGGAAAAAAGTTTGGGTC
                   AAAATGACACCGGAGAACGGATACTGGACTATGGGCCTGACTGATGGGAATAAGTATC
                   GGGCTCTCACTGAGCCCAGAACCAACCTGAAACTTCCTGAGCCTCCTAGGAAAGTGGG
                   GGTCATCCTGGACTATGAGACTGGACATATCTCGTTCTACAATGCCACGGATGGATCT
                   CATATCTACACATTTCTGCACGCCTCTTCCTCTGAGCCTCTGTATCCTGTATTCAGAA
                   TTTTGACCTTGGAGCCCACTGCCCTGACCGTTTGCCCAATACCAAAAGTAGAGAGTTC
                   CCCCGATCCCGACCTAGTGCCTGATCATTCCCTGGAGATACCACTGACCCCAGGCTTA
                   GCTAATGAAAGTGGGCACCCTCAGGCTGAAGTAACATCTCTGCTTCTCCCTGCCCAGC
                   CTGGAGC
                   ORF Start: ATG at 189 ORF Stop: TGA at 945
                   SEQ ID NO:166         252 aa MW at 27148.7 kD
NOV38c,            MKMASSLAFLLLNFHVSLLLVQLLTPCSAQFSVLGPSGPILANVGEDADLPCHPFPTM
CG59454-04 Protein SAETMELKWVSSSLRQVVNVYADGKEVEDRQSAPYRGRTSILRDGITAGKAALRIHNV
Sequence           TASDSGKYLCYFQDGDFYEKALVELKVAALGSNLHVEVKGYEDGGIHLECRSTGWYPQ
                   PQIQWSNAKGENIPAVEAPVVADGVGLYEVAASVIMRGGSGEGVSCIIRNSLLGLEKT
                   ASISIAESLQEELKRKKSST

[0519] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 38B.

TABLE 38B
Comparison of NOV38a against NOV38b through NOV38c.
	NOV38a Residues/	Identities/Similarities for
Protein Sequence	Match Residues	the Matched Region
NOV38b	33 . . . 151	118/119 (99%)
	26 . . . 144	118/119 (99%)
NOV38c	33 . . . 246	208/214 (97%)
	26 . . . 239	210/214 (97%)

[0520] Further analysis of the NOV38a protein yielded the following properties shown in Table 38C.

TABLE 38C
Protein Sequence Properties NOV38a
PSort     0.6850 probability located in endoplasmic reticulum
analysis: (membrane); 0.6400 probability located in plasma membrane;
          0.4600 probability located in Golgi body;
          0.1000 probability located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 37 and 38
analysis:

[0521] A search of the NOV38a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 38D.

TABLE 38D
Geneseq Results for NOV38a
		NOV38a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAW99661	Human secreted protein clone cc 130_1	8 . . . 341	323/334 (96%)	0.0
	protein - Homo sapiens, 334 aa.	1 . . . 334	325/334 (96%)
	[WO9907840-A1, 18-FEB-1999]
AAW71592	Human myelin oligodendrocyte	8 . . . 334	315/327 (96%)	e−178
	glycoprotein-like protein - Homo	1 . . . 327	318/327 (96%)
	sapiens, 331 aa. [WO9833912-A1, 06-
	AUG-1998]
AAW78917	Bovine butyrophilin protein BTF4 -	8 . . . 323	304/316 (96%)	e−172
	Bos sp, 319 aa. [WO9814466-A1, 09-	1 . . . 316	307/316 (96%)
	APR-1998]
AAW78916	Bovine butyrophilin protein BTF3 -	8 . . . 333	290/326 (88%)	e−165
	Bos sp, 584 aa. [WO9814466-A1, 09-	1 . . . 326	303/326 (91%)
	APR-1998]
AAW78918	Bovine butyrophilin protein BTF5 -	8 . . . 335	273/328 (83%)	e−156
	Bos sp, 513 aa. [WO9814466-A1, 09-	1 . . . 328	294/328 (89%)
	APR-1998]

[0522] In a BLAST search of public sequence databases, the NOV38a protein was found to have homology to the proteins shown in the BLASTP data in Table 38E.

TABLE 38E
Public BLASTP Results for NOV38a
		NOV38a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9NR44	BUTYROPHILIN, SUBFAMILY 3,	8 . . . 341	325/334 (97%)	0.0
	MEMBER A2 - Homo sapiens	1 . . . 334	327/334 (97%)
	(Human), 334 aa.
Q9BU81	SIMILAR TO BUTYROPHILIN,	8 . . . 341	322/334 (96%)	0.0
	SUBFAMILY 3, MEMBER A2	1 . . . 334	325/334 (96%)
	(DJ45P21.5) - Homo sapiens (Human),
	334 aa.
P78410	HYPOTHETICAL 39.4 KDA	8 . . . 341	322/334 (96%)	0.0
	PROTEIN - Homo sapiens (Human),	1 . . . 334	325/334 (96%)
	359 aa.
O15338	BUTYROPHILIN - Homo sapiens	12 . . . 341	320/330 (96%)	e−180
	(Human), 357 aa.	3 . . . 332	322/330 (96%)
O00477	BUTYROPHILIN - Homo sapiens	8 . . . 323	304/316 (96%)	e−171
	(Human), 319 aa.	1 . . . 316	307/316 (96%)

[0523] PFam analysis indicates that the NOV38a protein contains the domains shown in Table 38F.

TABLE 38F
Domain Analysis of NOV38a
		Identities/
	Nov38a	Similarities	Expect
Pfam Domain	Match Region	for the Matched Region	Value
ig: domain 1 of 1	52 . . . 135	14/85 (16%)	0.00069
		55/85 (65%)

Example 39

[0524] The NOV39 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 39A.

TABLE 39A
NOV39 Sequence Analysis
                   SEQ ID NO:167       9705 bp
NOV39a,            ATGGACCCTGCTCAGCGCCCGGCCCCTGGGGCTGCTATTGTCGAGGGCCTGCCCTCTC
CG59307-01 DNA     CCTCAGACGCCTCCCTGGAGAGCCAAGCTGGTGTTCGAGGGTCCACCCTGCTGCCCAA
Sequence           CAGCCCCGCGGCCACCAGAGGGCCGTCCCTGGCCCGGCTGTGTGCCCTGGTGGACCTG
                   TGTCTGGGCTGCTCCCGCTGCACCCAGCGGCTCAATGAAAGCACCTACGTCCTCCGTA
                   GGGTGGAGCATGACTGCTCCCGCGAGATCCTGCTGGCCCGCTTTAAGCAGGCCACCAA
                   GAGCAACGTCTGGCCCGTGGTGGGCTGCCGGCCCACCTTCCCAAGCCCCCTGTCCTAC
                   CAAGTCTGCCACTACTACAGCCCTGGGCTCGGCTGCCGGCGCCACCGAAACCGGTGCA
                   CCTTTGCCCGCAGTCGCCAGGAGGCCCTGGTCTGGACCTTCGAGCGTCAGCACAACCT
                   CCAGCGCCTATGGCTGAAGGCGGAGGTGCAGCGCAGCGGGGCCCAGGGAGGGGCAGGC
                   CGGGCGGCCGACGCCATCCTTACGGAGTTTGGCGGCCGCTTCGAGCTGCTTTGCTCCC
                   TCTGCTTCAGGCGCTGTCCCCCATGCATCTGTCGCGTGGACCCCCAGGGGCAGTGCCC
                   TGAGCACGGAGCCTGCCCCTCCCTCCTCCCCACGTGAGCCCCGAGGGCCGCCGCAAAG
                   CAACAGTTTGTGGTGGTGAGGCCGCGGCCCCGGGCCGGCCAGCCTCCTGCCTACTGCA
                   GGTTTGTGGGGCGTGGGCAGCCGTGCTGGCGTGGGGAGTCCCGCTGCCAGTTTGCACA
                   CAGCCCCGTGGAGATGGCTGTGTGGGAGGCCGAGCAGCTGGGTGGCCTCCAGCGCGGG
                   GACCTGCTCACACCCCCTGCCCCTGATGGCGACGGGCCCACGGCCCCCCTTGGCCAGC
                   CCCCTGGGGCCCAGCTGTACTGCCCGGCCTGCTTGGTCACCTGCCACTCTCAGGAGGC
                   CTTCGAGAACCACTGCGCATCCTCGGAGCACGCACAGATGGTGGCCTTCGACCAGCCC
                   CTGCCCTGGGACCACCGTTCCCCACCCCCGGGACTCTCCAAGTTCGAGCTCTGCCCAA
                   AGCCTGACCTCTGTGAGTATGGGGACGCCTGCACCAAGGCACACTCAGCACAGGAGCT
                   GCAGGAGTGGGTCCGGCGCACGCAGGCTGTGGAGCTGCGGGGGCAGGCGGCCTCGCAG
                   GACGGGCTGGTGCCCTACCAGGAGCGGCTGCTGGCCGAGTACCAGCGCAGCACCAGTG
                   AGGTCCTTGTGCTGGCAGAGACCCTTGATGGAGTGCGTGTCACCTGCAACCAGCCCCT
                   GATGTACCAGGCCCAGGAGAGGAAGACCCAGTACAGCTGGACGTTTGCCGTCCACTCT
                   GAGGAGCCCCTGCTACACGTGGCCCTGCTGAAGCAGGAGCCAGGAGCCGACTTCTCTC
                   TGGTGGCTCCCGGCCTCCCGCCAGGCCGGCTCTACGCACGGGGTGAGCGCTTCCGTGT
                   GCCCAGCTCCACTGCCCACTTCCAGGTGGGAGTGCGTGTGCAGGCTGCCTCGTTCGGC
                   ACCTTTGAGCAATGGGTGGTCTTCGACTTTGGCCGCCGGCCGGTGCTGCTACAAAAGC
                   TGGGGCTGCAGCTGGGCCAGGGGCGTCCCCCAGGACCCTGCAGGAATCTGGCGCTCGG
                   CCACCCTGAGGAGATGGAGCGCTGGCACACTGGCAACCGCCACGTGGTGCCTGGCGTC
                   GAGCGGACGGCCGAGCAGACGGCCCTGATGGCCAAGTACAAGGGCCCTGCCCTGGCCC
                   TGGAGTTCAACCGCAGCAGCGTGGCCTCGGGCCCCATCTCACCAACCAACTATCGGCA
                   GAGGATGCACCAGTTTCTCTATGAGGAGGAGGCGGCTCAGCAGCAGCTGGTGGCCAAG
                   CTGACCCTGCGGGCCCAGGTGTTCCTGAAGACGGCATTGCAGACGCCAGCGCTGAACA
                   TGCTCTTCGCGCCTCCGGGAGCACTGTACGCAGAGGTCCCCGTCCCCTCCTCCCTGAT
                   GCCAGACACAGACCAGGGCTTCCTGCTGGCCCGGGCGGTCAGCACAGCCCTGGTGGCC
                   CCTGTACCTGCACCCGACAATACGGTGTTCGAGGTGCGGCTGGAGAGGCGGGCCAGCT
                   CAGAGCAGGCGCTGTGGCTGCTGCTTCCGGCCCGCTGCTGCTTGGCCCTCGGGCTGCA
                   GCCTGAGGCCCGCCTGGTCCTGGAGGTGCAGTTCCAGATTGACCCGATGACCTTCCGC
                   CTCTGGCACCAGGCAGTGGACACACTGCCTGACGAGCAGCTGGTGGTGCCCGACTTGC
                   CCACCTGCGCCCTGCCCAGACCTTGGTCTGTCCCACCCTTGCGGCGTGGCAACCGCAA
                   GCAGGAGCTGGCCGTGGCGCTCATCGCGGGCTGGGGCCCTGGGGATGGGAGGCGTGTC
                   CCCCCGCTACTCATCTATGGCCCCTTTGGCACCGGCAAGACCTACACGCTGGCCATGG
                   CCTCCCTGGAGGTCATCCGGAGGCCTGAAACCAAGGTGCTCATCTGCACACACACCAA
                   CAGTCTACACCGGGCAGGCGGTCACCCCCTGGATGTGCTCCACTCCTCTGATTCTGCA
                   CTCCCTGTAGCCGACCAGCTTTGGGCTTTGGCTTTATCAGGCCCAGCTCAGGCCACCG
                   AGGGTGGCCGGGTCTGCTGTCAGGAGGGACACCAGTGTTTGCTGCTCACCTCTGACAG
                   CCAGACAAGGGCTGTGCTCAGGGGCAGCTCGGCTGGGCACACAGTAGGTGCTTTAGCG
                   GACAGCACTGAGGCCCCCAGCAAGAACCCCATGAGCTCCTCCCCCTCCCGCAGTGCCG
                   CCGACATCTACATCCGGGAGTATTTCCACAGCCACGTCAGCGGCGGCCACCCCGAGGC
                   CACTCCTCTCCGTGTGATGTACACGGACCCGCCGCTGAGCCAGACGGACCCAGTCACG
                   CTGCAGTACTGTTGCCTGACCCACGACCGCCAGGCTTTCCGCCCGCCCACACGGGCAG
                   AGCTGGCGCGGCACCGCGTGGTGGTCACCACCACCTCCCAGGCCCGTGAGCTCAGCCT
                   GCCGGTCGGCTTCTTCTCCCACATTCTCATCGATGAGGCGGCCCAGATGCTGGAGTGC
                   GAGGCCCTCACCCCGCTGGCCTATGCCTCGCACGGCACCCGCCTCGTGCTGGCGGGCG
                   ACCACATGCAGGTCACACCCCGGCTGTTCAGTGTGGCCAGGGCCCGGCCGGCCGAGCA
                   CACGCTGCTGCACCGCCTCTTCCTGTGCTACCAGCAGGAGACTCACGAGGTGGCGCGG
                   CAGAGCCGCCTGGTCTTCCACGAGAACTACCGCTGCACGGACGCCATTGTCAGCTTCA
                   TCTCGCGGCACTTCTACGTGGCCAAGGGCAACCCCATCCACGCCAGCGGCAAGGTTCC
                   GCCCCACCCCCGCCACTACCCGCTCATGTTCTGCCACGTGGCGGGCAGCCCAGACCGG
                   GACATGTCCATGGCGTCCTGGCTGAATCTGGCTGAGATTGCGCAGGTCGTCGAGAAGG
                   TGCAGGAGGCCTACAACACCTGGCCCAGCTGCTGGGGCGGCCGCGAGCAGAGGTGCAT
                   CTGTGTCGTTTCCCACGGTGCCCAGGTCAGTGCACTGAGGCAGGAGCTGAGGAGGCGG
                   GACCTAGGCCAGGTGTCTGTCGGCAGTTTTGAGATCCTGCCAGGGCGGCAGTTCCGGG
                   TCGTGGTGCTCAGCACTGTGCACACCTGCCAGAGCCTGCTCAGCCCTGGCGCACTCGC
                   CCCTGAGTTCTTCACCGACGCCCGCGTGCTCAACACCGTCCTGACCCGCGCCCAGTCC
                   CAGCTGGTGGTAGTGGGGGACGCCGTGGCCCTCTGCTCCTTCGGGGCCTGCGGCAAGC
                   TCTGGGAGAGCTTCATCCGTGAGTGCGTGGAGCGGCACAGTGTCTGCCCCGAGGGCCT
                   GTCCATGGAGCAGGTCGAGCAGGGTGTGGCGCAGAGACGGCGCTGGCCTCCCCGAGGC
                   ACACAGGCTGGGCCACCGGGCAACTGGGAGGCTGCCCCAGACCCAGTAGGGGACCTGG
                   CCGAGGAGCAGGCGGCTGTGGTGACGGCCATGGTGAAGGCAGAGCCGGGAGATGAGGC
                   TCTGAGCCCAGCATCCCGTGACATCACGGCAACCACAGCGCAGACGGAGGCTGCGGCA
                   GCACCAGCAGGAGACCCAGTGAAGGAAGACGTGGTGCCCGGGCCCTGTGCGGCAGGAG
                   CGGCTGCTGCAGCGGGCGTGGAGTCCACGGAGGCTGAGGATGCAGAGGCTGACTTCTG
                   GCCGTGGGACGGGGAGCTCAACGCTGACGACGCCATCCTACGGGAGCTTCTGGACGAG
                   AGCCAGAAGGTGATGGTGACCGTCGGGGAGGACGGGCTGCTGGACACTGTCGCCAGGC
                   CCGAGTCCCTGCAGCAGGCCCGGCTGTACGAGAACCTGCCCCCGGCTGCGCTACGGAA
                   GCTGCTGCACGCGGAGCCCGAGCGGTACCGCCACTGCTCTTTCGTGCCAGAGACCTTC
                   GACCGGGCGTCAGCCATCCCGCTGGACGATGCCTCCTCCGGCCCCATCCACGTCAGGG
                   GCCGCCTGGACTGTGGGATGGCCTTCGCCGGGGATGAGGTGCTGGTGCAGCTCCTTTC
                   GGGAGACAAGGCGCCCGAGGGGCGGCTTCGGGGCCGCGTGCTGGGCGTGCTGAAGAGG
                   AAGAGGCACGAGCTGGCGTTTGTGTGCCGCATGGACACGTGGGACCCGCGCATCATGC
                   TCCCCATCAATGGCTCCGTGACCAAGATCTTCGTGGCCGAGCTGAAGGACCCATCGCA
                   GGTCCCCATCTACAGCCTCCGGAAGGGCCGCCTGCAGCGTGTGGGGCTTGAGAGGCTC
                   ACCCCCGAGGCCCGGCACAGCCGGCTCTTCTGGGTCCAAATTGTCCTGTGGCGGCAAG
                   GCTTCTACTACCCGCTGGGCATCGTCCGGGAGGTGCTGCCTGAGGCCAGCACCTGGGA
                   GCAGGGCCTCCGCATCCTCGGCCTGCAGTACAGCTTGAGGGTGCCCCCGTCGGACCAG
                   GCCACCATCACCAAGGTGCTGCAGAAATACCACACGGAGCTTGGCCGCGTTGCCCGCC
                   GCCGAGAGGACTGCCGCGCCTTCTTGACCTTCACTGTGGACCCCCAGGGCGCCTGCAA
                   CCTCGATGATGCCCTCAGTGTCCGAGACCTGGGTCCCAGGTGCGAGGTGGCTGTGCAC
                   ATCACTGATGTGGCCAGCTTCGTGCCCAGGGACGGCGTGCTGGACGTGGAGGCGCGAA
                   GGCAGGGCGCTGCGTTCTATGCCCCCGGCAGGGAGCCAGTGCCCATGCTGCCGGCCAG
                   CCTCTGCCAGCACGTCCTCAGCCTCCTGCCTGGCCGGGACCGCCTGGCCATCTCCCTG
                   TTCCTCACCATGGAGAAGGCCAGTGGCCAGCTGAAGAGCCTGCGCTTTGCACCCTCCG
                   TGGTCCAGTCTGACCGCCAGCTGTCCTACGAGGAGGCGGAGGAGGTGATCAGGCAGCA
                   CCCGGGTGCCGGCCGTGAGCTGCCGGCCCGCCTGGACTCCGTGGACGCCTGCGTCGTG
                   GCCGCGTCCTACTTCTCTCCGCTGCTGCGCCGGCACCGCCTGCGGTCCGACTGCTTCT
                   ATGAGCAGCCGGACGAGGACGGCACCCTGGGCTTCCGCGCGGCCCACATCATGGTGAA
                   GGAGTACATGATTCAGTTTAATAGGCTCGTGGCTGAGTTCCTGGTGGGCAGCGAGTGC
                   ACGCGGACGGTCACGCCTCTGCGGTGGCAGCCAGCACCCCGCAGCCAGCAGCTCAAGG
                   CCCTGTGTGAGAAGCATGGGGACCGGGTGCCCCTGTCACTGCACCTCGGCCACCACCT
                   GCACGGCGGCGGGGGCAGTCCCCCCGACACGCGGCTGCACCTCCTGGCCTCCCTCTGG
                   AAGCAGGTCCAGTTTGCTGCCCGCACCCACCACTACCAACAGATGGTGGACTTGGTCA
                   CCACCGACGACATGCACCCATTCCTGGCTCCTGCAGGCCGCGACCTCCGCAAGGCCCT
                   GGAGCGCTCGGCGTTCGGCCGCTGCGCCCGGGGCCACCAGCAGCAGCGCGGCCACTAC
                   TCGCTGCAGGTGGACTGGTACACGTGGGCCACCTCGCCCATCCGCAGGTACCTGGACG
                   TGGTGTTGCAGCGGCAGATCCTGCTGGCGCTGGGCCATGCGGGCTCTGCCTACTCTGC
                   CAGGGACATCGATGGGCTCTGCCAGGCCTTCAGCCTCCAGCACGCACTTGCCCAGAGC
                   TATCAGCGGCGGGCGCGCAGCCTGCACCTGGCCGTGCAGCTCAAGGCCCAGCCTCTGG
                   ACAAGCTGGGCTTCGTGGTGGACCTGGAGGCGGGCTCCCGCTGCTTCCGGCTGCTCTT
                   CCCCAGCAACCGCGAGACGCTGCCTGACCCCTGCCCCGTCCCCTACGGCTCCCTGCAG
                   CTGGCCGAGCACCCCCACGCCCTGGCAGGCCGGCCGGGCCTGCGGCTCCTGTGGCGGC
                   GCCGTGTCTACTCAGCGCAGGGATCCAGCCCGCCCCTGCCACTGCCTGGCACTGTGCC
                   GGACCCACACACCCTGGCCGTGGAGACGGCCCTGTGGAAGCAGCTGCTGGAGCTGGTG
                   GAGCTGCAGCGCTGGCCGGAGGCGGCTGCTCTCATCCAGGAGAAGGGCGAGGCGTCCC
                   AGCGGCGGGAGCTGGTGCAGGTGCAGCGGAGCCACTGTGGCCATTTCCTGGAGGTGGC
                   CCGGGAGCTGGGCAGTGGGGACACCCTGCAGGTGCAGCTCGGCACCAGCCTCCAGCAC
                   GCTTCCTGGTACCGAGCCCTCAGCTCTGGACGGTGGCACCGGGCTTCAGCCTCTGCC
                   TGGAGCACGTGGAGCGGCCCGGAGACTGCTTCTCAGGCCGTGTGTACCGGGCCCCGAG
                   GGACCGGTACCGCGACCTGGATGAGTACGCCTGCGTGTGGGAACCATTCTGCGCCCTG
                   GAGTCGGCCACCGGCGCGGTTGCCGAGAATGACTCCGTCACACTTCAGCACCTGAGTG
                   TCTCCTGGGAGGCGTCACGGACGCCGCAGGGGCAGCTGCAGGGCGCCTTCCGCCTGGA
                   GGCCGCCTTCCTCGAGGAGAACTGTGCCGACATCAACTTCAGCTGCTGCTACCTCTGC
                   ATCCCCCTCGAGCCGCTGCCGGCTCCCACCGCCAGCCCACGCCCTGCGCCCAGCACCC
                   TCGGCCCTGGCCTGAATCTTGACCCCGGCACCTATACCTCGGTGGCCCACGGGCAGAC
                   CTCTTCGTCCACCACATGGGCATGGAGAAGGTTCCGGAAGAGGTGCTGAGGCCGGGCA
                   CCCTGTTCACCGTTGAGCTGCTGCCCAAGCAGCTTCCTGATCTCCGCAAGGAGGAAGC
                   CGTGCGTGGACTAGAGGAGGCGTCCCCGCTGGTCACCAGCATCGCACTGGGCCGGCCT
                   GTCCCGCAGCCCCTCTGCAGAGCCCCACCCTGCATGAGTGCTCAGGGAGGCTGCCCCC
                   TCTCAGTGATCCCCAGCAGGTTCCTGGAGCGGCAGACCTACAACATCCCCGGAGGCCG
                   CCACAAGCTGAACCCCAGCCACAACGTGGCGGTCAGGCACGCTCTGGAGAAGCCTTTC
                   ACGGTCATTCAGGGCCCACCAGGTACAGGGAAGACGATCGTGGGCCTCCACATCGTAT
                   TCTGGTTTCATAAATCAAACCAGGAGCAGGTGCAGCCCGGAGGCCCCCCCCGTGGGCA
                   GAAGCGGCTGGGGGGTCCCTCCATCTTGTACTGCGGCCCCTCCAACAAGTCGGTGGAT
                   GTCCTGGCAGGACTGCTCCTGAGAAGGATGGAGCTGAAGCCCCTCCGTGTGTACAGTG
                   AGCAGGCTGAGCCCAGCGACTTCCCAGTGCCGCGTGTGGGCAGCAGGAAGCTGCTCAG
                   GAAGAGCCCCCGGGAGGGGAGGCCGAACCAGAGCCTCAGGAGCATCACCCTGCACCAC
                   CGGATCCGCCAGGCCCCCAACCCTTACTCGTCGGAAATCAAGGCCTTTGACACCCGGC
                   TGCAGAGAGGGGAGCTCTTCTCCAGCGAGGACCTGGTCTGGTACAAGAAGGTCTTGTG
                   GGAGGCTCGGAAGTTCGAGCTGGACCGGCATGAGGTCATCCTCTGCACCTGCTCCTGT
                   GCAGCCTCTGCCAGCCTCAAAATCCTGGACGTGAGGCAGATCCTTCTTGACGAGGCAG
                   GCATGGCCACGCAACCTGAAACCCTCATCCCCCTGGTGCAGTTCCCACAGGCCGAGAA
                   GGTGGTTCTTCTCGGAGACCACAAGCAGCTGCGGCCTGTGGTCAAGAATGAGCGGCTG
                   CAAAACCTGGGTCTGGACCGGTCTCTGTTCGAGCGGTACCACGAGGACGCACATATGC
                   TGGACACTCAGTACCGCATGCATGAGGGCATCTGTGCCTTCCCCTCTGTCGCGTTCTA
                   CAAGAGCAACCTGAAGACGTGGCACGGCCTGAGGAGGCCGCCCAGTGTCCTGGGCCAC
                   GCTGGCAAGGAGAGCTGCCCTGTCATCTTTGGCCACGTGCAGCGCCACGAGCGGAGCC
                   TGCTGGTGTCCACGGACGAAGGGAATGAGAACTCCAAGGCCAACCTGGACGAGGTGGC
                   TGAGGTGGTCCGTATCACCAAGCAGCTGACCCTGGGGAGGACCGTAGAGCCCCAGGAC
                   ATCGCCGTCCTCACGCCCTACAACGCGCAGGCCTCTGAGATCAGCAAGGCCCTTCGGC
                   GAGAGGGCATCGCCCCGGTGGCCCTGTCCTCCATCACCAAGAGCCAGGGGAGCGAGTG
                   GCGCTATGTGCTGGTGAGCACCGTCCGCACCTGTCCCAAGAGCGACCTGGACCAGCGG
                   CCCACCAAGAGCTGGCTCAAGAAGTTTCTGGGCTTCGTTGTGGACCCCAACCAAGTGA
                   ATGTGGCTGTCACGCGGGCCCAGGAGGGGCTCTGCCTGATCGGTGAGGGCGGGGCTGG
                   GCTCTTCCAGGGTGGGAACACAGGAGACCACCTCCTTCTGCGCTGCTCCCCCCTCTGG
                   CGTAGCCTCCTGGACTTCTGCGAGGCTCAGCAGACCCTCGTGCCTGCCGGCCAGGCCC
                   GGTGTCTCCGGCTGCCTGTGTGGGCAGGGGAGGGCCGTGCCTGGTGTGGTGGGGACAA
                   GCCACAGCTCCAGAGCTGCTCCGGTGTCACCAGGCTGGCCAAGTCCAAAGTCCCTGAG
                   GCCACCAGCCTTGACTGTCCTGCTGGTCCCACTTTTAAAGCTGCTCCCCAGGACCCCC
                   TGGCCGCTGTGGACTGGGGTCCCTCCGCACCTGGCCCATTTGTGGCTGCGTCCACAGG
                   GGCTCCTGTGGCCTCCCAGAGCCAGCTCGGGGGTCAGATGGTCGCGGGGGCTATGGTC
                   ACTGTGGGAAAAGAGGTTCTGGGCATCTGTGGAGGGAGGGGTGGAGCATGGAGTCTCC
                   AGGACTGTGGCCCCGTTGGTGTGCTGGACGGGCCCTGCCTTGAAGACCATGTCTATTC
                   TTGGACCGTCATGAAATAA
                   ORF Start: ATG at 1 ORF Stop: TAA at 9703
                   SEQ ID NO:168       3234 aa MW at 355870.4 kD
NOV39a,            MDPAQRPAPGAAIVEGLPSPRSSNVIGLRRGSLVVDGPPSRPPEVADTATAKASTWAS
CG59307-01 Protein GLRTVANSSSGLRCPVSSGASDASLESQAGVRGSTLLPNSPAATRGPSLARLCALVDL
Sequence           CLGCSRCTQRLNESTYVLRRVEHDCSREILLARFKQATKSKVWRVVGCRPTFPRPLCY
                   QVCHYYSPGLGCRRHRNRCTFARSREEALVWTFERQHNLQRLWLKAEVQGSGAQGGAG
                   RAADAILTEFGGRFELLCSLCFRRCPPCICRVDPQGQCPEHGACPSLLAHVSAEGRRK
                   QQFVVVRPRPRACQPPAYCRFVGRGQPCWRGESRCQFAHSAVEMAVWEAEQLGGLQRG
                   DLLTPPAPDGDGRTAPLGQPPGAQLYCPACLVTCHSQEAFENHCASSEHAQMVAFDQA
                   LPWEHRSPPPGLSKFELCPKPDLCEYGDACTKAHSAQELQEWVRRTQAVELRGQAAWQ
                   DGLVPYQERLLAEYQRSSSEVLVLAETLDGVRVTCNQPLMYQAQERKTQYSWTFAVHS
                   EEPLLHVALLKQEPGADFSLVAPGLPPGRLYARGERFRVPSSTADFQVGVRVQAASFG
                   TFEQWVVFDFGRRPVLLQKLGLQLGQGRRPGPCRNLALGHPEEMERWHTCNRHVVPGV
                   ERTAEQTALMAKYKGPALALEFNRSSVASGPISPTNYRQRMHQFLYEEEAAQQQLVAK
                   LTLRGQVFLKTALQTPALNMLFAPPGALYAEVPVPSSLMPDTDQGFLLGRAVSTALVA
                   PVPAPDNTVFEVRLERRASSEQALWLLLPARCCLALGLQPEARLVLEVQFQIDPMTFR
                   LWHQAVDTLPEEQLVVPDLPTCALPRPWSVPPLRRGNRKQELAVALIAGWGPGDGRRV
                   PPLLIYGPFGTGKTYTLAMASLEVIRRPETKVLICTHTNSLHRACGHPLDVLQSSDSA
                   LPVADQLWALALSGPAQGTEGGRVCCQEGHQCLLLTSDSQTRAVLRGSSAGHTVGALA
                   DSTEAPSKKPMSSSPSRSAADIYIREYFHSHVSGGHPEATPLRVMYTDRPLSQTDPVT
                   LQYCCLTDDRQAFRPPTRAELARHRVVVTTTSQARELRVPVGFFSHILIDEAAQMLEC
                   EALTPLAYASHGTRLVLAGDHMQVTPRLFSVARARAAEHTLLHRLFLCYQQETHEVAR
                   QSRLVFHENYRCTDAIVSFISRHFYVAKGNPIHARGKVPPHPRHYPLMFCHVAGSPDR
                   DMSMASWLNLAEIAQVVEKVQEAYNTWPSCWGGREQRCICVVSHGAQVSALRQELRRR
                   DLGQVSVGSFEILPGRQFRVVVLSTVHTCQSLLSPGALAPEFFTDARVLNTVLTRAQS
                   QLVVVGDAVALCSFGACGKLWESFIRECVERHSVCPEGLSMEQVEQGVAQRRRWPPRG
                   TQAGAAGNWEAAPEPVGDLAEEQAAVVTAMVKAEPGDEALSPASRDITATTAQTEAAA
                   APAGDAVKEDVVPGACAAGAAAAAGVESTEAEDAEADFWPWDGELNADDAILRELLDE
                   SQKVMVTVGEDGLLDTVARPESLQQARLYENLPPAALRKLLHAEPERYRHCSFVPETF
                   ERASAIPLDDASSGPIQVRGRLDCGMAFAGDEVLVQLLSGDKAPEGRLRGRVLGVLKR
                   KRHELAFVCRMDTWDPRIMVPINGSVTKIFVAELKDPSQVPIYSLRKGRLQRVGLERL
                   TAEARHSRLFWVQIVLWRQGFYYPLCIVREVLPEASTWEQGLRILGLEYSLRVPPSDQ
                   ATITKVLQKYHTELGRVAGRREDCRAFLTFTVDPQGACNLDDALSVRDLGPRCEVAVH
                   ITDVASFVPRDGVLDVEARRQGAAFYAPGREPVPMLPASLCQDVLSLLPGRDRLAISL
                   FLTMEKASGQLKSLRFAPSVVQSDRQLSYEEAEEVIRQHPGAGRELPARLDSVDACVV
                   AACYFSRLLRRHRLRSDCFYEQPDEDGTLGFRAAHIMVKEYMIQFNRLVAEFLVGSEC
                   TRTVTPLRWQPAPRSQQLKALCEKHGDRVPLSLHLGHHLHGGGGSPPDTRLHLLASLW
                   KQVQFAARTQDYEQMVDLVTTDDMHPFLAPAGRDLRKALERSAFGRCARGHQQQGGHY
                   SLQVDWYTWATSPIRRYLDVVLQRQILLALGHGGSAYSARDIDGLCQAFSLQHALAQS
                   YQRRARSLHLAVQLKAQPLDKLGFVVDVEAGSRCFRLLFPSNRETLPDPCPVPYGSLQ
                   LAEHPHALAGRPGLRLLWRRRVYSAQGSSPPLPLPGTVPDPHTLAVETALWKQLLELV
                   ELQRWPEAAALIQEKGEASQRRELVQVQRSHCGHFLEVARELGSGDTLQVQLGTSLQH
                   GFLVPSPQLWTVAPGFSLCLEHVERPGDCFSGRVYRAPRDRYRDVDEYACVWEPFCAL
                   ESATGAVAENDSVTLQHLSVSWEASRTPQGQLQGAFRLEAAFLEENCADINFSCCYLC
                   IRLEGLPAPTASPRPGPSSLGPGLNVDPGTYTWVAHGQTQDWDQERRADRQEAPRRVH
                   LFVHHMCMEKVPEEVLRPGTLFTVELLPKQLPDLRKEEAVRGLEEASPLVTSIALGRP
                   VPQPLCRAPPCMSAQGGCPLSVIPSRFLERQTYNIPGGRHKLNPSQNVAVREALEKPF
                   TVIQGPPGTGKTIVGLHIVFWFHKSNQEQVQPGGPPRGEKRLGGPCILYCGPSNKSVD
                   VLAGLLLRRMELKPLRVYSEQAEASEFPVPRVGSRKLLRKSPREGRPNQSLRSITLHH
                   RIRQAPNPYSSEIKAFDTRLQRGELFSREDLVWYKKVLWEARKFELDRHEVILCTCSC
                   AASASLKILDVRQILVDEAGMATEPETLIPLVQFPQAEKVVLLGDHKQLRPVVKNERL
                   QNLGLDRSLFERYHEDAHMLDTQYRMHEGICAFPSVAFYKSKLKTWQGLRRPPSVLGH
                   AGKESCPVIFGHVQGHERSLLVSTDEGNENSKANLEEVAEVVRITKQLTLGRTVEPQD
                   IAVLTPYNAQASEISKALRREGIAGVAVSSITKSQGSEWRYVLVSTVRTCAKSDLDQR
                   PTKSWLKKFLGFVVDPNQVNVAVTRAQEGLCLIGEGGAGLFQGGNTGDHLLLRCCPLW
                   RSLLDFCEAQQTLVPAGQGRCLRLPVWGGEGRAWCGGDKPQLQSCSGVTRLAKSKVPE
                   ATSLDCPAGPTFKAAPQDPLAAVDWGPSAPGPFVAASTGAPVASQSQLGGQMVAGAMV
                   TVGKEVLGICGGRGGAWSLQDCGPVGVLDGPCLEDHVYSWTVMK

[0525] Further analysis of the NOV39a protein yielded the following properties shown in Table 39B.

TABLE 39B
Protein Sequence Properties NOV39a
PSort     0.7000 probability located in plasma membrane;
analysis: 0.3500 probability located in nucleus;
          0.3000 probability located in microbody (peroxisome);
          0.2000 probability located in endoplasmic
          reticulum (membrane)
SignalP   No Known Signal Sequence Indicated
analysis:

[0526] A search of the NOV39a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 39C.

TABLE 39C
Geneseq Results for NOV39a
		NOV39a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAB94712	Human protein sequence SEQ ID	334 . . . 523	190/190 (100%)	e−112
	NO: 15712 - Homo sapiens, 293 aa.	1 . . . 190	190/190 (100%)
	[EP 1074617-A2, 07-FEB-2001]
AAU23357	Novel human enzyme polypeptide	1759 . . . 1901	141/143 (98%)	5e−75
	#443 - Homo sapiens, 143 aa.	1 . . . 143	141/143 (98%)
	[WO200155301-A2, 02-AUG-2001]
ABB25190	Protein #7189 encoded by probe for	817 . . . 909	93/93 (100%)	4e−49
	measuring heart cell gene expression -	1 . . . 93	93/93 (100%)
	Homo sapiens, 93 aa. [WO200157274-
	A2, 09-AUG-2001]
AAM74813	Human bone marrow expressed probe	817 . . . 909	93/93 (100%)	4e−49
	encoded protein SEQ ID NO: 35119 -	1 . . . 93	93/93 (100%)
	Homo sapiens, 93 aa. [WO200157276-
	A2, 09-AUG-2001]
AAM62011	Human brain expressed single exon	817 . . . 909	93/93 (100%)	4e−49
	34116 - Homo sapiens, 93 aa.	1 . . . 93	93/93 (100%)
	[WO200157275-A2, 09-AUG-2001]

[0527] In a BLAST search of public sequence databases, the NOV39a protein was found to have homology to the proteins shown in the BLASTP data in Table 39D.

TABLE 39D
Public BLASTP Results for NOV39a
		NOV39a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9C094	KIAA1769 PROTEIN - Homo sapiens	963 . . . 3099	2102/2137 (98%)	0.0
	(Human), 2114 aa (fragment).	1 . . . 2110	2104/2137 (98%)
Q9BYK8	DJ697K14.6 (NOVEL PROTEIN,	992 . . . 3099	1985/2108 (94%)	0.0
	KIAA1769) - Homo sapiens (Human),	565 . . . 2563	1988/2108 (94%)
	2567 aa.
Q9BGV5	HYPOTHETICAL 60.5 KDA	2244 . . . 2754	460/511 (90%)	0.0
	PROTEIN - Macaca fascicularis	3 . . . 499	475/511 (92%)
	(Crab eating macaque) (Cynomolgus
	monkey), 545 aa.
Q922U3	UNKNOWN (PROTEIN FOR	2453 . . . 3090	463/694 (66%)	0.0
	IMAGE: 3589116) - Mus musculus	1 . . . 681	529/694 (75%)
	(Mouse), 717 aa (fragment).
Q96ND3	CDNA FLJ31049 FIS, CLONE	2678 . . . 3099	405/422 (95%)	0.0
	HSYRA2000510, WEAKLY	1 . . . 409	405/422 (95%)
	SIMILAR TO NAM7 PROTEIN -
	Homo sapiens (Human), 413 aa.

[0528] PFam analysis indicates that the NOV39a protein contains the domains shown in Table 39E.

TABLE 39E
Domain Analysis of NOV39a
		Identities/
		Similarities
	NOV39a Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
zf-CCCH: domain	304 . . . 331	11/28 (39%)	1.1
1 of 2		19/28 (68%)
zf-CCCH: domain	419 . . . 442	11/27 (41%)	2.3
2 of 2		16/27 (59%)
Runt: domain	1734 . . . 1756	6/23 (26%)	0.7
1 of 1		18/23 (78%)
RNB: domain	1682 . . . 2036	98/414 (24%)	2.1e−29
1 of 1		240/414 (58%)
UvrD-helicase: domain	2594 . . . 2622	14/29 (48%)	2.4
1 of 2		23/29 (79%)
UPF0066: domain	2591 . . . 2692	25/138 (18%)	5.3
1 of 1		62/138 (45%)
UvrD-helicase: domain	2951 . . . 2981	15/32 (47%)	1.7
2 of 2		25/32 (78%)

Example 40

[0529] The NOV40 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 40A.

TABLE 40A
NOV40 Sequence Analysis
                   SEQ ID NO:169        11603 bp
NOV40a,            CCCTCCATTGCTATGGATACCGAATCCACTTATTCTGGATATTCTTACTATTCAAGTC
CG59713-01 DNA     ATTCGAAAAAATCTCACAGACAAAGGGAAAGAACTAGAGAGAGACACAAGTCACCCCG
Sequence           GAATAAAGACGGCAGAGGGTCAGAAAAGTCTGTCACCATTCAACCTCCCACTGGAGAG
                   CCCCTGTTGGGAAATGATTCTACTCGGACAGAGGAACAGGATGACAACTGGGGAGAGA
                   CCACCACGGCCATCACAGGCACCTCGGAGCACAGCATATCCCAAGAGGACATTGCCAG
                   GATCAGCAAGGACATGGAGGACAGCGTGGGGCTGGATTGCAAACGCTACCTGGGCCTC
                   ACCGTCGCCTCTTTTCTTGGACTTCTAGTTTTCCTCACCCCTATTGCCTTCATCCTTT
                   TACCTCCCATCCTGTGGAGGGATGAGCTGGAGCCTTGTGGCACAATTTGTGAGGGGCT
                   CTTTATCTCCATGGCATTCAAACTCCTCATTCTGCTCATAGCGACCTGCGCACTTTTT
                   TTCCGCAAGCGGAGAGCTGACATGCCACGGGTGTTTGTGTTTCGTGCCCTTTTGTTGG
                   TCCTCATCTTTCTCTTTGTGGTTTCCTATTGGCTTTTTTACGGGGTCCGCATTTTGGA
                   CTCTCGGGACCGGAATTACCAGGGCATTGTGCAATATGCAGTCTCCCTTGTGGATGCC
                   CTCCTCTTCATCCATTACCTGGCCATCGTCCTGCTCGAGCTCAGGCAGCTGCAGCCCA
                   TGTTCACGCTGCAGGTGGTCCGCTCCACCGATGGCGAGTCCCGCTTCTACAGCCTGGG
                   ACACCTCAGTATCCAGCGAGCAGCATTGGTGGTCCTAGAAAATTACTACAAAGATTTC
                   ACCATCTATAACCCAAACCTCCTAACAGCCTCCAAATTCCGAGCAGCCAAGCATATGG
                   CCGGGCTGAAAGTCTACAATGTATTCCCCAAAGGCCCCAGTAACAATGCCACTGGCCA
                   GTCCCGGGCCATGATTGCTGCAGCTGCTCGGCGCAGGGACTCAAGCCACAACGAGTTG
                   TATTATCAAGAGGCCGAACATGAACGGCGAGTAAAGAAGCGGAAAGCAAGGCTGGTGG
                   TTGCAGTGGAAGAGGCCTTCATCCACATTCAGCGTCTCCAGGCTGAGCAGCAGCAGAA
                   AGCCCCAGGGGAGGTGATGGACCCTAGGGAGGCCGCCCACGCCATTTTCCCCTCCATG
                   GCCAGGGCTCTCCAGAAGTACCTGCGCATCACCCGGCAGCAGAACTACCACAGCATGG
                   AGAGCATCCTGCAGCACCTGGCCTTCTGCATCACCAACGCCATGACCCCCAAGGCCTT
                   CCTAGAACGGTACCTCAGTGCGGGCCCCACCCTGCAATATGACAAGGACCGCTGGCTC
                   TCTACACAGTGGAGGCTTGTCAGTGATGAGGCTGTGACTAATGGATTACGGGATGGAA
                   TTGTGTTCGTCCTTAAGTGCTTGGACTTCAGCCTCGTAGTCAATGTGAAGAAAATTCC
                   ATTCATCATACTCTCTGAAGAGTTCATAGACCCCAAATCTCACAAATTTGTCCTTCGC
                   TTACAGTCTGAGACATCCGTTTAAAAGTTCTATATTT
                   ORF Start: ATG at 13 ORF Stop: TAA at 1588
                   SEQ ID NO:170        525aa MW at 60231.6 kD
NOV40a,            MDTESTYSGYSYYSSHSKKSHRQRERTRERHKSPRNKDGRGSEKSVTIQPPTGEPLLG
CG59713-01 Protein NDSTRTEEQDDNWGETTTAITGTSEHSISQEDIARISKDMEDSVGLDCKRYLGLTVAS
Sequence           FLGLLVFLTPIAFILLPPILWRDELEPCGTICEGLFISMAFKLLILLIGTWALFFRKR
                   RADMPRVFVFRALLLVLIFLFVVSYWLFYGVRILDSRDRNYQGIVQYAVSLVDALLFI
                   HYLAIVLLELRQLQPMFTLQVVRSTDGESRFYSLGHLSIQRAALVVLENYYKDFTIYN
                   PNLLTASKFRAAKHMAGLKVYNVFPKGPSNNATGQSRAMIAAAARRRDSSHNELYYEE
                   AEHERRVKKRKARLVVAVEEAFIHIQRLQAEEQQKAPGEVMDPREAAQAIFPSMARAL
                   QKYLRITRQQNYHSMESILQHLAFCITNGMTPKAFLERYLSAGPTLQYDKDRWLSTQW
                   RLVSDEAVTNGLRDGIVFVLKCLDFSLVVNVKKIPFIILSEEFIDPKSHKFVLRLQSE
                   TSV
                   SEQ ID NO:171        342 bp
NOV40b,            GGATCCATGGATACCGAATCCACTTATTCTGGATATTCTTACTATTCAAGTCATTCGA
170645777 DNA      AAAAATCTCACAGACAAGGGGAAAGAACTAGAGAGAGACACAAGTCACCCCGGAATAA
Sequence           AGACGGCAGAGGGTCAGAAAAGTCTGTCACCATTCAACCTCCCACTGGAGGGCCCCTG
                   TTGGGAAATGATTCTACTCGGACAGAGGAAGTTCAGGATGACAACTGGGGAGAGACCA
                   CCACGGCCATCACAGGCACCTCGGAGCACAGCATATCCCAAGAGGACATTGCCAGGAT
                   CAGCAAGGACATGGAGGACAGCGTGGGGCTGGATTGCAAACGCTACCTCGAG
                   ORF Start: GGA at 1  ORF Stop: b at 343
                   SEQ ID NO:172        114aa MW at 12715.5 kD
NOV40b,            GSMDTESTYSGYSYYSSHSKKSHRQGERTRERHKSPRNKDGRGSEKSVTIQPPTGGPL
170645777 Protein  LGNDSTRTEEVQDDNWGETTTAITGTSEHSISQEDIARISKDMEDSVGLDCKRYLE
Sequence

[0530] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 40B.

TABLE 40B
Comparison of NOV40a against NOV40b and NOV40c.
	NOV40a Residues/	Identities/Similarities for the
Protein Sequence	Match Residues	Matched Region
NOV40b	1 . . . 110	91/111 (81%)
	3 . . . 113	91/111 (81%)

[0531] Further analysis of the NOV40a protein yielded the following properties shown in Table 40C.

TABLE 40C
Protein Sequence Properties NOV40a
PSort     0.6000 probability located in plasma membrane;
analysis: 0.4000 probability located in Golgi body;
          0.3000 probability located in endoplasmic reticulum
          (membrane); 0.3000 probability located in
          microbody (peroxisome)
SignalP   No Known Signal Sequence Indicated
analysis:

[0532] A search of the NOV40a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 40D.

TABLE 40D
Geneseq Results for NOV40a
		NOV40a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAY73493	Human secreted protein clone yk224_1	98 . . . 525	425/428 (99%)	0.0
	protein sequence SEQ ID NO: 208 -	1 . . . 426	425/428 (99%)
	Homo sapiens, 426 aa. [WO9958642-
	A2, 18-NOV-1999]
AAG81268	Human AFP protein sequence SEQ ID	178 . . . 525	343/348 (98%)	0.0
	NO: 54 - Homo sapiens, 346 aa.	1 . . . 346	343/348 (98%)
	[WO200129221-A2, 26-APR-2001]
AAY86275	Human secreted protein HSRGW16,	269 . . . 525	254/257 (98%)	e−141
	SEQ ID NO: 190 - Homo sapiens, 295	41 . . . 295	254/257 (98%)
	aa. [WO9966041-A1, 23-DEC-1999]
AAB45189	Human secreted protein sequence	359 . . . 525	166/167 (99%)	2e−90
	encoded by gene 18 SEQ ID NO: 130 -	1 . . . 167	166/167 (99%)
	Homo sapiens, 167 aa. [WO200058467-
	A1, 05-OCT-2000]
AAY86492	Human gene 61-encoded protein	258 . . . 426	160/169 (94%)	3e−83
	fragment, SEQ ID NO: 407 - Homo	42 . . . 208	161/169 (94%)
	sapiens, 236 aa. [WO9966041-A1, 23-
	DEC-1999]

[0533] In a BLAST search of public sequence databases, the NOV40a protein was found to have homology to the proteins shown in the BLASTP data in Table 40E.

TABLE 40E
Public BLASTP Results for NOV40a
		NOV40a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q923Z8	LTAP - Mus musculus (Mouse),	1 . . . 525	382/525 (72%)	0.0
	521 aa.	1 . . . 521	455/525 (85%)
Q9ULK5	KIAA1215 PROTEIN - Homo	1 . . . 525	384/525 (73%)	0.0
	(fragment).	55 . . . 575	453/525 (86%)
AAK63188	LPP1 - Mus musculus (Mouse),	1 . . . 525	380/525 (72%)	0.0
	521 aa.	1 . . . 521	454/525 (86%)
Q90X64	STRABISMUS - Xenopus laevis	1 . . . 525	383/525 (72%)	0.0
	(African clawed frog), 521 aa.	1 . . . 521	448/525 (84%)
Q91ZD4	LPPI - Mus musculus (Mouse),	1 . . . 525	380/526 (72%)	0.0
	522 aa.	1 . . . 522	454/526 (86%)

[0534] PFam analysis indicates that the NOV40a protein contains the domains shown in the Table 40F.

TABLE 40F
Domain Analysis of NOV40a
		Identities/
	NOV40a	Similarities for the
Pfam Domain	Match Region	Matched Region	Expect Value
No Significant Matches Found

Example 41

[0535] The NOV41 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 41A.

TABLE 41A
NOV41 Sequence Analysis
                   SEQ ID NO:173       1066 bp
NOV41a,            GACAAAACATGGTTCAAGCATCTGGGCACAGGCGGTCCACCCGTGGCTCCAAAATGGT
CG59570-01 DNA     CTCCTGGTCCGTGATAGCAAAGATCCAGGAAATATCGTGCGAGGAAGATGAGAGGAAG
Sequence           ATGGTGCGAGAGTTCTTGGCCGAGTTCATGAGCACATATGTCATGATGGTATTCGGCC
                   TTGGTTCTGTGGCCCATATGGTTCTAAATAAAACATATGGGAGCTACCTTGGTGTCAA
                   CTTGGGTTTTGGCTTCGGGGTCACCATGGGAGTCCACGTGGCAGGCCGCATCTCTGGA
                   GCCCACATGAATGCAGCTGTGACCTTCACTAACTGTGCGCTGGGCCGCGTGCCCTGGA
                   GGAAGTTTCCAGTCCATGTGCTGGGGCAGTTCCTGGGCTCCTTCCTGGCAGCTGCCAC
                   CATCTACAGTCTCTTCTACAGCGCCATTCTCCACTTTTCGGGTGGAGAGCTGATGGTG
                   ACCGGTCCCTTTGCTACAGCTGGCATTTTTGCCACCTACCTTCCTGATCACATGACAT
                   TGTGGCGGGGCTTCCTGAATGAGGAGTGGCTGACCAGGATGCTCCAGCTGTGTCTCTT
                   CACCATCACGGACCAGGAGAACAACCCAGCACTGCCAGGAACACACGCGCTGGTGATA
                   AGCATCCTCGTGGTCATCATCAGGGTGTCCCATGGCATAAACACAGGATATGCCATCA
                   ATCCATCCCGGGACCCGCCCCCCAGCATCTTCACCTTCATTGCTGGCTGGGGCAAACA
                   GGTCTTCAGCGATGGGGAGAACTGGTGGTGGGTGCCAGTGGTGGCACCACTTCTGGGT
                   GCCTCTCTAGGTGGCATCATCTACCTGGTCTTCATTGGCTCCACCATCCCACGGGAGC
                   CCCTGAAATTGGAGGACTCTGTGGCGTATGAAGACCACGGGATAACCGTATTGCCCAA
                   GATGGGATCTCATGAACCCATGATCTCTCCCCTCACCCTCATCTCCGTGAGCCTTGCC
                   AACAGATCTTCAGTCCACTCTGCCCCACCCTTACATGAATCCATGGCCCTAGAGCACT
                   TCTAAGCAGAGATTATTTGTGA
                   ORF Start: ATG at 9 ORF Stop: TAA at 1047
                   SEQ ID NO:174       346 aa MW at38029.9 kD
NOV41a,            MVQASGHRRSTRGSKMVSWSVIAKIQEIWCEEDERKMVREFLAEFMSTYVMMVFGLGS
CG59570-01 Protein VAHMVLNKTYGSYLGVNLGFGFGVTMGVHVAGRISGAHMNAAVTFTNCALGRVPWRKF
Sequence           PVHVLGQFLGSFLAAATIYSLFYSAILHFSGGELMVTGPFATAGIFATYLPDHMTLWR
                   GFLNEEWLTRMLQLCLFTITDQENNPALPGTHALVISILVVIIRVSHGINTGYAINPS
                   RDPPPSIFTFIAGWGKQVFSDGENWWWVPVVAPLLGASLGGIIYLVFIGSTIPREPLK
                   LEDSVAYEDHGITVLPKNGSHEPMISPLTLISVSLANRSSVHSAPPLHESMALEHF

[0536] Further analysis of the NOV41a protein yielded the following properties shown in Table 41B.

TABLE 41B
Protein Sequence Properties NOV41a
PSort     0.8586 probability located in mitochondrial inner membrane;
analysis: 0.6000 probability located in plasma membrane;
          0.4000 probability located in Golgi body;
          0.3568 probability located in mitochondrial
          intermembrane space
SignalP   No Known Signal Sequence Indicated
analysis:

[0537] A search of the NOV41 a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 41C.

TABLE 41C
Geneseq Results for NOV41a
		NOV41a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAW87644	A protein with water channel activity -	1 . . . 346	316/346 (91%)	0.0
	Homo sapiens, 342 aa. [WO9843997-	1 . . . 342	323/346 (93%)
	A1, 08-OCT-1998]
AAY70455	Human membrane channel protein-5	5 . . . 346	312/343 (90%)	e−179
	(MECHP-5) - Homo sapiens, 341 aa.	3 . . . 341	319/343 (92%)
	[WO200012711-A2, 09-MAR-2000]
AAY70468	Human membrane channel protein-18	37 . . . 296	104/261 (39%)	7e−56
	(MECHP-18) - Homo sapiens, 301 aa.	20 . . . 280	162/261 (61%)
	[WO200012711-A2, 09-MAR-2000]
AAB65991	Human secreted protein BLAST search	133 . . . 280	62/148 (41%)	9e−33
	protein SEQ ID NO: 131 - Homo	1 . . . 148	99/148 (66%)
	sapiens, 177 aa. [WO200077023-A1,
	21-DEC-2000]
AAB65992	Human secreted protein BLAST search	133 . . . 280	62/148 (41%)	4e−31
	protein SEQ ID NO: 132 - Homo	1 . . . 148	96/148 (63%)
	21-DEC-2000]

[0538] In a BLAST search of public sequence databases, the NOV41a protein was found to have homology to the proteins shown in the BLASTP data in Table 41D.

TABLE 41D
Public BLASTP Results for NOV41a
		NOV41a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
CAD13298	BA251O17.3 (SIMILAR TO	1 . . . 346	345/346 (99%)	0.0
	AQUAPORIN 7) - Homo sapiens	1 . . . 346	346/346 (99%)
	(Human), 346 aa.
O14520	Aquaporin 7 (Aquaporin-7 like)	1 . . . 346	317/346 (91%)	0.0
	(Aquaporin adipose) (AQPap) -	1 . . . 342	324/346 (93%)
	Homo sapiens (Human), 342 aa.
O54794	Aquaporin 7 - Mus musculus	16 . . . 296	201/281 (71%)	e−114
	(Mouse), 303 aa.	1 . . . 277	233/281 (82%)
P56403	Aquaporin 7 - Rattus norvegicus	20 . . . 285	188/266 (70%)	e−107
	(Rat), 269 aa.	4 . . . 265	220/266 (82%)
P47862	Aquaporin 3 (31.4 kDa water channel	36 . . . 292	120/258 (46%)	2e−68
	protein) - Rattus norvegicus (Rat),	20 . . . 277	175/258 (67%)
	292 aa.

[0539] PFam analysis indicates that the NOV41a protein contains the domains shown in the Table 41E.

TABLE 41E
Domain Analysis of NOV41a
		Identities/Similarities
	NOV41a	for the	Expect
Pfam Domain	Match Region	Matched Region	Value
MIP: domain 1 of 1	31 . . . 276	78/268 (29%)	5.2e−56
		180/268 (67%)

Example 42

[0540] The NOV42 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 42A.

TABLE 42A
NOV42 Sequence Analysis
                   SEQ ID NO:175        895 bp
NOV42a,            CTGTCGTGGTTGTGGAATGCAAACGCCAGCACATAATGGAAACAGGACCTGAAGACCC
CG56162-02 DNA     TTCCAGCATGCCAGAGGAAAGTTCCCCCAGGCGGACCCCGCAGAGCATTCCCTACCAG
Sequence           GACCTCCCTCACCTGGTCAATGCAGACGGACAGTACCTCTTCTGCAGGTACTGGAAAC
                   CCACAGGCACACCCAAGGCCCTCATCTTTGTGTCCCATGGAGCCGGAGAGCACAGTGG
                   CCGCTATGAAGAGCTGGCTCGGATGCTGATGGGGCTGGACCTGCTGGTGTTCGCCCAC
                   GACCATGTTGGCCACGGACAGAGCGAAGGGGAGAGGATGGTAGTGTCTGACTTCCACG
                   TTTTCGTCAGGGATGTGTTGCAGCATGTGCATTCCATGCAGAAAGACTACCCTGGGCT
                   TCCTGTCTTCCTTCTGGGCCACTCCATGGGAGGCGCCATCGCCATCCTCACGGCCGCA
                   GAGAGGCCGGGCCACTTCGCCGGCATGGTACTCATTTCGCCTCTGGTTCTTGCCAATC
                   CTGAATCTGCAACAACTTTCAAGGTCGACATTTATAACTCAGACCCCCTGATCTGCCG
                   GGCAGGGCTGAAGGTGTGCTTCGGCATCCAACTGCTGAATGCCGTCTCACGGGTGGAG
                   CGCGCCCTCCCCAAGCTGACTGTGCCCTTCCTGCTGCTCCAGGGCTCCGCCGATCGCC
                   TATGTGACAGCAAAGGGGCCCACCTGCTCATGGAGTTAGCCAACAGCCAGGACAAGAC
                   TCTCAAGATTTATGAAGGTGCCTACCATGTTCTCCACAAGGAGCTTCCTGAAGTCACC
                   AACTCCGTCTTCCATGAAATAAACATGTGGGTCTCTCAAAGGACAGCCACGGCAGGAA
                   CTGCGTCCCCACCCTGAATGCATTG
                   ORF Start: ATG at 36 ORF Stop: TGA at 885
                   SEQ ID NO:176        283 aa MW at 31122.4 kD
NOV42a,            METGPEDPSSMPEESSPRRTPQSIPYQDLPHLVNADGQYLFCRYWKPTGTPKALIFVS
CG56162-02 Protein HGAGEHSGRYEELARMLMGLDLLVFAHDHVGHGQSEGERMVVSDFHVFVRDVLQHVDS
Sequence           MQKDYPGLPVFLLGHSMGGAIAILTAAERPGHFAGMVLISPLVLANPESATTFKVDIY
                   NSDPLICRAGLKVCFGIQLLNAVSRVERALPKLTVPFLLLQGSADRLCDSKGAHLLME
                   LAKSQDKTLKIYEGAYHVLHKELPEVTNSVFHEINMWVSQRTATAGTASPP
                   SEQ ID NO:177        861 bp
NOV42b,            AGATCTATGGAACAGGACCTGAAGACCCTTCCAGCATGCCAGAGGAAAGTTCCCCCA
174228465 DNA      GGCGGACCCCGCAGAGCATTCCCTACCAGGACCTCCCTCACCTGGTCAATGCAGACGG
Sequence           ACAGTACCTCTTCTGCAGGTACTGGAAACCCACAGGCACACCCAAGGCCCTCATCTTT
                   GTGTCCCATGGAGCCGGAGAGCACAGTGGCCGCTATGAAGAGCTGGCTCGGATGCTGA
                   TGGGGCTGGACCTGCTGGTGTTCGCCCACGACCATGTTGGCCACGGACAGAGCGAAGG
                   GGAGAGGATGGTAGTGTCTGACTTCCACGTTTTCGTCAGGGATGTGTTGCAGCATGTG
                   GATTCCATGCAGAAAGACTACCCTGGGCTTCCTGTCTTCCTTCTGGGCCACTCCATGG
                   GAGGCGCCATCGCCATCCTCACGGCCGCAGAGAGGCCGGGCCACTTCGCCGGCATGGT
                   ACTCATTTCGCCTCTGGTTCTTGCCAATCCTGAATCTGCAACAACTTTCAAGGTCGAC
                   ATTTATAACTCAGACCCCCTGATCTGCCGGGCAGGGCTGAAGGTGTGCTTCGGCATCC
                   AACTGCTGAATGCCGTCTCACGGGTGGAGCGCGCCCTCCCCAAGCTGACTGTGCCCTT
                   CCTGCTGCTCCAGGGCTCTGCCGATCGCCTATGTGACAGCAAAGGGGCCTACCTGCTC
                   ATGGAGTTAGCCAAGAGCCAGGACAAGACTCTCAAGATTTATGAAGGTGCCTACCATG
                   TTCTCCACAAGGAGCTTCCTGAAGTCACCAACTCCGTCTTCCATGAAATAAACATGTG
                   GGTCTCTCAAAGGACAGCCACGGCAGGAACTGCGTCCCCACCCCTCGAG
                   ORF Start: AGA at 1  ORF Stop: 8 at 862
                   SEQ ID NO:178        287 aa MW at 31634.0 kD
NOV42b,            RSMETGPEDPSSMPEESSPRRTPQSIPYQDLPHLVNADGQYLFCRYWKPTGTPKALIF
174228465 Protein  VSHGAGEHSGRYEELARMLMGLDLLVFAHDHVGHGQSEGERMVVSDFHVFVRDVLQHV
Sequence           DSMQKDYPGLPVFLLGHSMGGAIAILTAAERPGHFAGMVLISPLVLANPESATTFKVD
                   IYNSDPLICRAGLKVCFGIQLLNAVSRVERALPKLTVPFLLLQGSADRLCDSKGAYLL
                   MELAKSQDKTLKIYEGAYHVLHKELPEVTNSVFHEINMWVSQRTATAGTASPPLE

[0541] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 42B.

TABLE 42B
Comparison of NOV42a against NOV42b and NOV42c.
	NOV42a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV42b	1 . . . 283	269/283 (95%)
	3 . . . 285	270/283 (95%)

[0542] Further analysis of the NOV42a protein yielded the following properties shown in Table 42C.

TABLE 42C
Protein Sequence Properties NOV42a
PSort     0.4500 probability located in cytoplasm;
analysis: 0.4273 probability located in microbody (peroxisome);
          0.2034 probability located in lysosome (lumen);
          0.1000 probability located in mitochondrial matrix space
SignalP   No Known Signal Sequence Indicated
analysis:

[0543] A search of the NOV42a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 42D.

TABLE 42D
Geneseq Results for NOV42a
		NOV42a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAG10770	Arabidopsis thaliana protein fragment	37 . . . 273	86/271 (31%)	9e−27
	SEQ ID NO: 9224 - Arabidopsis	104 . . . 371	126/271 (45%)
	thaliana, 383 aa. [EP1033405-A2, 06-
	SEP-2000]
AAG10769	Arabidopsis thaliana protein fragment	37 . . . 273	86/271 (31%)	9e−27
	SEQ ID NO: 9223 - Arabidopsis	111 . . . 378	126/271 (45%)
	thaliana, 390 aa. [EP1033405-A2, 06-
	SEP-2000]
AAG10768	Arabidopsis thaliana protein fragment	37 . . . 273	86/271 (31%)	9e−27
	SEQ ID NO: 9222 - Arabidopsis	140 . . . 407	126/271 (45%)
	thaliana, 419 aa. [EP1033405-A2, 06-
	SEP-2000]
AAG16436	Arabidopsis thaliana protein fragment	31 . . . 279	80/286 (27%)	6e−24
	SEQ ID NO: 17083 - Arabidopsis	11 . . . 296	133/286 (45%)
	thaliana, 301 aa. [EP1033405-A2, 06-
	SEP-2000]
AAG46122	Arabidopsis thaliana protein fragment	34 . . . 275	83/281 (29%)	2e−23
	SEQ ID NO: 57993 - Arabidopsis	15 . . . 295	132/281 (46%)
	thaliana, 351 aa. [EP1033405-A2, 06-
	SEP-2000]

[0544] In a BLAST search of public sequence databases, the NOV42a protein was found to have homology to the proteins shown in the BLASTP data in Table 42E.

TABLE 42E
Public BLASTP Results for NOV42a
		NOV42a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q99685	LYSOPHOSPHOLIPASE HOMOLOG	1 . . . 283	282/313 (90%)	e−160
	(LYSOPHOSPHOLIPASE-LIKE) -	1 . . . 313	283/313 (90%)
	Homo sapiens (Human), 313 aa.
Q96AA5	MONOGLYCERIDE LIPASE (EC	11 . . . 283	272/303 (89%)	e−154
	3.1.1.23) - Homo sapiens (Human),	1 . . . 303	273/303 (89%)
	303 aa.
O35678	MONOGLYCERIDE LIPASE (EC	11 . . . 283	230/303 (75%)	e−133
	3.1.1.23) - Mus musculus (Mouse), 303	1 . . . 303	255/303 (83%)
	aa.
O11456	H14-E - Ectromelia virus, 277 aa.	32 . . . 273	122/270 (45%)	6e−64
		6 . . . 274	168/270 (62%)
P87627	41KBP FRAGMENT FROM LEFT	32 . . . 273	121/270 (44%)	5e−63
	END OF GENOME - Cowpox virus	6 . . . 274	167/270 (61%)
	(CPV), 276 aa.

[0545] PFam analysis indicates that the NOV42a protein contains the domains shown in the Table 42F.

TABLE 42F
Domain Analysis of NOV42a
		Identities/
	NOV42a Match	Similarities for	Expect
Pfam Domain	Region	the Matched Region	Value
abhydrolase: domain	80 . . . 270	46/247 (19%)	0.033
1 of 1		134/247 (54%)
Thioesterase: domain	53 . . . 270	47/271 (17%)	1.7
1 of 1		139/271 (51%)

Example 43

[0546] The NOV43 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 43A.

TABLE 43A
NOV43 Sequence Analysis
                   SEQ ID NO:179        2018 bp
NOV43a,            GCGCCCCCCACCCTTCCGGCCCCCCAGAACCCGCGCCATCCCCCGGAGCCTCCCCAGA
CG59681-01 DNA     GCTGGCCGCGCAGGATGGGGCGCCCTCAGGCCCACGCTGCTGCCGCCTTCGCTGCCGCT
Sequence           GCTGCTGCTCCTAATGCTAGGAATGGGATGCTGGGCCCGGGAGGTGCTGGTCCCCGAG
                   GGGCCCTTGTACCGCGTGGCTGGCACAGCTGTCTCCATCTCCTGCAATGTGACCGGCT
                   ATGAGGGCCCTGCCCAGCAGAACTTCCAGTGGTTCCTCTATAGGCCCGAGGCCCCAGA
                   TACTGCACTGGGCATTGTCAGTACCAAGGATACCCAGTTCTCCTATGCTGTCTTCAAG
                   TCCCCAGTGGTGGCCCGTGAGGTGCAGGTGCAGCGCCTACAAGGTGATGCCGTGGTGC
                   TCAAGATTGCCCCCCTGCAGGCCCAGGATGCCGGCATTTATGAGTGCCACACCCCCTC
                   CACTGATACCCGCTACCTGGGCAGCTACAGCGGCAAGGTGGAGCTGAGAGTTCTTCCA
                   GATGTCCTCCAGGTGTCTGCTGCCCCCCCAGGGCCCCGAGGCCGCCAGGCCCCAACCT
                   CACCCCCACGCATGACGGTGCATCAGGGGCAGGAGCTGGCACTGGGCTGCCTGGCGAG
                   GACAAGCACACAGAAGCACACACACCTGGCAGTGTCCTTTGGGCGATCTGTGCCCGAG
                   GCACCAGTTGGGCGGTCAACTCTGCAGGAAGTGGTGGGAATCCGGTCAGACTTGGCCG
                   TGGAGGCTGGAGCTCCCTATGCTGAGCGATTCGCTGCAGGGGAGCTTCGTCTGGGCAA
                   GGAAGGGACCGATCGGTACCGCATGGTAGTAGGGGGTGCCCAGGCAGGGGACGCAGGC
                   ACCTACCACTGCACTGCCGCTGAGTGGATTCAGGATCCTGATGGCAGCTGGGCCCAGA
                   TTGCAGAGAAAAGGGCCGTCCTGGCCCACGTGGATGTGCAGGCACTGTCCAGCCAGCT
                   GGCAGTGACAGTGGGGCCTGGTGAACGTCGGATCGGCCCAGGGGAGCCCTTGGAACTG
                   CTGTGCAATGTGTCAGGGGCACTTCCCCCAGCAGGCCGTCATGCTGCATACTCTGTAG
                   GTTGGGAGATGGCACCTGCCGGGGCACCTGGGCCCGGCCGCCTGGTAGCCCAGCTGGA
                   CACAGAGGGTGTGGGCAGCCTGGGCCCTGGCTATGAGGGCCGACACATTGCCATGGAG
                   AAGGTGGCATCCAGAACATACCGGCTACGGCTAGAGGCTCCCACGCCTGGTGATGCGG
                   GCACCTACCGCTGCCTCGCCAAAGCCTATGTTCGAGGGTCTGGGACCCGGCTTCGTGA
                   AGCAGCCAGTGCCCGTTCCCGGCCTCTCCCTGTACATGTGCGGGAGGAAGGTGTGGTG
                   CTGGAGGCTGTGGCATGGCTAGCAGGAGGCACAGTGTACCGCGGGGAGACTGCCTCCC
                   TGCTGTGCAACATCTCTGTGCGGGGTGGCCCCCCAGGACTGCGGCTGGCCGCCAGCTG
                   GTGGGTGGAGCGACCAGAGGACGGAGAGCTCAGCTCTGTCCCTGCCCAGCTGGTGGGT
                   GGCGTAGGCCAGGATGGTGTGGCAGAGCTGGGAGTCCGGCCTGGAGGAGGCCCTGTCA
                   GCGTAGAGCTGGTGGGGCCCCGAAGCCATCGGCTGAGACTACACAGCTTGGGGCCCGA
                   GGATGAAGGCGTGTACCACTGTGCCCCCAGCGCCTGGGTGCAGCATGCCGACTACAGC
                   TGCTACCAGGCGGGCAGTGCCCGCTCAGGGCCTGTTACAGTCTACCCCTACATGCATG
                   GTGAGTGACACCCCCTCCACCCTCCTCACTCTGCCTTCCTCCTGGCCTCTGCCACTGG
                   CCTTCCCTTCCCATCTTCTGACCCTCCTGCTACTATCTCTCTCCTCCACATTATGTCA
                   CATCAACTCTCAAAAAATCCAACTTCCAGCCCTGCAGTGCCCACCTGCACGGGGTCCT
                   CTGTGGTTGATGCTGACTTGCATGCTGAGGGTGCATGGTGGGCAGC
                   ORF Start: ATG at 73 ORF Stop: TGA at 1804
                   SEQ ID NO:180        577 aa MW at 61171.8 kD
NOV43a,            MCALRPTLLPPSLPLLLLLMLGMCCWAREVLVPEGPLYRVAGTAVSISCNVTGYEGPA
CG59681-01 Protein QQNFEWFLYRPEAPDTALGIVSTKDTQFSYAVFKSRVVAGEVQVQRLQGDAVVLKIAR
Sequence           LQAQDAGIYECHTPSTDTRYLGSYSGKVELRVLPDVLQVSAAPPGPRGRQAPTSPPRM
                   TVHEGQELALGCLARTSTQKHTHLAVSFGRSVPEAPVGRSTLQEVVGIRSDLAVEAGA
                   PYAERLAAGELRLGKEGTDRYRMVVGGAQAGDAGTYHCTAAEWIQDPDGSWAQIAEKR
                   AVLAHVDVQALSSQLAVTVGPGERRIGPGEPLELLCNVSGALPPAGRHAAYSVGWEMA
                   PAGAPGPGRLVAQLDTEGVGSLGPGYEGRHIAMEKVASRTYRLRLEAARPGDAGTYRC
                   LAKAYVRGSGTRLREAASARSRPLPVHVREEGVVLEAVAWLAGGTVYRGETASLLCNI
                   SVRGGPPGLRLAASWWVERPEDGELSSVPAQLVGGVGQDGVAELGVRPGGGPVSVELV
                   GPRSHRLRLHSLCPEDEGVYHCAPSAWVQHADYSWYQACSARSGPVTVYPYMHGE
                   SEQ ID NO:181        1662 bp
NOV43b,            AGATCTCGGGAGGTGCTGGTCCCCGAGGGGCCCTTGTACCGCGTCGCTGGCACAGCTG
174308213 DNA      TCTCCATCTCCTGCAATGTGACCGGCTATGAGGGCCCTGCCCAGCAGAACTTCGAGTG
Sequence           GTTCCTGTATAGGCCCGAGGCCCCAGATACTGCACTGGGCATTGTCAGTACCAAGGAT
                   ACCCAGTTCTCCTATGCTGTCTTCAAGTCCCGAGTGGTGGCGGGTGAGGTGCAGGTGC
                   AGCGCCTACAAGGTGATGCCGTGGTGCTCAAGATTGCCCGCCTGCAGGCCCAGGATGC
                   CGGCATTTATGAGTGCCACACCCCCTCCACTGATACCCGCTACCTGGGCAGCTACAGC
                   GGCAAGGTGCAGCTGAGAGTTCTTCCAGATCTCCTCCAGGTGTCTGCTCCCCCCCCAG
                   GGCCCCGAGGCCGCCAGGCCCCAACCTCACCCCCACGCATGACGGTGCATGAGGGGCA
                   GGAGCTGGCACTGGGCTGCCTGGCGAGGACAAGCACACAGAAGCACACACACCTGGCA
                   GTGTCCTTTGGGCGATCTCTGCCCGAGGCACCAGTTGGGCGGTCAACTCTGCAGGAAG
                   TGGTGGGAATCCGGTCAGACTTGGCCGTGGAGGCTGGAGCTCCCTATGCTGAGCGATT
                   GGCTGCAGGGGAGCTTCGTCTGGGCAAGGAAGGGACCGATCCGTACCCCATGGTAGTA
                   GGGGGTCCCCAGGCAGGGCACGCAGGCACCTACCACTGCACTGCCGCTGAGTGGATTC
                   AGGATCCTGATGGCAGCTGGGCCCAGATTGCAGAGAAAAGGGCCGTCCTGGCCCACGT
                   GGATGTGCAGACGCTGTCCAGCCAGCTGGCAGTGACAGTGGGGCCTGGTGAACGTCGG
                   CAGGCCGTCATGCTGCATACTCTGTAGGTTGGGAGATGGCACCTGCGGGGGCACCTGG
                   GCCCGGCCGCCTGGTAGCCCAGCTGGACACAGAGGGTGTGGGCAGCCTGGGCCCTGGC
                   TATGAGGGCCGACACATTGCCATGGAGAAGGTGGCATCCAGAACATACCGGCTACGGC
                   TAGAGGCTGCCAGGCCTGGTGATGCGGGCACCTACCGCTGCCTCCCCAAAGCCTATGT
                   TCGAGGGTCTGGGACCCGGCTTCGTGAAGCAGCCAGTGCCCGTTCCCGGCCTCTCCCT
                   GTACATGTGCGGGAGGAAGGTGTGGTGCTGGAGGCTGTGGCATGGCTAGCAGGAGGCA
                   CAGTGTACCGCGGGGAGACTGCCTCCCTGCTGTGCAACATCTCTGTGCGGGGTGGCCC
                   CCCAGGACTGCGGCTGGCCGCCAGCTGGTGGGTGGAGCGACCAGAGGACGGAGAGCTC
                   AGCTCTGTCCCTGCCCAGCTGGTGGGTGGCGTAGGCCAGGATGGTGTGGCAGAGCTGG
                   GAGTCCGGCCTGCAGGAGGCCCTGTCAGCGTAGAGCTGGTGGGGCCCCGAAGCCATCG
                   GCTGAGACTACACAGCTTGGGGCCCGAGGATGAAGGCGTGTACCACTGTGCCCCCAGC
                   GCCTGGGTGCAGCATGCCGACTACAGCTGGTACCAGGCGGGCAGTGCCCGCTCAGGGC
                   CTGTTACAGTCTACCCCTATATGCATGGTGAGCTCGAG
                   ORF Start: AGA at 1  ORF Stop: A at 1663
                   SEQ ID NO:182        554 aa MW at 58826.7 kD
NOV43b,            RSREVLVPEGPLYRVAGTAVSISCNVTGYEGPAQQNFEWFLYRPEAPDTALGIVSTKD
174308213 Protein  TQFSYAVFKSRVVAGEVQVQRLQGDAVVLKIARLQAQDAGIYECHTPSTDTRYLGSYS
Sequence           GKVELRVLPDVLQVSAAPPGPRGRQAPTSPPRMTVHEGQELALGCLARTSTQKHTHLA
                   VSFGRSVPEAPVGRSTLQEVVGIRSDLAVEAGAPYAERLAAGELRLGKEGTDRYRMVV
                   GGAQAGDAGTYHCTAAEWIQDPDGSWAQIAEKRAVLAHVDVQTLSSQLAVTVGPGERR
                   IGPGEPLELLCNVSGALPPAGRHAAYSVGWEMAPAGAPGPGRLVAQLDTEGVGSLGPG
                   YEGRHIAMEKVASRTYRLRLEAARPGDAGTYRCLAKAYVRGSGTRLREAASARSRPLP
                   VHVREEGVVLEAVAWLAGGTVYRGETASLLCNISVRGGPPCLRLAASWWVERPEDGEL
                   SSVPAQLVGGVGQDGVAELGVRPGGGPVSVELVGPRSHRLRLHSLGPEDEGVYHCAPS
                   AWVQHADYSWYQAGSARSGPVTVYPYMHGELE
                   SEQ ID NO:183        1662 bp
NOV43c,            AGATCTCCGGAGGTGCTGGTCCCCGAGGGGCCCTTGTACCGCGTGGCTGGCACAGCTG
174308218 DNA      TCTCCATCTCCTGCAATGTGACCGGCTATGAGGGCCCTGCCCAGCAGAACTTCGAGTG
Sequence           CTTCCTGTATAGGCCCGAGGCCCCACATACTCCACTGCGCATTGTCACTACCAAGGAT
                   ACCCAGTTCTCCTATGCTGTCTTCAAGTCCCGAGTGGTGGCGGGTGAGGTGCAGGTGC
                   AGCGCCTACAAGGTGATGCCGTGGTGCTCAAGATTGCCCGCCTGCAGGCCCAGGATGC
                   CGGCATTTATGAGTGCCACACCCCCTCCACTGATACCCGCTACCTGGGCAGCTACAGC
                   GGCAAGGTGGAGCTGAGAGTTCTTCCAGATGTCCTCCAGGTGTCTGCTGCCCCCCCAG
                   GGCCCCGAGGCCGCCAGGCCCCAACCTCACCCCCACGCATGACGGTGCATGAGGGGCA
                   GGAGCTGGCACTGGGCTGCCTGGCGAGGACAAGCACACAGAAGCACACACACCTGGCA
                   GTGTCCTTTGGGCGATCTGTGCCCGAGGCACCAGTTGGGCGGTCAACTCTGCAGGAAG
                   TGGTGGGAATCCGGTCAGACTTGGCCGTGCAGGCTGGAGCTCCCTATGCTGAGCGATT
                   GGCTGCAGGGGAGCTTCGTCTGCGCAAGGAAGGCACCGATCGGTACCGCATGGTAGTA
                   GGGGGTGCCCAGGCAGGGGACGCAGGCACCTACCACTGCACTGCCGCTGAGTGGATTC
                   AGGATCCTGATGGCAGCTGGGCCCAGATTGCAGAGAAAAGGGCCGTCCTGGCCCACGT
                   GGATGTGCAGACGCTGTCCAGCCAGCTGGCAGTGACAGTGGGGCCTGGTGAACGTCGG
                   ATCGGCCCAGGGGACCCCTTGGAACTGCTGTGCAATGTGTCAGGGGCACTTCCCCCAG
                   CAGGCCGTCATGCTGCATACTCTGTAGGTTGGGAGATGGCACCTGCGGGGGCACCTGG
                   GCCCGGCCGCCTGGTAGCCCAGCTGGACACAGAGGGTGTGGGCAGCCTGGGCCCTGGC
                   TATGAGGCCCGACACATTCCCATGGAGAAGGTGGCATCCAGAACATACCGGCTACGGC
                   TAGAGGCTGCCAGGCCTGGTGATGCGGGCACCTACCGCTGCCTCGCCAAAGCCTATGT
                   TCGAGGGTCTGGGACCCGGCTTCGTGAAGCAGCCAGTGCCTGTTCCCGCCCTCTCCCT
                   GTACATGTGCGGGAGGAAGGTGTGGTGCTGGAGGCTGTGGCATGGCTAGCAGGAGGCA
                   CAGTGTACCGCGGGGAGACTGCCTCCCTGCTGTGCAACATCTCTGTGCGGGGTGCCCC
                   CCCAGGACTGCGGCTGGCCOCCAGCTGGTGGGTGGAGCGACCAGAGGACGGAGAGCTC
                   AGCTCTGTCCCTGCCCAGCTGGTGGGTGGCGTAGGCCAGGATGGTGTGGCAGAGCTGG
                   GAGTCCGGCCTGGAGGAGGCCCTGTCAGCGTAGAGCTGGTGGGGCCCCGAAGCCATCG
                   GCTGAGACTACACAGCTTGGGGCCCGAGGATGAAGGCGTGTACCACTGTCCCCCCAGC
                   GCCTGGGTGCAGCATGCCGACTACAGCTGGTACCAGGCGGGCAGTGCCCGCTCAGGGC
                   CTGTTACAGTCTACCCCTACATGCATCGTGAGCTCGAG
                   ORF Start: AGA at 1  ORF Stop: A at 1663
                   SEQ ID NO:184        554 aa MW at 58773.7 kD
NOV43c,            RSREVLVPEGPLYRVAGTAVSISCNVTGYEGPAQQNFEWFLYRPEAPDTALGIVSTKD
1743082 18 Protein TQFSYAVFKSRVVAGEVQVQRLQGDAVVLKIARLQAQDAGIYECHTPSTDTRYLGSYS
Sequence                                GKVELRVLPDVLQVSAAPPGPRGRQAPTSPPRMTVHEGQELALGCLARTSTQKHTHLA
                   VSFGRSVPEAPVGRSTLQEVVGIRSDLAVEAGAPYAERLAAGELRLGKEGTDRYRMVV
                   GGAQAGDAGTYHCTAAEWIQDPDGSWAQIAEKRAVLAHVDVQTLSSQLAVTVGPGERR
                   IGPGEPLELLCNVSGALPPAGRHAAYSVGWEMAPAGAPGPGRLVAQLDTEGVGSLGPG
                   YEGRHIAMEKVASRTYRLRLEAARPGDAGTYRCLAKAYVRGSGTRLREAASACSRPLP
                   VHVREEGVVLEAVAWLAGGTVYRGETASLLCNISVRGGPPGLRLAASWWVERPEDGEL
                   SSVPAQLVGGVGQDGVAELGVRPGGGPVSVELVGPRSHRLRLHSLGPEDEGVYHCAPS
                   AWVQHADYSWYQAGSARSGPVTVYPYMHGELE
                   SEQ ID NO:185        11662 bp
NOV43d,            AGATCTCGGGAGGTGCTGGTCCCCGAGGGGCCCTTGTACCGCGTGGCTGGCACAGCTG
174308224 DNA      TCTCCATCTCCTGCAATGTGACCGGCTATGAGGGCCCTGCCCACCAGAACTTCGAGTG
Sequence           GTTCCTGTATAGGCCCGAGGCCCCAGATACTGCACTGGGCATTGTCAGTACCAAGGAT
                   ACCCAGTTCTCCTATGCTGTCTTCAAGTCCCGAGTGGTGGCGGGTGAGGTGCAGGTGC
                   AGCGCCTACAAGGTGATGCCGTGGTCCTCAAGATTGCCCGCCTGCAGGCCCAGGATGC
                   CGGCATTTATGAGTGCCACACCCCCTCCACTGATACCCGCTACCTGGGCAGCTACAGC
                   GGCAAGGTGGAGCTGAGAGTTCTTCCAGATGTCCTCCAGGTGTCTGCTGCCCCCCCAG
                   GGCCCCGAGGCCGCCAGOCCCCAACCTCACCCCCACGCATGACGGTGCATGAGGCGCA
                   GGAGTTGGCACTGGGCTGCCTGCCGAGGACAAGCACACAGAAGCACACACACCTGGCA
                   GTGTCCTTTGGGCGATCTGTGCCCGAGCCACCAGTTGGGCGGTCAACTCTGCAGGAAG
                   TGGTGGGAATCCGGTCAGACTTGGCCGTGGAGGCTGGAGCTCCCTATGCTGAGCGATT
                   GGCTGCAGGGGAGCTTCGTCTGGGCAAGGAAGGGACCGATCGGTACCGCATGGTAGTA
                   GGGGGTGCCCAGGCAGGGGACGCAGGCACCTACCACTGCACTGCCGCTGAOTGGATTC
                   AGGATCCTGATGGCAGCTGGGCCCAGATTGCAGAGAAAAGGGCCGTCCTCGCCCACGT
                   GGATGTGCAGACGCTGTCCAGCCAGCTGGCAGTGACAGTGGGGCCTGGTGAACGTCGG
                   ATCGGCCCAGGGGAGCCCTTGGAACTGCTGTGCAATGTGTCAGGGGCACTTCCCCCAG
                   CAGGCCGTCATGCTGCATACTCTCTAGGTTGGGAGATGGCACCTGCGGGGGCACCTGG
                   GCCCGGCCGCCTGGTAGCCCAGCTGGACACAGAGGGTGTGCGCAGCCTGGGCCCTGGC
                   TATGAGGGCCGACACATTGCCATGGAGAAGGTGGCATCCAGAACATACCGGCTACGGC
                   TAGAGGCTGCCAGGCCTGGTGATGCGGGCACCTACCGCTGCCTCGCCAAACCCTATGT
                   TCGAGGGTCTGGGACCCGGCTTCGTGAAGCAGCCAGTGCCCGTTCCCGGCCTCTCCCT
                   GTACATGTGCGGGAGGAAGGTGTGGTGCTGGAGGCTGTGGCATGGCTAGCAGGAGGCA
                   CAGTGTACCGCGGGGAGACTGCCTCCCTGCTGTGCAACATCTCTGTGCGGGGTGGCCC
                   CCCAGGACTGCGGCTGGCCGCCAGCTGGTGGGTGGAGCGACCAGAGGACCGAGAGCTC
                   AGCTCTGTCCCTGCCCAGCTGGTGGGTGGCGTAGGCCAGGATGGTGTGGCAGAGCTGG
                   GAGTCCGGCCTGGAGGAGGCCCTGTCAGCGTAGAGCTGGTGGGGCCCCGAAGCCATCG
                   GCTGAGACTACACAGCTTGGGACCCGAGGATGAAGGCGTGTACCACTGTGCCCCCAGC
                   GCCTGGGTGCAGCATGCCGACTACAGCTGGTACCAGGCGGGCAGTGCCCGCTCAGGGC
                   CTGTTACAGTCTACCCCTACATGCATGGTGAGCTCGAG
                   ORF Start: AGA at 1  ORF Stop: A at 1663
                   SEQ ID NO:186        554 aa MW at 58826.7 kD
NOV43d,            RSREVLVPEGPLYRVAGTAVSISCNVTGYEGPAQQNFEWFLYRPEAPDTALGIVSTKD
174308224 Protein  TQFSYAVFKSRVVAGEVQVQRLQGDAVVLKIARLQAQDAGIYECHTPSTDTRYLGSYS
Sequence           GKVELRVLPDVLQVSAAPPGPRGRQAPTSPPRMTVHEGQELALGCLARTSTQKHTHLA
                   VSFGRSVPEAPVGRSTLQEVVGIRSDLAVEAGAPYAERLAAGELRLCKEGTDRYRMVV
                   GGAQAGDAGTYHCTAAEWIQDPDGSWAQIAEKRAVLAHVDVQTLSSQLAVTVGPGERR
                   IGPGEPLELLCNVSGALPPAGRHAAYSVGWEMAPAGAPGPGRLVAQLDTEGVGSLGPG
                   YEGRHIANEKVASRTYRLRLEAARPGDACTYRCLAKAYVRGSGTRLREAASARSRPLP
                   VHVREEGVVLEAVAWLAGGTVYRGETASLLCNISVRGGPPGLRLAASWWVERPEDGEL
                   SSVPAQLVGGVGQDGVAELGVRPGGGPVSVELVGPRSHRLRLHSLGPEDEGVYHCAPS
                   AWVQHADYSWYQAGSARSGPVTVYPYMHGELE

[0547] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 43B.

TABLE 43B
Comparison of NOV43a against NOV43b through NOV43d.
	NOV43a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV43b	27 . . . 577	525/551 (95%)
	2 . . . 552	526/551 (95%)
NOV43c	27 . . . 577	524/551 (95%)
	2 . . . 552	525/551 (95%)
NOV43d	27 . . . 577	525/551 (95%)
	2 . . . 552	526/551 (95%)

[0548] Further analysis of the NOV43a protein yielded the following properties shown in Table 43C.

TABLE 43C
Protein Sequence Properties NOV43a
PSort     0.8497 probability located in lysosome (lumen);
analysis: 0.5947 probability located in outside;
          0.1197 probability located in microbody (peroxisome);
          0.1000 probabilitylocated in endoplasmic
          reticulum (membrane)
SignalP   Cleavage site between residues 28 and 29
analysis:

[0549] A search of the NOV43a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 43D.

TABLE 43D
Geneseq Results for NOV43a
		NOV43a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAM24248	Human EST encoded protein SEQ ID	1 . . . 575	574/575 (99%)	0.0
	NO: 1773 - Homo sapiens, 613 aa.	1 . . . 575	574/575 (99%)
	[WO200154477-A2, 02-AUG-2001]
AAB90544	Human secreted protein, SEQ ID NO:	1 . . . 575	574/575 (99%)	0.0
	82 - Homo sapiens, 613 aa.	1 . . . 575	574/575 (99%)
	[WO200121658-A1, 29-MAR-2001]
AAB15536	Human immune system molecule from	1 . . . 575	574/575 (99%)	0.0
	Incyte clone 2705028 - Homo sapiens,	1 . . . 575	574/575 (99%)
	613 aa. [WO200060080-A2,
	12-OCT-2000]
AAB90560	Human secreted protein, SEQ ID NO:	1 . . . 575	573/575 (99%)	0.0
	98 - Homo sapiens, 613 aa.	1 . . . 575	573/575 (99%)
	[WO200121658-A1, 29-MAR-2001]
AAB81411	Partial human IgSF protein, SEQ ID	136 . . . 575	437/440 (99%)	0.0
	NO: 5 - Homo sapiens, 478 aa.	1 . . . 440	439/440 (99%)
	[WO200127278-A2, 19-APR-2001]

[0550] In a BLAST search of public sequence databases, the NOV43a protein was found to have homology to the proteins shown in the BLASTP data in Table 43E.

TABLE 43E
Public BLASTP Results for NOV43a
		NOV43a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q969P0	EWI2 (CD81 PARTNER 3) -	1 . . . 575	574/575 (99%)	0.0
	Homo sapiens (Human), 613 aa.	1 . . . 575	574/575 (99%)
AAL02217	IMMUNOGLOBULIN	1 . . . 575	508/575 (88%)	0.0
	SUPERFAMILY RECEPTOR PGRL -	1 . . . 573	542/575 (93%)
	Mus musculus (Mouse), 611 aa.
Q9BTG9	PROTEIN - Homo sapiens (Human),	4 . . . 449	445/446 (99%)	0.0
	487 aa (fragment).
CAC37841	SEQUENCE 4 FROM PATENT	136 . . . 575	437/440 (99%)	0.0
	WO0127278 - Homo sapiens	1 . . . 440	439/440 (99%)
	(Human), 478 aa (fragment).
CAC37842	SEQUENCE 6 FROM PATENT	174 . . . 575	401/402 (99%)	0.0
	WO0127278 - Homo sapiens	1 . . . 402	401/402 (99%)
	(Human), 440 aa.

[0551] PFam analysis indicates that the NOV43a protein contains the domains shown in the Table 43F.

TABLE 43F
Domain Analysis of NOV43a
		Identities/
		Similarities
	NOV43a	for the
Pfam Domain	Match Region	Matched Region	Expect Value
ig: domain 1 of 4	42 . . . 129	13/89 (15%)	0.0011
		55/89 (62%)
ig: domain 2 of 4	179 . . . 272	8/97 (8%)	0.74
		58/97 (60%)
ig: domain 3 of 4	319 . . . 408	15/91 (16%)	0.00012
		60/91 (66%)
ig: domain 4 of 4	455 . . . 546	15/93 (16%)	3.7e−05
		61/93 (66%)

Example 44

[0552] The NOV44 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 44A.

TABLE 44A
NOV44 Sequence Analysis
                   SEQ ID NO:187         3201 bp
NOV44a,            AGAGTCCTCAGCAGGGTAGCCGAGCCCAGGCCACTTCTGCTGAGGATGGGGCAGGCTG
CG59869-01 DNA     GGGTCTGGGTGTGGCCTGGGGTGGCTCAGGGCTGGAACTGCTGCCTGATTCCTGTGTG
Sequence           GGGAGAAGCTCAGTGGCCGTTTCCTGCCACTGACAAGGATTTCACATGCAGAAGAGAA
                   AAGGCCCCCCTCCACCCCCCGCATTCCCTGCCGACTGAGAGCCAGTGTTTGCTGCCCT
                   TGCTGGGGGCGGGTAGGAAACCCTGAGCTTCCTGATGCGGAGTCATGAAGCAGAGTCC
                   TCGGGAAGGCATCTCCCCAACCTTCCCTCATCTCTGGCGGCCCTCTTGGGCCTCTGAC
                   CCAGCCCCTCCCCGGGCCAGGCTCACAGAAGCTGGCTTCTGGGACTGTCCTGGGCCCA
                   AGTGGGCACCTGCGCCAGCCCCACCTGTGCCTGGGCTGTGGCCCCTTCCTACAGGGCG
                   CTCACCATGGCCCCGCCGCTCCTGCTGCTGCTGCTGGCCAGTGGAGCGGCCGCCTGCC
                   CGCTGCCCTGCGTCTGCCAGAACCTGTCCGAGTCGCTCAGCACCCTCTGTGCCCACCG
                   AGGCCTGCTGTTTGTGCCGCCCAACGTGGACCGGCGCACAGTGGAGCTGCGGCTGGCT
                   GACAACTTCATCCAGGCCCTGGGGCCCCCTGACTTCCGCAACATGACGGGACTGGTGG
                   ACCTGACACTGTCTCGCAATGCCATCACCCGCATTGGGGCCCGCGCCTTTGGGGACCT
                   CGAGAGCCTGCGTTCCCTCCACCTTGACGGCAACAGGCTGGTGGAGCTGGGCACCGGG
                   ACCCTCCGGGGCCCCGTCAATCTGCAGCACCTCATCCTCAGCGGCAACCAGCTGGGCC
                   GCATCGCGCCGGGAGCCTTCCACGACTTCCTAGAGAGCCTGGAGGACCTGGACCTGTC
                   CTACAACAACCTCCGGCAGGTGCCCTGGGCCGGCATCGGCGCCATGCCTGCCCTGCAC
                   ACCCTCAACCTGGACCATAACCTTATTGACGCACTGCCCCCAGGCGCCTTCGCCCAGC
                   TCGGTCAGCTCTCCCGCCTGGACCTCACCTCCAACCGCCTGGCCACGCTGGCTCCGGA
                   CCCGCTTTTCTCTCGTGCGCGTCATGCAGAGGCCTCTCCCGCCCCCCTGGTGCTGAGC
                   TTTAGCGGGAACCCCCTGCACTGCAACTGTGAGCTGCTGTGGCTGCGGCGGCTGGCGC
                   GGCCGGACGACCTGGAAACGTGCGCCTCCCCGCCCCGCCTGGCCCGCCGCTACTTCTG
                   GGCAGTGCCCGAGGGCGAGTTCTCCTGTGAGCCGCCCCTCATTGCCCGCCACACGCAG
                   CGCCTCTGGGTGCTGGAAGGCCAGCGGGCCACGCTGCGGTGCCGGGCCCTGGGTGACC
                   CCGCGCCTACCATGCACTGGGTCGGTCCTGACGACCGGTTGGTTGGCAACTCCTCCCG
                   AGCCCGGGCTTTCCCCAACGCGACCTTAGAGATTGGGCTGACCGGCGCTCGGGACGCT
                   GGGGGCTACACCTGCATCGCCACCAACCCTGCTGGTGAGGCCACAGCCCGAGTAGAAC
                   TGCOGGTGCTGGCCTTGCCCCATGGTGGGAACAGCAGTGCCGAGGGGGGCCGCCCCGG
                   GCCCTCGGACATCGCCGCCTCCGCTCGCACTGCTCCCGAGGGTGAGGGGACGCTGGAG
                   TCTGAGCCAGCCGTGCAGGTGACGGAGGTGACCGCCACCTCAGGGCTGGTGAGCTGGG
                   GTCCCGGGCGGCCAGCCGACCCAGTGTGGATGTTCCAAATCCAGTACAACAGCACCGA
                   CACCTCGTCCCCGGCGCTGACTATGACCTCTGCCTGCTGGCCTTGTCACCGGCCGCTG
                   GGCCCTCTGACCTCACGGCCACCAGGCTGCTGGGCTGTGCCCATTTCTCCACGCTGCC
                   GGCCTCGCCCCTGTGCCACGCCCTGCAGGCCCACGTGCTGGGCGGGACCCTGACCGTG
                   GCCGTGGGGGGTGTGCTGGTGGCTGCCTTACTGGTCTTCACTGTGGCCTTGCTGGTTC
                   GGGGCCGGGGGGCCCGAAATGGCCGCCTCCCCCTCAAGCTCAGCCACGTCCAGTCCCA
                   GACCAATGGAGGCCCCAGCCCCACACCCAAGGCCCACCCGCCGCGGGAGCCCCCCGCC
                   CCGGCCGCAGCGCAGCTGCTCTCTGGACCTGGGAGATGCCGGGTGCTACGGTTATGCC
                   AGGCGCCTGGGAGGAGCTTCGGCCCGACCGAGCCACTCTGTGCATGGGGGGCTGCTCG
                   GGGCAGGGTGCCGGGGGGTAGGAGGCAGCGCCGAGCGGCTGGAAGAGAGTGTGGTGTG
                   ATGGACGGGCAGCTTCCTGTGTGCTCCAAGGGATGAGCCTCGTGGGGCAGAGGGCCCG
                   GGGCCGCCGCCTCGCCTGGGAGTCCCTCCCTGGTTTTTATTCTCAGTACCTCAGGCTC
                   CCCTGTGTACTTGGAGGGGCAGGGAGCCCTTTCCTCGGTTCTGGCCTCCAGACCAGGG
                   TAAGGGCAGGCCCCTCCAACAGGTGCTCACAGCCACCGAGGCAGGGGCTGCAGCCACC
                   CACTGGGAGTCTTGTTTTTATTTATAATAAAATTGTTGGGGACACCTCAAAAAAAAAA
                   AAGCCCACAAATTCCCCGAGGGACAATTACGGTACAGCGTCATGACAAAGGCCCACAG
                   AGTCAAAACCCAAACCGCGCCCTTACAAGCCAGACGGCACAGTCTCGGTCACGAGACA
                   CTCTGGATCATCCACACAAGTACCCAGACAAACGAGCGCACCATCGCTCTACCCCCCC
                   ACCGGGCCCGCGGCCCCACCCACCCACAGGACGCACCCGCGCAGCGCCAGCACCCACA
                   CCACGCGGCCACCAACGACGACACGCACCACCGACAAGCGACACGCACAGCACCGCCA
                   CGAACAAGACGCTGGAGCTCCTCCGGCACGCGCCCGCAGGCCCCCCGCCCACACGACC
                   GCCTCCAACACCCCCGCGCGCGCCCTCCACACGAGGACAACGAAACACAAACCAGGCG
                   GCACCCCGACGCGCAGCCACCCAGCGCCACCGCACGCACACCCCCCAGCGAGCGACGC
                   CCCAACGCGCGCAGCACGGCCACAGGAGCGCGCACCCCCACCGAACCTAGTTGGTAGA
                   TAGCAGGTTGC
                   ORF Start: ATG at 471 ORF Stop: TGA at 2412
                   SEQ ID NO:188         647 aa MW at 68097.9 kD
NOV44a,            MAPPLLLLLLASGAAACPLPCVCQNLSESLSTLCAHRGLLFVPPNVDRRTVELRLADN
CG59869-01 Protein FIQALGPPDFRNNTGLVDLTLSRNAITRIGARAFGDLESLRSLHLDGNRLVELGTGSL
Sequence           RGPVNLQHLILSGNQLGRIAPGAFDDFLESLEDLDLSYNNLRQVPWAGIGANPALHTL
                   NLDHNLIDALPPGAFAQLGQLSRLDLTSNRLATLAPDPLFSRGRDAEASPAPLVLSFS
                   GNPLHCNCELLWLRRLARPDDLETCASPPGLAGRYFWAVPEGEFSCEPPLIARHTQRL
                   WVLEGQRATLRCRALGDPAPTMHWVGPDDRLVGNSSRARAFPNGTLEIGVTGAGDAGG
                   YTCIATNPAGEATARVELRVLALPHGGNSSAEGGRPGPSDIAASARTAAEGEGTLESE
                   PAVQVTEVTATSGLVSWGPGRPADPVWMFQIQYNSSEDETLIYRIVPASSHHFLLKHL
                   VPGADYDLCLLALSPAAGPSDLTATRLLGCAHFSTLPASPLCHALQAHVLGGTLTVAV
                   GGVLVAALLVFTVALLVRGRGAGNGRLPLKLSHVQSQTNGGPSPTPKAHPPREPPAPA
                   AAQLLSCPGRCRVLRLCQAPGRSLGPTEPLCAWGAARGRVPGGRRQRRAAGRECGVMD
                   GQLPVCSKG
                   SEQ ID NO:189         2451 bp
NOV44b,            AGAGTCCTCAGCAGGGTAGCCGAGGCCAGGCCACTTCTGCTGAGGATCGGGCAGGCTG
CG59869-02 DNA     GGGTGTGGGTGTGGCCTGGGGTGGCTCAGGGCTGGAACTGCTGCCTGATTCCTGTGTG
Sequence           CGGAGAAGCTCAGTGGCCGTTTGCTGCCACTGACAAGGATTTCACATGCAGAAGAGAA
                   AAGGCCCCCCTCCACCCCCCGCATTCCCTGCCGAGTGAGAGCCAGTGTTTGCTGCCCT
                   TGCTGGGGGCGGGTAGGAAACCCTGACCTTCCTCATGCGGAGTCATGAAGCAGAGTCC
                   TCGGGAAGGCATCTCCCCAACCTTCCCTCATCTCTGGCGCCCCTCTTGGGCCTCTGAC
                   CCAGCCCCTCCCCGGGCCAGGCTCACAGAAGCTGGCTTCTGGGACTGTCCTGGGCCCA
                   AGTCGGCACCTGCGCCAGCCCCACCTGTGCCTGGGCTGTGGCCCCTTCCTACAGGGCG
                   CTCACCATGGCCCCGCCGCTCCTCCTGCTGCTGCTGGCCAGTGGAGCGGCCGCCTGCC
                   CGCTGCCCTGCGTCTGCCAGAACCTGTCCGAGTCGCTCAGCACCCTCTGTGCCCACCG
                   AGGCCTGCTGTTTGTGCCGCCCAACGTGGACCGGCGCACAGTGGAGCTCCGGCTGGCT
                   GACAACTTCATCCAGGCCCTGGGGCCCCCTGACTTCCGCAACATGACGGGACTGGTGG
                   ACCTGACACTGTCTCGCAATGCCATCACCCGCATTGGGGCCCGCGCCTTTGGGGACCT
                   CGAGAGCCTGCGTTCCCTCCACCTTGACGGCAACAGGCTGGTGGAGCTGGGCACCGGG
                   AGCCTCCGGGGCCCCGTCAATCTGCAGCACCTCATCCTCAGCCGCAACCAGCTGGGCC
                   GCATCGCGCCGGGAGCCTTCGACGACTTCCTAGAGAGCCTGGAGGACCTGGACCTGTC
                   CTACAACAACCTCCGGCAGGTGCCCTGGGCCGGCATCGGCGCCATGCCTGCCCTGCAC
                   ACCCTCAACCTGGACCATAACCTTATTGACGCACTGCCCCCAGGCGCCTTCGCCCAGC
                   TCGGTCAGCTCTCCCGCCTGGACCTCACCTCCAACCGCCTGGCCACGCTGGCTCCGGA
                   CCCGCTTTTCTCTCGTGGGCGTGATGCAGAGGCCTCTCCCGCCCCCCTGGTGCTGAGC
                   TTTAGCGGGAACCCCCTGCACTCCAACTGTGAGCTGCTGTGGCTGCGGCGGCTGGCGC
                   GGCCGGACGACCTGGAAACGTGCGCCTCCCCGCCCGGCCTGGCCGCCCGCTACTTCTG
                   GCCAGTCCCCGAGGGCGAGTTCTCCTGTGAGCCGCCCCTCATTGCCCGCCACACGCAG
                   CGCCTCTGGGTGCTGGAAGGCCAGCGGGCCACGCTGCGGTGCCGGGCCCTGGGTGACC
                   CCGCGCCTACCATGCACTGGGTCGGTCCTGACGACCGGTTGGTTGGCAACTCCTCCCG
                   AGCCCGGGCTTTCCCCAACGGGACCTTAGAGATTGGGGTGACCGGCGCTGGGGACGCT
                   GGGGGCTACACCTGCATCGCCACCAACCCTGCTGGTGAGGCCACAGCCCGAGTAGAAC
                   TGCGGGTGCTGGCCTTGCCCCATGGTGGGAACAGCAGTGCCGAGGGGGGCCGCCCCGG
                   GCCCTCCGACATCGCCGCCTCCGCTCGCACTGCTGCCGAGGGTGAGGGGACGCTGGAG
                   TCTGACCCAGCCGTGCAGGTGACGGAGGTGACCGCCACCTCAGGGCTGGTGAGCTGGG
                   GTCCCGGGCGGCCAGCCGACCCAGTGTGGATGTTCCAAATCCAGTACAACAGCAGCGA
                   AGATGAGACCCTCATCTACCGGATTGTCCCAGCCTCCAGCCACCACTTCCTGCTGAAG
                   CACCCCGTCCCCGGCGCTGACTATGACCTCTGCCTGCTGGCCTTGTCACCGGCCGCTG
                   GGCCCTCTGACCTCACGGCCACCAGGCTGCTGGGCTGTGCCCATTTCTCCACGCTGCC
                   GGCCTCGCCCCTGTGCCACGCCCTGCAGGCCCACGTGCTGGGCGGGACCCTGACCGTG
                   GCCGTGGGGCGTGTGCTGGTGGCTGCAGCCCCTGCCTCGGTGGCTGTGAGCACCTGTT
                   GGAGGGGCCTGCCCTTACCCTGGTCTGGAGGCCAGAACCGAGGAAAGGGCTCCCTGCC
                   CCTCCAAGTACACAGGGGAGCCTGAGGTACTGAGAATAAAAACCAGGCAGGGACTCCC
                   AGGCCAGGCGGCGGCCCCGGGCCCTCTGCCCCACGAGGCTCATCCCTTGGAGCACACA
                   GGAAGCTGCCCGTCCATCACACCACACTCTCTTCCAGCCGCTCGGCGCTGCCTCCTAC
                   CCCCCGGCACCCTGCCCCGAGCAGCCCCCCATGCACAGAGTGGCTCCGTCGGGCCTAC
                   GCTCCTCCCAGGCGCCTGGCATAACCGTAGCACCCGGCATCTCCCAGGTCCAGAGACC
                   AGCTGCGCTGCGGCC
                   ORF Start: ATG at 471 ORF Stop: TGA at 2169
                   SEQ ID NO:190         566 aa MW at 59683.1 kD
NOV44b,            MAPPLLLLLLASGAAACPLPCVCQNLSESLSTLCAHRGLLFVPPNVDRRTVELRLADN
CG59869-02 Protein FIQALGPPDFRNMTGLVDLTLSRNAITRIGARAFGDLESLRSLHLDGNRLVELGTGSL
Sequence           RGPVNLQHLILSGNQLGRIAPGAFDDFLESLEDLDLSYNNLRQVPWAGIGAMPALHTL
                   NLDHNLIDALPPGAFAQLGQLSRLDLTSNRLATLAPDPLFSRGRDAEASPAPLVLSFS
                   GNPLHCNCELLWLRRLARPDDLETCASPPGLAGRYFWAVPEGEFSCEPPLIARHTQRL
                   WVLEGQPATLRCRALGDPAPTMHWVGPDDRLVGNSSRARAFPNGTLEIGVTGAGDAGG
                   YTCIATNPAGEATARVELRVLALPHGGNSSAEGGRPGPSDIAASARTAAEGEGTLESE
                   PAVQVTEVTATSGLVSWGPGRPADPVWMFQIQYNSSEDETLIYRIVPASSHHFLLKHP
                   VPGADYDLCLLALSPAAGPSDLTATRLLGCAHFSTLPASPLCHALQAHVLGGTLTVAV
                   GGVLVAAAPASVAVSTCWRGLPLPWSGGQNRGKGSLPLQVHRGA
                   SEQ ID NO:191         2563 bp
NOV44c,            TCCCAATCTGGAGGGGAACGTTGCACCCCAGCCCCAGGAGGCCCTGCCCGTGTGAAGA
CG59869-03 DNA     GCCAGCCAAGTGGGCACCTGCGCCAGCCCCACCTGTGCCTGCCTGTGGCCCCTTCCTA
Sequence           CAGGGCGCTCACCATGCCCCCCGCGCTCCTGCTGCTGCTGCTGGCCAGTGGAGCGGCC
                   GCCTGCCCCCTGCCCTGCGTCTGCCAGAACCTGTCCGAGTCGCTCAGCACCCTCTGTG
                   CCCACCGACGCCTGCTGTTTCTGCCGCCCAACGTGGACCGGCGCACAGTGGAGCTGCG
                   GCTGGCTGACAACTTCATCCAGGCCCTCGGGCCCCCCGACTTCCGCAACATGACGGGA
                   CTGGTGGACCTGACACTGTCTCGCAATGCCATCACCCGCATTGCGGCCCGCGCCTTTG
                   GGGACCTCGAGAGCCTACGTTCCCTCCACCTTGACGGCAACAGGCTGGTGGAGCTGGG
                   CACCGCGAGCCTCCGGGGCCCCGTCAATCTGCAGCACCTCATCCTCAGCGGCAACCAG
                   CTGGGCCGCATCGCGCCGGGAGCCTTCGACGACTTCCTAGAGAGCCTGGAGGACCTGG
                   ACCTGTCCTACAACAACCTCCGGCAGGTGCCCTGGGCCGGCATCGGCGCCATGCCTGC
                   CCTGCACACCCTCAACCTGGACCATAACCTTATTGACGCACTGCCCCCAGGCGCCTTC
                   GCCCAGCTCGGTCAGCTCTCCCGCCTGGACCTCACCTCCAACCGCCTGGCCACGCTGG
                   CTCCGGACCCGCTTTTCTCTCGTGGGCGTGATGCAGAGGCCTCTCCCGCCCCCCTGGT
                   GCTGAGCTTTAGCGGGAACCCCCTGCACTGCAACTGTGAGCTGCTCTGGCTGCGGCGG
                   CTGGCGCGGCCGGACGACCTGGAAACGTGCGCCTCCCCGCCCGGCCTGGCCGGCCGCT
                   ACTTCTGGGCAGTGCCCGAGGGCGAGTTCTCCTGTGAGCCGCCCCTCATTGCCCGCCA
                   CACGCAGCGCCTCTGGGTGCTGGAAGGCCAGCGGGCCACGCTGCGGTGCCGGGCCCTG
                   GGTGACCCCGCGCCTACCATGCACTGGGTCGGTCCTGACGACCGGTTGGTTGGCAACT
                   CCTCCCGAGCCCGGGCTTTCCCCAACGGGACCTTAGAGATTGGGGTGACCGGCGCTGG
                   GGACGCTGGGGGCTACACCTGCATCGCCACCAACCCTGCTGGTGAGGCCACAGCCCGA
                   GTAGAACTGCGGGTGCTGGCCTTGCCCCATGGTGGGAACAGCAGTCCCGAGGGGGGCC
                   GCCCGGGCCCTCGGACATCGGCCCCATGGTGGGAACAGCAGTGCCGAGGGGGGCCGCC
                   CGGGCCCTCGGACATCGCCGCCTCCGCTCGCACTGCTGCCGAGGGTGAGGGGACGCTG
                   GAGTCTGAGCCAGCCGTGCAGGTGACGGAGGTGACCGCCACCTCAGGGCTGGTGAACT
                   GGGGTCCCCGGCAGCCAGCGACCCACGTGTGGATGTTCCAAATCCAGTACAACAGCAG
                   CGAAGATGAGACCCTCATCTGCCGGATTGTCCCAGCCTCCAGCCACCACTTCCTGCTG
                   AAGCACCTCGTCCCCGGCGCTGACTATGACCTCTGCCTGCTCGCCTTGTCACCGGCCG
                   CTGGGCCCTCTGACCTCACGGCCACCAGGCTGCTGGGCTGTGCCCATTTCTCCACGCT
                   GCCGGCCTCGCCCCTGTGCCACGCCCTGCAGGCCCACGTGCTGGGCGGGACCCTGACC
                   GTGGCCGTGGGGGGTGTGCTGGTGGCTGCCTTACTGGTCTTCACTGTGGCCTTGCTCG
                   TTCGGGGCCGGGGGGCCGGAAATGGCCGCCTCCCCCTCAAGCTCAGCCACGTCCAGTC
                   CCACACCAATGGAGGCCCCAGCCCCACACCCAAGGCCCACCCGCCGCGGAGCCCCCCG
                   CCCCGGCCGCAGCGCAGCTGCTCTCTGGACCTGGGAGATGCCGGGTGCTACGGTTATG
                   CCAGGCGCCTGGGAGGAGCTTGGGCCCGACGGAGCCACTCTGTCCATGGGGGGCTGCT
                   CGGGGCAGGGTGCCGGGGGGTAGGAAGGGAGCCCTCCTGGAGAAGGCGCGAGTCTTGC
                   TGTGCTGAGGAGCCTGCCGTGGACCGCCTCAGCGCCCCCTACACCACTCTCGCCCTGA
                   GGACCAGCACCCTGAGGAAGCTCCAGGGAGGCAGGTATCAGCTCGGCAGACACAAGAG
                   CTTGCATGGCCAGGGCCCCCACAGTGAAAATGACCCCGAGTTGGGGCAAGCTCCCCAT
                   CAAGGGAGACCGCCGCGGAGCCCCCCGCCCCGGCCGCAGCGCAGCTGCTCTCTGGACC
                   TGGGAGATGCCGGGTGCTACGGTTATGCCAGGCGCCTGGGAGGAGCTTGGGCCCGACG
                   GAGCCACTCTGTGCATGGGGGGCTGCTCGGGGCAGGGTGCCGGGGGGTAGGAGGCAGC
                   GCCGAGCGGCTGGAAGAGAGTGTGGTGTGATGGACGGGCAGCTTCCTGTGTGCTCCAA
                   GGGATGAGCCTCGTGCGGCAGAGGGCCCGGGGCCGCCGCCTGGCCTGGGAGTCCCTCC
                   CTGGTTTTTAT
                   ORF Start: ATG at 130 ORF Stop: TGA at 2464
                   SEQ ID NO:192         778 aa MW at 82472.5 kD
NOV44c,            MAPALLLLLLASGAAACPLPCVCQNLSESLSTLCAHRGLLFVPPNVDRRTVELRLADN
CG59869-03 Protein FIQALGPPDFRNMTGLVDLTLSRNAITRIGARAFGDLESLRSLHLDGNRLVELGTGSL
Sequence           RGPVNLQHLILSGNQLGRIAPGAFDDFLESLEDLDLSYNNLRQVPWAGIGAMPALHTL
                   NLDHNLIDALPPGAFAQLGQLSRLDLTSNRLATLAPDPLFSRGRDAEASPAPLVLSFS
                   GNPLHCNCELLWLRRLARPDDLETCASPPGLAGRYFWAVPEGEFSCEPPLIARHTQRL
                   WVLEGQRATLRCRALGDPAPTMHWVGPDDRLVGNSSRARAFPNGTLEIGVTGAGDAGG
                   YTCIATNPAGEATARVELRVLALPHGGNSSAEGGRPGPRTSAPWWEQQCRGGPPGPSD
                   IAASARTAAEGEGTLESEPAVQVTEVTATSGLVNWGPRQPATHVWMFQIQYNSSEDET
                   LICRIVPASSHHFLLKHLVPGADYDLCLLALSPAAGPSDLTATRLLGCAHFSTLPASP
                   LCHALQAHVLGGTLTVAVGGVLVAALLVFTVALLVRGRGAGNGRLPLKLSHVQSQTNG
                   GPSPTPKAHPPRSPPPRPQRSCSLDLGDAGCYGYARRLGGAWARRSHSVHCGLLGAGC
                   RGVGREPSWRRRESCCAEEPAVDRLSAPYTTLALRTSTLRKLQGGRYQLGRHKSLHGQ
                   GPHSENDPELGQAPHQGRPPRSPPPRPQRSCSLDLGDAGCYGYARRLGGAWARRSHSV
                   HGGLLGAGCRGVGGSAERLEESVV

[0553] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 44B.

TABLE 44B
Comparison of NOV44a against NOV44b through NOV44c.
	NOV44a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV44b	21 . . . 512	477/492 (96%)
	21 . . . 512	477/492 (96%)
NOV44c	21 . . . 563	496/561 (88%)
	21 . . . 581	498/561 (88%)

[0554] Further analysis of the NOV44a protein yielded the following properties shown in Table 44C.

TABLE 44C
Protein Sequence Properties NOV44a
PSort     0.4600 probability located in plasma membrane; 0.1000
analysis: probability located in endoplasmic reticulum (membrane);
          0.1000 probability located in endoplasmic reticulum (lumen);
          0.1000 probability located in outside
SignalP   Cleavage site between residues 17 and 18
analysis:

[0555] A search of the NOV44a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 44D.

TABLE 44D
Geneseq Results for NOV44a
		NOV44a	Identities/
Geneseq	Protein/Organism/Length [Patent #,	Residues/	Similarities for	Expect
Identifier	Date]	Residues	Region	Value
AAB70072	Human secreted protein #11 -	168 . . . 577	408/410 (99%)	0.0
	Homo sapiens, 468 aa. [WO200112776-A2,	1 . . . 410	408/410 (99%)
	22-FEB-2001]
AAB12448	Human hh00149 protein SEQ ID NO: 4 -	9 . . . 577	330/590 (55%)	e−180
	Homo sapiens, 785 aa.	4 . . . 592	408/590 (68%)
	[WO200031255-A1, 02-JUN-2000]
AAB09968	Human brain-specific transmembrane	9 . . . 577	330/590 (55%)	e−180
	glycoprotein - Homo sapiens, 789 aa.	8 . . . 596	408/590 (68%)
	[WO200031256-A1, 02-JUN-2000]
AAU28092	Novel human secretory protein, Seq ID	9 . . . 577	329/590 (55%)	e−179
	No 261 - Homo sapiens, 789 aa.	8 . . . 596	407/590 (68%)
	[WO200166689-A2, 13-SEP-2001]
AAM39059	Human polypeptide SEQ ID NO 2204 -	9 . . . 577	329/590 (55%)	e−179
	Homo sapiens, 789 aa.	8 . . . 596	407/590 (68%)
	[WO200153312-a1, 26-JUL-2001]

[0556] In a BLAST search of public sequence databases, the NOV44a protein was found to have homology to the proteins shown in the BLASTP data in Table 44E.

TABLE 44E
Public BLASTP Results for NOV44a
		NOV44a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q9ULH4	KIAA1246 PROTEIN - Homo sapiens	9 . . . 577	330/590 (55%)	e−179
	(Human), 832 aa (fragment).	51 . . . 639	408/590 (68%)
Q9BE71	HYPHOTHETICAL 84.7 KDA	9 . . . 577	328/590 (55%)	e−178
	PROTEIN - Macaca fascicularis (Crab	8 . . . 596	406/590 (68%)
	eating macaque) (Cynomolgus
	monkey), 789 aa.
Q9CYK3	5730420O05RIK PROTEIN -	9 . . . 577	327/595 (54%)	e−174
	Mus musculus (Mouse), 788 aa.	8 . . . 601	407/595 (67%)
CAD10239	SEQUENCE 1 FROM PATENT	4 . . . 582	329/608 (54%)	e−171
	WO0172827 - Homo sapiens (Human),	5 . . . 608	398/608 (65%)
	628 aa.
Q9BTN0	HYPOTHETICAL 66.3 KDA	4 . . . 582	329/608 (54%)	e−171
	PROTEIN - Homo sapiens (Human),	5 . . . 608	398/608 (65%)
	628 aa.

[0557] PFam analysis indicates that the NOV44a protein contains the domains shown in the Table 44F.

TABLE 44F
Domain Analysis of NOV44a
		Identities/
		Similarities
Pfam Domain	NOV44a Match Region	for the Matched Region	Expect Value
LRRNT: domain 1 of 1	16 . . . 47	12/33 (36%)	1
		20/33 (61%)
LRR: domain 1 of 7	49 . . . 72	8/25 (32%)	75
		15/25 (60%)
LRR: domain 2 of 7	73 . . . 96	8/25 (32%)	1.4
		15/25 (60%)
LRR: domain 3 of 7	97 . . . 120	7/25 (28%)	0.82
		19/25 (76%)
LRR: domain 4 of 7	121 . . . 144	9/25 (36%)	0.022
		17/25 (68%)
LRR: domain 5 of 7	146 . . . 169	12/25 (48%)	0.049
		19/25 (76%)
LRR: domain 6 of 7	170 . . . 193	9/25 (36%)	0.0096
		18/25 (72%)
LRR: domain 7 of 7	194 . . . 214	9/25 (36%)	86
		15/25 (60%)
LRRCT: domain 1 of 1	234 . . . 279	21/54 (39%)	1.1e−05
		37/54 (69%)
ig: domain 1 of 1	295 . . . 353	15/62 (24%)	9e−10
		43/62 (69%)
fn3: domain 1 of 1	404 . . . 487	21/86 (24%)	2.7e−08
		58/86 (67%)

Example 45

[0558] The NOV45 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 45A.

TABLE 45A
NOV45 Sequence Analysis
                   SEQ ID NO:193        704 bp
NOV45a,            GAAGCGCQGAGGCCCGTCCCGGTGGCCGGGGAGCGGGCGGGTGGGGGCGCCATGTGGT
CG59859-01 DNA     TCATGTACCTGCTGAGCTGGCTGTCGCTCTTCATCCAGGTGGCCTTCATCACGCTGGC
Sequence           TGTCGCGGCTGGACTCTATTACCTGGCAGAACTGATAGAAGAATACACAGTGGCCACC
                   AGCAGGATCATAAAATACATGATCTGGTTCTCCACCGCTGTACTGATTGGCCTCTACG
                   TCTTTGAGCGCTTCCCCACCAGCATGATTGGAGTGGGCCTATTCACCAACCTCGTCTA
                   CTTTGGCCTCCTCCAGACCTTCCCCTTCATCATGCTCACCTCGCCTAACTTCATCCTG
                   TCGTGTGGACTAGTGGTGGTGAATCATTACCTAGCATTTCAGTTTTTTGCAGAAGAAT
                   ATTATCCCTTCTCAGAGGTCCTGGCCTATTTCACTTTCTGCCTGTGGATAATTCCGTT
                   TGCGTTTTTTGTGTCACTTTCGGCCGGGGAGAACGTCCTGCCCTCTACCATGCAGCCA
                   GGAGATGATGTCGTCTCCAATTATTTCACCAAAGGCAAGCGGGGCAAACGCTTAGGGA
                   TCCTGGTTGTCTTCTCCTTCATCAAAGAGGCCATTCTACCCAGTCGTCAGAAGATATA
                   CTGACCCCCATGCAGGCAGGATGTGGGGGGCAAGATCAGGAGAGTCAGGCCCCTGGGC
                   CTCTATGC
                   ORF Start: ATG at 52 ORF Stop: TGA at 640
                   SEQ ID NO:194        196 aa MW at 22537.4 kD
NOV45a,            MWFMYLLSWLSLFIQVAFITLAVAAGLYYLAELIEEYTVATSRIIKYMIWFSTAVLIG
CG59859-01 Protein LYVFERFPTSMIGVGLFTNLVYFGLLQTFPFIMLTSPNFILSCGLVVVNHYLAFQFFA
Sequence           EEYYPFSEVLAYFTFCLWIIPFAFFVSLSAGENVLPSTMQPGDDVVSNYFTKGKRGKR
                   LGILVVFSFIKEAILPSRQKIY
                   SEQ ID NO:195        619 bp
NOV45b,            CATGTGGTTCATGTACCTGCTGAGCTGGCTGTCGCTCTTCATCCAGGTGGCCTTCATC
CG59859-02 DNA     ACGCTGGCTGTCGCGGCTGGACTCTATTACCTGGCAGAACTGATAGAAGAATACACAG
Sequence           TGGCCACCAGCAGGATCATAAAATACATGATCTGGTTCTCCACCGCTGTACTGATTGG
                   CCTCTACGTCTTTGAGCGCTTCCCCACCAGCATGATTGGAGTGGGCCTATTCACCAAC
                   CTCGTCTACTTTGGCCTCCTCCAGACCTTCCCCTTCATCATGCTGACCTCGCCTAACT
                   TCATCCTGTCGTGTGGACTAGTGGTGGTGAATCATTACCTAGCATTTCAGTTTTTTGC
                   AGAAGAATATTATCCCTTCTCAGAGGTCCTGGCCTATTTCACTTTCTGCCTGTGGATA
                   ATTCCGTTTGCGTTTTTTGTGTCACTTTCGGCCGGGGAGAACGTCCTGCCCTCTACCA
                   TGCAGCCAGGAGATGATGTCGTCTCCAATTATTTCACCAAAGGCAAGCGGGGCAAACG
                   CTTAGGGATCCTGGTTGTCTTCTCCTTCATCAAAGAGGCCATTCTACCCAGTCGTCAG
                   AAGATATACTGACCCCCATGCAGGTACATGAACCACATG
                   ORF Start: ATG at 2  ORF Stop: TGA at 590
                   SEQ ID NO:196        196 aa MW at 22537.4 kD
NOV45b,            MWFMYLLSWLSLFIQVAFITLAVAAGLYYLAELIEEYTVATSRIIKYMIWFSTAVLIG
CG59859-02 Protein LYVFERFPTSMIGVGLFTNLVYFGLLQTFPFIMLTSPNFILSCGLVVVNHYLAFQFFA
Sequence           EEYYPFSEVLAYFTFCLWIIPFAFFVSLSAGENVLPSTMQPGDDVVSNYFTKGKRGKR
                   LGILVVFSFIKEAILPSRQKIY

[0559] Sequence comparison of the above protein sequences yields the following sequence relationships shown in Table 45B.

TABLE 45B
Comparison of NOV45a against NOV45b and NOV45c.
	NOV45a Residues/	Identities/Similarities
Protein Sequence	Match Residues	for the Matched Region
NOV45b	1 . . . 196	196/196 (100%)
	1 . . . 196	196/196 (100%)

[0560] Further analysis of the NOV45a protein yielded the following properties shown in Table 45C.

TABLE 45C
Protein Sequence Properties NOV45a
PSort     0.6400 probability located in plasma membrane; 0.4600
analysis: probability located in Golgi body; 0.3700 probability located
          in endoplasmic reticulum (membrane); 0.1000 probability
          located in endoplasmic reticulum (lumen)
SignalP   Cleavage site between residues 25 and 26
analysis:

[0561] A search of the NOV45a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 45D.

TABLE 45D
Geneseq Results for NOV45a
		NOV45a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAU12255	Human PRO4325 polypeptide	1 . . . 196	196/196 (100%)	e−111
	sequence - Homo sapiens, 196 aa.	1 . . . 196	196/196 (100%)
	[WO200140466-A2, 07-JUN-2001]
AAM40045	Human polypeptide SEQ ID NO 3190 -	1 . . . 196	196/196 (100%)	e−111
	Homo sapiens, 196 aa.	1 . . . 196	196/196 (100%)
	[WO200153312-A1, 26-JUL-2001]
AAM41831	Human polypeptide SEQ ID NO 6762 -	1 . . . 173	173/173 (100%)	5e−98
	Homo sapiens, 203 aa.	31 . . . 203	173/173 (100%)
	[WO200153312-A1, 26-JUL-2001]
AAM93368	Human polypeptide, SEQ ID NO: 2935 -	91 . . . 196	106/106 (100%)	6e−57
	Homo sapiens, 106 aa. [EP1130094-	1 . . . 106	106/106 (100%)
	A2, 05-SEP-2001]
ABB18676	Protein #675 encoded by probe for	51 . . . 101	51/51 (100%)	8e−23
	measuring heart cell gene expression -	1 . . . 51	51/51 (100%)
	Homo sapiens, 51 aa. [WO200157274-
	A2, 09-AUG-2001]

[0562] In a BLAST search of public sequence databases, the NOV45a protein was found to have homology to the proteins shown in the BLASTP data in Table 45E.

TABLE 45E
Public BLASTP Results for NOV45a
Protein		NOV45a	Identities/
Accession		Residues/	Similarities for	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
Q62302	TESTIS EXPRESSED PROTEIN 261	1 . . . 196	195/196 (99%)	e−110
	(TEG-261) (TESTIS EXPRESSED	1 . . . 196	196/196 (99%)
	GENE 261) - Mus musculus (Mouse),
	196 aa.
AAH20251	HYPOTHETICAL 17.0 KDA	48 . . . 196	149/149 (100%)	1e−82
	PROTEIN - Homo sapiens (Human),	1 . . . 149	149/149 (100%)
	149 aa.
Q96FM0	UNKNOWN (PROTEIN FOR	84 . . . 196	113/113 (100%)	1e−60
	IMAGE: 3855224) - Homo sapiens	1 . . . 113	113/113 (100%)
	(Human), 113 aa (fragment).
Q9W1R8	CG3500 PROTEIN - Drosophila	1 . . . 194	99/198 (50%)	9e−49
	melanogaster (Fruit fly), 198 aa.	1 . . . 195	135/198 (68%)
JC5386	steroidogenic acute regulatory protein -	48 . . . 133	86/86 (100%)	7e−45
	rat, 362 aa.	1 . . . 86	86/86 (100%)

[0563] PFam analysis predicts that the NOV45a protein contains the domains shown in the Table 45F.

TABLE 45F
Domain Analysis of NOV45a
		Identities/
	NOV45a	Similarities	Expect
Pfam Domain	Match Region	for the Matched Region	Value
No Significant Matches Found

Example 46

[0564] The NOV46 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 46A.

TABLE 46A
NOV46 Sequence Analysis
                   SEQ ID NO:197        4798 bp
NOV46a,            GAAACAGGTCAAAATGAGCAAGAGACGCATGAGCGTGGGTCAGCAAACATGGGCTCTT
CG59913-01 DNA     CTCTGCAAGAACTGTCTCAAAAAATGGAGAATGAAAAGACAGACCTTGTTGGAATGGC
Sequence           TCTTTTCATTTCTTCTGGTACTGTTTCTGTACCTATTTTTCTCCAATTTACATCAAGT
                   TCATGACACTCCTCAAATGTCTTCAATGGATCTGGGACGTGTAGATAGTTTTAATGAT
                   ACTAATTATGTTATTGCATTTGCACCTGAATCCAAAACTACCCAAGAGATAATGAACA
                   AAGTGGCTTCAGCCCCATTCCTAGCAGGAAGAACAATCATGGGGTGGCCTGATGAAAA
                   AAGCATGGATGAATTGGATTTGAACTATTCAATAGACGCACTGAGAGTCATCTTTACT
                   GATACCTTCTCCTACCATTTGAAGTTTTCTTGGGGACATAGAATCCCCATGATGAAAG
                   AGCACAGAGACCATTCAGCTCACTGTCAAGCAGTGAATGAAAAAATGAAGTGTGAAGG
                   TTCAGAGTTCTGGGAGAAAGGCTTTGTACCTTTTCAAGCTGCCATTAATGCTGCTATC
                   ATAGAAGTGAGTACAAATCATTCAGTGATGGAACAGCTGATGTCAGTTACTGGTGTAC
                   ATATGAAGATATTACCTTTTGTTGCCCAAGGAGGAGTTGCAACTGATTTTTTCATTTT
                   CTTTTGCATTATTTCTTTTTCTACATTTATATACTATGTATCAGTCAATGTTACACAA
                   GAAAGACAATACATTACGTCATTGATGACAATGATGGGACTCCGAGAGTCAGCATTCT
                   GGCTTTCCTGGGGTTTGATGTATGCTGGCTTCATCCTTATCATGGCCACTTTAATGGC
                   TCTTATTGTAAAATCTGCACAAATTGTCGTCCTGACTGGTTTTGTGATGGTCTTCACC
                   CTCTTTCTCCTCTATGGCCTGTCTTTGGTGAGTTTAGCTTTCCTGATGAGTGTGTTGA
                   TAAAGAAACCTTTCCTTACGGGCTTGGTTGTGTTTCTCCTTATTGTCTTTTGGGGGAT
                   CCTGGGATTCCCAGCATTGTATACACGTCTTCCTGCATTTTTGGAATGGACTTTGTGT
                   CTTCTTAGCCCCTTTGCCTTCACTGTTGGGATGGCCCAGCTTATACATTTGGACTATG
                   ATGTGAATTCTAATGCCCACTTGCATTCTTCACAAAATCCATACCTCATAATAGCTAC
                   TCTTTTCATGTTGGTTTTTGACACCCTTCTGTATTTGGTATTGACATTATATTTTGAC
                   AAAATTTTGCCCGGTGAATATGGACATCGATGTTCTCCCTTGTTTTTCCTGAAATCCT
                   GTTTTTGGTTTCAACACGGAAGGGCTAATCATGTGGTCCTTGAGAATGAAACAGATTC
                   TGATCCTACACCTAATGACTGTTTTGAACCAGTGTCTCCAGAATTCTGTGGGAAAGAA
                   GCCATCAGAATCAAAAATCTTAAAAAAGAATATGCAGGGAAGTGTGAGAGAGTAGAAG
                   CTTTGAAAGGTGTGGTGTTTOACATATATGAAGGCCAGATCACTGCCCTCCTTGGTCA
                   CAGTGGAGCTGGAAAAACTACCCTGTTAAACATACTTAGTGGGTTGTCAGTTCCAACA
                   TCAGGTTCAGTCACTGTCTATAATCACACACTTTCAAGAATGGCTCATATAGAAAATA
                   TCAGCAAGTTCACTGGATTTTGTCCACAATCCAATGTGCAATTTGGATTTCTCACTGT
                   GAAAGAAAACCTCAGGCTGTTTGCTAAAATAAAAGGGATTTTGCCACATGAAGTGGAG
                   AAAGAGGTATTGCTATTGGATGAACCGACTCCTGCATTGCATCCTCTTTCAAGGCACC
                   GAATATGGAATCTCCTGAAAGAGGGGAAATCAGACAGAGTAATTCTCTTCAGCACCCA
                   GTTTATAGATGAGGCTGACATTCTGGCGGACAGGAAGGTGTTCATATCCAATGGGAAG
                   CTGAAGTGTGCAGGCTCTTCTCTGTTCCTTAAGAAGAAATGGGGCATAGGCTACCATT
                   TAAGTTTGCATCTGAATGAAAGGTGTGATCCAGAGAGTATAACATCACTGGTTAAGCA
                   GCACATCTCTGATGCCAAATTGACAGCACAAAGTGAAGAAAAACTTGTATATATTTTG
                   CCTTTGGAAACGACAAACAAATTTCCAGAACTTTACAGGGATCTTGATAGATGTTCTA
                   ACCAAGGCATTGAGGATTATGGTGTTTCCATAACAACTTTGAATGAGGTGTTTCTGAA
                   ATTAGAAGGAAAATCAACTATTGATGAATCAGATATTGGAATTTGGGGACAATTACAA
                   ACTGATGGGGCAAAAGATATAGGAAGCCTTGTTGAGCTGGAACAAGTTTTGTCTTCCT
                   TCCACGAAACAAGGAAAACAATCAGTGGCGTGGCGCTCTGGAGGCAGCAGGTCTGTGC
                   AATAGCAAAAGTTCGCTTCCTAAAGTTAAAGAAAGAAAGAAAAAGCCTGCTGCATAGA
                   TTATTGCTTTTTGGTATTAGCTTTATCCCTCAACTTTTGGAACATCTATTCTACGAGT
                   CATATCAGAAAAGTTACCCGTGGGAACTGTCTCCAAATACATACTTCCTCTCACCAGG
                   ACAACAACCACAGGATCCTCTGACCCATTTACTGGTCATCAATAAGACAGGTTCAACC
                   ATTGATAACTTTTTACATTCACTGAGGCGACAGAACATAGCTATAGAAGTGGATGCCT
                   TTGGAACTAGAAATGGCACAGATGACCCATCTTACAATGGTGCTATCATTGTGTCAGG
                   TGATGAAAAGGATCACAGATTTTCAATAGCATGTAATACAAAACGGCTGAATTGCTTT
                   CCTGTCCTCCTGGATGTCATTAGCAATGGACTACTTGGAATTTTTAATTCGTCAGAAC
                   ACATTCAGACTGACAGAAGCACATTTTTTGAAGAGCATATGGATTATGAGTATGGGTA
                   CCGAAGTAACACCTTCTTCTGGATACCGATGGCAGCCTCTTTCACTCCATACATTGCA
                   ATGAGCAGCATTGGTCACTACAAAGTAAGAGCTCATTCCCAGCTACGGATTTCAGGCC
                   TCTACCCTTCTGCATACTGGTTTGCCCAAGCACTGGTGGATGTTTCCCTGTACTTTTT
                   GATCCTCCTGCTAATGCAAATAATGGATTATATTTTTAGCCCAGAGGAGATTATATTT
                   ATAATTCAAAACCTGTTAATTCAAGTAAGTGGCAGCAATTTTGAAATGGTTTTATTAG
                   ACTATTTTTTCATGAATGCAGTAATATCATTAATCTTAAACCAAAGAACTTCAAATTA
                   CCTGTGCTATTGCATAGTTTTGGTGGTCATCTTCTCGATAGTTGCTACTGATCTAAAT
                   GAATATGGATTTCTAGGGCTATTTTTTGGCACCATGTTAATACCTCCCTTCACATTGA
                   TTGGCTCTCTATTCATTTTTTCTGAGGTAAGTAGTTCCACTTATAGCTCAAGAAACAA
                   AATTGTCCTTTTACCTTTTATTTGCAAAAGAGTGGGGTACCTTCATTTTCTCATTTTT
                   CTTTTCATTCTGCGATGCCTAGAAATGAACTGCAGGAAGAAACTAATGAGAAAGGATC
                   CTGTGTTCAGAATTTCTCCAAGAAGCAACGCTATTTTTCCAAACCCAGAAGAGCCTGA
                   AGGAGAGGAGGAAGATATCCAGATGGAAAGAATGAGAACAGTGAATGCTATGGCTGTG
                   CGAGACTTTGATGAGACACCCGTCATCATTGCCAGCTGTCTACGGAAGGAATATGCAG
                   GCAAAAAGAAAAATTGCTTTTCTAAAAGGAAGAAAAAAATTGCCACAAGAAATGTCTC
                   TTTTTGTGTTAAAAAAGGTGAAGTTATAGGACTGTTAGGACACAATGGAGCTGGTAAA
                   AGTACAACTATTAAGATGATAACTGGAGACACAAAACCAACTGCAGGACAGGTCATTT
                   TGAAAGGGAGCGGTGGAGGGGAACCCCTGGGCTTCCTGGGGTACTGCCCTCAGGAGAA
                   TGCGCTGTGGCCCAACCTGACAGTGAGGCAGCACCTGGAGGTGTACGCTGCCGTGAAA
                   GGTCTCAGGAAAGGGGACGCAATGATCGCCATCACACGGTTAGTGGATGCGCTCAAGC
                   TGCAGGACCAGCTGAAGGCTCCCGTGAAGACCTTGTCAGAGGGAATAAAGCGAAAGCT
                   GTGCTTTGTGCTGAGCATCCTGGGGAACCCGTCAGTGGTGCTTCTGGATGAGCCGTCG
                   ACCGGGATGGACCCCGAGGGGCAGCAGCAAATGTGGCAGGTGATTCGGGCCACCTTTA
                   GAAACACGGAGAGGGGCGCCCTCCTGACCACCCACTACATGGCAGAGGCTGAGGCGGT
                   GTGTGACCGAGTGGCCATCATGGTGTCAGGAAGCCTGAGGTGTATTGGTTCCATCCAA
                   CACCTGAAAAGCAAATTTGGCAAAGACTACCTGCTGGAGATGAAGCTGAAGAACCTGG
                   CACAAATGGAGCCCCTCCATGCAGAGATCCTGAGGCTTTTCCCCCAGGCTGCTCAGCA
                   GGAAAGGTTCTCCTCCCTGATGGTCTATAAGTTGCCTGTTGAGGATGTGCGACCTTTA
                   TCACAGGCTTTCTTCAAATTAGAGATAGTTAAACAGAGTTTCGACCTGGAGGAGTACA
                   GCCTCTCACAGTCTACCCTGGAGCAGGTTTTCCTGGAGCTCTCCAAGGAGCAGGAGCT
                   GGGTGATCTTGAAGAGGACTTTGATCCCTCGGTGAAGTGGAAACTCCTCCTGCAGGAA
                   GAGCCTTAAAGCTCCAAATACCCTATATCTTTCTTTAATCCT
                   ORF Start: ATG at 14 ORF Stop: TAA at 4763
                   SEQ ID NO:198        1583 aa MW at 179792.1 kD
NOV46a,            MSKRRMSVGQQTWALLCKNCLKKWRMKRQTLLEWLFSFLLVLFLYLFFSNLHQVHDTP
CG59913-01 Protein QMSSMDLGRVDSFNDTNYVIAFAPESKTTQEIMNKVASAPFLAGRTIMGWPDEKSMDE
Sequence           LDLNYSIDAVRVIFTDTFSYHLKFSWGHRIPMMKEHRDHSAHCQAVNEKMKCEGSEFW
EKGFVAFQAAINAAIIEVSTNHSVMEQLMSVTGVHMKILPFVAQGGVATDFFIFFCII
                   SFSTFIYYVSVNVTQERQYITSLMTMMGLRESAFWLSWGLMYAGFILIMATLMALIVK
                   SAQIVVLTGFVMVFTLFLLYGLSLVSLAFLMSVLIKKPFLTGLVVFLLIVFWGILGFP
                   ALYTRLPAFLEWTLCLLSPFAFTVGMAQLIHLDYDVNSNAHLDSSQNPYLIIATLFML
                   VFDTLLYLVLTLYFDKILPGEYGHRCSPLFFLKSCPWFQHGRANHVVLENETDSDPTP
                   NDCFEPVSPEFCGKEAIRIKNLKKEYAGKCERVEALKGVVFDIYEGQITALLGHSGAG
                   KTTLLNILSGLSVPTSGSVTVYNHTLSRMADIENISKFTGFCPQSNVQFGFLTVKENL
                   RLFAKIKGILPHEVEKEVLLLDEPTAGLDPLSRHRIWNLLKEGKSDRVILFSTQFIDE
                   ADILADRKVFISNGKLKCAGSSLFLKKKWGIGYHLSLHLNERCDPESITSLVKQHISD
                   AKLTAQSEEKLVYILPLERTNKFPELYRDLDRCSNQGIEDYGVSITTLNEVFLKLEGK
                   STIDESDIGIWGQLQTDGAKDIGSLVELEQVLSSFHETRKTISGVALWRQQVCAIAKV
                   RFLKLKKERKSLLHRLLLFGISFIPQLLEHLFYESYQKSYPWELSPNTYFLSPGQQPQ
                   DPLTHLLVINKTGSTIDNFLHSLRRQNIAIEVDAFGTRNGTDDPSYNGAIIVSGDEKD
                   HRFSIACNTKRLNCFPVLLDVISNGLLGIFNSSEHIQTDRSTFFEEHMDYEYGYRSNT
                   FFWIPMAASFTPYIAMSSIGDYKVPAHSQLRISGLYPSAYWFGQALVDVSLYFLILLL
                   MQIMDYIFSPEEIIFIIQNLLIQVSGSNFEMVLLDYFFMNAVISLILNQRTSNYLCYC
                   IVLVVIFSIVATDLNEYGFLGLFFGTMLIPPFTLIGSLFIFSEVSSSTYSSRNKIVLL
                   PFICKRVGYLHFLIFLFILRCLEMNCRKKLMRKDPVFRISPRSNAIFPNPEEPEGEEE
                   DIQMERMRTVNAMAVRDFDETPVIIASCLRKEYAGKKKNCFSKRKKKIATRNVSFCVK
                   KGEVIGLLGHNGAGKSTTIKMITGDTKPTAGQVILKGSGGOEPLGFLCYCPQENALWP
                   NLTVRQHLEVYAAVKGLRKGDAMIAITRLVDALKLQDQLKAPVKTLSEGIKRKLCFVL
                   SILGNPSVVLLDEPSTGMDPEGQQQMWQVIRATFRNTERGALLTTHYMAEAEAVCDRV
                   AIMVSGRLRCIGSIQHLKSKFGKDYLLEMKLKNLAQMEPLHAEILRLFPQAAQQERFS
                   SLMVYKLPVEDVRPLSQAFFKLEIVKQSFDLEEYSLSQSTLEQVFLELSKEQELGDLE
                   EDFDPSVKWKLLLQEEP

[0565] Further analysis of the NOV46a protein yielded the following properties shown in Table 46B.

TABLE 46B
Protein Sequence Properties NOV46a
PSort     0.8000 probability located in plasma membrane; 0.6281
analysis: probability located in mitochondrial inner membrane;
          0.4410 probability located in mitochondrial intermembrane
          space; 0.4000 probability located in Golgi body
SignalP   Cleavage site between residues 54 and 55
analysis:

[0566] A search of the NOV46a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 46C.

TABLE 46C
Geneseq Results for NOV46a
		NOV46a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAM93187	Human polypeptide, SEQ ID NO: 2559 -	374 . . . 816	442/483 (91%)	0.0
	Homo sapiens, 483 aa. [EP1130094-	1 . . . 483	442/483 (91%)
	A2, 05-SEP-2001]
AAB67309	ABC transport related protein #3 -	1222 . . . 1583	330/362 (91%)	0.0
	Homo sapiens, 362 aa.	1 . . . 362	348/362 (95%)
	[WO200107658-A1, 01-FEB-2001]
AAU18484	Human endocrine polypeptide SEQ ID	1232 . . . 1534	216/303 (71%)	e−122
	No 439 - Homo sapiens, 310 aa.	9 . . . 309	253/303 (83%)
	[WO200155364-A2, 02-AUG-2001]
AAE09582	Human gene 2 encoded ABC	1232 . . . 1534	216/303 (71%)	e−122
	transporter protein HDPVY34, SEQ ID	9 . . . 309	253/303 (83%)
	NO: 24 - Homo sapiens, 310 aa.
	[WO200155208-A1, 02-AUG-2001]
AAM42360	Human polypeptide SEQ ID NO 93 -	1232 . . . 1534	216/303 (71%)	e−122
	Homo sapiens, 310 aa.	9 . . . 309	253/303 (83%)
	[WO200155449-A1, 02-AUG-2001]

[0567] In a BLAST search of public sequence databases, the NOV46a protein was found to have homology to the proteins shown in the BLASTP data in Table 46D.

TABLE 46D
Public BLASTP Results for NOV46a
		NOV46a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
AAK30024	ATP-BINDING CASSETTE A9 -	1 . . . 1583	1521/1629 (93%)	0.0
	Homo sapiens (Human), 1624 aa.	1 . . . 1624	1541/1629 (94%)
O94911	(Human), 1581 aa.	1 . . . 1581	1313/1588 (82%)	0.0
AAK30025	ATP-BINDING CASSETTE A10 -	91 . . . 1583	920/1557 (59%)	0.0
	Homo sapiens (Human), 1543 aa.	1 . . . 1543	1159/1557 (74%)
AAK30023	ATP-BINDING CASSETTE A6 -	1 . . . 1578	906/1630 (55%)	0.0
	Homo sapiens (Human), 1617 aa.	1 . . . 1611	1153/1630 (70%)
Q96MD8	CDNA FLJ32506 FIS, CLONE	1 . . . 816	809/856 (94%)	0.0
	SMINT1000042, WEAKLY SIMILAR	1 . . . 856	813/856 (94%)
	TO ATP-BINDING CASSETTE, SUB-
	FAMILY A, MEMBER 3 - Homo
	sapiens (Human), 856 aa (fragment).

[0568] PFam analysis indicates that the NOV46a protein contains the domains shown in the Table 46E.

TABLE 46E
Domain Analysis of NOV46a
		Identities/
		Similarities
Pfam Domain	NOV46a Match Region	for the Matched Region	Expect Value
Cyto_ox_2: domain 1 of 1	136 . . . 424	54/408 (13%)	7
		190/408 (47%)
PRK: domain 1 of 2	512 . . . 525	8/14 (57%)	14
		11/14 (79%)
ABC_tran: domain 1 of 2	510 . . . 652	56/199 (28%)	3.2e−25
		120/199 (60%)
biopterin_H: domain 1 of 1	719 . . . 732	7/16 (44%)	9.1
		10/16 (62%)
PRK: domain 2 of 2	1280 . . . 1299	10/20 (50%)	2.1
		15/20 (75%)
ABC_tran: domain 2 of 2	1278 . . . 1456	60/200 (30%)	1.6e−44
		139/200 (70%)

Example 47

[0569] The NOV47 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 47A.

TABLE 47A
NOV47 Sequence Analysis
                   SEQ ID NO:199        4766 bp
NOV47a,            CGAATAGGCTAAATGAATATGAAACAGAAAAGCGTGTATCAGCAAACCAAAGCACTTC
CG59909-01 DNA     TGTGCAAGAATTTTCTTAAGAAATGGAGGATGAAAAGAGAGAGCTTATTGGAATGGGG
Sequence           CCTCTCAATACTTCTAGGACTGTGTATTGCTCTGTTTTCCAGTTCCATGAGAAATGTC
                   CAGTTTCCTGGAATGGCTCCTCAGAATCTGCGAAGGGTAGATAAATTTAATAGCTCTT
                   CTTTAATGGTTGTGTATACACCAATATCTAATTTAACCCAGCACATAATGAATAAAAC
                   AGCACTTGCTCCTCTTTTGAAAGGTAGGAGTGTCATTGGGGCACCAAATAAAACACAC
                   ATGGACGAAATACTTCTGGAAAATTTACCATATGCTATGGGAATCATCTTTAATGAAA
                   CTTTCTCTTATAAGTTAATATTTTTCCAGGGATATAACAGTCCACTTTGGAAAGAAGA
                   TTTCTCAGGTACAGCTCATTGCTGGGATGGATATGGTGAGTTTTCATGTACATTGACC
                   AAATACTGGAATAGAGGATTTGTGGCTTTACAAACAGCTATTAATACTGCCATTATAG
                   AAATCACAACCAATCACCCTGTGATGGAGGAGTTGATGTCAGTTACTGCTATAACTAT
                   GAAGACATTACCTTTCATAACTAAAAATCTTCTTCACAATGAGATGTTTATTTTATTC
                   TTCTTGCTTCATTTCTCCCCACTTGTATATTTTATATCACTCAATGTAACAAAAGAGA
                   GAAAAAAGTCTAAGAATTTGATGAAAATGATGGGTCTCCAAGATTCAGCATTCTGGCT
                   CTCCTGGGGTCTAATCTATGCTGGCTTCATCTTTATTATTTCCATATTCGTTACAATT
                   ATCATAACATTCACCCAAATTATAGTCATGACTGGCTTCATGGTCATATTTATACTCT
                   TTTTTTTATATGGCTTATCTTTGGTAGCTTTGGTGTTCCTGATGAGTGTGCTGTTAAA
                   GAAAGCTGTCCTCACCAATTTGGTTGTGTTTCTCCTTACCCTCTTTTGGGGATCTCTG
                   GGATTCACTGTATTTTATGAACAACTTCCTTCATCTCTGGAGTGGATTTTGAATATTT
                   GTAGCCCTTTTGCCTTTACTACTGGAATGATTCAGGTAATCAAACTGGATTATAACTT
                   GAATGGTGTAATTTTTCCTGACCCTTCAGGAGACTCATATACAATGATAGCAACTTTT
                   TCTATGTTGCTTTTGGATGGTCTCATCTACTTGCTATTGGCATTATACTTTGACAAAA
                   TTGTTTCCAACACCAAAGGACTAATGCTAAGGTTATTGAGAAAGAAATCGATGCTGAG
                   CATCCCTCTGATGATTATTTTGAACCAGTAGCTCCTGAATTCCAACGAAAAGPAGCCA
                   TCAGAATCAGAAATGTTAAGAAGGAATATAAAGGAAAATCTGGAAAAGTGGAAGCATT
                   GAAAGGTTTGCTCTTTGACATATATGAAGGTCAAATCACGGCAATCCTGGGTCACAGT
                   GGAGCTGGCAAATCTTCACTGCTAAATATTCTTAATGGATTGTCTGTTCCAACAGAAG
                   GTTCAGTTACCATCTATAATAAAAATCTCTCTGAAATGCAAGACTTGGAGGAAATCAG
                   AAAGATAACTGGCGTCTGTCCTCAATTCAATGTTCAATTTGACATACTCACCGTGAAG
                   GAAAACCTCAGCCTGTTTGCTAAAATAAAAGGGATTCATCTAAAGGAAGTGGAACAAG
                   AGATTTTGCTTTTAGATGAACCAACTACTGGATTGGATCCCTTTTCCAGAGATCAAGT
                   GTGGACCCTCCTGAGAGAGCGTAGAGCAGATCATGTGATCCTTTTCAGTACCCAGTCC
                   ATGGATGAGGCTGACATCCTGGCTGATAGAAAAGTGATCATGTCCAATGGGAGACTGA
                   AGTGTGCAGGTTCTTCTATGTTTTTGAAAAGAAGGTGGGGTCTTGGATATCACCTAAG
                   TTTACATAGGAATGAAATATGTAACCCAGAACAAATAACATCCTTCATTACTCATCAC
                   ATCCCCGATGCTAAATTAAAAACAGAAAACAAAGAAAAGCTTGTATATACTTTGCCAC
                   TGGAAAGGACAAATACATTTCCAGATCTTTTCAGTGATCTGGATAAGTGTTCTGACCA
                   GGGAGTGACAGGTTATGACATTTCCATGTCAACTCTAAATGAAGTCTTTATGAAACTG
                   GAAGGACAGTCAACTATCGAACAAGGTAAAGCCATTTGTATAATTCACAGACAAGTGG
                   AGATGATAAGAGACTCAGAAAGCCTCAATGAAATGGAGCTGGCTCACTCTTCCTTCTC
                   TGAAATGCAGACAGCTGTGAGTGACATGGGCCTCTGGAGAATGCAAGTCTTTGCCATG
                   GCACGGCTCCGTTTCTTAAAGTTAAAACGTCAAACTAAAGTGTTATTGACCCTGTTAT
                   TGGTATTTGGAATCGCAATATTCCCTTTGATTGTTGAAAATATAATGTATGCTATGTT
                   AAATGAAAAGATCGATTGGGAATTTAAAAACGAATTGTATTTTCTCTCTCCTGGACAA
                   CTTCCCCAGGAACCCCGTACCAGCCTGTTGATCATCAATAACACAGGTTCAAATATTG
                   AAGATTTTATAAAATCACTGAAGCATCAAAATATACTTTTGGAAGTAGATGACTTTGA
                   AAACAGAAATGGTACTGATGGCCTCTCATACAATGGAGCTATCATAGTTTGTTTCTGT
                   TTTAAGGATTATAGATTTTCAGTTGTGTGTAATACCAAGAGATTGCACTGTTTTCCAA
                   TTCTTATGAATATTATCAGCAATGGGCTACTTCAAATGTTTAATCACACACAACATAT
                   TCGAATTGAGTCAAGCCCATTTAGCCACATAGCACTCTGGACTGGGTTGCCGGATGGT
                   TCCTTTTTCTTATTTTTGGTTCTATGTAGCATTTCTCCTTATATCACCATGGGCAGCA
                   TCAGTCATTACAAGGTAAGAGCTAAGTCCCAGCTATGGATTTCAGGCCTCTACACTTC
                   TGCTTACTGGTGTGGGCAGGCACTAGTGGACGTCACCTTCTTCATTTTAATTCTCCTT
                   TTAATGTATTTAATTTTCTACATAGAAAACATGCAGTACCTTCTTATTACATATTTCT
                   TTTATGCTCACGTTATAGTTACTCCTGGTTATGCAGCTTCTCTTGTCTTCTTCATATA
                   TATGATATCATTTATTTTTCGCAAAAGGAGAAAAAACAGTGGCCTTTGGTCATTTTAC
                   TTCTTTTTTGCCTCCACCATCATGTTTTCCATCACTTTAATCAATCATTTTGACCTAA
                   GTATATTGATTACCACCATGGTATTGGTTCCTTCATATACCTTGCTTGGATTTAAAAC
                   TTTTTTGGAAGTGAGAGACCAGGAGCACTACAGAGAATTGAGTGCCACTGATTTTCTA
                   GTCTGCTTCATACCCTACTTTCAGACTTTGCTATTCGTTTTTGTTCTAAGATGCATGG
                   AACTAAAATGTGGAAAGAAAAGAATGCGAAAAGATCCTGTTTTCAGGATTTCCCCCCA
                   AAGTAGAGATGCTAAGCCAAATCCAGAAGAACCCATAGATGAAGATGAAGATATTCAA
                   ACAGAAAGAATAAGAACAGCCACTGCTCTGACCACTTCAATCTTAGATGAGAAACCTG
                   TTATAATTGCCAGCTGTCTACACAAAGAATATGCAGGCCAGAAGAAAAGTTGCTTTTC
                   AAAGAGGAAGAAGAAAATAGCAGCAAGAAATATCTCTTTCTGTGTTCAAGAAGGTGAA
                   ATTTTGGGATTGCTAGGACCCAATGGTGCTGGAAAAAGTTCATCTATTAGAATCATAT
                   CTGGGATCACAAAGCCAACTGCTGGAGAGGTAGTGCTGAAAGGCTGCAGTTCAGTTTT
                   GGGCCACCTGGGGTACTGCCCTCAAGAGAACGTGCTGTGGCCCATGCTGACGTTGAGG
                   GAACACCTGGAGGTGTATGCTGCCGTCAAGGGGCTCAGGAAAGCGCACGCGAGGCTCG
                   CCATCGCAAGGAGATTAGTGAGTGCTTTCAAACTGCATGAGCAGCTGAATGTTCCTGT
                   GCAGAAATTAACAGCAGGAATCACGAGAAAGTTGTGTTTTGTGCTGAGCCTCCTGGGA
                   AACTCACCTGTCTTGCTCCTGGATGAACCATCTACGGGCATAGACCCCACAGGGCAGC
                   AGCAAATGTGGCAGGCAATCCAGGCAGTCGTTAAAAACACAGAGACAGGTGTCCTCCT
                   GACCACCCATAACCTGGCTGAGGCGGAAGCCTTGTGTGACCGTGTGGCCATCATGGTG
                   TCTGGAAGGCTTAGATGCATTGGCTCCATCCAACACCTGAAAAACAAACTTGGCAAGG
                   ATTACATTCTAGAGCTAAAAGTGAAGGAAACGTCTCAAGTGACTTTGGTCCACACTGA
                   GATTCTGAAGCTTTTCCCACAGGCTGCAGGGCAGGAAAGGTATTCCTCTTTGTTAACC
                   TATAAGCTGCCCGTGGCAGACGTTTACCCTCTATCACAGACCTTTCACAAATTAGAAG
                   CAGTGAAGCATAACTTTAACCTGGAAGAATACAGCCTTTCTCAGTGCACACTGGAGAA
                   GGTATTCTTAGAGCTTTCTAAAGAACAGGAAGTAGGAAATTTTGATGAAGAAATTGAT
                   ACAACAATGAGATGGAAACTCCTCCCTCATTCAGATGAACCTTAAAACCTCAAACCTA
                   GTAATTTTTT
                   ORF Start: ATG at 13 ORF Stop: TAA at 4741
                   SEQ ID NO:200        1576 aa MW at 179721.1 kD
NOV47a,            MNMKQKSVYQQTKALLCKNFLKKWRMKRESLLEWGLSILLGLCIALFSSSMRNVQFPG
CG59909-01 Protein MAPQNLGRTDKFNSSSLMVVYTPISNLTQQIMNKTALAPLLKGRSVIGAPNKTHMDEI
Sequence           LLENLPYAMGIIFNETFSYKLIFFQGYNSPLWKEDFSGTAHCWDGYGEFSCTLTKYWN
                   RGFVALQTAINTAIIEITTNHPVMEELMSVTAITMKTLPFITKNLLHNEMFILFFLLH
                   FSPLVYFISLNVTKERKKSKNLMKMMGLQDSAFWLSWGLIYAGFIFIISIFVTIIITF
                   TQIIVMTGFMVIFILFFLYGLSLVALVFLMSVLLKKAVLTNLVVFLLTLFWGCLGFTV
                   FYEQLPSSLEWILNICSPFAFTTGMIQVIKLDYNLNGVIFPDPSGDSYTMIATFSMLL
                   LDGLIYLLLALYFDKILPCKDERHYSPLFFLNSSSCFQHQRTNAKVIEKEIDAEHPSD
                   DYFEPVAPEFQCKEAIRIRNVKKEYKGKSGKVEALKGLLFDIYEGQITAILGHSGAGK
                   SSLLNILNGLSVPTEGSVTIYNKNLSEMQDLEEIRKITGVCPQFNVQFDILTVKENLS
                   LFAKIKGIHLKEVEQEILLLDEPTTGLDPFSRDQVWSLLRERRADHVILFSTQSMDEA
                   DILADRKVIMSNGRLKCAGSSMFLKRRWGLGYHLSLHRNEICNPEQITSFITHHIPDA
                   KLKTENKEKLVYTLPLERTNTFPDLFSDLDKCSDQCVTGYDISMSTLNEVFMKLEGQS
                   TIEQGKAICIIHRQVEMIRDSESLNEMELAHSSFSEMQTAVSDMGLWRMQVFAMARLR
                   FLKLKRQTKVLLTLLLVFGIAIFPLIVENIMYAMLNEKIDWEFKNELYFLSPGQLPQE
                   PRTSLLIINNTGSNIEDFIKSLKHQNILLEVDDFENRNGTDGLSYNGAIIVCFCFKDY
                   RFSVVCNTKRLHCFPILMNIISNGLLQMFNHTQHIRIESSPFSHIGLWTGLPDGSFFL
                   FLVLCSISPYITMCSISDYKVRAKSQLWISGLYTSAYWCGQALVDVSFFILILLLMYL
                   IFYIENMQYLLITYFFYAQVIVTPGYAASLVFFIYMISFIFRKRRKNSGLWSFYFFFA
                   STIMFSITLINHFDLSILITTMVLVPSYTLLGFKTFLEVRDQEHYRELSATDFLVCFI
                   PYFQTLLFVFVLRCMELKCGKKRMRKDPVFRISPQSRDAKPNPEEPIDEDEDIQTERI
                   RTATALTTSILDEKPVIIASCLHKEYAGQKKSCFSKRKKKIAARNISFCVQEGEILGL
                   LGPNGAGKSSSIRMISGITKPTAGEVVLKGCSSVLGHLGYCPQENVLWPMLTLREHLE
                   VYAAVKGLRKADARLAIARRLVSAFKLHEQLNVPVQKLTAGITRKLCFVLSLLGNSPV
                   LLLDEPSTGIDPTCQQQMWQAIQAVVKNTERGVLLTTHNLAEAEALCDRVAIMVSGRL
                   RCIGSIQHLKNKLGKDYILELKVKETSQVTLVHTEILKLFPQAAGQERYSSLLTYKLP
                   VADVYPLSQTFHKLEAVKHNFNLEEYSLSQCTLEKVFLELSKEQEVGNFDEEIDTTMR
                   WKLLPHSDEP

[0570] Further analysis of the NOV47a protein yielded the following properties shown in Table 47B.

TABLE 47B
Protein Sequence Properties NOV47a
PSort     0.8000 probability located in plasma membrane; 0.4000
analysis: probability located in Golgi body; 0.3000 probability located
          in endoplasmic reticulum (membrane); 0.3000 probability
          located in microbody (peroxisome)
SignalP   Cleavage site between residues 51 and 52
analysis:

[0571] A search of the NOV47a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 47C.

TABLE 47C
Geneseq Results for NOV47a
		NOV47a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAU18484	Human endocrine polypeptide SEQ ID	1229 . . . 1526	294/298 (98%)	e−164
	No 439 - Homo sapiens, 310 aa.	13 . . . 309	294/298 (98%)
	[WO200155364-A2, 02-AUG-2001]
AAE09582	Human gene 2 encoded ABC	1229 . . . 1526	294/298 (98%)	e−164
	transporter protein HDPVY34, SEQ ID	13 . . . 309	294/298 (98%)
	NO: 24 - Homo sapiens, 310 aa.
	[WO200155208-A1, 02-AUG-2001]
AAM42360	Human polypeptide SEQ ID NO 93 -	1229 . . . 1526	294/298 (98%)	e−164
	Homo sapiens, 310 aa.	13 . . . 309	294/298 (98%)
	[WO200155449-A1, 02-AUG-2001)
AAM93187	Human polypeptide, SEQ ID NO: 2559 -	373 . . . 815	273/483 (56%)	e−149
	Homo sapiens, 483 aa. [EP1130094-	1 . . . 483	339/483 (69%)
	A2, 05-SEP-2001]
AAB67309	ABC transport related protein #3 -	1216 . . . 1574	256/361 (70%)	e−146
	Homo sapiens, 362 aa.	2 . . . 361	303/361 (83%)
	[WO200107658-A1, 01-FEB-2001]

[0572] In a BLAST search of public sequence databases, the NOV47a protein was found to have homology to the proteins shown in the BLASTP data in Table 47D.

TABLE 47D
Public BLASTP Results for NOV47a
		Residues/
Accession		Match	Similarities for the
Number	Protein/Organism/Length	Residues	Matched Portion	Value
AAK30023	ATP-BINDING CASSETTE A6 -	1 . . . 1576	1544/1626 (94%)	0.0
	Homo sapiens (Human), 1617 aa.	1 . . . 1617	1549/1626 (94%)
O94911	KIAA0822 PROTEIN - Homo	1 . . . 1574	929/1581 (58%)	0.0
	sapiens (Human), 1581 aa.	1 . . . 1580	1149/1581 (71%)
AAK30025	ATP-BINDING CASSETTE A10 -	90 . . . 1574	922/1543 (59%)	0.0
	Homo sapiens (Human), 1543	1 . . . 1542	1126/1543 (72%)
	aa.
AAK30024	ATP-BINDING CASSETTE A9 -	1 . . . 1570	917/1620 (56%)	0.0
	Homo sapiens (Human), 1624 aa.	1 . . . 1619	1162/1620 (71%)
AAK30022	ATP-BINDING CASSETTE A5 -	3 . . . 1568	653/1651 (39%)	0.0
	Homo sapiens (Human), 1642 aa.	5 . . . 1633	969/1651 (58%)

[0573] PFam analysis indicates that the NOV47a protein contains the domains shown in the Table 47E.

TABLE 47E
Domain Analysis of NOV47a
		Identities/
	NOV47a	Similarities
	Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
Peptidase_S26: domain 1	1 . . . 46	14/47 (30%)	7.9
of 1		35/47 (74%)
Virus_HS: domain 1 of 1	169 . . . 174	4/6 (67%)	2.1
		6/6 (100%)
ABC_tran: domain 1 of 2	509 . . . 651	58/199 (29%)	4.7e−26
		117/199 (59%)
7tm_1: domain 1 of 1	1053 . . . 1085	6/34 (18%)	0.46
		25/34 (74%)
ABC_tran: domain 2 of 2	1271 . . . 1448	59/199 (30%)	8.7e−44
		137/199 (69%)

Example 48

[0574] The NOV48 clone was analyzed, and the nucleotide and polypeptide sequences are shown in Table 48A.

TABLE 48A
NOV48 Sequence Analysis
                   SEQ ID NO:201        1599 bp
NOV48a,            CGCAGCAGTTTGTGTTCCCTGATGGAAAATGAAGCCTCATCTACTGACTCTCCCATCC
CG59945-01 DNA     AAAAAGACTTGAGGGCAAACGAGGACAAAAGTTCCCACGAGGTGGGCACTGCGGGAAG
Sequence           GAGGCCCACGACCCCGAGATTCTCCGGCGACCCCGGCGGGCCACCCCGGGCCGGTGAG
                   GGTTCCCGCGGCACGTGTGCGGCGGCGCCCGCCGCTTCCCCCGCCGCCCGGGAAGGTC
                   ACGCCGCCCGGACGCCGAGGCTCTCCCCGTGCCCCGCTCCCTCCGCCCCGCACACTCC
                   CGTGACCAGCCCCATCTCCAGCCAGGTGGTGGGCAGTGAGCCACTACAGTACATCATG
                   GCAGAGCCGGCCAGGCCTGACAGTCCAAAGGGCTCCTCGGAGACAGAGACCGAGCCTC
                   CTGTGGCCCTGGCCCCTGGTCCAGCTCCCACCCACTGCCTCCCAGGCCACAAGGAAGA
                   GGAGGATGGGGAGGGGGCTGGGCCTGGCGAGCAGGGCGGTGGGAAGCTGGTGCTCAGC
                   TCCCTGTCCAAGCGCCTCTGCCTGGTCTGTGGGGACGTGGCCTCCGGCTACCACTGCG
                   GTGTGTCATCCTGTGAGGACTGCAAAGCCTTCTTCAAGAGGACCATCCAGCCCAGTAT
                   GGAGTACAGCTGTCTGGCCTCCAACGAGTGTGAGATCACCAAGCGGAGACGCAACCCC
                   TGTCAGGCCTGCCGCTTCACCAAGAGCCTGCGGCTTCACCAAGAGCCTGCGGGAGCCC
                   GCCTGGACCGCGTCCGGGGTGGGCGGGAGTACAAGCCGTGCCCAGAGGTGGACCCGCT
                   GCCCTTCCCGGGCGCCTTCCCTGCTGGGCCCCTGGCAGTCGCTGGAGGCCCCCAGACG
                   ACAGGCCCAGTGAATGCACTGGTGTCTCATCTAATGGTGGTTGAGCCTGAGAAGCTCT
                   ATGCCTTGCCCGACCCTGCTGGCCCTGATGGGCACCTTCCAGCCGTGGCTACCCTCTG
                   TGACCTCTTTGACCGAGAGATCGTGGTCACCATCAGCTGGGCCAAGAGCATCCCACGC
                   TTCTCATCGCTGTCGCTGTCTGACCAGATGTCAGTACTGCAGAGAGTATGGATGGAGG
                   TGCTGGTGCCGGGTGTGGCCCAGCGCTCACTGCCACTGCAGGATGAGTTGGCCTTCGC
                   TGAGGACTTAGTCCTGGATGAACAGGGGGCACGGGCAGCTGGCCTGGGGGAACTGGGG
                   GCTGCCCTGCTGCAACTGGTGCGGCGGCTGCAGTCCCTGCGGCTGGAGCGAGGGGAGT
                   ACGTTCTACTGAAGGCCCTGGCCCTTGCCAATTCAGACTCTGTGCCCATCGAAGATGC
                   CGAGGCTGTGGAGCAGCTGCCAGAAGCTCCGCACGAGGCCCTGCTGGAGTATGAAGCC
                   GGCCGAGCTGGCACCGGAGGGGGTGCTGAGCGGCGGCGGCCACGCAGGCTGCTGTTCA
                   CGCTACCGCTCCTCCACCAGACAGCGGGCAAAGTGCTGGCCCATTTCTATGGGGTGAA
                   GCTGGAGGGCAAGGTGCCCATGCACAAGCTGTTCTTGGAGATGCTCGAGGCCATGATG
                   GACTGA+E, UNS GGCGAGGGGTGGGACTGGTGGGGGTTC
                   ORF Start: ATG at 22 ORF Stop: TGA at 1570
                   SEQ ID NO:202        516 aa MW at 54706.5 kD
NOV48a,            MENEASSTDSPIQKDLRAKEDKSSHEVGTAGRRPTTPRFSGDPGGPPRGGEGSRGTCA
CG59945-01 Protein AAPAASPAAREGHAARTPRLSPCPAPSAPHTPVTSAMSSQVVGSEPLQYIMAEPARPD
Sequence           SPKGSSETETEPPVALAPGPAPTHCLPGHKEEEDGEGAGPGEQGGGKLVLSSLSKRLC
                   LVCGDVASCYHCCVSSCEDCKAFFKRTIQGSMEYSCLASNECEITKRRRKACQACRFT
                   KSLRLHQEPAGARLDRVRGGREYKRCPEVDPLPFPGAFPAGPLAVAGGPQTTGPVNAL
                   VSHLMVVEPEKLYALPDPAGPDGHLPAVATLCDLFDREIVVTISWAKSIPGFSSLSLS
                   DQMSVLQRVWMEVLVPGVAQRSLPLQDELAFAEDLVLDEEGARAAGLGELGAALLQLV
                   RRLQSLRLERGEYVLLKALALANSDSVPTEDAEAVEQLPEAPHEALLEYEAGRAGTGG
                   GAERRRPGRLLFTLPLLHQTAGKVLAHFYGVKLEGKVPMHKLFLEMLEAMMD

[0575] Further analysis of the NOV48a protein yielded the following properties shown in Table 48B.

TABLE 48B
Protein Sequence Properties NOV48a
PSort     0.7000 probability located in nucleus; 0.3000 probability
analysis: located in microbody (peroxisome); 0.1000 probability located
          in mitochondrial matrix space; 0.1000 probability located in
          lysosome (lumen)
SignalP   No Known Signal Sequence Indicated
analysis:

[0576] A search of the NOV48a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 48C.

TABLE 48C
Geneseq Results for NOV48a
		NOV48a	Identities/
		Residues/	Similarities for
Geneseq	Protein/Organism/Length [Patent #,	Match	the Matched	Expect
Identifier	Date]	Residues	Region	Value
AAM39411	Human polypeptide SEQ ID NO 2556 -	4 . . . 516	418/520 (80%)	0.0
	Homo sapiens, 552 aa.	36 . . . 552	432/520 (82%)
	[WO200153312-A1, 26-JUL-2001]
AAP80930	Sequence of human estrogen-related	4 . . . 516	409/521 (78%)	0.0
	receptor protein (hERR1) - Homo	4 . . . 521	425/521 (81%)
	sapiens, 521 aa. [WO8803168-A, 05-
	MAY-1988]
AAM41197	Human polypeptide SEQ ID NO 6128 -	4 . . . 516	406/521 (77%)	0.0
	Homo sapiens, 556 aa.	39 . . . 556	422/521 (80%)
	[WO200153312-A1, 26-JUL-2001]
AAY83822	Human nuclear receptor nNR1 - Homo	100 . . . 513	227/438 (51%)	e−115
	sapiens, 500 aa. [US6054295-A, 25-	8 . . . 431	287/438 (64%)
	APR-2000]
AAB12970	Human oestrogen related receptor 4	100 . . . 513	227/438 (51%)	e−115
	(ERR4) protein sequence - Homo	8 . . . 431	287/438 (64%)
	sapiens, 433 aa. [WO200042180-A1,
	20-JUL-2000]

[0577] In a BLAST search of public sequence databases, the NOV48a protein was found to have homology to the proteins shown in the BLASTP data in Table 48D.

TABLE 48D
Public BLASTP Results for NOV48a
		NOV48a	Identities/
Protein		Residues/	Similarities for
Accession		Match	the Matched	Expect
Number	Protein/Organism/Length	Residues	Portion	Value
P11474	Steroid hormone receptor ERR1	4 . . . 516	418/519 (80%)	0.0
	(Estrogen-related receptor, alpha) (ERR-	4 . . . 519	432/519 (82%)
	alpha) (Estrogen receptor-like 1) - Homo
	sapiens (Human), 519 aa.
A29345	precursor - human, 521 aa.	4 . . . 521	425/521 (81%)	0.0
E1262508	SEQUENCE 18 FROM PATENT	4 . . . 513	404/518 (77%)	0.0
	WO9709348 - Homo sapiens (Human),	4 . . . 518	421/518 (80%)
	518 aa.
O08580	Steroid hormone receptor ERR1	66 . . . 516	393/463 (84%)	0.0
	(Estrogen-related receptor, alpha) (ERR-	2 . . . 462	404/463 (86%)
	alpha) (Estrogen receptor-like 1) - Mus
	musculus (Mouse), 462 aa (fragment).
Q96102	UNKNOWN (PROTEIN FOR	199 . . . 516	289/320 (90%)	e−158
	IMAGE: 4301880) - Homo sapiens	4 . . . 323	296/320 (92%)
	(Human), 323 aa (fragment).

[0578] PFam analysis indicates that the NOV48a protein contains the domains shown in the Table 48E.

TABLE 48E
Domain Analysis of NOV48a
		Identities/
		Similarities
	NOV48a Match	for the Matched	Expect
Pfam Domain	Region	Region	Value
zf-C4: domain 1 of 1	172 . . . 233	35/63 (56%)	9.3e−36
		58/63 (92%)
hormone_rec: domain 1	326 . . . 511	58/209 (28%)	2.2e−30
of 1		136/209 (65%)

Example B

[0579] Identification of NOVX Clones

[0580] The novel NOVX target sequences identified in the present invention may have been subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain—amygdala, brain—cerebellum, brain—hippocampus, brain—substantia nigra, brain—thalamus, brain—whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma—Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.

[0581] Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2. 1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

Example C

Quantitative Expression Analysis of Clones in Various Cells and Tissues

[0582] The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoimmune diseases), Panel CNSD.01 (containing central nervous system samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer's diseased brains).

[0583] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

[0584] First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.

[0585] In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 μg of total RNA were performed in a volume of 20 μl and incubated for 60 minutes at 42° C. This reaction can be scaled up to 50 μg of total RNA in a final volume of 100 μl . sscDNA samples are then normalized to reference nucleic acids as described previously, using 1× TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

[0586] Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration=250 nM, primer melting temperature (Tm) range=58°-60° C., primer optimal Tm=59° C., maximum primer difference=2° C., probe does not have 5′G, probe Tm must be 10° C. greater than primer Tm, amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, Tex., USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5′ and 3′ ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200 nM.

[0587] PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 48° C. for 30 minutes followed by amplification/PCR cycles as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

[0588] When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1× TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification was performed as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were analyzed and processed as described previously.

[0589] Panels 1, 1.1, 1.2, and 1.3D

[0590] The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

[0591] In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:

[0592] ca.=carcinoma,

[0593] *=established from metastasis,

[0594] met=metastasis,

[0595] s cell var=small cell variant,

[0596] non-s=non-sm=non-small,

[0597] squam=squamous,

[0598] pl. eff pl effusion=pleural effusion,

[0599] glio=glioma,

[0600] astro=astrocytoma, and

[0601] neuro=neuroblastoma.

[0602] General_Screening_Panel_v1.4

[0603] The plates for Panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panel 1.4 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panel 1.4 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panel 1.4 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.

[0604] Panels 2D and 2.2

[0605] The plates for Panels 2D and 2.2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have “matched margins” obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted “NAT” in the results below. The tumor tissue and the “matched margins” are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, Calif.), Research Genetics, and Invitrogen.

[0606] Panel 3D

[0607] The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.

[0608] Panels 4D, 4R, and 4.1D

[0609] Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D)/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, Calif.) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, Calif.). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, Pa.).

[0610] Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, Md.) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

[0611] Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco/Life Technologies, Rockville, Md.), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μg/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10−5M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.

[0612] Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, Utah), 100 μnon essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μg/ml for 6 and 12-14 hours.

[0613] CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) and plated at 106 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μg/ml anti-CD28 (Pharmingen) and 3 ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethaniol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

[0614] To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μg/ml or anti-CD40 (Pharmingen) at approximately 10 μg/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24, 48 and 72 hours.

[0615] To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μg/ml anti-CD28 (Pharmingen) and 2 μg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, Md.) were cultured at 105-106 cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μg/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μg/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μg/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

[0616] The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×105 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×105 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10−5M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

[0617] For these cell lines and blood cells, RNA was prepared by lysing approximately 107 cells/ml using Trizol (Gibco BRL). Briefly, {fraction (1/10)} volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at −20° C. overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μl of RNAse-free water and 35 μl buffer (Promega) 5 μl DTT, 7 μl RNAsin and 8 μl DNAse were added. The tube was incubated at 37° C. for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with {fraction (1/10)}volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at −80° C.

[0618] AI_Comprehensive Panel_v1.0

[0619] The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, Md). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.

[0620] Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

[0621] Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.

[0622] Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.

[0623] Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-1anti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

[0624] In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:

[0625] AI=Autoimmunity

[0626] Syn=Synovial

[0627] Normal=No apparent disease

[0628] Rep22 /Rep20=individual patients

[0629] RA=Rheumatoid arthritis

[0630] Backus=From Backus Hospital

[0631] OA=Osteoarthritis

[0632] (SS) (BA) (MF)=Individual patients

[0633] Adj=Adjacent tissue

[0634] Match control=adjacent tissues

[0635] -M=Male

[0636] -F=Female

[0637] COPD=Chronic obstructive pulmonary disease

[0638] Panels 5D and 5I

[0639] The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

[0640] In the Gestational Diabetes study subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:

Patient 2   Diabetic Hispanic, overweight, not on insulin
Patient 7-9 Nondiabetic Caucasian and obese (BMI > 30)
Patient 10  Diabetic Hispanic, overweight, on insulin
Patient 11  Nondiabetic African American and overweight
Patient 12  Diabetic Hispanic on insulin

[0641] Adipocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr. 2 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:

[0642] Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose

[0643] Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated

[0644] Donor 2 and 3 AD: Adipose, Adipose Differentiated

[0645] Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.

[0646] Panel 51 contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 51.

[0647] In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:

[0648] GO Adipose=Greater Omentum Adipose

[0649] SK=Skeletal Muscle

[0650] UT=Uterus

[0651] PL=Placenta

[0652] AD=Adipose Differentiated

[0653] AM=Adipose Midway Differentiated

[0654] U=Undifferentiated Stem Cells

[0655] Panel CNSD.01

[0656] The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathlology.

[0657] Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supernuclear Palsy, Depression, and “Normal controls”. Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

[0658] In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

[0659] PSP=Progressive supranuclear palsy

[0660] Sub Nigra=Substantia nigra

[0661] Glob Palladus=Globus palladus

[0662] Temp Pole=Temporal pole

[0663] Cing Gyr=Cingulate gyrus

[0664] BA 4=Brodman Area 4

[0665] Panel CNS_Neurodegeneration_V1.0

[0666] The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

[0667] Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from “Normal controls” who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0=no evidence of plaques, 3=severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a “control” region within AD patients. Not all brain regions are represented in all cases.

[0668] In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:

[0669] AD=Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy

[0670] Control=Control brains; patient not demented, showing no neuropathology

[0671] Control (Path)=Control brains; patient not demented but showing sever AD-like pathology

[0672] SupTemporal Ctx=Superior Temporal Cortex

[0673] Inf Temporal Ctx=Inferior Temporal Cortex

A. NOV1a (CC58546-01: ADILICAN)

[0674] Expression of gene CG58546-01 was assessed using the primer-probe sets Ag2933, Ag3370 and Ag3837, described in Tables AA, AB and AC.

TABLE AA
Probe Name Ag2933
			Start
Primers	Sequences	Length	Position
Forward	5′-caccaccactaagccagaac-3′	(SEQ ID NO:203)	20	4546
Probe	TET-5′-ttctcagtccaagaacatctcaaatatgt-3′-TAMRA	(SEQ ID NO:204)
Reverse	5′-ggattccccatgtaattcaag-3′	(SEQ ID NO:205)	21	4618

[0675]

TABLE AB
Probe Name Ag3370
			Start
Primers	Sequences	Length	Position
Forward	5′-agctggattcttccaaacaga-3′	(SEQ ID NO:206)	21	1844
Probe	TET-5′-tcacatgtatacatgctgccaaatgg-3′-TAMRA	(SEQ ID NO: 207)	26	1892
Reverse	5′-acctttgggatggaaagagtt-3′	(SEQ ID NO:208)	21	1918

[0676]

TABLE AC
Probe Name Ag3837
			Start
Primers	Sequences	Length	Position
Forward	5′-acgagcttgaggatgtggat-3′	(SEQ ID N0:209)	20	4260
Probe	TET-5′-ttttgtcctctgtgacagtctccaca-3′-TAMRA	(SEQ ID NO:210)	26	4293
Reverse	5′-gcttcttcctggtgaaatgg-3′	(SEQ ID N0:211)	20	4319

[0677] CNS_neurodegeneration_v1.0 Summary: Ag2933/Ag3370 Expression of the CG58546-01 gene is low/undetectable (CTs>35) across all of the samples on this panel.

[0678] General_screening_panel_v1.4 Summary: Ag3370/Ag3837 The amp plots suggest that there were experimental difficulties with these runs.

[0679] Panel 1.3D Summary: Ag2933 Expression of the CG58546-01 gene is low/undetectable (CTs>35) across all of the samples on this panel.

B. NOV2a and NOV2b (CG58598-01 and CG58598-02: BRAIN-SPECIFIC TM PROTEIN)

[0680] Expression of genes CG58598-01 and CG58598-02 was assessed using the primer-probe set Ag3383, described in Table BA. Results of the RTQ-PCR runs are shown in Tables BB, BC, and BD. Please note that CG58598-02 represents a full-length physical clone of the CG58598-01 gene, validating the prediction of the gene sequence.

TABLE BA
Probe Name Ag3383
			Start
Primers	Sequences	Length	Position
Forward	5′-ttcatqggagtgaggatagttg-3′	(SEQ ID NO:212)	22	367
Probe	TET-5′-ctgcaataatggcaattaccggcatt-3′-TAMRA	(SEQ ID NO:213)	26	389
Reverse	5′-cgtggaaattatctgcatatgc-3′	(SEQ ID NO:214)	22	424

[0681]

TABLE BB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3383,		Rel. Exp.(%) Ag3383,
Tissue Name	Run 210154822	Tissue Name	Run 210154822
AD 1 Hippo	0.0	Control (Path) 3	0.0
		Temporal Ctx
AD 2 Hippo	15.9	Control (Path) 4	15.2
		Temporal Ctx
AD 3 Hippo	1.8	AD 1 Occipital Ctx	8.1
AD 4 Hippo	0.0	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 Hippo	80.7	AD 3 Occipital Ctx	2.2
AD 6 Hippo	3.0	AD 4 Occipital Ctx	11.9
Control 2 Hippo	26.2	AD 5 Occipital Ctx	40.9
Control 4 Hippo	4.4	AD 6 Occipital Ctx	11.9
Control (Path) 3	0.0	Control 1 Occipital	0.0
Hippo		Ctx
AD 1 Temporal Ctx	0.0	Control 2 Occipital	100.0
		Ctx
AD 2 Temporal Ctx	8.4	Control 3 Occipital	7.2
		Ctx
AD 3 Temporal Ctx	0.0	Control 4 Occipital	0.0
		Ctx
AD 4 Temporal Ctx	3.3	Control (Path) 1	45.4
		Occipital Ctx
AD 5 Inf Temporal	13.6	Control (Path) 2	3.5
Ctx		Occipital Ctx
AD 5 Sup Temporal	6.5	Control (Path) 3	0.0
Ctx		Occipital Ctx
AD 6 Inf Temporal	8.5	Control (Path) 4	4.4
Ctx		Occipital Ctx
AD 6 Sup Temporal	0.0	Control 1 Parietal	0.0
Ctx		Ctx
Control 1 Temporal	0.0	Control 2 Parietal	7.5
Ctx		Ctx
Control 2 Temporal	24.1	Control 3 Parietal	12.9
Ctx		Ctx
Control 3 Temporal	9.3	Control (Path) 1	28.1
Ctx		Parietal Ctx
Control 3 Temporal	0.0	Control (Path) 2	9.2
Ctx		Parietal Ctx
Control (Path) 1	21.6	Control (Path) 3	0.0
Temporal Ctx		Parietal Ctx
Control (Path) 2	8.5	Control (Path) 4	19.8
Temporal Ctx		Parietal Ctx

[0682]

TABLE BC
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3383,		Rel. Exp.(%) Ag3383,
Tissue Name	Run 213496699	Tissue Name	Run 213496699
Adipose	0.0	Renal ca. TK-10	0.0
Melanoma*	0.0	Bladder	0.3
Hs688(A).T
Melanoma*	0.0	Gastric ca. (liver met.)	0.0
Hs688(B).T		NCI-N87
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma*	0.0	Colon ca. SW-948	0.0
LOXIMVI
Melanoma* SK-	0.0	Colon ca. SW480	0.0
MEL-5
Squamous cell	0.2	Colon ca.* (SW480	0.0
carcinoma SCC-4		met) SW620
Testis Pool	2.8	Colon ca. HT29	0.0
Prostate ca.* (bone	0.3	Colon ca. HCT-116	0.0
met) PC-3
Prostate Pool	5.7	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	0.0
Uterus Pool	0.3	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	0.0	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	3.8
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	0.0
Ovarian ca. IGROV-1	0.6	Stomach Pool	0.0
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	1.8
Ovary	0.0	Fetal Heart	0.0
Breast ca. MCF-7	0.0	Heart Pool	1.4
Breast ca. MDA-	0.0	Lymph Node Pool	2.7
MB-231
Breast ca. BT 549	0.2	Fetal Skeletal Muscle	0.4
Breast ca. T47D	0.0	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	0.0	Spleen Pool	0.0
Breast Pool	3.3	Thymus Pool	0.7
Trachea	0.6	CNS cancer (glio/astro)	53.6
		U87-MG
Lung	0.0	CNS cancer (glio/astro)	0.0
		U-118-MG
Fetal Lung	0.0	CNS cancer (neuro; met)	0.0
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	0.0
		539
Lung ca. LX-1	3.4	CNS cancer (astro)	0.0
		SNB-75
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-	0.0
		19
Lung ca. SHP-77	54.0	CNS cancer (glio) SF-	0.3
		295
Lung ca. A549	0.0	Brain (Amygdala) Pool	1.6
Lung ca. NCI-H526	79.0	Brain (cerebellum)	100.0
Lung ca. NCI-H23	0.0	Brain (fetal)	9.9
Lung ca. NCI-H460	0.0	Brain (Hippocampus)	6.3
		Pool
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	4.6
Lung ca. NCI-H522	0.0	Brain (Substantia nigra)	3.5
		Pool
Liver	0.0	Brain (Thalamus) Pool	5.6
Fetal Liver	0.0	Brain (whole)	15.4
Liver ca. HepG2	0.0	Spinal Cord Pool	6.8
Kidney Pool	6.9	Adrenal Gland	0.0
Fetal Kidney	7.7	Pituitary gland Pool	0.4
Renal ca. 786-0	0.0	Salivary Gland	0.0
Renal ca. A498	0.0	Thyroid (female)	11.4
Renal ca. ACHN	26.4	Pancreatic ca. CAPAN2	0.4
Renal ca. UO-31	0.6	Pancreas Pool	2.8

[0683]

TABLE BD
Panel CNS_1
	Rel. Exp.(%) Ag3383,		Rel. Exp.(%) Ag3383,
Tissue Name	Run 171787529	Tissue Name	Run 171787529
BA4 Control	0.0	BA17 PSP	2.7
BA4 Control2	12.1	BA17 PSP2	0.0
BA4	0.0	Sub Nigra Control	0.0
Alzheimer's2
BA4 Parkinson's	0.0	Sub Nigra Control2	16.5
BA4	15.5	Sub Nigra	4.1
Parkinson's2		Alzheimer's2
BA4	8.2	Sub Nigra	25.5
Huntington's		Parkinson's2
BA4	0.0	Sub Nigra	30.4
Huntington's2		Huntington's
BA4 PSP	0.0	Sub Nigra	0.0
		Huntington's2
BA4 PSP2	5.5	Sub Nigra PSP2	0.0
BA4 Depression	0.0	Sub Nigra	0.0
		Depression
BA4	0.0	Sub Nigra	9.5
Depression2		Depression2
BA7 Control	4.1	Glob Palladus	0.0
		Control
BA7 Control2	4.1	Glob Palladus	5.8
		Control2
BA7	0.0	Glob Palladus	5.3
Alzheimer's2		Alzheimer's
BA7 Parkinson's	0.0	Glob Palladus	0.0
		Alzheimer's2
BA7	100.0	Glob Palladus	18.3
Parkinson's2		Parkinson's
BA7	0.0	Glob Palladus	0.0
Huntington's		Parkinson's2
BA7	0.0	Glob Palladus PSP	3.7
Huntington's2
BA7 PSP	0.0	Glob Palladus PSP2	0.0
BA7 PSP2	6.2	Glob Palladus	0.0
		Depression
BA7 Depression	0.0	Temp Pole Control	0.0
BA9 Control	0.0	Temp Pole Control2	0.0
BA9 Control2	18.4	Temp Pole	0.0
		Alzheimer's
BA9 Alzheimer's	0.0	Temp Pole	0.0
		Alzheimer's2
BA9	5.4	Temp Pole	0.0
Alzheimer's2		Parkinson's
BA9 Parkinson's	0.0	Temp Pole	0.0
		Parkinson's2
BA9	14.2	Temp Pole	5.0
Parkinson's2		Huntington's
BA9	0.0	Temp Pole PSP	0.0
Huntington's
BA9	0.0	Temp Pole PSP2	0.0
Huntington's2
BA9 PSP	0.0	Temp Pole	0.0
		Depression2
BA9 PSP2	0.0	Cing Gyr Control	0.0
BA9 Depression	0.0	Cing Gyr Control2	0.0
BA9	0.0	Cing Gyr Alzheimer's	0.0
Depression2
BA17 Control	8.4	Cing Gyr	0.0
		Alzheimer's2
BA17 Control2	9.0	Cing Gyr Parkinson's	0.0
BA17	0.0	Cing Gyr	0.0
Alzheimer's2		Parkinson's2
BA17	5.7	Cing Gyr	0.0
Parkinson's		Huntington's
BA17	17.3	Cing Gyr	0.0
Parkinson's2		Huntington's2
BA17	12.0	Cing Gyr PSP	4.5
Huntington's
BA17	0.0	Cing Gyr PSP2	0.0
Huntington's2
BA17	0.0	Cing Gyr Depression	0.0
Depression
BA17	4.1	Cing Gyr	0.0
Depression2		Depression2

[0684] CNS_neurodegeneration_v1.0 Summary: Ag3383 This panel confirms the expression of the CG58598-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. The brain preferential expression of this novel protein in both this panel and panel 1.4 suggests that this protein product may be a drug target for the treatment of neurologic disorders.

[0685] General_screening_panel_v1.4 Summary: Ag3383 Expression of the CG58598-01 gene appears to be preferential to the brain, with the highest level of expression in the cerebellum (CT=30.2). Please see Panel CNS_neurodegeneration_v1.0 for discussion of utility in the central nervous system. There is also expression in the CNS cancer cell line U87-MG (CT=3.1) but no expression in any other CNS cancer cell line. Therefore, expression of this gene can be used to distinguish between the U87-MG cell line and other CNS cancer cell lilies on this panel.

[0686] Additionally, there is low to moderate expression of this gene in renal and lung cancer cell lines. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.

[0687] Panel 2.2 Summary: Ag3383—Expression of the CG58598-01 gene is low/undetectable (CTs>35) across all of the samples on this panel.

[0688] Panel 4D Summary: Ag3383—Expression of the CG58598-01 gene is low/undetectable (CTs>35) across all of the samples on this panel.

[0689] Panel CNS—1 Summary: Ag3383 Expression in this panel confirms expression of the CG58598-01 gene in the brain. Please see Panel CNS_neurodegeneration_v1.0 for discussion of utility in the central nervous system.

C. NOV3a (CG57833-01: AMINO ACID TRANSPORTER)

[0690] Expression of gene CG57833-01 was assessed using the primer-probe set Ag3341, described in Table CA. Results of the RTRQ-PCR runs are shown in Tables CB and CC.

TABLE CA
Probe Name Ag3341
			Start
Primers	Sequences	Length	Position
Forward	5′-aacactaactgtgcccattgtc-3′	(SEQ ID NO:215)	22	1284
Probe	TET-5′-tcccaattcgtacatcagtgatcaca-3′-TAMRA	(SEQ ID NO:216)	26	1310
Reverse	5′-gaaatgtcgtatccagctgaag-3′	(SEQ ID NO:217)	22	1356

[0691]

TABLE CB
Panel 1.3D
	Rel. Exp.(%) Ag3341,		Rel. Exp.(%) Ag3341,
Tissue Name	Run 165524268	Tissue Name	Run 165524268
Liver adenocarcinoma	0.2	Kidney (fetal)	6.9
Pancreas	0.8	Renal ca. 786-0	0.1
Pancreatic ca. CAPAN 2	1.6	Renal ca. A498	0.2
Adrenal gland	0.5	Renal ca. RXF 393	0.4
Thyroid	0.1	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.1
Pituitary gland	0.3	Renal ca. TK-10	0.0
Brain (fetal)	0.4	Liver	100.0
Brain (whole)	0.2	Liver (fetal)	54.3
Brain (amygdala)	0.0	Liver ca.	0.7
		(hepatoblast) HepG2
Brain (cerebellum)	0.0	Lung	0.2
Brain (hippocampus)	0.1	Lung (fetal)	0.2
Brain (substantia nigra)	0.0	Lung ca. (small cell)	0.1
		LX-1
Brain (thalamus)	0.3	Lung ca. (small cell)	0.0
		NCI-H69
Cerebral Cortex	0.0	Lung ca. (s.cell var.)	0.1
		SHP-77
Spinal cord	0.2	Lung ca. (large	0.6
		cell)NCI-H460
glio/astro U87-MG	0.0	Lung ca. (non-sm.	0.0
		cell) A549
glio/astro U-118-MG	1.6	Lung ca. (non-s.cell)	0.0
		NCI-H23
astrocytoma SW1783	3.2	Lung ca. (non-s.cell)	0.8
		HOP-62
neuro*; met SK-N-AS	0.1	Lung ca. (non-s.cl)	0.1
		NCI-H522
astrocytoma SF-539	0.0	Lung ca. (squam.)	0.0
		SW 900
astrocytoma SNB-75	0.1	Lung ca. (squam.)	0.2
		NCI-H596
glioma SNB-19	0.0	Mammary gland	0.0
glioma U251	0.0	Breast ca.* (pl.ef)	0.0
		MCF-7
glioma SF-295	0.5	Breast ca.* (pl.ef)	5.3
		MDA-MB-231
Heart (fetal)	0.0	Breast ca.* (pl.ef)	0.0
		T47D
Heart	0.0	Breast ca. BT-549	0.0
Skeletal muscle (fetal)	0.3	Breast ca. MDA-N	0.0
Skeletal muscle	31.0	Ovary	0.2
Bone marrow	0.3	Ovarian ca. OVCAR-3	0.5
Thymus	0.1	Ovarian ca. OVCAR-4	0.0
Spleen	0.0	Ovarian ca. OVCAR-5	3.0
Lymph node	0.5	Ovarian ca. OVCAR-8	0.0
Colorectal	0.2	Ovarian ca. IGROV-1	0.1
Stomach	0.0	Ovarian ca.* (ascites)	0.0
		SK-OV-3
Small intestine	0.8	Uterus	2.0
Colon ca. SW480	0.0	Placenta	0.0
Colon ca.*	0.1	Prostate	0.3
SW620(SW480 met)
Colon ca. HT29	0.0	Prostate ca.* (bone	0.0
		met)PC-3
Colon ca. HCT-116	0.0	Testis	0.0
Colon ca. CaCo-2	10.2	Melanoma	1.1
		Hs688(A).T
Colon ca.	0.1	Melanoma* (met)	0.2
tissue(ODO3866)		Hs688(B).T
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca.* (liver met)	0.0	Melanoma M14	0.0
NCI-N87
Bladder	10.2	Melanoma LOX	0.0
		IMVI
Trachea	0.3	Melanoma* (met)	0.0
		SK-MEL-5
Kidney	0.7	Adipose	0.8

[0692]

TABLE CC
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3341, Run		Ag3341, Run
Tissue Name	165222714	Tissue Name	165222714
Secondary Th1 act	1.5	HUVEC IL-1 beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.8
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN	4.2
		gamma
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.8
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC	0.0
		none
Primary Th1 act	0.6	Lung Microvascular EC	0.7
		TNFalpha + IL-1 beta
Primary Th2 act	1.4	Microvascular Dermal EC	9.7
		none
Primary Tr1 act	0.0	Microsvasular Dermal EC	0.5
		TNFalpha + IL-1 beta
Primary Th1 rest	0.0	Bronchial epithelium	14.5
		TNFalpha + IL1 beta
Primary Th2 rest	0.0	Small airway epithelium	1.0
		none
Primary Tr1 rest	0.0	Small airway epithelium	23.0
		TNFalpha + IL-1 beta
CD45RA CD4	12.6	Coronery artery SMC rest	3.3
lymphocyte act
CD45RO CD4	0.9	Coronery artery SMC	0.0
lymphocyte act		TNFalpha + IL-1 beta
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8	0.0	Astrocytes TNFalpha + IL-1	0.0
lymphocyte rest		beta
Secondary CD8	0.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	0.0	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	0.0	CCD1106 (Keratinocytes)	3.0
CD95 CH11		none
LAK cells rest	0.0	CCD1106 (Keratinocytes)	5.4
		TNFalpha + IL-1 beta
LAK cells IL-2	0.9	Liver cirrhosis	100.0
LAK cells IL-2 + IL-12	0.0	Lupus kidney	1.8
LAK cells IL-2 + IFN	0.0	NCI-H292 none	46.0
gamma
LAK cells IL-2 + IL-18	0.0	NCI-H292 IL-4	72.7
LAK cells	0.0	NCI-H292 IL-9	56.3
PMA/ionomycin
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	39.2
Two Way MLR 3 day	0.0	NCI-H292 IFN gamma	87.1
Two Way MLR 5 day	0.0	HPAEC none	2.0
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1	0.0
		beta
PBMC rest	0.0	Lung fibroblast none	14.4
PBMC PWM	0.8	Lung fibroblast TNF	2.5
		alpha + IL-1 beta
PBMC PHA-L	0.0	Lung fibroblast IL-4	15.4
Ramos (B cell) none	0.0	Lung fibroblast IL-9	11.3
Ramos (B cell)	0.0	Lung fibroblast IL-13	12.0
ionomycin
B lymphocytes PWM	0.0	Lung fibroblast IFN	21.2
		gamma
B lymphocytes CD40L	0.0	Dermal fibroblast	66.9
and IL-4		CCD1070 rest
EOL-1 dbcAMP	0.0	Dermal fibroblast	28.3
		CCD1070 TNF alpha
EOL-1 dbcAMP	0.0	Dermal fibroblast	27.0
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	0.0	Dermal fibroblast IFN	1.1
		gamma
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	3.2
Dendritic cells anti-	0.0	IBD Colitis 2	0.0
CD40
Monocytes rest	0.0	IBD Crohn's	0.9
Monocytes LPS	0.0	Colon	6.9
Macrophages rest	0.0	Lung	1.4
Macrophages LPS	0.0	Thymus	40.9
HUVEC none	0.8	Kidney	6.9
HUVEC starved	3.9

[0693] Panel 1.3D Summary: Ag3341 The CG57833-01 gene codes for amino acid transporter HNAT3. Tissue distribution of this gene is similar to the results previously reported (Ref. 1) with highest expression of this gene in liver sample (CT=28.2). High expression of this gene is also detected in fetal liver (CT=29). Therefore, expression of this gene can be used to distinguish liver samples from other samples used in this panel. In addition, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of liver related diseases such as liver cirrhosis.

[0694] Low expression of this gene is also seen in ovarian cancer OVCAR-5, colon cancer CaCo-2, astrocytoma SW1783, glio/astro U-118-MG, and pancreatic cancer CAPAN 2 cell lines (CTs=33-34). Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of lung cancer or ovarian cancer.

[0695] Significant expression of this gene is also detected in skeletal muscle (CT=29.9). Interestingly, this gene is expressed at much higher levels in adult (CT=29.9) when compared to fetal skeletal Muscle (CT=36.6). This observation suggests that expression of this gene can be used to distinguish adult from fetal skeletal muscle. Furthermore, therapeutic modulation of the amino acid transporter encoded by this gene could be useful in treatment of muscle related diseases. More specifically, treatment of weak or dystrophic muscle with the protein encoded by this gene could restore muscle mass or function.

[0696] In addition, moderate expression of this gene is also detected in fetal kidney and bladder (CTs=31-32). Interestingly, this gene is expressed at much higher levels in fetal (CT=32) when compared to adult kidney (CT=35.3). Therefore, expression of this gene can be used to distinguish fetal from adult kidney. Furthermore, therapeutic modulation of the amino acid transporter encoded by this gene could be useful in treatment of renal diseases.

[0697] References.

[0698] 1. Gu S, Adan-Rice D, Leach R J, Jaiang J X. (2001) A novel human amino acid transporter, hNAT3: cDNA cloning, chromosomal mapping, genomic structure, expression, and functional characterization. Genomics 74(3):262-72.

[0699] Panel 4D Summary: Ag3341 Highest expression of CG57833-01 is seen in liver cirrhosis samples (CT=31.3). The amino acid transporter encoded for by this gene could potentially allow cells within the liver to respond to specific microenvironmental signals. Therefore, therapies designed with the protein encoded for by this gene may potentially modulate liver function and play a role in the identification and treatment of inflammatory or autoimmune diseases which affect the liver including liver cirrhosis and fibrosis.

[0700] Significant expression of this gene is also seen in thymus, dermal fibroblast, lung fibroblast, NCI-H292 cell lines, and TNFalpha+IL-1 beta treated bronchial and small airway epithelium samples (CTs=32-34). Interestingly, this gene is expressed at much higher levels in TNFalpha+IL-1 beta treated small airway epithelium (CT=33.4) when compared to untreated cells (CT=37.9). This observation suggests that expression of this gene can be used to distinguish the cytokine treated from untreated small airway epithelium. Furthermore, modulation of the expression or activity of the protein encoded by this gene through the application of small molecule therapeutics may be useful in the treatment of asthma, COPD, psoriasis and emphysema.

D. NOV4a, NOV4b, AND NOV4c (CG57853-01, CG57853-02, and CC57853-03: ILEAL SODIUM/BILE ACID COTRANSPORTER)

[0701] Expression of gene CG57853-01, CG57853-02, and CG57853-03 was assessed using the primer-probe sets Ag3350 and Ag2838, described in Tables DA and DB. Results of the RTQ-PCR runs are shown in Tables DC, DD and DE. Please note that CG57853-03 represents a full-length physical clone of the CG57853-01 gene, validating the prediction of the gene sequence.

TABLE DA
Probe Name Ag3350
			Start
Primer	Sequences	Length	Position
Forward	5′-cttagctcttgccgttattcag-3′	(SEQ ID NO:218)	22	938
Probe	TET-5′-aggccaatttagcttctgtggctcct-3′-TAMRA	SEQ ID NO:219)	26	979
Reverse	5′-catttcacatccagaacacatg-3′	(SEQ ID NO:220)	22	1016

[0702]

TABLE DB
Probe Name Ag2838
			Start
Primers	Sequences	Length	Position
Forward	5′-tcttagctcttgccgttattca-3′	(SEQ ID NO:221)	22	937
Probe	TET-5′-aggccaatttagcttctgtggctcct-3′-TAMRA	(SEQ ID NO:222)	26	979
Reverse	5′-acatccagaacacatggctact-3′	(SEQ ID NO:223)	22	1010

[0703]

TABLE DC
CNS_neurodegeneration_v1.0
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3350, Run		Ag3350, Run
Tissue Name	210141593	Tissue Name	210141593
AD 1 Hippo	5.7	Control (Path) 3	0.4
		Temporal Ctx
AD 2 Hippo	12.1	Control (Path) 4	57.8
		Temporal Ctx
AD 3 Hippo	3.2	AD 1 Occipital Ctx	18.7
AD 4 Hippo	0.9	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 Hippo	100.0	AD 3 Occipital Ctx	4.7
AD 6 Hippo	78.5	AD 4 Occipital Ctx	6.7
Control 2 Hippo	12.9	AD 5 Occipital Ctx	19.9
Control 4 Hippo	1.4	AD 6 Occipital Ctx	37.4
Control (Path) 3	0.0	Control 1 Occipital	2.1
Hippo		Ctx
AD 1 Temporal	10.2	Control 2 Occipital	45.4
Ctx		Ctx
AD 2 Temporal	59.9	Control 3 Occipital	6.5
Ctx		Ctx
AD 3 Temporal	4.7	Control 4 Occipital	1.4
Ctx		Ctx
AD 4 Temporal	5.9	Control (Path) 1	46.3
Ctx		Occipital Ctx
AD 5 Inf	95.3	Control (Path) 2	8.3
Temporal Ctx		Occipital Ctx
AD 5 Sup	33.9	Control (Path) 3	0.0
Temporal Ctx		Occipital Ctx
AD 6 Inf	66.0	Control (Path) 4	6.6
Temporal Ctx		Occipital Ctx
AD 6 Sup	95.9	Control 1 Parietal	1.0
Temporal Ctx		Ctx
Control 1	1.5	Control 2 Parietal	12.3
Temporal Ctx		Ctx
Control 2	14.8	Control 3 Parietal	7.2
Temporal Ctx		Ctx
Control 3	3.3	Control (Path) 1	29.3
Temporal Ctx		Parietal Ctx
Control 3	55.1	Control (Path) 2	63.3
Temporal Ctx		Parietal Ctx
Control (Path) 1	39.5	Control (Path) 3	1.3
Temporal Ctx		Parietal Ctx
Control (Path) 2	24.0	Control (Path) 4	24.1
Temporal Ctx		Parietal Ctx

[0704]

TABLE DD
General_screening_panel_v1.4
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3350, Run		Ag3350, Run
Tissue Name	216523465	Tissue Name	216523465
Adipose	1.8	Renal ca. TK-10	28.7
Melanoma*	1.0	Bladder	4.2
Hs688(A).T
Melanoma*	2.1	Gastric ca. (liver	100.0
Hs688(B).T		met.) NCI-N87
Melanoma* M14	3.8	Gastric ca.	11.7
		KATO III
Melanoma*	3.1	Colon ca. SW-948	6.4
LOXIMVI
Melanoma* SK-	3.3	Colon ca. SW480	12.3
MEL-5
Squamous cell	4.2	Colon ca.* (SW480	17.0
carcinoma SCC-4		met) SW620
Testis Pool	6.9	Colon ca. HT29	13.7
Prostate ca.*	19.9	Colon ca. HCT-116	10.4
(bone met) PC-3
Prostate Pool	3.4	Colon ca. CaCo-2	48.0
Placenta	0.0	Colon cancer tissue	14.5
Uterus Pool	0.3	Colon ca. SW1116	0.7
Ovarian ca.	14.3	Colon ca. Colo-205	14.0
OVCAR-3
Ovarian ca.	12.4	Colon ca. SW-48	16.0
SK-OV-3
Ovarian ca.	2.1	Colon Pool	2.6
OVCAR-4
Ovarian ca.	62.0	Small Intestine Pool	4.9
OVCAR-5
Ovarian ca.	1.8	Stomach Pool	3.2
IGROV-1
Ovarian ca.	2.7	Bone Marrow Pool	2.9
OVCAR-8
Ovary	3.4	Fetal Heart	2.5
Breast ca. MCF-7	4.6	Heart Pool	0.9
Breast ca. MDA-	10.2	Lymph Node Pool	5.3
MB-231
Breast ca. BT 549	14.1	Fetal Skeletal	4.3
		Muscle
Breast ca. T47D	62.4	Skeletal Muscle	2.0
		Pool
Breast ca.	1.6	Spleen Pool	1.4
MDA-N
Breast Pool	3.7	Thymus Pool	1.9
Trachea	15.4	CNS cancer	2.0
		(glio/astro) U87-MG
Lung	3.4	CNS cancer (glio/	3.6
		astro) U-118-MG
Fetal Lung	8.8	CNS cancer (neuro;	2.1
		met) SK-N-AS
Lung ca.	0.1	CNS cancer (astro)	3.8
NCI-N417		SF-539
Lung ca. LX-1	17.3	CNS cancer (astro)	2.8
		SNB-75
Lung ca.	2.9	CNS cancer (glio)	2.5
NCI-H146		SNB-19
Lung ca. SHP-77	4.7	CNS cancer (glio)	6.0
		SF-295
Lung ca. A549	7.2	Brain (Amygdala)	0.8
		Pool
Lung ca.	8.2	Brain (cerebellum)	6.0
NCI-H526
Lung ca.	6.9	Brain (fetal)	8.0
NCI-H23
Lung ca.	7.6	Brain	3.5
NCI-H460		(Hippocampus) Pool
Lung ca. HOP-62	3.5	Cerebral Cortex	2.0
		Pool
Lung ca.	5.0	Brain (Substantia	0.8
NCI-H522		nigra) Pool
Liver	0.8	Brain (Thalamus)	6.0
		Pool
Fetal Liver	45.1	Brain (whole)	2.5
Liver ca. HepG2	20.0	Spinal Cord Pool	1.2
Kidney Pool	8.1	Adrenal Gland	0.6
Fetal Kidney	13.5	Pituitary gland Pool	1.8
Renal ca. 786-0	7.2	Salivary Gland	1.0
Renal ca. A498	4.2	Thyroid (female)	0.2
Renal ca. ACHN	3.8	Pancreatic ca.	6.3
		CAPAN2
Renal ca. UO-31	3.0	Pancreas Pool	3.5

[0705]

TABLE DE
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3350, Run		Ag3350, Run
Tissue Name	165222880	Tissue Name	165222880
Secondary Th1	3.0	HUVEC IL-1 beta	0.0
act
Secondary Th2	4.1	HUVEC IFN	3.7
act		gamma
Secondary Tr1 act	3.5	HUVEC TNF	1.3
		alpha + IFN gamma
Secondary Th1	0.0	HUVEC TNF	2.5
rest		alpha + IL4
Secondary Th2	2.2	HUVEC IL-11	1.1
rest
Secondary Tr1	1.9	Lung Microvascular	4.6
rest		EC none
Primary Th1 act	4.0	Lung Microvascular	4.9
		EC TNF alpha +
		IL-1 beta
Primary Th2 act	3.2	Microvascular	3.2
		Dermal EC none
Primary Tr1 act	3.5	Microvasular	1.7
		Dermal EC
		TNF alpha +
		IL-1 beta
Primary Th1 rest	6.6	Bronchial	7.1
		epithelium TNF
		alpha + IL1 beta
Primary Th2 rest	3.8	Small airway	2.7
		epithelium none
Primary Tr1 rest	4.0	Small airway	25.7
		epithelium
		TNF alpha +
		IL-1 beta
CD45RA CD4	4.0	Coronery artery	1.8
lymphocyte act		SMC rest
CD45RO CD4	3.7	Coronery artery	1.1
lymphocyte act		SMC TNF alpha +
		IL-1 beta
CD8 lymphocyte	2.4	Astrocytes rest	3.3
act
Secondary CD8	2.9	Astrocytes	4.4
lymphocyte rest		TNF alpha +
		IL-1 beta
Secondary CD8	2.1	KU-812 (Basophil)	12.3
lymphocyte act		rest
CD4 lymphocyte	0.6	KU-812 (Basophil)	26.1
none		PMA/ionomycin
2ry Th1/Th2/	3.7	CCD1106	6.8
Tr1_anti-CD95		(Keratinocytes)
CH11		none
LAK cells rest	1.0	CCD1106	2.9
		(Keratinocytes)
		TNF alpha +
		IL-1 beta
LAK cells IL-2	3.4	Liver cirrhosis	7.4
LAK cells IL-2 +	3.3	Lupus kidney	1.9
IL-12
LAK cells IL-2 +	6.7	NCI-H292 none	7.7
IFN gamma
LAK cells IL-2 +	4.5	NCI-H292 IL-4	11.9
IL-18
LAK cells	1.4	NCI-H292 IL-9	8.1
PMA/ionomycin
NK Cells IL-2	0.8	NCI-H292 IL-13	6.6
rest
Two Way MLR 3	1.7	NCI-H292 IFN	8.7
day		gamma
Two Way MLR 5	3.1	HPAEC none	3.5
day
Two Way MLR 7	1.0	HPAEC TNF	1.8
day		alpha + IL-1 beta
PBMC rest	0.3	Lung fibroblast	2.0
		none
PBMC PWM	14.5	Lung fibroblast TNF	1.1
		alpha + IL-1 beta
PBMC PHA-L	4.9	Lung fibroblast IL-4	7.6
Ramos (B cell)	3.2	Lung fibroblast IL-9	3.6
none
Ramos (B cell)	13.2	Lung fibroblast	2.0
ionomycin		IL-13
B lymphocytes	15.8	Lung fibroblast	2.9
PWM		IFN gamma
B lymphocytes	4.7	Dermal fibroblast	7.7
CD40L and IL-4		CCD1070 rest
EOL-1 dbcAMP	4.6	Dermal fibroblast	6.6
		CCD1070 TNF
		alpha
EOL-1 dbcAMP	2.5	Dermal fibroblast	1.7
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells	0.2	Dermal fibroblast	0.6
none		IFN gamma
Dendritic cells	0.3	Dermal fibroblast	6.7
LPS		IL-4
Dendritic cells	0.7	IBD Colitis 2	0.7
anti-CD40
Monocytes rest	0.0	IBD Crohn's	4.0
Monocytes LPS	0.0	Colon	86.5
Macrophages rest	0.0	Lung	3.6
Macrophages LPS	0.0	Thymus	100.0
HUVEC none	2.0	Kidney	7.7
HUVEC starved	5.7

[0706] CNS_neurodegeneration_v1.0 Summary: Ag3350 This panel does not show differential expression of the CG57853-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

[0707] General_screening_panel_v1.4 Summary: Ag3350—The CG157853-01 gene encodes a novel ileal sodium-bile acid cotransporter. Ileal sodium-dependent bile acid transporters play a role in the absorption of bile acids, regulating levels of bile acids in the large intestine and preventing accumulation of cytotoxic secondary bile acids in the colon (Ref. 1). The highest expression of this gene is seen in gastric cancer cell line NCI-N87 (CT=29.5). Significant expression of this gene is also associated with CNS, colon, renal, liver, lung, breast, ovarian and prostate cancers as well as melanomas. Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic inhibition using antibodies or small molecule drugs might be of use in the treatment of these cancers.

[0708] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, fetal skeletal muscle, heart, fetal liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as intestinal bile acid malabsorption (IBAM), hypertriglyceridemia, obesity and diabetes.

[0709] Interestingly, this gene is expressed at much higher levels in fetal (CT=30.6) when compared to adult liver (CT=36.5). This observation suggests that expression of this gene can be used to distinguish fetal from adult liver. In addition, modulation of expression of this gene may be useful in the treatment of liver related disease such as liver cirrhosis, and cholestasis.

[0710] This gene is also widely expressed in tissues originating in the central nervous system. These tissues include the hippocampus, thalamus, and cerebellum. This transporter gene most likely plays a role in the uptake of nutrients. Blockade of this transporter may decrease the loss of neurons due to excitotoxicity during ischemic stroke. In addition, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0711] References.

[0712] 1. Small D M. (1997) Point mutations in the ileal bile salt transporter cause leaks in the enterohepatic circulation leading to severe chronic diarrhea and malabsorption. J Clin Invest 99(8):1807-8

[0713] 2. Montagnani M, Love M W, Rossel P, Dawson P A, Qvist P. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand J Gastroenterol Octiber 2001;36(10):1077-80.

[0714] 3. Wang W, Xue S, Ingles S A, Chen Q, Diep A T, Frankl H D, Stolz A, Haile R W. An association between genetic polymorphisms in the ileal sodium-dependent bile acid transporter gene and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2001 Sep;10(9):931-6.

[0715] 4. Duane W C, Hartich L A, Bartman A E, Flo S B. Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J Lipid Res September 2000;41(9):1384-9.

[0716] Panel 1.3D Summary: Ag2838—Results using this primer pair are in very good agreement with the results obtained using Ag3350 on panel 1.4. Please see panel 1.4 for discussion.

[0717] Panel 4D Summary: Ag3350 Moderate to low expression of the CG57853-01 gene is seen in many samples on this panel, with the highest expression in thymus tissue (CT=29.3). This gene is expressed at low to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the A-cell, B-cell, endothelial cell, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and ostearthritis.

[0718] Interestingly, high expression of this gene is detected in normal colon (CT=29.5), but expression of this gene is decreased in colon samples from patients with IBD colitis (CT=36.4) and Crohn's disease (CT=34.0). Therefore, therapeutic modulation of the activity of the transporter encoded by this gene may be useful in the treatment of inflammatory bowel disease.

[0719] In addition, expression of this gene is up regulated in PWM/PHA-L-stimulated PBMC (CTs=32-33.6), compared to resting PBMC cells (CT=37.6). Thus, expression of this gene may be used as a marker for activated PBMC cells.

E. NOV5a AND NOV5b (CG57829-01 AND CC57829-05: A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN MOTIFS 1)

[0720] Expression of gene CG57829-01 and CG57829-05 was assessed using the primer-probe sets Ag3340 and Ag554, described in Tables EA and EB. Results of the RTQ-PCR runs are shown in Tables EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL and EM. Please note that CG57829-05 represents a full-length physical clone.

TABLE EA
Probe Name Ag3340
			Start
Primers	Sequences	Length	Positon
Forward	5′-aatggcactggctacttctatg-3′	(SEQ ID NO:224)	22	1894
Probe	TET-5′-acgctgtgctctcctgactccacct-3′-TAMRA	(SEQ ID NO: 225)	25	1942
Reverse	5′-cacttgccttggacacaga-3′	(SEQ ID NO:226)	19	1970

[0721]

TABLE EB
Probe Name Ag554
			Start
Primers	Sequences	Length	Position
Forward	5′-cctggcagaagaagctgaaca-3′	(SEQ ID NO:227)	21	905
Probe	TET-5′-tgacaagcaccccgagtactgggac-3′-TAMRA	(SEQ ID NO:228)	25	933
Reverse	5′-tgcctggtgaagaggatgg-3′	(SEQ ID NO:229)	19	962

[0722]

TABLE EC
AI_comprehensive panel_v1.0
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3340, Run		Ag3340, Run
Tissue Name	211063355	Tissue Name	211063355
110967 COPD-F	2.5	112427 Match	1.3
		Control Psoriasis-F
110980 COPD-F	1.3	112418 Psoriasis-M	2.5
110968 COPD-M	3.6	112723 Match	0.0
		Control Psoriasis-M
110977 COPD-M	2.4	112419 Psoriasis-M	2.4
110989	6.2	112424 Match	1.0
Emphysema-F		Control Psoriasis-M
110992	12.2	112420 Psoriasis-M	11.3
Emphysema-F
110993	5.0	112425 Match	0.0
Emphysema-F		Control Psoriasis-M
110994	2.4	104689 (MF) OA	6.2
Emphysema-F		Bone-Backus
110995	14.2	104690 (MF) Adj	8.1
Emphysema-F		“Normal” Bone-
		Backus
110996	13.5	104691 (MF) OA	12.5
Emphysema-F		Synovium-Backus
110997	0.0	104692 (BA) OA	0.0
Asthma-M		Cartilage-Backus
111001	5.5	104694 (BA) OA	6.7
Asthma-M		Bone-Backus
111002	4.1	104695 (BA) Adj	8.0
Asthma-M		“Normal” Bone-
		Backus
111003 Atopic	10.6	104696 (BA) OA	25.2
Asthma-F		Synovium-Backus
111004 Atopic	9.2	104700 (SS) OA	1.9
Asthma-F		Bone-Backus
111005 Atopic	6.6	104701 (SS) Adj	11.9
Asthma-F		“Normal” Bone-
		Backus
111006 Atopic	1.5	104702 (SS) OA	32.3
Asthma-F		Synovium-Backus
111417	3.3	117093 OA	6.9
Allergy-M		Cartilage Rep7
112347	0.2	112672 OA Bone5	1.5
Allergy-M
112349 Normal	0.1	112673 OA	0.9
Lung-F		Synovium5
112357 Normal	4.1	112674 OA	0.8
Lung-F		Synovial
		Fluid cells5
112354 Normal	1.7	117100 OA	1.9
Lung-M		Cartilage Rep14
112374 Crohns-F	5.2	112756 OA Bone9	2.7
112389 Match	1.8	112757 OA	2.1
Control Crohns-F		Synovium9
112375 Crohns-F	3.6	112758 OA	4.6
		Synovial
		Fluid Cells9
112732 Match	0.4	117125 RA	7.6
Control Crohns-F		Cartilage Rep2
112725 Crohns-M	0.1	113492 Bone2 RA	2.5
112387 Match	2.7	113493 Synovium2	1.1
Control		RA
Crohns-M
112378 Crohns-M	0.1	113494 Syn Fluid	0.9
		Cells RA
112390 Match	1.7	113499 Cartilage4	2.9
Control		RA
Crohns-M
112726 Crohns-M	10.2	113500 Bone4 RA	1.6
112731 Match	1.5	113501 Synovium4	2.0
Control		RA
Crohns-M
112380 Ulcer	0.6	113502 Syn Fluid	0.4
Col-F		Cells4 RA
112734 Match	0.6	113495 Cartilage3	1.7
Control Ulcer		RA
Col-F
112384 Ulcer	23.7	113496 Bone3 RA	3.1
Col-F
112737 Match	2.9	113497 Synovium3	1.2
Control Ulcer		RA
Col-F
112386 Ulcer	2.6	113498 Syn Fluid	2.6
Col-F		Cells3 RA
112738 Match	4.9	117106 Normal	7.1
Control Ulcer		Cartilage Rep20
Col-F
112381 Ulcer	0.1	113663 Bone3	0.2
Col-M		Normal
112735 Match	1.2	113664 Synovium3	0.1
Control Ulcer		Normal
Col-M
112382 Ulcer	1.5	113665 Syn Fluid	0.1
Col-M		Cells3 Normal
112394 Match	0.4	117107 Normal	1.0
Control Ulcer		Cartilage Rep22
Col-M
112383 Ulcer	100.0	113667 Bone4	1.1
Col-M		Normal
112736 Match	0.8	113668 Synovium4	1.6
Control Ulcer		Normal
Col-M
112423	0.0	113669 Syn Fluid	2.8
Psoriasis-F		Cells4 Normal

[0723]

TABLE ED
CNS_neurodegeneration_v1.0
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3340, Run		Ag3340, Run
Tissue Name	210139046	Tissue Name	210139046
AD 1 Hippo	0.0	Control (Path) 3	22.5
		Temporal Ctx
AD 2 Hippo	51.4	Control (Path) 4	32.1
		Temporal Ctx
AD 3 Hippo	12.7	AD 1 Occipital Ctx	17.8
AD 4 Hippo	14.3	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	12.9	AD 3 Occipital Ctx	0.0
AD 6 Hippo	40.3	AD 4 Occipital Ctx	23.8
Control 2 Hippo	36.3	AD 5 Occipital Ctx	9.0
Conirol 4 Hippo	40.3	AD 6 Occipital Ctx	100.0
Control (Path) 3	4.3	Control 1 Occipital	15.1
Hippo		Ctx
AD 1 Temporal	0.0	Control 2 Occipital	25.0
Ctx		Ctx
AD 2 Temporal	69.7	Control 3 Occipital	38.4
Ctx		Ctx
AD 3 Temporal	16.4	Control 4 Occipital	8.1
Ctx		Ctx
AD 4 Temporal	47.6	Control (Path) 1	35.6
Ctx		Occipital Ctx
AD 5 Inf	85.9	Control (Path) 2	0.0
Temporal Ctx		Occipital Ctx
AD 5 Sup	44.4	Control (Path) 3	0.0
Temporal Ctx		Occipital Ctx
AD 6 Inf	79.6	Control (Path) 4	11.4
Temporal Ctx		Occipital Ctx
AD 6 Sup	57.0	Control 1 Parietal	29.3
Temporal Ctx		Ctx
Control 1	9.3	Control 2 Parietal	53.6
Temporal Ctx		Ctx
Control 2	32.3	Control 3 Parietal	37.4
Temporal Ctx		Ctx
Control 3	19.6	Control (Path) 1	18.7
Temporal Ctx		Parietal Ctx
Control 4	13.2	Control (Path) 2	29.5
Temporal Ctx		Parietal Ctx
Control (Path) 1	77.4	Control (Path) 3	7.0
Temporal Ctx		Parietal Ctx
Control (Path) 2	39.0	Control (Path) 4	38.7
Temporal Ctx		Parietal Ctx

[0724]

TABLE EE
General_screening_panel_v1.4
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag3340, Run	Ag3340, Run		Ag3340, Run	Ag3340, Run
Tissue Name	213333210	217049357	Tissue Name	213333210	217049357
Adipose	9.2	9.1	Renal ca. TK-10	3.5	4.5
Melanoma*	0.0	0.0	Bladder	1.7	2.3
Hs688(A).T
Melanoma*	1.7	1.9	Gastric ca. (liver	3.3	4.0
Hs688(B).T			met.) NCI-N87
Melanoma*	0.0	0.0	Gastric ca. KATO	5.9	7.7
M14			III
Melanoma*	0.0	0.0	Colon ca. SW-	3.9	4.6
LOXIMVI			948
Melanoma*	0.2	0.4	Colon ca. SW480	21.0	24.3
SK-MEL-5
Squamous cell	0.1	0.2	Colon ca.*	1.8	1.6
carcinoma			(SW480 met)
SCC-4			SW620
Testis Pool	2.1	1.1	Colon ca. HT29	0.0	0.0
Prostate ca.*	4.1	3.6	Colon ca. HCT-	1.1	1.0
(bone met)			116
PC-3
Prostate Pool	0.6	0.4	Colon ca. CaCo-2	1.9	2.2
Placenta	6.6	6.7	Colon cancer	2.8	2.6
			tissue
Uterus Pool	0.5	0.5	Colon ca.	0.1	0.2
			SW1116
Ovarian ca.	50.0	37.1	Colon ca. Colo-	0.1	0.2
OVCAR-3			205
Ovarian ca.	43.2	29.9	Colon ca. SW-48	0.0	0.0
SK-OV-3
Ovarian ca.	31.4	36.6	Colon Pool	2.5	3.1
OVCAR-4
Ovarian ca.	28.1	33.0	Small Intestine	0.4	0.8
OVCAR-5			Pool
Ovarian ca.	8.5	8.5	Stomach Pool	1.8	1.5
IGROV-1
Ovarian ca.	3.6	5.7	Bone Marrow	0.7	0.7
OVCAR-8			Pool
Ovary	1.1	1.2	Fetal Heart	6.7	7.6
Breast ca.	0.8	0.6	Heart Pool	2.5	2.8
MCF-7
Breast ca.	100.0	100.0	Lymph Node	4.0	5.0
MDA-MB-231			Pool
Breast ca. BT	46.0	43.5	Fetal Skeletal	2.4	1.9
549			Muscle
Breast ca.	78.5	72.2	Skeletal Muscle	1.5	1.2
T47D			Pool
Breast ca.	0.0	0.0	Spleen Pool	0.9	1.0
MDA-N
Breast Pool	2.1	1.7	Thymus Pool	2.2	2.1
Trachea	1.0	1.7	CNS cancer	0.0	0.0
			(glio/astro) U87-
			MG
Lung	0.4	0.3	CNS cancer	46.0	52.5
			(glio/astro) U-
			118-MG
Fetal Lung	14.4	14.7	CNS cancer	1.4	1.6
			(neuro;met) SK-
			N-AS
Lung ca. NCI-	0.2	0.0	CNS cancer	3.0	3.1
N417			(astro) SF-539
Lung ca. LX-1	4.5	4.4	CNS cancer	13.2	27.9
			(astro) SNB-75
Lung ca. NCI-	0.0	0.0	CNS cancer (glio)	7.2	9.1
H146			SNB-19
Lung ca. SHP-	17.4	17.7	CNS cancer (glio)	1.8	1.7
77			SF-295
Lung ca. A549	8.4	6.6	Brain (Amygdala)	0.2	0.1
			Pool
Lung ca. NCI-	0.0	0.0	Brain	0.2	0.3
H526			(cerebellum)
Lung ca. NCI-	0.4	0.3	Brain (fetal)	3.0	1.8
H23
Lung ca. NCI-	0.1	0.1	Brain	0.4	0.4
H460			(Hippocampus)
			Pool
Lung ca.	0.7	0.5	Cerebral Cortex	0.5	0.2
HOP-62			Pool
Lung ca. NCI-	0.2	0.1	Brain (Substantia	0.6	0.2
H522			nigra) Pool
Liver	0.0	0.0	Brain (Thalamus)	0.2	0.2
			Pool
Fetal Liver	0.8	0.8	Brain (whole)	0.6	0.7
Liver ca.	0.0	0.0	Spinal Cord Pool	1.1	1.0
HepG2
Kidney Pool	2.6	2.5	Adrenal Gland	1.2	0.9
Fetal Kidney	12.4	15.1	Pituitary gland	0.3	0.4
			Pool
Renal ca. 786-0	15.8	18.7	Salivary Gland	0.3	0.2
Renal ca.	3.5	4.1	Thyroid (female)	2.9	2.6
A498
Renal ca.	53.6	48.0	Pancreatic ca.	1.7	1.6
ACHN			CAPAN2
Renal ca. UO-	13.1	13.0	Pancreas Pool	7.1	5.3
31

[0725]

TABLE EF
Panel 1.1
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag554, Run		Ag554, Run
Tissue Name	109665128	Tissue Name	109665128
Adrenal gland	0.1	Renal ca. UO-31	6.2
Bladder	4.2	Renal ca. RXF 393	0.2
Brain (amygdala)	0.0	Liver	0.3
Brain	0.0	Liver (fetal)	0.7
(cerebellum)
Brain	0.1	Liver ca.	0.0
(hippocampus)		(hepatoblast) HepG2
Brain (substantia	0.0	Lung	4.3
nigra)
Brain (thalamus)	0.0	Lung (fetal)	13.2
Cerebral Cortex	0.0	Lung ca. (non-s.	0.3
		cell) HOP-62
Brain (fetal)	0.5	Lung ca. (large	0.0
		cell) NCI-H460
Brain (whole)	0.0	Lung ca. (non-s.)	0.0
		cell) NCI-H23
glio/astro	34.9	Lung ca. (non-s.cl)	0.0
U-118-MG		NCI-H522
astrocytoma	1.7	Lung ca. (non-sm.	0.1
SF-539		cell) A549
astrocytoma	13.3	Lung ca. (s.cell	9.9
SNB-75		var.) SHP-77
astrocytoma	1.2	Lung ca. (small	3.2
SW1783		cell) LX-1
glioma U251	24.0	Lung ca. (small	0.1
		cell) NCI-H69
glioma SF-295	0.0	Lung ca. (squam.)	0.0
		SW 900
glioma SNB-19	27.0	Lung ca. (squam.)	0.6
		NCI-H596
glio/astro	0.0	Lymph node	1.9
U87-MG
neuro*; met	0.1	Spleen	0.0
SK-N-AS
Mammary gland	34.9	Thymus	0.1
Breast ca. BT-549	8.4	Ovary	13.0
Breast ca.	0.0	Ovarian ca.	4.6
MDA-N		IGROV-1
Breast ca.*	95.3	Ovarian ca.	100.0
(pl.ef) T47D		OVCAR-3
Breast ca.*	0.0	Ovarian ca.	88.3
(pl.ef) MCF-7		OVCAR-4
Breast ca.*	50.0	Ovarian ca.	44.4
(pl.ef)		OVCAR-5
MDA-MB-231
Small intestine	0.5	Ovarian ca.	0.0
		OVCAR-8
Colorectal	1.1	Ovarian ca.*	57.4
		(ascites) SK-OV-3
Colon ca. HT29	0.0	Pancreas	0.0
Colon ca.	0.0	Pancreatic ca.	0.0
CaCo-2		CAPAN2
Colon ca.	0.0	Pituitary gland	0.8
HCT-15
Colon ca.	0.0	Placenta	21.6
HCT-116
Colon ca.	0.0	Prostate	0.0
HCC-2998
Colon ca. SW480	7.5	Prostate ca.* (bone	3.0
		met) PC-3
Colon ca.*	0.4	Salivary gland	0.0
SW620 (SW480
met)
Stomach	5.4	Trachea	0.6
Gastric ca. (liver	1.1	Spinal cord	1.4
met) NCI-N87
Heart	54.7	Testis	0.0
Skeletal muscle	69.7	Thyroid	6.5
(Fetal)
Skeletal muscle	0.9	Uterus	1.1
Endothelial cells	0.0	Melanoma M14	0.0
Heart (Fetal)	55.9	Melanoma LOX	0.0
		IMVI
Kidney	35.6	Melanoma	0.0
		UACC-62
Kidney (fetal)	59.9	Melanoma	0.0
		SK-MEL-28
Renal ca. 786-0	16.6	Melanoma* (met)	0.0
		SK-MEL-5
Renal ca. A498	7.7	Melanoma	0.0
		Hs688(A).T
Renal ca. ACHN	94.6	Melanoma* (met)	0.0
		Hs688(B).T
Renal ca. TK-10	5.8

[0726]

TABLE EG
Panel 1.2
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag554, Run	Ag554, Run		Ag554, Run	Ag554, Run
Tissue Name	121754027	124088899	Tissue Name	121754027	124088899
Endothelial cells	0.0	0.0	Renal ca. 786-0	5.8	0.0
Heart (Fetal)	69.3	56.6	Renal ca. A498	2.3	0.0
Pancreas	0.0	0.0	Renal ca. RXF	0.0	0.0
			393
Pancreatic ca.	0.0	0.0	Renal ca.	44.1	9.6
CAPAN 2			ACHN
Adrenal Gland	0.1	0.0	Renal ca. UO-	0.5	0.0
			31
Thyroid	0.2	0.0	Renal ca. TK-	0.1	0.0
			10
Salivary gland	0.0	0.0	Liver	0.1	0.0
Pituitary gland	0.0	0.0	Liver (fetal)	0.0	0.0
Brain (fetal)	0.0	0.0	Liver ca.	0.0	0.0
			(hepatoblast)
			HepG2
Brain (whole)	0.0	0.0	Lung	3.2	0.0
Brain (amygdala)	0.0	0.0	Lung (fetal)	6.0	0.4
Brain	0.0	0.0	Lung ca. (small	0.0	0.0
(cerebellum)			cell) LX-1
Brain	0.0	0.0	Lung ca. (small	0.0	0.0
(hippocampus)			cell) NCI-H69
Brain (thalamus)	0.0	0.0	Lung ca. (s.cell	4.2	0.0
			var.) SHP-77
Cerebral Cortex	0.0	0.0	Lung ca. (large	0.0	0.0
			cell)NCI-H460
Spinal cord	0.0	0.0	Lung ca. (non-	0.0	0.0
			sm. cell) A549
glio/astro U87-	0.0	0.0	Lung ca. (non-	0.0	0.0
MG			s.cell) NCI-
			H23
glio/astro U-118-	18.0	0.2	Lung ca. (non-	0.0	0.0
MG			s.cell) HOP-62
astrocytoma	0.0	0.0	Lung ca. (non-	0.0	0.0
SW1783			s.cl) NCI-H522
neuro*; met SK-	0.0	0.0	Lung ca.	0.0	0.0
N-AS			(squam.) SW
			900
astrocytoma SF-	0.0	0.0	Lung ca.	0.0	0.0
539			(squam.) NCI-
			H596
astrocytoma	1.2	0.0	Mammary	24.1	18.0
SNB-75			gland
glioma SNB-19	14.7	2.8	Breast ca.*	0.0	0.0
			(pl.ef) MCF-7
glioma U251	6.2	0.0	Breast ca.*	31.0	12.7
			(pl.ef) MDA-
			MB-231
glioma SF-295	0.0	0.0	Breast ca.* (pl.	39.8	17.6
			ef) T47D
Heart	79.0	6.4	Breast ca. BT-	12.2	0.6
			549
Skeletal Muscle	0.0	0.0	Breast ca.	0.0	0.0
			MDA-N
Bone marrow	0.0	0.0	Ovary	7.4	0.0
Thymus	0.0	0.0	Ovarian ca.	37.1	24.8
			OVCAR-3
Spleen	0.0	0.0	Ovarian ca.	54.3	16.7
			OVCAR-4
Lymph node	0.0	0.0	Ovarian ca.	16.6	2.9
			OVCAR-5
Colorectal Tissue	1.5	0.0	Ovarian ca.	0.0	0.0
			OVCAR-8
Stomach	5.3	0.0	Ovarian ca.	2.1	0.0
			IGROV-1
Small intestine	0.0	0.0	Ovarian ca.	21.2	4.7
			(ascites) SK-
			OV-3
Colon ca.	0.0	0.0	Uterus	0.1	0.0
SW480
Colon ca.*	0.0	0.0	Placenta	38.7	2.2
SW620 (SW480
met)
Colon ca. HT29	0.0	0.0	Prostate	0.0	0.0
Colon ca. HCT-	0.0	0.0	Prostate ca.*	5.6	0.0
116			(bone met)
			PC-3
Colon ca. CaCo-2	0.0	0.0	Testis	0.0	0.0
Colon ca. Tissue	0.1	0.0	Melanoma	0.0	0.0
(ODO3866)			Hs688(A).T
Colon ca. HCC-	0.0	0.0	Melanoma*	0.0	0.0
2998			(met)
			Hs688(B).T
Gastric ca.*	0.7	0.0	Melanoma	0.0	0.0
(liver met) NCI-			UACC-62
N87
Bladder	1.9	0.0	Melanoma	0.0	0.0
			M14
Trachea	0.2	0.0	Melanoma	0.0	0.0
			LOX IMVI
Kidney	11.0	0.6	Melanoma*	0.0	0.0
			(met) SK-
			MEL-5
Kidney (fetal)	100.0	100.0

[0727]

TABLE EH
Panel 1.3D
	Rel. Exp.(%) Ag554,		Rel. Exp.(%) Ag554,
Tissue Name	Run 165702013	Tissue Name	Run 165702013
Liver adenocarcinoma	0.2	Kidney (fetal)	15.7
Pancreas	0.1	Renal ca. 786-0	9.0
Pancreatic ca. CAPAN2	0.6	Renal ca. A498	7.3
Adrenal gland	0.8	Renal ca. RXF 393	4.1
Thyroid	5.0	Renal ca. ACHN	42.9
Salivary gland	0.7	Renal ca. UO-31	33.9
Pituitary gland	0.8	Renal ca. TK-10	2.2
Brain (fetal)	0.3	Liver	0.3
Brain (whole)	0.2	Liver (fetal)	1.3
Brain (amygdala)	1.2	Liver ca.	0.0
		(hepatoblast) HepG2
Brain (cerebellum)	0.2	Lung	5.4
Brain (hippocampus)	1.2	Lung (fetal)	10.7
Brain (substantia nigra)	0.5	Lung ca. (small cell)	2.7
		LX-1
Brain (thalamus)	0.3	Lung ca. (small cell)	1.1
		NCI-H69
Cerebral Cortex	0.7	Lung ca. (s.cell var.)	19.3
		SHP-77
Spinal cord	1.9	Lung ca. (large	0.7
		cell) NCI-H460
glio/astro U87-MG	0.0	Lung ca. (non-sm.	1 .2
		cell) A549
glio/astro U-118-MG	75.8	Lung ca. (non-s.cell)	0.0
		NCI-H23
astrocytoma SW1783	5.1	Lung ca. (non-s.cell)	1.0
		HOP-62
neuro*; met SK-N-AS	0.7	Lung ca. (non-s.cl)	0.0
		NCI-H522
astrocytoma SF-539	3.3	Lung ca. (squam.)	0.8
		SW 900
astrocytoma SNB-75	13.5	Lung ca. (squam.)	1.3
		NCI-H596
glioma SNB-19	24.0	Mammary gland	15.3
glioma U251	48.0	Breast ca.* (pl.ef)	0.9
		MCF-7
glioma SF-295	0.3	Breast ca.* (pl.ef)	100.0
		MDA-MB-231
Heart (fetal)	22.2	Breast ca.* (pl.ef)	34.6
		T47D
Heart	10.7	Breast ca. BT-549	21.3
Skeletal muscle (fetal)	22.1	Breast ca. MDA-N	0.0
Skeletal muscle	2.4	Ovary	3.1
Bone marrow	0.0	Ovarian ca. OVCAR-3	31.9
Thymus	0.8	Ovarian ca. OVCAR-4	43.2
Spleen	1.2	Ovarian ca. OVCAR-5	19.3
Lymph node	4.3	Ovarian ca. OVCAR-8	0.0
Colorectal	3.0	Ovarian ca. IGROV-1	2.2
Stomach	3.0	Ovarian ca.* (ascites)	22.7
		SK-OV-3
Small intestine	2.9	Uterus	4.4
Colon ca. SW480	5.0	Placenta	6.7
Colon ca.*	0.5	Prostate	0.9
SW620(SW480 met)
Colon ca. HT29	0.0	Prostate ca.* (bone	2.2
		met) PC-3
Colon ca. HCT-116	0.0	Testis	1.0
Colon ca. CaCo-2	0.5	Melanoma	0.0
		Hs688(A).T
Colon ca.	2.3	Melanoma* (met)	1.4
tissue (ODO3866)		Hs688(B).T
Colon ca. HCC-2998	0.0	Melanoma UACC-62	1.0
Gastric ca.* (liver met)	3.5	Melanoma M14	0.0
NCI-N87
Bladder	1.2	Melanoma LOX	0.0
		IMVI
Trachea	1.7	Melanoma* (met)	0.3
		SK-MEL-5
Kidney	7.9	Adipose	23.2

[0728]

TABLE EI
Panel 2.1
	Rel. Exp.(%) Ag3340,		Rel. Exp.(%) Ag3340,
Tissue Name	Run 170686167	Tissue Name	Run 170686167
Normal Colon	6.0	Kidney Cancer	7.0
		9010320
Colon cancer (OD06064)	0.9	Kidney margin	14.7
		9010321
Colon cancer margin	1.4	Kidney Cancer	4.2
(OD06064)		8120607
Colon cancer (OD06159)	0.3	Kidney margin	7.8
		8120608
Colon cancer margin	0.3	Normal Uterus	11.1
(OD06159)
Colon cancer (OD06298-	2.6	Uterus Cancer	6.1
08)
Colon cancer margin	1.4	Normal Thyroid	1.4
(OD06298-018)
Colon Cancer Gr.2 ascend	3.0	Thyroid Cancer	18.2
colon (ODO3921)
Colon Cancer margin	2.1	Thyroid Cancer	0.6
(ODO3921)		A302152
Colon cancer metastasis	2.5	Thyroid margin	4.4
(OD06104)		A302153
Lung margin (OD06104)	1.6	Normal Breast	22.1
Colon mets to lung	0.0	Breast Cancer	10.4
(OD04451-01)
Lung margin (OD04451-	3.5	Breast Cancer	6.7
02)
Normal Prostate	0.8	Breast Cancer	24.8
		(OD04590-01)
Prostate Cancer	0.4	Breast Cancer Mets	29.3
(OD04410)		(OD04590-03)
Prostate margin	1.9	Breast Cancer	100.0
(OD04410)		Metastasis
Normal Lung	14.4	Breast Cancer	3.4
Invasive poor diff. lung	0.3	Breast Cancer	14.4
adeno 1 (ODO4945-01)		9100266
Lung margin (ODO4945-	11.1	Breast margin	6.8
03)		9100265
Lung Malignant Cancer	2.6	Breast Cancer	4.7
(OD03126)		A209073
Lung margin (OD03126)	1.2	Breast margin	16.8
		A2090734
Lung Cancer (OD05014A)	1.0	Normal Liver	0.9
Lung margin (OD05014B)	4.2	Liver Cancer 1026	3.0
Lung Cancer (OD04237-	1.8	Liver Cancer 1025	0.4
01)
Lung margin (OD04237-	5.1	Liver Cancer 6004-T	0.1
02)
Ocular Mel Met to Liver	0.0	Liver Tissue 6004-N	0.0
(ODO4310)
Liver margin (ODO4310)	0.7	Liver Cancer 6005-T	5.9
Melanoma Mets to Lung	1.0	Liver Tissue 6005-N	3.7
(OD04321)
Lung margin (OD04321)	6.4	Liver Cancer	0.3
Normal Kidney	20.9	Normal Bladder	2.2
Kidney Ca, Nuclear grade	23.3	Bladder Cancer	1.7
2 (OD04338)
Kidney margin (OD04338)	1.6	Bladder Cancer	0.9
Kidney Ca Nuclear grade	4.5	Normal Ovary	5.6
1/2 (OD04339)
Kidney margin (OD04339)	5.0	Ovarian Cancer	4.9
Kidney Ca, Clear cell type	1.6	Ovarian cancer	2.7
(OD04340)		(OD06145)
Kidney margin (OD04340)	10.4	Ovarian cancer	3.1
		margin (OD06145)
Kidney Ca, Nuclear grade	0.4	Normal Stomach	24.8
3 (OD04348)
Kidney margin (OD04348)	8.5	Gastric Cancer	0.0
		9060397
Kidney Cancer (OD04450-	0.5	Stomach margin	16.5
01)		9060396
Kidney margin (OD04450-	12.7	Gastric Cancer	4.9
03)		9060395
Kidney Cancer 8120613	0.0	Stomach margin	11.3
		9060394
Kidney margin 8120614	6.2	Gastric Cancer	2.1
		064005

[0729]

TABLE EJ
Panel 2D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag554, Run	Ag554, Run		Ag554, Run	Ag554, Run
Tissue Name	145968942	145968960	Tissue Name	145968942	145968960
Normal Colon	12.9	15.4	Kidney Margin	12.2	14.3
			8120608
CC Well to Mod	1.9	1.9	Kidney Cancer	0.2	0.2
Diff (ODO3866)			8120613
CC Margin	3.0	3.8	Kidney Margin	8.7	16.2
(ODO3866)			8120614
CC Gr.2	1.4	1.8	Kidney Cancer	17.1	21.3
rectosigmoid			9010320
(ODO3868)
CC Margin	1.2	1.4	Kidney Margin	16.6	18.9
(ODO3868)			9010321
CC Mod Diff	0.5	0.5	Normal Uterus	2.9	4.2
(ODO3920)
CC Margin	0.8	1.5	Uterus Cancer	5.3	4.7
(ODO3920)			064011
CC Gr.2 ascend	7.1	9.9	Normal	5.6	7.0
colon			Thyroid
(ODO3921)
CC Margin	1.2	1.9	Thyroid	20.2	28.7
(ODO3921)			Cancer 064010
CC from Partial	1.6	2.7	Thyroid	1.4	1.4
Hepatectomy			Cancer
(ODO4309) Mets			A302152
Liver Margin	0.7	1.0	Thyroid	7.3	9.0
(ODO4309)			Margin
			A302153
Colon mets to	3.1	5.8	Normal Breast	23.0	29.9
lung (OD04451-
01)
Lung Margin	2.7	1.8	Breast Cancer	28.3	34.6
(OD04451-02)			(OD04566)
Normal Prostate	0.7	0.5	Breast Cancer	87.7	80.7
6546-1			(OD04590-01)
Prostate Cancer	1.1	0.9	Breast Cancer	100.0	100.0
(OD04410)			Mets
			(OD04590-03)
Prostate Margin	2.5	2.2	Breast Cancer	76.8	81.2
(OD04410)			Metastasis
			(OD04655-05)
Prostate Cancer	1.7	1.4	Breast Cancer	10.2	11.1
(OD04720-01)			064006
Prostate Margin	2.1	3.6	Breast Cancer	19.9	20.0
(OD04720-02)			1024
Normal Lung	7.0	11.1	Breast Cancer	26.2	31.6
061010			9100266
Lung Met to	0.4	0.9	Breast Margin	10.1	13.2
Muscle			9100265
(ODO4286)
Muscle Margin	2.9	6.9	Breast Cancer	13.6	21.6
(ODO4286)			A209073
Lung Malignant	2.0	3.2	Breast Margin	10.4	12.3
Cancer			A209073
(OD03126)
Lung Margin	3.6	6.5	Normal Liver	0.5	0.4
(OD03126)
Lung Cancer	4.1	7.8	Liver Cancer	0.5	0.3
(OD04404)			064003
Lung Margin	19.3	20.0	Liver Cancer	0.2	0.3
(OD04404)			1025
Lung Cancer	0.4	0.7	Liver Cancer	1.9	2.7
(OD04565)			1026
Lung Margin	3.9	3.3	Liver Cancer	0.2	0.5
(OD04565)			6004-T
Lung Cancer	3.0	4.8	Liver Tissue	0.2	0.3
(OD04237-01)			6004-N
Lung Margin	8.0	8.1	Liver Cancer	2.0	2.2
(OD04237-02)			6005-T
Ocular Mel Met	0.0	0.2	Liver Tissue	1.2	1.3
to Liver			6005-N
(ODO4310)
Liver Margin	0.6	1.0	Normal	3.1	3.3
(ODO4310)			Bladder
Melanoma Mets	1.5	2.6	Bladder Cancer	1.7	1.5
to Lung			1023
(OD04321)
Lung Margin	6.4	9.8	Bladder Cancer	0.6	0.8
(OD04321)			A302173
Normal Kidney	27.0	54.0	Bladder Cancer	0.8	0.9
			(OD04718-01)
Kidney Ca,	2.3	3.1	Bladder	42.6	53.6
Nuclear grade 2			Normal
(OD04338)			Adjacent
			(OD04718-03)
Kidney Margin	11.7	16.0	Normal Ovary	3.3	4.0
(OD04338)
Kidney Ca	7.5	7.1	Ovarian	15.0	18.9
Nuclear grade 1/2			Cancer 064008
(OD04339)
Kidney Margin	14.9	16.8	Ovarian	1.3	1.7
(OD04339)			Cancer
			(OD04768-07)
Kidney Ca, Clear	1.5	2.3	Ovary Margin	9.8	9.7
cell type			(OD04768-08)
(OD04340)
Kidney Margin	19.8	18.3	Normal	14.8	15.1
(OD04340)			Stomach
Kidney Ca,	0.8	1.2	Gastric Cancer	3.0	3.1
Nuclear grade 3			9060358
(OD04348)
Kidney Margin	13.5	19.3	Stomach	8.0	7.7
(OD04348)			Margin
			9060359
Kidney Cancer	1.5	1.9	Gastric Cancer	2.8	3.1
(OD04622-01)			9060395
Kidney Margin	4.7	5.8	Stomach	8.1	8.7
(OD04622-03)			Margin
			9060394
Kidney Cancer	0.1	0.2	Gastric Cancer	0.5	0.9
(OD04450-01)			9060397
Kidney Margin	11.1	17.7	Stomach	9.8	9.7
(OD04450-03)			Margin
			9060396
Kidney Cancer	2.1	3.1	Gastric Cancer	1.7	2.6
8120607			064005

[0730]

TABLE EK
Panel 3D
	Rel. Exp.(%) Ag554,		Rel. Exp.(%) Ag554,
Tissue Name	Run 164886640	Tissue Name	Run 164886640
Daoy-Medulloblastoma	18.3	Ca Ski-Cervical epidermoid	6.6
		carcinoma (metastasis)
TE671-Medulloblastoma	1.0	ES-2-Ovarian clear cell	0.9
		carcinoma
D283 Med-	1.8	Ramos-Stimulated with	0.0
Medulloblastoma		PMA/ionomycin 6h
PFSK-1-Primitive	0.0	Ramos-Stimulated with	0.0
Neuroectodermal		PMA/ionomycin 14h
XF-498-CNS	46.7	MEG-01-Chronic	0.0
		myelogenous leukemia
		(megokaryoblast)
SNB-78-Glioma	1.2	Raji-Burkitt's lymphoma	0.0
SF-268-Glioblastoma	3.5	Daudi-Burkitt's lymphoma	0.0
T98G-Glioblastoma	3.5	U266-B-cell plasmacytoma	0.0
SK-N-SH-Neuroblastoma	2.1	CA46-Burkitt's lymphoma	0.0
(metastasis)
SF-295-Glioblastoma	2.9	RL-non-Hodgkin's B-cell	0.0
		lymphoma
Cerebellum	0.0	JM1-pre-B-cell lymphoma	0.0
Cerebellum	0.1	Jurkat-T cell leukemia	0.0
NCI-H292-	13.8	TF-1-Erythroleukemia	0.0
Mucoepidermoid lung
carcinoma
DMS-114-Small cell lung	1.1	HUT 78-T-cell lymphoma	0.0
cancer
DMS-79-Small cell lung	77.9	U937-Histiocytic lymphoma	0.0
cancer
NCI-H146-Small cell	0.0	KU-812-Myelogenous	0.0
lung cancer		leukemia
NCI-H526-Small cell	0.6	769-P-Clear cell renal	2.8
lung cancer		carcinoma
NCI-N417-Small cell	0.0	Caki-2-Clear cell renal	2.4
lung cancer		carcinoma
NCI-H82-Small cell lung	3.1	SW 839-Clear cell renal	4.8
cancer		carcinoma
NCI-H157-Squamous	18.9	G401-Wilms' tumor	0.0
cell lung cancer
(metastasis)
NCI-H1155-Large cell	3.5	Hs766T-Pancreatic carcinoma	13.5
lung cancer		(LN metastasis)
NCI-H1299-Large cell	0.0	CAPAN-1-Pancreatic	2.2
lung cancer		adenocarcinoma (liver
		metastasis)
NCI-H727-Lung	27.9	SU86.86-Pancreatic	8.7
carcinoid		carcinoma (liver metastasis)
NCI-UMC-11-Lung	0.2	BxPC-3-Pancreatic	5.3
carcinoid		adenocarcinoma
LX-1-Small cell lung	2.9	HPAC-Pancreatic	13.9
cancer		adenocarcinoma
Colo-205-Colon cancer	2.0	MIA PaCa-2-Pancreatic	13.6
		carcinoma
KM12-Colon cancer	7.0	CFPAC-1-Pancreatic ductal	23.0
		adenocarcinoma
KM20L2-Colon cancer	0.0	PANC-1-Pancreatic	100.0
		epithelioid ductal carcinoma
NCI-H716-Colon cancer	0.3	T24-Bladder carcinoma	7.5
		(transitional cell)
SW-48-Colon	0.0	5637-Bladder carcinoma	2.3
adenocarcinoma
SW1116-Colon	0.7	HT-1197-Bladder carcinoma	0.3
adenocarcinoma
LS 174T-Colon	1.4	UM-UC-3-Bladder carcinma	0.0
adenocarcinoma		(transitional cell)
SW-948-Colon	2.7	A204-Rhabdomyosarcoma	0.0
adenocarcinoma
SW-480-Colon	0.0	HT-1080-Fibrosarcoma	5.7
adenocarcinoma
NCI-SNU-5-Gastric	17.4	MG-63-Osteosarcoma	7.4
carcinoma
KATO III-Gastric	0.2	SK-LMS-1-Leiomyosarcoma	10.8
carcinoma		(vulva)
NCI-SNU-16-Gastric	6.9	SJRH30-Rhabdomyosarcoma	8.2
carcinoma		(met to bone marrow)
NCI-SNU-1-Gastric	0.0	A431-Epidermoid carcinoma	6.3
carcinoma
RF-1-Gastric	0.0	WM266-4-Melanoma	0.0
adenocarcinoma
RF-48-Gastric	0.0	DU 145-Prostate carcinoma	0.0
adenocarcinoma		(brain metastasis)
MKN-45-Gastric	9.3	MDA-MB-468-Breast	0.0
carcinoma		adenocarcinoma
NCI-N87-Gastric	2.2	SCC-4-Squamous cell	0.0
carcinoma		carcinoma of tongue
OVCAR-5-Ovarian	6.5	SCC-9-Squamous cell	0.0
carcinoma		carcinoma of tongue
RL95-2-Uterine	0.2	SCC-15-Squamous cell	0.7
carcinoma		carcinoma of tongue
HelaS3-Cervical	0.9	CAL 27-Squamous cell	0.6
adenocarcinoma		carcinoma of tongue

[0731]

TABLE EL
Panel 4.1D
	Rel.	Rel.		Rel.	Rel.
	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)
	Ag3340,	Ag3340,		Ag3340,	Ag3340,
	Run	Run		Run	Run
Tissue Name	170737060	170766524	Tissue Name	170737060	170766524
Secondary Th1 act	0.2	0.0	HUVEC IL-1 beta	0.0	0.0
Secondary Th2 act	0.0	0.0	HUVEC IFN	0.0	0.0
			gamma
Secondary Tr1 act	0.0	0.0	HUVEC TNF	0.0	0.0
			alpha + IFN
			gamma
SecondaryTh1 rest	0.0	0.0	HUVEC TNF	1.2	1.8
			alpha + IL4
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.2	0.0
Secondary Tr1 rest	0.0	0.0	Lung	1.7	2.0
			Microvascular EC
			none
Primary Th1 act	0.0	0.0	Lung	0.0	0.0
			Microvascular EC
			TNF alpha + IL-
			1 beta
Primary Th2 act	0.0	0.0	Microvascular	0.5	1.2
			Dermal EC none
Primary Tr1 act	0.0	1.5	Microsvasular	0.0	0.0
			Dermal EC
			TNF alpha + IL-
			1 beta
Primary Th1 rest	0.0	0.0	Bronchial	0.6	0.4
			epithelium
			TNF alpha +
			IL1 beta
Primary Th2 rest	0.0	0.0	Small airway	0.0	1.9
			epithelium none
Primary Tr1 rest	0.2	0.0	Small airway	0.4	0.3
			epithelium
			TNF alpha + IL-
			1 beta
CD45RA CD4	1.3	0.4	Coronery artery	2.6	7.6
lymphocyte act			SMC rest
CD45RO CD4	0.0	0.0	Coronery artery	3.1	2.9
lymphocyte act			SMC TNF alpha +
			IL-1 beta
CD8 lymphocyte	0.0	0.0	Astrocytes rest	18.4	35.4
act
Secondary CD8	0.0	0.0	Astrocytes	7.0	11.7
lymphocyte rest			TNF alpha + IL-
			1 beta
Secondary CD8	0.0	0.0	KU-812 (Basophil)	0.0	0.0
lymphocyte act			rest
CD4 lymphocyte	0.0	0.0	KU-812 (Basophil)	0.4	0.0
none			PMA/ionomycin
2ry	0.0	0.0	CCD1106	10.3	8.5
Th1/Th2/Tr1_anti-			(Keratinocytes)
CD95 CH11			none
LAK cells rest	0.0	0.0	CCD1106	1.2	3.3
			(Keratinocytes)
			TNF alpha + IL-
			1 beta
LAK cells IL-2	0.4	0.0	Liver cirrhosis	0.3	0.9
LAK cells IL-2 +	0.0	0.0	NCI-H292 none	1.1	5.6
IL-12
LAK cells IL-	0.0	0.0	NCI-H292 IL-4	28.1	42.3
2 + IFN gamma
LAK cells IL-2 +	0.0	0.0	NCI-H292 IL-9	4.3	10.1
IL-18
LAK cells	0.0	0.4	NCI-H292 IL-13	46.7	52.1
PMA/ionomycin
NK Cells IL-2 rest	0.2	0.8	NCI-H292 IFN	0.8	8.1
			gamma
Two Way MLR 3	0.0	0.0	HPAEC none	0.0	1.5
day
Two Way MLR 5	0.0	0.0	HPAEC TNF	0.0	3.9
day			alpha + IL-1 beta
Two Way MLR 7	0.0	0.0	Lung fibroblast	76.3	74.7
day			none
PBMC rest	0.0	0.0	Lung fibroblast	0.8	2.2
			TNF alpha + IL-1
			beta
PBMC PWM	0.0	0.0	Lung fibroblast IL-4	100.0	92.7
PBMC PHA-L	0.0	0.3	Lung fibroblast IL-9	48.3	48.0
Ramos (B cell)	0.0	0.0	Lung fibroblast IL-	100.0	100.0
none			13
Ramos (B cell)	0.0	0.0	Lung fibroblast	32.1	51.4
ionomycin			IFN gamma
B lymphocytes	0.0	0.0	Dermal fibroblast	4.5	7.4
PWM			CCD1070 rest
B lymphocytes	0.0	0.0	Dermal fibroblast	3.0	3.1
CD40L and IL-4			CCD1070 TNF
			alpha
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast	1.8	2.2
			CCD1070 IL-1
			beta
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast	2.7	6.5
PMA/ionomycin			IFN gamma
Dendritic cells none	0.6	0.0	Dermal fibroblast	40.9	43.2
			IL-4
Dendritic cells LPS	0.2	0.5	Dermal Fibroblasts	8.0	9.2
			rest
Dendritic cells anti-	4.5	3.4	Neutrophils	1.1	0.9
CD40			TNFa + LPS
Monocytes rest	0.0	0.0	Neutrophils rest	2.2	0.0
Monocytes LPS	0.0	0.0	Colon	3.5	2.3
Macrophages rest	0.9	1.1	Lung	7.0	8.5
Macrophages LPS	0.0	0.0	Thymus	5.0	12.8
HUVEC none	0.1	0.0	Kidney	21.2	36.1
HUVEC starved	0.3	0.0

[0732]

TABLE EM
Panel 4D
	Rel.	Rel.		Rel.	Rel.
	Exp. (%)	Exp. (%)		Exp. (%)	Exp. (%)
	Ag3340,	Ag554,		Ag3340,	Ag554,
	Run	Run		Run	Run
Tissue Name	165222713	164886924	Tissue Name	165222713	164886924
Secondary Th1 act	0.0	0.1	HUVEC IL-1 beta	0.0	0.0
Secondary Th2 act	0.0	0.1	HUVEC IFN	0.0	0.0
			gamma
Secondary Tr1 act	0.0	0.1	HUVEC TNF	0.0	0.0
			alpha + IFN
			gamma
Secondary Th1 rest	0.0	0.0	HUVEC TNF	0.6	0.5
			alpha + IL4
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.1	0.0
Secondary Tr1 rest	0.1	0.0	Lung	0.4	0.9
			Microvascular EC
			none
Primary Th1 act	0.0	0.0	Lung	0.1	0.2
			Microvascular EC
			TNF alpha + IL-
			1 beta
Primary Th2 act	0.0	0.0	Microvascular	0.3	0.6
			Dermal EC none
Primary Tr1 act	0.0	0.0	Microsvasular	0.0	0.1
			Dermal EC
			TNF alpha + IL-
			1 beta
Primary Th1 rest	0.0	0.0	Bronchial	0.0	0.4
			epithelium
			TNF alpha +
			IL1 beta
Primary Th2 rest	0.0	0.0	Small airway	0.5	0.2
			epithelium none
Primary Tr1 rest	0.3	0.0	Small airway	0.4	1.0
			epithelium
			TNF alpha + IL-
			1 beta
CD45RA CD4	0.1	0.4	Coronery artery	2.7	3.5
lymphocyte act			SMC rest
CD45RO CD4	0.0	0.0	Coronery artery	1.2	0.8
lymphocyte act			SMC TNF alpha +
			IL-1 beta
CD8 lymphocyte	0.0	0.0	Astrocytes rest	19.5	21.8
act
Secondary CD8	0.0	0.0	Astrocytes	7.0	6.9
lymphocyte rest			TNF alpha + IL-
			1 beta
Secondary CD8	0.0	0.0	KU-812 (Basophil)	0.0	0.0
lymphocyte act			rest
CD4 lymphocyte	0.0	0.0	KU-812 (Basophil)	0.0	0.0
none			PMA/ionomycin
2ry	0.1	0.1	CCD1106	2.8	3.4
Th1/Th2/Tr1_anti-			(Keratinocytes)
CD95 CH11			none
LAK cells rest	0.0	0.0	CCD1106	2.3	1.3
			(Keratinocytes)
			TNF alpha + IL-
			1 beta
LAK cells IL-2	0.0	0.0	Liver cirrhosis	0.6	1.6
LAK cells IL-2 +	0.1	0.0	Lupus kidney	0.5	0.9
IL-12
LAK cells IL-	0.0	0.0	NCI-H292 none	2.7	2.7
2 + IFN gamma
LAK cells IL-2 +	0.1	0.1	NCI-H292 IL-4	33.4	39.5
IL-18
LAK-cells	0.1	0.0	NCI-H292 IL-9	4.6	3.5
PMA/ionomycin
NK Cells IL-2 rest	0.1	0.2	NCI-H292 IL-13	31.0	26.1
Two Way MLR 3	0.0	0.0	NCI-H292 IFN	3.4	3.6
day			gamma
Two Way MLR 5	0.0	0.2	HPAEC none	0.0	0.0
day
Two Way MLR 7	0.0	0.0	HPAEC TNF	0.0	0.0
day			alpha + IL-1 beta
PBMC rest	0.0	0.0	Lung fibroblast	36.9	53.6
			none
PBMC PWM	0.0	0.0	Lung fibroblast	0.6	0.8
			TNF alpha + IL-1
			beta
PBMC PHA-L	0.0	0.0	Lung fibroblast IL-4	100.0	100.0
Ramos (B cell)	0.0	0.0	Lung fibroblast IL-9	26.8	29.7
none
Ramos (B cell)	0.0	0.0	Lung fibroblast IL-	75.8	74.2
ionomycin			13
B lymphocytes	0.0	0.0	Lung fibroblast	32.8	36.6
PWM			IFN gamma
B lymphocytes	0.0	0.0	Dermal fibroblast	2.5	5.6
CD40L and IL-4			CCD1070 rest
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast	0.9	2.8
			CCD1070 TNF
			alpha
EOL-1 dbcAMP	0.1	0.0	Dermal fibroblast	0.4	0.4
PMA/ionomycin			CCD1070 IL-1
			beta
Dendritic cells none	0.2	0.6	Dermal fibroblast	0.6	2.8
			IFN gamma
Dendritic cells LPS	0.0	0.1	Dermal fibroblast	26.6	29.9
			IL-4
Dendritic cells anti-	1.2	2.0	IBD Colitis 2	0.4	0.7
CD40
Monocytes rest	0.0	0.0	IBD Crohn's	1.6	1.5
Monocytes LPS	0.0	0.0	Colon	1.8	2.5
Macrophages rest	0.3	0.9	Lung	4.8	8.5
Macrophages LPS	0.0	0.0	Thymus	16.3	24.7
HUVEC none	0.0	0.0	Kidney	3.4	3.8
HUVEC starved	0.0	0.4

[0733] AI_comprehensive panel_v1.0 Summary: Ag3340 The transcript is highly expressed in 3 out of 6 ulcerative colitis samples, but not in the matched control samples. Similarly, it is expressed in OA tissue and not in normal control samples. Asthma and emphysema lung samples express the transcript at higher levels than in normal lung.

[0734] The protein encoded for by CG57829-01 has homology to ADAMTS family of molecules suggesting that it may function as an enzyme. Based on its homology, it may contribute to the tissue destruction and remodeling processes associated with asthma, ulcerative colitis, emphysema and osteoarthritis. Therefore, blocking the function of the protein encoded for by CG57829-01 with antagonistic antibody therapeutics or small molecule therapeutics could reduce or inhibit tissue destruction in the lungs, intestine, or joints due to emphysema, allergy, asthma, colitis, or osteoarthritis.

[0735] CNS_neurodegeneration_v1.0 Summary: Ag3340 This panel does not show differential expression of the CG57829-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

[0736] General_screening_panel_v1.4 Summary: Ag3340 Two experiments with the same probe and primer set are in excellent agreement. Highest expression of the CG57829-01 gene is seen in breast cancer MDA-MB-231 cell line (CTs=25). As seen in Panel 1.1, 1.2, and 1.3, this gene has high expression in ovarian and breast cancer cell lines which is also confirmed in Panels 2.1 and 2D. Therefore, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furhtermore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of breast or ovarian cancer.

[0737] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, fetal liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0738] Interestingly, this gene is expressed at much higher levels in fetal (CT=32) when compared to adult liver (CT=36). This observation suggests that expression of this gene can be used to distinguish fetal from adult liver.

[0739] In addition, this gene is expressed at low to moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0740] This gene encodes a homologue of rat ADAMTS-1. Members belonging to ADAM and ADAMTS family has been found to play a role in various inflammatory processes such as arthritic diseases, as well as, development of cancer cachexia and thrombotic thrombocytopenic purpura (Ref. 1, 2, 3). Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these diseases.

[0741] References.

[0742] 1. Martel-Pelletier J, Welsch D J, Pelletier J P. (2001) Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 15(5):805-29

[0743] 2. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K. (1 997) Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombosponidin motifs as an inflammation associated gene. J Biol Chem 272(1):556-62.

[0744] 3. Levy G G, Nichols W C, Lian E C, Foroud T, McClintick J N, McGee B M, Yang A Y, Siemieniak D R, Stark K R, Gnippo R, Sarode R, Shurin S B, Chandrasekaran V, Stabler S P, Sabio H, Bouhassira E E, Upshaw J D Jr, Ginsburg D, Tsai H M. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413(6855):488-94

[0745] Panel 1.1 Summary: Ag554 Highest expression of the CG57829-01 gene is seen in ovarian cancer OVCAR-3 cell line (CT=22). Expression pattern of this gene in this panel is similar to that of panel 1.4. Please see panel 1.4 for discussion and potential utility of this gene.

[0746] Panel 1.2 Summary: Ag554 Highest expression of the CG57829-01 gene is seen in fetal kidney (CT=23.8). Interestingly, this gene is expressed at much higher levels in fetal (CT=23.8) when compared to adult kidney (CT=27-31). This observation suggests that expression of this gene can be used to distinguish fetal from adult kidney.

[0747] High expression of this gene is also seen in cluster of ovarian cancer, breat cancer, renal cancer, prostate cancer, CNS cancer cell lines, as well as in placenta, mammary glands, liver, trachea, stomach, colorectal, and heart. Please see panel 1.4 for discussion and potential utility of this gene.

[0748] Panel 1.3D Summary: Ag554 Highest expression of the CG57829-01 gene is seen in breast cancer MDA-MB-231 cell line (CT=27.8). Expression pattern of this gene in this panel is similar to that of panel 1.4. Please see panel 1.4 for discussion and potential utility of this gene.

[0749] Panel 2.1 Summary: Ag3340 Highest expression of the CG57829-01 gene is seen in breast cancer metastasis sample (CT=28). As seen in panel 1.4, expression of this gene is associated with most cancers. Interestingly, expression of this gene seems to be down-regulated in kidney cancers (OD04340, OD04348, OD04450-01, 8120614) and colon metastasis to lung (OD04451-01) (CTs=35-40) compared to the marginal control samples (CTs=31-33). Therefore, expression of this gene can be used as potential marker to distinguishing between these cancer and normal tissues.

[0750] Please see panel 1.4 for discussion and potential utility of this gene.

[0751] Panel 2D Summary: Ag554 Highest expression of the CG57829-01 gene is seen in breast cancer metastasis (OD04590-03) sample (CT=27). As seen in panel 1.4, expression of this gene is associated with most cancers, with high expression in breast cancer samples. Please see panel 1.4 for discussion and potential utility of this gene.

[0752] Panel 3D Summary: Ag554 Highest expression of the CG57829-01 gene is seen in PANC-1-Pancreatic epithelioid ductal carcinoma sample (CT=28). As seen in panel 1.4, expression of this gene is associated with most cancers, with high expression in XF-CNS, small cell lung and pancreatic cancers. Please see panel 1.4 for discussion and potential utility of this gene.

[0753] Panel 4.1D Summary: Ag3340 CG57829-01 is highly induced in the mucoepidermoid cell line NCI-H292 by IL-4 and IL-13 (CTs=29-30). Expression is also high in lung fibroblasts treated with IL-4 or IL-13 and dermal fibroblasts treated with IL-4 (CTs=28-29). These findings are consistent in 3 separate runs with two sets of primers and probes.

[0754] Potential Role(s) of CG57829-01 in Inflammation: The protein encoded for by CG57892-01 has homology to ADAMTS family of molecules suggesting that it may function as an enzyme (see references in panel 1.4). The expression of this transcript by lung fibroblasts, the goblet cell like cell line NCI-H292 and dermal fibroblasts, particularly after exposure to IL-4 and IL-13 is consistent with it participating in diseases such as asthma, psoriasis, emphysema and arthritis (Ref. 1, 2). Based on its homology, it may contribute to the tissue destruction and remodeling processes associated with asthma, psoriasis, emphysema and arthritis.

[0755] Blocking the function of the protein encoded for by CG57892-01 with antagonistic antibody therapeutics could reduce or inhibit tissue destruction in the lungs, skin, or joints due to emphysema, allergy, asthma, psoriasis, or arthritis.

[0756] References.

[0757] 1. Laliberte R, Rouabhia M, Bosse M, Chakir J. Decreased capacity of asthmatic bronchial fibroblasts to degrade collagen. Matrix Biol January 2001;19(8):743-53

[0758] 2. Vankemmelbeke M N, Holen I, Wilson A, Ilic M Z, Handley C J, Kelner G S, Clark M, Liu C, Maki R A, Burnett D, Buttle D J. Expression and activity of ADAMTS-5 in synovium. Eur J Biochem March 2001;268(5):1259-68

[0759] Panel 4D Summary: Ag554/Ag3340 Expression pattern for the CG57829-01 gene is same as seen in panel 4.1D with highest expression in IL-4 Stimulated lung fibroblast (CT=26.7). Please see the panel 4.1D for discussion and potential utility of this gene.

F. NOV6a (CG59197-01: TULIP 2)

[0760] Expression of gene CG59197-01 was assessed using the primier-probe set Ag3391, described in Table FA. Results of the RTQ-PCR runs are shown in Tables FB, FC and FD.

TABLE FA
Probe Name Ag3391
			Start
Primers	Sequences	Length	Position
Forward	5′-cctgaactctttgagagtccaa-3′	(SEQ ID NO:230)	22	1146
Probe	TET-5′-caaccttagtgtcctgtatccagatca-3′-TAMRA	(SEQ ID NO:231)	27	1195
Reverse	5′-ctccaggcatattctcttctga-3′	(SEQ ID NO:232)	22	1224

[0761]

TABLE FB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3391,		Rel. Exp.(%) Ag3391,
Tissue Name	Run 210349173	Tissue Name	Run 210349173
AD 1 Hippo	9.5	Control (Path) 3	5.7
		Temporal Ctx
AD 2 Hippo	24.5	Control (Path) 4	33.0
		Temporal Ctx
AD 3 Hippo	5.4	AD 1 Occipital Ctx	15.0
AD 4 Hippo	4.3	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 Hippo	85.9	AD 3 Occipital Ctx	5.4
AD 6 Hippo	46.7	AD 4 Occipital Ctx	18.8
Control 2 Hippo	22.5	AD 5 Occipital Ctx	38.2
Control 4 Hippo	8.6	AD 6 Occipital Ctx	34.4
Control (Path) 3	9.4	Control 1 Occipital	6.8
Hippo		Ctx
AD 1 Temporal Ctx	19.3	Control 2 Occipital	60.7
		Ctx
AD 2 Temporal Ctx	32.3	Control 3 Occipital	17.9
		Ctx
AD 3 Temporal Ctx	5.7	Control 4 Occipital	7.3
		Ctx
AD 4 Temporal Ctx	19.9	Control (Path) 1	97.3
		Occipital Ctx
AD 5 Inf Temporal	100.0	Control (Path) 2	12.2
Ctx		Occipital Ctx
AD 5 Sup Temporal	43.5	Control (Path) 3	5.1
Ctx		Occipital Ctx
AD 6 Inf Temporal	53.2	Control (Path) 4	16.6
Ctx		Occipital Ctx
AD 6 Sup Temporal	59.9	Control 1 Parietal	8.9
Ctx		Ctx
Control 1 Temporal	7.0	Control 2 Parietal	41.8
Ctx		Ctx
Control 2 Temporal	35.6	Control 3 Parietal	17.6
Ctx		Ctx
Control 3 Temporal	14.6	Control (Path) 1	73.7
Ctx		Parietal Ctx
Control 3 Temporal	8.7	Control (Path) 2	26.2
Ctx		Parietal Ctx
Control (Path) 1	57.0	Control (Path) 3	6.7
Temporal Ctx		Parietal Ctx
Control (Path) 2	36.9	Control (Path) 4	44.4
Temporal Ctx		Parietal Ctx

[0762]

TABLE FC
General_screening_panel v1.4
	Rel. Exp.(%) Ag3391,		Rel. Exp.(%) Ag3391,
Tissue Name	Run 216822195	Tissue Name	Run 216822195
Adipose	12.9	Renal ca. TK-10	25.9
Melanoma*	14.7	Bladder	30.6
Hs688(A).T
Melanoma*	14.3	Gastric ca. (liver met.)	30.6
Hs688(B).T		NCI-N87
Melanoma* M14	9.0	Gastric ca. KATO III	24.1
Melanoma*	12.0	Colon ca. SW-948	5.9
LOXIMVI
Melanoma* SK-	30.1	Colon ca. SW480	24.1
MEL-5
Squamous cell	6.9	Colon ca.* (SW480	20.9
carcinoma SCC-4		met) SW620
Testis Pool	16.0	Colon ca. HT29	7.2
Prostate ca.* (bone	35.6	Colon ca. HCT-116	39.8
met) PC-3
Prostate Pool	16.5	Colon ca. CaCo-2	24.1
Placenta	3.0	Colon cancer tissue	12.4
Uterus Pool	16.8	Colon ca. SW1116	7.6
Ovarian ca. OVCAR-3	24.5	Colon ca. Colo-205	2.2
Ovarian ca. SK-OV-3	54.3	Colon ca. SW-48	2.1
Ovarian ca. OVCAR-4	2.2	Colon Pool	36.9
Ovarian ca. OVCAR-5	49.0	Small Intestine Pool	44.4
Ovarian ca. IGROV-1	21.9	Stomach Pool	21.5
Ovarian ca. OVCAR-8	10.4	Bone Marrow Pool	18.8
Ovary	13.9	Fetal Heart	13.7
Breast ca. MCF-7	46.3	Heart Pool	18.0
Breast ca. MDA-	22.4	Lymph Node Pool	48.6
MB-231
Breast ca. BT 549	44.8	Fetal Skeletal Muscle	8.7
Breast ca. T47D	100.0	Skeletal Muscle Pool	21.2
Breast ca. MDA-N	9.3	Spleen Pool	17.9
Breast Pool	40.9	Thymus Pool	23.7
Trachea	17.4	CNS cancer (glio/astro)	18.6
		U87-MG
Lung	11.3	CNS cancer (glio/astro)	40.6
		U-118-MG
Fetal Lung	57.4	CNS cancer (neuro;met)	38.2
		SK-N-AS
Lung ca. NCI-N417	6.2	CNS cancer (astro) SF-	7.5
		539
Lung ca. LX-1	27.9	CNS cancer (astro)	35.6
		SNB-75
Lung ca. NCI-H146	8.7	CNS cancer (glio) SNB-	21.3
		19
Lung ca. SHP-77	46.7	CNS cancer (glio) SF-	35.6
		295
Lung ca. A549	30.4	Brain (Amygdala) Pool	28.1
Lung ca. NCI-H526	5.8	Brain (cerebellum)	33.7
Lung ca. NCI-H23	50.0	Brain (fetal)	65.5
Lung ca. NCI-H460	25.0	Brain (Hippocampus)	29.3
		Pool
Lung ca. HOP-62	10.8	Cerebral Cortex Pool	37.1
Lung ca. NCI-H522	26.2	Brain (Substantia nigra)	33.0
		Pool
Liver	0.6	Brain (Thalamus) Pool	49.3
Fetal Liver	15.5	Brain (whole)	21.2
Liver ca. HepG2	45.1	Spinal Cord Pool	23.5
Kidney Pool	70.2	Adrenal Gland	16.3
Fetal Kidney	28.3	Pituitary gland Pool	10.7
Renal ca. 786-0	12.2	Salivary Gland	3.4
Renal ca. A498	3.6	Thyroid (female)	16.2
Renal ca. ACHN	8.4	Pancreatic ca. CAPAN2	18.8
Renal ca. UO-31	14.4	Pancreas Pool	47.6

[0763]

TABLE FD
Panel 4D
	Rel. Exp.(%) Ag3391,		Rel. Exp.(%) Ag3391,
Tissue Name	Run 165296469	Tissue Name	Run 165296469
Secondary Th1 act	16.2	HUVEC IL-1 beta	8.4
Secondary Th2 act	20.3	HUVEC IFN gamma	17.3
Secondary Tr1 act	17.2	HUVEC TNF alpha + IFN	9.0
		gamma
Secondary Th1 rest	8.8	HUVEC TNF alpha + IL4	8.2
Secondary Th2 rest	7.3	HUVEC IL-11	4.4
Secondary Tr1 rest	9.6	Lung Microvascular EC	14.5
		none
Primary Th1 act	25.7	Lung Microvascular EC	10.6
		TNF alpha + IL-1 beta
Primary Th2 act	24.8	Microvascular Dermal EC	14.9
		none
Primary Tr1 act	39.2	Microsvasular Dermal EC	10.3
		TNF alpha + IL-1 beta
Primary Th1 rest	54.3	Bronchial epithelium	17.9
		TNF alpha + IL1 beta
Primary Th2 rest	31.6	Small airway epithelium	5.7
		none
Primary Tr1 rest	29.9	Small airway epithelium	43.5
		TNF alpha + IL-1 beta
CD45RA CD4	8.7	Coronery artery SMC rest	11.0
lymphocyte act
CD45RO CD4	16.6	Coronery artery SMC	6.4
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	12.7	Astrocytes rest	8.8
Secondary CD8	13.6	AstrocytesTNF alpha + IL-	7.3
lymphocyte rest		1 beta
Secondary CD8	9.5	KU-812 (Basophil) rest	4.9
lymphocyte act
CD4 lymphocyte none	7.6	KU-812 (Basophil)	26.8
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	12.9	CCD1106 (Keratinocytes)	8.0
CD95 CH11		none
LAK cells rest	14.5	CCD1106 (Keratinocytes)	3.9
		TNF alpha + IL-1 beta
LAK cells IL-2	16.4	Liver cirrhosis	4.0
LAK cells IL-2 + IL-12	18.7	Lupus kidney	3.6
LAK cells IL-2 + IFN	36.9	NCI-H292 none	29.9
gamma
LAK cells IL-2 + IL-18	33.4	NCI-H292 1L-4	50.3
LAK cells	18.9	NCI-H292 IL-9	34.2
PMA/ionomycin
NK Cells IL-2 rest	18.4	NCI-H292 IL-13	17.0
Two Way MLR 3 day	24.3	NCI-H292 IFN gamma	17.3
Two Way MLR 5 day	10.3	HPAEC none	8.0
Two Way MLR 7 day	7.5	HPAEC TNF alpha + IL-1	13.2
		beta
PBMC rest	8.7	Lung fibroblast none	7.0
PBMC PWM	61.1	Lung fibroblast TNF	5.3
		alpha + IL-1 beta
PBMC PHA-L	14.9	Lung fibroblast IL-4	14.6
Ramos (B cell) none	19.1	Lung fibroblast IL-9	15.8
Ramos (B cell)	100.0	Lung fibroblast IL-13	9.7
ionomycin
B lymphocytes PWM	65.1	Lung fibroblast IFN	17.4
		gamma
B lymphocytes CD40L	24.7	Dermal fibroblast	21.5
and IL-4		CCD1070 rest
EOL-1 dbcAMP	7.7	Dermal fibroblast	63.7
		CCD1070 TNF alpha
EOL-1 dbcAMP	12.4	Dermal fibroblast	8.5
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	13.1	Dermal fibroblast IFN	6.1
		gamma
Dendritic cells LPS	19.2	Dermal fibroblast IL-4	14.8
Dendritic cells anti-	12.3	IBD Colitis 2	2.1
CD40
Monocytes rest	14.8	IBD Crohn's	3.0
Monocytes LPS	29.9	Colon	23.2
Macrophages rest	18.8	Lung	11.0
Macrophages LPS	18.8	Thymus	34.9
HUVEC none	12.5	Kidney	25.2
HUVEC starved	28.9

[0764] CNS_neurodegeneration_v1.0 Summary: Ag3391 This panel confirms the expression of the CG59197-01 gene at significant levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[0765] General_screening_panel_v1.4 Summary: Ag3391 The CG59197-01 gene codes for a homologue of rat tuberin like protein, Tulip 2. Expression of this gene is ubiquitous in this panel, with highest expression in a breast cancer T47D cell line (CT=27). Expression of this gene appears to be higher in samples derived from breast, ovarian, prostate and melanoma cancer cell lines than in normal tissues. The widespread expression suggests that this gene product is involved in cell growth and proliferation. Thus, therapeutic modulation of the expression or function of this gene may be useful in the treatment of cancer.

[0766] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract (CTs=28-34). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity, and Types 1 and 2 diabetes.

[0767] Interestingly, this gene is expressed at much higher levels in fetal (CT=29.7) when compared to adult liver (CT=34.5). This observation suggests that expression of this gene can be used to distinguish fetal from adult liver.

[0768] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord (CTs=27-29). Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0769] Panel 4D Summary: Ag3391 Highest expression of the CG59197-01 gene is seen in ionomycin treated Ramos B cells (CT=27.6). This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

[0770] In addition, expression of this gene is up-regulated in TNFalpha+IL-1beta-treated small airway epithelium, and PWM-treated PBMC (CTs=28) as compared to the untreated counterparts (CTs=31). Thus, expression of this gene may be used to distinguish between cytokine-treated small airway epithelium and PWM-treated PBMC cells from their untreated counterparts.

G. NOV9a (CC58180-01: PROHIBITION)

[0771] Expression of gene CG58180-01 was assessed using the primer-probe set Ag3515, described in Table GA. Results of the RTQ-PCR runs are shown in Tables GB, GC and GD.

TABLE GA
Probe Name Ag3515
			Start
Primers	Sequences	Length	Position
Forward	5′-gcctttctccaccacgtaa-3′	(SEQ ID NO:233)	19	223
Probe	TET-5′-tgtaccaatcatcactggtagcaaaga-3′-TAMRA	(SEQ ID NO:234)	27	242
Reverse	5′-caacaggctggaagatgatg-3′	(SEQ ID NO:235)	20	296

[0772]

TABLE GB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3515,		Rel. Exp.(%) Ag3515,
Tissue Name	Run 210499747	Tissue Name	Run 210499747
AD 1 Hippo	12.4	Control (Path) 3	6.5
		Temporal Ctx
AD 2 Hippo	26.8	Control (Path) 4	40.1
		Temporal Ctx
AD 3 Hippo	8.2	AD 1 Occipital Ctx	18.7
AD 4 Hippo	11.0	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	71.7	AD 3 Occipital Ctx	19.3
AD 6 Hippo	100.0	AD 4 Occipital Ctx	36.6
Control 2 Hippo	15.3	AD 5 Occipital Ctx	15.1
Control 4 Hippo	21.9	AD 6 Occipital Ctx	31.4
Control (Path) 3	12.9	Control 1 Occipital	6.4
Hippo		Ctx
AD 1 Temporal Ctx	26.4	Control 2 Occipital	33.0
		Ctx
AD 2 Temporal Ctx	42.6	Control 3 Occipital	45.7
		Ctx
AD 3 Temporal Ctx	14.9	Control 4 Occipital	5.0
		Ctx
AD 4 Temporal Ctx	48.3	Control (Path) 1	95.3
		Occipital Ctx
AD 5 Inf Temporal Ctx	73.7	Control (Path) 2	27.7
Ctx		Occipital Ctx
AD 5 Sup Temporal	55.5	Control (Path) 3	3.5
Ctx		Occipital Ctx
AD 6 Inf Temporal	47.3	Control (Path) 4	36.1
Ctx		Occipital Ctx
AD 6 Sup Temporal	69.7	Control 1 Parietal	19.8
Ctx		Ctx
Control 1 Temporal	12.2	Control 2 Parietal	50.0
Ctx		Ctx
Control 2 Temporal	11.0	Control 3 Parietal	18.4
Ctx		Ctx
Control 3 Temporal	13.8	Control (Path) 1	47.0
Ctx		Parietal Ctx
Control 4 Temporal	11.7	Control (Path) 2	48.0
Ctx		Parietal Ctx
Control (Path) 1	51.4	Control (Path) 3	5.6
Temporal Ctx		Parietal Ctx
Control (Path) 2	55.9	Control (Path) 4	56.3
Temporal Ctx		Parietal Ctx

[0773]

TABLE GC
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3515,		Rel. Exp.(%) Ag3515,
Tissue Name	Run 216709850	Tissue Name	Run 216709850
Adipose	3.6	Renal ca. TK-10	21.6
Melanoma*	12.5	Bladder	46.3
Hs688(A).T
Melanoma*	12.0	Gastric ca. (liver met.)	57.4
Hs688(B).T		NCI-N87
Melanoma* M14	7.4	Gastric ca. KATO III	25.7
Melanoma*	7.3	Colon ca. SW-948	3.9
LOXIMVI
Melanoma* SK-	18.0	Colon ca. SW480	34.6
MEL-5
Squamous cell	5.2	Colon ca.* (SW480	37.4
carcinoma SCC-4		met) SW620
Testis Pool	6.5	Colon ca. HT29	15.4
Prostate ca.* (bone	6.1	Colon ca. HCT-116	49.7
met) PC-3
Prostate Pool	15.6	Colon ca. CaCo-2	51.1
Placenta	8.8	Colon cancer tissue	20.6
Uterus Pool	6.7	Colon ca. SW1116	6.0
Ovarian ca. OVCAR-3	12.2	Colon ca. Colo-205	3.0
Ovarian ca. SK-OV-3	46.3	Colon ca. SW-48	2.1
Ovarian ca. OVCAR-4	6.0	Colon Pool	30.4
Ovarian ca. OVCAR-5	27.0	Small Intestine Pool	35.1
Ovarian ca. IGROV-1	6.3	Stomach Pool	20.4
Ovarian ca. OVCAR-8	2.8	Bone Marrow Pool	15.4
Ovary	17.9	Fetal Heart	17.7
Breast ca. MCF-7	0.0	Heart Pool	9.3
Breast ca. MDA-	10.3	Lymph Node Pool	40.9
MB-231
Breast ca. BT 549	28.3	Fetal Skeletal Muscle	15.9
Breast ca. T47D	28.1	Skeletal Muscle Pool	13.8
Breast ca. MDA-N	4.9	Spleen Pool	20.9
Breast Pool	43.8	Thymus Pool	40.1
Trachea	25.3	CNS cancer (glio/astro)	29.3
		U87-MG
Lung	9.2	CNS cancer (glio/astro)	39.2
		U-118-MG
Fetal Lung	50.0	CNS cancer (neuro;met)	30.4
		SK-N-AS
Lung ca. NCI-N417	2.0	CNS cancer (astro) SF-	5.1
		539
Lung ca. LX-1	44.1	CNS cancer (astro)	3.4
		SNB-75
Lung ca. NCI-H146	4.6	CNS cancer (glio) SNB-	8.4
		19
Lung ca. SHP-77	27.4	CNS cancer (glio) SF-	41.5
		295
Lung ca. A549	26.8	Brain (Amygdala) Pool	5.8
Lung ca. NCI-H526	1.7	Brain (cerebellum)	20.6
Lung ca. NCI-H23	100.0	Brain (fetal)	23.7
Lung ca. NCI-H460	27.5	Brain (Hippocampus)	9.1
		Pool
Lung ca. HOP-62	16.5	Cerebral Cortex Pool	12.1
Lung ca. NCI-H522	30.4	Brain (Substantia nigra)	8.1
		Pool
Liver	0.4	Brain (Thalamus) Pool	8.5
Fetal Liver	6.6	Brain (whole)	8.9
Liver ca. HepG2	10.3	Spinal Cord Pool	7.2
Kidney Pool	40.1	Adrenal Gland	5.8
Fetal Kidney	60.3	Pituitary gland Pool	3.9
Renal ca. 786-0	0.0	Salivary Gland	6.7
Renal ca. A498	1.8	Thyroid (female)	3.3
Renal ca. ACHN	25.9	Pancreatic ca. CAPAN2	52.5
Renal ca. UO-31	12.5	Pancreas Pool	43.8

[0774]

TABLE GD
Panel 4D
	Rel. Exp.(%) Ag3515,		Rel. Exp.(%) Ag3515,
Tissue Name	Run 166407127	Tissue Name	Run 166407127
Secondary Th1 act	21.3	HUVEC IL-1 beta	4.8
Secondary Th2 act	32.3	HUVEC IFN gamma	20.2
Secondary Tr1 act	46.7	HUVEC TNF alpha + IFN	5.8
		gamma
Secondary Th1 rest	22.2	HUVEC TNF alpha + IL4	9.5
Secondary Th2 rest	20.7	HUVEC IL-11	14.7
Secondary Tr1 rest	28.3	Lung Microvascular EC	13.9
		none
Primary Th1 act	15.6	Lung Microvascular EC	15.4
		TNF alpha + IL-1 beta
Primary Th2 act	29.5	Microvascular Dermal EC	19.5
		none
Primary Tr1 act	38.2	Microsvasular Dermal EC	11.7
		TNF alpha + IL-1 beta
Primary Th1 rest	100.0	Bronchial epithelium	6.5
		TNF alpha + IL1 beta
Primary Th2 rest	46.7	Small airway epithelium	4.9
		none
Primary Tr1 rest	35.4	Small airway epithelium	24.3
		TNF alpha + IL-1 beta
CD45RA CD4	13.0	Coronery artery SMC rest	4.4
lymphocyte act
CD45RO CD4	29.9	Coronery artery SMC	3.5
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	24.3	Astrocytes rest	19.6
Secondary CD8	23.0	Astrocytes TNF alpha + IL-	24.3
lymphocyte rest		1 beta
Secondary CD8	19.8	KU-812 (Basophil) rest	15.2
lymphocyte act
CD4 lymphocyte none	14.7	KU-812 (Basophil)	32.8
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	41.5	CCD1106 (Keratinocytes)	16.4
CD95 CH11		none
LAK cells rest	13.9	CCD1106 (Keratinocytes)	62.9
		TNF alpha + IL-1 beta
LAK cells IL-2	32.8	Liver cirrhosis	6.4
LAK cells IL-2 + IL-12	32.3	Lupus kidney	18.0
LAK cells IL-2 + IFN	49.0	NCI-H292 none	35.8
gamma
LAK cells IL-2 + IL-18	36.1	NCI-H292 IL-4	29.7
LAK cells	11.7	NCI-H292 IL-9	31.4
PMA/ionomycin
NK Cells IL-2 rest	28.9	NCI-H292 IL-13	26.8
Two Way MLR 3 day	38.2	NCI-H292 IFN gamma	17.2
Two Way MLR 5 day	12.1	HPAEC none	8.3
Two Way MLR 7 day	15.7	HPAEC TNF alpha + IL-1	17.7
		beta
PBMC rest	8.5	Lung fibroblast none	22.4
PBMC PWM	25.2	Lung fibroblast TNF	9.9
		alpha + IL-1 beta
PBMC PHA-L	10.5	Lung fibroblast IL-4	15.4
Ramos (B cell) none	51.4	Lung fibroblast IL-9	12.0
Ramos (B cell)	17.3	Lung fibroblast IL-13	16.7
ionomycin
B lymphocytes PWM	18.6	Lung fibroblast IFN	11.3
		gamma
B lymphocytes CD40L	49.0	Dermal fibroblast	24.5
and IL-4		CCD1070 rest
EOL-1 dbcAMP	28.3	Dermal fibroblast	50.3
		CCD1070 TNF alpha
EOL-1 dbcAMP	50.7	Dermal fibroblast	14.6
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	19.6	Dermal fibroblast IFN	10.6
		gamma
Dendritic cells LPS	23.0	Dermal fibroblast IL-4	19.8
Dendritic cells anti-	19.1	IBD Colitis 2	5.8
CD40
Monocytes rest	47.6	IBD Crohn's	3.8
Monocytes LPS	16.8	Colon	61.6
Macrophages rest	20.7	Lung	9.3
Macrophages LPS	7.1	Thymus	32.1
HUVEC none	12.9	Kidney	54.0
HUVEC starved	22.8

[0775] CNS_neurodegeneration_v1.0 Summary: Ag3515 This panel does not show differential expression of the CG58180-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

[0776] General_screening_panel_v1.4 Summary: Ag3515 - Highest expression of the CG58180-01 gene is detected in lung cancer NCI-H23 cell line (CT=28.3). Expression of this gene is associated with gastric, pancreatic, brain, colon, renal, lung, breast, ovarian and prostate cancers, as well as, melanomas. This gene is a homologue of the human prohibitin (PHB), which has been found to be mutated in hereditary breast cancer (Ref. 1). Thus, expression of this gene could be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic modulation of the activity of this gene using antibodies or small molecule drugs might be of use in the treatment of these cancers.

[0777] In addition, this gene is expressed at significant levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0778] This gene product is also expressed in adipose, pancreas, adrenal, thyroid, pituitary, skeletal muscle, heart, and liver. This widespread expression in tissues with metabolic function suggests that this gene product may be important for the pathogenesis, diagnosis, and/or treatment of metabolic and endocrine diseases, including obesity and Types 1 and 2 diabetes.

[0779] References

[0780] 1. Sato T, Saito 1-1, Swenseni J, Olifant A, Wood C, Danner D, Sakamoto Tr, Takita K, Kasumi F, Miki Y, et al. The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer.: Cancer Res Mar. 15, 1992;52(6):1643-6.

[0781] Panel 4D Summary: Ag3515 - The CG58180-01 gene is expressed at low to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monolytic, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

H. NOV11a and NOV11b (CG59249-01 and CG59249-02: METALLAPROTEINASE-DISINTEGRIN BETA)

[0782] Expression of gene CG59249-01 and CG59249-02 was assessed using the primer-probe set Ag1930, described in Table HA. Results of the RTQ-PCR runs are shown in Table HB.

TABLE HA
Probe Name Ag1930
			Start
Primers	Sequences	Length	Position
Forward	5′-tatgcagtgtcaagccctttt-3′	(SEQ ID NO:236)	21	1558
Probe	TET-5′-ctaccaagtgaaagacggttccccag-3′-TAMRA	(SEQ ID NO:237)	26	1582
Reverse	5′-agtttccaaatcggttaccaat-3′	(SEQ ID NO:238)	22	1631

[0783]

TABLE HB
Panel 4D
	Rel. Exp.(%) Ag1930,		Rel. Exp.(%) Ag1930,
Tissue Name	Run 160658070	Tissue Name	Run 160658070
Secondary Th1 act	6.5	HUVEC IL-1 beta	1.1
Secondary Th2 act	4.4	HUVEC IFN gamma	11.6
Secondary Tr1 act	4.6	HUVEC TNF alpha + IFN	5.6
		gamma
Secondary Th1 rest	4.1	HUVEC TNF alpha + IL4	12.8
Secondary Th2 rest	4.2	HUVEC IL-11	14.7
Secondary Tr1 rest	2.0	Lung Microvascular EC	14.9
		none
Primary Th1 act	3.6	Lung Microvascular EC	12.0
		TNF alpha + IL-1 beta
Primary Th2 act	1.2	Microvascular Dermal EC	20.9
		none
Primary Tr1 act	3.5	Microsvasular Dermal EC	11.5
		TNF alpha + IL-1 beta
Primary Th1 rest	12.1	Bronchial epithelium	5.4
		TNF alpha + IL1 beta
Primary Th2 rest	13.9	Small airway epithelium	31.4
		none
Primary Tr1 rest	9.4	Small airway epithelium	100.0
		TNF alpha + IL-1 beta
CD45RA CD4	3.6	Coronery artery SMC rest	6.1
lymphocyte act
CD45RO CD4	8.9	Coronery artery SMC	10.3
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	1.7	Astrocytes rest	28.7
Secondary CD8	13.5	Astrocytes TNF alpha + IL-	21.8
lymphocyte rest		1 beta
Secondary CD8	3.4	KU-812 (Basophil) rest	36.6
lymphocyte act
CD4 lymphocyte none	16.6	KU-812 (Basophil)	84.7
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	3.6	CCD1106 (Keratinocytes)	10.3
CD95 CH11		none
LAK cells rest	11.9	CCD1106 (Keratinocytes)	1.6
		TNF alpha + IL-1 beta
LAK cells IL-2	14.4	Liver cirrhosis	32.5
LAK cells IL-2 + IL-12	17.9	Lupus kidney	20.9
LAK cells IL-2 + IFN	32.3	NCI-H292 none	38.7
gamma
LAK cells IL-2 + IL-18	35.6	NCI-H292 IL-4	16.4
LAK cells	1.4	NCI-H292 IL-9	53.2
PMA/ionomycin
NK Cells IL-2 rest	5.2	NCI-H292 IL-13	8.2
Two Way MLR 3 day	27.9	NCI-H292 IFN gamma	21.3
Two Way MLR 5 day	7.7	HPAEC none	4.1
Two Way MLR 7 day	8.2	HPAEC TNF alpha + IL-1	8.2
		beta
PBMC rest	7.0	Lung fibroblast none	21.3
PBMC PWM	47.0	Lung fibroblast TNF	10.7
		alpha + IL-1 beta
PBMC PHA-L	10.3	Lung fibroblast IL-4	17.0
Ramos (B cell) none	3.1	Lung fibroblast IL-9	24.0
Ramos (B cell)	20.2	Lung fibroblast IL-13	4.5
ionomycin
B lymphocytes PWM	11.1	Lung fibroblast IFN	11.8
		gamma
B lymphocytes CD40L	19.2	Dermal fibroblast	14.0
and IL-4		CCD1070 rest
EOL-1 dbcAMP	36.9	Dermal fibroblast	37.4
		CCD1070 TNF alpha
EOL-1 dbcAMP	47.3	Dermal fibroblast	5.6
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	11.0	Dermal fibroblast IFN	7.1
		gamma
Dendritic cells LPS	8.8	Dermal fibroblast IL-4	21.5
Dendritic cells anti-	27.5	IBD Colitis 2	7.9
CD40
Monocytes rest	4.0	IBD Crohn's	2.6
Monocytes LPS	3.3	Colon	25.5
Macrophages rest	6.3	Lung	4.4
Macrophages LPS	8.5	Thymus	29.7
HUVEC none	2.6	Kidney	100.0
HUVEC starved	12.2

[0784] Panel 4D Summary: Ag1930 The CG3CG59249-01 gene is widely expressed among the samples in this panel, with highest expression of this gene in the kidney and small airway epithelium treated with TNF-alpha and IL-1 beta (CTs=32). Low but significant levels of expression are also seen in both treated and untreated samples derived from the basophil cell line KU-812, the pulmonary mucoepidermoid cell line NCI-H292, LAK cells and eosinophils. This pattern of expression in a variety of cell types of significance in the immune response in health and disease suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosis, psoriasis, rheumatoid arthritis, and osteoarthritis.

I. NOV12a (CG58577-01: CASPR4)

[0785] Expression of gene CG58577-01 was assessed using the primer-probe set Ag3377, described in Table IA. Results of the RTQ-PCR runs are shown in Tables IB, IC, ID and IE.

TABLE IA
Probe Name Ag3377
			Start
Primer	Sequences	Length	Position
Forward	5′-cacagcattatccggagtttt-3′	(SEQ ID NO:239)	21	2372
Probe	TET-5′-tggcattaaagacttcattcgactcga-3′-TAMRA	(SEQ ID NO:240)	27	2435
Reverse	5′-ggtgatctctgaaggagagctt-3′	(SEQ ID NO:241)	22	2435

[0786]

TABLE IB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3377,		Rel. Exp.(%) Ag3377,
Tissue Name	Run 210154572	Tissue Name	Run 210154572
AD 1 Hippo	6.9	Control (Path) 3	2.4
		Temporal Ctx
AD 2 Hippo	23.3	Control (Path) 4	41.8
		Temporal Ctx
AD 3 Hippo	3.2	AD 1 Occipital Ctx	9.9
AD 4 Hippo	2.7	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 Hippo	79.0	AD 3 Occipital Ctx	3.7
AD 6 Hippo	31.0	AD 4 Occipital Ctx	11.2
Control 2 Hippo	28.7	AD 5 Occipital Ctx	47.3
Control 4 Hippo	2.8	AD 6 Occipital Ctx	20.3
Control (Path) 3	2.7	Control 1 Occipital	1.2
Hippo		Ctx
AD 1 Temporal Ctx	7.4	Control 2 Occipital	92.0
		Ctx
AD 2 Temporal Ctx	40.6	Control 3 Occipital	14.9
		Ctx
AD 3 Temporal Ctx	2.4	Control 4 Occipital	2.4
		Ctx
AD 4 Temporal Ctx	11.5	Control (Path) 1	100.0
		Occipital Ctx
AD 5 Inf Temporal	68.8	Control (Path) 2	14.7
Ctx		Occipital Ctx
AD 5 Sup Temporal	20.6	Control (Path) 3	1.2
Ctx		Occipital Ctx
AD 6 Inf Temporal	22.4	Control (Path) 4	15.0
Ctx		Occipital Ctx
AD 6 Sup Temporal	21.8	Control 1 Parietal	3.7
Ctx		Ctx
Control 1 Temporal	4.9	Control 2 Parietal	18.3
Ctx		Ctx
Control 2 Temporal	33.9	Control 3 Parietal	11.6
Ctx		Ctx
Control 3 Temporal	9.8	Control (Path) 1	87.1
Ctx		Parietal Ctx
Control 3 Temporal	26.2	Control (Path) 2	37.4
Ctx		Parietal Ctx
Control (Path) 1	61.1	Control (Path) 3	1.8
Temporal Ctx		Parietal Ctx
Control (Path) 2	26.4	Control (Path) 4	24.8
Temporal Ctx		Parietal Ctx

[0787]

TABLE IC
Panel 1.3D
	Rel. Exp.(%) Ag3377,		Rel. Exp.(%) Ag3377,
Tissue Name	Run 165674254	Tissue Name	Run 165674254
Liver adenocarcinoma	0.0	Kidney (fetal)	0.0
Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN2	0.0	Renal ca. A498	0.0
Adrenal gland	0.0	Renal ca. RXF 393	0.0
Thyroid	0.0	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.0
Pituitary gland	2.8	Renal ca. TK-10	0.0
Brain (fetal)	40.6	Liver	0.0
Brain (whole)	97.9	Liver (fetal)	0.0
Brain (amygdala)	64.2	Liver ca.	0.0
		(hepatoblast) HepG2
Brain (cerebellum)	50.7	Lung	0.0
Brain (hippocampus)	72.2	Lung (fetal)	0.0
Brain (substantia nigra)	22.5	Lung ca. (small cell)	0.0
		LX-1
Brain (thalamus)	100.0	Lung ca. (small cell)	0.0
		NCI-H69
Cerebral Cortex	91.4	Lung ca. (s.cell var.)	39.8
		SHP-77
Spinal cord	4.8	Lung ca. (large	0.0
		cell) NCI-H460
glio/astro U87-MG	0.0	Lung ca. (non-sm.	0.0
		cell) A549
glio/astro U-118-MG	0.0	Lung ca. (non-s.cell)	0.0
		NCI-H23
astrocytoma SW1783	0.0	Lung ca. (non-s.cell)	0.0
		HOP-62
neuro*; met SK-N-AS	28.9	Lung ca. (non-s.cl)	0.0
		NCI-H522
astrocytoma SF-539	0.0	Lung ca. (squam.)	0.0
		SW 900
astrocytoma SNB-75	0.0	Lung ca. (squam.)	0.0
		NCI-H596
glioma SNB-19	0.0	Mammary gland	1.7
glioma U251	0.0	Breast ca.* (pl.ef)	0.0
		MCF-7
glioma SF-295	0.0	Breast ca.* (pl.ef)	0.0
		MDA-MB-231
Heart (fetal)	0.0	Breast ca.* (pl.ef)	0.0
		T47D
Heart	0.0	Breast ca. BT-549	0.0
Skeletal muscle (fetal)	4.0	Breast ca. MDA-N	0.0
Skeletal muscle	0.0	Ovary	0.0
Bone marrow	0.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.0	Ovarian ca. OVCAR-4	0.0
Spleen	1.2	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	0.0
Colorectal	0.0	Ovarian ca. IGROV-1	0.0
Stomach	0.0	Ovarian ca.* (ascites)	0.0
		SK-OV-3
Small intestine	2.0	Uterus	0.0
Colon ca. SW480	0.0	Placenta	0.0
Colon ca.*	0.0	Prostate	0.0
SW620(SW480 met)
Colon ca. HT29	0.0	Prostate ca.* (bone	0.0
		met) PC-3
Colon ca. HCT-116	0.0	Testis	0.0
Colon ca. CaCo-2	0.0	Melanoma	0.0
		Hs688(A).T
Colon ca.	0.0	Melanoma* (met)	0.0
tissue (ODO3866)		Hs688(B).T
Colon ca. HCC-2998	0.0	Melanoma UACC-62	0.0
Gastric ca.* (liver met)	1.8	Melanoma M14	0.0
NCI-N87
Bladder	0.0	Melanoma LOX	0.0
		IMVI
Trachea	0.0	Melanoma* (met)	0.0
		SK-MEL-5
Kidney	0.0	Adipose	0.0

[0788]

TABLE ID
Panel 4D
	Rel. Exp.(%) Ag3377,		Rel. Exp.(%) Ag3377,
Tissue Name	Run 165296551	Tissue Name	Run 165296551
Secondary Th1 act	0.0	HUVEC IL-1 beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN	0.0
		gamma
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC	0.0
		none
Primary Th1 act	0.0	Lung Microvascular EC	0.0
		TNF alpha + IL-1 beta
Primary Th2 act	0.0	Microvascular Dermal EC	6.7
		none
Primary Tr1 act	0.0	Microsvasular Dermal EC	0.0
		TNF alpha + IL-1 beta
Primary Th1 rest	0.0	Bronchial epithelium	0.0
		TNF alpha + IL1 beta
Primary Th2 rest	0.0	Small airway epithelium	0.0
		none
Primary Tr1 rest	0.0	Small airway epithelium	0.0
		TNF alpha + IL-1 beta
CD45RA CD4	0.0	Coronery artery SMC rest	100.0
lymphocyte act
CD45RO CD4	0.0	Coronery artery SMC	70.7
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8	0.0	Astrocytes TNF alpha + IL-	0.0
lymphocyte rest		1 beta
Secondary CD8	0.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	0.0	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	0.0	CCD1106 (Keratinocytes)	0.0
CD95 CH11		none
LAK cells rest	0.0	CCD1106 (Keratinocytes)	0.0
		TNF alpha + IL-1 beta
LAK cells IL-2	0.0	Liver cirrhosis	0.0
LAK cells IL-2 + IL-12	0.0	Lupus kidney	0.0
LAK cells IL-2 + IFN	0.0	NCI-H292 none	0.0
gamma
LAK cells IL-2 + IL-18	0.0	NCI-H292 IL-4	0.0
LAK cells	0.0	NCI-H292 IL-9	0.0
PMA/ionomycin
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	0.0
Two Way MLR 3 day	0.0	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	0.0	HPAEC none	0.0
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1	0.0
		beta
PBMC rest	0.0	Lung fibroblast none	0.0
PBMC PWM	0.0	Lung fibroblast TNF	0.0
		alpha + IL-1 beta
PBMC PHA-L	0.0	Lung fibroblast IL-4	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell)	0.0	Lung fibroblast IL-13	0.0
ionomycin
B lymphocytes PWM	0.0	Lung fibroblast IFN	0.0
		gamma
B lymphocytes CD40L	0.0	Dermal fibroblast	0.0
and IL-4		CCD1070 rest
EOL-1 dbcAMP	0.0	Dermal fibroblast	0.0
		CCD1070 TNF alpha
EOL-1 dbcAMP	0.0	Dermal fibroblast	0.0
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	0.0	Dermal fibroblast IFN	0.0
		gamma
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-	0.0	IBD Colitis 2	5.3
CD40
Monocytes rest	0.0	IBD Crohn's	0.0
Monocytes LPS	0.0	Colon	9.0
Macrophages rest	0.0	Lung	0.0
Macrophages LPS	0.0	Thymus	81.8
HUVEC none	0.0	Kidney	47.3
HUVEC starved	0.0

[0789]

TABLE IE
Panel CNS_1
	Rel. Exp.(%) Ag3377,		Rel. Exp.(%) Ag3377,
Tissue Name	Run 171787512	Tissue Name	Run 171787512
BA4 Control	16.7	BA17 PSP	40.3
BA4 Control2	67.4	BA17 PSP2	20.0
BA4	3.4	Sub Nigra Control	38.2
Alzheimer's2
BA4 Parkinson's	29.1	Sub Nigra Control2	54.7
BA4	94.6	Sub Nigra	14.5
Parkinson's2		Alzheimer's2
BA4	42.3	Sub Nigra	34.4
Huntington's		Parkinson's2
BA4	7.1	Sub Nigra	60.3
Huntington's2		Huntington's
BA4 PSP	6.8	Sub Nigra	29.1
		Huntington's2
BA4 PSP2	39.8	Sub Nigra PSP2	3.0
BA4 Depression	17.3	Sub Nigra	4.2
		Depression
BA4	3.2	Sub Nigra	8.3
Depression2		Depression2
BA7 Control	60.3	Glob Palladus	1.4
		Control
BA7 Control2	42.0	Glob Palladus	3.0
		Control2
BA7	9.4	Glob Palladus	15.5
Alzheimer's2		Alzheimer's
BA7 Parkinson's	21.5	Glob Palladus	2.9
		Alzheimer's2
BA7	80.1	Glob Palladus	54.7
Parkinson's2		Parkinson's
BA7	74.7	Glob Palladus	1.7
Huntington's		Parkinson's2
BA7	42.0	Glob Palladus PSP	0.0
Huntington's2
BA7 PSP	40.1	Glob Palladus PSP2	2.7
BA7 PSP2	24.1	Glob Palladus	3.1
		Depression
BA7 Depression	15.7	Temp Pole Control	14.0
BA9 Control	29.5	Temp Pole Control2	87.1
BA9 Control2	100.0	Temp Pole	1.2
		Alzheimer's
BA9 Alzheimer's	3.0	Temp Pole	9.7
		Alzheimer's2
BA9	21.6	Temp Pole	25.7
Alzheimer's2		Parkinson's
BA9 Parkinson's	39.5	Temp Pole	21.9
		Parkinson's2
BA9	74.7	Temp Pole	48.0
Parkinson's2		Huntington's
BA9	62.0	Temp Pole PSP	1.7
Huntington's
BA9	2.6	Temp Pole PSP2	3.6
Huntington's2
BA9 PSP	10.8	Temp Pole	10.3
		Depression2
BA9 PSP2	1.6	Cing Gyr Control	99.3
BA9 Depression	8.2	Cing Gyr Control2	57.4
BA9	9.0	Cing Gyr Alzheimer's	18.6
Depression2
BA17 Control	88.9	Cing Gyr	4.3
		Alzheimer's2
BA17 Control2	84.1	Cing Gyr Parkinson's	11.0
BA17	6.1	Cing Gyr	24.5
Alzheimer's2		Parkinson's2
BA17	56.3	Cing Gyr	62.9
Parkinson's		Huntington's
BA17	80.1	Cing Gyr	11.1
Parkinson's2		Huntington's2
BA17	89.5	Cing Gyr PSP	17.1
Huntington's
BA17	25.2	Cing Gyr PSP2	1.4
Huntington's2
BA17	7.6	Cing Gyr Depression	4.3
Depression
BA17	18.7	Cing Gyr	9.8
Depression2		Depression2

[0790] CNS_neurodegeneration_v1.0 Summary: Ag3377 This panel confirms the expression of the CG58577-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.3D for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[0791] Panel 1.3D Summary: Ag3377 Expression of the CG58577-01 gene is seen almost exclusively in the brain. The highest level of expression is in the thalamus (CT=3 1.0), with low to moderate expression in amygdala, substanitia nigra, cerebellum, hippocampus and cerebral cortex. This gene encodes a protein homologous to the mouse Caspr4 protein. The Caspr proteins are contactin-associated transmembrane receptors that may function with contactin, in the recruitment and activation of neural intracellular signaling pathways. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0792] There is also low levels of expression in lung cancer cell line SHP-77 and neuroblastoma cancer cell line SK-N-AS (CTs=32). Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of lung cancer or neuroblastoma cancer.

[0793] References

[0794] 1. Peles E, Nativ M, Lustig M, Grumet M, Schilling J, Martinez R, Plowman G D, Schlessinger J. (1997) Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein-protein interactions. EMBO J 16(5):978-88.

[0795] Panel 4D Summary: Ag3377 Significant expression of the CG58577-01 gene is seen only in coronary artery, thymus, and kidney (CTs=33-34.8). Therefore expression of this gene can be used to distinguish between these samples and others on this panel. In addition, therapeutic modulation of the activity of the CASPR protein encoded by this gene may be useful in the treatment of asthma, restenosis, arthritis, systemic lupus erythematosus and kidney disorders.

[0796] Panel CNS—1 Summary: Ag3377—This panel confirms the expression of this gene at significant levels in the brain in an independent group of individuals. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

J. NOV14 (CG58575-01: PHOSPHATIDYLSERINE SYNTHASE-2)

[0797] Expression of gene CG58575-01 was assessed using the primer-probe set Ag3376, described in Table JA. Results of the RTQ-PCR runs are shown in Tables JB, JC, JD and JE.

TABLE JA
Probe Name Ag3376
			Start
Primer	Sequences	Length	Position
Forward	5′-atctacgacccagacaatgaga-3′	(SEQ ID NO:242)	22	592
Probe	TET-5′-cccctttcacaacatctgggacaagt-3′-TAMRA	(SEQ ID NO:243)	26	618
Reverse	5′-tcaggtaccagccaagaaagt-3′	(SEQ ID NO:244)	21	665

[0798]

TABLE JB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3376,		Rel. Exp.(%) Ag3376,
Tissue Name	Run 210154240	Tissue Name	Run 210154240
AD 1 Hippo	18.8	Control (Path) 3	6.1
		Temporal Ctx
AD 2 Hippo	48.3	Control (Path) 4	18.8
		Temporal Ctx
AD 3 Hippo	7.6	AD 1 Occipital Ctx	14.5
AD 4 Hippo	11.2	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	60.7	AD 3 Occipital Ctx	6.8
AD 6 Hippo	38.7	AD 4 Occipital Ctx	17.4
Control 2 Hippo	24.1	AD 5 Occipital Ctx	17.7
Control 4 Hippo	13.6	AD 6 Occipital Ctx	34.9
Control (Path) 3	9.4	Control 1 Occipital	3.7
Hippo		Ctx
AD 1 Temporal Ctx	20.0	Control 2 Occipital	52.5
		Ctx
AD 2 Temporal Ctx	35.6	Control 3 Occipital	14.8
		Ctx
AD 3 Temporal Ctx	8.4	Control 4 Occipital	8.0
		Ctx
AD 4 Temporal Ctx	18.4	Control (Path) 1	57.4
		Occipital Ctx
AD 5 Inf Temporal	100.0	Control (Path) 2	9.0
Ctx		Occipital Ctx
AD 5 Sup Temporal	59.9	Control (Path) 3	7.2
Ctx		Occipital Ctx
AD 6 Inf Temporal	39.2	Control (Path) 4	17.4
Ctx		Occipital Ctx
AD 6 Sup Temporal	40.1	Control 1 Parietal	7.9
Ctx		Ctx
Control 1 Temporal	8.1	Control 2 Parietal	47.3
Ctx		Ctx
Control 2 Temporal	31.2	Control 3 Parietal	19.1
Ctx		Ctx
Control 3 Temporal	14.8	Control (Path) 1	39.0
Ctx		Parietal Ctx
Control 4 Temporal	14.3	Control (Path) 2	17.4
Ctx		Parietal Ctx
Control (Path) 1	51.1	Control (Path) 3	4.5
Temporal Ctx		Parietal Ctx
Control (Path) 2	19.9	Control (Path) 4	26.8
Temporal Ctx		Parietal Ctx

[0799]

TABLE JC
Panel 1.3D
	Rel. Exp.(%) Ag3376,		Rel. Exp.(%) Ag3376,
Tissue Name	Run 165674234	Tissue Name	Run 165674234
Liver adenocarcinoma	19.1	Kidney (fetal)	13.8
Pancreas	7.5	Renal ca. 786-0	6.5
Pancreatic ca. CAPAN2	6.5	Renal ca. A498	12.4
Adrenal gland	13.5	Renal ca. RXF 393	21.9
Thyroid	11.7	Renal ca. ACHN	1.7
Salivary gland	10.2	Renal ca. UO-31	8.2
Pituitary gland	8.1	Renal ca. TK-10	8.0
Brain (fetal)	31.9	Liver	2.0
Brain (whole)	82.9	Liver (fetal)	7.0
Brain (amygdala)	50.3	Liver ca.	11.3
		(hepatoblast) HepG2
Brain (cerebellum)	57.0	Lung	8.4
Brain (hippocampus)	51.4	Lung (fetal)	3.6
Brain (substantia nigra)	30.4	Lung ca. (small cell)	8.4
		LX-1
Brain (thalamus)	51.8	Lung ca. (small cell)	0.7
		NCI-H69
Cerebral Cortex	27.5	Lung ca. (s.cell var.)	5.4
		SHP-77
Spinal cord	31.6	Lung ca. (large	21.5
		cell) NCI-H460
glio/astro U87-MG	6.3	Lung ca. (non-sm.	4.2
		cell) A549
glio/astro U-118-MG	7.7	Lung ca. (non-s.cell)	5.8
		NCI-H23
astrocytoma SW1783	2.3	Lung ca. (non-s.cell)	9.2
		HOP-62
neuro*; met SK-N-AS	6.6	Lung ca. (non-s.cl)	10.5
		NCI-H522
astrocytoma SF-539	1.7	Lung ca. (squam.)	1.8
		SW 900
astrocytoma SNB-75	4.7	Lung ca. (squam.)	9.7
		NCI-H596
glioma SNB-19	5.0	Mammary gland	15.7
glioma U251	17.3	Breast ca.* (pl.ef)	2.0
		MCF-7
glioma SF-295	4.2	Breast ca.* (pl.ef)	53.2
		MDA-MB-231
Heart (fetal)	29.1	Breast ca.* (pl.ef)	1.9
		T47D
Heart	11.6	Breast ca. BT-549	34.2
Skeletal muscle (fetal)	13.1	Breast ca. MDA-N	1.1
Skeletal muscle	44.4	Ovary	10.8
Bone marrow	4.5	Ovarian ca. OVCAR-3	6.5
Thymus	6.6	Ovarian ca. OVCAR-4	7.9
Spleen	12.6	Ovarian ca. OVCAR-5	5.2
Lymph node	14.5	Ovarian ca. OVCAR-8	3.9
Colorectal	2.1	Ovarian ca. IGROV-1	2.5
Stomach	13.7	Ovarian ca.* (ascites)	5.2
		SK-OV-3
Small intestine	14.8	Uterus	35.4
Colon ca. SW480	9.2	Placenta	11.6
Colon ca.*	4.9	Prostate	16.0
SW620(SW480 met)
Colon ca. HT29	3.4	Prostate ca.* (bone	11.0
		met) PC-3
Colon ca. HCT-116	8.3	Testis	100.0
Colon ca. CaCo-2	5.1	Melanoma	3.6
		Hs688(A).T
Colon ca.	8.5	Melanoma* (met)	4.1
tissue (ODO3866)		Hs688(B).T
Colon ca. HCC-2998	4.9	Melanoma UACC-62	20.4
Gastric ca.* (liver met)	11.9	Melanoma M14	10.2
NCI-N87
Bladder	1.9	Melanoma LOX	5.2
		IMVI
Trachea	7.2	Melanoma* (met)	4.0
		SK-MEL-5
Kidney	14.3	Adipose	2.5

[0800]

TABLE JD
Panel 4D
	Rel. Exp.(%) Ag3376,		Rel. Exp.(%) Ag3376,
Tissue Name	Run 165296548	Tissue Name	Run 165296548
Secondary Th1 act	41.2	HUVEC IL-1 beta	6.5
Secondary Th2 act	26.2	HUVEC IFN gamma	38.2
Secondary Tr1 act	36.3	HUVEC TNF alpha + IFN	18.4
		gamma
Secondary Th1 rest	4.4	HUVEC TNF alpha + IL4	22.5
Secondary Th2 rest	6.8	HUVEC IL-11	30.6
Secondary Tr1 rest	11.6	Lung Microvascular EC	32.1
		none
Primary Th1 act	15.5	Lung Microvascular EC	32.8
		TNF alpha + IL-1 beta
Primary Th2 act	21.2	Microvascular Dermal EC	40.6
		none
Primary Tr1 act	45.1	Microsvasular Dermal EC	28.7
		TNF alpha + IL-1 beta
Primary Th1 rest	20.4	Bronchial epithelium	62.9
		TNF alpha + IL1 beta
Primary Th2 rest	7.9	Small airway epithelium	19.6
		none
Primary Tr1 rest	9.3	Small airway epithelium	55.9
		TNF alpha + IL-1 beta
CD45RA CD4	13.4	Coronery artery SMC rest	34.4
lymphocyte act
CD45RO CD4	8.1	Coronery artery SMC	29.7
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	12.5	Astrocytes rest	28.9
Secondary CD8	12.9	Astrocytes TNF alpha + IL-	22.4
lymphocyte rest		1 beta
Secondary CD8	6.7	KU-812 (Basophil) rest	33.7
lymphocyte act
CD4 lymphocyte none	2.5	KU-812 (Basophil)	55.1
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	6.8	CCD1106 (Keratinocytes)	31.6
CD95 CH11		none
LAK cells rest	6.6	CCD1106 (Keratinocytes)	22.5
		TNF alpha + IL-1 beta
LAK cells IL-2	9.6	Liver cirrhosis	1.7
LAK cells IL-2 + IL-12	14.1	Lupus kidney	3.2
LAK cells IL-2 + IFN	12.9	NCI-H292 none	40.3
gamma
LAK cells IL-2 + IL-18	8.7	NCI-H292 IL-4	67.8
LAK cells	3.4	NCI-H292 IL-9	70.2
PMA/ionomycin
NK Cells IL-2 rest	4.8	NCI-H292 IL-13	48.3
Two Way MLR 3 day	9.1	NCI-H292 IFN gamma	42.3
Two Way MLR 5 day	14.5	HPAEC none	37.9
Two Way MLR 7 day	8.4	HPAEC TNF alpha + IL-1	23.0
		beta
PBMC rest	3.3	Lung fibroblast none	32.1
PBMC PWM	46.3	Lung fibroblast TNF alpha	19.2
		+ IL-1 beta
PBMC PHA-L	12.0	Lung fibroblast IL-4	76.3
Ramos (B cell) none	24.5	Lung fibroblast IL-9	49.7
Ramos (B cell)	100.0	Lung fibroblast IL-13	33.2
ionomycin
B lymphocytes PWM	57.8	Lung fibroblast IFN	79.6
		gamma
B lymphocytes CD40L	12.5	Dermal fibroblast	29.7
and IL-4		CCD1070 rest
EOL-1 dbcAMP	17.1	Dermal fibroblast	39.5
		CCD1070 TNF alpha
EOL-1 dbcAMP	6.7	Dermal fibroblast	21.0
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	7.5	Dermal fibroblast IFN	16.0
		gamma
Dendritic cells LPS	7.7	Dermal fibroblast IL-4	28.7
Dendritic cells anti-	5.4	IBD Colitis 2	0.3
CD40
Monocytes rest	12.5	IBD Crohn's	1.1
Monocytes LPS	3.4	Colon	11.2
Macrophages rest	23.0	Lung	14.6
Macrophages LPS	3.3	Thymus	59.9
HUVEC none	46.3	Kidney	26.8
HUVEC starved	34.9

[0801]

TABLE JE
Panel CNS_1
	Rel. Exp.(%) Ag3376,		Rel. Exp.(%) Ag3376,
Tissue Name	Run 171787488	Tissue Name	Run 171787488
BA4 Control	29.5	BA17 PSP	22.4
BA4 Control2	49.0	BA17 PSP2	11.3
BA4	3.5	Sub Nigra Control	66.9
Alzheimer's2
BA4 Parkinson's	52.9	Sub Nigra Control2	27.4
BA4	71.2	Sub Nigra	11.0
Parkinson's2		Alzheimer's2
BA4	44.4	Sub Nigra	100.0
Huntington's		Parkinson's2
BA4	24.3	Sub Nigra	77.4
Huntington's2		Huntington's
BA4 PSP	11.0	Sub Nigra	53.2
		Huntington's2
BA4 PSP2	20.6	Sub Nigra PSP2	8.7
BA4 Depression	15.6	Sub Nigra	9.9
		Depression
BA4	6.7	Sub Nigra	9.1
Depression2		Depression2
BA7 Control	42.3	Glob Palladus	34.4
		Control
BA7 Control2	44.8	Glob Palladus	29.9
		Control2
BA7	4.5	Glob Palladus	26.4
Alzheimer's2		Alzheimer's
BA7 Parkinson's	33.9	Glob Palladus	1.9
		Alzheimer's2
BA7	22.1	Glob Palladus	95.3
Parkinson's2		Parkinson's
BA7	40.1	Glob Palladus	26.6
Huntington's		Parkinson's2
BA7	79.6	Glob Palladus PSP	5.8
Huntington's2
BA7 PSP	22.4	Glob Palladus PSP2	6.4
BA7 PSP2	25.5	Glob Palladus	0.0
		Depression
BA7 Depression	19.1	Temp Pole Control	15.6
BA9 Control	24.0	Temp Pole Control2	35.8
BA9 Control2	92.7	Temp Pole	6.7
		Alzheimer's
BA9 Alzheimer's	9.9	Temp Pole	5.1
		Alzheimer's2
BA9	13.7	Temp Pole	37.1
Alzheimer's2		Parkinson's
BA9 Parkinson's	43.8	Temp Pole	36.9
		Parkinson's2
BA9	58.6	Temp Pole	53.6
Parkinson's2		Huntington's
BA9	49.7	Temp Pole PSP	1.4
Huntington's
BA9	19.5	Temp Pole PSP2	3.5
Huntington's2
BA9 PSP	14.1	Temp Pole	7.5
		Depression2
BA9 PSP2	2.0	Cing Gyr Control	80.7
BA9 Depression	11.3	Cing Gyr Control2	54.0
BA9	22.5	Cing Gyr Alzheimer's	24.8
Depression2
BA17 Control	65.1	Cing Gyr	6.8
		Alzheimer's2
BA17 Control2	67.4	Cing Gyr Parkinson's	70.2
BA17	8.2	Cing Gyr	47.3
Alzheimer's2		Parkinson's2
BA17	57.0	Cing Gyr	72.2
Parkinson's		Huntington's
BA17	46.7	Cing Gyr	23.5
Parkinson's2		Huntington's2
BA17	86.5	Cing Gyr PSP	12.1
Huntington's
BA17	19.3	Cing Gyr PSP2	3.8
Huntington's2
BA17	26.2	Cing Gyr Depression	11.4
Depression
BA17	42.0	Cing Gyr	11.8
Depression2		Depression2

[0802] CNS_neurodegeneration_v1.0 Summary: Ag3376 This panel does not show differential expression of the CG58575-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

[0803] Panel 1.3D Summary: Ag3376 The CG58575-01 gene encodes a putative phosphatidylserine synthase-2. In agreement with published results on the mouse homologue of this gene, the highest expression of this gene is in testis (CT=29.5).

[0804] Expression of this gene is confirmed in all regions of the brain. Phosphatidylserine synthase activity was found to be reduced in the mnd/mnd mouse, a model for the human degenerative disease neuronal ceroid lipofuscinosis. Therefore, this gene may play a role in neurodegenerative disorders in which there is an abnormal accumulation of lipids and proteins in cellular storage bodies.

[0805] In addition, expression of this gene is higher in breast cancer cell lines when compared to expression in normal breast tissue. Thus, expression of this gene could be used to differentiate between breast cancer cell lines and other samples on this panel and as a marker for breast cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of breast cancer.

[0806] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0807] References

[0808] 1. Vance J E, Stone S J, Faust J R. Abnormalities in mitochondria-associated membranes and phospholipid biosynthetic enzymes in the mnd/mnd mouse model of neuronal ceroid lipofuscinosis.Biochim Biophys Acta Feb. 18, 1997; 1344(3):286-99.

[0809] 2. Sturbois-Balcerzak B, Stone S J, Sreenivas A, Vance J E. Structure and expression of the murine phosphatidylserine syntilase-1 gene. J Biol Chem Mar. 16, 2001; 276(11):8205-12.

[0810] Panel 4D Summary: Ag3376 Highest expression of the CG58575-01 gene is seen in the B cell line Ramos treated with ionomycin (CT=29.3). Significant levels of expression are seen in activated and untreated NCI-H292 cells, IL-4, 1L-9, IL-13 and IFN gamma activated lung fibroblasts, human pulmonary aortic endothelial cells (treated and untreated), small airway epithelium (treated and untreated), treated bronchial epithelium and lung microvascular endothelial cells (treated and untreated). The expression of this gene in cells derived from or within the lung suggests that this gene may be involved in normal conditions as well as pathological and inflammatory lung disorders that include chronic obstructive pulmonary disease, asthma, allergy and emphysema. Moderate/low expression of this gene is also detected in treated and untreated HUVECs (endothelial cells), coronary artery smooth muscle cells (treated and untreated), treated and untreated astrocytes, treated KU-812 basophils, treated and untreated CCD1106 keratinocytes, IL-4 treated dermal fibroblasts, and normal tissues that include lung, colon, thymus and kidney. Expression in the various immune cell types (as well as in diseased tissue samples) suggests that therapeutic modulation of this gene product may ameliorate symptoms associated with infectious conditions as well as inflammatory and autoimmune disorders that include psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.

[0811] Panel CNS—1 Summary: AG3376 This panel confirms expression of the CG58575-01 gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

K. NOV16a (CG59239-01: MHC CLASS I)

[0812] Expression of gene CG59239-01 was assessed using the primer-probe sets Ag3516 and Ag3517, described in Tables KA and KB. Results of the RTQ-PCR runs are shown in Tables KC, KD and KE.

TABLE KA
Probe Name Ag3516
			Start
Primer	Sequences	Length	Position
Forward	5′-cggagaggagcagagataca-3′	(SEQ ID NO:245)	20	845
Probe	TET-5′-cagagcccctcaccctgagatgg-3′-TAMRA	(SEQ ID NO:246)	23	892
Reverse	5′-gatggtgggctgagaagac-3′	(SEQ ID NO:247)	19	920

[0813]

TABLE KB
Probe Name Ag3517
			Start
Primers	Sequenecs	Length	Position
Forward	5′-cggagaggagcagagataca-3′	(SEQ ID NO:248)	20	845
Probe	TET-5′-cagagcccctcaccctgagatgg-3′-TAMRA	(SEQ ID NO:249)	23	892
Reverse	5′-gatggtgggctgagaagac-3′	(SEQ ID NO:250)	19	920

[0814]

TABLE KC
CNS_neurodegeneration_v1.0
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag3516, Run	Ag3517, Run		Ag3516, Run	Ag3517, Run
Tissue Name	211005124	210629732	Tissue Name	211005124	210629732
AD 1 Hippo	48.6	34.2	Control	20.7	23.0
			(Path) 3
			Temporal
			Ctx
AD 2 Hippo	87.7	88.3	Control	32.8	28.3
			(Path) 4
			Temporal
			Ctx
AD 3 Hippo	10.9	10.7	AD 1	25.3	25.3
			Occipital Ctx
AD 4 Hippo	13.4	11.3	AD 2	0.0	0.0
			Occipital Ctx
			(Missing)
AD 5 Hippo	79.6	85.9	AD 3	9.8	10.3
			Occipital Ctx
AD 6 Hippo	59.5	57.0	AD 4	16.6	17.3
			Occipital Ctx
Control 2	63.7	71.2	AD 5	73.2	87.7
Hippo			Occipital Ctx
Control 4	33.9	24.7	AD 6	2.8	18.0
Hippo			Occipital Ctx
Control	11.1	11.3	Control 1	6.3	6.0
(Path) 3			Occipital Ctx
Hippo
AD 1	41.8	40.6	Control 2	100.0	100.0
Temporal			Occipital Ctx
Ctx
AD 2	52.9	78.5	Control 3	14.4	11.7
Temporal			Occipital Ctx
Ctx
AD 3	9.7	8.4	Control 4	12.8	12.2
Temporal			Occipital Ctx
Ctx
AD 4	24.1	23.2	Control	85.3	92.7
Temporal			(Path) 1
Ctx			Occipital Ctx
AD 5 Inf	87.1	87.7	Control	22.7	16.7
Temporal			(Path) 2
Ctx			Occipital Ctx
AD 5 Sup	79.0	85.9	Control	21.8	23.3
Temporal			(Path) 3
Ctx			Occipital Ctx
AD 6 Inf	48.3	52.5	Control	29.3	27.4
Temporal			(Path) 4
Ctx			Occipital Ctx
AD 6 Sup	46.3	50.3	Control 1	7.8	8.6
Temporal			Parietal Ctx
Ctx
Control 1	6.8	6.1	Control 2	59.9	70.2
Temporal			Parietal Ctx
Ctx
Control 2	61.6	79.6	Control 3	21.9	16.3
Temporal			Parietal Ctx
Ctx
Control 3	16.4	15.0	Control	69.3	84.1
Temporal			(Path) 1
Ctx			Parietal Ctx
Control 3	16.2	14.0	Control	47.3	51.1
Temporal			(Path) 2
Ctx			Parietal Ctx
Control	75.8	82.4	Control	20.2	23.5
(Path) 1			(Path) 3
Temporal			Parietal Ctx
Ctx
Control	49.7	45.7	Control	40.6	43.8
(Path) 2			(Path) 4
Temporal			Parietal Ctx
Ctx

[0815]

TABLE KD
General_screening_panel_v1.4
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag3516, Run	Ag3517, Run		Ag3516, Run	Ag3517, Run
Tissue Name	216861071	216862935	Tissue Name	216861071	216862935
Adipose	5.2	5.7	Renal ca. TK-10	6.4	9.5
Melanoma*	7.1	8.4	Bladder	15.4	18.2
Hs688(A).T
Melanoma*	5.7	6.0	Gastric ca. (liver	13.2	15.4
Hs688(B).T			met.) NCI-N87
Melanoma*	6.0	8.5	Gastric ca. KATO	62.9	52.9
M14			III
Melanoma*	1.5	1.5	Colon ca. SW-	3.4	3.3
LOXIMVI			948
Melanoma*	7.3	8.7	Colon ca. SW480	5.5	5.6
SK-MEL-5
Squamous cell	3.2	3.0	Colon ca.*	5.2	6.4
carcinoma			(SW480 met)
SCC-4			SW620
Testis Pool	1.4	1.3	Colon ca. HT29	4.8	5.3
Prostate ca.*	3.5	3.0	Colon ca. HCT-	3.7	5.7
(bone met)			116
PC-3
Prostate Pool	3.5	2.7	Colon ca. CaCo-2	7.2	9.7
Placenta	2.1	2.3	Colon cancer	30.6	54.0
			tissue
Uterus Pool	2.2	1.9	Colon ca.	0.0	0.0
			SW1116
Ovarian ca.	1.6	1.7	Colon ca. Colo-	6.2	5.5
OVCAR-3			205
Ovarian ca.	66.4	62.9	Colon ca. SW-48	18.8	19.9
SK-OV-3
Ovarian ca.	1.7	2.0	Colon Pool	3.9	4.9
OVCAR-4
Ovarian ca.	18.7	20.2	Small Intestine	9.1	10.0
OVCAR-5			Pool
Ovarian ca.	32.3	63.3	Stomach Pool	2.9	1.7
IGROV-1
Ovarian ca.	81.8	73.7	Bone Marrow	1.1	0.8
OVCAR-8			Pool
Ovary	5.3	6.2	Fetal Heart	0.9	1.1
Breast ca.	2.0	1.5	Heart Pool	2.9	3.1
MCF-7
Breast ca.	32.3	34.6	Lymph Node	2.9	2.7
MDA-MB-			Pool
231
Breast ca. BT	6.5	7.1	Fetal Skeletal	1.0	1.1
549			Muscle
Breast ca.	53.6	54.0	Skeletal Muscle	2.5	2.6
T47D			Pool
Breast ca.	5.8	5.6	Spleen Pool	16.2	15.2
MDA-N
Breast Pool	4.6	4.9	Thymus Pool	5.4	5.7
Trachea	9.8	8.9	CNS cancer	11.3	13.2
			(glio/astro) U87-
			MG
Lung	2.0	2.1	CNS cancer	3.1	2.8
			(glio/astro) U-
			118-MG
Fetal Lung	7.0	6.6	CNS cancer	2.1	2.7
			(neuro;net)SK-
			N-AS
Lung ca. NCI-	0.7	0.6	CNS cancer	27.4	24.1
N417			(astro) SF-539
Lung ca. LX-1	3.0	4.2	CNS cancer	100.0	100.0
			(astro) SNB-75
Lung ca. NCI-	1.2	1.3	CNS cancer (glio)	46.3	41.8
H146			SNB-19
Lung ca. SHP-	1.7	1.4	CNS cancer (glio)	62.4	66.4
77			SF-295
Lung ca. A549	1.6	1.1	Brain (Amygdala)	1.6	1.6
			Pool
Lung ca. NCI-	2.7	3.0	Brain	1.3	1.5
H526			(cerebellum)
Lung ca.NCI-	0.2	0.3	Brain (fetal)	0.7	0.8
H23
Lung ca. NCI-	14.7	12.0	Brain	1.5	1.6
H460			(Hippocampus)
			Pool
Lung ca.	19.9	21.3	Cerebral Cortex	1.2	1.2
HOP-62			Pool
Lung ca. NCI-	3.8	4.3	Brain (Substantia	2.5	2.6
H522			nigra) Pool
Liver	2.6	2.8	Brain (Thalamus)	1.4	1.5
			Pool
Fetal Liver	1.6	1.4	Brain (whole)	0.8	0.7
Liver ca.	4.9	6.4	Spinal Cord Pool	5.3	5.0
HepG2
Kidney Pool	12.0	11.9	Adrenal Gland	4.2	5.1
Fetal Kidney	0.9	1.1	Pituitary gland	2.8	2.5
			Pool
Renal ca. 786-0	9.2	8.9	Salivary Gland	1.7	1.6
Renal ca.	5.2	5 0	Thyroid (female)	11.8	12.2
A498
Renal ca.	3.3	3.4	Pancreatic ca.	10.4	9.7
ACHN			CAPAN2
Renal ca. UO-31	6.7	7.8	Pancreas Pool	7.0	7.5

[0816]

TABLE KE
Panel 4.1 D
	Rel.	Rel.		Rel.	Rel.
	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)
	Ag3516,	Ag3517,		Ag3516,	Ag3517,
	Run	Run		Run	Run
Tissue Name	169840392	169840401	Tissue Name	169840392	169840401
Secondary Th1 act	24.5	24.0	HUVEC IL-1 beta	14.0	12.6
Secondary Th2 act	49.3	54.7	HUVEC IFN	2.9	2.8
			gamma
Secondary Tr1 act	50.7	51.1	HUVEC TNF	27.2	27.4
			alpha + IFN
			gamma
Secondary Th1 rest	10.5	10.1	HUVEC TNF	12.3	12.1
			alpha + IL4
Secondary Th2 rest	13.6	12.5	HUVEC IL-11	1.6	0.9
Secondary Tr1 rest	12.1	12.0	Lung	7.5	5.7
			Microvascular EC
			none
Primary Th1 act	11.2	12.2	Lung	11.3	8.0
			Microvascular EC
			TNF alpha + IL-
			1 beta
Primary Th2 act	13.3	15.1	Microvascular	7.4	7.8
			Dermal EC none
Primary Tr1 act	14.1	14.3	Microvascular	19.3	22.5
			Dermal EC
			TNF alpha + IL-
			1 beta
Primary Th1 rest	33.4	36.6	Bronchial	3.8	3.5
			epithelium
			TNF alpha +
			IL1 beta
Primary Th2 rest	26.8	26.2	Small airway	3.1	2.7
			epithelium none
Primary Tr1 rest	45.7	37.9	Small airway	5.8	5.2
			epithelium
			TNF alpha + IL-
			1 beta
CD45RA CD4	27.0	24.8	Coronery artery	7.0	6.1
lymphocyte act			SMC rest
CD45RO CD4	38.7	37.9	Coronery artery	4.9	5.0
lymphocyte act			SMC TNF alpha +
			IL_1 beta
CD8 lymphocyte	47.3	42.3	Astrocytes rest	7.6	6.4
act
Secondary CD8	36.9	27.9	Astrocytes	9.2	7.6
lymphocyte rest			TNF alpha + IL-
			1 beta
Secondary CD8	25.7	25.0	KU-812 (Basophil)	0.9	0.6
lymphocyte act			rest
CD4 lymphocyte	14.0	13.1	KU-812 (Basophil)	2.4	2.2
none			PMA/ionomycin
2ry	38.7	40.9	CCD1106	2.4	2.3
Th1/Th2/Tr1_anti-			(Keratinocytes)
CD95 CH11			none
LAK cells rest	43.8	37.1	CCD1106	6.3	4.1
			(Kerationcytes)
			TNF alpha + IL-
			1 beta
LAK cells IL-2	27.9	28.5	Liver cirrhosis	6.5	6.6
LAK cells IL-2 +	51.4	48.0	NCI-H292 none	3.1	3.4
IL-12
LAK cells IL-	50.3	53.6	NCI-H292 IL-4	3.8	3.4
2 + IFN gamma
LAK cells IL-2 +	53.6	46.7	NCI-H292 IL-9	4.2	2.8
IL-18
LAK cells	48.3	41.5	NCI-H292 IL-13	2.5	2.4
PMA/ionomycin
NK Cells IL-2 rest	63.3	58.2	NCI-H292 IFN	10.0	9.4
			gamma
Two Way MLR 3	65.5	61.6	HPAEC none	4.9	3.1
day
Two Way MLR 5	49.0	53.6	HPAEC TNF	24.7	21.0
day			alpha + IL-1 beta
Two Way MLR 7	35.4	33.2	Lung fibroblast	8.8	7.1
day			none
PBMC rest	26.8	22.5	Lung fibroblast	42.3	33.9
			TNF alpha + IL-1
			beta
PBMC PWM	42.0	29.1	Lung fibroblast IL-4	8.7	7.2
PBMC PHA-L	29.3	36.9	Lung fibroblast IL-9	9.9	10.7
Ramos (B cell)	6.9	8.0	Lung fibroblast IL-	8.8	8.2
none			13
Ramos (B cell)	7.1	7.7	Lung fibroblast	23.2	18.8
ionomycin			IFN gamma
B lymphocytes	27.4	20.9	Dermal fibroblast	10.7	11.3
PWM			CCD1070 rest
B lymphocytes	54.7	40.9	Dermal fibroblast	28.5	22.4
CD40L and IL-4			CCD1070 TNF
			alpha
EOL-1 dbcAMP	2.6	3.0	Dermal fibroblast	6.7	6.3
			CCD1070 IL-1
			beta
EOL-1 dbcAMP	2.7	2.8	Dermal fibroblast	25.0	23.2
PMA/ionomycin			IFN gamma
Dendritic cells none	29.7	33.9	Dermal fibroblast	13.4	13.8
			IL-4
Dendritic cell LPS	57.4	53.2	Dermal Fibroblasts	5.0	3.5
			rest
Dendritic cells anti-	29.7	29.9	Neutrophils	51.8	45.4
CD40			TNFa + LPS
Monocytes rest	23.7	23.8	Neutrophils rest	76.8	75.3
Monocytes LPS	100.0	100.0	Colon	26.8	22.8
Macrophages rest	25.5	23.5	Lung	23.2	27.0
Macrophages LPS	61.1	60.3	Thymus	9.3	11.6
HUVEC none	4.4	6.3	Kidney	3.7	4.2
HUVEC starved	8.0	9.5

[0817] CNS_neurodegeneration_v1.0 Summary: Ag3516/Ag3517 This panel does not show differential expression of the CG59239-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

[0818] General_screening_panel_v1.4 Summary: Ag3516/Ag3517 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression of the CG59239-01 gene in a brain cancer cell line (CT=24). This gene encodes a major histocompatibility complex (MIJC) class I homologue. MHC Class I genes mediate the recognition of intracellular antigens by cytotoxic T cells and are typically ubiquitously expressed. Significant expression is also seen in clusters of cell lines derived from gastric, colon, lung, breast, ovarian and brain cancers. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of gastric, colon, lung, breast, ovarian and brain cancer.

[0819] Among tissues with metabolic function, this gene is expressed at moderate levels in adipose, adrenal gland, pancreas, pituitary, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal metabolic and neuroendocrine function and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0820] In addition, this gene shows moderate expression in all regions of the CNS examined. Inflammation has been implicated in many CNS neurodegenerative disorders, including Alzheimer's disease. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of neurodegenerative disorders such as Alzheillmer's disease, Parkinson's disease, and multiple sclerosis.

[0821] References:

[0822] 1. Bauer J, Rauschka H, Lassmann H. Inflammation in the nervous system: the human perspective. Glia November 2001;36(2):235-43

[0823] Panel 4.1D Summary: Ag3516/Ag3517 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression of the CG59239-01 gene in LPS-stimulated inonocytes (CT=24). This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

[0824] This gene encodes a major histocompatibility complex (MIHC) class I homolog. MHC class I-like molecules may have utility in forensics, such as in genotyping criminal suspects, and in settling paternity disputes. These antigens are ubiquitously expressed on all nucleated human cells except neurons and trophoblasts, and participate in antigen presentation of viral antigens in the adaptive immune response.

L. NOV17a (CG59295-0 1: OTOGELIN)

[0825] Expression of gene CG59295-01 was assessed using the primer-probe set Ag3534, described in Table LA. Results of the RTQ-PCR runs are shown in Tables LB, and LC.

TABLE LA
Probe Name Ag3534
			Start
Primer	Sequences	Length	Position
Forward	5′-agctgagtgtccctgtgagtt-3′	(SEQ ID NO:251)	21	1422
Probe	TET-5′-actctgtacccacctggctctgtggt-3′-TAMRA	(SEQ ID NO:252)	26	1450
Reverse	5′-tgcaagtattgcagtcttcctt-3′	(SEQ ID NO:253)	22	1477

[0826]

TABLE LB
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3534,		Rel. Exp.(%) Ag3534,
Tissue Name	Run 217044594	Tissue Name	Run 217044594
Adipose	0.0	Renal ca. TK-10	0.0
Melanoma*	0.0	Bladder	10.9
Hs688(A).T
Melanoma*	0.0	Gastric ca. (liver met.)	11.4
Hs688(B).T		NCI-N87
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma*	0.0	Colon ca. SW-948	0.0
LOXIMVI
Melanoma* SK-	0.0	Colon ca. SW480	20.3
MEL-5
Squamous cell	0.0	Colon ca.* (SW480	3.7
carcinoma SCC-4		met) SW620
Testis Pool	25.7	Colon ca. HT29	0.0
Prostate ca.* (bone	0.0	Colon ca. HCT-116	2.6
met) PC-3
Prostate Pool	0.0	Colon ca. CaCo-2	100.0
Placenta	0.0	Colon cancer tissue	0.0
Uterus Pool	0.0	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	9.2	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	0.0	Colon ca. SW-48	2.7
Ovarian ca. OVCAR-4	2.5	Colon Pool	6.0
Ovarian ca. OVCAR-5	11.7	Small Intestine Pool	3.0
Ovarian ca. IGROV-1	0.0	Stomach Pool	3.1
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	0.0
Ovary	0.0	Fetal Heart	2.9
Breast ca. MCF-7	0.0	Heart Pool	2.8
Breast ca. MDA-	0.0	Lymph Node Pool	2.6
MB-231
Breast ca. BT 549	0.0	Fetal Skeletal Muscle	0.0
Breast ca. T47D	23.5	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	0.0	Spleen Pool	0.0
Breast Pool	2.8	Thymus Pool	2.6
Trachea	0.0	CNS cancer (glio/astro)	0.0
		U87-MG
Lung	0.0	CNS cancer (glio/astro)	0.0
		U-118-MG
Fetal Lung	0.0	CNS cancer (neuro;met)	0.0
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	0.0
		539
Lung ca. LX-1	66.9	CNS cancer (astro)	0.0
		SNB-75
Lung ca. NCI-H146	19.1	CNS cancer (glio) SNB-	0.0
		19
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-	2.8
		295
Lung ca. A549	0.0	Brain (Amygdala) Pool	2.7
Lung ca. NCI-H526	4.8	Brain (cerebellum)	0.0
Lung ca. NCI-H23	3.9	Brain (fetal)	6.3
Lung ca. NCI-H460	2.7	Brain (Hippocampus)	5.2
		Pool
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	0.0
Lung ca. NCI-H522	0.0	Brain (Substantia nigra)	2.7
		Pool
Liver	0.0	Brain (Thalamus) Pool	0.0
Fetal Liver	0.0	Brain (whole)	0.0
Liver ca. HepG2	1.5	Spinal Cord Pool	5.5
Kidney Pool	0.0	Adrenal Gland	0.0
Fetal Kidney	10.7	Pituitary gland Pool	16.7
Renal ca. 786-0	0.0	Salivary Gland	0.0
Renal ca. A498	6.9	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.0	Pancreas Pool	4.3

[0827]

TABLE LC
Panel 4D
	Rel. Exp.(%) Ag3534,		Rel. Exp.(%) Ag3534,
Tissue Name	Run 166444750	Tissue Name	Run 166444750
Secondary Th1 act	2.4	HUVEC IL-1 beta	0.0
Secondary Th2 act	2.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	2.5	HUVEC TNF alpha + IFN	0.0
		gamma
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC	0.0
		none
Primary Th1 act	0.0	Lung Microvascular EC	0.0
		TNF alpha + IL-1 beta
Primary Th2 act	0.0	Microvascular Dermal EC	0.0
		none
Primary Tr1 act	0.0	Microsvasular Dermal EC	0.0
		TNF alpha + IL-1 beta
Primary Th1 rest	0.0	Bronchial epithelium	0.0
		TNF alpha + IL1 beta
Primary Th2 rest	0.0	Small airway epithelium	0.0
		none
Primary Tr1 rest	0.0	Small airway epithelium	0.0
		TNF alpha + IL-1 beta
CD45RA CD4	0.0	Coronery artery SMC rest	0.0
lymphocyte act
CD45RO CD4	0.0	Coronery artery SMC	0.0
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8	0.0	Astrocytes TNF alpha + IL-	0.0
lymphocyte rest		1 beta
Secondary CD8	0.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	0.0	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	0.0	CCD1106 (Keratinocytes)	0.0
CD95 CH11		none
LAK cells rest	0.0	CCD1106 (Keratinocytes)	0.0
		TNF alpha + IL-1 beta
LAK cells IL-2	0.0	Liver cirrhosis	100.0
LAK cells IL-2 + IL-12	0.0	Lupus kidney	6.0
LAK cells IL-2 + IFN	0.0	NCI-H292 none	0.0
gamma
LAK cells IL-2 + IL-18	0.0	NCI-H292 IL-4	0.0
LAK cells	0.0	NCI-H292 IL-9	0.0
PMA/ionomycin
NK Cells IL-2 rest	1.5	NCI-H292 IL-13	0.0
Two Way MLR 3 day	0.0	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	0.0	HPAEC none	0.0
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1	0.0
		beta
PBMC rest	0.0	Lung fibroblast none	0.0
PBMC PWM	0.0	Lung fibroblast TNF	0.0
		alpha + IL-1 beta
PBMC PHA-L	0.0	Lung fibroblast IL-4	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell)	0.0	Lung fibroblast IL-13	0.0
ionomycin
B lymphocytes PWM	0.0	Lung fibroblast IFN	0.0
		gamma
B lymphocytes CD40L	0.0	Dermal fibroblast	0.0
and IL-4		CCD1070 rest
EOL-1 dbcAMP	0.0	Dermal fibroblast	0.0
		CCD1070 TNF alpha
EOL-1 dbcAMP	0.0	Dermal fibroblast	0.0
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	2.7	Dermal fibroblast IFN	0.0
		gamma
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-	0.0	IBD Colitis 2	4.4
CD40
Monocytes rest	0.0	IBD Crohn's	0.0
Monocytes LPS	0.0	Colon	44.4
Macrophages rest	0.0	Lung	15.9
Macrophages LPS	0.0	Thymus	10.0
HUVEC none	0.0	Kidney	0.0
HUVEC starved	0.0

[0828] CNS_neurodegeneration_v1.0 Summary: Ag3534 Expression of the CG59295-01 gene is low/undetectable in all samples on this panel (CTs>35).

[0829] General_screening_panel_v1.4 Summary: Ag3534 Highest expression of the CG59295-01 gene is seen in a colon cancer cell line (CT=3 1). Low but significant levels of expression are seen in lung and breast cancer cell lines. Therefore, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker for colon cancer. This gene has been linked to deafness. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of deafness.

[0830] References:

[0831] Simmler M C, Cohen-Salmon M, El-Amraoui A, Guillaud L, Benichou J C, Petit C, Panthier J J.

[0832] Panel 4D Summary: Ag3534 Expression of the CG59295-01 gene is restricted to a few samples, with highest expression in liver cirrhosis (CT=32.2). Low but significant level of expression are also seen in lung and colon. In addition, expression is undetectable in colon from patients with IBD colitis and Crohn's and in liver on Panel 1.4. Thus, expression of this gene may be used to differentiate between normal and diseased liver and colon tissue. Also, therapeutic modulation of the activity of the otogelin protein encoded by this gene may be useful in the treatment of inflammatory bowel disease and inflammatory or autoimmune diseases which affect the liver including liver cirrhosis and fibrosis.

[0833] Panel CNS—1 Summary: Ag3534 Expression of the CG59295-01 gene is low/undetectable in all samples on this panel (CTs>35).

M. NOV18a (CG59293-01: Renal Organic Anion Transport Protein 1)

[0834] Expression of gene CG59293-01 was assessed using the primer-probe sets Ag3948, Ag3532 and Ag2874, described in Tables MA, MB and MC. Results of the RTQ-PCR runs are shown in Tables MD, ME, MF, MG, MH, MI, MJ and MK.

TABLE MA
Probe Name Ag3948
			Start
Primer	Sequences	Length	Position
Forward	5′-ctctattcttggtggcttcca-3′	(SEQ ID NO:254)	21	867
Probe	TET-5′-ctcctgcatggcaagtcccagttag-3′-TAMRA	(SEQ ID NO:255)	25	906
Reverse	5′-ccaccttctgcagattctgtac-3′	(SEQ ID NO:256)	22	993

[0835]

TABLE MB
Probe Name Ag3532
			Start
Primer	Sequences	Length	Position
Forward	5′-ccaactcaatcttggacctctt-3′	(SEQ ID NO:257)	22	1048
Probe	TET-5′-atccgcaaggtcacatgctgtctcat-3′-TAMRA	(SEQ ID NO:258)	26	1083
Reverse	5′-cagagttggagaaccaaatcac-3′	(SEQ ID NO:259)	22	1110

[0836]

TABLE MC
Probe Name Ag2874
			Start
Primers	Sequences	Length	Position
Forward	5′-ccaactcaatcttggacctctt-3′	(SEQ ID NO:260)	22	1048
Probe	TET-5′-atccgcaaggtcacatgctgtctcat-3′-TAMRA	(SEQ ID NO:261)	26	1083	JNO:261)	I
Reverse	5′-cagagttggagaaccaaatcac-3′	(SEQ ID NO:262)	22	1110

[0837]

TABLE MD
AI_comprehensive panel_v1.0
	Rel. Exp.(%) Ag3948,		Rel. Exp.(%) Ag3948,
Tissue Name	Run 247842315	Tissue Name	Run 247842315
110967 COPD-F	17.8	112427 Match Control	12.1
		Psoviasis-F
110980 COPD-F	6.7	112418 Psoriasis-M	11.2
110968 COPD-M	9.2	112723 Match Control	9.6
		Psoriasis-M
110977 COPD-M	20.0	112419 Psoriasis-M	30.6
110989 Emphysema-F	34.6	112424 Match Control	18.4
		Psoriasis-M
110992 Emphysema-F	0.0	112420 Psoriasis-M	94.6
110993 Emphysema-F	18.6	112425 Match Control	42.6
		Psoriasis-M
110994 Emphysema-F	9.2	104689 (MF) OA Bone-	20.2
		Backus
110995 Emphysema-F	100.0	104690 (MF) Adj	7.2
		“Normal” Bone-Backus
110996 Emphysema-F	5.2	104691 (MF) OA	10.0
		Synovium-Backus
110997 Asthma-M	18.0	104692 (BA) OA	0.0
		Cartilage-Backus
111001 Asthma-F	0.0	104694 (BA) OA Bone-	14.2
		Backus.
111002 Asthma-F	8.8	104695 (BA) Adj	7.5
		“Normal” Bone-Backus
111003 Atopic	5.6	104696 (BA) OA	13.9
Asthma-F		Synovium-Backus
111004 Atopic	41.5	104700 (SS) OA Bone-	35.6
Asthma-F		Backus
111005 Atopic	17.6	104701 (SS) Adj	8.7
Asthma-F		“Normal” Bone-Backus
111006 Atopic	0.0	104702 (SS) OA	26.8
Asthma-F		Synovium-Backus
111417 Allergy-M	2.4	117093 OA Cartilage	18.9
		Rep7
112347 Allergy-M	0.0	112672 OA Bone5	13.4
112349 Normal Lung-F	10.1	112673 OA Synovium5	0.0
112357 Normal Lung-F	9.2	112674 OA Synovial	5.8
		Fluid cells5
112354 Normal Lung-M	19.2	117100 OA Cartilage	14.8
		Rep14
112374 Crohns-F	28.3	112756 OA Bone9	21.0
112389 Match Control	15.2	112757 OA Synovium9	20.3
Crohns-F
112375 Crohns-F	14.3	112758 OA Synovial	7.2
		Fluid Cells9
112732 Match Control	92.7	117125 RA Cartilage	25.9
Crohns-F		Rep2
112725 Crohns-M	23.5	113492 Bone2 RA	10.9
112387 Match Control	13.6	113493 Synovium2 RA	8.8
Crohns-M
112378 Crohns-M	14.4	113494 Syn Fluid Cells	16.8
		RA
112390 Match Control	72.7	113499 Cartilage4 RA	12.9
Crohns-M
112726 Crohns-M	12.8	113500 Bone4 RA	20.7
112731 Match Control	65.5	113501 Synovium4 RA	13.8
Crohns-M
112380 Ulcer Col-F	18.6	113502 Syn Fluid	3.1
		Cells4 RA
112734 Match Control	89.5	113495 Cartilage3 RA	6.8
Ulcer Col-F
112384 Ulcer Col-F	57.8	113496 Bone3 RA	20.7
112737 Match Control	15.6	113497 Synovium3 RA	8.7
Ulcer Col-F
112386 Ulcer Col-F	2.7	113498 Syn Fluid	21.6
		Cells3 RA
112738 Match Control	4.3	117106 Normal	5.7
Ulcer Col-F		Cartilage Rep20
112381 Ulcer Col-M	0.0	113663 Bone3 Normal	16.2
112735 Match Control	58.2	113664 Synovium3	2.6
Ulcer Col-M		Normal
112382 Ulcer Col-M	8.4	113665 Syn Fluid	5.2
		Cells3 Normal
112394 Match Control	17.1	117107 Normal	11.0
Ulcer Col-M		Cartilage Rep22
112383 Ulcer Col-M	47.3	113667 Bone4 Normal	15.4
112736 Match Control	1.9	113668 Synovium4	20.2
Ulcer Col-M		Normal
112423 Psoriasis-F	27.4	113669 Syn Fluid	40.9
		Cells4 Normal

[0838]

TABLE ME
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3948,		Rel. Exp.(%) Ag3948,
Tissue Name	Run 212345604	Tissue Name	Run 212345604
AD 1 Hippo	0.0	Control (Path) 3	0.0
		Temporal Ctx
AD 2 Hippo	57.0	Control (Path) 4	33.4
		Temporal Ctx
AD 3 Hippo	32.5	AD 1 Occipital Ctx	67.8
AD 4 Hippo	0.0	AD 2 Occipital Ctx	5.3
		(Missing)
AD 5 Hippo	47.0	AD 3 Occipital Ctx	0.0
AD 6 Hippo	20.3	AD 4 Occipital Ctx	0.0
Control 2 Hippo	0.0	AD 5 Occipital Ctx	18.4
Control 4 Hippo	0.0	AD 6 Occipital Ctx	39.2
Control (Path) 3	0.0	Control 1 Occipital	0.0
Hippo		Ctx
AD 1 Temporal Ctx	0.0	Control 2 Occipital	79.6
		Ctx
AD 2 Temporal Ctx	16.7	Control 3 Occipital	42.0
		Ctx
AD 3 Temporal Ctx	14.9	Control 4 Occipital	0.0
		Ctx
AD 4 Temporal Ctx	0.0	Control (Path) 1	46.0
		Occipital Ctx
AD 5 Inf Temporal	100.0	Control (Path) 2	0.0
Ctx		Occipital Ctx
AD 5 Sup Temporal	0.0	Control (Path) 3	0.0
Ctx		Occipital Ctx
AD 6 Inf Temporal	65.1	Control (Path) 4	11.7
Ctx		Occipital Ctx
AD 6 Sup Temporal	91.4	Control 1 Parietal	10.3
Ctx		Ctx
Control 1 Temporal	0.0	Control 2 Parietal	49.3
Ctx		Ctx
Control 2 Temporal	0.0	Control 3 Parietal	0.0
Ctx		Ctx
Control 3 Temporal	0.0	Control (Path) 1	67.8
Ctx		Parietal Ctx
Control 3 Temporal	18.0	Control (Path) 2	14.4
Ctx		Parietal Ctx
Control (Path) 1	32.1	Control (Path) 3	0.0
Temporal Ctx		Parietal Ctx
Control (Path) 2	9.7	Control (Path) 4	20.4
Temporal Ctx		Parietal Ctx

[0839]

TABLE MF
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3948,		Rel. Exp.(%) Ag3948,
Tissue Name	Run 219279808	Tissue Name	Run 219279808
Adipose	0.3	Renal ca. TK-10	2.1
Melanoma*	0.5	Bladder	2.8
Hs688(A).T
Melanoma*	0.2	Gastric ca. (liver met.)	22.2
Hs688(B).T		NCI-N87
Melanoma* M14	0.2	Gastric ca. KATO III	4.0
Melanoma*	0.0	Colon ca. SW-948	0.1
LOXIMVI
Melanoma* SK-	0.1	Colon ca. SW480	10.5
MEL-5
Squamous cell	2.4	Colon ca.* (SW480	1.6
carcinoma SCC-4		met) SW620
Testis Pool	0.3	Colon ca. HT29	1.5
Prostate ca.* (bone	0.9	Colon ca. HCT-116	2.3
met) PC-3
Prostate Pool	0.3	Colon ca. CaCo-2	0.7
Placenta	0.2	Colon cancer tissue	0.2
Uterus Pool	0.1	Colon ca. SW1116	0.1
Ovarian ca. OVCAR-3	11.5	Colon ca. Colo-205	0.6
Ovarian ca. SK-OV-3	1.3	Colon ca. SW-48	0.8
Ovarian ca. OVCAR-4	0.4	Colon Pool	0.6
Ovarian ca. OVCAR-5	8.0	Small Intestine Pool	0.4
Ovarian ca. IGROV-1	1.9	Stomach Pool	0.1
Ovarian ca. OVCAR-8	0.5	Bone Marrow Pool	0.4
Ovary	0.4	Fetal Heart	0.1
Breast ca. MCF-7	3.2	Heart Pool	0.3
Breast ca. MDA-	2.3	Lymph Node Pool	0.7
MB-231
Breast ca. BT 549	0.2	Fetal Skeletal Muscle	0.6
Breast ca. T47D	9.6	Skeletal Muscle Pool	0.4
Breast ca. MDA-N	0.2	Spleen Pool	0.2
Breast Pool	0.7	Thymus Pool	0.3
Trachea	0.6	CNS cancer (glio/astro)	0.5
		U87-MG
Lung	0.2	CNS cancer (glio/astro)	0.1
		U-118-MG
Fetal Lung	1.7	CNS cancer (neuro;met)	0.4
		SK-N-AS
Lung ca. NCI-N417	0.1	CNS cancer (astro) SF-	0.1
		539
Lung ca. LX-1	100.0	CNS cancer (astro)	0.1
		SNB-75
Lung ca. NCI-H146	1.0	CNS cancer (glio) SNB-	0.9
		19
Lung ca. SHP-77	0.1	CNS cancer (glio) SF-	9.3
		295
Lung ca. A549	2.2	Brain (Amygdala) Pool	0.1
Lung ca. NCI-H526	0.1	Brain (cerebellum)	5.1
Lung ca. NCI-H23	0.9	Brain (fetal)	2.3
Lung ca. NCI-H460	0.2	Brain (Hippocampus)	0.0
		Pool
Lung ca. HOP-62	0.5	Cerebral Cortex Pool	0.0
Lung ca. NCI-H522	1.1	Brain (Substantia nigra)	0.2
		Pool
Liver	0.3	Brain (Thalamus) Pool	0.0
Fetal Liver	0.8	Brain (whole)	0.8
Liver ca. HepG2	0.2	Spinal Cord Pool	0.0
Kidney Pool	0.7	Adrenal Gland	0.2
Fetal Kidney	0.7	Pituitary gland Pool	0.0
Renal ca. 786-0	0.2	Salivary Gland	0.1
Renal ca. A498	0.2	Thyroid (female)	0.7
Renal ca. ACHN	0.2	Pancreatic ca. CAPAN2	3.8
Renal ca. UO-31	1.6	Pancreas Pool	0.6

[0840]

TABLE MG
Panel 1.3D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag2874, Run	Ag2874, Run		Ag2874, Run	Ag2874, Run
Tissue Name	161973724	165721687	Tissue Name	161973724	165721687
Liver	4.9	5.6	Kidney (fetal)	0.0	0.0
adenocarcinoma
Pancreas	0.0	0.0	Renal ca. 786-0	0.0	0.0
Pancreatic ca.	0.0	0.0	Renal ca. A498	0.0	0.0
CAPAN 2
Adrenal gland	0.0	0.0	Renal ca RXF	0.0	0.0
			393
Thyroid	0.0	6.3	Renal ca.	0.0	0.0
			ACHN
Salivary gland	0.0	0.0	Renal ca. UO-	0.0	0.0
			31
Pituitary gland	0.0	0.0	Renal ca. TK-	0.0	0.0
			10
Brain (fetal)	0.0	3.8	Liver	0.0	3.1
Brain (whole)	3.1	6.1	Liver (fetal)	0.0	0.0
Brain (amygdala)	4.3	0.0	Liver ca.	0.0	0.0
			(hepatoblast)
			HepG2
Brain (cerebellum)	1.8	7.6	Lung	0.0	0.0
Brain	0.0	0.0	Lung (fetal)	4.5	4.1
(hippocampus)
Brain (substantia	0.0	3.5	Lung ca.	100.0	100.0
nigra)			(small cell)
			LX-1
Brain (thalamus)	0.0	0.0	Lung ca.	0.0	3.2
			(small cell)
			NCI-H69
Cerebral Cortex	2.3	0.0	Lang ca. (s.cell	0.0	0.0
			var.) SHP-77
Spinal cord	0.0	0.0	Lung ca. (large	0.0	0.0
			cell) NCI-H460
glio/astro U87-MG	0.0	0.0	Lung ca. (non-	0.0	0.0
			sm. cell) A549
glio/astro U-118-	0.0	0.0	Lung ca. (non-	0.0	0.0
MG			s.cell) NCI-
			H23
astrocytoma	0.0	0.0	Lung ca. (non-	0.0	0.0
SW1783			s.cell) HOP-62
neuro*; met SK-N-	0.0	0.0	Lung ca. (non-	1.7	0.0
AS			s.cl) NCI-H522
astrocytoma SF-	3.8	0.0	Lung ca.	2.1	0.0
539			(squam.) SW
			900
astrocytoma SNB-	0.0	0.0	Lung ca.	0.0	0.0
75			(squam.) NCI-
			H596
glioma SNB-19	0.0	0.0	Mammary	0.0	0.0
			gland
glioma U251	0.0	0.0	Breast ca.*	13.9	0.0
			(pl.ef) MCF-7
glioma SF-295	10.7	12.5	Breast ca.*	2.6	0.0
			(pl.et) MDA-
			MB-231
Heart (fetal)	0.0	0.0	Breast ca.*	3.2	4.7
			(pl.ef) T47D
Heart	0.0	0.0	Breast ca. BT-549	0.0	0.0
Skeletal muscle	0.0	5.3	Breast ca.	0.0	0.0
(fetal)			MDA-N
Skeletal muscle	0.0	0.0	Ovary	0.0	0.0
Bone marrow	17.9	6.1	Ovarian ca.	24.1	4.7
			OVCAR-3
Thymus	18.7	0.0	Ovarian ca.	4.7	0.0
			OVCAR-4
Spleen	0.0	0.0	Ovarian ca.	4.8	4.8
			OVCAR-5
Lymph node	10.5	0.0	Ovarian ca.	0.0	0.0
			OVCAR-8
Colorectal	4.9	3.1	Ovarian ca.	3.0	0.0
			IGROV-1
Stomach	0.0	0.0	Ovarian ca.*	0.0	3.4
			(ascites) SK-
			OV-3
Small intestine	0.0	0.0	Uterus	0.0	6.5
Colon ca. SW480	2.7	0.0	Placenta	0.0	0.0
Colon ca.*	0.0	0.0	Prostate	10.8	2.7
SW620(SW480
met)
Colon ca. HT29	0.0	0.0	Prostate ca.*	0.0	0.0
			(bone met)PC-3
Colon Ca. HCT-	0.0	0.0	Testis	0.0	0.0
116
Colon ca. CaCo-2	0.0	0.0	Melanoma	0.0	0.0
			Hs688(A).T
Colon ca.	8.8	0.0	Melanoma*	0.0	0.0
tissue(ODO3866)			(met)
			Hs688(B).T
Colon Ca. HCC-	17.1	2.7	Melanoma	0.0	0.0
2998			UACC-62
Gastric ca.* (liver	28.9	13.4	Melanoma	0.0	0.0
met) NCI-N87			M14
Bladder	13.6	0.0	Melanoma	0.0	0.0
			LOX IMVI
Trachea	6.7	5.6	Melanoma *	0.0	0.0
			(met) SK-
			MEL-5
Kidney	2.6	0.0	Adipose	0.0	0.0

[0841]

TABLE MH
Panel 2D
	Rel. Exp.(%) Ag2874,		Rel. Exp.(%) Ag2874,
Tissue Name	Run 161973958	Tissue Name	Run 161973958
Normal Colon	24.3	Kidney Margin	0.0
		8120608
CC Well to Mod Diff	0.0	Kidney Cancer	0.0
(ODO3866)		8120613
CC Margin (ODO3866)	26.2	Kidney Margin	21.3
		8120614
CC Gr.2 rectosigmoid	0.0	Kidney Cancer	0.0
(ODO3868)		9010320
CC Margin (ODO3868)	13.8	Kidney Margin	0.0
		9010321
CC Mod Diff (ODO3920)	11.7	Normal Uterus	0.0
CC Margin (ODO3920)	0.0	Uterus Cancer 064011	10.8
CC Gr.2 ascend colon	65.1	Normal Thyroid	20.2
(ODO3921)
CC Margin (ODO3921)	0.0	Thyroid Cancer	42.6
		064010
CC from Partial	27.9	Thyroid Cancer	24.1
Hepatectomy (ODO4309)		A302152
Mets
Liver Margin (ODO4309)	0.0	Thyroid Margin	0.0
		A302153
Colon mets to lung	7.5	Normal Breast	0.0
(OD04451-01)
Lung Margin (OD04451-	0.0	Breast Cancer	0.0
02)		(OD04566)
Normal Prostate 6546-1	13.0	Breast Cancer	49.7
		(OD04590-01)
Prostate Cancer	0.0	Breast Cancer Mets	18.8
(OD04410)		(OD04590-03)
Prostate Margin	0.0	Breast Cancer	58.2
(OD04410)		Metastasis (OD04655-
		05)
Prostate Cancer	59.5	Breast Cancer 064006	40.9
(OD04720-01)
Prostate Margin	28.7	Breast Cancer 1024	100.0
(OD04720-02)
Normal Lung 061010	0.0	Breast Cancer	9.7
		9100266
Lung Met to Muscle	0.0	Breast Margin	43.5
(ODO4286)		9100265
Muscle Margin	0.0	Breast Cancer	32.5
(ODO4286)		A209073
Lung Malignant Cancer	0.0	Breast Margin	13.4
(OD03126)		A209073
Lung Margin (OD03126)	11.3	Normal Liver	0.0
Lung Cancer (OD04404)	0.0	Liver Cancer 064003	0.0
Lung Margin (OD04404)	0.0	Liver Cancer 1025	0.0
Lung Cancer (OD04565)	16.3	Liver Cancer 1026	0.0
Lung Margin (OD04565)	0.0	Liver Cancer 6004-T	0.0
Lung Cancer (OD04237-	0.0	Liver Tissue 6004-N	0.0
01)
Lung Margin (OD04237-	0.0	Liver Cancer 6005-T	0.0
02)
Ocular Mel Met to Liver	0.0	Liver Tissue 6005-N	0.0
(ODO4310)
Liver Margin (ODO4310)	0.0	Normal Bladder	58.2
Melanoma Mets to Lung	0.0	Bladder Cancer 1023	0.0
(OD04321)
Lung Margin (OD04321)	0.0	Bladder Cancer	16.6
		A302173
Normal Kidney	16.5	Bladder Cancer	66.0
		(OD04718-01)
Kidney Ca, Nuclear grade	16.0	Bladder Normal	0.0
2 (OD04338)		Adjacent (OD04718-
		03)
Kidney Margin	14.1	Normal Ovary	0.0
(OD04338)
Kidney Ca Nuclear grade	13.9	Ovarian Cancer	85.9
1/2 (OD04339)		064008
Kidney Margin	13.0	Ovarian Cancer	0.0
(OD04339)		(OD04768-07)
Kidney Ca, Clear cell type	0.0	Ovary Margin	0.0
(OD04340)		(OD04768-08)
Kidney Margin	0.0	Normal Stomach	14.7
(OD04340)
Kidney Ca, Nuclear grade	14.8	Gastric Cancer	0.0
3 (OD04348)		9060358
Kidney Margin	0.0	Stomach Margin	0.0
(OD04348)		9060359
Kidney Cancer	0.0	Gastric Cancer	0.0
(OD04622-01)		9060395
Kidney Margin	0.0	Stomach Margin	14.0
(OD04622-03)		9060394
Kidney Cancer	0.0	Gastric Cancer	17.2
(OD04450-01)		9060397
Kidney Margin	19.2	Stomach Margin	0.0
(OD04450-03)		9060396
Kidney Cancer 8120607	23.5	Gastric Cancer 064005	20.3

[0842]

TABLE MI
Panel 3D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag2874, Run		Ag2874, Run
Tissue Name	164543575	Tissue Name	164543575
Daoy-Medulloblastoma	0.0	Ca Ski-Cervical epidermoid	0.0
		carcinoma (metastasis)
TE671-Medulloblastoma	0.0	ES-2-Ovarian clear cell-	0.0
		carcinoma
D283 Med-	0.0	Ramos-Stimulated with	0.0
Medulloblastoma		PMA/ionomycin 6 h
PFSK-1-Primitive	0.0	Ramos-Stimulated with	0.0
Neuroectodermal		PMA/ionomycin 14 h
XF-498-CNS	0.0	MEG-01-Chronic
		myelogenous leukemia	0.0
		(megokaryoblast)
SNB-78-Glioma	0.0	Raji-Burkitt's lymphoma	3.3
SF-268-Glioblastoma	0.0	Daudi-Burkitt's lymphoma	0.0
T98G-Glioblastoma	0.0	U266-B-cell plasmacytoma	0.0
SK-N-SH-	0.0	CA46-Burkitt's lymphoma	0.0
Neuroblastoma
(metastasis)
SF-295-Glioblastoma	0.0	RL-non-Hodgkin's B-cell	0.0
		lymphoma
Cerebellum	0.5	JM1-pre-B-cell lymphoma	0.0
Cerebellum	2.3	Jurkat-T cell leukemia	0.0
NCI-H292-	16.8	TF-1-Erythroleukemia	0.0
Mucoepidermoid lung
carcinoma
DMS-114-Small cell	0.0	HUT 78-T-cell lymphoma	8.2
lung cancer
DMS-79-Small cell lung	4.2	U937-Histiocytic lymphoma	0.0
cancer
NCI-H146-Small cell	0.0	KU-812-Myelogenous	0.0
lung cancer		leukemia
NCI-H526-Small cell	0.0	769-P-Clear cell renal	0.0
lung cancer		carcinoma
NCI-N417-Small cell	0.0	Caki-2-Clear cell renal	0.0
lung cancer		carcinoma
NCI-H82-Small cell lung	0.0	SW 839-Clear cell renal	2.9
cancer		carcinoma
NCI-H157-Squamous	0.0	G401-Wilm's tumor	0.0
cell lung cancer
(metastasis)
NCI-H1155-Large cell	0.0	Hs766GT-Pancreatic carcinoma	3.6
lung cancer		(LN metastasis)
NCI-H1299-Large cell	16.6	CAPAN-1-Pancreatic	4.4
lung cancer		adenocarcinoma (liver
		metastasis)
NCI-H727-Lung	0.0	SU86.86-Pancreatic	100.0
carcinoid		carcinoma (liver metastasis)
NCI-UMC-11-Lung	0.0	BxPC-3-Pancreatic	0.0
carcinoid		adenocarcinoma
LX-1-Small cell lung	48.0	HPAC-Pancreatic	3.6
cancer		adenocarcinoma
Colo-205-Colon cancer	9.9	MIA PaCa-2-Pancreatic	0.0
		carcinoma
KM12-Colon cancer	0.0	CFPAC-1-Pancreatic ductal	4.4
		adenocarcinoma
KM20L2-Colon cancer	0.0	PANC-1-Pancreatic	0.0
		epithelioid ductal carcinoma
NCI-H716-Colon cancer	0.0	T24-Bladder carcinoma	3.9
		(transitional cell)
SW-48-Colon	0.0	5637-Bladder carcinoma	0.0
adenocarcinoma
SW1116-Colon	0.0	HT-1197-Bladder carcinoma	0.0
adenocarcinoma
LS 174T-Colon	8.3	UM-UC-3-Bladder carcinma	0.0
adenocarcinoma		(transitional cell)
SW-948-Colon	5.1	A204-Rhabdomyosarcoma	0.0
adenocarcinoma
SW-480-Colon	0.0	HT-1080-Fibrosarcoma	0.0
adenocarcinoma
NCI-SNU-5-Gastric	13.5	MG-63-Osteosarcoma	0.0
carcinoma
KATO III-Gastric	0.0	SK-LMS-1-Leiomyosarcoma	4.1
carcinoma		(vulva)
NCI-SNU-16-Gastric	0.0	SJRH30-Rhabdomyosarcoma	0.0
carcinoma		(met to bone marrow)
NCI-SNU-1-Gastric	0.0	A431-Epidermoid carcinoma	0.0
carcinoma
RF-1-Gastric	0.0	WM266-4-Melanoma	0.0
adenocarcinoma
RF-48-Gastric	0.0	DU 145-Prostate carcinoma	0.0
adenocarcinoma		(brain metastasis)
MKN-45-Gastric	0.0	MDA-MB-468-Breast	6.5
carcinoma		adenocarcinoma
NCI-N87-Gastric	0.0	SCC-4-Squamous cell	0.0
carcinoma		carcinoma of tongue
OVCAR-5-Ovarian	10.2	SCC-9-Squamous cell	0.0
carcinoma		carcinoma of tongue
RL95-2-Uterine	0.0	SCC-15-Squamous cell	0.0
carcinoma		carcinoma of tongue
HelaS3-Cervical	0.0	CAL 27-Squamous cell	21.6
adenocarcinoma		carcinoma of tongue

[0843]

TABLE MJ
Panel 4.1D
	Rel.Exp.(%)		Rel.Exp.(%)
	Ag3948, Run		Ag3948, Run
Tissue Name	170684837	Tissue Name	170684837
Secondary Th1 act	1.6	HUVEC IL-1 beta	3.1
Secondary Th2 act	8.6	HUVEC IFN gamma	7.4
Secondary Tr1 act	4.4	HUVEC TNF alpha + IFN	2.7
		gamma
Secondary Th1 rest	0.3	HUVEC TNF alpha + IL4	0.9
Secondary Th2 rest	3.9	HUVEC IL-11	6.0
Secondary Tr1 rest	1.6	Lung Microvascular EC	7.3
		none
Primary Th1 act	0.3	Lung Microvascular EC	2.7
		TNF alpha + IL-1 beta
Primary Th2 act	1.6	1 Microvascular Dermal EC	0.0
		none
Primary Tr1 act	0.0	Microsvascular Dermal EC	0.5
		TNF alpha + IL-1 beta
Primary Th1 rest	0.0	Bronchial epithelium	15.5
		TNF alpha + IL1 beta
Primary Th2 rest	1.6	Small airway epitheliurn	6.3
		none
Primary Tr1 rest	0.4	Small airway epithelium	20.4
		TNF alpha + IL-1 beta
CD45RA CD4	0.0	Coronery artery SMC rest	6.0
lymphocyte act
CD45RO CD4	1.2	Coronery artery SMC	1.6
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	2.8	Astrocytes rest	0.3
Secondary CD8	2.0	Astrocytes TNF alpha + IL-	1.5
lymphocyte rest		1 beta
Secondary CD8	1.2	KU-812 (Basophil) rest	3.4
lymphocyte act
CD4 lymphocyte none	1.6	KU-812 (Basophil)	6.3
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	4.6	CCD1106 (Keratinocytes)	14.6
CD95 CH11		none
LAK cells rest	1.6	CCD1106 (Keratinocytes)	20.6
		TNF alpha + IL-1 beta
LAK cells IL-2	1.7	Liver cirrhosis	0.0
LAK cells IL-2 + IL-12	3.6	NCI-H292 none	49.7
LAK cells IL-2 + IFN	0.0	NCI-H292 IL-4	79.6
gamma
LAK cells IL-2 + IL-18	1.7	NCI-H292 IL-9	92.7
LAK cells	0.0	NCI-H292 IL-13	58.2
PMA/ionomycin
NK Cells IL-2 rest	4.9	NCI-H292 IFN gamma	50.0
Two Way MLR 3 day	3.1	HPAEC none	8.6
Two Way MLR 5 day	1.4	HPAEC TNF alpha + IL-1	3.5
		beta
Two Way MLR 7 day	4.1	Lung fibroblast none	2.7
PBMC rest	2.5	Lung fibroblast TNF	2.9
		alpha + IL-1 beta
PBMC PWM	2.3	Lung fibroblast IL-4	2.9
PBMC PHA-L	0.4	Lung fibroblast IL-9	4.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	5.5
Ramos (B cell)	0.0	Lung fibroblast IFN	5.8
ionomycin		gamma
B lymphocytes PWM	0.0	Dermal fibroblast	16.2
		CCD1070 rest
B lymphocytes CD40L	7.6	Dermal fibroblast	4.7
and IL-4		CCD1070 TNF alpha
EOL-1 dbcAMP	1.9	Dermal fibroblast	1.8
		CCD1070 IL-1 beta
EOL-1 dbcAMP	5.5	Dermal fibroblast IFN	6.7
PMA/ionomycin		gamma
Dendritic cells none	1.6	Dermal fibroblast IL-4	4.1
Dendritic cells LPS	0.0	Dermal fibroblasts rest	12.2
Dendritic cells anti-	0.7	Neutrophils TNFa + LPS	0.7
CD40
Monocytes rest	2.8	Neutrophils rest	1.5
Monocytes LPS	9.3	Colon	5.5
Macrophages rest	0.0	Lung	11.6
Macrophages LPS	0.8	Thymus	40.6
HUVEC none	0.3	Kidney	100.0
HUVEC starved	9.9

[0844]

TABLE MK
Panel 4D
	Rel.	Rel.		Rel.	Rel.
	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)
	Ag2874,	Ag3532,		Ag2874,	Ag3532,
	Run	Run		Run	Run
Tissue Name	159776813	166444749	Tissue Name	159776813	166444749
Secondary Th1 act	0.0	0.0	HUVEC IL- 1 beta	0.0	0.0
Secondary Th2 act	0.0	0.0	HUVEC IFN	4.4	5.5
			gamma
Secondary Tr1 act	0.0	7.2	HUVEC TNF	0.0	0.0
			alpha + IFN
			gamma
Secondary Th1 rest	0.0	0.0	HUVEC TNF	0.0	0.0
			alpha + IL4
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.0	0.0
Secondary Tr1 rest	0.0	3.3	Lung	0.0	9.0
			Microvascular EC
			none
Primary Th1 act	0.0	0.0	Lung	0.0	0.0
			Microvascular EC
			TNF alpha + IL-
			1 beta
Primary Th2 act	0.0	0.0	Microvascular	0.0	0.0
			Dermal EC none
Primary Tr1 act	0.0	0.0	Microsvascular	0.0	0.0
			Dermal EC
			TNF alpha + IL-
			1 beta
Primary Th1 rest	0.0	6.4	Bronchial	0.0	0.0
			epithelium
			TNF alpha +
			IL1 beta
Primary Th2 rest	5.6	0.0	Small airway	5.2	21.2
			epithelium none
Primary Tr1 rest	8.6	0.0	Small airway	25.5	19.6
			epithelium
			TNF alpha + IL-
			1 beta
CD45RA CD4	0.0	0.0	Coronery artery	0.0	2.1
lymphocyte act			SMC rest
CD45RO CD4	0.0	0.0	Coronery artery	0.0	0.0
lymphocyte act			SMC TNF alpha +
			IL-1 beta
CD8 lymphocyte	0.0	0.0	Astrocytes rest	0.0	0.0
act
Secondary CD8	0.0	0.0	Astrocytes	0.0	5.8
lymphocyte rest			TNF alpha + IL-
			1 beta
Secondary CD8	0.0	0.0	KU-812 (Basophil)	0.0	0.0
lymphocyte act			rest
CD4 lymphocyte	4.1	6.9	KU-812 (Basophil)	0.0	3.0
none			PMA/ionomycin
2ry	0.0	0.0	CCD1106	13.5	6.7
Th1/Th2/Tr1_anti-			(Keratinocytes)
CD95 CH11			none
LAK cells rest	0.0	0.0	CCD1106	0.0	69.3
			(Keratinocytes)
			TNF alpha + IL-
			1 beta
LAK cells IL-2	0.0	0.0	Liver cirrhosis	0.0	0.0
LAK cells IL-2 +	0.0	0.0	Lupus kidney	0.0	4.2
IL-12
LAK cells IL-	0.0	3.5	NCI-H292 none	71.7	85.9
2 + IFN gamma
LAK cells IL-2 +	0.0	0.0	NCI-H292 IL-4	53.6	100.0
IL-18
LAK cells	0.0	0.0	NCI-H292 IL-9	100.0	68.8
PMA/ionomycin
NK Cells IL-2 rest	0.0	3.4	NCI-H292 IL-13	36.9	60.3
Two Way MLR 3	0.0	0.0	NCI-H292 IFN	8.1	64.2
day			gamma
Two Way MLR 5	0.0	7.0	HPAEC none	0.0	0.0
day
Two Way MLR 7	0.0	0.9	HPAEC TNF	0.0	0.0
day			alpha + IL-1 beta
PBMC rest	0.0	0.0	Lung fibroblast	0.0	0.0
			none
PBMC PWM	8.2	6.9	Lung fibroblast	4.0	4.9
			TNF alpha + IL-1
			beta
PBMC PHA-L	0.0	0.0	Lung fibroblast IL-4	0.0	0.0
Ramos (B cell)	0.0	0.0	Lung fibroblast IL-9	4.6	0.0
none
Ramos (B cell)	0.0	0.0	Lung fibroblast IL-	0.0	0.0
ionomycin			13
B lymphocytes	0.0	3.4	Lung fibroblast	5.0	0.0
PWM			IFN gamma
B lymphocytes	0.0	5.0	Dermal fibroblast	4.6	3.0
CD40L and IL-4			CCD1070 rest
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast	0.0	0.0
			CCD1070 TNF
			alpha
EOL-1 dbcAMP	3.7	0.0	Dermal fibroblast	0.0	0.0
PMA/ionomycin			CCD1070 IL-1
			beta
Dendritic cells none	0.0	0.0	Dermal fibroblast	4.6	6.6
			IFN gamma
Dendritic cells LPS	0.0	0.0	Dermal fibroblast	0.0	6.5
			IL-4
Dendritic cells anti-	0.0	2.1	IBD Colitis 2	0.0	0.0
CD40
Monocytes rest	4.5	0.0	IBD Crohn's	0.0	0.0
Monocytes LPS	8.6	2.7	Colon	12.0	13.7
Macrophages rest	0.0	0.0	Lung	0.0	0.0
Macrophages LPS	0.0	0.0	Thymus	0.0	7.6
HUVEC none	0.0	0.0	Kidney	4.0	17.6
HUVEC starved	0.0	3.5

[0845] AI_comprehensive panel_v1.0 Summary: Ag3948 This panel confirms expression of the CG59293-01 gene in tissue samples related to the immune and inflammatory response. Please see Panels 4 and 4.1D for discussion of utility of this gene in inflammation.

[0846] CNS_neurodegeneration_v1.0 Summary: Ag3948 This panel does not show differential expression of the CG59293-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel General_screening_panel_v1.4 for discussion of utility of this gene in the central nervous system. Ag3532 Expression of the CG59293-01 gene is low/undetectable in all samples on this panel (CTs>35).

[0847] General_screening_panel_v1.4 Summary: Ag3948 The expression of the CG59293-01 gene, an organic anion transporter homolog, is highest in a small cell lung cancer line LX-1 (CT-28.2). This gene is also expressed in some ovarian, breast, CNS, gastric. pancreatic, renal and colon cancer cell lines. Therefore, expression of this gene may be associated with these forms of cancer and therapeutic modulation of this gene might be of use in the treatment or diagnosis of these cancers.

[0848] This gene is also expressed at low levels in the cerebellum and fetal brain. The organic anion transporters are involved in transport across the blood brain barrier. This gene may therefore be of use in drug delivery to the CNS, specifically for compounds such as nerve growth factors protein therapeutics which are believed to have numerous uses in the CNS, but lack a delivery system.

[0849] References:

[0850] Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier P J, Sekine T, Endou H, Suzuki H, Sugiyama Y. Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier.

[0851] Panel 1.3D Summary: Ag2874 The expression of the CG59293-01 gene was assessed in two independent runs on this panel with reasonable concordance between the runs. The highest expression is seen in a small cell lung cancer line LX-1 (CTs=3 1-32), consistent with expression in Panel 1.3D. This gene is also expressed in some ovarian, breast, CNS, gastric and colon cancer cell lines. Therefore, expression of this gene might be associated with these forms of cancer and therapeutic modulation of this gene might be of use in the treatment or diagnosis of these cancers.

[0852] Panel 2D Summary: Ag2874 The CG59293-01 gene is expressed at low levels in the tissues used for panel 2D. The highest expression is seen in a breast cancer sample (CT=34.2). Significant expression is also seen in single samples of ovarian, bladder, prostate and colon cancers compared with the normal adjacent tissue. This indicates that the expression of this gene might be associated with these forms of cancer and therapeutic modulation of this gene might be of use in the treatment or diagnosis of these cancers.

[0853] Panel 3D Summary: Ag2874 Highest expression of the CG59293-01 gene is seen in a pancreatic cancer cell line (CT=31.6). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel. In addition, significant expression of this gene is associated with samples derived from lung cancer cell lines (CTs=32-34), an ovarian cancer, gastric cancer and squamous cell carcinoma of tongue. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.

[0854] Panel 4D Summary: Ag3498 The highest expression of the CG59293-01 gene is found in the kidney and in the pulmonary muco-epidermoid cell line NCI-H292 (CTs=31). The expression of this gene, although constitutive in the H292 cell line, is up regulated upon treatment with IL-4, II-9 and IL-13, cytokines that have been linked to the pathogenesis of asthma and/or COPD.

[0855] This gene is also found in small airway epithelium and keratinocytes treated with the inflammatory cytokines TNF-a and IL-1b. Therefore, modulation of the expression or activity of the protein encoded by this transcript through the application or small molecule therapeutics may be useful in the treatment of asthma, COPD, emphysema, psoriasis and wound healing.

[0856] Panel 4D Summary: Ag2874/Ag3532 The expression of the CG59293-01 transcript detected by two sets of primers was observed mostly in NCI-H292 (CFs=32-33). Up-regulation of this transcript in H292 was found upon treatment with IL-4 (Ag 3532) or IL-9 (Ag 2874), both cytokines are involved in the pathogenesis of asthma and/or COPD. This transcript was also detected in small airway epithelium and keratinocytes. Therefore, modulation of the expression or activity of the protein encoded by this transcript by small molecules could be useful for the treatment of asthma, COPD and or emphysema and also for the treatment of skin inflammatory diseases such as psoriasis or wound healing.

N. NOV19a (CG59284-01: SOLUTE CARRIER FAMILY 22)

[0857] Expression of gene CG59284-01 was assessed using the primer-probe set Ag3528, described in Table NA.

TABLE NA
Probe Name Ag3528
			Start
Primers	Sequences	Length	Position
Forward	5′-gtgtggatggctggqtctat-3′	(SEQ ID NO:263)	20	437
Probe	TET-5′-cagcatcttcacctccacaatcgtg-3′-TAMRA	(SEQ ID NO:264)	25	462
Revers	5′-ttcagagcatgagagtcacaca-3′	(SEQ ID NO:265)	22	503

[0858] CNS_neurodegeneration_v1.0 Summary: Ag3528 Expression of the CG59284-01 gene is low/undetectable in all samples on this panel (CTs>35).

[0859] General_screen_panel_v1.4 Summary: Ag3528 Expression of the CG59284-01 gene is low/undetectable in all samples on this panel (CTs>35).

[0860] Panel 4.1D Summary: Ag3528 Expression of the CG59284-01 gene is low/undetectable in all samples on this panel (CTs>35).

O. NOV20a (CG59278-01: OLFACTORY RECEPTOR P2)

[0861] Expression of gene CG59278-01 was assessed using the primer-probe set Ag3526, described in Table OA. Results of the RTQ-PCR runs are shown in Table OB.

TABLE OA
Probe Name Ag3526
			Start
Primers	Sequences	Length	Position
Forward	5′-gtagtgccaaggccttctctac-3′	(SEQ ID NO:266)	22	738
Probe	TET-5′-ctcccacgtaactgtggtggcactat-3′-TAMRA	(SEQ ID NO:267)	26	766
Reverse	5′-actgtgaaggcagaagcataga-3′	(SEQ ID NO:268)	22	792

[0862]

TABLE OB
Panel 4.1D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3526, Run		Ag3526, Run
Tissue Name	169840752	Tissue Name	169840752
Secondary Th1 act	0.0	HUVEC IL-1 beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.5	HUVEC TNF alpha + IFN	0.0
		gamma
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC	0.0
		none
Primary Th1 act	0.0	Lung Microvascular EC	0.0
		TNF alpha + IL-1 beta
Primary Th2 act	0.3	Microvascular Dermal EC	0.0
		none
Primary Tr1 act	0.0	Microsvasular Dermal EC	0.0
		TNF alpha + IL-1 beta
Primary Th1 rest	0.0	Bronchial epithelium	0.0
		TNF alpha + IL1 beta
Primary Th2 rest	0.0	Small airway epithelium	0.0
		none
Primary Tr1 rest	0.0	Small airway epithelium	0.0
		TNF alpha + IL-1 beta
CD45RA CD4	0.0	Coronery artery SMC rest	0.0
lymphocyte act
CD45RO CD4	0.0	Coronery artery SMC	0.0
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8	0.0	Astrocytes TNF alpha + IL-	0.0
lymphocyte rest		1 beta
Secondary CD8	0.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	0.0	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	0.0	CCD1106 (Keratinocytes)	0.0
CD95 CH11		none
LAK cells rest	0.0	CCD1106 (Keratinocytes)	0.0
		TNF alpha + IL-1 beta
LAK cells IL-2	0.0	Liver cirrhosis	0.0
LAK cells IL-2 + IL-12	0.0	NCI-H292 none	0.0
LAK cells IL-2 + IFN	0.0	NCI-H292 IL-4	0.0
gamma
LAK cells IL-2 + IL-18	0.0	NCI-H292 IL-9	0.0
LAK cells	0.4	NCI-H292 IL-13	0.0
PMA/ionomycin
NK Cells IL-2 rest	0.0	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	0.0	HPAEC none	0.0
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1	0.0
		beta
Two Way MLR 7 day	0.0	Lung fibroblast none	0.0
PBMC rest	0.0	Lung fibroblast TNF	0.0
		alpha + IL-1 beta
PBMC PWM	0.0	Lung fibroblast IL-4	0.8
PBMC PHA-L	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.4
Ramos (B cell)	0.0	Lung fibroblast IFN	0.0
ionomycin		gamma
B lymphocytes PWM	0.0	Dermal fibroblast	0.0
		CCD1070 rest
B lymphocytes CD40L	0.0	Dermal fibroblast	0.0
and IL-4		CCD1070 TNF alpha
EOL-1 dbcAMP	0.0	Dermal fibroblast	0.0
		CCD1070 IL-1 beta
EOL-1 dbcAMP	0.0	Dermal fibroblast IFN	0.0
PMA/ionomycin		gamma
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells LPS	0.6	Dermal Fibroblasts rest	0.0
Dendritic cells anti-	0.3	Neutrophils TNFa + LPS	0.4
CD40
Monocytes rest	7.0	Neutrophils rest	100.0
Monocytes LPS	5.6	Colon	0.0
Macrophages rest	0.7	Lung	0.4
Macrophages LPS	0.0	Thymus	0.7
HUVEC none	0.0	Kidney	0.0
HUVEC starved	0.0

[0863] CNS_neurodegeneration_v1.0 Summary: Ag3526 Expression of the CG59278-01 gene is low/undetectable in all samples on this panel (CTs>35).

[0864] General_screening_panel_v1.4 Summary: Ag3526 Expression of the CG59278-01 gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown). This gene encodes a G protein-coupled receptor (GPCR), a type of cell surface receptor involved in signal transduction. This gene product is most similar to members of the odorant receptor subfamily of GPCRs. Based on analogy to other odorant receptor genes, we predict that expression of this gene may be highest in nasal epithelium, a sample not represented on this panel.

[0865] Panel 4.1 D Summary: Ag3526 Expression of the CG59278-01 gene is restricted to a sample derived from resting neutrophils (CT=28.2). Thus, expression of this gene could be used as a marker of these cells. This expression is markedly reduced (CT=36.3) in neutrophils activated by TNF-alpha+LPS. This expression profile suggest that the protein encoded by this gene is produced by resting neutrophils but not by activated neutrophils. Therefore, the gene product may reduce activation of these inflammatory cells and be useful as a protein therapeutic to reduce or eliminate the symptoms in patients with Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis. In addition, small molecule or antibody antagonists of this gene product may be effective in increasing the immune response in patients with AIDS or other immunodeficiencies.

P. NOV21a and NOV21b (CG59274-01 and CG59274-02: LIPOMA HMGIC FUSION PARTNER)

[0866] Expression of gene CG59274-01 and CG59274-02 was assessed using the primer-probe set Ag3525, described in Table PA. Results of the RTQ-PCR runs are shown in Tables PB, PC and PD. Please note that CG59274-02 represents a full-length physical clone of the CG59274-01 gene, validating the prediction of the gene sequence.

TABLE PA
Probe Name Ag3525
			Start
Primer	Sequences	Length	Position
Forward	5′-gagagcatcatgaggaatacca-3′	(SEQ ID NO:269)	22	664
Probe	TET-5′-accattgcctcaaaccttgagctttg-3′-TAMRA	(SEQ ID NO:270)	26	707
Reverse	5′-ccaccctctccaatcttcttt-3′	(SEQ ID NO:271)	21	733

[0867]

TABLE PB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3525,		Rel. Exp.(%) Ag3525,
Tissue Name	Run 210630172	Tissue Name	Run 210630172
AD 1 Hippo	8.7	Control (Path) 3	8.1
		Temporal Ctx
AD 2 Hippo	50.0	Control (Path) 4	39.2
		Temporal Ctx
AD 3 Hippo	4.2	AD 1 Occipital Ctx	7.6
AD 4 Hippo	10.4	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	36.3	AD 3 Occipital Ctx	1.1
AD 6 Hippo	100.0	AD 4 Occipital Ctx	15.4
Control 2 Hippo	28.5	AD 5 Occipital Ctx	7.9
Control 4 Hippo	31.9	AD 6 Occipital Ctx	18.0
Control (Path) 3	7.2	Control 1 Occipital	0.0
Hippo		Ctx
AD 1 Temporal Ctx	18.4	Control 2 Occipital	20.7
		Ctx
AD 2 Temporal Ctx	39.0	Control 3 Occipital	6.0
		Ctx
AD 3 Temporal Ctx	3.0	Control 4 Occipital	16.6
		Ctx
AD 4 Temporal Ctx	26.6	Control (Path) 1	49.0
		Occipital Ctx
AD 5 Inf Temporal	40.9	Control (Path) 2	6.4
Ctx		Occipital Ctx
AD 5 SupTemporal	60.7	Control (Path) 3	3.1
Ctx		Occipital Ctx
AD 6 Inf Temporal	50.3	Control (Path) 4	4.5
Ctx		Occipital Ctx
AD 6 Sup Temporal	49.0	Control 1 Parietal	0.6
Ctx		Ctx
Control 1 Temporal	0.6	Control 2 Parietal	30.6
Ctx		Ctx
Control 2 Temporal	22.1	Control 3 Parietal	5.3
Ctx		Ctx
Control 3 Temporal	12.2	Control (Path) 1	30.6
Ctx		Parietal Ctx
Control 4 Temporal	28.9	Control (Path) 2	23.8
Ctx		Parietal Ctx
Control (Path) 1	30.6	Control (Path) 3	2.6
Temporal Ctx		Parietal Ctx
Control (Path) 2	23.7	Control (Path) 4	19.8
Temporal Ctx		Parietal Ctx

[0868]

TABLE PC
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3525,		Rel. Exp.(%) Ag3525,
Tissue Name	Run 220356041	Tissue Name	Run 220356041
Adipose	1.9	Renal ca. TK-10	0.7
Melanoma*	0.0	Bladder	0.6
Hs688(A).T
Melanoma*	0.0	Gastric ca. (liver met.)	1.9
Hs688(B).T		NCI-N87
Melanoma* M14	0.7	Gastric ca. KATO III	0.0
Melanoma*	0.0	Colon ca. SW-948	0.0
LOXIMVI
Melanoma* SK-	0.0	Colon ca. SW480	0.6
MEL-5
Squamous cell	0.7	Colon ca.* (SW480	0.0
carcinoma SCC-4		met) SW620
Testis Pool	2.6	Colon ca. HT29	0.0
Prostate ca.* (bone	0.0	Colon ca. HCT-116	0.0
met) PC-3
Prostate Pool	5.3	Colon ca. CaCo-2	0.7
Placenta	1.2	Colon cancer tissue	0.0
Uterus Pool	0.9	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	11.9	Colon ca.Colo-205	0.0
Ovarian ca. SK-OV-3	0.0	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	3.6
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	4.2
Ovarian ca. IGROV-1	1.4	Stomach Pool	0.4
Ovarian ca. OVCAR-8	2.0	Bone Marrow Pool	1.7
Ovary	8.5	Fetal Heart	4.2
Breast ca. MCF-7	1.8	Heart Pool	3.1
Breast ca. MDA-	0.0	Lymph Node Pool	2.7
MB-231
Breast ca. BT 549	1.9	Fetal Skeletal Muscle	0.5
Breast ca. T47D	1.1	Skeletal Muscle Pool	5.4
Breast ca. MDA-N	2.7	Spleen Pool	6.7
Breast Pool	0.7	Thymus Pool	9.9
Trachea	39.8	CNS cancer (glio/astro)	0.0
		U87-MG
Lung	5.0	CNS cancer (glio/astro)	0.0
		U-118-MG
Fetal Lung	13.7	CNS cancer (neuro; met)	0.6
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	0.0
		539
Lung ca. LX-1	0.0	CNS cancer (astro)	4.6
		SNB-75
Lung ca. NCI-H146	4.8	CNS cancer (glio) SNB-19	0.7
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-295	5.9
Lung ca. A549	0.0	Brain (Amygdala) Pool	46.3
Lung ca. NCI-H526	0.0	Brain (cerebellum)	4.6
Lung ca. NCI-H23	1.1	Brain (fetal)	6.4
Lung ca. NCI-H460	0.0	Brain (Hippocampus)	70.2
		Pool
Lung ca.HOP-62	0.0	Cebrebral Cortex Pool	49.7
Lung ca. NCI-H522	0.0	Brain (Substantia nigra)	23.5
		Pool
Liver	0.0	Brain (Thalamus) Pool	100.0
Fetal Liver	1.3	Brain (whole)	21.8
Liver ca. HepG2	0.0	Spinal Cord Pool	18.4
Kidney Pool	8.4	Adrenal Gland	3.1
Fetal Kidney	8.5	Pituitary gland Pool	50.3
Renal ca. 786-0	0.0	Salivary Gland	7.7
Renal ca. A498	0.0	Thyroid (female)	17.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.4	Pancreas Pool	0.0

[0869]

TABLE PD
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3525, Run		Ag3525, Run
Tissue Name	166446262	Tissue Name	166446262
Secondary Th1 act	0.0	HUVEC IL-1 beta	0.0
Secondary Th2 act	6.6	HUVEC IFN gamma	0.0
Secondary Tr1 act	4.5	HUVEC TNF alpha + IFN	0.0
		gamma
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	3.3	HUVEC IL-11	0.0
Secondary Tr1 rest	6.7	Lung Microvasular EC	8.5
		none
Primary Th1 act	0.0	Lung Microvascular EC	20.4
		TNF alpha + IL-1 beta
Primary Th2 act	6.3	Microvascular Dermal EC	0.0
		none
Primary Tr1 act	6.7	Microsvascular Dermal EC	0.0
		TNF alpha + IL-1 beta
Primary Th1 rest	33.4	Bronchial epithelium	0.0
		TNF alpha + IL-1 beta
Primary Th2 rest	18.4	Small airway epithelium	0.0
		none
Primary Tr1 rest	14.4	Small airway epithelium	3.0
		TNF alpha + IL-1 beta
CD45RA CD4	6.0	Coronery artery SMC rest	9.7
lymphocyte act
CD45RO CD4	5.1	Coronery artery SMC	10.8
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	21.6	Astrocytes rest	3.6
Secondary CD8	3.3	Astrocytes TNF alpha + IL-	30.4
lymphocyte rest		1 beta
Secondary CD8	5.1	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	2.7	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	13.2	CCD1106 (Keratinocytes)	0.0
CD95 CH11		none
LAK cells rest	3.6	CCD1106 (Keratinocytes)	3.3
		TNF alpha + IL-1 beta
LAK cells IL-2	45.7	Liver cirrhosis	83.5
LAK cells IL-2 + IL-12	46.7	Lupus kidney	4.6
LAK cells IL-2 + IFN	40.1	NCI-H292 none	0.0
gamma
LAK cells IL-2 + IL-18	20.4	NCI-H292 IL-4	0.0
LAK cells	7.5	NCI-H292 IL-9	0.0
PMA/ionomycin
NK Cells IL-2 rest	8.0	NCI-H292 IL-13	0.0
Two Way MLR 3 day	100.0	NCI-H292 IFN gamma	3.8
Two Way MLR 5 day	13.7	HPAEC none	35.4
Two Way MLR 7 day	10.7	HPAEC TNF alpha + IL-1	3.0
		beta
PBMC rest	6.6	Lung fibroblast none	3.4
PBMC PWM	9.4	Lung fibroblast TNF	0.0
		alpha + IL-1 beta
PBMC PHA-L	0.0	Lung fibroblast IL-4	6.8
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell)	0.0	Lung fibroblast IL-13	3.3
ionomycin
B lymphocytes PWM	54.3	Lung fibroblast IFN	89.5
		gamma
B lymphocytes CD40L	9.7	Dermal fibroblast	6.0
and IL-4		CCD1070 rest
EOL-1 dbcAMP	0.0	Dermal fibrobaslat	4.2
		CCD1070 TNF alpha
EOL-1 dbcAMP	0.0	Dermal fibroblast	0.0
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	3.3	Dermal fibroblast IFN	0.0
		gamma
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-	0.0	IBD Colitis 2	3.2
CD40
Monocytes rest	0.0	IBD Crohn's	18.6
Monocytes LPS	0.0	Colon	72.2
Macrophages rest	4.2	Lung	9.7
Macrophages LPS	0.0	Thymus	37.6
HUVEC none	0.0	Kidney	62.9
HUVEC starved	0.0

[0870] CNS_neurodegeneration_v1.0 Summary: Ag3525 This panel does not show differential expression of the CG59274-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

[0871] General_screening_panel_v1.4 Summary: Ag3525 The CG59274-01 gene exhibits highly brain preferential expression, with moderate to low levels of expression seen in all regions of the brain examined in this panel. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of neurologic disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, stroke and schizophrenia.

[0872] Among metabolic tissues, expression of this gene is limited to the thyroid. Thus, this gene product may also be effective in treating thyroidopathies.

[0873] Panel 4D Summary: Ag3525 The CG59274-01 gene is expressed in normal kidney, thymus and colon as well as in activated LAK cells(CTs=-32-33). The gene is also expressed at lower but still significant levels in primary resting T cells, with highest expression seen in a sample derived from an MLR reaction (CT=32). Thus, the protein encoded by this transcript could be important in the function of LAK cells. LAK cells are important in immunosurveillance against bacterial and viral infected cells, as well as transformed cells. Therapeutics designed with this transcript or the protein encoded by it could be important in the treatment of viral and bacterial diseases and cancer.

Q. NOV23a and NOV23b (CG57734-01 and CG57734-02: LIPID ASSOCIATED PROTEIN)

[0874] Expression of gene CG57734-01 and CG57734-01 was assessed using the primer-probe set Ag572, described in Table QA. Please note that CG57734-02 represents a full-length physical clone of the CG57734-01 gene, validating the prediction of the gene sequence.

TABLE QA
Probe Name Ag572
			Start
Primers	Sequences	Length	Position
Forward	5′-ctgcgcttcgatgtgtacaac-3′	(SEQ ID NO:272)	21	431
Probe	TET-5′-actccaaaaccaacatctccaaaccgaag-3′-TAMRA	(SEQ ID NO:273)	29	456
Reverse	5′-ggaacgcttgtcccaggaa-3′	(SEQ ID NO:274)	19	488

[0875] Panel 1.1 Summary: Ag5734 Expression of the CG57734-01 gene is low/undetectable in all samples on this panel (CTs>35).

R. NOV25a (CG59885-01: HGFR)

[0876] Expression of gene CG59885-01 was assessed using the primer-probe set Ag1684, described in Table RA. Results of the RTQ-PCR runs are shown in Tables RB, RC, RD, RE, RF, and RG.

TABLE RA
Probe Name Ag1684
			Start
Primer	Sequences	Length	Position
Forward	5′-tgaagcaggaaggaactttaca-3′	(SEQ ID NO:275)	22	2582
Probe	TET-5′-tggcatgtcaacatcgctctaattca-3′-TAMRA	(SEQ ID NO:276)	26	2605
Reverse	5′-gggaaggagtggtacaacaga-3′	(SEQ ID NO:277)	21	2638

[0877]

TABLE RB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag1684,		Rel. Exp.(%), Ag1684,
Tissue Name	Run 207624860	Tissue Name	Run 207624860
AD 1 Hippo	1.7	Control (Path) 3	2.3
		Temporal Ctx
AD 2 Hippo	9.7	Control (Path) 4	8.2
		Temporal Ctx
AD 3 Hippo	6.2	AD 1 Occipital Ctx	7.9
AD 4 Hippo	3.1	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	100.0	AD 3 Occipital Ctx	1.7
AD 6 Hippo	14.1	AD 4 Occipital Ctx	11.3
Control 2 Hippo	15.2	AD 5 Occipital Ctx	7.5
Control 4 Hippo	2.0	AD 6 Occipital Ctx	24.7
Control (Path) 3	3.3	Control 1 Occipital	2.0
Hippo		Ctx
AD 1 Temporal Ctx	1.1	Control 2 Occipital	76.3
		Ctx
AD 2 Temporal Ctx	9.0	Control 3 Occipital	6.7
		Ctx
AD 3 Temporal Ctx	1.8	Control 4 Occipital	2.8
		Ctx
AD 4 Temporal Ctx	7.2	Control (Path) 1	60.7
		Occipital Ctx
AD 5 Inf Temporal	53.6	Control (Path) 2	6.7
Ctx		Occipital Ctx
AD 5 SupTemporal	18.4	Control (Path) 3	1.7
Ctx		Occipital Ctx
AD 6 Inf Temporal	10.8	Control (Path) 4	6.8
Ctx		Occipital Ctx
AD 6 Sup Temporal	10.5	Control 1 Parietal	1.5
Ctx		Ctx
Control 1 Temporal	1.2	Control 2 Parietal	11.0
Ctx		Ctx
Control 2 Temporal	29.9	Control 3 Parietal	3.3
Ctx		Ctx
Control 3 Temporal	3.3	Control (Path) 1	37.9
Ctx		Parietal Ctx
Control 4 Temporal	2.0	Control (Path) 2	6.4
Ctx		Parietal Ctx
Control (Path) 1	28.1	Control (Path) 3	0.4
Temporal Ctx		Parietal Ctx
Control (Path) 2	12.2	Control (Path) 4	10.0
Temporal Ctx		Parietal Ctx

[0878]

TABLE RC
General_screening_panel_v1.4
	Rel. Exp.(%) Ag1684,		Rel. Exp.(%) Ag1684,
Tissue Name	Run 208022075	Tissue Name	Run 208022075
Adipose	3.0	Renal ca. TK-10	23.2
Melanoma*	5.4	Bladder	3.9
Hs688(A).T
Melanoma*	5.8	Gastric ca. (liver met.)	27.9
Hs688(B).T		NCI-N87
Melanoma* M14	0.0	Gastric ca. KATO III	67.4
Melanoma*	10.2	Colon ca. SW-948	8.9
LOXIMVI
Melanoma* SK-	80.7	Colon ca. SW480	0.6
MEL-5
Squamous cell	15.2	Colon ca.* (SW480	9.6
carcinoma SCC-4		met) SW620
Testis Pool	0.2	Colon ca. HT29	14.7
Prostate ca.* (bone	37.6	Colon ca. HCT-116	36.6
met) PC-3
Prostate Pool	0.5	Colon ca. CaCo-2	23.5
Placenta	1.2	Colon cancer tissue	9.1
Uterus Pool	0.5	Colon ca. SW1116	1.7
Ovarian ca. OVCAR-3	5.1	Colon ca. Colo-205	2.0
Ovarian ca. SK-OV-3	14.8	Colon ca. SW-48	2.3
Ovarian ca. OVCAR-4	7.6	Colon Pool	0.9
Ovarian ca. OVCAR-5	29.9	Small Intestine Pool	0.5
Ovarian ca. IGROV-1	9.1	Stomach Pool	0.9
Ovarian ca. OVCAR-8	2.6	Bone Marrow Pool	0.4
Ovary	0.4	Fetal Heart	0.2
Breast ca. MCF-7	2.5	Heart Pool	0.5
Breast ca. MDA-	14.5	Lymph Node Pool	1.1
MB-231
Breast ca. BT 549	3.7	Fetal Skeletal Muscle	0.4
Breast ca. T47D	29.3	Skeletal Muscle Pool	1.9
Breast ca. MDA-N	15.4	Spleen Pool	1.7
Breast Pool	1.1	Thymus Pool	0.7
Trachea	1.7	CNS cancer (glio/astro)	25.7
		U87-MG
Lung	0.2	CNS cancer (glio/astro)	38.2
		U-118-MG
Fetal Lung	13.5	CNS cancer (neuro; met)	0.0
		SK-N-AS
Lung ca. NCI-N417	1.1	CNS cancer (astro) SF-539	2.2
Lung ca. LX-1	16.6	CNS cancer (astro) SNB-75	12.6
Lung ca. NCI-H146	1.2	CNS cancer (glio) SNB-19	7.8
Lung ca. SHP-77	3.0	CNS cancer (glio) SF-295	19.1
Lung ca. A549	23.8	Brain (Amygdala) Pool	0.3
Lung ca. NCI-H526	2.8	Brain (cerebellum)	0.0
Lung ca. NCI-H23	7.7	Brain (fetal)	1.7
Lung ca. NCI-H460	4.8	Brain (Hippocampus) Pool	0.5
Lung ca. HOP-62	11.7	Cerebral Cortex Pool	1.0
Lung ca. NCI-H522	0.1	Brain (Substantia nigra)	0.2
		Pool
Liver	1.5	Brain (Thalamus) Pool	1.6
Fetal Liver	8.8	Brain (whole)	2.1
Liver ca. HepG2	7.7	Spinal Cord Pool	0.2
Kidney Pool	1.2	Adrenal Gland	0.1
Fetal Kidney	2.6	Pituitary gland Pool	0.6
Renal ca. 786-0	26.1	Salivary Gland	0.3
Renal ca. A498	19.1	Thyroid (female)	3.3
Renal ca. ACHN	20.4	Pancreatic ca. CAPAN2	59.0
Renal ca. UO-31	100.0	Pancreas Pool	5.0

[0879]

TABLE RD
Panel 1.3D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag1684, Run	Ag1684, Run		Ag1684, Run	Ag1684, Run
Tissue Name	158401632	165526993	Tissue Name	158401632	165526993
Liver	26.4	31.4	Kidney (fetal)	4.8	5.3
adenocarcinoma
Pancreas	0.4	0.9	Renal ca. 786-0	34.2	35.8
Pancreatic ca.	26.6	70.2	Renal ca. A498	95.3	73.7
CAPAN 2
Adrenal gland	0.3	0.3	Renal ca. RXF 393	13.3	55.9
Thyroid	3.7	2.7	Renal ca.	14.0	25.2
			ACHN
Salivary gland	0.4	1.2	Renal ca. UO-31	28.9	35.4
Pituitary gland	1.3	1.3	Renal ca. TK-10	19.1	17.9
Brain (fetal)	1.5	2.5	Liver	1.1	1.1
Brain (whole)	2.6	0.0	Liver (fetal)	2.7	4.2
Brain (amygdala)	1.8	2.0	Liver ca.	9.5	7.1
			(hepatoblast)
			HepG2
Brain (cerebellum)	0.0	0.3	Lung	2.5	1.0
Brain	26.1	4.9	Lung (fetal)	3.0	1.5
(hippocampus)
Brain (substantia	0.1	0.2	Lung ca.	11.8	11.3
nigra)			(small cell)
			LX-1
Brain (thalamus)	0.5	0.3	Lung ca.	13.6	3.4
			(small cell)
			NCI-H69
Cerebral Cortex	4.1	0.8	Lung ca. (s. cell	7.4	6.4
			var.) SHP-77
Spinal cord	0.9	2.0	Lung ca. (large	2.9	15.9
			cell) NCI-H460
glio/astro U87-MG	26.6	22.2	Lung ca. (non-	13.9	11.8
			sm. cell) A549
glio/astro U-118-	100.0	100.0	Lung ca. (non-	7.5	6.7
MG			s. cell) NCI-H23
astrocytoma	53.2	62.4	Lung ca. (non-	11.3	17.0
SW1783			s. cell) HOP-62
neuro*; met SK-N-	0.2	0.1	Lung ca. (non-	0.2	0.1
AS			s. cl) NCI-H522
astrocytoma SF-	2.8	2.7	Lung ca.	45.4	92.0
539			(squam.) SW
			900
astrocytoma SNB-	69.3	71.2	Lung ca.	1.6	5.3
75			(squam.) NCI-
			H596
glioma SNB-19	7.5	12.2	Mammary	1.5	3.2
			gland
glioma U251	3.6	18.2	Breast ca.*	3.9	4.2
			(pl. ef) MCF-7
glioma SF-295	27.9	25.0	Breast ca.*	87.1	51.1
			(pl. ef) MDA-
			MB-231
Heart (fetal)	0.1	0.0	Breast ca.*	0.4	0.6
			(pl. ef) T47D
Heart	0.4	1.9	Breast ca. BT-549	54.3	35.4
Skeletal muscle	4.6	0.5	Breast ca.	29.1	11.1
(fetal)			MDA-N
Skeletal muscle	2.0	8.9	Ovary	0.2	0.0
Bone marrow	0.1	0.0	Ovarian ca.	1.7	4.2
			OVCAR-3
Thymus	0.1	0.2	Ovarian ca.	3.4	10.9
			OVCAR-4
Spleen	1.3	1.0	Ovarian ca.	24.1	17.1
			OVCAR-5
Lymph node	0.4	2.4	Ovarian ca.	6.8	3.2
			OVCAR-8
Colorectal	1.6	0.9	Ovarian ca.	9.2	11.3
			IGROV-1
Stomach	1.8	3.2	Ovarian ca.*	12.0	11.5
			(ascites) SK-OV-3
Small intestine	1.3	1.8	Uterus	0.8	3.0
Colon ca. SW480	0.8	0.6	Placenta	6.8	5.8
Colon ca.*	15.2	12.9	Prostate	0.5	0.5
SW620(SW480
met)
Colon ca. HT29	18.9	10.1	Prostate ca.*	15.2	22.5
			(bone met) PC-3
Colon ca. HCT-116	25.2	20.7	Testis	0.1	0.1
Colon ca. CaCo-2	15.0	11.3	Melanoma	3.6	3.7
			Hs688(A).T
Colon ca.	22.4	11.0	Melanoma*	1.2	2.4
tissue(ODO3866)			(met)
			Hs688(B).T
Colon ca. HCC-	44.4	14.4	Melanoma	0.3	2.5
2998			UACC-62
Gastric ca.* (liver	52.9	52.5	Melanoma	0.0	0.5
met) NCI-N87			M14
Bladder	2.9	3.1	Melanoma	5.6	2.9
			LOX IMVI
Trachea	4.8	3.7	Melanoma*	55.1	44.1
			(met) SK-MEL-5
Kidney	1.3	2.8	Adipose	4.1	1.9

[0880]

TABLE RE
Panel 2D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag1684, Run	Ag1684, Run		Ag1684, Run	Ag1684, Run
Tissue Name	158403763	164981024	Tissue Name	158403763	164981024
Normal Colon	6.3	9.7	Kidney Margin	1.0	1.0
			8120608
CC Well to Mod	8.8	12.6	Kidney Cancer	11.3	10.2
Diff (ODO3866)			8120613
CC Margin	1.5	1.9	Kidney Margin	2.7	1.7
(ODO3866)			8120614
CC Gr.2	0.7	0.8	Kidney Cancer	15.1	17.2
rectosigmoid			9010320
(ODO3868)
CC Margin	0.3	0.7	Kidney Margin	7.1	9.1
(ODO3868)			9010321
CC Mod Diff	4.3	6.1	Normal Uterus	0.6	0.9
(ODO3920)
CC Margin	1.1	1.0	Uterus Cancer	2.5	2.5
(ODO3920)			064011
CC Gr.2 ascend	21.8	17.3	Normal	3.6	2.9
colon			Thyroid
(ODO3921)
CC Margin	2.2	2.1	Thyroid	37.1	46.0
(ODO3921)			Cancer 064010
CC from Partial	32.3	22.5	Thyroid	31.6	26.6
Hepatectomy			Cancer
(ODO4309) Mets			A302152
Liver Margin	8.0	5.8	Thyroid	6.1	5.4
(ODO4309)			Margin
			A302153
Colon mets to	5.4	2.9	Normal Breast	4.9	3.0
lung (OD04451-
01)
Lung Margin	2.7	3.5	Breast Cancer	0.3	0.2
(OD04451-02)			(OD04566)
Normal Prostate	0.5	3.0	Breast Cancer	1.4	1.3
6546-1			(OD04590-01)
Prostate Cancer	1.9	1.9	Breast Cancer	1.5	1.8
(OD04410)			Mets
			(OD04590-03)
Prostate Margin	1.6	1.3	Breast Cancer	0.5	0.7
(OD04410)			Metastasis
			(OD04655-05)
Prostate Cancer	3.7	2.7	Breast Cancer	1.0	1.1
(OD04720-01)			064006
Prostate Margin	6.7	5.7	Breast Cancer	3.3	3.0
(OD04720-02)			1024
Normal Lung	7.7	6.5	Breast Cancer	0.6	1.0
061010			9100266
Lung Met to	12.9	11.3	Breast Margin	0.7	0.8
Muscle			9100265
(ODO4286)
Muscle Margin	2.2	2.6	Breast Cancer	2.0	2.5
(ODO4286)			A209073
Lung Malignant	8.0	7.1	Breast Margin	1.8	1.6
Cancer			A209073
(OD03126)
Lung Margin	14.8	9.7	Normal Liver	4.3	5.1
(OD03126)
Lung Cancer	15.0	15.0	Liver Cancer	10.9	11.0
(OD04404)			064003
Lung Margin	7.8	14.7	Liver Cancer	3.2	2.4
(OD04404)			1025
Lung Cancer	7.6	10.7	Liver Cancer	2.1	2.3
(OD04565)			1026
Lung Margin	3.7	5.5	Liver Cancer	4.2	5.0
(OD04565)			6004-T
Lung Cancer	2.6	2.0	Liver Tissue	4.2	5.3
(OD04237-01)			6004-N
Lung Margin	4.6	4.7	Liver Cancer	2.2	2.6
(OD04237-02)			6005-T
Ocular Mel Met	24.3	21.0	Liver Tissue	1.1	1.2
to Liver			6005-N
(ODO4310)
Liver Margin	8.1	7.7	Normal	7.7	7.6
(ODO4310)			Bladder
Melanoma Mets	2.6	2.4	Bladder	0.7	0.9
to Lung			Cancer 1023
(OD04321)
Lung Margin	6.7	7.1	Bladder	4.0	4.1
(OD04321)			Cancer
			A302173
Normal Kidney	15.5	15.2	Bladder	36.1	46.3
			Cancer
			(OD04718-01)
Kidney Ca,	100.0	100.0	Bladder	1.1	1.3
Nuclear grade 2			Normal
(OD04338)			Adjacent
			(OD04718-03)
Kidney Margin	8.4	8.7	Normal Ovary	0.1	0.0
(OD04338)
Kidney Ca	11.6	10.4	Ovarian	29.3	29.3
Nuclear grade 1/2			Cancer 064008
(OD04339)
Kidney Margin	11.2	12.6	Ovarian	11.5	14.8
(OD04339)			Cancer
			(OD04768-07)
Kidney Ca, Clear	50.3	43.8	Ovary Margin	0.9	1.2
cell type			(OD04768-08)
(OD04340)
Kidney Margin	8.5	8.9	Normal	3.2	3.9
(OD04340)			Stomach
Kidney Ca,	24.5	22.5	Gastric Cancer	0.5	1.1
Nuclear grade 3			9060358
(OD04348)
Kidney Margin	7.1	8.4	Stomach	2.2	3.3
(OD04348)			Margin
			9060359
Kidney Cancer	9.5	12.0	Gastric Cancer	8.9	8.6
(OD04622-01)			9060395
Kidney Margin	1.0	1.6	Stomach	3.8	2.6
(OD04622-03)			Margin
			9060394
Kidney Cancer	24.0	23.0	Gastric Cancer	17.0	33.7
(OD04450-01)			9060397
Kidney Margin	6.9	5.8	Stomach	1.2	1.4
(OD04450-03)			Margin
			9060396
Kidney Cancer	6.0	6.5	Gastric Cancer	8.8	6.8
8120607			064005

[0881]

TABLE RF
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag1684, Run		Ag1684, Run
Tissue Name	158404018	Tissue Name	158404018
Secondary Th1 act	0.5	HUVEC IL-1 beta	9.3
Secondary Th2 act	0.1	HUVEC IFN gamma	22.5
Secondary Tr1 act	0.4	HUVEC TNF alpha + IFN	17.7
		gamma
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	9.7
Secondary Th2 rest	0.0	HUVEC IL-11	5.9
Secondary Tr1 rest	0.0	Lung Microvascular EC	7.2
		none
Primary Th1 act	0.1	Lung Microvascular EC	5.2
		TNF alpha + IL-1 beta
Primary Th2 act	0.5	Microvascular Dermal EC	20.2
		none
Primary Tr1 act	0.2	Microsvasular Dermal EC	8.8
		TNF alpha + IL-1 beta
Primary Th1 rest	0.0	Bronchial epithelium	11.8
		TNF alpha + IL-1 beta
Primary Th2 rest	0.0	Small airway epithelium	10.6
		none
Primary Tr1 rest	0.0	Small airway epithelium	97.3
		TNF alpha + IL-1 beta
CD45RA CD4	7.7	Coronery artery SMC rest	4.2
lymphocyte act
CD45RO CD4	0.2	Coronery artery SMC	2.6
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	0.0	Astrocytes rest	12.3
Secondary CD8	0.1	Astrocytes TNF alpha + IL-	11.2
lymphocyte rest		1 beta
Secondary CD8	0.3	KU-812 (Basophil) rest	0.1
lymphocyte act
CD4 lymphocyte none	0.0	KU-812 (Basophil)	0.8
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	0.0	CCD1106 (Keratinocytes)	17.3
CD95 CH11		none
LAK cells rest	0.1	CCD1106 (Keratinocytes)	7.5
		TNF alpha + IL-1 beta
LAK cells IL-2	0.2	Liver cirrhosis	1.4
LAK cells IL-2 + IL-12	0.1	Lupus kidney	1.5
LAK cells IL-2 + IFN	0.4	NCI-H292 none	62.9
gamma
LAK cells IL-2 + IL-18	0.3	NCI-H292 IL-4	100.0
LAK cells	0.9	NCI-H292 IL-9	40.9
PMA/ionomycin
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	46.0
Two Way MLR 3 day	0.1	NCI-H292 IFN gamma	49.3
Two Way MLR 5 day	0.1	HPAEC none	8.0
Two Way MLR 7 day	0.1	HPAEC TNF alpha + IL-1	11.8
		beta
PBMC rest	0.0	Lung fibroblast none	4.5
PBMC PWM	0.7	Lung fibroblast TNF	1.7
		alpha + IL-1 beta
PBMC PHA-L	0.5	Lung fibroblast IL-4	13.0
Ramos (B cell) none	0.0	Lung fibroblast IL-9	7.7
Ramos (B cell)	0.0	Lung fibroblast IL-13	5.7
ionomycin
B lymphocytes PWM	3.1	Lung fibroblast IFN	14.8
		gamma
B lymphocytes CD40L	1.1	Dermal fibroblast	26.4
and IL-4		CCD1070 rest
EOL-1 dbcAMP	0.0	Dermal fibroblast	16.7
		CCD1070 TNF alpha
EOL-1 dbcAMP	0.0	Dermal fibroblast	5.7
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	0.1	Dermal fibroblast IFN	3.6
		gamma
Dendritic cells LPS	0.2	Dermal fibroblast IL-4	1.9
Dendritic cells anti-	0.0	IBD Colitis 2	0.2
CD40
Monocytes rest	0.0	IBD Crohn's	0.0
Monocytes LPS	22.5	Colon	4.4
Macrophages rest	0.3	Lung	5.7
Macrophages LPS	1.2	Thymus	12.5
HUVEC none	11.7	Kidney	2.6
HUVEC starved	18.7

[0882]

TABLE RG
Panel 5 Islet
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag1684, Run		Ag1684, Run
Tissue Name	224084580	Tissue Name	224084580
97457_Patient-	12.7	94709_Donor 2 AM - A_adipose	3.1
02go_adipose
97476_Patient-	2.8	94710_Donor 2 AM - B_adipose	15.4
07sk_skeletal muscle
97477_Patient-	1.2	94711_Donor 2 AM - C_adipose	9.0
07ut_uterus
97478_Patient-	15.4	94712_Donor 2 AD - A_adipose	14.7
07pl_placenta
99167_Bayer	30.6	94713_Donor 2 AD - B_adipose	9.5
Patient 1
97482_Patient-	2.1	94714_Donor 2 AD - C_adipose	17.0
08ut_uterus
97483_Patient-	13.5	94742_Donor 3 U -	1.5
08pl_placenta		A_Mesenchymal Stem Cells
97486_Patient-	1.6	94743_Donor 3 U -	38.4
09sk_skeletal muscle		B_Mesenchymal Stem Cells
97487_Patient-	2.8	94730_Donor 3 AM - A_adipose	37.6
09ut_uterus
97488_Patient-	7.3	94731_Donor 3 AM - B_adipose	9.9
09pl_placenta
97492_Patient-	9.2	94732_Donor 3 AM - C_adipose	4.0
10ut_uterus
97493_Patient-	22.5	94733_Donor 3 AD - A_adipose	17.9
10pl_placenta
97495_Patient-	15.5	94734_Donor 3 AD - B_adipose	4.7
11go_adipose
97496_Patient-	6.8	94735_Donor 3 AD - C_adipose	39.0
11sk_skeletal muscle
97497_Patient-	3.0	77138_Liver_HepG2untreated	27.4
11ut_uterus
97498_Patient-	13.2	73556_Heart_Cardiac stromal cells	2.5
11pl_placenta		(primary)
97500_Patient-	22.5	81735_Small Intestine	4.6
12go_adipose
97501_Patient-	12.2	72409_Kidney_Proximal	16.5
12sk_skeletal muscle		Convoluted Tubule
97502_Patient-	3.3	82685_Small intestine_Duodenum	3.5
12ut_uterus
97503_Patient-	16.0	90650_Adrenal_Adrenocortical	0.0
12pl_placenta		adenoma
94721_Donor 2 U -	11.1	72410_Kidney_HRCE	100.0
A_Mesenchymal
Stem Cells
94722_Donor 2 U -	6.9	72411_Kidney_HRE	50.7
B_Mesenchymal Stem
Cells
94723_Donor 2 U -	2.2	73139_Uterus_Uterine smooth	11.7
C_Mesenchymal Stem		muscle cells
Cells

[0883] CNS_neurodegeneration_v1.0 Summary: Ag1684 This panel does not show differential expression of the CG59885-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.4 for discussion of utility of this gene in the central nervous system.

[0884] General_screening_panel_v1.4 Summary: Ag1684 Highest expression of the CG59885-01 gene is seen in a renal cancer cell line (CT=20). Overall, expression appears to be much higher in cancer cell lines than in samples from normal tissue. Significant levels of expression are also seen in cell lines derived from pancreatic, brain, colon, gastric, lung, breast, ovarian, and melanoma cancers. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of cancer. Furthermore, therapeutic modulation of the expression or function of this gene with a human monoclonal antibody is anticipated to limit or block the extent of metastasis and growth in most tumors.

[0885] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0886] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system and may be a target of neurologic diseases such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0887] Panel 1.3D Summary: Ag1684 Expression of the CG59885-01 gene confirms the results of Panel 1.4. Please see Panel 1.4 for discussion of utility of this gene in cancer, metabolic disease and the central nervous system.

[0888] Panel 2D Summary: Ag1684 Two experiments with the same probe and primer produce results that are in excellent agreement, with highest expression of the CG59885-01 gene in kidney cancer (CTs=24-25). In addition, expression of this gene is higher in gastric, bladder, ovarian, thyroid, kidney and colon cancers when compared to expression in the corresponding normal adjacent tissue. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.

[0889] Panel 3D Summary: Ag1684 Results from one experiment with the CG59885-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[0890] Panel 4D Summary: Ag1684 Highest expression of the CG59885-01 gene is seen in the NCI-H292 mucoepidermoid cell line treated with IL-4 (CT=25). Significant levels of expression are also seen in a cluster of treated and untreated NCI-H292 mucoepidermoid cells, IL-4, IL-9, IL-13 and IFN gamma activated lung fibroblasts, human pulmonary aortic endothelial cells (treated and untreated), small airway epithelium (treated and untreated), treated bronchial epithelium and lung microvascular endothelial cells (treated and untreated). The expression of this gene in cells derived from or within the lung suggests that this gene may be involved in normal conditions as well as pathological and inflammatory lung disorders that include chronic obstructive pulmonary disease, asthma, allergy and emphysema.

[0891] Moderate levels of expression are also detected in treated and untreated HUVECs (endothelial cells), coronary artery smooth muscle cells (treated and untreated), treated and untreated astrocytes, KU-812 basophils, keratinocytes, dermal fibroblasts, and normal tissues from lung, colon, thymus and kidney. Expression in these immune cell types and tissues suggests that therapeutic modulation of this gene product may ameliorate symptoms associated with infectious conditions as well as inflammatory and autoimmune disorders that include psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.

[0892] Interestingly, expression of this gene is stimulated in TNFalpha+IL-1 beta treated small airway epithelium (CT=25) and LPS-treated monocytes (CT=27) as compared to their untreated counterparts (CTs=28-40). Thus, expression of this gene can be used to distinguish these treated cells from their untreated counterparts. This gene codes for a variant of hepatocyte growth factor receptor, HGFR-MET. HGFR-MET is a transmembrane tyrosine kinase proto-oncogene, required for the action of hepatocyte growth factor (HGF) (Ref. 1). Recently, it was shown that HGF modulates the function of monocytes in a paracrine/autocrine manner (Ref.2). The expression of the HGFR-MET gene in LPS-treated monocytes, suggests a role for this gene product in initiating inflammatory reactions. Therefore, modulation of the expression or activity of HGFR-MET through the application of monoclonal antibodies may reduce or prevent early stages of inflammation and reduce the severity of inflammatory diseases such as psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis and other lung inflammatory diseases.

[0893] References.

[0894] 1. Stella M C, Comoglio P M. (1999) HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol December 1999;31(12):1357-62

[0895] 2. Galimi F, Cottone E, Vigna E, Arena N, Boccaccio C, Giordano S, Naldini L, Comoglio P M. (2001) Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol 166(2):1241-7.

[0896] Panel 5 Islet Summary: Ag1684 Highest expression of the CG59885-01 gene is seen in kidney-HRCE samples (CT=29.8). In addition, moderate to low expression is also detected in pancreatic islet cells (patient 1), adipose, mesenchymal stem cells, placenta, skeletal muscle from number of donor and patients. Please see panel 1.4 for the potential utility of this gene.

S. NOV26a (CG93443-01: Novel LIV-1 Like Gene)

[0897] Expression of gene CG93443-01 was assessed using the primer-probe sets Ag2552 and Ag3855, described in Tables SA and SB. Results of the RTQ-PCR runs are shown in Tables SC, SD, SE, SF, SG, and SH.

TABLE SA
Probe Name Ag2552
			Start
Primers	Sequences	Length	Position
Forward	5′-cttctgataccctgccctagtc-3′	(SEQ ID NO:278)	22	2167
Probe	TET-5′-ccccacctttgacttaagatcccaca-3′-TAMRA	(SEQ ID NO:282)	26	2189
Reverse	5′-ctataggggcttctggtttctg-3′	(SEQ ID NO:280)	22	0

[0898]

TABLE SB
Probe Name Ag3855
			Start
Primer	Sequences	Length	Position
Forward	5′-cagctgagtggagcctacac-3′	(SEQ ID NO:281)	20	1140
Probe	TET-5′-caggaccagctcagccagtcagag-3′-TAMRA	(SEQ ID NO:282)	24	1182
Reverse	5′-cagggagccgtacagatatct-3′	(SEQ ID NO:283)	21	1206

[0899]

TABLE SC
AI_comprehensive panel_v1.0
	Rel. Exp.(%) Ag2552,		Rel. Exp.(%) Ag2552,
Tissue Name	Run 229393908	Tissue Name	Run 229393908
110967 COPD-F	8.3	112427 Match Control	19.6
		Psoriasis-F
110980 COPD-F	5.6	112418 Psoriasis-M	14.8
110968 COPD-M	14.7	112723 Match Control	12.7
		Psoriasis-M
110977 COPD-M	13.6	112419 Psoriasis-M	14.0
110989 Emphysema-F	23.3	112424 Match Control	12.1
		Psoriasis-M
110992 Emphysema-F	23.5	112420 Psoriasis-M	29.1
110993 Emphysema-F	7.3	112425 Match Control	18.4
		Psoriasis-M
110994 EmPhysema-F	2.5	104689 (MF) OA Bone-	10.2
		Backus
110995 Emphysema-F	40.1	104690 (MF) Adj	4.8
		“Normal” Bone-Backus
110996 Emphysema-F	20.6	104691 (MF) OA	4.5
		Synovium-Backus
110997 Asthma-M	11.5	104692 (BA) OA	25.0
		Cartilage-Backus
111001 Asthma-F	5.1	104694 (BA) OA Bone-	9.3
		Backus
111002 Asthma-F	25.0	104695 (BA) Adj	4.8
		“Normal” Bone-Backus
111003 Atopic	16.7	104696 (BA) OA	5.8
Asthma-F		Synovium-Backus
111004 Atopic	45.4	104700 (SS) OA Bone-	6.7
Asthma-F		Backus
111005 Atopic	22.5	104701 (SS) Adj	6.2
Asthma-F		“Normal” Bone-Backus
111006 Atopic	5.1	104702 (SS) OA	9.9
Asthma-F		Synovium-Backus
111417 Allergy-M	11.0	117093 OA Cartilage	8.4
		Rep7
112347 Allergy-M	21.0	112672 OA Bone5	6.3
112349 Normal	12.5	112673 OA Synovium5	3.6
Lung-F
112357 Normal	31.2	112674 OA Synovial	3.0
Lung-F		Fluid cells5
112354 Normal	10.4	117100 OA Cartilage	9.9
Lung-M		Rep14
112374 Crohns-F	19.9	112756 OA Bone9	100.0
112389 Match Control	5.6	112757 OA Synovium9	3.0
Crohns-F
112375 Crohns-F	13.5	112758 OA Synovial	4.1
		Fluid Cells9
112732 Match Control	10.4	117125 RA Cartilage	6.1
Crohns-F		Rep2
112725 Crohns-M	9.3	113492 Bone2 RA	6.8
112387 Match Control	6.6	113493 Synovium2 RA	4.0
Crohns-M
112378 Crohns-M	12.5	113494 Syn Fluid Cells	7.3
		RA
112390 Match Control	13.4	113499 Cartilage4 RA	14.9
Crohns-M
112726 Crohns-M	15.6	113500 Bone4 RA	16.8
112731 Match Control	6.2	113501 Synovium4 RA	13.2
Crohns-M
112380 Ulcer Col-F	7.0	113502 Syn Fluid	12.2
		Cells4 RA
112734 Match Control	23.5	113495 Cartilage3 RA	7.7
Ulcer Col-F
112384 Ulcer Col-F	22.7	113496 Bone3 RA	10.1
112737 Match Control	17.3	113497 Synovium3 RA	4.7
Ulcer Col-F
112386 Ulcer Col-F	0.5	113498 Syn Fluid	8.6
		Cells3 RA
112738 Match Control	17.6	117106 Normal	5.7
Ulcer Col-F		Cartilage Rep20
112381 Ulcer Col-M	2.4	113663 Bone3 Normal	2.6
112735 Match Control	12.9	113664 Synovium3	4.3
Ulcer Col-M		Normal
112382 Ulcer Col-M	7.2	113665 Syn Fluid	4.0
		Cells3 Normal
112394 Match Control	3.7	117107 Normal	1.1
Ulcer Col-M		Cartilage Rep22
112383 Ulcer Col-M	11.7	113667 Bone4 Normal	3.1
112736 Match Control	6.8	113668 Synovium4	7.2
Ulcer Col-M		Normal
112423 Psoriasis-F	8.1	113669 Syn Fluid	6.8
		Cells4 Normal

[0900]

TABLE SD
Panel 1.3D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag2552, Run	Ag2552, Run		Ag2552, Run	Ag2552, Run
Tissue Name	161905842	163728051	Tissue Name	161905842	163728051
Liver	0.8	0.7	Kidney (fetal)	16.3	17.0
adenocarcinoma
Pancreas	0.7	1.4	Renal ca. 786-0	6.9	4.7
Pancreatic ca.	26.4	18.6	Renal ca. A498	14.0	15.7
CAPAN 2
Adrenal gland	1.5	1.1	Renal ca. RXF	12.2	16.8
			393
Thyroid	8.5	15.7	Renal ca.	5.0	4.0
			ACHN
Salivary gland	1.7	0.8	Renal ca. UO-	10.6	5.1
			31
Pituitary gland	0.8	0.2	Renal ca. TK-	16.4	10.4
			10
Brain (fetal)	0.4	1.1	Liver	0.7	0.7
Brain (whole)	1.0	2.0	Liver (fetal)	3.2	3.4
Brain (amygdala)	3.1	2.5	Liver ca.	19.9	18.8
			(hepatoblast)
			HepG2
Brain (cerebellum)	0.6	0.5	Lung	3.8	4.6
Brain	5.4	3.2	Lung (fetal)	3.6	5.1
(hippocampus)
Brain (substantia	0.7	0.7	Lung ca.	9.8	8.2
nigra)			(small cell)
			LX-1
Brain (thalamus)	0.4	0.1	Lung ca.	1.8	1.2
			(small cell)
			NCI-H69
Cerebral Cortex	10.6	12.1	Lung ca. (s.cell	13.7	16.3
			var.) SHP-77
Spinal cord	2.1	3.3	Lung ca. (large	2.5	3.7
			cell) NCI-H460
glio/astro U87-MG	14.8	18.0	Lung ca. (non-	6.0	7.3
			sm. cell) A549
glio/astro U-118-	2.0	1.2	Lung ca. (non-	32.3	35.1
MG			s.cell) NCI-
			H23
astrocytoma	9.5	10.2	Lung ca. (non-	8.8	10.0
SW1783			s.cell) HOP-62
neuro*; met SK-N-	11.9	11.4	Lung ca. (non-	7.5	6.5
AS			s.cl) NCI-H522
astrocytoma SF-	5.8	6.9	Lung ca.	5.3	8.4
539			(squam.) SW
			900
astrocytoma SNB-	4.2	4.5	Lung ca.	6.1	4.4
75			(squam.) NCI-
			H596
glioma SNB-19	0.2	0.1	Mammary	5.9	2.8
			gland
glioma U251	0.5	1.2	Breast ca.*	23.8	29.7
			(pl.ef) MCF-7
glioma SF-295	0.3	0.0	Breast ca.*	10.4	9.3
			(pl.ef) MDA-
			MB-231
Heart (fetal)	16.8	18.8	Breast ca.*	7.8	10.2
			(pl.ef) T47D
Heart	1.6	1.9	Breast ca. BT-	5.3	6.6
			549
Skeletal muscle	24.1	28.5	Breast ca.	7.7	10.0
(fetal)			MDA-N
Skeletal muscle	4.8	4.7	Ovary	15.4	15.9
Bone marrow	1.3	1.2	Ovarian ca.	10.1	7.6
			OVCAR-3
Thymus	11.4	9.5	Ovarian ca.	11.0	14.6
			OVCAR-4
Spleen	3.0	3.2	Ovarian ca.	4.7	2.7
			OVCAR-5
Lymph node	0.8	0.7	Ovarian ca.	10.4	10.4
			OVCAR-8
Colorectal	16.8	16.7	Ovarian ca.	35.8	31.4
			IGROV-1
Stomach	2.7	2.6	Ovarian ca.*	17.4	18.7
			(ascites) SK-
			OV-3
Small intestine	20.3	15.8	Uterus	1.3	0.6
Colon ca. SW480	11.9	10.8	Placenta	1.8	2.2
Colon ca.*	8.8	6.9	Prostate	2.3	3.9
SW620(SW480
met)
Colon ca. HT29	7.5	6.7	Prostate ca.*
			(bone met)PC-3	27.7	37.9
Colon ca. HCT-	16.6	17.3	Testis	6.5	5.2
116
Colon ca. CaCo-2	8.9	8.1	Melanoma	1.9	2.5
			Hs688(A).T
Colon ca.	59.9	64.6	Melanoma*	1.5	2.5
tissue(ODO3866)			(met)
			Hs688(B).T
Colon ca. HCC-	9.9	11.8	Melanoma	3.3	4.7
2998			UACC-62
Gastric ca.* (liver	100.0	100.0	Melanoma	3.1	3.3
met) NCI-N87			M14
Bladder	11.1	10.0	Melanoma	7.2	5.1
			LOX IMVI
Trachea	6.5	5.7	Melanoma*	7.3	6.8
			(met) SK-
			MEL-5
Kidney	58.6	54.0	Adipose	4.0	1.5

[0901]

TABLE SE
Panel 2D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag2552, Run	Ag2552, Run		Ag2552, Run	Ag2552, Run
Tissue Name	161905843	163578013	Tissue Name	161905843	163578013
Normal Colon	26.8	27.5	Kidney Margin	51.1	52.5
			8120608
CC Well to Mod	25.9	36.6	Kidney Cancer	33.0	38.4
Diff(ODO3866)			8120613
CC Margin	10.3	13.6	Kidney Margin	81.8	65.1
(ODO3866)			8120614
CC Gr.2	20.9	27.9	Kidney Cancer	10.7	15.0
rectosigmoid			9010320
(ODO3868)
CC Margin	1.8	1.7	Kidney Margin	45.7	50.3
(ODO3868)			9010321
CC Mod Diff	42.6	52.5	Normal Uterus	1.6	2.2
(ODO3920)
CC Margin	7.5	9.0	Uterus Cancer	5.8	8.2
(ODO3920)			064011
CC Gr.2 ascend	100.0	94.6	Normal	2.8	7.5
colon			Thyroid
(ODO3921)
CC Margin	11.7	11.3	Thyroid	9.5	11.7
(ODO3921)			Cancer 064010
CC from Partial	81.8	95.9	Thyroid	3.9	6.3
Hepatectomy			Cancer
(ODO4309) Mets			A302152
Liver Margin	3.7	3.5	Thyroid	17.0	19.8
(ODO4309)			Margin
			A302153
Colon mets to	19.1	14.7	Normal Breast	13.2	5.6
lung (OD04451-
01)
Lung Margin	5.0	5.9	Breast Cancer	11.7	12.9
(OD04451-02)			(OD04566)
Normal Prostate	2.0	20.2	Breast Cancer	11.8	13.5
6546-1			(OD04590-01)
Prostate Cancer	7.6	10.2	Breast Cancer	10.4	14.7
(OD04410)			Mets
			(OD04590-03)
Prostate Margin	12.6	12.1	Breast Cancer	43.2	49.0
(OD04410)			Metastasis
			(OD04655-05)
Prostate Cancer	6.1	6.2	Breast Cancer	12.6	15.8
(OD04720-01)			064006
Prostate Margin	8.4	10.3	Breast Cancer	17.0	17.0
(OD04720-02)			1024
Normal Lung	11.3	11.3	Breast Cancer	10.0	27.0
061010			9100265
Lung Met to	15.0	12.9	Breast Margin	7.4	11.2
Muscle			9100265
(ODO4286)
Muscle Margin	2.6	4.6	Breast Cancer	21.5	25.3
(ODO4286)			A209073
Lung Malignant	21.0	23.2	Breast Margin	8.2	8.8
Cancer			A209073
(OD03126)
Lung Margin	13.4	12.9	Normal Liver	1.5	3.0
(OD03126)
Lung Cancer	20.0	17.6	Liver Cancer	0.4	0.1
(OD04404)			064003
Lung Margin	2.6	4.5	Liver Cancer	1.4	1.6
(OD04404)			1025
Lung Cancer	9.5	13.1	Liver Cancer	10.7	15.2
(OD04565)			1026
Lung Margin	4.2	5.8	Liver Cancer	2.3	2.0
(OD04565)			6004-T
Lung Cancer	18.8	20.0	Liver Tissue	22.5	22.2
(OD04237-01)			6004-N
Lung Margin	6.3	6.7	Liver Cancer	11.0	10.6
(OD04237-02)			6005-T
Ocular Mel Met	20.2	28.1	Liver Tissue	1.4	1.9
to Liver			6005-N
(ODO4310)
Liver Margin	2.0	2.5	Normal	13.0	13.4
(ODO4310)			Bladder
Melanoma Mets	7.3	10.5	Bladder	8.1	6.3
to Lung			Cancer 1023
(OD04321)
Lung Margin	9.3	4.8	Bladder	4.8	5.6
(OD04321)			Cancer
			A302173
Normal Kidney	26.6	19.9	Bladder	52.1	50.7
			Cancer
			(OD04718-01)
Kidney Ca,	2.1	2.4	Bladder	1.8	3.4
Nuclear grade 2			Normal
(OD04338)			Adjacent
			(OD04718-03)
Kidney Margin	7.3	8.4	Normal Ovary	5.3	5.8
(OD04338)
Kidney Ca	12.2	11.3	Ovarian	76.8	83.5
Nuclear grade 1/2			Cancer 064008
(OD04339)
Kidney Margin	31.0	36.3	Ovarian	85.3	100.0
(OD04339)			Cancer
			(OD04768-07)
Kidney Ca, Clear	6.0	7.9	Ovary Margin	2.3	1.2
cell type			(OD04768-08)
(OD04340)
Kidney Margin	24.5	22.1	Normal	4.3	2.9
(OD04340)			Stomach
Kidney Ca,	5.7	7.2	Gastric Cancer	3.6	5.5
Nuclear grade 3			9060358
(OD04348)
Kidney Margin	11.8	15.0	Stomach	9.0	8.3
(OD04348)			Margin
			9060359
Kidney Cancer	6.7	8.4	Gastric Cancer	18.6	30.1
(OD04622-01)			9060395
Kidney Margin	5.0	4.8	Stomach	21.6	20.7
(OD04622-03)			Margin
			9060394
Kidney Cancer	5.4	12.8	Gastric Cancer	84.7	81.8
(OD04450-01)			9060397
Kidney Margin	8.7	10.7	Stomach	9.2	10.1
(OD04450-03)			Margin
			9060396
Kidney Cancer	4.8	6.0	Gastric Cancer	14.5	12.9
8120607			064005

[0902]

TABLE SF
Panel 3D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag2552, Run		Ag2552, Run
Tissue Name	163482707	Tissue Name	163482707
Daoy-Medulloblastoma	0.6	Ca Ski-Cervical epidermoid	47.3
		carcinoma (metastasis)
TE671-Medulloblastoma	0.0	ES-2-Ovarian clear cell	10.2
		carcinoma
D283 Med-	30.8	Ramos-Stimulated with	0.0
Medulloblastoma		PMA/ionomycin 6h
PFSK-1-Primitive	3.7	Ramos-Stimulated with	0.0
Neuroectodermal		PMA/ionomycin 14h
XF-498-CNS	1.8	MEG-01-Chronic
		myelogenous leukemia	17.3
		(megokaryoblast)
SNB-78-Glioma	0.4	Raji-Burkitt's lymphoma	9.3
SF-268-Glioblastoma	2.6	Daudi-Burkitt's lymphoma	0.0
T98G-Glioblastoma	0.2	U266-B-cell plasmacytoma	6.7
SK-N-SH-	7.6	CA46-Burkitt's lymphoma	12.2
Neuroblastoma
(metastasis)
SF-295-Glioblastoma	0.0	RL-non-Hodgkin's B-cell	6.6
		lymphoma
Cerebellum	0.3	JM1-pre-B-cell lymphoma	9.9
Cerebellum	0.5	Jurkat-T cell leukemia	9.2
NCI-H292-	0.0	TF-1 -Erythroleukemia	74.7
Mucoepidermoid lung
carcinoma
DMS-114-Small cell	4.2	HUT 78-T-cell lymphoma	11.3
lung cancer
DMS-79-Small cell lung	54.0	U937-Histiocytic lymphoma	22.2
cancer
NCI-H146-Small cell	16.7	KU-812-Myelogenous	56.3
lung cancer		leukemia
NCI-H526-Small cell	31.0	769-P-Clear cell renal	16.2
lung cancer		carcinoma
NCI-N417-Small cell	7.9	Caki-2-Clear cell renal	23.2
lung cancer		carcinoma
NCI-H82-Small cell lung	10.5	SW 839-Clear cell renal	8.0
cancer		carcinoma
NCI-H157-Squamous	8.6	G401-Wilms'tumor	1.6
cell lung cancer
(metastasis)
NCI-H1155-Large cell	25.3	Hs766T-Pancreatic carcinoma	3.2
lung cancer		(LN metastasis)
NCI-H1299-Large cell	21.8	CAPAN-1-Pancreatic	19.1
lung cancer		adenocarcinoma (liver
		metastasis)
NCI-H727-Lung	12.7	SU86.86-Pancreatic	11.3
carcinoid		carcinoma (liver metastasis)
NCI-UMC-11-Lung	19.2	BxPC-3-Pancreatic	18.7
carcinoid		adenocarcinoma
LX-1-Small cell lung	10.7	HPAC-Pancreatic	33.9
cancer		adenocarcinoma
Colo-205-Colon cancer	17.4	MIA PaCa-2-Pancreatic	2.0
		carcinoma
KM12-Colon cancer	31.0	CFPAC-1-Pancreatic ductal	26.6
		adenocarcinoma
KM20L2-Colon cancer	15.5	PANC-1-Pancreatic	12.9
		epithelioid ductal carcinoma
NCI-H716-Colon cancer	17.9	T24-Bladder carcinma	7.7
		(transitional cell)
SW-48-Colon	44.8	5637-Bladder carcinoma	15.0
adenocarcinoma
SW1116-Colon	4.7	HT-1197-Bladder carcinoma	13.2
adenocarcinoma
LS 174T-Colon	20.7	UM-UC-3-Bladder carcinma	0.8
adenocarcinoma		(transitional cell)
SW-948-Colon	4.1	A204-Rhabdomyosarcoma	1.6
adenocarcinoma
SW-480-Colon	16.8	HT-1080-Fibrosarcoma	3.4
adenocarcinoma
NCI-SNU-5-Gastric	13.8	MG-63-Osteosarcoma	3.9
carcinoma
KATO III-Gastric	100.0	SK-LMS-1-Leiomyosarcoma	3.9
carcinoma		(vulva)
NCI-SNU-16-Gastric	0.2	SJRH30-Rhabdomyosarcoma	0.1
carcinoma		(met to bone marrow)
NCI-SNU-1-Gastric	33.7	A431-Epidermoid carcinoma	6.9
carcinoma
RF-1-Gastric	0.0	WM266-4-Melanoma	5.0
adenocarcinoma
RF-48-Gastric	0.0	DU 145-Prostate carcinoma	0.1
adenocarcinoma		(brain metastasis)
MKN-45-Gastric	8.4	MDA-MB-468-Breast	4.7
carcinoma		adenocarcinoma
NCI-N87-Gastric	29.9	SCC-4-Squamous cell	0.3
carcinoma		carcinoma of tongue
OVCAR-5-Ovarian	3.7	SCC-9-Squamous cell	0.4
carcinoma		carcinoma of tongue
RL95-2-Uterine	13.6	SCC-15-Squamous cell	0.1
carcinoma		carcinoma of tongue
HelaS3-Cervical	2.7	CAL 27-Squamous cell	15.4
adenocarcinoma		carcinoma of tongue

[0903]

TABLE SG
Panel 4.1D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3855, Run		Ag3855, Run
Tissue Name	170120695	Tissue Name	170120695
Secondary Th1 act	0.0	HUVEC IL-1 beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN	0.0
		gamma
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC	0.0
		none
Primary Th1 act	0.0	Lung Microvascular EC	0.0
		TNF alpha + IL-1 beta
Primary Th2 act	0.0	Microvascular Dermal EC	0.0
		none
Primary Tr1 act	0.0	Microvascular Dermal EC	0.0
		TNF alpha + IL-1 beta
primary Th1 rest	0.0	Bronchial epithelium	0.0
		TNF alpha + IL 1 beta
Primary Th2 rest	0.0	Small airway epithelium	0.0
		none
Primary Tr1 rest	0.0	Small airway epithelium	0.0
		TNF alpha + IL-1 beta
CD45RA CD4	0.0	Coronery artery SMC rest	0.0
lymphocyte act
CD45RO CD4	0.0	Coronery artery SMC	0.0
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8	0.0	Astrocytes TNF alpha + IL-	0.0
lymphocyte rest		1 beta
Secondary CD8	0.0	KU-812 (Basophil) rest	0.1
lymphocyte act
CD4 lymphocyte none	0.0	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	0.0	CCD1106 (Keratinocytes)	0.0
CD95 CH11		none
LAK cells rest	0.0	CCD1106 (Keratinocytes)	0.0
		TNF alpha + IL-1 beta
LAK cells IL-2	0.0	Liver cirrhosis	0.0
LAK cells IL-2 + IL-12	0.0	NCI-H292 none	0.0
LAK cells IL-2 + IFN	0.0	NCI-H292 IL-4	0.0
gamma
LAK cells IL-2 + IL-18	0.0	NCI-H292 IL-9	0.0
LAK cells	0.0	NCI-H292 IL-13	0.0
PMA/ionomycin
NK Cells IL-2 rest	0.0	NCI-H292 IFN gamrna	0.0
Two Way MLR 3 day	0.0	HPAEC none	0.0
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1	0.0
		beta
Two Way MLR 7 day	0.0	Lung fibroblast none	0.0
PBMC rest	0.0	Lung fibroblast TNF	0.0
		alpha + IL-1 beta
PBMC PWM	0.0	Lung fibroblast IL-4	0.0
PBMC PHA-L	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.0
Ramos (B cell)	100.0	Lung fibroblast IFN	0.0
ionomycin		gamma
B lymphocytes PWM	0.0	Dermal fibroblast	0.0
		CCD1070 rest
B lymphocytes CD40L	0.0	Dermal fibroblast	0.0
and IL-4		CCD1070 TNF alpha
EOL-1 dbcAMP	0.0	Dermal fibroblast	0.0
		CCD1070 IL-1 beta
EOL-1 dbcAMP	0.0	Dermal fibroblast IFN	0.0
PMA/ionomycin		gamma
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.0
Dendritic cells anti-	0.0	Neutrophils TNFa + LPS	0.0
CD40
Monocytes rest	0.0	Neutrophils rest	0.0
Monocytes LPS	0.0	Colon	1.8
Macrophages rest	0.0	Lung	0.0
Macrophages LPS	0.0	Thymus	0.0
HUVEC none	0.0	Kidney	1.5
HUVEC starved	0.0

[0904]

TABLE SH
Panel 4D
	Rel.	Rel.	Rel.		Rel.	Rel.	Rel.
	Exp.(%)	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)	Exp.(%)
	Ag2552,	Ag2552,	Ag2552,		Ag2552,	Ag2552,	Ag2552,
	Run	Run	Run		Run	Run	Run
Tissue Name	161905844	163724375	163727960	Tissue Name	161905844	163724375	163727960
Secondary Th1 act	5.9	9.7	9.9	HUVEC IL-	1.0	1.2	0.8
				1 beta
Secondary Th2 act	8.8	7.9	9.7	HUVEC IFN	5.6	2.9	3.1
				gamma
Secondary Tr1 act	10.6	8.6	11.7	HUVEC TNF	2.9	3.5	4.0
				alpha + IFN
				gamma
Secondary Th1	1.1	0.5	1.7	HUVEC TNF	3.6	5.0	4.2
rest				alpha + IL4
Secondary Th2	2.1	1.5	1.7	HUVEC IL-11	2.3	3.4	3.0
rest
Secondary Tr1	1.0	1.3	1.5	Lung	4.3	6.7	6.6
rest				Microvascular
				EC none
Primary Th1 act	7.0	5.7	5.7	Lung	2.2	4.9	5.8
				Microvascular
				EC TNF alpha +
				IL-1 beta
Primary Th2 act	4.8	6.5	4.4	Microvascular	5.1	5.7	5.4
				Dermal EC none
Primary Tr1 act	8.7	6.6	7.4	Microsvascular	3.4	3.0	2.7
				Dermal EC
				TNF alpha + IL-
				1 beta
Primary Th1 rest	8.7	9.9	12.7	Bronchial	2.6	14.6	14.6
				epithelium
				TNF alpha +
				IL1 beta
Primary Th2 rest	6.7	4.8	4.5	Small airway	7.1	6.9	7.3
				epithelium none
Primary Tr1 rest	12.4	6.7	10.8	Small airway	26.8	23.3	27.9
				epithelium
				TNF alpha + IL-
				1 beta
CD45RA CD4	4.3	5.7	6.6	Coronery artery	1.6	1.7	2.3
lymphocyte act				SMC rest
CD45RO CD4	8.1	8.5	9.9	Coronery artery	1.1	1.6	1.3
lymphocyte act				SMC TNF alpha +
				IL-1 beta
CD8 lymphocyte	9.9	7.6	12.1	Astrocytes rest	6.1	5.6	5.8
act
Secondary CD8	15.9	11.7	14.9	Astrocytes	3.2	3.7	5.3
lymphocyte rest				TNF alpha + IL-
				1 beta
Secondary CD8	2.6	4.1	3.5	KU-812	81.2	78.5	90.1
lymphocyte act				(Basophil) rest
CD4 lymphocyte	1.7	1.6	1.5	KU-812	100.0	100.0	100.0
none				(Basophil)
				PMA/ionomycin
2ry	2.9	3.8	5.1	CCD1106	15.4	18.6	21.9
Th1/Th2/Tr1_anti-				(Keratinocytes)
CD95 CH11				none
LAK cells rest	4.1	3.5	4.0	CCD1106	2.6	10.6	15.1
				(Keratinocytes)
				TNF alpha + IL-
				1 beta
LAK cells IL-2	6.8	6.0	8.5	Liver cirrhosis	1.2	1.2	1.6
LAK cells IL-	6.2	7.5	5.8	Lupus kidney	1.7	1.6	2.7
2 + IL-12
LAK cells IL-	10.2	6.6	7.5	NCI-H292 none	0.1	0.0	0.0
2 + IFN gamma
LAK cells IL-2 +	13.5	8.0	6.8	NCI-H292 IL-4	0.1	0.1	0.1
IL-18
LAK cells	2.5	2.8	3.1	NCI-H292 IL-9	0.0	0.1	0.2
PMA/ionomycin
NK Cells IL-2 rest	3.2	3.4	3.3	NCI-H292 IL-	0.1	0.2	0.0
				13
Two Way MLR 3	5.2	4.9	6.1	NCI-H292 IFN	0.1	0.0	0.2
day				gamma
Two Way MLR 5	4.2	4.7	6.0	HPAEC none	3.1	4.8	6.1
day
Two Way MLR 7	4.3	5.6	5.6	HPAEC TNF	2.7	3.5	3.0
day				alpha + IL-1
				beta
PBMC rest	2.3	2.4	2.5	Lung fibroblast	7.6	6.7	7.6
				none
PBMC PWM	14.4	16.7	18.7	Lung fibroblast	4.1	3.8	4.2
				TNF alpha + IL-
				1 beta
PBMC PHA-L	10.2	10.5	12.3	Lung fibroblast	12.0	10.7	14.2
				IL-4
Ramos (B cell)	0.0	0.0	0.0	Lung fibroblast	11.1	10.9	11.4
none				IL-9
Ramos (B cell)	0.0	0.0	0.0	Lung fibroblast	8.9	9.8	9.2
ionomycin				IL-13
B lymphocytes	73.2	42.0	48.6	Lung fibroblast	9.2	12.1	17.0
PWM				IFN gamma
B lymphocytes	31.9	13.4	15.5	Dermal	8.7	8.8	11.2
CD40L and IL-4				fibroblast
				CCD1070 rest
EOL-1 dbcAMP	29.5	26.1	26.4	Dermal	15.4	11.0	13.6
				fibroblast
				CCD1070 TNF
				alpha
EOL-1 dbcAMP	14.0	13.1	11.4	Dermal	6.0	5.9	4.4
PMA/ionomycin				fibroblast
				CCD1070 IL-1
				beta
Dendritic cells	5.1	4.2	3.9	Dermal	1.7	2.7	3.1
none				fibroblast IFN
				gamma
Dendritic cells	3.5	1.9	3.3	Dermal	3.3	3.3	3.9
LPS				fibroblast IL-4
Dendritic cells	5.5	7.2	7.4	IBD Colitis 2	0.5	0.3	0.4
anti-CD40
Monocytes rest	5.7	5.3	6.8	IBD Crohn's	6.4	6.6	10.9
Monocytes LPS	1.0	0.9	1.6	Colon	68.8	67.4	68.8
Macrophages rest	10.9	8.7	9.9	Lung	8.8	8.1	7.6
Macrophages LPS	1.9	1.3	2.8	Thymus	53.6	51.4	59.9
HUVEC none	4.3	3.1	3.2	Kidney	7.9	8.2	7.8
HUVEC starved	20.3	4.4	3.8

[0905] AI_comprehensive panel_v1.0 Summary: Ag2552 Highest expression of the CG93443-01 gene is detected in 112756 osteoarthritis bone9 sample (CT=28). Moderate expression of this gene is seen most of the samples used in this panel. Please see panel 4D for the potential utility of this gene. Results from a second experiment with this gene suggests that expression of this gene is low/undetectable (CTs>35) across all of the samples on this panel.

[0906] CNS_neurodegeneration_v1.0 Summary: Ag3855 Expression of the CG93443-01 gene is low/undetectable (CTs>35) across all of the samples on this panel.

[0907] General_screening_panel_v1.4 Summary: Ag3855 Results from one experiment with the CG93443-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[0908] Panel 1.3D Summary: Ag2552 Two experiments with the same probe and primer produce results that are in excellent agreement, with highest expression of the CG93443-01 gene in gastric cancer NCI-N87 cell line (CTs=27-28). In addition, significant expression of this gene is seen in renal, ovarian, breast, lung, liver, pancreatic and colon cancer cell lines, as well as in melanomas. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.

[0909] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancrease, adipose, adrenal gland, thyroid, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0910] Interestingly, this gene is expressed at much higher levels in fetal (CTs=30) when compared to adult heart (CTs=33.4-34). This observation suggests that expression of this gene can be used to distinguish fetal from adult heart.

[0911] In addition, this gene is expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[0912] Panel 2D Summary: Ag2552 Two experiments with the same probe and primer produce results that are in excellent agreement, with high expression of the CG93443-01 gene in colon cancer grade 2 ascend colon (ODO3921), colon cancer from Partial hepatectomy (ODO4309) metastasis, and ovarian cancer (CTs=27). In addition, expression of this gene is higher in gastric, bladder, ovarian, and colon cancers when compared to expression in the corresponding normal adjacent tissue. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.

[0913] Panel 3D Summary: Ag2552 Highest expression of the CG93443-01 gene is detected in KATO III-gastric carcinoma (CT=25.5). In addition, expression of this gene is higher in medulloblastoma, small cell lung cancer, gastric, cervical epidermoid carcinoma, B and T cell leukemia and lymphomas, erythroleukemia, KU-812 myelogenous leukemia, pancreatic, bladder and colon cancers. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of these cancers.

[0914] Panel 4.1D Summary: Ag3855 Highest expression of the CG93443-01 gene is detected exclusively in ionomycin treated Ramos B cells (CT=26.8). Furthermore, expression of this gene is low/undetectable in resting Ramos B cells (CT=40). Thus, expression of this gene can be used to distinguish ionomycin treated Ramos cells from the untreated cells and also from other samples used in this panel. Also, expression of this gene in stimulated Ramos B cells suggests that this gene may be involved in rheumatic disease including rheumatoid arthritis, lupus, osteoarthritis, and hyperproliferative B cell disorders.

[0915] In addition, low but significant expression of this gene is also seen in colon and kidney (CTs=32). Furthermore, expression of this gene is decreased in colon samples from patients with IBD colitis and Crohn's disease relative to normal colon. Therefore, therapeutic modulation of the activity of this gene product may be useful in the treatment of inflammatory bowel disease and kidney related disease such as lupus and glomerulonephritis.

[0916] Panel 4D Summary: Ag2552 Three experiments with the same probe and primer produce results that are in excellent agreement, with highest expression of the CG93443-01 gene in KU-812 (Basophil) cells (CTs=26-27). This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

T. NOV27a (CG50838-01: LEUCINE-RICH REPEAT TRANSMEMBRANE PROTEIN FLRT3)

[0917] Expression of gene CG50838-01 was assessed using the primer-probe sets Ag92, Ag2763 and Ag92b, described in Tables TA, TB and TC. Results of the RTQ-PCR runs are shown in Tables TD, TE, TF, TG, TH, TI and TJ.

TABLE TA
Probe Name Ag92
			Start
Primers	Sequences	Length	Position
Forward	5′-ggctaaatcctgtccatctgtgt-3′	(SEQ ID NO:284)	23	538
Probe	TET-5′-atgaaacccgcatcgcagcga-3′-TAMRA	(SEQ ID NO:285)	21	562
Reverse	5′-aatggatgtcagaaagcgatca-3′	(SEQ ID NO:286)	22	592

[0918]

TABLE TB
Probe Name Ag2763
			Start
Primers	Sequences	Length	Position
Forward	5′-gcttggatgataatcgcatatc-3′	(SEQ ID NO:287)	22	999
Probe	TET-5′-ttcatcaccatctcttcaaggtcatca-3′-TAMRA	(SEQ ID NO:288)	26	1027
Reverse	5′-tgattgttcaacaggtttccat-3′	(SEQ ID NO:289)	22	1077

[0919]

TABLE TC
Probe Name Ag92b
			Start
Primer	Sequences	Length	Position
Forward	5′-gcagttagcatagaagagggagca-3′	(SEQ ID NO:290)	24	881
Probe	TET-5′-tccgagacagcaactatctccgactgc-3′-TAMRA	(SEQ ID NO:291)	27	906
Reverse	5′-taagqtgattacgggacaggaaa-3′	(SEQ ID NO:292)	23	934

[0920]

TABLE TD
AI_comprehensive panel_v1.0
	Rel. Exp.(%) Ag92,		Rel. Exp.(%) Ag92,
Tissue Name	Run 228157507	Tissue Name	Run 228157507
110967 COPD-F	6.3	112427 Match Control	31.0
		Psoriasis-F
110980 COPD-F	1.6	112418 Psoriasis-M	4.5
110968 COPD-M	3.9	112723 Match Control	35.6
		Psoriasis-M
110977 COPD-M	6.7	112419 Psoriasis-M	8.0
110989 Emphysema-F	10.1	112424 Match Control	6.4
		Psoriasis-M
110992 Emphysema-F	4.1	112420 Psoriasis-M	14.6
110993 Emphysema-F	4.7	112425 Match Control	25.7
		Psoriasis-M
110994 Ernphysema-F	2.2	104689 (MF) OA Bone-	9.8
		Backus
110995 Emphysema-F	9.0	104690 (MF) Adj	2.8
		“Normal” Bone-Backus
110996 Emphysema-F	2.5	104691 (MF) OA	0.6
		Synovium-Backus
110997 Asthma-M	3.6	104692 (BA) OA	0.4
		Cartilage-Backus
111001 Asthma-F	12.5	104694 (BA) OA Bone-	11.0
		Backus
111002 Asthma-F	12.7	104695 (BA) Adj	2.7
		“Normal” Bone-Backus
111003 Atopic	10.0	104696 (BA) OA	0.4
Asthma-F		Synovium-Backus
111004 Atopic	8.7	104700 (SS) OA Bone-	8.0
Asthma-F		Backus
111005 Atopic	8.1	104701 (SS) Adj	5.3
Asthma-F		“Normal” Bone-Backus
111006 Atopic	2.6	104702 (SS) OA	1.1
Asthma-F		Synovium-Backus
111417 Allergy-M	9.7	117093 OA Cartilage	7.7
		Rep7
1112347 Allergy-M	5.2	112672 OA Bone5	7.2
112349 Normal Lung-F	6.0	112673 OA Synovium5	2.7
112357 Normal Lung-F	35.4	112674 OA Synovial	2.4
		Fluid cells5
112354 Normal Lung-M	14.0	117100 OA Cartilage	1.5
		Rep14
112374 Crohns-F	4.8	112756 OA Bone9	9.7
112389 Match Control	3.5	112757 OA Synovium9	1.4
Crohns-F
112375 Crohns-F	3.7	112758 OA Synovial	6.5
		Fluid Cells9
112732 Match Control	0.1	117125 RA Cartilage	4.0
Crohns-F		Rep2
112725 Crohns-M	6.9	113492 Bone2 RA	87.1
112387 Match Control	2.0	113493 Synovium2 RA	38.4
Crohns-M
112378 Crohns-M	11.4	113494 Syn	64.6
		Fluid Cells RA
112390 Match Control	16.7	113499 Cartilage4 RA	88.9
Crohns-M
112726 Crohns-M	5.8	113500 Bone4 RA	83.5
112731 Match Control	6.3	113501 Synovium4 RA	55.1
Crohns-M
112380 Ulcer Col-F	11.7	113502 Syn Fluid Cells4	51.4
		RA
112734 Match Control	1.5	113495 Cartilage3 RA	79.6
Ulcer Col-F
112384 Ulcer Col-F	10.1	113496 Bone3 RA	94.6
112737 Match Control	2.7	113497 Synovium3 RA	47.0
Ulcer Col-F
112386 Ulcer Col-F	2.5	113498 Syn Fluid Cells3	100.0
		RA
112738 Match Control	2.8	117106 Normal	1.1
Ulcer Col-F		Cartilage Rep20
112381 Ulcer Col-M	2.4	113663 Bone3 Normal	6.1
112735 Match Control	14.6	113664 Synovium3	2.9
Ulcer Col-M		Normal
112382 Ulcer Col-M	5.4	113665 Syn Fluid Cells3	4.5
		Normal
112394 Match Control	1.6	117107 Normal	2.8
Ulcer Col-M		Cartilage Rep22
112383 Ulcer Col-M	6.4	113667 Bone4 Normal	2.9
112736 Match Control	1.9	113668 Synovium4	3.4
Ulcer Col-M		Normal
112423 Psoriasis-F	11.0	113669 Syn Fluid Cells4	2.9
		Normal

[0921]

TABLE TE
CNS_neurodegeneration_v1.0
	Rel.		Rel.		Rel.		Rel.
	Exp.(%)	Rel.	Exp.(%)		Exp.(%)	Rel.	Exp.(%)
	Ag2763,	Exp.(%)	Ag92b,		Ag2763,	Exp.(%)	Ag92b,
Tissue	Run	Ag92, Run	Run	Tissue	Run	Ag92, Run	Run
Name	206985755	206974451	225000617	Name	206985755	206974451	225000617
AD 1	2.5	7.8	12.4	Control	0.5	2.4	1.4
Hippo				(Path) 3
				Temporal
				Ctx
AD 2	4.0	9.8	13.3	Control	8.4	26.2	26.8
Hippo				(Path) 4
				Temporal
				Ctx
AD 3	0.8	3.1	4.1	AD 1	4.8	18.4	16.2
Hippo				Occipital
				Ctx
AD 4	0.5	3.1	2.8	AD 2	0.0	0.0	0.0
Hippo				Occipital
				Ctx
				(Missing)
AD 5	37.6	100.0	100.0	AD 3	0.7	2.4	3.0
Hippo				Occipital
				Ctx
AD 6	15.2	33.9	28.1	AD 4	3.3	13.5	11.5
Hippo				Occipital
				Ctx
Control 2	7.4	23.2	15.0	AD 5	18.6	46.0	12.9
Hippo				Occipital
				Ctx
Control 4	0.9	2.1	4.5	AD 6	6.2	15.4	35.8
Hippo				Occipital
				Ctx
Control	0.9	3.4	3.3	Control 1	0.1	0.9	1.5
(Path) 3				Occipital
Hippo				Ctx
AD 1	1.9	8.7	7.6	Control 2	40.1	68.3	65.1
Temporal				Occipital
Ctx				Ctx
AD 2	7.9	23.3	26.8	Control 3	5.4	13.4	21.9
Temporal				Occipital
Ctx				Ctx
AD 3	100.0	2.4	1.7	Control 4	0.7	2.1	1.2
Temporal				Occipital
Ctx				Ctx
AD 4	3.2	12.9	14.2	Control	28.5	69.3	58.6
Temporal				(Path) 1
Ctx				Occipital
				Ctx
AD 5 Inf	28.5	75.3	14.3	Control	3.3	10.8	12.9
Temporal				(Path) 2
Ctx				Occipital
				Ctx
AD 5 Sup	8.9	21.2	29.5	Control	0.1	1.5	0.9
Temporal				(Path) 3
Ctx				Occipital
				Ctx
AD 6 Inf	9.2	27.9	27.7	Control	5.3	17.4	13.1
Temporal				(Path) 4
Ctx				Occipital
				Ctx
AD 6 Sup	12.0	31.4	14.1	Control 1	0.5	1.6	1.6
Temporal				Parietal
Ctx				Ctx
Control 1	0.3	2.0	1.9	Control 2	9.9	23.3	27.5
Temporal				Parietal
Ctx				Ctx
Control 2	16.5	25.7	28.3	Control 3	3.8	11.9	14.0
Temporal				Parietal
Ctx				Ctx
Control 3	2.8	11.3	13.6	Control	26.1	50.0	45.7
Temporal				(Path) 1
Ctx				Parietal
				Ctx
Control 3	1.0	4.3	3.8	Control	5.6	13.5	9.8
Temporal				(Path) 2
Ctx				Parietal
				Ctx
Control	18.9	37.9	25.7	Control	0.2	1.7	1.5
(Path) 1				(Path) 3
Temporal				Parietal
Ctx				Ctx
Control	8.0	26.4	26.2	Control	13.2	39.5	14.5
(Path) 2				(Path) 4
Temporal				Parietal
Ctx				Ctx

[0922]

TABLE 1F
Panel I
	Rel.		Rel.		Rel.		Rel.
	Exp.(%)	Rel.	Exp.(%)		Exp.(%)	Rel.	Exp.(%)
	Ag92,	Exp.(%)	Ag92b,		Ag92,	Exp.(%)	Ag92b,
	Run	Ag92, Run	Run	Tissue	Run	Ag92, Run	Run
Tissue Name	87586687	124961889	87584661	Name	87586687	124961889	87584661
Endothelial	0.0	0.0	0.1	Renal ca.	0.5	0.0	1.0
cells				786-0
Endothelial	0.1	0.0	0.2	Renal ca.	0.4	0.0	0.9
cells (treated)				A498
Pancreas	1.6	0.0	1.9	Renal ca.	0.4	0.0	0.9
				RXF 393
Pancreatic ca.	3.3	0.0	4.2	Renal ca.	0.9	0.0	2.7
CAPAN 2				ACHN
Adrenal gland	0.9	0.0	1.1	Renal ca.	0.8	0.0	1.8
				UO-31
Thyroid	4.1	0.0	4.6	Renal ca.	7.8	0.7	22.1
				TK-10
Salivary gland	0.2	0.0	0.8	Liver	2.6	0.0	3.9
Pituitary gland	0.6	0.0	0.5	Liver (fetal)	2.9	0.0	6.7
Brain (fetal)	2.6	0.0	3.0	Liver ca.	0.0	0.0	0.0
				(hepatoblast)
				HepG2
Brain (whole)	16.3	27.7	21.5	Lung	3.1	19.9	5.5
Brain	0.4	0.0	4.6	Lung (fetal)	10.7	3.0	21.2
(amygdala)
Brain	100.0	100.0	100.0	Lung ca.	0.9	0.0	3.8
(cerebellum)				(small cell)
				LX-1
Brain	12.2	0.0	10.1	Lung ca.	5.3	0.0	8.2
(hippocampus)				(small cell)
				NCI-H69
Brain	0.2	0.0	2.5	Lung ca.	0.0	0.0	2.9
(substantia				(s.cell var.)
nigra)				SHP-77
Brain	2.9	0.0	6.2	Lung ca.	0.0	4.1	3.5
(thalamus)				(large
				cell)NCI-
				H460
Brain	1.5	0.0	2.6	Lung ca.	5.8	0.4	13.7
(hypothalamus)				(non-sm.
				cell) A549
Spinal cord	1.1	0.0	4.5	Lung ca.	0.3	0.0	0.2
				(non-s.cell)
				NCI-H23
glio/astro U87-	0.1	0.0	0.1	Lung ca.	2.7	0.0	3.9
MG				(non-s.cell)
				HOP-62
glio/astro U-	0.1	0.0	0.1	Lung ca.	1.6	0.0	4.2
118-MG				(non-s.cl)
				NCI-H522
astrocytoma	0.2	0.0	0.5	Lung ca.	4.3	0.0	7.0
SW1783				(squam.) SW
				900
neuro*; met	1.1	0.0	2.7	Lung ca.	6.0	0.0	5.5
SK-N-AS				(squam.)
				NCI-H596
astrocytoma	0.0	0.0	0.0	Mammary	2.5	0.0	6.7
SF-539				gland
astrocytoma	9.5	5.0	23.2	Breast ca.*	4.5	0.0	3.7
SNB-75				(pl.ef)
				MCF-7
glioma SNB-19	4.4	0.0	10.6	Breast ca.*	0.0	0.0	0.0
				(pl.ef)
				MDA-MB-
				231
glioma U251	0.0	0.0	0.1	Breast ca.*	0.1	0.0	1.8
				(pl. ef)
				T47D
glioma SF-295	0.0	0.0	0.0	Breast ca.	0.0	0.0	2.0
				BT-549
Heart	0.5	0.0	0.6	Breast ca.	1.5	0.0	2.1
				MDA-N
Skeletal muscle	2.2	0.0	1.9	Ovary	0.9	0.0	3.0
Bone marrow	0.0	0.0	0.2	Ovarian ca.	0.8	0.0	0.9
				OVCAR-3
Thymus	13.8	0.0	15.2	Ovarian ca.	0.6	0.0	0.7
				OVCAR-4
Spleen	0.0	0.0	0.4	Ovarian ca.	16.3	9.6	28.3
				OVCAR-5
Lymph node	0.2	0.0	0.6	Ovarian ca.	0.6	0.0	0.3
				OVCAR-8
Colon	3.4	0.0	3.6	Ovarian ca.	6.9	0.1	15.2
(ascending)				IGROV-1
Stomach	13.1	0.1	14.9	Ovarian ca.	2.8	0.0	7.0
				(ascites) SK-
				OV-3
Small intestine	1.2	0.0	2.6	Uterus	10.2	18.8	19.5
Colon ca.	0.1	0.0	0.1	Placenta	1.6	0.0	2.5
SW480
Colon ca.*	0.0	0.0	0.1	Prostate	6.4	0.0	11.3
SW620
(SW480 met)
Colon ca.	1.0	0.0	1.4	Prostate ca.*	0.0	0.2	1.4
HT29				(bone met)
				PC-3
Colon ca.	0.0	0.0	0.2	Testis	22.2	25.5	19.1
HCT-116
Colon ca.	20.9	25.0	45.7	Melanoma	0.2	0.0	0.3
CaCo-2				Hs688(A).T
Colon ca.	0.8	0.0	0.4	Melanoma*	0.1	0.0	0.4
HCT-15				(met)
				Hs688(B).T
Colon ca.	0.4	0.0	1.6	Melanoma	1.3	0.0	0.9
HCC-2998				UACC-62
Gastric ca.*	19.9	36.3	46.7	Melanoma	1.3	0.0	0.7
(liver met)				M14
NCI-N87
Bladder	2.0	0.1	3.1	Melanoma	0.1	0.0	0.5
				LOX IMVI
Trachea	4.5	0.0	7.6	Melanoma*	0.6	0.0	0.3
				(met) SK-
				MEL-5
Kidney	7.7	0.0	19.2	Melanoma	1.0	0.0	1.2
				SK-MEL-28
Kidney (fetal)	20.7	3.9	31.2

[0923]

TABLE TG
Panel 1.3D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag2763, Run	Ag92b, Run		Ag2763, Run	Ag92b, Run
Tissue Name	165527214	165974816	Tissue Name	165527214	165974816
Liver	4.1	3.8	Kidney (fetal)	35.1	51.8
adenocarcinoma
Pancreas	1.5	1.7	Renal ca. 786-0	2.0	2.6
Pancreatic ca.	14.0	25.9	Renal ca. A498	3.7	3.1
CAPAN 2
Adrenal gland	0.9	4.3	Renal ca. RXF	4.0	4.1
			393
Thyroid	5.6	4.5	Renal ca.	3.2	9.3
			ACHN
Salivary gland	1.5	1.1	Renal ca. UO-	10.5	18.4
			31
Pituitary gland	4.3	6.3	Renal ca. TK-	22.1	33.9
			10
Brain (fetal)	20.4	20.6	Liver	3.1	4.8
Brain (whole)	47.3	95.3	Liver (fetal)	18.7	20.7
Brain (amygdala)	24.0	38.2	Liver ca.	0.0	0.0
			(hepatoblast)
			HepG2
Brain (cerebellum)	49.0	64.6	Lung	23.7	44.1
Brain	28.3	36.1	Lung (fetal)	18.0	50.0
(hippocampus)
Brain (substantia	3.8	6.8	Lung ca.	7.1	15.4
nigra)			(small cell)
			LX-1
Brain (thalamus)	32.1	45.1	Lung ca.	6.1	43.8
			(small cell)
			NCI-H69
Cerebral Cortex	15.7	26.2	Lung ca. (s.cell	4.7	3.7
			var.) SHP-77
Spinal cord	6.2	22.4	Lung ca. (large	9.3	3.8
			cell)NCI-H460
glio/astro U87-MG	0.6	0.0	Lung ca. (non-	14.1	19.8
			sm. cell) A549
glio/astro U-118-	1.2	0.6	Lung ca. (non-	0.0	0.8
MG			s.cell) NCI-	0.0	0.8
			H23
astrocytoma	0.9	4.7	Lung ca. (non-	10.5	16.2
SW1783			s.cell) HOP-62
neuro*; met SK-N-	6.6	5.6	Lung ca. (non-	2.0	2.9
AS			s.cl) NCI-H522
astrocytoma SF-	0.0	1.7	Lung ca.	3.5	12.4
539			(squam.) SW
			900
astrocytoma SNB-	15.6	11.3	Lung ca.	9.0	15.9
75			(squam.) NCI-
			H596
glioma SNB-19	12.7	39.0	Mammary	2.8	1.2
			gland
glioma U251	0.3	0.0	Breast ca.*	3.1	3.5
			(pl.ef) MCF-7
glioma SF-295	0.0	0.0	Breast ca.*	0.2	0.0
			(pl.ef) MDA-
			MB-231
Heart (fetal)	0.3	0.3	Breast ca.*	1.1	2.9
			(pl.ef) T47D
Heart	1.6	0.6	Breast ca. BT-	6.7	2.9
			549
Skeletal muscle	3.4	1.0	Breast ca.	0.8	2.8
(fetal)			MDA-N
Skeletal muscle	8.2	9.9	Ovary	0.4	1.2
Bone marrow	0.0	2.4	Ovarian ca.	3.2	3.2
			OVCAR-3
Thymus	2.6	6.9	Ovarian ca.	1.8	7.7
			OVCAR-4
Spleen	0.4	0.6	Ovarian ca.	48.6	100.0
			OVCAR-5
Lymph node	0.3	4.0	Ovarian ca.	1.5	0.5
			OVCAR-8
Colorectal	1.7	2.4	Ovarian ca.	22.4	88.3
			IGROV-1
Stomach	11.6	11.9	Ovarian ca.*	6.8	34.2
			(ascites) SK-
			OV-3
Small intestine	9.6	2.5	Uterus	2.2	2.0
Colon ca. SW480	0.3	1.4	Placenta	1.1	8.5
Colon ca.*	0.8	4.1	Prostate	12.2	4.7
SW620(SW480
met)
Colon ca. HT29	1.6	1.9	Prostate ca.*	1.6	0.0
			(bone met)PC-3
Colon ca. HCT-	0.4	0.5	Testis	2.6	2.5
116
Colon ca. CaCo-2	34.6	92.7	Melanoma	0.5	0.9
			Hs688(A).T
Colon ca.	1.9	6.2	Melanoma*	0.3	0.7
tissue(ODO3866)			(met)
			Hs688(B).T
Colon ca. HCC-	4.2	1.4	Melanoma	7.2	9.9
2998			UACC-62
Gastric ca.* (liver	100.0	79.0	Melanoma	2.6	1.7
met) NCI-N87			M14
Bladder	11.2	19.8	Melanoma	0.0	0.0
			LOX IMVI
Trachea	3.8	5.9	Melanoma*	0.4	0.0
			(met) SK-
			MEL-5
Kidney	27.7	33.2	Adipose	9.0	19.6

[0924]

TABLE TH
Panel 2D
	Rel.	Rel.	Rel.		Rel.	Rel.	Rel.
	Exp. (%)	Exp. (%)	Exp. (%)		Exp. (%)	Exp. (%)	Exp. (%)
	Ag2763,	Ag92,	Ag92b,		Ag2763,	Ag92,	Ag92b,
Tissue	Run	Run	Run	Tissue	Run	Run	Run
Name	162555842	149912056	151275585	Name	162555842	149912056	151275585
Normal	9.7	7.0	7.5	Kidney	5.1	6.8	4.4
Colon				Margin
				8120608
CC Well to	0.7	0.5	0.7	Kidney	0.2	0.2	0.1
Mod Diff				Cancer
(ODO3866)				8120613
CC Margin	1.2	1.3	0.7	Kidney	3.4	3.1	3.3
(ODO3866)				Margin
				8120614
CC Gr.2	1.0	0.5	0.9	Kidney	2.6	4.2	2.5
rectosigmoid				Cancer
(ODO3868)				9010320
CC Margin	0.6	0.8	0.6	Kidney	11.0	13.7	15.3
(ODO3868)				Margin
				9010321
CC Mod	1.0	0.5	1.0	Normal	2.2	1.2	0.9
Diff				Uterus
(ODO3920)
CC Margin	2.1	1.5	2.2	Uterus	4.5	3.5	3.8
(ODO3920)				Cancer
				064011
CC Gr.2	4.5	2.0	2.5	Normal	3.2	2.7	2.3
ascend colon				Thyroid
(ODO3921)
CC Margin	2.2	1.6	1.3	Thyroid	7.9	21.9	16.5
(ODO3921)				Cancer
				064010
CC from	4.4	4.1	3.1	Thyroid	10.4	12.7	10.6
Partial				Cancer
Hepatectomy				A302152
(ODO4309)
Mets
Liver Margin	4.9	3.0	4.1	Thyroid	8.5	6.0	4.8
(ODO4309)				Margin
				A302153
Colon mets	3.1	2.2	3.1	Normal	5.2	4.1	3.2
to lung				Breast
(OD04451-
01)
Lung Margin	12.3	11.3	9.7	Breast	0.9	0.7	0.7
(OD04451-				Cancer
02)				(OD04566)
Normal	42.0	5.9	6.2	Breast	2.9	2.5	2.0
Prostate				Cancer
6546-1				(OD04590-
				01)
Prostate	6.7	6.4	5.4	Breast	2.1	1.8	1.4
Cancer				Cancer
(OD04410)				Mets
				(OD04590-
				03)
Prostate	10.4	7.7	8.2	Breast	44.8	50.3	30.4
Margin				Cancer
(OD04410)				Metastasis
				(OD04655-
				05)
Prostate	15.9	13.3	12.6	Breast	1.5	1.2	1.2
Cancer				Cancer
(OD04720-				064006
01)
Prostate	35.8	27.7	30.6	Breast	2.0	2.1	1.8
Margin				Cancer
(OD04720-				1024
02)
Normal	30.6	21.5	19.9	Breast	3.9	2.1	2.1
Lung 061010				Cancer
				9100266
Lung Met to	0.5	0.4	0.3	Breast	0.9	0.9	1.1
Muscle				Margin
(ODO4286)				9100265
Muscle	1.1	0.3	0.3	Breast	8.7	5.6	5.6
Margin				Cancer
(ODO4286)				A209073
Lung	14.7	10.4	9.3	Breast	2.6	3.4	2.6
Malignant				Margin
Cancer				A209073
(OD03126)
Lung Margin	80.1	56.6	53.6	Normal	1.7	1.2	1.3
(OD03126)
Lung Cancer	19.1	22.1	15.6	Liver	0.1	0.4	0.5
(OD04404)				Cancer
				064003
Lung Margin	26.8	36.6	22.1	Liver	1.5	1.7	1.3
(OD04404)				Cancer
				1025
Lung Cancer	6.1	4.9	5.0	Liver	0.9	0.5	0.6
(OD04565)				Cancer
				1026
Lung Margin	14.7	19.2	15.5	Liver	1.5	2.4	1.6
(OD04565)				Cancer
				6004-T
Lung Cancer	5.6	5.3	4.3	Liver	0.4	0.3	0.5
(OD04237-				Tissue
01)				6004-N
Lung Margin	28.7	32.5	28.7	Liver	0.6	0.9	0.7
(OD04237-				Cancer
02)				6005-T
Ocular Mel	0.4	0.1	0.1	Liver	0.2	0.2	0.3
Met to Liver				Tissue
(ODO4310)				6005-N
Liver Margin	5.8	3.5	3.6	Normal	9.7	11.0	10.4
(ODO4310)				Bladder
Melanoma	6.0	5.0	4.7	Bladder	0.2	0.2	0.5
Mets to				Cancer
Lung				1023
(OD04321)
Lung Margin	62.9	57.8	38.7	Bladder	2.0	1.8	1.4
(OD04321)				Cancer
				A302173
Normal	45.4	55.9	25.3	Bladder	1.2	0.7	1.2
Kidney				Cancer
				(OD04718-
				01)
Kidney Ca,	69.7	55.1	49.3	Bladder	2.7	3.4	3.5
Nuclear				Normal
grade 2				Adjacent
(OD04338)				(OD04718-
				03)
Kidney	21.3	24.7	19.2	Normal	1.2	0.9	0.9
Margin				Ovary
(OD04338)
Kidney Ca	16.2	19.9	27.9	Ovarian	3.3	3.7	2.5
Nuclear				Cancer
grade 1/2				064008
(OD04339)
Kidney	41.2	33.9	29.5	Ovarian	0.9	0.5	0.7
Margin				Cancer
(OD04339)				(OD04768-
				07)
Kidney Ca,	29.3	34.9	25.0	Ovary	1.0	1.6	0.9
Clear cell				Margin
type				(OD04768-
(OD04340)				08)
Kidney	20.0	26.6	19.6	Normal	6.9	7.2	7.0
Margin				Stomach
(OD04340)
Kidney Ca,	0.6	0.3	0.4	Gastric	0.5	0.7	0.5
Nuclear				Cancer
grade 3				9060358
(OD04348)
Kidney	30.8	20.9	21.5	Stomach	3.7	2.8	2.5
Margin				Margin
(OD04348)				9060359
Kidney	0.7	0.3	0.6	Gastric	6.3	6.9	5.6
Cancer				Cancer
(OD04622-				9060395
01)
Kidney	2.9	2.9	4.5	Stomach	2.4	3.6	2.5
Margin				Margin
(OD04622-				9060394
03)
Kidney	100.0	100.0	100.0	Gastric	5.1	4.3	3.8
Cancer				Cancer
(OD04450-				9060397
01)
Kidney	36.1	29.3	24.1	Stomach	1.5	0.9	1.3
Margin				Margin
(OD04450-				9060396
03)
Kidney	1.8	1.5	1.3	Gastric	10.7	7.0	10.4
Cancer				Cancer
8120607				064005

[0925]

TABLE TI
Panel 3D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag92b, Run		Ag92b, Run
Tissue Name	165919165	Tissue Name	165919165
Daoy-Medulloblastoma	0.4	Ca Ski-Cervical epidermoid	0.1
		carcinoma (metastasis)
TE671-Medulloblastoma	0.4	ES-2-Ovarian clear cell	0.2
		carcinoma
D283 Med-	3.3	Ramos-Stimulated with	0.0
Medulloblastoma		PMA/ionomycin 6h
PFSK-1-Primitive	15.1	Ramos-Stimulated with	0.0
Neuroectodermal		PMA/ionomycin 14h
XF-498-CNS	100.0	MEG-01-Chronic	0.5
		myelogenous leukemia
		(megokaryoblast)
SNB-78-Glioma	0.1	Raji-Burkitt's lymphoma	0.0
SF-268-Glioblastoma	0.0	Daudi-Burkitt's lymphoma	0.1
T98G-Glioblastoma	1.0	U266-B-cell plasmacytoma	0.0
SK-N-SH-Neuroblastoma	6.3	CA46-Burkitt's lymphoma	0.0
(metastasis)
SF-295-Glioblastoma	0.0	RL-non-Hodgkin's B-cell	0.0
		lymphoma
Cerebellum	41.2	JM1-pre-B-cell lymphoma	0.0
Cerebellum	1.8	Jurkat-T cell leukemia	0.0
NCI-H292-	0.7	TF-1-Erythroleukemia	0.1
Mucoepidermoid lung
carcinoma
DMS-114-Small cell	0.2	HUT 78-T-cell lymphoma	0.0
lung cancer
DMS-79-Small cell lung	0.9	U937-Histiocytic lymphoma	0.0
cancer
NCI-H146-Small cell	5.5	KU-812-Myelogenous	0.3
lung cancer		leukemia
NCI-H526-Small cell	0.8	769-P-Clear cell renal	0.8
lung cancer		carcinoma
NCI-N417-Small cell	1.7	Caki-2-Clear cell renal	18.8
lung cancer		carcinoma
NCI-H82-Small cell lung	3.8	SW 839-Clear cell renal	1.2
cancer		carcinoma
NCI-H157-Squamous	0.0	G401-Wilms'tumor	0.0
cell lung cancer
(metastasis)
NCI-H1155-Large cell	0.2	Hs766T-Pancreatic carcinoma	0.3
lung cancer		(LN metastasis)
NCI-H1299-Large cell	0.2	CAPAN-1-Pancreatic	2.0
lung cancer		adenocarcinoma (liver
		metastasis)
NCI-H727-Lung	84.1	SU86.86-Pancreatic	1.8
carcinoid		carcinoma (liver metastasis)
NCI-UMC-11-Lung	24.3	BxPC-3-Pancreatic	6.9
carcinoid		adenocarcinoma
LX-1-Small cell lung	5.8	HPAC-Pancreatic	6.9
cancer		adenocarcinoma
Colo-205-Colon cancer	0.4	MIA PaCa-2-Pancreatic	0.1
		carcinoma
KM12-Colon cancer	1.2	CFPAC-1-Pancreatic ductal	6.0
		adenocarcinoma
KM20L2-Colon cancer	1.9	PANC-1-Pancreatic	0.4
		epithelioid ductal carcinoma
NCI-H716-Colon cancer	40.9	T24-Bladder carcinma	4.6
		(transitional cell)
SW-48-Colon	0.0	5637-Bladder carcinoma	2.6
adenocarcinoma
SW1116-Colon	1.4	HT-1197-Bladder carcinoma	0.0
adenocarcinoma
LS 174T-Colon	1.2	UM-UC-3-Bladder carcinma	0.0
adenocarcinoma		(transitional cell)
SW-948-Colon	0.2	A204-Rhabdomyosarcoma	0.0
adenocarcinoma
SW-480-Colon	0.1	HT-1080-Fibrosarcoma	1.2
adenocarcinoma
NCI-SNU-5-Gastric	0.1	MG-63-Osteosarcoma	1.4
carcinoma
KATO III-Gastric	17.3	SK-LMS-1-Leiomyosarcoma	0.8
carcinoma		(vulva)
NCI-SNU-16-Gastric	0.9	SJRH30-Rhabdomyosarcoma	1.6
carcinoma		(met to bone marrow)
NCI-SNU-1-Gastric	6.0	A431-Epidermoid carcinoma	0.0
carcinoma
RF-1-Gastric	0.1	WM266-4-Melanoma	7.0
adenocarcinoma
RF-48-Gastric	0.5	DU 145-Prostate carcinoma	0.0
adenocarcinoma		(brain metastasis)
MKN-45-Gastric	7.2	MDA-MB-468-Breast	0.3
carcinoma		adenocarcinoma
NCI-N87-Gastric	6.7	SCC-4-Squamous cell	0.0
carcinoma		carcinoma of tongue
OVCAR-5-Ovarian	1.1	SCC-9-Squamous cell	0.0
carcinoma		carcinoma of tongue
RL95-2-Uterine	0.6	SCC-15-Squamous cell	0.1
carcinoma		carcinoma of tongue
HelaS3-Cervical	0.3	CAL 27-Squamous cell	0.5
adenocarcinoma		carcinoma of tongue

[0926]

TABLE TJ
Panel 4D
	Rel.	Rel.	Rel.		Rel.	Rel.	Rel.
	Exp.(%)	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)	Exp.(%)
	Ag2763,	Ag92,	Ag92b,		Ag2763,	Ag92,	Ag92b,
	Run	Run	Run		Run	Run	Run
Tissue Name	162015245	149912706	151965831	Tissue Name	162015245	149912706	151965831
Secondary Th1 act	0.0	0.0	0.1	HUVEC IL-	0.1	0.2	0.6
				1 beta
Secondary Th2 act	0.0	0.0	0.2	HUVEC IFN	0.1	0.3	0.2
				gamma
Secondary Tr1 act	0.0	0.0	0.0	HUVEC TNF	0.1	0.1	0.1
				alpha + IFN
				gamma
Secondary Th1	0.0	0.0	0.0	HUVEC TNF	1.4	0.9	1.1
rest				alpha + IL4
Secondary Th2	0.0	0.0	0.0	HUVEC IL-11	0.1	0.1	0.2
rest
Secondary Tr1	0.0	0.0	0.0	Lung	0.0	0.0	0.2
rest				Microvascular
				EC none
Primary Th1 act	0.0	0.0	0.0	Lung	0.0	0.0	0.1
				Microvascular
				EC TNF alpha +
				IL-1 beta
Primary Th2 act	0.0	0.0	0.0	Microvascular	0.0	0.0	0.1
				Dermal EC none
Primary Tr1 act	0.0	0.0	0.1	Microsvasular	0.0	0.0	0.0
				Dermal EC
				TNF alpha + IL-
				1 beta
Primary Th1 rest	0.0	0.0	0.0	Bronchial	34.9	15.0	4.0
				epithelium
				TNF alpha +
				IL1 beta
Primary Th2 rest	0.0	0.0	0.0	Small airway	11.5	11.2	10.1
				epithelium none
Primary Tr1 rest	0.0	0.0	0.0	Small airway	77.9	81.2	87.1
				epithelium
				TNF alpha + IL-
				1 beta
CD45RA CD4	0.6	1.4	1.3	Coronery artery	0.2	0.2	0.3
lymphocyte act				SMC rest
CD45RO CD4	0.0	0.0	0.0	Coronery artery	0.1	0.1	0.2
lymphocyte act				SMC TNF alpha +
				IL-1 beta
CD8 lymphocyte	0.0	0.0	0.0	Astrocytes rest	2.6	3.1	2.8
act
Secondary CD8	0.0	0.0	0.0	Astrocytes	1.1	1.2	1.4
lymphocyte rest				TNF alpha + IL-
				1 beta
Secondary CD8	0.0	0.0	0.0	KU-812	1.0	1.5	1.3
lymphocyte act				(Basophil) rest
CD4 lymphocyte	0.0	0.0	0.0	KU-812	2.1	1.4	1.1
none				(Basophil)
				PMA/ionomycin
2ry	0.0	0.0	0.0	CCD1106	100.0	81.2	60.3
Th1/Th2/Tr1_anti-				(Keratinocytes)
CD95 CH11				none
LAK cells rest	0.0	0.0	0.0	CCD1106	14.7	5.1	2.9
				(Keratinocytes)
				TNF alpha + IL-
				1 beta
LAK cells IL-2	0.0	0.0	0.0	Liver cirrhosis	4.6	5.1	4.9
LAK cells IL-	0.0	0.0	0.0	Lupus kidney	5.9	6.3	8.0
2 + IL-12
LAK cells IL-	0.0	0.0	0.0	NCI-H292 none	2.1	2.0	1.4
2 + IFN gamma
LAK cells IL-2 +	0.1	0.0	0.0	NCI-H292 IL-4	1.9	1.4	1.3
IL-18
LAK cells	0.0	0.0	0.0	NCI-H292 IL-9	1.7	3.4	1.5
PMA/ionomycin
NK Cells IL-2 rest	0.0	0.0	0.0	NCI-H292 IL-	0.9	1.8	0.8
				13
Two Way MLR 3	0.0	0.0	0.0	NCI-H292 IFN	0.5	0.4	0.6
day				gamma
Two Way MLR 5	0.0	0.0	0.0	HPAEC none	0.4	0.4	1.1
day
Two Way MLR 7	0.0	0.0	0.0	HPAEC TNF	0.0	0.0	0.3
day				alpha + IL-1
				beta
PBMC rest	0.0	0.0	0.0	Lung fibroblast	6.9	9.6	9.2
				none
PBMC PWM	0.0	0.0	0.2	Lung fibroblast	11.8	4.6	15.5
				TNF alpha + IL-
				1 beta
PBMC PHA-L	0.1	0.0	0.0	Lung fibroblast	37.9	42.3	47.3
				IL-4
Ramos (B cell)	0.0	0.0	0.2	Lung fibroblast	18.8	18.3	23.3
none				IL-9
Ramos (B cell)	0.0	0.0	0.0	Lung fibroblast	17.3	20.0	23.8
ionomycin				IL-13
B lymphocytes	0.0	0.0	0.2	Lung fibroblast	14.1	11.8	12.7
PWM				IFN gamma
B lymphocytes	0.1	0.1	0.1	Dermal	4.9	4.4	4.4
CD40L and IL-4				fibroblast
				CCD1070 rest
EOL-1 dbcAMP	0.0	0.0	0.0	Dermal	1.3	1.9	2.9
				fibroblast
				CCD1070 TNF
				alpha
EOL-1 dbcAMP	0.0	0.0	0.0	Dermal	0.7	1.5	1.6
PMA/ionomycin				fibroblast
				CCD1070 IL-1
				beta
Dendritic cells	0.0	0.0	0.0	Dermal	0.3	0.2	0.7
none				fibroblast IFN
				gamma
Dendritic cells	0.0	0.1	0.1	Dermal	3.6	6.6	6.6
LPS				fibroblast IL-4
Dendritic cells	0.0	0.0	0.0	IBD Colitis 2	0.4	0.2	0.0
anti-CD40
Monocytes rest	0.0	0.0	0.0	IBD Crohn's	0.6	0.3	0.4
Monocytes LPS	0.0	0.0	0.0	Colon	5.5	6.5	4.1
Macrophages rest	0.0	0.0	0.1	Lung	58.6	57.0	69.3
Macrophages LPS	0.0	0.0	0.0	Thymus	84.7	100.0	100.0
HUVEC none	0.5	0.5	0.5	Kidney	13.5	15.1	25.0
HUVEC starved	1.0	0.4	0.5

[0927] AI_comprehensive panel_v1.0 Summary: Ag92 Highest expression of the CG50838-01 gene is found in in rheumatoid arthritis (RA) synovium fluid cells (CT=28). This gene shows higher expression in synovium, cartilage and bone samples from rheumatide arthritis patient (CTs=28-29) as compared to orthoarthritis patients (CTs=31-35). Therefore, therapeutic modulation of the activity of the GPCR encoded by this gene may be useful in the treatment of patients suffering from rheumatoid arthritis.

[0928] In addition, low expression of this gene is seen in almost all the samples derived from normal and diseased patients. Please see panel 4D for potential utility of this gene.

[0929] CNS_neurodegeneration_v1.0 Summary: Ag92b This panel does not show differential expression of the CG50838-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1 and 1.3D for discussion of utility of this gene in the central nervous system. Results from two additional experiments with the probe and primer sets Ag92 and Ag2763 are not included. The amp plot indicates that there were experimental difficulties with these runs.

[0930] Panel 1 Summary: Ag92/Ag92b Three experiments show highest expression of the CG50838-01 gene in the cerebellum (CTs=24-27). In addition, expression is seen in the hippocampus, thalamus and hypothalamus. This gene encodes a fibronectin leucine rich transmembrane protein 3 (FLRT3), a member of the leucine rich repeats (LRR) protein family. FLRT proteins may play a role in cell adhesion and/or receptor signaling (Ref. 1). Several of LRR proteins, such as connectin, slit, chaoptin, and Toll have pivotal roles in neuronal development in Drosophila and may play significant but distinct roles in neural development and in the adult nervous system of humans (Ref. 2). In Drosophilia, the LRR region of axon guidance proteins has been shown to be critical for their function (especially in axon repulsion). Since the leucine-rich-repeat protein encoded by this gene shows high expression in the cerebellum, it is an excellent candidate neuronal guidance protein for axons, dendrites and/or growth cones in general. Therefore, therapeutic modulation of the levels of this protein, or possible signaling via this protein, may be of utility in enhancing/directing compensatory synaptogenesis and fiber growth in the CNS in response to neuronal death (stroke, head trauma), axon lesion (spinal cord injury), or neurodegeneration (Alzheimer's, Parkinson's, Huntington's, vascular dementia or any neurodegenerative disease).

[0931] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adrenal gland, pancreas, thyroid, skeletal muscle, heart, and adult and fetal liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[0932] In addition, there is expression in cell lines derived from pancreatic, gastric, colon, ovarian and lung cancer cell lines. Thus, based upon this pattern of gene expression, the therapeutic modulation of the activity of the this gene product might be of use in the treatment of these cancers.

[0933] Reference.

[0934] 1. Lacy S E, Bonnemann C G, Buzney E A, Kunkel L M. Identification of FLRT1, FLRT2, and FLRT3: a novel family of transmembrane leucine-rich repeat proteins. Genomics Dec. 15, 1999; 15;62(3):417-26

[0935] 2. Battye R., Stevens A., Perry R. L., Jacobs J. R. (2001) Repellent signaling by Slit requires the leucine-rich repeats. J. Neurosci. 21: 4290-4298.

[0936] Panel 1.3D Summary: Ag2763/Ag92b Two experiments with the different probe and primer sets produce results that are in excellent agreement, with high expression of the CG50838-01 gene in gastric cancer NCI-N87, colon cancer CoCa2, ovarian cancer OVCAR-5 (CTs=29-31). Thus, expression of this gene can be used as a marker for detection these cancers. In addition, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.

[0937] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels in adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[0938] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease epilepsy, multiple sclerosis, schizophrenia and depression.

[0939] Panel 2D Summary: Ag2763/Ag92/Ag92b Three experiments with the different probe and primer sets produce results that are in excellent agreement, with highest expression of the CG50838-01 gene in the kidney cancer (OD04450-01) sample (CTs=27). In addition, expression of this gene is much lower in the corresponding control margin sample (CT=29). Significant expression of this gene is also seen in nuclear grade 2 kidney cancer and breast cancers. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of kidney or breast cancer.

[0940] Panel 3D Summary: Ag92b Highest expression of the CG50838-01 gene is detected in a sample derived from a brain cancer cell line (XF-498) and NCI-H727-lung carcinoid (CTs=27). Therefore, expression of this gene can be used to distinguish these samples from other samples in this panel. In addition, substantial expression of this gene is also seen in primitive neuroectodermal, medulloblastoma, mucoepidermoid lung carcinoma, small cell lung cancer, gastric cancer, ovarian cancer, pancreatic cancer, osteosarcoma, fibrosarcoma and colon cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.

[0941] In addition this panel also confirms expression of this gene in CNS, especially cerebellum. See panel 1 for potential utility of this gene.

[0942] Panel 4D Summary: Ag2763, 92a, 92b Three experiments with the different probe and primer sets produce results that are in excellent agreement, with high expression of this gene in untreated CCD1106 (keratinocytes), thymus, TNFalpha+IL-1beta treated small airway epithelium, and lung (CTs=27-28). Therefore, expression of this gene can be used to distinguish this sample from other samples in the panel. Interestingly, expression of this gene considerably reduced in untreated small airway epithelium and TNFalpha+IL-1beta treated keratinocytes. Thus, expression of this gene can be used to distinguish between these treated versus untreated cells.

[0943] In addition, significant expression of this gene is also seen in activated CD45RA CD4 lymphocyte, TNFalpha+IL1beta treated bronchial epithelium, NCI-H292 cells, lung and dermal fibroblasts, liver cirrhosis, lupus kidney, lung and kidney. This gene codes for a fibronectin leucine rich transmembrane protein 3 (FLRT3) like molecule, a member of the fibronectin leucine rich transmembrane protein (FLRT) family. These proteins may play a role in cell adhesion and/or receptor signaling (See Ref. 1 in panel 1). This gene may play a role in maintaining normal integrity of lung, and kidney tissue. Therefore, therapeutic modulation of the activity of the FLRT3 encoded by this gene may be beneficial for the reduction or elimination of the symptoms caused by inflammation in lung epithelia in chronic obstructive pulmonary disease, and in asthma, allergy, emphysema, kidney related diseases such as lupus and glomerulonephritis and liver cirrhosis.

U. NOV28a (CG58567-01: PROTOCADHERIN)

[0944] Expression of gene CG58567-01 was assessed using the primer-probe set Ag2897, described in Table UA. Results of the RTQ-PCR runs are shown in Tables UB, UC, UD, UE, UF, UG and UH.

TABLE UA
Probe Name Ag2897
			Start
Primers	Sequences	Length	Position
Forward	5′-tgacaggggatattcatgctaa-3′	(SEQ ID NO:293)	22	1565
Probe	TET-5′-tggcaataaatactgcctcacagtcca-3′-TAMRA	(SEQ ID NO:294)	27	1608
Reverse	5′-agttgcatcacctttgtctttg-3′	(SEQ ID NO:295)	22	1638

[0945]

TABLE UB
AI_comprehensive panel_v1.0
	Rel. Exp.(%) Ag2897,		Rel. Exp.(%) Ag2897,
Tissue Name	Run 229662505	Tissue Name	Run 229662505
110967 COPD-F	4.7	112427 Match Control	100.0
		Psoriasis-F
110980 COPD-F	22.5	112418 Psoriasis-M	2.8
110968 COPD-M	8.5	112723 Match Control	14.3
		Psoriasis-M
110977 COPD-M	51.8	112419 Psoriasis-M	10.7
110989 Emphysema-F	51.8	112424 Match Control	8.7
		Psoriasis-M
110992 Emphysema-F	5.0	112420 Psoriasis-M	40.1
110993 Emphysema-F	5.6	112425 Match Control	65.1
		Psoriasis-M
110994 Emphysema-F	3.3	104689 (MF) OA Bone-	1.7
		Backus
110995 Emphysema-F	13.2	104690 (MF) Adj	4.5
		“Normal” Bone-Backus
110996 Emphysema-F	0.6	104691 (MF) OA	9.5
		Synovium-Backus
110997 Asthma-M	1.4	104692 (BA) OA	3.1
		Cartilage-Backus
111001 Asthma-F	8.1	104694 (BA) OA Bone-	1.3
		Backus
111002 Asthma-F	12.5	104695 (BA) Adj	1.8
		“Normal” Bone-Backus
111003 Atopic	12.8	104696 (BA) OA	5.0
Asthma-F		Synovium-Backus
111004 Atopic	12.3	104700 (SS) OA Bone-	5.2
Asthma-F		Backus
111005 Atopic	6.1	104701 (SS) Adj	7.0
Asthma-F		“Normal” Bone-Backus
111006 Atopic	3.7	104702 (SS) OA	12.7
Asthma-F		Synovium-Backus
111417 Allergy-M	7.7	117093 OA Cartilage	15.1
		Rep7
112347 Allergy-M	0.8	112672 OA Bone5	15.9
112349 Normal	0.8	112673 OA Synovium5	8.2
Lung-F
112357 Normal	20.2	112674 OA Synovial	7.9
Lung-F		Fluid cells5
112354 Normal	2.1	117100 OA Cartilage	1.3
Lung-M		Rep14
112374 Crohns-F	4.7	112756 OA Bone9	0.8
112389 Match Control	2.1	112757 OA Synovium9	0.4
Crohns-F
112375 Crohns-F	6.7	112758 OA Synovial	10.2
		Fluid Cells9
112732 Match Control	2.2	117125 RA Cartilage	6.5
Crohns-F		Rep2
112725 Crohns-M	18.9	113492 Bone2 RA	2.2
112387 Match Control	11.2	113493 Synovium2 RA	0.2
Crohns-M
112378 Crohns-M	1.3	113494 Syn Fluid Cells	2.0
		RA
112390 Match Control	62.4	113499 Cartilage4 RA	1.6
Crohns-M
112726 Crohns-M	9.6	113500 Bone4 RA	1.3
112731 Match Control	16.0	113501 Synovium4 RA	1.9
Crohns-M
112380 Ulcer Col-F	21.2	113502 Syn Fluid	1.0
		Cells4 RA
112734 Match Control	4.5	113495 Cartilage3 RA	1.1
Ulcer Col-F
112384 Ulcer Col-F	17.3	113496 Bone3 RA	1.4
112737 Match Control	5.2	113497 Synovium3 RA	0.2
Ulcer Col-F
112386 Ulcer Col-F	5.3	113498 Syn Fluid	1.2
		Cells3 RA
112738 Match Control	2.7	117106 Normal	0.3
Ulcer Col-F		Cartilage Rep20
112381 Ulcer Col-M	0.3	113663 Bone3 Normal	2.8
112735 Match Control	23.7	113664 Synovium3	0.2
Ulcer Col-M		Normal
112382 Ulcer Col-M	5.8	113665 Syn Fluid	1.3
		Cells3 Normal
112394 Match Control	6.5	117107 Normal	9.2
Ulcer Col-M		Cartilage Rep22
112383 Ulcer Col-M	1.6	113667 Bone4 Normal	9.5
112736 Match Control	1.3	113668 Synovium4	6.1
Ulcer Col-M		Normal
112423 Psoriasis-F	7.9	113669 Syn Fluid	10.2
		Cells4 Normal

[0946]

TABLE UC
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag2897,		Rel. Exp.(%) Ag2897,
Tissue Name	Run 209734745	Tissue Name	Run 209734745
AD 1 Hippo	6.5	Control (Path) 3	8.9
		Temporal Ctx
AD 2 Hippo	31.9	Control (Path) 4	46.7
		Temporal Ctx
AD 3 Hippo	1.6	AD 1 Occipital Ctx	5.6
AD 4 Hippo	7.3	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	46.3	AD 3 Occipital Ctx	6.1
AD 6 Hippo	44.4	AD 4 Occipital Ctx	23.0
Control 2 Hippo	24.0	AD 5 Occipital Ctx	11.3
Control 4 Hippo	15.7	AD 6 Occipital Ctx	22.5
Control (Path) 3	0.0	Control 1 Occipital	1.6
Hippo		Ctx
AD 1 Temporal Ctx	3.0	Control 2 Occipital	17.7
		Ctx
AD 2 Temporal Ctx	38.7	Control 3 Occipital	9.1
		Ctx
AD 3 Temporal Ctx	3.5	Control 4 Occipital	8.7
		Ctx
AD 4 Temporal Ctx	23.0	Control (Path) 1	92.0
		Occipital Ctx
AD 5 Inf Temporal	79.0	Control (Path) 2	0.8
Ctx		Occipital Ctx
AD 5 Sup Temporal	43.5	Control (Path) 3	1.6
Ctx		Occipital Ctx
AD 6 Inf Temporal	41.8	Control (Path) 4	7.6
Ctx		Occipital Ctx
AD 6 Sup Temporal	41.2	Control 1 Parietal	4.2
Ctx		Ctx
Control 1 Temporal	12.3	Control 2 Parietal	47.3
Ctx		Ctx
Control 2 Temporal	50.3	Control 3 Parietal	10.1
Ctx		Ctx
Control 3 Temporal	17.8	Control (Path) 1	100.0
Ctx		Parietal Ctx
Control 4 Temporal	9.3	Control (Path) 2	13.4
Ctx		Parietal Ctx
Control (Path) 1	70.2	Control (Path) 3	4.2
Temporal Ctx		Parietal Ctx
Control (Path) 2	29.3	Control (Path) 4	33.2
Temporal Ctx		Parietal Ctx

[0947]

TABLE UD
Panel 1.3D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag2897, Run	Ag2897, Run		Ag2897, Run	Ag2897, Run
Tissue Name	161905860	165518166	Tissue Name	161905860	165518166
Liver	0.0	0.0	Kidney (fetal)	2.8	2.4
adenocarcinoma
Pancreas	1.4	2.4	Renal ca. 786-0	0.9	3.3
Pancreatic ca.	0.0	0.0	Renal ca. A498	13.9	23.7
CAPAN 2
Adrenal gland	1.4	0.0	Renal ca. RXF	0.0	0.0
			393
Thyroid	0.0	0.0	Renal ca.	0.0	0.0
			ACHN
Salivary gland	0.0	0.0	Renal ca. UO-	0.0	0.0
			31
Pituitary gland	4.1	9.0	Renal ca. TK-	0.0	0.0
			10
Brain (fetal)	7.1	17.8	Liver	0.0	2.9
Brain (whole)	21.0	59.0	Liver (fetal)	0.4	0.0
Brain (amygdala)	24.7	37.9	Liver ca.	0.0	0.0
			(hepatoblast)
			HepG2
Brain (cerebellum)	5.6	28.5	Lung	1.4	0.0
Brain	25.2	25.3	Lung (fetal)	6.8	11.0
(hippocampus)
Brain (substantia	0.9	17.1	Lung ca.	0.0	0.0
nigra)			(small cell)
			LX-1
Brain (thalamus)	4.1	23.0	Lung ca.	0.0	4.1
			(small cell)
			NCI-H69
Cerebral Cortex	100.0	22.2	Lung ca. (s.cell	1.0	0.0
			var.) SHP-77
Spinal cord	68.8	100.0	Lung ca. (large	0.0	0.0
			cell) NCI-H460
glio/astro U87-MG	54.3	10.4	Lung ca. (non-	0.0	0.0
			sm. cell) A549
glio/astro U-118-	1.5	20.4	Lung ca. (non-	0.0	3.0
MG			s.cell) NCI-
			H23
astrocytoma	16.3	0.0	Lung ca. (non-	0.6	7.5
SW1783			s.cell) HOP-62
neuro*; met SK-N-	0.0	0.0	Lung ca. (non-	0.0	0.0
AS			s.cl) NCI-H522
astrocytoma SF-	0.0	4.3	Lung ca.	4.6	8.6
539			(squam.) SW
			900
astrocytoma SNB-	18.4	28.7	Lung ca.	0.0	0.0
75			(squam.) NCI-
			H596
glioma SNB-19	0.0	2.6	Mammary	7.9	17.1
			gland
glioma U251	3.1	27.0	Breast ca.*	0.0	0.0
			(pl.ef) MCF-7
glioma SF-295	4.8	2.2	Breast ca.*	0.0	14.5
			(pl.ef) MDA-
			MB-231
Heart (fetal)	0.0	0.0	Breast ca.*	0.0	0.0
			(pl.ef) T47D
Heart	1.4	0.0	Breast ca. BT-	0.0	12.2
			549
Skeletal muscle	77.4	0.0	Breast ca.	0.0	0.0
(fetal)			MDA-N
Skeletal muscle	1.1	14.1	Ovary	12.1	6.1
Bone marrow	0.0	2.5	Ovarian ca.	3.8	12.1
			OVCAR-3
Thymus	2.1	2.4	Ovarian ca.	0.0	0.0
			OVCAR-4
Spleen	0.0	4.4	Ovarian ca.	32.5	25.5
			OVCAR-5
Lymph node	0.0	4.8	Ovarian ca.	1.9	0.0
			OVCAR-8
Colorectal	10.7	0.0	Ovarian ca.	0.0	0.0
			IGROV-1
Stomach	8.7	64.6	Ovarian ca.*	0.0	0.0
			(ascites) SK-
			OV-3
Small intestine	7.2	18.9	Uterus	12.4	66.4
Colon ca. SW480	0.0	0.0	Placenta	0.0	2.3
Colon ca.*	0.0	0.0	Prostate	0.0	0.0
SW620(SW480
met)
Colon ca. HT29	0.0	0.0	Prostate ca.*	0.0	0.0
			(bone met)PC-3
Colon ca. HCT-	0.0	0.0	Testis	56.3	68.8
116
Colon ca. CaCo-2	0.0	0.0	Melanoma	1.3	8.2
			Hs688(A).T
Colon ca.	1.7	8.1	Melanoma*	2.5	4.8
tissue(ODO3866)			(met)
			Hs688(B).T
Colon ca. HCC-	0.0	0.0	Melanoma	1.5	2.8
2998			UACC-62
Gastric ca.* (liver	10.3	7.7	Melanoma	0.0	0.0
met) NCI-N87			M14
Bladder	14.2	29.3	Melanoma	0.0	0.0
			LOX IMVI
Trachea	4.1	0.0	Melanoma*	0.0	0.0
			(met) SK-
			MEL-5
Kidney	0.0	0.0	Adipose	7.2	0.0

[0948]

TABLE UE
Panel 2D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag2897, Run	Ag2897, Run		Ag2897, Run	Ag2897, Run
Tissue Name	161905861	164997312	Tissue Name	161905861	164997312
Normal Colon	83.5	90.1	Kidney Margin	1.3	0.9
			8120608
CC Well to Mod	0.0	7.2	Kidney Cancer	1.4	1.6
Diff (ODO3866)			8120613
CC Margin	16.0	16.6	Kidney Margin	0.9	1.5
(ODO3866)			8120614
CC Gr.2	0.0	0.0	Kidney Cancer	21.6	16.0
rectosigmoid			9010320
(ODO3868)
CC Margin	6.3	3.6	Kidney Margin	1.9	0.5
(ODO3868)			9010321
CC Mod Diff	0.9	2.1	Normal Uterus	9.5	10.9
(ODO3920)
CC Margin	19.1	11.7	Uterus Cancer	68.3	71.2
(ODO3920)			064011
CC Gr.2 ascend	8.8	9.2	Normal	3.3	0.8
colon			Thyroid
(ODO3921)
CC Margin	6.9	7.5	Thyroid	2.0	6.9
(ODO3921)			Cancer 064010
CC from Partial	0.9	3.3	Thyroid	8.9	12.2
Hepatectomy			Cancer
(ODO4309) Mets			A302152
Liver Margin	0.7	2.0	Thyroid	1.0	0.7
(ODO4309)			Margin
			A302153
Colon mets to	0.0	0.0	Normal Breast	15.9	15.3
lung (OD04451-
01)
Lung Margin	1.9	1.0	Breast Cancer	4.3	6.3
(OD04451-02)			(OD04566)
Normal Prostate	3.9	10.7	Breast Cancer	7.3	2.8
6546-1			(OD04590-01)
Prostate Cancer	17.3	11.6	Breast Cancer	9.4	4.8
(OD04410)			Mets
			(OD04590-03)
Prostate Margin	25.0	15.5	Breast Cancer	3.6	0.9
(OD04410)			Metastasis
			(OD04655-05)
Prostate Cancer	28.3	11.7	Breast Cancer	8.4	11.6
(OD04720-01)			064006
Prostate Margin	29.9	20.4	Breast Cancer	2.6	4.3
(OD04720-02)			1024
Normal Lung	16.2	15.1	Breast Cancer	1.9	2.0
061010			9100266
Lung Met to	1.2	0.0	Breast Margin	7.4	5.4
Muscle			9100265
(ODO4286)
Muscle Margin	8.2	1.6	Breast Cancer	20.0	13.6
(ODO4286)			A209073
Lung Malignant	7.0	2.2	Breast Margin	5.0	12.0
Cancer			A209073
(OD03126)
Lung Margin	2.3	3.0	Normal Liver	0.9	1.0
(OD03126)
Lung Cancer	8.2	3.1	Liver Cancer	0.0	0.0
(OD04404)			064003
Lung Margin	11.1	10.2	Liver Cancer	2.4	0.0
(OD04404)			1025
Lung Cancer	0.0	0.9	Liver Cancer	0.0	0.0
(OD04565)			1026
Lung Margin	1.9	5.0	Liver Cancer	0.0	1.0
(OD04565)			6004-T
Lung Cancer	95.3	55.9	Liver Tissue	0.0	0.0
(OD04237-01)			6004-N
Lung Margin	4.0	2.3	Liver Cancer	0.0	0.0
(OD04237-02)			6005-T
Ocular Mel Met	0.0	0.0	Liver Tissue	0.0	0.0
to Liver			6005-N
(ODO4310)
Liver Margin	2.7	0.8	Normal	18.0	13.8
(ODO4310)			Bladder
Melanoma Mets	0.0	1.7	Bladder	1.0	0.7
to Lung			Cancer 1023
(OD04321)
Lung Margin	10.1	6.6	Bladder	10.9	2.6
(OD04321)			Cancer
			A302173
Normal Kidney	14.8	16.4	Bladder	0.0	1.9
			Cancer
			(OD04718-01)
Kidney Ca,	93.3	100.0	Bladder	33.2	31.0
Nuclear grade 2			Normal
(OD04338)			Adjacent
			(OD04718-03)
Kidney Margin	14.3	2.0	Normal Ovary	0.0	4.8
(OD04338)
Kidney Ca	5.0	2.0	Ovarian	100.0	62.0
Nuclear grade 1/2			Cancer 064008
(OD04339)
Kidney Margin	4.1	3.0	Ovarian	49.7	38.7
(OD04339)			Cancer
			(OD04768-07)
Kidney Ca, Clear	27.0	17.4	Ovary Margin	6.3	2.5
cell type			(OD04768-08)
(OD04340)
Kidney Margin	6.4	12.7	Normal	28.1	18.7
(OD04340)			Stomach
Kidney Ca,	1.9	2.1	Gastric Cancer	11.0	14.1
Nuclear grade 3			9060358
(OD04348)
Kidney Margin	4.7	6.2	Stomach	15.9	29.7
(OD04348)			Margin
			9060359
Kidney Cancer	50.0	38.4	Gastric Cancer	15.0	6.8
(OD04622-01)			9060395
Kidney Margin	4.2	0.0	Stomach	26.6	26.4
(OD04622-03)			Margin
			9060394
Kidney Cancer	2.6	3.6	Gastric Cancer	2.7	1.7
(OD04450-01)			9060397
Kidney Margin	14.2	10.5	Stomach	28.1	33.0
(OD04450-03)			Margin
			9060396
Kidney Cancer	1.9	0.0	Gastric Cancer	27.7	33.4
8120607			064005

[0949]

TABLE UF
Panel 3D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag2897, Run		Ag2897, Run
Tissue Name	164629841	Tissue Name	164629841
Daoy-Medulloblastoma	0.0	Ca Ski-Cervical epidermoid	0.0
		carcinoma (metastasis)
TE671-Medulloblastoma	0.0	ES-2-Ovarian clear cell	0.8
		carcinoma
D283 Med-	0.0	Ramos-Stimulated with	0.0
Medulloblastoma		PMA/ionomycin 6h
PFSK-1-Primitive	0.0	Ramos-Stimulated with	0.0
Neuroectodermal		PMA/ionomycin 14h
XF-498-CNS	0.6	MEG-01-Chronic	0.0
		myelogenous leukemia
		(megokaryoblast)
SNB-78-Glioma	6.0	Raji-Burkitt's lymphoma	0.0
SF-268-Glioblastoma	0.0	Daudi-Burkitt's lymphoma	0.0
T98G-Glioblastoma	0.0	U266-B-cell plasmacytoma	0.0
SK-N-SH-	0.0	CA46-Burkitt's lymphoma	0.0
Neuroblastoma
(metastasis)
SF-295-Glioblastoma	0.0	RL-non-Hodgkin's B-cell	0.0
		lymphoma
Cerebellum	7.1	JM1-pre-B-cell lymphoma	0.0
Cerebellum	0.0	Jurkat-T cell leukemia	0.0
NCI-H292-	0.0	TF-1-Erythroleukemia	0.0
Mucoepidermoid lung
carcinoma
DMS-114-Small cell	0.0	HUT 78-T-cell lymphoma	0.0
lung cancer
DMS-79-Small cell lung	0.8	U937-Histiocytic lymphoma	0.0
cancer
NCI-H146-Small cell	1.3	KU-812-Myelogenous	0.0
lung cancer		leukemia
NCI-H526-Small cell	100.0	769-P-Clear cell renal	0.0
lung cancer		carcinoma
NCI-N417-Small cell	0.0	Caki-2-Clear cell renal	0.9
lung cancer		carcinoma
NCI-H82-Small cell lung	0.0	SW 839-Clear cell renal	0.0
cancer		carcinoma
NCI-H157-Squamous	0.0	G401-Wilms'tumor	0.0
cell lung cancer
(metastasis)
NCI-H1155-Large cell	3.2	Hs766T-Pancreatic carcinoma	0.0
lung cancer		(LN metastasis)
NCI-H1299-Large cell	1.9	CAPAN-1-Pancreatic	0.0
lung cancer		adenocarcinoma (liver
		metastasis)
NCI-H727-Lung	0.0	SU86.86-Pancreatic	0.6
carcinoid		carcinoma (liver metastasis)
NCI-UMC-11-Lung	2.1	BxPC-3-Pancreatic	0.0
carcinoid		adenocarcinoma
LX-1-Small cell lung	0.0	HPAC-Pancreatic	0.0
cancer		adenocarcinoma
Colo-205-Colon cancer	0.0	MIA PaCa-2-Pancreatic	0.0
		carcinoma
KM12-Colon cancer	2.6	CFPAC-1-Pancreatic ductal	0.4
		adenocarcinoma
KM20L2-Colon cancer	0.0	PANC-1-Pancreatic	0.0
		epithelioid ductal carcinoma
NCI-H716-Colon cancer	31.0	T24-Bladder carcinma	0.0
		(transitional cell)
SW-48-Colon	0.0	5637-Bladder carcinoma	0.0
adenocarcinoma
SW1116-Colon	0.0	HT-1197-Bladder carcinoma	0.0
adenocarcinoma
LS 174T-Colon	0.0	UM-UC-3-Bladder carcinma	0.0
adenocarcinoma		(transitional cell)
SW-948-Colon	0.0	A204-Rhabdomyosarcoma	0.0
adenocarcinoma
SW-480-Colon	1.5	HT-1080-Fibrosarcoma	0.8
adenocarcinoma
NCI-SNU-5-Gastric	0.0	MG-63-Osteosarcoma	0.0
carcinoma
KATO III-Gastric	0.0	SK-LMS-1-Leiomyosarcoma	0.0
carcinoma		(vulva)
NCI-SNU-16-Gastric	0.8	SJRH30-Rhabdomyosarcoma	0.0
carcinoma		(met to bone marrow)
NCI-SNU-1-Gastric	0.0	A431-Epidermoid carcinoma	0.0
carcinoma
RF-1-Gastric	0.0	WM266-4-Melanoma	1.2
adenocarcinoma
RF-48-Gastric	0.8	DU 145-Prostate carcinoma	0.0
adenocarcinoma		(brain metastasis)
MKN-45-Gastric	0.0	MDA-MB-468-Breast	0.8
carcinoma		adenocarcinoma
NCI-N87-Gastric	0.3	SCC-4-Squamous cell	0.0
carcinoma		carcinoma of tongue
OVCAR-5-Ovarian	0.0	SCC-9-Squamous cell	0.0
carcinoma		carcinoma of tongue
RL95-2-Uterine	0.0	SCC-15-Squamous cell	0.0
carcinoma		carcinoma of tongue
HelaS3-Cervical	0.0	CAL 27-Squamous cell	0.0
adenocarcinoma		carcinoma of tongue

[0950]

TABLE UG
Panel 4D
	Rel.	Rel.		Rel.	Rel.
	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)
	Ag2897,	Ag2897,		Ag2897,	Ag2897,
	Run	Run		Run	Run
Tissue Name	161905862	163586314	Tissue Name	161905862	163586314
Secondary Th1 act	0.0	0.0	HUVEC IL-1 beta	0.0	0.0
Secondary Th2 act	0.0	0.0	HUVEC IFN	0.0	0.0
			gamma
Secondary Tr1 act	0.0	0.0	HUVEC TNF	0.0	0.0
			alpha + IFN
			gamma
Secondary Th1 rest	0.0	0.0	HUVEC TNF	0.0	0.0
			alpha + IL4
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.0	0.0
Secondary Tr1 rest	0.0	0.0	Lung	0.0	0.0
			Microvascular EC
			none
Primary Th1 act	0.0	0.0	Lung	7.9	22.8
			Microvascular EC
			TNF alpha + IL-
			1 beta
Primary Th2 act	0.0	0.0	Microvascular	0.0	0.0
			Dermal EC none
Primary Tr1 act	0.0	0.0	Microsvasular	16.2	0.0
			Dermal EC
			TNF alpha + IL-
			1 beta
Primary Th1 rest	9.3	20.7	Bronchial	4.4	0.0
			epithelium
			TNF alpha +
			IL1 beta
Primary Th2 rest	0.0	9.0	Small airway	10.4	9.7
			epithelium none
Primary Tr1 rest	9.8	0.0	Small airway	100.0	75.8
			epithelium
			TNF alpha + IL-
			1 beta
CD45RA CD4	0.0	0.0	Coronery artery	0.0	9.9
lymphocyte act			SMC rest
CD45RO CD4	0.0	0.0	Coronery artery	16.8	9.0
lymphocyte act			SMC TNF alpha +
			IL-1 beta
CD8 lymphocyte	0.0	0.0	Astrocytes rest	40.6	0.0
act
Secondary CD8	0.0	0.0	Astrocytes	56.6	100.0
lymphocyte rest			TNF alpha + IL-
			1 beta
Secondary CD8	0.0	0.0	KU-812 (Basophil)	0.0	0.0
lymphocyte act			rest
CD4 lymphocyte	0.0	0.0	KU-812 (Basophil)	0.0	0.0
none			PMA/ionomycin
2ry	0.0	0.0	CCD1106	0.0	0.0
Th1/Th2/Tr1_anti-			(Keratinocytes)
CD95 CH11			none
LAK cells rest	10.9	0.0	CCD1106	0.0	0.0
			(Keratinocytes)
			TNF alpha + IL-
			1 beta
LAK cells IL-2	0.0	0.0	Liver cirrhosis	17.2	8.2
LAK cells IL-2 +	0.0	0.0	Lupus kidney	8.4	9.6
IL-12
LAK cells IL-	0.0	0.0	NCI-H292 none	0.0	0.0
2 + IFN gamma
LAK cells IL-2 +	0.0	0.0	NCI-H292 IL-4	0.0	0.0
IL-18
LAK cells	0.0	0.0	NCI-H292 IL-9	0.0	0.0
PMA/ionomycin
NK Cells IL-2 rest	0.0	0.0	NCI-H292 IL-13	0.0	0.0
Two Way MLR 3	0.0	9.3	NCI-H292 IFN	0.0	0.0
day			gamma
Two Way MLR 5	0.0	0.0	HPAEC none	0.0	0.0
day
Two Way MLR 7	0.0	0.0	HPAEC TNF	0.0	0.0
day			alpha + IL-1 beta
PBMC rest	0.0	0.0	Lung fibroblast	0.0	0.0
			none
PBMC PWM	0.0	0.0	Lung fibroblast	0.0	18.8
			TNF alpha + IL-1
			beta
PBMC PHA-L	8.9	0.0	Lung fibroblast IL-4	0.0	17.7
Ramos (B cell)	0.0	0.0	Lung fibroblast IL-9	0.0	0.0
none
Ramos (B cell)	0.0	0.0	Lung fibroblast IL-	0.0	0.0
ionomycin			13
B lymphocytes	0.0	0.0	Lung fibroblast	0.0	0.0
PWM			IFN gamma
B lymphocytes	0.0	0.0	Dermal fibroblast	18.7	5.1
CD40L and IL-4			CCD1070 rest
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast	45.4	29.5
			CCD1070 TNF
			alpha
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast	33.7	85.9
PMA/ionomycin			CCD1070 IL-1
			beta
Dendritic cells none	0.0	0.0	Dermal fibroblast	0.0	0.0
			IFN gamma
Dendritic cells LPS	0.0	0.0	Dermal fibroblast	0.0	8.4
			IL-4
Dendritic cells anti-	0.0	0.0	IBD Colitis 2	0.0	9.9
CD40
Monocytes rest	0.0	0.0	IBD Crohn's	7.7	0.0
Monocytes LPS	0.0	0.0	Colon	62.4	39.2
Macrophages rest	0.0	0.0	Lung	9.9	22.1
Macrophages LPS	0.0	0.0	Thymus	27.7	35.8
HUVEC none	0.0	0.0	Kidney	18.9	20.6
HUVEC starved	0.0	0.0

[0951]

TABLE UH
Panel CNS_1
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag2897, Run		Ag2897, Run
Tissue Name	171688457	Tissue Name	171688457
BA4 Control	29.7	BA17 PSP	24.3
BA4 Control2	37.6	BA17 PSP2	0.0
BA4	0.0	Sub Nigra Control	25.9
Alzheimer's2
BA4 Parkinson's	23.8	Sub Nigra Control2	33.4
BA4	38.7	Sub Nigra	0.0
Parkinson's2		Alzheimer's2
BA4	18.4	Sub Nigra	26.6
Huntington's		Parkinson's2
BA4	0.0	Sub Nigra	13.9
Huntington's2		Huntington's
BA4 PSP	8.0	Sub Nigra	8.7
		Huntington's2
BA4 PSP2	37.6	Sub Nigra PSP2	0.0
BA4 Depression	15.6	Sub Nigra	0.0
		Depression
BA4	4.6	Sub Nigra	2.8
Depression2		Depression2
BA7 Control	56.6	Glob Palladus	4.1
		Control
BA7 Control2	6.0	Glob Palladus	23.7
		Control2
BA7	7.3	Glob Palladus	3.8
Alzheimer's2		Alzheimer's
BA7 Parkinson's	10.8	Glob Palladus	0.0
		Alzheimer's2
BA7	27.2	Glob Palladus	51.1
Parkinson's2		Parkinson's
BA7	56.3	Glob Palladus	3.5
Huntington's		Parkinson's2
BA7	10.8	Glob Palladus PSP	0.0
Huntington's2
BA7 PSP	21.5	Glob Palladus PSP2	0.0
BA7 PSP2	21.3	Glob Palladus	0.0
		Depression
BA7 Depression	5.4	Temp Pole Control	15.9
BA9 Control	31.6	Temp Pole Control2	37.9
BA9 Control2	100.0	Temp Pole	0.0
		Alzheimer's
BA9 Alzheimer's	3.8	Temp Pole	0.0
		Alzheimer's2
BA9	3.7	Temp Pole	34.2
Alzheimer's2		Parkinson's
BA9 Parkinson's	19.2	Temp Pole	10.8
		Parkinson's2
BA9	30.6	Temp Pole	17.7
Parkinson's2		Huntington's
BA9	27.2	Temp Pole PSP	5.8
Huntington's
BA9	9.0	Temp Pole PSP2	0.0
Huntington's2
BA9 PSP	0.0	Temp Pole	15.3
		Depression2
BA9 PSP2	16.5	Cing Gyr Control	76.3
BA9 Depression	2.7	Cing Gyr Control2	54.0
BA9	6.7	Cing Gyr	12.1
Depression2		Alzheimer's
BA17 Control	25.9	Cing Gyr	2.9
		Alzheimer's2
BA17 Control2	14.8	Cing Gyr	26.6
		Parkinson's
BA17	7.9	Cing Gyr	38.2
Alzheimer's2		Parkinson's2
BA17	9.5	Cing Gyr	36.1
Parkinson's		Huntington's
BA17	8.8	Cing Gyr	8.1
Parkinson's2		Huntington's2
BA17	18.3	Cing Gyr PSP	8.3
Huntington's
BA17	0.0	Cing Gry PSP2	4.0
Huntington's2
BA17	7.6	Cing Gyr	0.0
Depression		Depression
BA17	3.7	Cing Gyr	2.9
Depression2		Depression2

[0952] AI_comprehensive panel_v1.0 Summary: Ag2897 Highest expression of the CG58567-01 gene is detected in match control psoriasis sample (CT=30). Furthermore, this expression is down-regulated in the corresponding psoriasis sample (CT=33). Therefore expression of this gene can be used to distinguish between these samples. In addition, the expression of this gene is up-regulated in lung from emphysema and COPD patients, which is consistent with its expression in “stressed” small airway epithelium, lung fibroblasts and lung endothelium (treated with TNF-a and IL-1). Therapeutic modulation of the expression of this putative protein and/or signaling via this protein by antibodies, small molecules or protein therapeutics may inhibit inflammation in lung tissue clue to asthma, emphysema and other COPD type diseases

[0953] CNS_neurodegeneration_v1.0 Summary: Ag2897 This panel does not show differential expression of the CG58567-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

[0954] Panel 1.3D Summary: Ag2897 Two experiments with the same probe and primer show highest expression of this gene, a protocadherin homolog, in the spinal cord and the cerebral cortex (CTs=31.5). Low levels of expression are also seen in other regions of the brain including the amygdala and the hippocampus. The cadherins have been shown to be critical for CNS development, specifically for the guidance of axons, dendrites and/or growth cones in general. Therapeutic modulation of the levels of this protein, or possible signaling via this protein may be of utility in enhancing/directing compensatory synaptogenesis and fiber growth in the CNS in response to neuronal death (stroke, head trauma), axon lesion (spinal cord injury), or neurodegeneration (Alzheimer's, Parkinson's, Huntington's, vascular dementia or any neurodegenerative disease). Since protocadherins play an important role in synaptogenesis this gene product may also be involved in depression, schizophrenia, which also involve synaptogeneisis. Because this cadherin shows highest expression in the cerebellum, this is also an excellent candidate for the spinocerebellar ataxias as well.

[0955] Significant levels of expression are also seen in cell lines derived from ovarian, renal and brain cancers. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of ovarian, renal and brain cancers.

[0956] References:

[0957] Hilschmann N, Barnikol H U, Barnikol-Watanabe S, Gotz H, Kratzin H, Thinnes F P. The immunoglobulin-like genetic predetermination of the brain: the protocadherins, blueprint of the neuronal network. Naturwissenschaften January 2001;88(1):2-12

[0958] Panel 2D Summary: Ag2897 Two experiments with the same probe and primer produce results that are in reasonable agreement, with highest expression of the CG58567-01 gene in ovarian and kidney cancers (CTs=30.5). Significant levels of expression are also seen in lung and uterine cancers. In addition, higher levels of expression arc seen in these cancers than in the corresponding normal adjacent tissues. Thus, therapeutic targeting of this gene product with a human monoclonal antibody is anticipated to limit or block the extent of tumor cell migration and invasion, preferably in kidney, lung, uterine and ovarian tumor tumors.

[0959] Panel 3D Summary: Ag2897 Highest expression of the CG58567-01 gene is seen in a lung cancer cell line (CT=30.1). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel. Please see panel 2D for the utility of this gene.

[0960] Panel 4D Summary: Ag2897 Two experiments with the same probe and primer produce results that are in reasonable agreement, with the CG58567-01 gene highly up-regulated in small airway epithelium and astrocytes stimulated with TNF-alpha and IL-1 beta (CTs=33-34). Other tissues in the lung also up regulate the expression of this gene including lung microvascular endothelium and lung fibroblasts in response to TNF alpha or the Th2 elaborated cytokine IL-4. This suggests that this molecule could be expressed as a result of inflammation particularly during asthma since TNFalpha and IL-4 may play important roles in the pathology of this disease. Based on the expression profile of this transcript and the types of cytokines which induce it, antibodies to CG58567-01 may inhibit inflammation in lung tissue due to asthma, emphysema and other COPD type diseases.

[0961] Panel CNS—1 Summary: Ag2897 The results of this panel confirm expression of the CG58567-01 gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

V. NOV28b and NOV28c (CG58567-05, CG58567-06: PROTOCADHERIN LIKE)

[0962] Expression of gene CG58567-05 and CG58567-06 was assessed using the primer-probe sets Ag2897 and Ag705, described in Tables VA and VB. Results of the RTQ-PCR runs are shown in Tables VC, VD, VE, VF, VG, VH, VI and VJ.

TABLE VA
Probe Name Ag2897
			Start
Primers	Sequences	Length	Position
Forward	5′-tgacaggggatattcatgctaa-3′	(SEQ ID NO:293)	22	7385
Probe	TET-5′-tggcaataaatactgcctcacagtcca-3′-TAMRA	(SEQ ID NO:297)	27	7428
Reverse	5′-agttgcatcacctttgtctttg-3′	(SEQ ID NO:298)	22	7458

[0963]

TABLE VB
Probe Name Ag705
			Start
Primers	Sequences	Length	Position
Forward	5′-gcattcaccattgatcctatgt-3′	(SEQ ID NO:299)	22	2980
Probe	TET-5′-acattgaaaaccagcaacaccctcg-3′-TAMRA	(SEQ ID NO:300)	25	3007
Reverse	5′-gtatgctgagatctggcttcac-3′	(SEQ ID NO:301)	22	3035

[0964]

TABLE VC
AI_comprehensive panel_v1.0
	Rel. Exp.(%) Ag2897,		Rel. Exp.(%) Ag2897,
Tissue Name	Run 229662505	Tissue Name	Run 229662505
110967 COPD-F	4.7	112427 Match Control	100.0
		Psoriasis-F
110980 COPD-F	22.5	112418 Psoriasis-M	2.8
110968 COPD-M	8.5	112723 Match Control	14.3
		Psoriasis-M
110977 COPD-M	51.8	112419 Psoriasis-M	10.7
110989 Emphysema-F	51.8	112424 Match Control	8.7
		Psoriasis-M
110992 Emphysema-F	5.0	112420 Psoriasis-M	40.1
110993 Emphysema-F	5.6	112425 Match Control	65.1
		Psoriasis-M
110994 Emphysema-F	3.3	104689 (MF) OA Bone-	1.7
		Backus
110995 Emphysema-F	13.2	104690 (MF) Adj	4.5
		“Normal” Bone-Backus
110996 Emphysema-F	0.6	104691 (MF) OA	9.5
		Synovium-Backus
110997 Asthma-M	1.4	104692 (BA) OA	3.1
		Cartilage-Backus
111001 Asthma-F	8.1	104694 (BA) OA Bone-	1.3
		Backus
111002 Asthma-F	12.5	104695 (BA) Adj	1.8
		“Normal” Bone-Backus
111003 Atopic	12.8	104696 (BA) OA	5.0
Asthma-F		Synovium-Backus
111004 Atopic	12.3	104700 (SS) OA Bone-	5.2
Asthma-F		Backus
111005 Atopic	6.1	104701 (SS) Adj	7.0
Asthma-F		“Normal” Bone-Backus
111006 Atopic	3.7	104702 (SS) OA	12.7
Asthma-F		Synovium-Backus
111417 Allergy-M	7.7	117093 OA Cartilage	15.1
		Rep7
112347 Allergy-M	0.8	112672 OA Bone5	15.9
112349 Normal	0.8	112673 OA Synovium5	8.2
Lung-F
112357 Normal	20.2	112674 OA Synovial	7.9
Lung-F		Fluid cells5
112354 Normal	2.1	117100 OA Cartilage	1.3
Lung-M		Rep14
112374 Crohns-F	4.7	112756 OA Bone9	0.8
112389 Match Control	2.1	112757 OA Synovium9	0.4
Crohns-F
112375 Crohns-F	6.7	112758 OA Synovial	10.2
		Fluid Cells9
112732 Match Control	2.2	117125 RA Cartilage	6.5
Crohns-F		Rep2
112725 Crohns-M	18.9	113492 Bone2 RA	2.2
112387 Match Control	11.2	113493 Synovium2 RA	0.2
Crohns-M
112378 Crohns-M	1.3	113494 Syn Fluid Cells	2.0
		RA
112390 Match Control	62.4	113499 Cartilage4 RA	1.6
Crohns-M
112726 Crohns-M	9.6	113500 Bone4 RA	1.3
112731 Match Control	16.0	113501 Synovium4 RA	1.9
Crohns-M
112380 Ulcer Col-F	21.2	113502 Syn Fluid	1.0
		Cells4 RA
112734 Match Control	4.5	113495 Cartilage3 RA	1.1
Ulcer Col-F
112384 Ulcer Col-F	17.3	113496 Bone3 RA	1.4
112737 Match Control	5.2	113497 Synovium3 RA	0.2
Ulcer Col-F
112386 Ulcer Col-F	5.3	113498 Syn Fluid	1.2
		Cells3 RA
112738 Match Control	2.7	117106 Normal	0.3
Ulcer Col-F		Cartilage Rep20
112381 Ulcer Col-M	0.3	113663 Bone3 Normal	2.8
112735 Match Control	23.7	113664 Synovium3	0.2
Ulcer Col-M		Normal
112382 Ulcer Col-M	5.8	113665 Syn Fluid	1.3
		Cells3 Normal
112394 Match Control	6.5	117107 Normal	9.2
Ulcer Col-M		Cartilage Rep22
112383 Ulcer Col-M	1.6	113667 Bone4 Normal	9.5
112736 Match Control	1.3	113668 Synovium4	6.1
Ulcer Col-M		Normal
112423 Psoriasis-F	7.9	113669 Syn Fluid	10.2
		Cells4 Normal

[0965]

TABLE VD
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag2897,		Rel. Exp.(%) Ag2897,
Tissue Name	Run 209734745	Tissue Name	Run 209734745
AD 1 Hippo	6.5	Control (Path) 3	8.9
		Temporal Ctx
AD 2 Hippo	31.9	Control (Path) 4	46.7
		Temporal Ctx
AD 3 Hippo	1.6	AD 1 Occipital Ctx	5.6
AD 4 Hippo	7.3	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 Hippo	46.3	AD 4 Occipital Ctx	6.1
AD 6 Hippo	44.4	AD 5 Occipital Ctx	23.0
Control 2 Hippo	24.0	AD 5 Occipital Ctx	11.3
Control 4 Hippo	15.7	AD 6 Occipital Ctx	22.5
Control (Path) 3	0.0	Control 1 Occipital	1.6
Hippo		Ctx
AD 1 Temporal Ctx	3.0	Control 2 Occipital	17.7
		Ctx
AD 2 Temporal Ctx	38.7	Control 3 Occipital	9.1
		Ctx
AD 3 Temporal Ctx	3.5	Control 4 Occipital	8.7
		Ctx
AD 4 Temporal Ctx	23.0	Control (Path) 1	92.0
		Occipital Ctx
AD 5 Inf Temporal	79.0	Control (Path) 2	0.8
Ctx		Occipital Ctx
AD 5 Sup Temporal	43.5	Control (Path) 3	1.6
Ctx		Occipital Ctx
AD 6 Inf Temporal	41.8	Control (Path) 4	7.6
Ctx		Occipital Ctx
AD 6 Sup Temporal	41.2	Control 1 Parietal	4.2
Ctx		Ctx
Control 1 Temporal	12.3	Control 2 Parietal	47.3
Ctx		Ctx
Control 2 Temporal	50.3	Control 3 Parietal	10.1
Ctx		Ctx
Control 3 Temporal	17.8	Control (Path) 1	100.0
Ctx		Parietal Ctx
Control 4 Temporal	9.3	Control (Path) 2	13.4
Ctx		Parietal Ctx
Control (Path) 1	70.2	Control (Path) 3	4.2
Temporal Ctx		Parietal Ctx
Control (Path) 2	29.3	Control (Path) 4	33.2
Temporal Ctx		Parietal Ctx

[0966]

TABLE VE
Panel 1.2
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag705, Run	Ag705, Run		Ag705, Run	Ag705, Run
Tissue Name	118753904	132960873	Tissue Name	118753904	132960873
Endothelial cells	0.0	0.0	Renal ca. 786-0	0.1	0.0
Heart (Fetal)	0.2	0.0	Renal ca. A498	2.7	0.0
Pancreas	5.0	0.0	Renal ca. RXF	0.0	0.0
			393
Pancreatic ca.	0.0	0.0	Renal ca.	0.0	0.0
CAPAN 2			ACHN
Adrenal Gland	3.0	0.0	Renal ca. UO-	0.0	0.0
			31
Thyroid	1.2	0.0	Renal ca. TK-	0.0	0.0
			10
Salivary gland	0.8	0.0	Liver	0.4	0.0
Pituitary gland	19.8	0.3	Liver(fetal)	0.0	0.0
Brain (fetal)	4.9	0.0	Liver ca.	0.1	0.0
			(hepatoblast)
			HepG2
Brain (whole)	27.2	18.4	Lung	0.5	0.0
Brain (amygdala)	5.8	0.8	Lung (fetal)	2.3	0.0
Brain	0.5	0.0	Lung ca. (small	0.0	0.0
(cerebellum)			cell) LX-1
Brain	21.9	7.9	Lung ca. (small	0.0	0.0
(hippocampus)			cell) NCI-H69
Brain (thalamus)	2.8	0.0	Lung ca. (s.cell	0.0	0.0
			var.) SHP-77
Cerebral Cortex	56.6	100.0	Lung ca. (large	0.0	0.0
			cell) NCI-H460
Spinal cord	32.8	11.4	Lung ca. (non-	0.0	0.0
			sm. cell) A549
glio/astro U87	62.4	19.1	Lung ca. (non-	0.2	0.0
MG			s.cell) NCI-
			H23
glio/astro U-118-	0.2	0.0	Lung ca. (non-	1.6	0.0
MG			s.cell) HOP-62
astrocytoma	0.1	0.0	Lung ca. (non-	0.0	0.0
SW1783			s.cl) NCI-H522
neuro*; met SK-	0.0	0.0	Lung ca.	0.5	0.0
N-AS			(squam.) SW
			900
astrocytoma SF-	0.1	0.0	Lung ca.	0.0	0.0
539			(squam.) NCI-
			H596
astrocytoma	34.9	7.6	Mammary	14.2	5.4
SNB-75			gland
glioma SNB-19	0.4	0.0	Breast ca.*	0.0	0.0
			(pl.ef) MCF-7
glioma U251	0.1	0.0	Breast ca.*	0.0	0.0
			(pl.ef) MDA-
			MB-231
glioma SF-295	0.4	0.0	Breast ca.* (pl.	0.7	0.0
			ef) T47D
Heart	0.1	0.0	Breast ca. BT-	0.4	0.0
			549
Skeletal Muscle	1.0	0.0	Breast ca.	0.0	0.0
			MDA-N
Bone marrow	0.0	0.0	Ovary	2.0	0.1
Thymus	0.0	0.0	Ovarian ca.	14.5	0.9
			OVCAR-3
Spleen	0.0	0.0	Ovarian ca.	0.0	0.0
			OVCAR-4
Lymph node	0.6	0.0	Ovarian ca.	100.0	9.3
			OVCAR-5
Colorectal Tissue	1.2	0.1	Ovarian ca.	0.4	0.0
			OVCAR-8
Stomach	35.4	15.9	Ovarian ca.	0.0	0.0
			IGROV-1
Small intestine	5.7	0.0	Ovarian ca.	0.0	0.0
			(ascites) SK-
			OV-3
Colon ca.	0.0	0.0	Uterus	5.0	2.0
SW480
Colon ca.*	0.0	0.0	Placenta	0.2	0.0
SW620 (SW480
met)
Colon ca. HT29	0.0	0.0	Prostate	2.6	0.5
Colon ca. HCT-	0.0	0.0	Prostate ca.*	0.0	0.0
116			(bone met)
			PC-3
Colon ca. CaCo-2	0.1	0.0	Testis	96.6	9.5
Colon ca. Tissue	0.0	0.0	Melanoma	0.1	0.0
(ODO3866)			Hs688(A).T
Colon ca. HCC-	0.1	0.0	Melanoma*	4.2	0.0
2998			(met)
			Hs688(B).T
Gastric ca.*	7.2	0.0	Melanoma	0.1	0.0
(liver met) NCI-			UACC-62
N87
Bladder	5.2	0.1	Melanoma	0.0	0.0
			M14
Trachea	1.0	0.5	Melanoma	0.0	0.0
			LOX IMVI
Kidney	1.5	0.0	Melanoma*	0.0	0.0
			(met) SK-
			MEL-5
Kidney (fetal)	6.4	0.2

[0967]

TABLE VF
Panel 1.3D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag2897, Run	Ag2897, Run		Ag2897, Run	Ag2897, Run
Tissue Name	161905860	165518166	Tissue Name	161905860	165518166
Liver	0.0	0.0	Kidney (fetal)	2.8	2.4
adenocarcinoma
Pancreas	1.4	2.4	Renal ca. 786-0	0.9	3.3
Pancreatic ca.	0.0	0.0	Renal ca. A498	13.9	23.7
CAPAN 2
Adrenal gland	1.4	0.0	Renal ca. RXF	0.0	0.0
			393
Thyroid	0.0	0.0	Renal ca.	0.0	0.0
			ACHN
Salivary gland	0.0	0.0	Renal ca. UO-	0.0	0.0
			31
Pituitary gland	4.1	9.0	Renal ca. TK-	0.0	0.0
			10
Brain (fetal)	7.1	17.8	Liver	0.0	2.9
Brain (whole)	21.0	59.0	Liver (fetal)	0.4	0.0
Brain (amygdala)	24.7	37.9	Liver ca.	0.0	0.0
			(hepatoblast)
			HepG2
Brain (cerebellum)	5.6	28.5	Lung	1.4	0.0
Brain	25.2	25.3	Lung (fetal)	6.8	11.0
(hippocampus)
Brain (substantia	0.9	17.1	Lung ca.	0.0	0.0
nigra)			(small cell)
			LX-1
Brain (thalamus)	4.1	23.0	Lung ca.	0.0	4.1
			(small cell)
			NCI-H69
Cerebral Cortex	100.0	22.2	Lung ca. (s.cell	1.0	0.0
			var:) SHP-77
Spinal cord	68.8	100.0	Lung ca. (large	0.0	0.0
			cell) NCI-H460
glio/astro U87-MG	54.3	10.4	Lung ca. (non-	0.0	0.0
			sm. cell) A549
glio/astro U-118-	1.5	20.4	Lung ca. (non-	0.0	3.0
MG			s.cell) NCI-
			H23
astrocytoma	16.3	0.0	Lung ca. (non-	0.6	7.5
SW1783			s.cell) HOP-62
neuro*; met SK-N-	0.0	0.0	Lung ca. (non-	0.0	0.0
AS			s.cl) NCI-H522
astrocytoma SF-	0.0	4.3	Lung ca.	4.6	8.6
539			(squam.) SW
			900
astrocytoma SNB-	18.4	28.7	Lung ca.	0.0	0.0
75			(squam.) NCI-
			H596
glioma SNB-19	0.0	2.6	Mammary	7.9	17.1
			gland
glioma U251	3.1	27.0	Breast ca.*	0.0	0.0
			(pl.ef) MCF-7
glioma SF-295	4.8	2.2	Breast ca.*	0.0	14.5
			(pl.ef) MDA-
			MB-231
Heart (fetal)	0.0	0.0	Breast ca.*	0.0	0.0
			(pl.ef) T47D
Heart	1.4	0.0	Breast ca. BT-	0.0	12.2
			549
Skeletal muscle	77.4	0.0	Breast ca.	0.0	0.0
(fetal)			MDA-N
Skeletal muscle	1.1	14.1	Ovary	12.1	6.1
Bone marrow	0.0	2.5	Ovarian ca.	3.8	12.1
			OVCAR-3
Thymus	2.1	2.4	Ovarian ca.	0.0	0.0
			OVCAR-4
Spleen	0.0	4.4	Ovarian ca.	32.5	25.5
			OVCAR-5
Lymph node	0.0	4.8	Ovarian ca.	1.9	0.0
			OVCAR-8
Colorectal	10.7	0.0	Ovarian ca.	0.0	0.0
			IGROV-1
Stomach	8.7	64.6	Ovarian ca.*	0.0	0.0
			(ascites) SK-
			OV-3
Small intestine	7.2	18.9	Uterus	12.4	66.4
Colon ca. SW480	0.0	0.0	Placenta	0.0	2.3
Colon ca.*	0.0	0.0	Prostate	0.0	0.0
SW620(SW480
met)
Colon ca. HT29	0.0	0.0	Prostate ca.*	0.0	0.0
			(bone met)PC-3
Colon ca. HCT-	0.0	0.0	Testis	56.3	68.8
116
Colon ca. CaCo-2	0.0	0.0	Melanoma	1.3	8.2
			Hs688(A).T
Colon ca.	1.7	8.1	Melanoma*	2.5	4.8
tissue(ODO3866)			(met)
			Hs688(B).T
Colon ca. HCC-	0.0	0.0	Melanoma	1.5	2.8
2998			UACC-62
Gastric ca.* (liver	10.3	7.7	Melanoma	0.0	0.0
met) NCI-N87			M14
Bladder	14.2	29.3	Melanoma	0.0	0.0
			LOX IMVI
Trachea	4.1	0.0	Melanoma*	0.0	0.0
			(met) SK-
			MEL-5
Kidney	0.0	0.0	Adipose	7.2	0.0

[0968]

TABLE VG
Panel 2D
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag2897, Run	Ag2897, Run		Ag2897, Run	Ag2897, Run
Tissue Name	161905861	164997312	Tissue Name	161905861	164997312
Normal Colon	83.5	90.1	Kidney Margin	1.3	0.9
			8120608
CC Well to Mod	0.0	7.2	Kidney Cancer	1.4	1.6
Diff (ODO3866)			8120613
CC Margin	16.0	16.6	Kidney Margin	0.9	1.5
(ODO3866)			8120614
CC Gr.2	0.0	0.0	Kidney Cancer	21.6	16.0
rectosigmoid			9010320
(ODO3868)
CC Margin	6.3	3.6	Kidney Margin	1.9	0.5
(ODO3868)			9010321
CC Mod Diff	0.9	2.1	Normal Uterus	9.5	10.9
(ODO3920)
CC Margin	19.1	11.7	Uterus Cancer	68.3	71.2
(ODO3920)			064011
CC Gr.2 ascend	8.8	9.2	Normal	3.3	0.8
colon			Thyroid
(ODO3921)
CC Margin	6.9	7.5	Thyroid	2.0	6.9
(ODO3921)			Cancer 064010
CC from Partial	0.9	3.3	Thyroid	8.9	12.2
Hepatectomy			Cancer
(ODO4309) Mets			A302152
Liver Margin	0.7	2.0	Thyroid	1.0	0.7
(ODO4309)			Margin
			A302153
Colon mets to	0.0	0.0	Normal Breast	15.9	15.3
lung (OD04451-
01)
Lung Margin	1.9	1.0	Breast Cancer	4.3	6.3
(OD04451-02)			(OD04566)
Normal Prostate	3.9	10.7	Breast Cancer	7.3	2.8
6546-1			(OD04590-01)
Prostate Cancer	17.3	11.6	Breast Cancer	9.4	4.8
(OD04410)			Mets
			(OD04590-03)
Prostate Margin	25.0	15.5	Breast Cancer	3.6	0.9
(OD04410)			Metastasis
			(OD04655-05)
Prostate Cancer	28.3	11.7	Breast Cancer	8.4	11.6
(OD04720-01)			064006
Prostate Margin	29.9	20.4	Breast Cancer	2.6	4.3
(OD04720-02)			1024
Normal Lung	16.2	15.1	Breast Cancer	1.9	2.0
061010			9100266
Lung Met to	1.2	0.0	Breast Margin	7.4	5.4
Muscle			9100265
(ODO4286)
Muscle Margin	8.2	1.6	Breast Cancer	20.0	13.6
(ODO4286)			A209073
Lung Malignant	7.0	2.2	Breast Margin	5.0	12.0
Cancer			A209073
(OD03126)
Lung Margin	2.3	3.0	Normal Liver	0.9	1.0
(OD03126)
Lung Cancer	8.2	3.1	Liver Cancer	0.0	0.0
(OD04404)			064003
Lung Margin	11.1	10.2	Liver Cancer	2.4	0.0
(OD04404)			1025
Lung Cancer	0.0	0.9	Liver Cancer	0.0	0.0
(OD04565)			1026
Lung Margin	1.9	5.0	Liver Cancer	0.0	1.0
(OD04565)			6004-T
Lung Cancer	95.3	55.9	Liver Tissue	0.0	0.0
(OD04237-01)			6004-N
Lung Margin	4.0	2.3	Liver Cancer	0.0	0.0
(OD04237-02)			6005-T
Ocular Mel Met	0.0	0.0	Liver Tissue	0.0	0.0
to Liver			6005-N
(ODO4310)
Liver Margin	2.7	0.8	Normal	18.0	13.8
(ODO4310)			Bladder
Melanoma Mets	0.0	1.7	Bladder	1.0	0.7
to Lung			Cancer 1023
(OD04321)
Lung Margin	10.1	6.6	Bladder	10.9	2.6
(OD04321)			Cancer
			A302173
Normal Kidney	14.8	16.4	Bladder	0.0	1.9
			Cancer
			(OD04718-01)
Kidney Ca,	93.3	100.0	Bladder	33.2	31.0
Nuclear grade 2			Normal
(OD04338)			Adjacent
			(OD04718-03)
Kidney Margin	14.3	2.0	Normal Ovary	0.0	4.8
(OD04338)
Kidney Ca	5.0	2.0	Ovarian	100.0	62.0
Nuclear grade 1/2			Cancer 064008
(OD04339)
Kidney Margin	4.1	3.0	Ovarian	49.7	38.7
(OD04339)			Cancer
			(OD04768-07)
Kidney Ca, Clear	27.0	17.4	Ovary Margin	6.3	2.5
cell type			(OD04768-08)
(OD04340)
Kidney Margin	6.4	12.7	Normal	28.1	18.7
(OD04340)			Stomach
Kidney Ca,	1.9	2.1	Gastric Cancer	11.0	14.1
Nuclear grade 3			9060358
(OD04348)
Kidney Margin	4.7	6.2	Stomach	15.9	29.7
(OD04348)			Margin
			9060359
Kidney Cancer	50.0	38.4	Gastric Cancer	15.0	6.8
(OD04622-01)			9060395
Kidney Margin	4.2	0.0	Stomach	26.6	26.4
(OD04622-03)			Margin
			9060394
Kidney Cancer	2.6	3.6	Gastric Cancer	2.7	1.7
(OD04450-01)			9060397
Kidney Margin	14.2	10.5	Stomach	28.1	33.0
(OD04450-03)			Margin
			9060396
Kidney Cancer	1.9	0.0	Gastric Cancer	27.7	33.4
8120607			064005

[0969]

TABLE VH
Panel 3D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag2897, Run		Ag2897, Run
Tissue Name	164629841	Tissue Name	164629841
Daoy-Medulloblastoma	0.0	Ca Ski-Cervical epidermoid	0.0
		carcinoma (metastasis)
TE671-Medulloblastoma	0.0	ES-2-Ovarian clear cell	0.8
		carcinoma
D283 Med-	0.0	Ramos-Stimulated with	0.0
Medulloblastoma		PMA/ionomycin 6h
PFSK-1-Primitive	0.0	Ramos-Stimulated with	0.0
Neuroectodermal		PMA/ionomycin 14h
XF-498-CNS	0.6	MEG-01-Chronic	0.0
		myelogenous leukemia
		(megokaryoblast)
SNB-78-Glioma	6.0	Raji-Burkitt's lymphoma	0.0
SF-268-Glioblastoma	0.0	Daudi-Burkitt's lymphoma	0.0
T98G-Glioblastoma	0.0	U266-B-cell plasmacytoma	0.0
SK-N-SH-	0.0	CA46-Burkitt's lymphoma	0.0
Neuroblastoma
(metastasis)
SF-295-Glioblastoma	0.0	RL-non-Hodgkin's B-cell	0.0
		lymphoma
Cerebellum	7.1	JM1-pre-B-cell lymphoma	0.0
Cerebellum	0.0	Jurkat-T cell leukemia	0.0
NCI-H292-	0.0	TF-1-Erythroleukemia	0.0
Mucoepidermoid lung
carcinoma
DMS-114-Small cell	0.0	HUT 78-T-cell lymphoma	0.0
lung cancer
DMS-79-Small cell lung	0.8	U937-Histiocytic lymphoma	0.0
cancer
NCI-H146-Small cell	1.3	KU-812-Myelogenous	0.0
lung cancer		leukemia
NCI-H526-Small cell	100.0	769-P-Clear cell renal	0.0
lung cancer		carcinoma
NCI-N417-Small cell	0.0	Caki-2-Clear cell renal	0.9
lung cancer		carcinoma
NCI-H82-Small cell lung	0.0	SW 839-Clear cell renal	0.0
cancer		carcinoma
NCI-H157-Squamous	0.0	G401-Wilms' tumor	0.0
cell lung cancer
(metastasis)
NCI-H1155-Large cell	3.2	Hs766T-Pancreatic carcinoma	0.0
lung cancer		(LN metastasis)
NCI-H1299-Large cell	1.9	CAPAN-1-Pancreatic	0.0
lung cancer		adenocarcinoma (liver
		metastasis)
NCI-H727-Lung	0.0	SU86.86-Pancreatic	0.6
carcinoid		carcinoma (liver metastasis)
NCI-UMC-11-Lung	2.1	BxPC-3-Pancreatic	0.0
carcinoid		adenocarcinoma
LX-1-Small cell lung	0.0	HPAC-Pancreatic	0.0
cancer		adenocarcinoma
Colo-205-Colon cancer	0.0	MIA PaCa-2-Pancreatic	0.0
		carcinoma
KM12-Colon cancer	2.6	CFPAC-1-Pancreatic ductal	0.4
		adenocarcinoma
KM20L2-Colon cancer	0.0	PANC-1-Pancreatic	0.0
		epithelioid ductal carcinoma
NCI-H716-Colon cancer	31.0	T24-Bladder carcinma	0.0
		(transitional cell)
SW-48-Colon	0.0	5637-Bladder carcinoma	0.0
adenocarcinoma
SW1116-Colon	0.0	HT-1197-Bladder carcinoma	0.0
adenocarcinoma
LS 174T-Colon	0.0	UM-UC-3-Bladder carcinma	0.0
adenocarcinoma		(transitional cell)
SW-948-Colon	0.0	A204-Rhabdomyosarcoma	0.0
adenocarcinoma
SW-480-Colon	1.5	HT-1080-Fibrosarcoma	0.8
adenocarcinoma
NCI-SNU-5-Gastric	0.0	MG-63-Osteosarcoma	0.0
carcinoma
KATO III-Gastric	0.0	SK-LMS-1-Leiomyosarcoma	0.0
carcinoma		(vulva)
NCI-SNU-16-Gastric	0.8	SJRH30-Rhabdomyosarcoma	0.0
carcinoma		(met to bone marrow)
NCI-SNU-1-Gastric	0.0	A431-Epidermoid carcinoma	0.0
carcinoma
RF-1-Gastric	0.0	WM266-4-Melanoma	1.2
adenocarcinorna
RF-48-Gastric	0.8	DU 145-Prostate carcinoma	0.0
adenocarcinoma		(brain metastasis)
MKN-45-Gastric	0.0	MDA-MB-468-Breast	0.8
carcinoma		adenocarcinoma
NCI-N87-Gastric	0.3	SCC-4-Squamous cell	0.0
carcinoma		carcinoma of tongue
OVCAR-5-Ovarian	0.0	SCC-9-Squamous cell	0.0
carcinoma		carcinoma of tongue
RL95-2-Uterine	0.0	SCC-15-Squamous cell	0.0
carcinoma		carcinoma of tongue
HelaS3-Cervical	0.0	CAL 27-Squamous cell	0.0
adenocarcinoma		carcinoma of tongue

[0970]

TABLE VI
Panel 4D
	Rel.	Rel.		Rel.	Rel.
	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)
	Ag2897,	Ag2897,		Ag2897,	Ag2897,
	Run	Run		Run	Run
Tissue Name	161905862	163586314	Tissue Name	161905862	163586314
Secondary Th1 act	0.0	0.0	HUVEC IL-1 beta	0.0	0.0
Secondary Th2 act	0.0	0.0	HUVEC IFN	0.0	0.0
			gamma
Secondary Tr1 act	0.0	0.0	HUVEC TNF	0.0	0.0
			alpha + IFN
			gamma
Secondary Th1 rest	0.0	0.0	HUVEC TNF	0.0	0.0
			alpha + IL4
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.0	0.0
Secondary Tr1 rest	0.0	0.0	Lung	0.0	0.0
			Microvascular EC
			none
Primary Th1 act	0.0	0.0	Lung	7.9	22.8
			Microvascular EC
			TNF alpha + IL-
			1 beta
Primary Th2 act	0.0	0.0	Microvascular	0.0	0.0
			Dermal EC none
Primary Tr1 act	0.0	0.0	Microsvasular	16.2	0.0
			Dermal EC
			TNF alpha + IL-
			1 beta
Primary Th1 rest	9.3	20.7	Bronchial	4.4	0.0
			epithelium
			TNF alpha +
			IL1 beta
Primary Th2 rest	0.0	9.0	Small airway	10.4	9.7
			epithelium none
Primary Tr1 rest	9.8	0.0	Small airway	100.0	75.8
			epithelium
			TNF alpha + IL-
			1 beta
CD45RA CD4	0.0	0.0	Coronery artery	0.0	9.9
lymphocyte act			SMC rest
CD45RO CD4	0.0	0.0	Coronery artery	16.8	9.0
lymphocyte act			SMC TNF alpha +
			IL-1 beta
CD8 lymphocyte	0.0	0.0	Astrocytes rest	40.6	0.0
act
Secondary CD8	0.0	0.0	Astrocytes	56.6	100.0
lymphocyte rest			TNF alpha + IL-
			1 beta
Secondary CD8	0.0	0.0	KU-812 (Basophil)	0.0	0.0
lymphocyte act			rest
CD4 lymphocyte	0.0	0.0	KU-812 (Basophil)	0.0	0.0
none			PMA/ionomycin
2ry	0.0	0.0	CCD1106	0.0	0.0
Th1/Th2/Tr1_anti-			(Keratinocytes)
CD95 Ch11			none
LAK cells rest	10.9	0.0	CCD1106	0.0	0.0
			(Keratinocytes)
			TNF alpha + IL-
			1 beta
LAK cells IL-2	0.0	0.0	Liver cirrhosis	17.2	8.2
LAK cells IL-2 +	0.0	0.0	Lupus kidney	8.4	9.6
IL-12
LAK cells IL-	0.0	0.0	NCI-H292 none	0.0	0.0
2 + IFN gamma
LAK cells IL-2 +	0.0	0.0	NCI-H292 IL-4	0.0	0.0
IL-18
LAK cells	0.0	0.0	NCI-H292 IL-9	0.0	0.0
PMA/ionomycin
NK Cells IL-2 rest	0.0	0.0	NCI-H292 IL-13	0.0	0.0
Two Way MLR 3	0.0	9.3	NCI-H292 IFN	0.0	0.0
day			gamma
Two Way MLR 5	0.0	0.0	HPAEC none	0.0	0.0
day
Two Way MLR 7	0.0	0.0	HPAEC TNF	0.0	0.0
day			alpha + IL-1 beta
PBMC rest	0.0	0.0	Lung fibroblast	0.0	0.0
			none
PBMC PWM	0.0	0.0	Lung fibroblast	0.0	18.8
			TNF alpha + IL-1
			beta
PBMC PHA-L	8.9	0.0	Lung fibroblast IL-4	0.0	17.7
Ramos (B cell)	0.0	0.0	Lung fibroblast IL-9	0.0	0.0
none
Ramos (B cell)	0.0	0.0	Lung fibroblast IL-	0.0	0.0
ionomycin			13
B lymphocytes	0.0	0.0	Lung fibroblast	0.0	0.0
PWM			IFN gamma
B lymphocytes	0.0	0.0	Dermal fibroblast	18.7	5.1
CD40L and IL-4			CCD1070 rest
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast	45.4	29.5
			CCD1070 TNF
			alpha
EOL-1 dbcAMP	0.0	0.0	Dermal fibroblast	33.7	85.9
PMA/ionomycin			CCD1070 IL-1
			beta
Dendritic cells none	0.0	0.0	Dermal fibroblast	0.0	0.0
			IFN gamma
Dendritic cells LPS	0.0	0.0	Dermal fibroblast	0.0	8.4
			IL-4
Dendritic cells anti-	0.0	0.0	IBD Colitis 2	0.0	9.9
CD40
Monocytes rest	0.0	0.0	IBD Crohn's	7.7	0.0
Monocytes LPS	0.0	0.0	Colon	62.4	39.2
Macrophages rest	0.0	0.0	Lung	9.9	22.1
Macrophages LPS	0.0	0.0	Thymus	27.7	35.8
HUVEC none	0.0	0.0	Kidney	18.9	20.6
HUVEC starved	0.0	0.0

[0971]

TABLE VJ
Panel CNS_1
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag2897, Run		Ag2897, Run
Tissue Name	171688457	Tissue Name	171688457
BA4 Control	29.7	BA17 PSP	24.3
BA4 Control2	37.6	BA17 PSP2	0.0
BA4	0.0	Sub Nigra Control	25.9
Alzheimer's2
BA4 Parkinson's	23.8	Sub Nigra Control2	33.4
BA4	38.7	Sub Nigra	0.0
Parkinson's2		Alzheimer's2
BA4	18.4	Sub Nigra	26.6
Huntington's		Parkinson's2
BA4	0.0	Sub Nigra	13.9
Huntington's2		Huntington's
BA4 PSP	8.0	Sub Nigra	8.7
		Huntington's2
BA4 PSP2	37.6	Sub Nigra PSP2	0.0
BA4 Depression	15.6	Sub Nigra	0.0
		Depression
BA4	4.6	Sub Nigra	2.8
Depression2		Depression2
BA7 Control	56.6	Glob Palladus	4.1
		Control
BA7 Control2	6.0	Glob Palladus	23.7
		Control2
BA7	7.3	Glob Palladus	3.8
Alzheimer's2		Alzheimer's
BA7 Parkinson's	10.8	Glob Palladus	0.0
		Alzheimer's2
BA7	27.2	Glob Palladus	51.1
Parkinson's2		Parkinson's
BA7	56.3	Glob Palladus	3.5
Huntington's		Parkinson's2
BA7	10.8	Glob Palladus PSP	0.0
Huntington's2
BA7 PSP	21.5	Glob Palladus PSP2	0.0
BA7 PSP2	21.3	Glob Palladus	0.0
		Depression
BA7 Depression	5.4	Temp Pole Control	15.9
BA9 Control	31.6	Temp Pole Control2	37.9
BA9 Control2	100.0	Temp Pole	0.0
		Alzheimer's
BA9 Alzheimer's	3.8	Temp Pole	0.0
		Alzheimer's2
BA9	3.7	Temp Pole	34.2
Alzheimer's2		Parkinson's
BA9 Parkinson's	19.2	Temp Pole	10.8
		Parkinson's2
BA9	30.6	Temp Pole	17.7
Parkinson's2		Huntington's
BA9	27.2	Temp Pole PSP	5.8
Huntington's
BA9	9.0	Temp Pole PSP2	0.0
Huntington's
BA9 PSP	0.0	Temp Pole	15.3
		Depression2
BA9 PSP2	16.5	Cing Gyr Control	76.3
BA9 Depression	2.7	Cing Gyr Control2	54.0
BA9	6.7	Cing Gyr	12.1
Depression2		Alzheimer's
BA17 Control	25.9	Cing Gyr	2.9
		Alzheimer's2
BA17 Control2	14.8	Cing Gyr	26.6
		Parkinson's
BA17	7.9	Cing Gyr	38.2
Alzheimer's2		Parkinson's2
BA17	9.5	Cing Gyr	36.1
Parkinson's		Huntington's
BA17	8.8	Cing Gyr	8.1
Parkinson's2		Huntington's2
BA17	18.3	Cing Gyr PSP	8.3
Huntington's
BA17	0.0	Cing Gyr PSP2	4.0
Huntington's2
BA17	7.6	Cing Gyr	0.0
Depression		Depression
BA17	3.7	Cing Gyr	2.9
Depression2		Depression2

[0972] AI_comprehensive panel_v1.0 Summary: Ag2897 Highest expression of the CG58567-01 gene is detected in 112427 match control psoriasis sample-F (CT=30). Furthermore, this expression is down-regulated in the corresponding psoriasis sample (CT=33). Therefore expression of this gene can be used to distinguish between these samples. In addition, the expression of this gene is up-regulated in lung from emphysema and COPD patients, which is consistent with its expression in “stressed” small airway epithelium, lung fibroblasts and lung endothelium (treated with TNF-a and IL-1). Therapeutic modulation of the expression of this putative protein and/or signaling via this protein by antibodies, small moleculesvor protein therapeutics may inhibit inflammation in lung tissue due to asthma, emphysema and other COPD type diseases

[0973] CNS_neurodegeneration_v1.0 Summary: Ag2897 This panel does not show differential expression of the CG58567-01 gene in Alzheimer's disease. However, this expression profile confirms the presence of this gene in the brain. Please see panel 1.3D for discussion of utility of this gene in the central nervous system.

[0974] Panel 1.2 Summary: Ag705 Two experiments with the same probe and primer show highest expression of the CG58567-05 gene in an ovarian cancer cell line and the cerebral cortex (CTs=25-26). This gene is also expressed in other parts of the central nervous system, including the spinal cord, amygdala, and hippocampus. Please see Panel 1.3D for further discussion of utility of this gene in the central nervous system.

[0975] In addition to expression in the ovarian cancer cell line, this gene is also expressed in a cluster of cell lines derived from ovarian and brain cancers. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of ovarian and brain cancers.

[0976] Panel 1.3D Summary: Ag2897 Tow experiments with the same probe and primer show highest expression of this gene, a protocadherin homolog, in the spinal cord and the cerebral cortex (CTs=31.5). Low levels of expression are also seen in other regions of the brain including the amygdala and the hippocampus. The cadherins have been shown to be critical for CNS development, specifically for the guidance of axons, dendrites and/or growth cones in general. Therapeutic modulation of the levels of this protein, or possible signaling via this protein may be of utility in enhancing/directing compensatory synaptogenesis and fiber growth in the CNS in response to neuronal death (stroke, head trauma), axon lesion (spinal cord injury), or neurodegeneration (Alzheimer's, Parkinson's, Huntingdon's, vascular dementia or any neurodegenerative disease). Since protocadherins play an important role in synaptogenesis this gene product may also be involved in depression, schizophrenia, which also involve synaptogenesis. Because this cadherin shows highest expression in the cerebellum, this is also an excellent candidate for the spinocerebellar ataxias as well.

[0977] Significant levels of expression are also seen in cell lines derived from ovarian, renal and brain cancers. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of ovarian, renal and brain cancers.

[0978] References:

[0979] Hilschmann N, Barnikol H U, Barnikol-Watanabe S, Gotz H, Kratzin H, Thinnes F P. The immunoglobulin-like genetic predetermination of the brain; the protocadherins, blueprint of the neuronal network. Naturwissenschaften January 2001;88(1):2-12

[0980] Panel 2D Summary: Ag2897 Two experiments with the same probe and primer produce results that are in reasonable agreement, with highest expression of the CG58567-01 gene in ovarian and kidney cancers (CTs=30.5). Significant levels of expression are also seen in lung and uterine cancers. In addition, higher levels of expression are seen in these cancers than in the corresponding normal adjacent tissues. Thus, therapeutic targeting of this gene product with a human monoclonal antibody is anticipated to limit or block the extent of tumor cell migration and invasion, preferably in kidney, lung, uterine and ovarian tumor tumors.

[0981] Panel 3D Summary: Ag2897 Highest expression of the CG58567-01 gene is seen in a lung cancer cell line (CT=30.1). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel. Please see Panel 2D for further discussion of utility of this gene in cancer.

[0982] Panel 4D Summary: Ag2897 Two experiments with the same probe and primer produce results that are in reasonable agreement, with the CG58567-01 gene highly up-regulated in small airway epithelium and astrocytes stimulated with TNF-alpha and IL-1 beta (CTs=33-34). Other tissues in the lung also up regulate the expression of this gene including lung microvascular endothelium and lung fibroblasts in response to TNF alpha or the Th2 elaborated cytokine IL-4. This suggests that this molecule could be expressed as a result of inflammation particularly during asthma since TNFalpha and IL-4 may play important roles in the pathology of this disease. Based on the expression profile of this transcript and the types of cytokines which induce it, antibodies to CG58567-01 may inhibit inflammation in lung tissue due to asthma, emphysema and other COPD type diseases.

[0983] Panel CNS—1 Summary: Ag2897 The results of this panel confirm expression of the CG58567-01 gene in the brain. Please see Panel 1.3D for discussion of utility of this gene in the central nervous system.

W. NOV29and NOV29c (CG59243-01 and CG59243-02; MITOCHONDRIAL CARRIER PROTEIN)

[0984] Expression of gene CG59243-01 and CG59243-02 was assessed using the primer-probe set Ag3415, described in Table WA. Results of the RTQ-PCR runs are shown in Tables WB, WC, WD, and WE. Please note that CG59243-02 represents a full-length physical clone of the CG59243-01 gene, validating the prediction of the gene sequence.

TABLE WA
Probe Name Ag3415
			Start
Primers	Sequences	Length	Position
Forward	5′-tataaggttgtgttccggca-3′	(SEQ ID NO:302)	20	145
Probe	TET-5′-gcagtgtcagaggctgtgagacagct-3′-TAMRA	(SEQ ID NO:303)	26	181
Reverse	5′-tattgaggaccctcatgcca-3′	(SEQ ID NO:304)	20	208

[0985]

TABLE WB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3415,		Rel. Exp.(%) Ag3415,
Tissue Name	Run 206533692	Tissue Name	Run 206533692
AD 1 Hippo	40.6	Control (Path) 3	15.5
		Temporal Ctx
AD 2 Hippo	43.2	Control (Path) 4	28.3
		Temporal Ctx
AD 3 Hippo	13.2	AD 1 Occipital Ctx	17.2
AD 4 Hippo	13.9	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	79.0	AD 3 Occipital Ctx	7.2
AD 6 Hippo	40.6	AD 4 Occipital Ctx	21.9
Control 2 Hippo	18.0	AD 5 Occipital Ctx	4.7
Control 4 Hippo	36.6	AD 6 Occipital Ctx	25.3
Control (Path) 3	8.4	Control 1 Occipital	8.0
Hippo		Ctx
AD 1 Temporal Ctx	28.9	Control 2 Occipital	48.6
		Ctx
AD 2 Temporal Ctx	42.0	Control 3 Occipital	11.0
		Ctx
AD 3 Temporal Ctx	13.8	Control 4 Occipital	16.5
		Ctx
AD 4 Temporal Ctx	22.5	Control (Path) 1	100.0
		Occipital Ctx
AD 5 Inf Temporal	73.7	Control (Path) 2	14.0
Ctx		Occipital Ctx
AD 5 Sup Temporal	65.5	Control (Path) 3	5.8
Ctx		Occipital Ctx
AD 6 Inf Temporal	27.0	Control (Path) 4	24.3
Ctx		Occipital Ctx
AD 6 Sup Temporal	20.0	Control 1 Parietal	21.0
Ctx		Ctx
Control 1 Temporal	18.7	Control 2 Parietal	49.0
Ctx		Ctx
Control 2 Temporal	27.9	Control 3 Parietal	9.0
Ctx		Ctx
Control 3 Temporal	9.3	Control (Path) 1	55.9
Ctx		Parietal Ctx
Control 4 Temporal	17.4	Control (Path) 2	31.4
Ctx		Parietal Ctx
Control (Path) 1	34.9	Control (Path) 3	4.6
Temporal Ctx		Parietal Ctx
Control (Path) 2	33.2	Control (Path) 4	44.4
Temporal Ctx		Parietal Ctx

[0986]

TABLE WC
Panel 1.3D
	Rel. Exp.(%) Ag3415,		Rel. Exp.(%) Ag3415,
Tissue Name	Run 167617385	Tissue Name	Run 167617385
Liver adenocarcinoma	0.0	Kidney (fetal)	19.8
Pancreas	1.1	Renal ca. 786-0	13.7
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	2.6
Adrenal gland	0.9	Renal ca. RXF 393	9.1
Thyroid	0.0	Renal ca. ACHN	13.5
Salivary gland	0.0	Renal ca. UO-31	20.6
Pituitary gland	5.6	Renal ca. TK-10	32.8
Brain (fetal)	55.1	Liver	4.5
Brain (whole)	20.0	Liver (fetal)	0.0
Brain (amygdala)	23.2	Liver ca.	2.3
		(hepatoblast) HepG2
Brain (cerebellum)	17.3	Lung	5.9
Brain (hippocampus)	12.5	Lung (fetal)	4.8
Brain (substantia nigra)	26.2	Lung ca. (small cell)	2.8
		LX-1
Brain (thalamus)	23.8	Lung ca. (small cell)	2.7
		NCI-H69
Cerebral Cortex	32.5	Lung ca. (s.cell var.)	89.5
		SHP-77
Spinal cord	20.2	Lung ca. (large	2.6
		cell) NCI-H460
glio/astro U87-MG	0.0	Lung ca. (non-sm.	0.0
		cell) A549
glio/astro U-118-MG	2.1	Lung ca. (non-s.cell)	3.7
		NCI-H23
astrocytoma SW1783	15.9	Lung ca. (non-s.cell)	8.2
		HOP-62
neuro*; met SK-N-AS	8.3	Lung ca. (non-s.cl)	17.3
		NCI-H522
astrocytoma SF-539	2.3	Lung ca. (squam.)	6.4
		SW 900
astrocytoma SNB-75	6.7	Lung ca. (squam.)	18.8
		NCI-H596
glioma SNB-19	0.0	Mammary gland	1.1
glioma U251	23.5	Breast ca.* (pl.ef)	2.2
		MCF-7
glioma SF-295	0.0	Breast ca.* (pl.ef)	2.6
		MDA-MB-231
Heart (fetal)	10.0	Breast ca.* (pl.ef)	1.3
		T47D
Heart	4.6	Breast ca. BT-549	7.7
Skeletal muscle (fetal)	2.0	Breast ca. MDA-N	12.2
Skeletal muscle	3.4	Ovary	4.2
Bone marrow	3.8	Ovarian ca. OVCAR-3	17.7
Thymus	5.4	Ovarian ca. OVCAR-4	0.0
Spleen	24.8	Ovarian ca. OVCAR-5	0.0
Lymph node	43.5	Ovarian ca. OVCAR-8	3.5
Colorectal	6.0	Ovarian ca. IGROV-1	2.4
Stomach	6.8	Ovarian ca.* (ascites)	3.5
		SK-OV-3
Small intestine	9.3	Uterus	4.4
Colon ca. SW480	6.5	Placenta	1.9
Colon ca.*	100.0	Prostate	0.0
SW620 (SW480 met)
Colon ca. HT29	0.0	Prostate ca.* (bone	0.0
		met) PC-3
Colon ca. HCT-116	0.0	Testis	14.4
Colon ca. CaCo-2	3.8	Melanoma	0.0
		Hs688(A).T
Colon ca.	0.0	Melanoma* (met)	0.0
tissue(ODO3866)		Hs688(B).T
Colon ca. HCC-2998	0.0	Melanoma UACC-62	5.1
Gastric ca.* (liver met)	0.0	Melanoma M14	0.0
NCI-N87
Bladder	6.4	Melanoma LOX	0.0
		IMVI
Trachea	0.0	Melanoma* (met)	2.1
		SK-MEL-5
Kidney	0.0	Adipose	3.3

[0987]

TABLE WD
Panel 2D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3415, Run		Ag3415, Run
Tissue Name	169596730	Tissue Name	169596730
Normal Colon	39.0	Kidney Margin	0.0
		8120608
CC Well to Mod Diff	8.7	Kidney Cancer	7.7
(ODO3866)		8120613
CC Margin (ODO3866)	0.0	Kidney Margin	0.0
		8120614
CC Gr.2 rectosigmoid	11.7	Kidney Cancer	7.7
(ODO3868)		9010320
CC Margin (ODO3868)	0.8	Kidney Margin	0.0
		9010321
CC Mod Diff (ODO3920)	7.6	Normal Uterus	2.0
CC Margin (ODO3920)	3.6	Uterus Cancer 064011	23.3
CC Gr.2 ascend colon	19.9	Normal Thyroid	2.0
(ODO3921)
CC Margin (ODO3921)	10.2	Thyroid Cancer	4.4
		064010
CC from Partial	1.9	Thyroid Cancer	2.3
Hepatectomy (ODO4309)		A302152
Mets
Liver Margin (ODO4309)	3.1	Thyroid Margin	5.9
		A302153
Colon mets to lung	3.6	Normal Breast	19.6
(OD04451-01)
Lung Margin (OD04451-	2.5	Breast Cancer	5.3
02)		(OD04566)
Normal Prostate 6546-1	1.1	Breast Cancer	16.5
		(OD04590-01)
Prostate Cancer	14.5	Breast Cancer Mets	29.5
(OD04410)		(OD04590-03)
Prostate Margin	17.0	Breast Cancer	12.9
(OD04610)		Metastasis (OD04655-05)
Prostate Cancer	10.6	Breast Cancer 064006	13.6
(OD04720-01)
Prostate Margin	16.3	Breast Cancer 1024	7.4
(OD04720-02)
Normal Lung 061010	60.3	Breast Cancer	10.1
		9100266
Lung Met to Muscle	1.8	Breast Margin	5.0
(ODO4286)		9100265
Muscle Margin	2.0	Breast Cancer	31.9
(ODO4286)		A209073
Lung Malignant Cancer	7.7	Breast Margin	10.5
(OD03126)		A209073
Lung Margin (OD03126)	12.6	Normal Liver	4.3
Lung Cancer (OD04404)	15.5	Liver Cancer 064003	0.0
Lung Margin (OD04404)	7.6	Liver Cancer 1025	1.9
Lung Cancer (OD04565)	1.8	Liver Cancer 1026	1.9
Lung Margin (OD04565)	22.5	Liver Cancer 6004-T	4.9
Lung Cancer (OD04237-	100.0	Liver Tissue 6004-N	6.6
01)
Lung Margin (OD04237-	7.2	Liver Cancer 6005-T	14.7
02)
Ocular Mel Met to Liver	0.0	Liver Tissue 6005-N	5.3
(ODO4310)
Liver Margin (ODO4310)	3.6	Normal Bladder	34.2
Melanoma Mets to Lung	3.6	Bladder Cancer 1023	2.1
(OD04321)
Lung Margin (OD04321)	14.7	Bladder Cancer	23.5
		A302173
Normal Kidney	4.7	Bladder Cancer	17.1
		(OD04718-01)
Kidney Ca, Nuclear grade	19.9	Bladder Normal	4.1
2 (OD04338)		Adjacent (OD04718-
		03)
Kidney Margin	3.2	Normal Ovary	3.4
(OD04338)
Kidney Ca Nuclear grade	25.2	Ovarian Cancer	14.2
1/2 (OD04339)		064008
Kidney Margin	2.2	Ovarian Cancer	4.1
(OD04339)		(OD04768-07)
Kidney Ca, Clear cell type	6.1	Ovary Margin	8.2
(OD04340)		(OD04768-08)
Kidney Margin	0.0	Normal Stomach	29.3
(OD04340)
Kidney Ca, Nuclear grade	0.0	Gastric Cancer	9.9
3 (OD04348)		9060358
Kidney Margin	11.4	Stomach Margin	10.7
(OD04348)		9060359
Kidney Cancer	23.8	Gastric Cancer	16.4
(OD04622-01)		9060395
Kidney Margin	7.0	Stomach Margin	17.0
(OD04622-03)		9060394
Kidney Cancer	15.9	Gastric Cancer	5.1
(OD04450-01)		9060397
Kidney Margin	1.7	Stomach Margin	7.7
(OD04450-03)		9060396
Kidney Cancer 8120607	4.4	Gastric Cancer 064005	34.6

[0988]

TABLE WE
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3415, Run		Ag3415, Run
Tissue Name	166385451	Tissue Name	166385451
Secondary Th1 act	1.4	HUVEC IL-1 beta	1.5
Secondary Th2 act	0.4	HUVEC IFN gamma	1.7
Secondary Tr1 act	3.1	HUVEC TNF alpha + IFN	1.3
		gamma
Secondary Th1 rest	1.6	HUVEC TNF alpha + IL4	4.2
Secondary Th2 rest	0.8	HUVEC IL-11	1.6
Secondary Tr1 rest	0.5	Lung Microvascular EC	3.3
		none
Primary Th1 act	3.6	Lung Microvascular EC	4.7
		TNF alpha + IL-1 beta
Primary Th2 act	2.0	Microvascular Dermal EC	1.3
		none
Primary Tr1 act	0.9	Microvascular Dermal EC	1.1
		TNF alpha + IL-1 beta
Primary Th1 rest	3.9	Bronchial epithelium	0.0
		TNF alpha + IL-1 beta
Primary Th2 rest	1.5	Small airway epithelium	0.0
		none
Primary Tr1 rest	0.9	Small airway epithelium	0.2
		TNF alpha + IL-1 beta
CD45RA CD4	2.6	Coronery artery SMC rest	0.1
lymphocyte act
CD45RO CD4	8.5	Coronery artery SMC	0.0
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	17.1	Astrocytes rest	3.1
Secondary CD8	4.9	Astrocytes TNF alpha + IL-	0.5
lymphocyte rest		1 beta
Secondary CD8	5.9	KU-812 (Basophil) rest	1.2
lymphocyte act
CD4 lymphocyte none	2.1	KU-812 (Basophil)	4.3
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	1.9	CCD1106 (Keratinocytes)	2.2
CD95 CH11		none
LAK cells rest	7.9	CCD1106 (Keratinocytes)	0.8
		TNFa1pha + IL-1 beta
LAK cells IL-2	30.8	Liver cirrhosis	2.7
LAK cells IL-2 + IL-12	6.0	Lupus kidney	0.0
LAK cells IL-2 + IFN	7.4	NCI-H292 none	0.3
gamma
LAK cells IL-2 + IL-18	11.7	NCI-H292 IL-4	0.0
LAK cells	1.1	NCI-H292 IL-9	0.0
PMA/ionomycin
NK Cells IL-2 rest	19.8	NCI-H292 IL-13	0.0
Two Way MLR 3 day	9.5	NCI-H292 IFN gamma	0.7
Two Way MLR 5 day	4.1	HPAEC none	1.5
Two Way MLR 7 day	12.5	HPAEC TNF alpha + IL-1	0.5
		beta
PBMC rest	4.1	Lung fibroblast none	0.0
PBMC PWM	28.3	Lung fibroblast TNF	0.2
		alpha + IL-1 beta
PBMC PHA-L	10.8	Lung fibroblast IL-4	2.1
Ramos (B cell) none	34.6	Lung fibroblast IL-9	0.5
Ramos (B cell)	100.0	Lung fibroblast IL-13	0.8
ionomycin
B lymphocytes PWM	32.3	Lung fibroblast IFN	0.8
		gamma
B lymphocytes CD40L	7.0	Dermal fibroblast	0.7
and IL-4		CCD1070 rest
EOL-1 dbcAMP	0.0	Dermal fibroblast	28.7
		CCD1070 TNF alpha
EOL-1 dbcAMP	0.5	Dermal fibroblast	0.0
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	0.4	Dermal fibroblast IFN	0.0
		gamma
Dendritic cells LPS	0.2	Dermal fibroblast IL-4	0.3
Dendritic cells anti-	0.3	IBD Colitis 2	0.7
CD40
Monocytes rest	0.2	IBD Crohn's	0.0
Monocytes LPS	1.6	Colon	4.0
Macrophages rest	0.5	Lung	1.1
Macrophages LPS	0.2	Thymus	0.7
HUVEC none	2.1	Kidney	3.0
HUVEC starved	3.1

[0989] AI_comprehensive panel_v1.0 Summary: Ag3415 Results from one experiment with the CG59243-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[0990] CNS_neurodegeneration_v1.0 Summary: Ag3415 This panel confirms the expression of the CG59243-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's disease postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.3D for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[0991] Panel 1.3D Summary: Ag3415 Highest expression of the CG59243-01 gene is seen in a colon cancer cell line (CT=33.2), with significant expression also seen in a lung cancer cell line. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of colon or lung cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon or lung cancer.

[0992] In addition, this gene is expressed at low levels in fetal brain and cerebral cortex. Therefore, this gene may play a role in central nervous system development and CNS disorders such as Alzheimer's disease, Parkinson's disease, seizures, epilepsy, multiple sclerosis, schizophrenia and depression.

[0993] Panel 2D Summary: Ag3415 Highest expression of the CG59243-01 gene is seen in a lung cancer (CT=32.5), consistent with expression in Panel 1.3D. Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel. Please see Panel 1.3D for a discussion of the potential utility of this gene in treatment of cancer.

[0994] Panel 4D Summary: Ag3415 Highest expression of the CG59243-01 gene is seen in the B cell line Ramos, treated with ionomycin (CT=29.5). Low, but significant levels of expression of this transcript are also seen in activated B cells (B cells treated with PWM or CD40L+IL4). This transcript is also expressed in PBMC treated with the B cell mitogen, PWM, confirming the importance of this gene's expression in activated B cells. B cells represent a principle component of immunity and contribute to the immune response in a number of important functional roles, including antibody production. For example, production of antibodies against self-antigens is a major component in an autoimmune disorders such a systemic lupus erythematosus. Since B cells play an important role in autoimmunity, inflammatory processes and inflammatory cascades, therapeutic modulation of this gene product may reduce or eliminate the symptoms or patients suffering from asthma, allergies, chronic obstructive pulmonary disease, emphysema, Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, osteoarthritis, and other autoimmune disorders including systemic lupus erythematosus.

X. NOV30a (CG59534-01: MEMBRANE GLYCOPROTEIN)

[0995] Expression of gene CG59534-01 was assessed using the primer-probe sets Ag5041 and Ag5043, described in Tables XA and XB. Results of the RTQ-PCR runs are shown in Tables XC and XD.

TABLE XA
Probe Name Ag5041
			Start
Primers	Sequences	Length	Position
Forward	5′-ggtgttggtacctgtggattt-3′	(SEQ ID NO:305)	21	4154
Probe	TET-5′-tctatactgatgttttcgttttgccaa-3′-TAMRA	(SEQ ID NO:306)	27	4176
Reverse	5′-cccaaggccaatgtaatactc-3′	(SEQ ID NO:307)	21	4209

[0996]

TABLE XB
Probe Name Ag5043
			Start
Primers	Sequences	Length	Position
Forward	5′-cacaagcaaaaggtcagaaca-3′	(SEQ ID NO:308)	21	4024
Probe	TET-5′-aaacactgcctttcctcctcctctta-3′-TAMRA	(SEQ ID NO:309)	26	4048
Reverse	5′-ggccacatttgcttttatcata-3′	(SEQ ID NO:310)	22	4077

[0997]

TABLE XC
General_screening_panel_v1.5
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag5041, Run	Ag5043, Run		Ag5041, Run	Ag5043, Run
Tissue Name	228967328	228969275	Tissue Name	228967328	228969275
Adipose	1.1	4.3	Renal ca. TK-10	2.4	10.3
Melanoma*	0.8	4.2	Bladder	3.7	15.2
Hs688(A).T
Melanoma*	1.1	2.7	Gastric ca. (liver	100.0	5.5
Hs688(B).T			met.) NCI-N87
Melanoma*	0.6	2.6	Gastric ca. KATO	13.8	77.9
M14			III
Melanoma*	2.4	7.7	Colon ca. SW-	1.4	4.0
LOXIMVI			948
Melanoma*	1.0	5.5	Colon ca. SW480	3.0	12.2
SK-MEL-5
Squamous cell	0.7	3.0	Colon ca.*	5.3	23.0
carcinoma			(SW480 met)
SCC-4			SW620
Testis Pool	2.1	5.9	Colon ca. HT29	1.3	5.5
Prostate ca.*	0.3	1.3	Colon ca. HCT-	0.9	4.0
(bone met)			116
PC-3
Prostate Pool	4.6	11.0	Colon ca. CaCo-2	5.4	25.7
Placenta	0.2	1.0	Colon cancer	2.2	9.3
			tissue
Uterus Pool	2.7	3.5	Colon ca.	0.7	2.2
			SW1116
Ovarian ca.	3.0	13.7	Colon ca. Colo-	1.3	3.6
OVCAR-3			205
Ovarian ca.	1.6	7.3	Colon ca. SW-48	1.3	3.5
SK-OV-3
Ovarian ca.	0.9	2.9	Colon Pool	3.4	0.6
OVCAR-4
Ovarian ca.	10.7	65.5	Small Intestine	3.4	15.6
OVCAR-5			Pool
Ovarian ca.	11.8	71.7	Stomach Pool	3.6	11.7
IGROV-1
Ovarian ca.	5.0	25.3	Bone Marrow	2.4	5.2
OVCAR-8			Pool
Ovary	1.1	6.2	Fetal Heart	2.6	4.4
Breast ca.	3.6	20.0	Heart Pool	1.7	3.0
MCF-7
Breast ca.	2.3	9.7	Lymph Node	6.9	24.1
MDA-MB-			Pool
231
Breast ca. BT	0.8	2.0	Fetal Skeletal	2.1	10.3
549			Muscle
Breast ca.	10.3	24.8	Skeletal Muscle	8.3	28.3
T47D			Pool
Breast ca.	1.6	6.0	Spleen Pool	0.8	2.1
MDA-N
Breast Pool	4.3	22.8	Thymus Pool	3.5	12.5
Trachea	2.5	11.3	CNS cancer	7.4	36.1
			(glio/astro) U87-
			MG
Lung	1.9	8.2	CNS cancer	17.0	100.0
			(glio/astro) U-
			118-MG
Fetal Lung	5.6	29.1	CNS cancer	1.2	5.1
			(neuro;met) SK-
			N-AS
Lung ca. NCI-	0.8	3.8	CNS cancer	3.3	13.5
N417			(astro) SF-539
Lung ca. LX-1	2.8	11.1	CNS cancer	7.1	34.4
			(astro) SNB-75
Lung ca. NCI-	0.6	2.8	CNS cancer (glio)	14.0	80.1
H146			SNB-19
Lung ca. SHP-	3.6	20.9	CNS cancer (glio)	2.9	11.9
77			SF-295
Lung ca. A549	1.1	2.8	Brain (Amygdala)	2.7	10.6
			Pool
Lung ca. NCI-	0.6	2.4	Brain	7.8	50.0
H526			(cerebellum)
Lung ca. NCI-	1.6	5.6	Brain (fetal)	2.8	16.8
H23
Lung ca. NCI-	1.2	2.8	Brain	4.9	20.2
H460			(Hippocampus)
			Pool
Lung ca.	1.2	4.3	Cerebral Cortex	5.0	18.8
HOP-62			Pool
Lung ca. NCI-	0.4	1.3	Brain (Substantia	3.0	11.0
H522			nigra) Pool
Liver	0.1	0.4	Brain (Thalamus)	6.5	24.1
			Pool
Fetal Liver	0.7	3.1	Brain (whole)	2.4	11.3
Liver ca.	2.8	12.1	Spinal Cord Pool	4.2	14.1
HepG2
Kidney Pool	5.0	21.6	Adrenal Gland	0.6	2.2
Fetal Kidney	1.5	4.8	Pituitary gland	1.5	5.1
			Pool
Renal ca. 786-0	0.4	1.9	Salivary Gland	0.7	2.1
Renal ca.	0.3	0.8	Thyroid (female)	0.9	3.3
A498
Renal ca.	0.4	1.8	Pancreatic ca.	0.5	1.5
ACHN			CAPAN2
Renal ca. UO-	1.8	8.5	Pancreas Pool	5.8	28.9
31

[0998]

TABLE XD
Panel 4.1D
	Rel.	Rel.		Rel.	Rel.
	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)
	Ag5041,	Ag5043,		Ag5041,	Ag5043,
	Run	Run		Run	Run
Tissue Name	223784808	223785123	Tissue Name	223784808	223785123
Secondary Th1 act	37.4	15.3	HUVEC IL-1 beta	37.6	28.5
Secondary Th2 act	25.3	9.6	HUVEC IFN	31.6	9.0
			gamma
Secondary Tr1 act	33.0	14.1	HUVEC TNF	19.6	10.2
			alpha + IFN
			gamma
Secondary Th1 rest	14.7	8.2	HUVEC TNF	29.3	19.2
			alpha + IL4
Secondary Th2 rest	13.5	10.5	HUVEC IL-11	13.5	7.5
Secondary Tr1 rest	10.8	8.1	Lung	28.5	11.7
			Microvascular EC
			none
Primary Th1 act	33.7	20.2	Lung	28.7	16.7
			Microvascular EC
			TNF alpha + IL-
			1 beta
Primary Th2 act	47.6	19.3	Microvascular	9.6	6.2
			Dermal EC none
Primary Tr1 act	32.5	19.2	Microsvasular	23.8	11.4
			Dermal EC
			TNF alpha + IL-
			1 beta
Primary Th1 rest	15.9	5.2	Bronchial	11.4	5.6
			epithelium
			TNF alpha +
			IL1 beta
Primary Th2 rest	13.0	6.6	Small airway	3.6	2.3
			epithelium none
Primary Tr1 rest	17.7	11.0	Small airway	4.1	3.7
			epithelium
			TNF alpha + IL-
			1 beta
CD45RA CD4	40.1	11.0	Coronery artery	12.8	6.0
lymphocyte act			SMC rest
CD45RO CD4	30.6	15.4	Coronery artery	22.4	11.0
lymphocyte act			SMC TNF alpha +
			IL-1 beta
CD8 lymphocyte	28.9	16.3	Astrocytes rest	17.4	8.3
act
Secondary CD8	29.3	17.6	Astrocytes	37.1	38.7
lymphocyte rest			TNF alpha + IL-
			1 beta
Secondary CD8	18.7	9.9	KU-812 (Basophil)	9.0	4.5
lymphocyte act			rest
CD4 lymphocyte	33.0	12.3	KU-812 (Basophil)	9.5	6.6
none			PMA/ionomycin
2ry	33.7	13.8	CCD1106	16.7	10.6
Th1/Th2/Tr1_anti-			(Keratinocytes)
CD95 CH11			none
LAK cells rest	24.7	10.1	CCD1106	7.4	4.0
			(Keratinocytes)
			TNF alpha + IL-
			1 beta
LAK cells IL-2	26.1	8.4	Liver cirrhosis	10.4	3.9
LAK cells IL-2 +	28.1	11.3	NCI-H292 none	8.1	4.9
IL-12
LAK cells IL-	28.9	14.6	NCI-H292 IL-4	6.7	4.0
2 + IFN gamma
LAK cells IL-2 +	30.4	14.9	NCI-H292 IL-9	7.2	4.0
IL-18
LAK cells	36.6	21.9	NCI-H292 IL-13	10.6	4.7
PMA/ionomycin
NK Cells IL-2 rest	28.7	17.8	NCI-H292 IFN	7.1	2.1
			gamma
Two Way MLR 3	26.4	10.5	HPAEC none	21.9	11.6
day
Two Way MLR 5	22.5	9.2	HPAEC TNF	81.2	37.1
day			alpha + IL-1 beta
Two Way MLR 7	16.0	15.8	Lung fibroblast	46.3	24.3
day			none
PBMC rest	11.2	5.6	Lung fibroblast	73.7	29.5
			TNF alpha + IL-1
			beta
PBMC PWM	31.6	14.0	Lung fibroblast IL-4	49.0	22.1
PBMC PHA-L	20.2	9.8	Lung fibroblast IL-9	39.5	100.0
Ramos (B cell)	78.5	49.7	Lung fibroblast IL-	54.7	28.1
none			13
Ramos (B cell)	100.0	53.6	Lung fibroblast	55.5	36.1
ionomycin			IFN gamma
B lymphocytes	20.6	6.8	Dermal fibroblast	15.3	8.6
PWM			CCD1070 rest
B lymphocytes	22.1	8.7	Dermal fibroblast	33.4	25.5
CD40L and IL-4			CCD1070 TNF
			alpha
EOL-1 dbcAMP	3.8	1.3	Dermal fibroblast	57.4	27.4
			CCD1070 IL-1
			beta
EOL-1 dbcAMP	3.2	1.1	Dermal fibroblast	25.9	14.3
PMA/ionomycin			IFN gamma
Dendritic cells none	4.5	1.9	Dermal fibroblast	29.3	9.0
			IL-4
Dendritic cells LPS	5.5	2.8	Dermal Fibroblasts	10.4	4.9
			rest
Dendritic cells anti-	3.3	1.7	Neutrophils	3.5	1.2
CD40			TNFa + LPS
Monocytes rest	6.3	3.5	Neutrophils rest	3.8	2.2
Monocytes LPS	6.4	4.3	Colon	12.2	8.5
Macrophages rest	4.8	2.8	Lung	11.2	8.2
Macrophages LPS	1.1	0.9	Thymus	14.6	8.4
HUVEC none	15.9	9.2	Kidney	33.4	25.5
HUVEC starved	28.5	19.1

[0999] General_screening_panel_v1.5 Summary: Ag5041 l/Ag5043 Two experiments with two different probe and primer sets show highest expression of the CG59534-01 gene, a putative membrane glycoprotein, in cell lines derived from brain cancer and gastric cancer (CTs=24-29). Significant expression of this gene is also seen in cell lines derived from brain cancer, ovarian cancer, and gastric cancer. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of colon, ovarian, and brain cancers.

[1000] Among tissues with metabolic function, this gene is expressed at moderate to low levels in pituitary, adipose, adrenal gland, pancreas, thyroid, and adult and fetal skeletal muscle, heart, and liver. This widespread expression among these tissues suggests that this gene product may play a role in normal neuroendocrine and metabolic and that disregulated expression of this gene may contribute to neuroendocrine disorders or metabolic diseases, such as obesity and diabetes.

[1001] In addition, this molecule novel membrane glycoprotein is expressed at moderate to low levels in the CNS and may be a small molecule target for the treatment of neurologic diseases such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1002] Panel 4.1D Summary: Ag5041/Ag5043 Two experiments with two different probe and primer sets show highest expression of the CG59534-01 gene, a putative membrane glycoprotein, in IL-9 treated fibroblasts and the B cell line Ramos treated with ionomycin (CTs=29-30). This gene is also gene is expressed at moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

Y. NOV31a and NOV31b (CG59289-01 and CG59289-02: CRUMBS LIKE)

[1003] Expression of gene CG59289-01 and CG59289-02 was assessed using the primer-probe sets Ag3530 and Ag1932, described in Tables YA and YB. Results of the RTQ-PCR runs are shown in Tables YC, and YD.

TABLE YA
Probe Name Ag3530
			Start
Primers	Sequences	Length	Position
Forward	5′-gtgctgggatttcacagtacac-3′	(SEQ ID NO:311)	22	123
Probe	TET-5′-tgctacttgcctaggcaaagtcacgt-3′-TAMRA	(SEQ ID NO:312)	26	147
Reverse	5′-ccagtctgtcctcgttttgtag-3′	(SEQ ID NO: 313)	22	186

[1004]

TABLE YB
Probe Name Ag1932
			Start
Primers	Sequences	Length	Position
Forward	5′-gagtctggggtccacagttac-3′	(SEQ ID NO:314)	21	1588
Probe	TET-5′-acctggtacccatggaccgttctgt-3′-TAMRA	(SEQ ID NO:315)	25	1623
Reverse	5′-ccatcacagagaaggtggtatt-3′	(SEQ ID NO:316)	22	1654

[1005]

TABLE YC
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3530,		Rel. Exp.(%) Ag3530,
Tissue Name	Run 210631247	Tissue Name	Run 210631247
AD 1 Hippo	23.7	Control (Path) 3	6.3
		Temporal Ctx
AD 2 Hippo	52.1	Control (Path) 4	53.2
		Temporal Ctx
AD 3 Hippo	10.2	AD 1 Occipital Ctx	25.3
AD 4 Hippo	24.7	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	46.0	AD 3 Occipital Ctx	10.2
AD 6 Hippo	51.8	AD 4 Occipital Ctx	12.4
Control 2 Hippo	23.2	AD 5 Occipital Ctx	2.4
Control 4 Hippo	25.9	AD 6 Occipital Ctx	18.3
Control (Path) 3	8.5	Control 1 Occipital	8.7
Hippo		Ctx
AD 1 Temporal Ctx	13.8	Control 2 Occipital	31.2
		Ctx
AD 2 Temporal Ctx	20.7	Control 3 Occipital	14.5
		Ctx
AD 3 Temporal Ctx	14.4	Control 4 Occipital	18.9
		Ctx
AD 4 Temporal Ctx	37.6	Control (Path) 1	100.0
		Occipital Ctx
AD 5 Inf Temporal	63.3	Control (Path) 2	24.7
Ctx		Occipital Ctx
AD 5 Sup Temporal	72.2	Control (Path) 3	7.2
Ctx		Occipital Ctx
AD 6 Inf Temporal	48.3	Control (Path) 4	20.3
Ctx		Occipital Ctx
AD 6 Sup Temporal	61.6	Control 1 Parietal	24.5
Ctx		Ctx
Control 1 Temporal	7.8	Control 2 Parietal	70.2
Ctx		Ctx
Control 2 Temporal	19.9	Control 3 Parietal	23.0
Ctx		Ctx
Control 3 Temporal	9.0	Control (Path) 1	79.6
Ctx		Parietal Ctx
Control 4 Temporal	6.4	Control (Path) 2	37.6
Ctx		Parietal Ctx
Control (Path) 1	39.8	Control (Path) 3	0.0
Temporal Ctx		Parietal Ctx
Control (Path) 2	35.1	Control (Path) 4	37.1
Temporal Ctx		Parietal Ctx

[1006]

TABLE YD
Panel 4D
	Rel.	Rel.		Rel.	Rel.
	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)
	Ag1932,	Ag3530,		Ag1932,	Ag3530,
	Run	Run		Run	Run
Tissue Name	161561619	166446356	Tissue Name	161561619	166446356
Secondary Th1 act	0.0	0.0	HUVEC IL-1 beta	0.0	0.0
Secondary Th2 act	0.0	0.0	HUVEC IFN	0.0	0.0
			gamma
Secondary Tr1 act	0.0	0.0	HUVEC TNF	0.0	0.0
			alpha + IFN
			gamma
Secondary Th1 rest	0.0	0.0	HUVEC TNF	0.0	0.0
			alpha + IL4
Secondary Th2 rest	0.0	0.0	HUVEC IL-11	0.0	0.0
Secondary Tr1 rest	0.0	0.0	Lung	0.0	0.0
			Microvascular EC
			none
Primary Th1 act	1.7	0.0	Lung	0.0	0.0
			Microvascular EC
			TNF alpha + IL-
			1 beta
Primary Th2 act	0.0	1.3	Microvascular	0.0	0.0
			Dermal EC none
Primary Tr1 act	0.0	0.0	Microsvasular	0.0	0.0
			Dermal EC
			TNF alpha + IL-
			1 beta
Primary Th1 rest	0.0	0.0	Bronchial	0.0	0.0
			epithelium
			TNF alpha +
			IL1 beta
Primary Th2 rest	2.9	0.0	Small airway	2.3	0.0
			epithelium none
Primary Tr1 rest	3.0	2.0	Small airway	0.0	0.0
			epithelium
			TNF alpha + IL-
			1 beta
CD45RA CD4	1.5	3.5	Coronery artery	62.9	0.0
lymphocyte act			SMC rest
CD45RO CD4	0.0	0.0	Coronery artery	0.0	0.0
lymphocyte act			SMC TNF alpha +
			IL-1 beta
CD8 lymphocyte	0.0	0.0	Astrocytes rest	12.9	1.2
act
Secondary CD8	0.0	0.0	Astrocytes	4.3	6.1
lymphocyte rest			TNF alpha + IL-	4.3	6.1
			1 beta
Secondary CD8	1.7	0.0	KU-812 (Basophil)	36.9	7.2
lymphocyte act			rest
CD4 lymphocyte	8.9	2.4	KU-812 (Basophil)	23.0	14.2
none			PMA/ionomycin
2ry	0.0	1.0	CCD1106	0.0	0.0
Th1/Th2/Tr1_anti-			(Keratinocytes)
CD95 CH11			none
LAK cells rest	1.7	2.6	CCD1106	0.0	0.0
			(Keratinocytes)
			TNF alpha + IL-
			1 beta
LAK cells IL-2	0.0	0.0	Liver cirrhosis	8.5	35.6
LAK cells IL-2 +	2.1	0.8	Lupus kidney	4.3	4.0
IL-12
LAK cells IL-	0.0	1.5	NCI-H292 none	0.0	0.0
2 + IFN gamma
LAK cells IL-2 +	0.7	5.7	NCI-H292 IL-4	6.4	0.0
IL-18
LAK cells	0.0	0.0	NCI-H292 IL-9	0.0	0.0
PMA/ionomycin
NK Cells IL-2 rest	0.0	0.0	NCI-H292 IL-13	0.0	0.0
Two Way MLR 3	5.8	8.0	NCI-H292 IFN	11.7	0.0
day			gamma
Two Way MLR 5	1.7	0.0	HPAEC none	0.0	0.0
day
Two Way MLR 7	0.0	0.0	HPAEC TNF	0.0	0.0
day			alpha + IL-1 beta
PBMC rest	19.5	4.5	Lung fibroblast	0.0	0.0
			none
PBMC PWM	0.5	0.0	Lung fibroblast	0.0	0.0
			TNF alpha + IL-1
			beta
PBMC PHA-L	0.0	2.8	Lung fibroblast IL-4	0.0	0.0
Ramos (B cell)	4.0	50.3	Lung fibroblast IL-9	0.0	0.0
none
Ramos (B cell)	16.2	9.6	Lung fibroblast IL-	0.0	0.0
ionomycin			13
B lymphocytes	4.7	7.0	Lung fibroblast	0.0	1.2
PWM			IFN gamma
B lymphocytes	26.6	90.1	Dermal fibroblast	0.0	0.0
CD40L and IL-4			CCD1070 rest
EOL-1 dbcAMP	0.0	0.6	Dermal fibroblast	6.6	2.4
			CCD1070 TNF
			alpha
EOL-1 dbcAMP	3.2	0.0	Dermal fibroblast	0.0	0.0
PMA/ionomycin			CCD1070 IL-1
			beta
Dendritic cells none	69.3	50.0	Dermal fibroblast	0.0	0.0
			IFN gamma
Dendritic cells LPS	4.8	10.0	Dermal fibroblast	2.4	0.0
			IL-4
Dendritic cells anti-	95.9	99.3	IBD Colitis 2	0.0	2.8
CD40
Monocytes rest	20.6	7.9	IBD Crohn's	0.0	0.0
Monocytes LPS	4.4	0.0	Colon	39.5	100.0
Macrophages rest	0.0	0.0	Lung	13.1	12.0
Macrophages LPS	0.0	0.0	Thymus	100.0	8.9
HUVEC none	0.0	0.0	Kidney	8.4	5.5
HUVEC starved	0.0	0.0

[1007] CNS_neurodegeneration_v1.0 Summary: Ag3530 This panel confirms the expression of CG59289-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment.

[1008] The CG59289-01 gene codes for Drosophila CRUMB1 (CRB1) homologue, a protein essential for establishing and maintaining epithelial polarity. In mouse, Crb1 was shown to be expressed exclusively in the eye, and the central nervous system (Ref. 1). Therefore, similar to the mouse orthologue, the CG59289-01 gene may be expressed in eye and central nervous system and may play a role in retinal and central nervous system disorders such as retinal dystrophies, Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1009] Reference.

[1010] 1. den Hollander A I, Ghiani M, de Kok Y J, Wijnholds J, Ballabio A, Cremers F P, Broccoli V. (2002) Isolation of Crb1, a mouse homologue of Drosophila crumbs, and analysis of its expression pattern in eye and brain. Mech Dev 110(1-2):203-7

[1011] General_screening_panel_v1.4 Summary: Ag3530 Results from one experiment with the CG59289-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[1012] Panel 4D Summary: Ag3530 Highest expression of the CG59289-01 gene is seen in normal colon (CT=31). Therefore, expression of this gene may be used to distinguish colon from the other tissues on this panel. Furthermore, expression of this gene is decreased in colon samples from patients with IBD colitis and Crohn's disease relative to normal colon. Therefore, therapeutic modulation of the activity of the protein encoded by this gene may be useful in the treatment of inflammatory bowel disease.

[1013] Significant expression is also seen in dendritic cells (DC) and is upregulated in response to CD40. In addition, expression in colon may also result from dendritic cells present in these tissue. Therefore, therapeutic utilization of the protein encoded by this transcript may be important in the treatment of diseases where antigen presentation, a function of mature dendritic cells, plays an important role such as asthma, rheumatoid arthritis, IBD, and psoriasis.

[1014] Results from a second experiment with the probe primer set Ag1932 are not included. The amp plot indicates that there were experimental difficulties with this run.

Z. NOV32a (CG57111-01: PROTOCADHERIN)

[1015] Expression of gene CG57111-01 was assessed using the primer-probe sets Ag3242, Ag1012, Ag1096 and Ag704, described in Tables ZA, ZB, ZC and ZD. Results of the RTQ-PCR runs are shown in Tables ZE, ZF, ZG, ZH, ZI, ZJ, and ZK.

TABLE ZA
Probe Name Ag3242
			Start
Primers	Sequences	Length	Position
Forward	5′-gggaccaatgctcaaattactt-3′	(SEQ ID NO:317)	22	1038
Probe	TET-5′-tcagaaagttccacaagcatctaagga-3′-TAMRA	(SEQ ID NO:318)	27	1070
Reverse	5′-atgactccagtgttttcatcca-3′	(SEQ ID NO:319)	22	1108

[1016]

TABLE ZB
Probe Name Ag1012
			Start
Primers	Sequences	Length	Position
Forward	5′-catcatcatagctgaggatggt-3′	(SEQ ID NO:320)	22	0
Probe	TET-5′-acttttgggcagtgcactctcaccat-3′-TAMRA	(SEQ ID NO:321)	26	0
Reverse	5′-agggcaattgtcattaatgtca-3′	(SEQ ID NO:322)	22	923

[1017]

TABLE ZC
Probe Name Ag1096
			Start
Primers	Sequences	Length	Position
Forward	5′-actttggaagaggcattgct-3′	(SEQ ID NO:323)	20	2403
Probe	TET-5′-cagacagattatgggctccatcgctt3′-TAMRA	(SEQ ID NO:324)	26	2424
Reverse	5′-ctcgggataaccatgatcact-3′	(SEQ ID NO:325)	21	2463

[1018]

TABLE ZD
Probe Name Ag704
			Start
Primers	Sequences	Length	Position
Forward	5′-agacttggggaccaatgct-3′	(SEQ ID NO:326)	19	1031
Probe	TET-5′-tcagaaagttccacaagcatctaagga-3′-TAMRA	(SEQ ID NO:327)	27	1070	271	1070
Reverse	5′-tgactccagtgtttcatcca-3′	(SEQ ID NO:328)	21	1108

[1019]

TABLE ZE
AI_comprehensive panel_v1.0
	Rel. Exp.(%) Ag3242,		Rel. Exp.(%) Ag3242,
Tissue Name	Run 253058919	Tissue Name	Run 253058919
110967 COPD-F	28.9	112427 Match Control	55.9
		Psoriasis-F
110980 COPD-F	6.7	112418 Psoriasis-M	25.7
110968 COPD-M	19.9	112723 Match Control	0.0
		Psoriasis-M
110977 COPD-M	8.4	112419 Psoriasis-M	66.0
110989 Emphysema-F	49.3	112424 Match Control	42.0
		Psoriasis-M
110992 Emphysema-F	22.8	112420 Psoriasis-M	44.4
110993 Emphysema-F	31.0	112425 Match Control	24.3
		Psoriasis-M
110994 Emphysema-F	12.7	104689 (MF) OA Bone-	81.2
		Backus
110995 Emphysema-F	25.5	104690 (MF) Adj	16.6
		“Normal” Bone-Backus
110996 Emphysema-F	15.8	104691 (MF) OA	1.5
		Synovium-Backus
110997 Asthma-M	7.5	104692 (BA) OA	7.4
		Cartilage-Backus
111001 Asthma-F	30.4	104694 (BA) OA Bone-	56.3
		Backus
111002 Asthma-F	45.4	104695 (BA) Adj	31.6
		“Normal” Bone-Backus
111003 Atopic	45.1	104696 (BA) OA	0.0
Asthma-F		Synovium-Backus
111004 Atopic	22.4	104700 (SS) OA Bone-	63.7
Asthma-F		Backus
111005 Atopic	25.3	104701 (SS) Adj	63.3
Asthma-F		“Normal” Bone-Backus
111006 Atopic	13.9	104702 (SS) OA	6.1
Asthma-F		Synovium-Backus
111417 Allergy-M	15.1	117093 OA Cartilage	16.3
		Rep7
112347 Allergy-M	5.0	112672 OA Bone5	13.2
112349 Normal	1.9	112673 OA Synovium5	5.4
Lung-F
112357 Normal	5.1	112674 OA Synovial	7.7
Lung-F		Fluid cells5
112354 Normal	11.6	117100 OA Cartilage	4.5
Lung-M		Rep14
112374 Crohns-F	32.5	112756 OA Bone9	17.1
112389 Match Control	14.4	112757 OA Synovium9	21.8
Crohns-F
112375 Crohns-F	36.1	112758 OA Synovial	13.3
		Fluid Cells9
112732 Match Control	0.0	117125 RA Cartilage	28.1
Crohns-F		Rep2
112725 Crohns-M	45.4	113492 Bone2 RA	34.2
112387 Match Control	18.3	113493 Synovium2 RA	8.9
Crohns-M
112378 Crohns-M	3.8	113494 Syn Fluid Cells	25.7
		RA
112390 Match Control	22.4	113499 Cartilage4 RA	45.1
Crohns-M
112726 Crohns-M	45.7	113500 Bone4 RA	47.3
112731 Match Control	12.6	113501 Synovium4 RA	42.6
Crohns-M
112380 Ulcer Col-F	28.3	113502 Syn Fluid	25.5
		Cells4 RA
112734 Match Control	0.8	113495 Cartilage3 RA	33.7
Ulcer Col-F
112384 Ulcer Col-F	100.0	113496 Bone3 RA	38.7
112737 Match Control	28.1	113497 Synovium3 RA	18.2
Ulcer Col-F
112386 Ulcer Col-F	25.5	113498 Syn Fluid	30.8
		Cells3 RA
112738 Match Control	2.1	117106 Normal	0.0
Ulcer Col-F		Cartilage Rep20
112381 Ulcer Col-M	2.3	113663 Bone3 Normal	2.8
112735 Match Control	53.6	113664 Synovium3	0.0
Ulcer Col-M		Normal
112382 Ulcer Col-M	15.3	113665 Syn Fluid	2.9
		Cells3 Normal
112394 Match Control	10.2	117107 Normal	10.5
Ulcer Col-M		Cartilage Rep22
112383 Ulcer Col-M	45.4	113667 Bone4 Normal	17.2
112736 Match Control	4.0	113668 Synovium4	17.0
Ulcer Col-M		Normal
112423 Psoriasis-F	90.1	113669 Syn Fluid	36.3
		Cells4 Normal

[1020]

TABLE ZF
CNS_neurodegeneration_v1.0
	Rel.	Rel.	Rel.		Rel.	Rel.	Rel.
	Exp.(%)	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)	Exp.(%)
	Ag1012,	Ag1096,	Ag3242,		Ag1012,	Ag1096,	Ag3242,
	Run	Run	Run	Tissue	Run	Run	Run
Tissue Name	206989720	206231465	206533581	Name	206989720	206231465	206533581
AD 1 Hippo	34.6	27.0	16.5	Control	1.0	0.9	1.4
				(Path) 3
				Temporal
				Ctx
AD 2 Hippo	18.6	11.5	16.8	Control	11.2	11.8	4.9
				(Path) 4
				Temporal
				Ctx
AD 3 Hippo	6.0	8.8	5.3	AD 1	5.0	6.2	2.9
				Occipital
				Ctx
AD 4 Hippo	2.6	2.0	1.9	AD 2	0.0	0.0	0.0
				Occipital
				Ctx
				(Missing)
AD 5 hippo	44.8	46.7	36.6	AD 3	4.1	5.6	2.8
				Occipital
				Ctx
AD 6 Hippo	100.0	100.0	100.0	AD 4	3.8	6.3	4.1
				Occipital
				Ctx
Control 2	46.3	51.1	35.1	AD 5	5.7	25.0	16.8
Hippo				Occipital
				Ctx
Control 4	5.6	5.3	4.0	AD 6	24.3	5.3	1.0
Hippo				Occipital
				Ctx
Control	4.0	4.6	1.0	Control 1	0.2	0.8	0.3
(Path) 3				Occipital
Hippo				Ctx
AD 1	4.7	3.6	2.7	Control 2	22.1	17.1	19.5
Temporal				Occipital
Ctx				Ctx
AD 2	13.3	12.5	7.5	Control 3	3.9	3.1	3.5
Temporal				Occipital
Ctx				Ctx
AD 3	0.9	2.5	1.0	Control 4	1.0	1.4	0.8
Temporal				Occipital
Ctx				Ctx
AD 4	5.4	6.3	3.3	Control	36.9	34.6	30.1
Temporal				(Path) 1
Ctx				Occipital
				Ctx
AD 5 Inf	80.7	74.7	59.5	Control	2.5	2.2	0.6
Temporal				(Path) 2
Ctx				Occipital
				Ctx
AD 5	74.2	66.0	61.6	Control	1.0	0.7	0.4
SupTemporal				(Path) 3
Ctx				Occipital
				Ctx
AD 6 Inf	12.1	12.2	12.2	Control	2.1	3.2	1.4
Temporal				(Path) 4
Ctx				Occipital
				Ctx
AD 6 Sup	13.6	14.7	12.3	Control 1	1.3	1.3	1.4
Temporal				Parietal
Ctx				Ctx
Control 1	1.6	1.9	2.2	Control 2	20.3	21.8	19.6
Temporal				Parietal
Ctx				Ctx
Control 2	27.4	21.8	22.2	Control 3	5.9	5.9	5.7
Temporal				Parietal
Ctx				Ctx
Control 3	4.8	5.9	4.6	Control	40.3	38.7	38.7
Temporal				(Path) 1
Ctx				Parietal
				Ctx
Control 4	1.3	1.7	0.9	Control	8.4	9.5	4.3
Temporal				(Path) 2
Ctx				Parietal
				Ctx
Control	35.1	33.9	28.7	Control	1.4	1.4	0.5
(Path) 1				(Path) 3
Temporal				Parietal
Ctx				Ctx
Control	15.1	17.3	12.3	Control	15.0	16.8	15.5
(Path) 2				(Path) 4
Temporal				Parietal
Ctx				Ctx

[1021]

TABLE ZG
Panel 1.2
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag1096,	Ag1096,		Ag1096,	Ag1096,
	Run	Run		Run	Run
Tissue Name	125094875	134204525	Tissue Name	125094875	134204525
Endothelial cells	0.0	0.0	Renal ca. 786-0	0.0	0.0
Heart (Fetal)	4.5	5.6	Renal ca. A498	0.0	0.0
Pancreas	0.2	0.3	Renal ca. RXF	0.1	0.1
			393
Pancreatic ca.	0.0	0.0	Renal ca.	31.4	80.1
CAPAN 2			ACHN
Adrenal Gland	1.6	2.8	Renal ca. UO-	0.0	0.0
			31
Thyroid	0.1	0.4	Renal ca. TK-	1.0	1.3
			10
Salivary gland	3.0	4.8	Liver	1.9	5.3
Pituitary gland	2.7	6.7	Liver (fetal)	0.8	1.7
Brain (fetal)	2.1	7.9	Liver ca.	0.0	0.0
			(hepatoblast)
			HepG2
Brain (whole)	9.9	39.8	Lung	1.7	5.9
(amugdala)	15.0	34.2	Lung (fetal)	1.8	9.9
Brain	0.8	1.9	Lung ca. (small	0.4	1.2
(cerebellum)			cell) LX-1
Brain	39.0	73.2	Lung ca. (small	0.2	0.5
(hippocampus)			cell) NCI-H69
Brain (thalamus)	2.5	9.2	Lung ca. (s.cell	2.3	2.6
			var.) SHP-77
Cerebral Cortex	27.0	56.3	Lung ca. (large	50.7	100.0
			cell) NCI-H460
Spinal cord	2.2	4.8	Lung ca. (non-	0.1	0.0
			sin. cell) A549
glio/astro U87-	0.1	0.2	Lung ca. (non-	5.4	4.0
MG			s.cell) NCI-
			H23
glio/astro U-118-	0.1	0.2	Lung ca. (non-	15.3	33.2
MG			s.cell) HOP-62
astrocytoma	0.0	0.0	Lung ca. (non-	0.0	0.0
SW1783			s.cl) NCI-H522
neuro*; met SK-	6.9	7.3	Lung ca.	5.4	12.5
N-AS			(squam.) SW
			900
astrocytoma SF-	0.0	0.0	Lung ca.	0.0	0.1
539			(squam.) NCI-
			H596
astrocytoma	7.0	6.8	Mammary	0.6	2.7
SNB-75			gland
glioma SNB-19	2.4	2.2	Breast ca.*	0.0	0.0
			(pl.ef) MCF-7
glioma U251	5.5	11.6	Breast ca.*	0.0	0.0
			(pl.ef) MDA-
			MB-231
glioma SF-295	0.0	0.0	Breast ca.* (pl.	0.9	1.1
			ef) T47D
Heart	13.2	15.5	Breast ca. BT-	0.7	0.7
			549
Skeletal Muscle	1.1	1.2	Breast ca.	0.0	0.0
			MDA-N
Bone marrow	0.0	0.1	Ovary	0.6	0.4
Thymus	0.5	1.7	Ovarian ca.	0.5	0.3
			OVCAR-3
Spleen	0.4	0.8	Ovarian ca.	0.5	0.3
			OVCAR-4
Lymph node	0.2	0.2	Ovarian ca.	15.4	15.2
			OVCAR-5
Colorectal	4.3	8.1	Ovarian ca.	0.4	1.2
Tissue			OVCAR-8
Stomach	3.9	8.8	Ovarian ca.	0.1	0.0
			IGROV-1
Small intestine	1.9	3.7	Ovarian ca.	1.9	1.3
			(ascites) SK-
			OV-3
Colon ca.*	0.0	0.1	Uterus	2.2	10.6
SW480
Colon ca.*	0.1	0.2	Placenta	8.2	10.1
SW620 (SW480
met)
Colon ca. HT29	0.0	0.1	Prostate	3.4	3.5
Colon ca. HCT-	0.0	0.0	Prostate	2.6	3.5
116			(bone met)
			PC-3
Colon ca. CaCo-2	0.0	0.0	Testis	1.3	2.1
Colon ca. Tissue	0.3	1.1	Melanoma	0.0	0.0
(ODO3866)			Hs688(A).T
Colon ca. HCC-	2.9	4.3	Melanoma*	0.0	0.1
2998			(met)
			Hs688(B).T
Gastric ca.*	0.0	0.0	Melanoma	0.0	0.0
(liver met) NCI-			UACC-62
N87
Bladder	0.4	0.7	Melanoma	0.5	0.1
			M14
Trachea	3.6	16.5	Melanoma	0.1	0.0
			LOX IMVI
Kidney	13.2	2.7	Melanoma*	100.0	86.5
			(met) SK-
			MEL-5
Kidney (fetal)	7.2	10.3

[1022]

TABLE ZH
Panel 1.3D
	Rel.	Rel.	Rel.		Rel.	Rel.	Rel.
	Exp.(%)	Exp.(%)	Exp.(%)		Exp.(%)	Exp.(%)	Exp.(%)
	Ag1012,	Ag1012,	Ag3242,		Ag1012,	Ag1012,	Ag3242,
	Run	Run	Run	Tissue	Run	Run	Run
Tissue Name	157255773	165486783	165524415	Name	157255773	165486783	165524415
Liver	0.0	0.0	0.0	Kidney	3.1	3.0	2.7
adenocarcinoma				(fetal)
Pancreas	0.1	0.7	1.0	Renal ca.	0.0	0.0	0.0
				786-0
Pancreatic ca.	0.0	0.0	0.0	Renal ca.	0.5	1.3	0.0
CAPAN 2				A498
Adrenal gland	0.8	0.9	0.3	Renal ca.	0.3	1.2	0.4
				RXF 393
Thyroid	0.2	0.0	0.0	Renal ca.	44.8	95.9	100.0
				ACHN
Salivary gland	0.4	2.4	0.6	Renal ca.	0.0	2.5	0.0
				UO-31
Pituitary gland	2.6	3.9	4.8	Renal ca.	1.1	2.4	1.1
				TK-10
Brain (fetal)	6.3	11.7	11.8	Liver	0.2	1.6	1.0
Brain (whole)	11.4	37.9	40.6	Liver (fetal)	0.3	1.3	0.0
Brain (amygdala)	19.5	38.4	31.6	Liver ca.	0.0	0.0	0.0
				(hepatoblast)
				HepG2
Brain	0.3	3.1	3.0	Lung	4.2	3.9	4.8
(cerebellum)
Brain	100.0	78.5	76.3	Lung (fetal)	3.8	2.9	2.2
(hippocampus)
Brain (substantia	1.9	6.3	2.1	Lung ca.	0.9	0.7	3.7
nigra)				(small cell)
				LX-1
Brain (thalamus)	4.7	17.0	6.3	Lung ca.	0.4	1.3	0.0
				(small cell)
				NCI-H69
Cerebral Cortex	34.4	40.6	27.7	Lung ca.	16.7	17.3	16.0
				(s.cell var.)
				SHP-77
Spinal cord	1.9	4.2	7.7	Lung ca.	8.2	51.1	46.0
				(large
				cell) NCI-
				H460
glio/astro U87-	0.4	1.5	0.6	Lung ca.	0.0	0.0	0.0
MG				(non-sm.
				cell) A549
gilo/astro U-118-	0.3	0.0	0.5	Lung ca.	3.8	6.3	8.0
MG				(non-s.cell)
				NCI-H23
astrocytoma	0.0	0.0	0.0	Lung ca.	9.5	21.6	13.6
SW1783				(non-s.cell)
				HOP-62
neuro*; met SK-	27.4	11.9	7.5	Lung ca.	0.0	0.0	0.0
N-AS				(non-s.cl)
				NCI-H522
astrocytoma SF-	0.2	0.0	0.0	Lung ca.	8.0	19.8	18.8
539				(squam.)
				SW 900
astrocytoma	12.6	15.0	8.4	Lung ca.	0.0	0.6	0.0
SNB-75				(squam.)
				NCI-H596
glioma SNB-19	2.8	3.8	3.0	Mammary	0.9	0.8	1.4
				gland
glioma U251	14.0	100.0	66.4	Breast ca.*	0.0	0.0	0.0
				(pl.ef) MCF-7
glioma SF-295	0.0	0.0	0.6	Breast ca.*	0.0	0.0	0.0
				(pl.ef)
				MDA-MB-
				231
Heart (fetal)	8.3	4.9	3.7	Breast ca.*	1.1	2.0	1.4
				(pl.ef) T47D
Heart	1.3	2.8	1.7	Breast ca.	2.0	1.2	1.6
				BT-549
Skeletal muscle	36.1	11.9	6.9	Breast ca.	0.0	0.0	0.0
(fetal)				MDA-N
Skeletal muscle	0.3	2.7	1.9	Ovary	1.1	0.0	1.5
Bone marrow	0.0	0.0	0.0	Ovarian ca.	0.4	2.1	1.4
				OVCAR-3
Thymus	1.7	0.7	0.4	Ovarian ca.	0.0	0.0	0.0
				OVCAR-4
Spleen	0.6	1.2	0.0	Ovarian ca.	17.7	20.9	24.8
				OVCAR-5
Lymph node	0.2	0.0	0.0	Ovarian ca.	1.2	0.9	0.6
				OVCAR-8
Colorectal	7.0	9.1	3.5	Ovarian ca.	0.0	0.0	0.0
				IGROV-1
Stomach	1.4	5.6	2.5	Ovarian ca.*	2.0	2.2	5.4
				(ascites) SK-
				OV-3
Small intestine	1.0	9.4	7.2	Uterus	3.8	12.4	15.5
Colon ca. SW480	0.0	0.0	0.0	Placenta	3.5	4.6	1.1
Colon ca.*	0.5	0.0	0.0	Prostate	0.7	3.1	1.4
SW620(SW480
met)
Colon ca. HT29	0.0	0.0	0.0	Prostate ca.*	0.4	2.5	0.4
				(bone
				met)PC-3
Colon ca. HCT-	0.0	0.0	0.0	Testis	2.1	1.5	2.3
116
Colon ca. CaCo-2	0.4	0.0	0.0	Melanoma	0.0	0.0	0.0
				Hs688(A).T
Colon ca.	0.3	0.7	0.0	Melanoma*	0.0	0.0	0.0
tissue(ODO3866)				(met)
				Hs688(B).T
Colon ca. HCC-	12.4	5.1	2.1	Melanoma	0.2	0.0	0.0
2998				UACC-62
Gastric ca.*	0.0	0.0	0.0	Melanoma	0.0	1.5	1.6
(liver met) NCI-				M14
N87
Bladder	0.3	0.7	0.0	Melanoma	1.6	0.0	0.0
				LOX IMVI
Trachea	9.2	7.5	9.0	Melanoma*	68.8	50.7	58.6
				(met) SK-
				MEL-5
Kidney	1.3	5.5	1.5	Adipose	1.1	1.2	1.5

[1023]

TABLE ZI
Panel 2.2
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3242, Run		Ag3242, Run
Tissue Name	174443348	Tissue Name	174443348
Normal Colon	4.4	Kidney Margin	1.0
		(OD04348)
Colon cancer (OD06064)	1.8	Kidney malignant	0.4
		cancer (OD06204B)
Colon Margin	8.9	Kidney normal adjacent	1.8
(OD06064)		tissue (OD06204E)
Colon cancer (OD06159)	2.0	Kidney Cancer	2.3
		(OD04450-01)
Colon Margin	7.1	Kidney Margin	0.9
(OD06159)		(OD04450-03)
Colon cancer (OD06297-	2.4	Kidney Cancer 8120613	0.0
04)
Colon Margin	2.2	Kidney Margin 8120614	0.4
(OD06297-05)
CC Gr.2 ascend colon	0.9	Kidney Cancer 9010320	1.4
(ODO3921)
CC Margin (ODO3921)	3.8	Kidney Margin 9010321	1.3
Colon cancer metastasis	0.7	Kidney Cancer 8120607	0.8
(OD06104)
Lung Margin (OD06104)	0.0	Kidney Margin 8120608	0.2
Colon mets to lung	1.7	Normal Uterus	5.3
(OD04451-01)
Lung Margin (OD04451-	10.1	Uterine Cancer 064011	0.5
02)
Normal Prostate	0.4	Normal Thyroid	0.0
Prostate Cancer	0.3	Thyroid Cancer 064010	0.7
(OD04410)
Prostate Margin	0.0	Thyroid Cancer	0.9
(OD04410)		A302152
Normal Ovary	0.0	Thyroid Margin	0.0
		A302153
Ovarian cancer	0.0	Normal Breast	0.6
(OD06283-03)
Ovarian Margin	0.0	Breast Cancer	0.0
(OD06283-07)		(OD04566)
Ovarian Cancer 064008	1.9	Breast Cancer 1024	2.1
Ovarian cancer	0.0	Breast Cancer	0.0
(OD06145)		(OD04590-01)
Ovarian Margin	0.0	Breast Cancer Mets	0.0
(OD06145)		(OD04590-03)
Ovarian cancer	0.0	Breast Cancer	0.4
(OD06455-03)		Metastasis (OD04655-
		05)
Ovarian Margin	1.2	Breast Cancer 064006	0.7
(OD06455-07)
Normal Lung	2.3	Breast Cancer 9100266	0.7
Invasive poor diff. lung	1.1	Breast Margin 9100265	0.2
adeno (ODO4945-01
Lung Margin	1.6	Breast Cancer A209073	0.0
(ODO4945-03)
Lung Malignant Cancer	0.7	Breast Margin	0.0
(OD03126)		A2090734
Lung Margin (OD03126)	1.2	Breast cancer	0.4
		(OD06083)
Lung Cancer	1.2	Breast cancer node	0.9
(OD05014A)		metastasis (OD06083)
Lung Margin	4.4	Normal Liver	1.3
(OD05014B)
Lung cancer (OD06081)	0.8	Liver Cancer 1026	0.3
Lung Margin (OD06081)	2.8	Liver Cancer 1025	0.0
Lung Cancer (OD04237-	0.0	Liver Cancer 6004-T	0.0
01)
Lung Margin (OD04237-	6.0	Liver Tissue 6004-N	0.0
02)
Ocular Melanoma	100.0	Liver Cancer 6005-T	2.7
Metastasis
Ocular Melanoma	0.7	Liver Tissue 6005-N	3.3
Margin (Liver)
Melanoma Metastasis	1.2	Liver Cancer 064003	7.1
Melanoma Margin	4.9	Normal Bladder	0.0
(Lung)
Normal Kidney	0.0	Bladder Cancer 1023	0.0
Kidney Ca, Nuclear	1.3	Bladder Cancer	0.3
grade 2 (OD04338)		A302173
Kidney Margin	0.4	Normal Stomach	5.8
(OD04338)
Kidney Ca Nuclear grade	0.6	Gastric Cancer 9060397	0.0
1/2 (OD04339)
Kidney Margin	1.6	Stomach Margin	2.6
(OD04339		9060396
Kidney Ca, Clear cell	0.0	Gastric Cancer 9060395	2.2
type (OD04340)
Kidney Margin	1.1	Stomach Margin	3.4
(OD04340)		9060394
Kidney Ca, Nuclear	0.0	Gastric Cancer 064005	0.3
grade 3 (OD04348)

[1024]

TABLE ZJ
Panel 4D
	Rel. Exp.(%)	Rel. Exp.(%)	Rel. Exp.(%)	Rel. Exp.(%)
	Ag1012, Run	Ag1012, Run	Ag1096, Run	Ag3242, Run
Tissue Name	157263859	164036950	160353275	164390548
Secondary Th1 act	0.0	0.0	0.0	0.0
Secondary Th2 act	0.0	0.0	0.0	0.0
Secondary Tr1 act	0.0	0.0	0.0	0.0
Secondary Th1 rest	0.0	0.0	0.0	0.0
Secondary Th2 rest	0.0	0.0	0.0	0.0
Secondary Tr1 rest	0.0	0.0	0.0	0.0
Primary Th1 act	0.0	0.0	0.0	0.0
Primary Th2 act	0.0	0.7	0.0	0.0
Primary Tr1 act	0.0	0.0	0.0	0.0
Primary Th1 rest	0.0	0.0	0.0	0.0
Primary Th2 rest	0.0	0.0	0.0	0.0
Primary Tr1 rest	0.7	0.0	0.0	0.0
CD45RA CD4	0.0	0.9	0.0	0.0
lymphocyte act
CD45RO CD4	0.0	0.0	0.0	0.0
lymphocyte act
CD8 lymphocyte act	100.0	0.0	1.3	0.0
Secondary CD8	0.0	0.0	0.7	0.0
lymphocyte rest
Secondary CD8	0.0	0.0	0.0	0.0
lymphocyte act
CD4 lymphocyte none	0.0	0.0	0.0	0.0
2ry Th1/Th2/Tr1_anti-	0.0	0.0	0.0	0.0
CD95 CH11
LAK cells rest	0.0	0.0	0.0	0.0
LAK cells IL-2	0.0	0.0	0.0	0.0
LAK cells IL-2 + IL-12	0.0	2.3	0.0	0.0
LAK cells IL-2 + IFN	0.0	0.0	0.8	0.0
gamma
LAK cells IL-2 + IL-18	0.3	0.0	0.0	0.0
LAK cells	0.0	0.0	0.0	0.0
PMA/ionomycin
NK Cells IL-2 rest	0.0	1.9	0.8	0.0
Two Way MLR 3 day	0.0	0.0	0.0	0.0
Two Way MLR 5 day	0.0	0.0	0.0	0.0
Two Way MLR 7 day	0.0	0.0	1.5	0.0
PBMC rest	0.0	0.0	0.0	0.0
PBMC PWM	0.0	0.0	0.0	0.0
PBMC PHA-L	0.0	0.0	0.0	0.0
Ramos (B cell) none	0.0	0.0	0.0	0.0
Ramos (B cell)	0.0	0.0	0.0	0.0
ionomycin
B lymphocytes PWM	0.0	0.0	0.0	0.0
B lymphocytes CD40L	0.0	0.4	0.0	0.0
and IL-4
EOL-1 dbcAMP	0.0	0.0	0.0	0.0
EOL-1 dbcAMP	0.0	0.0	0.0	0.0
PMA/ionomycin
Dendritic cells none	0.0	0.0	0.0	0.0
Dendritic cells LPS	0.0	0.0	0.0	0.0
Dendritic cells anti-	0.0	0.0	0.0	0.0
CD40
Monocytes rest	0.0	0.0	0.0	0.0
Monocytes LPS	0.0	0.0	1.7	0.0
Macrophages rest	0.0	0.0	0.0	0.0
Macrophages LPS	0.6	0.0	0.0	0.0
HUVEC none	0.7	0.0	0.0	0.0
HUVEC starved	0.0	0.0	0.0	0.0
HUVEC IL-1 beta	0.0	0.0	0.0	0.0
HUVEC IFN gamma	0.0	0.0	0.4	0.0
HUVEC TNF alpha +	0.0	0.0	0.0	0.0
IFN gamma
HUVEC TNF alpha +	0.0	0.0	2.0	0.0
IL4
HUVEC IL-11	0.0	0.0	0.0	0.0
Lung Microvascular EC	0.0	0.0	0.0	0.0
none
Lung Microvascular EC	0.0	0.0	0.0	0.0
TNF alpha + IL-1 beta
Microvascular Dermal	0.0	0.0	0.0	0.0
EC none
Microsvasular Dermal	0.0	0.0	0.0	0.0
EC TNF alpha + IL-
1 beta
Bronchial epithelium	0.0	1.1	0.0	0.0
TNF alpha + IL-1 beta
Small airway epithelium	0.9	1.2	0.0	0.0
none
Small airway epithelium	12.6	9.4	6.5	11.7
TNF alpha + IL-1 beta
Coronery artery SMC	0.0	0.0	0.7	0.0
rest
Coronery artery SMC	0.0	0.0	0.0	0.0
TNF alpha + IL-1 beta
Astrocytes rest	10.7	15.4	13.9	16.8
AstrocytesTNF alpha +	3.8	9.1	3.6	5.3
IL-1 beta
KU-812 (Basophil) rest	1.5	0.0	0.9	1.0
KU-812 (Basophil)	90.8	100.0	100.0	100.0
PMA/ionomycin
CCD1106	0.0	0.0	0.0	0.0
(Keratinocytes) none
CCD1106	0.7	0.0	0.0	0.0
(Keratinocytes)
TNF alpha + IL-1 beta
Liver cirrhosis	8.1	5.4	1.9	3.8
Lupus kidney	0.0	1.1	1.3	1.4
NCI-H292 none	44.1	58.2	42.9	48.0
NCI-H292 IL-4	21.8	19.3	14.7	14.8
NCI-H292 IL-9	40.9	60.3	40.6	36.6
NCI-H292 IL-13	5.9	7.4	12.2	7.4
NCI-H292 IFN gamma	11.3	11.8	16.8	10.9
HPAEC none	0.0	0.0	0.0	0.0
HPAEC TNF alpha +	0.0	0.0	0.0	0.0
IL-1 beta
Lung fibroblast none	0.0	0.0	0.0	1.7
Lung fibroblast TNF	0.0	0.0	0.0	0.0
alpha + IL-1 beta
Lung fibroblast IL-4	0.0	0.0	1.7	0.0
Lung fibroblast IL-9	0.0	0.0	0.0	0.0
Lung fibroblast IL-13	0.0	0.0	0.7	0.0
Lung fibroblast IFN	0.0	0.0	0.0	0.0
gamma
Dermal fibroblast	0.0	0.0	0.0	0.0
CCD1070 rest
Dermal fibroblast	0.0	0.0	0.0	0.0
CCD1070 TNF alpha
Dermal fibroblast	0.0	0.0	0.9	0.0
CCD1070 IL-1 beta
Dermal fibroblast IFN	0.0	2.1	0.0	0.0
gamma
Dermal fibroblast IL-4	0.0	0.0	0.0	0.0
IBD Colitis 2	0.0	0.5	0.8	2.6
IBD Crohn's	0.9	2.1	0.0	2.0
Colon	22.1	14.6	28.1	23.2
Lung	74.7	38.7	34.9	51.4
Thymus	23.2	27.4	35.1	28.3
Kidney	8.0	11.7	8.2	7.4

[1025]

TABLE ZK
Panel CNS_1
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag1012, Run		Ag1012, Run
Tissue Name	171629312	Tissue Name	171629312
BA4 Control	29.1	BA17 PSP	1.9
BA4 Control2	52.1	BA17 PSP2	3.1
BA4	1.4	Sub Nigra Control	21.2
Alzheimer's2
BA4 Parkinson's	24.0	Sub Nigra Control2	5.3
BA4	49.7	Sub Nigra	18.9
Parkinson's2		Alzheimer's2
BA4	19.1	Sub Nigra	65.1
Huntington's		Parkinson's2
BA4	1.3	Sub Nigra	45.4
Huntington's2		Huntington's
BA4 PSP	6.2	Sub Nigra	100.0
		Huntington's2
BA4 PSP2	9.7	Sub Nigra PSP2	4.7
BA4 Depression	13.0	Sub Nigra	2.9
		Depression
BA4	2.4	Sub Nigra	25.2
Depression2		Depression2
BA7 Control	36.1	Glob Palladus	7.5
		Control
BA7 Control2	22.8	Glob Palladus	14.2
		Control2
BA7	2.4	Glob Palladus	7.1
Alzheimer's2		Alzheimer's
BA7 Parkinson's	6.9	Glob Palladus	4.7
		Alzheimer's2
BA7	34.4	Glob Palladus	36.1
Parkinson's2		Parkinson's
BA7	36.6	Globa Palladus	10.5
Huntington's		Parkinson's2
BA7	32.5	Glob Palladus PSP	1.1
Huntington's2
BA7 PSP	26.4	Glob Palladus PSP2	5.4
BA7 PSP2	12.9	Glob Palladus	1.0
		Depression
BA7 Depression	1.1	Temp Pole Control	16.5
BA9 Control	17.0	Temp Pole Control2	59.0
BA9 Control2	90.1	Temp Pole	1.2
		Alzheimer's
BA9 Alzheimer's	0.0	Temp Pole	2.7
		Alzheimer's2
BA9	2.8	Temp Pole	8.1
Alzheimer's2		Parkinson's
BA9 Parkinson's	11.8	Temp Pole	20.3
		Parkinson's2
BA9	43.2	Temp Pole	30.6
Parkinson's2		Huntington's
BA9	25.5	Temp Pole PSP	1.1
Huntington's
BA9	3.7	Temp Pole PSP2	2.1
Huntington's 2
BA9 PSP	10.7	Temp Pole	1.6
		Depression2
BA9 PSP2	0.0	Cing Gyr Control	64.6
BA9 Depression	3.8	Cing Gyr Control2	42.9
BA9	8.0	Cing Gyr	16.3
Depression2		Alzheimer's
BA17 Control	15.0	Cing Gyr	0.7
		Alzheimer's2
BA17 Control2	24.5	Cing Gyr	17.8
		Parkinson's
BA17	2.8	Cing Gyr	28.5
Alzheimer's2		Parkinson's2
BA17	13.2	Cing Gyr	68.8
Parkinson's		Huntington's
BA17	23.3	Cing Gyr	18.4
Parkinson's2		Huntington's2
BA17	15.3	Cing Gyr PSP	9.9
Huntington's
BA17	5.0	Cing Gyr PSP2	3.2
Huntington's2
BA17	1.7	Cing Gyr	3.5
Depression		Depression
BA17	19.9	Cing Gyr	10.5
Depression2		Depression2

[1026] AI_comprehensive panel_v1.0 Summary: Ag3242 Expression of the CG59985-01 gene is ubiquitous in this panel, with high expression in samples derived from patients suffering from ulcerative colitis, Crohn's disease and psoriasis (CTs=33). In addition, significant expression is also seen in samples derived from synovium, cartilage and bone of rheumatoid arthritis. Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene may be useful in the treatment of inflammatory bowel diseases and rheumatoid arthritis.

[1027] CNS_neurodegeneration_v1.0 Summary: AG1012/Ag1096/Ag3242. Three experiments with three different probe and primer sets produce results that are in excellent agreement, with highest expression of the CG57448-01 gene in the hippocampus of a patient with Alzheimer's disease. No change is detected in the expression of this gene in the postmortem Alzheimer'diseased brain when compared to controls; however this panel confirms the expression of this gene in the CNS in an independent group of patients. See panel 1.2 for a discussion of utility. A third experiment with the probe and primer set Ag704 shows low/undetectable levels of expression (CTs>35). (Data not shown) The data suggest that there is a probability of a probe failure.

[1028] Panel 1.2 Summary: Ag1096/Ag3242 Two experiments with two different probe and primer sets produce results that are in excellent agreement, with highest expression of the CG57448-01 gene in cancer cell lines derived from lung cancer and melanoma (CTs=24-25). Significant levels of expression are also seen in a renal cancer cell line, ovarian cancer cell lines and brain cancer cell lines. Thus, expression of this gene could be used to differentiate between these samples and other samples on this panel and as a diagnostic marker for the presence of these cancers. This gene encodes a protein that is homologous to cadherin, a cell-adhesion molecule. Therefore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung, renal and melanoma cancers.

[1029] Expression of the this gene is also high in many regions of the brain, including the amygdala, thalamus, cerebellum, and cerebral cortex, with highest expression in the hippocampus. Expression is also detected in the spinal cord. Cadherins can act as axon guidance and cell adhesion proteins, specifically during development and in the response to injury (ref 1). Therefore, manipulation of levels of this protein may be of use in inducing a compensatory synaptogenic response to neuronal death in Alzheimer's disease, Parkinson's disease, Huntingdon's disease, spinocerebellar ataxia, progressive supranuclear palsy, ALS, head trauma, stroke, or any other disease/condition associated with neuronal loss.

[1030] Among tissues with metabolic function, this gene is moderately expressed in pituitary gland, adrenal gland, thyroid, pancrease, skeletal muscle, and liver, reflecting the widespread role of cadherins in cell-cell adhesion. This expression suggests that this gene product may play a role in normal metabolic and neuroendocrine function and that dysregulated expression of this gene may contribute to metabolic diseases (such as obesity and diabetes) or neuroendocrine disorders.

[1031] References:

[1032] Ranscht B. (2000) Cadherins: molecular codes for axon guidance and synapse formation. Int. J. Dev. Neurosci. 18: 643-651.

[1033] Panel 1.3D Summary: Ag3242 Highest expression of the CG57448-01 gene is seen in a renal cancer cell line (CT=31.1). Significant expression is also seen in cell lines derived from ovarian cancer, lung cancer, brain cancer and melanoma. This is in concordance with the results in the previous panel. Please see Panel 1.2 for discussion of utility of this gene in the treatment of cancer.

[1034] As in the previous panel, this gene is also highly expressed in the central nervous system. Please see Panel 1.2 for a fuller discussion of utility of this gene in the central nervous system.

[1035] Results from a second experiment with the probe primer set Ag704 are not included. The amp plot indicates that there is high probability of a probe failure.

[1036] Panel 2.2 Summary: Ag3242 Highest expression of the CG57448-01 gene is seen in a sample derived from an ocular melanoma metastasis (CT=29). Thus, expression of this gene could be used to differentiate between this sample and other samples on this pane.

[1037] Panel 2D Summary: Ag704 Results from one experiment with the CG57448-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[1038] Panel 3D Summary: Ag1012 Results from one experiment with the CG57448-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[1039] Panel 4D Summary: Ag1096/Ag3242 Two experiments with two different probe and primer sets produce results that are in excellent agreement, with highest expression of the CG57448-01 gene in the basophil cell line (KU-812) treated with PMA/ionomycin (CTs=30-32). Significant expression is also seen in a cluster of treated and untreated samples derived from the muco-epidermoid cell line NCI-H292. Thus, this gene, which encodes a cadherin homolog, is expressed in both a cell line that is often used as a model of airway epithelium (NCI-H292) and a cell line that is a reasonable model for the inflammatory cells that contribute to various inflammatory lung diseases. This suggests that therapeutic modulation of this gene product may reduce or eliminate the symptoms of patients suffering from pathological and inflammatory lung disorders, including chronic obstructive pulmonary disease, asthma, allergy and emphysema.

[1040] Low but significant levels of expression are also seen in the samples derived from normal colon, kidney, lung and thymus. This suggests that this gene product may play a role in the homeostasis of these tissues. Therefore, therapeutic modulation of the expression or function of the gene product may be important for maintaining or restoring normal function to this organs during inflammation.

[1041] Results from a third experiment with the probe primer set Ag704 are not included. The amp plot indicates that there is a high probability of a probe failure.

[1042] Panel CNS—1 Summary: Ag1012 This panel confirms the expression of the CG57448-01 gene at low levels in the brains of an independent group of individuals. Please see Panel 1.2 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

AA. NOV33c (CG59363-03: BAB26184 LIKE)

[1043] Expression of gene CG59363-03 was assessed using the primer-probe set Ag5254, described in Table AAA.

TABLE AAA
Probe Name Ag5254
			Start
Primers	Sequences	Length	Position
Forward	5′-gtcggtgctgcgctt-3′	(SEQ ID NO:329)	15	881
Probe	TET-5′-cctagcctgtcagactgccttggtc-3′-TAMRA	(SEQ ID NO:330)	25	908
Reverse	5′-agggccctggggaa-3′	(SEQ ID NO:331)	14	933

[1044] CNS_neurodegeneration_v.1.0 Summary: Ag5254 Expression of the CG55966-03 gene is low/undetectable in all samples on this panel (CTs>35).

[1045] General_screening_panel_v1.5 Summary: Ag5254 Expression of the CG55966-03 gene is low/undetectable in all samples on this panel (CTs>35).

[1046] Panel 4.1D Summary: Ag5254 Expression of the CG55966-03 gene is low/undetectable in all samples on this panel (CTs>35).

AB. NOV34a 9CG59301-01: ANDROGEN RECEPTOR-LIKE)

[1047] Expression of gene CG59301-01 was assessed using the primer-probe set Ag3536, described in Table ABA. Results of the RTQ-PCR runs are shown in Tables ABB, ABC, ABD, and ABE.

TABLE ABA
Probe Name Ag3536
			Start
Primers	Sequences	Length	Position
Forward	5′-cagctctgcccatcttcat-3′	(SEQ ID NO:332)	19	919
Probe	TET-5′-ccagctctctggccagtgcctct-3′-TAMRA	(SEQ ID NO:333)	23	957	(SEQ ID	23	1	~"
Reverse	5′-gcaggtggtgacaccatcta-3′	(SEQ ID NO:334)	20	980

[1048]

TABLE ABB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3536,		Rel. Exp.(%) Ag3536,
Tissue Name	Run 210631621	Tissue Name	Run 210631621
AD 1 Hippo	51.1	Control (Path) 3	7.5
		Temporal Ctx
AD 2 Hippo	48.3	Control (Path) 4	13.4
		Temporal Ctx
AD 3 Hippo	37.4	AD 1 Occipital Ctx	4.0
AD 4 Hippo	11.5	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	44.1	AD 3 Occipital Ctx	44.4
AD 6 Hippo	15.3	AD 4 Occipital Ctx	26.1
Control 2 Hippo	54.7	AD 5 Occipital Ctx	15.2
Control 4 Hippo	21.0	AD 6 Occipital Ctx	19.6
Control (Path) 3	0.0	Control 1 Occipital	18.9
Hippo		Ctx
AD 1 Temporal Ctx	62.9	Control 2 Occipital	11.5
		Ctx
AD 2 Temporal Ctx	20.4	Control 3 Occipital	70.2
		Ctx
AD 3 Temporal Ctx	42.0	Control 4 Occipital	21.3
		Ctx
AD 4 Temporal Ctx	38.4	Control (Path) 1	37.4
		Occipital Ctx
AD 5 Inf Temporal	41.2	Control (Path) 2	25.9
Ctx		Occipital Ctx
AD 5 Sup Temporal	67.8	Control (Path) 3	10.1
Ctx		Occipital Ctx
AD 6 Inf Temporal	88.9	Control (Path) 4	0.0
Ctx		Occipital Ctx
AD 6 Sup Temporal	88.9	Control 1 Parietal	9.0
Ctx		Ctx
Control 1 Temporal	19.8	Control 2 Parietal	100.0
Ctx		Ctx
Control 2 Temporal	11.0	Control 3 Parietal	13.4
Ctx		Ctx
Control 3 Temporal	46.0	Control (Path) 1	46.0
Ctx		Parietal Ctx
Control 4 Temporal	23.7	Control (Path) 2	43.5
Ctx		Parietal Ctx
Control (Path) 1	73.7	Control (Path) 3	0.0
Temporal Ctx		Parietal Ctx
Control (Path) 2	27.2	Control (Path) 4	86.5
Temporal Ctx		Parietal Ctx

[1049]

TABLE ABC
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3536,		Rel. Exp.(%) Ag3536,
Tissue Name	Run 213391032	Tissue Name	Run 213391032
Adipose	0.0	Renal ca. TK-10	13.9
Melanoma*	1.6	Bladder	9.5
Hs688(A).T
Melanoma*	1.5	Gastric ca. (liver met.)	20.3
Hs688(B).T		NCI-N87
Melanoma* M14	0.0	Gastric ca. KATO III	3.6
Melanoma*	1.2	Colon ca. SW-948	0.9
LOXIMVI
Melanoma* SK-	5.5	Colon ca. SW480	33.9
MEL-5
Squamous cell	2.0	Colon ca.* (SW480	12.9
carcinoma SCC-4		met) SW620
Testis Pool	4.8	Colon ca. HT29	6.9
Prostate ca.* (bone	12.6	Colon ca. HCT-116	6.0
met) PC-3
Prostate Pool	15.9	Colon ca. CaCo-2	32.3
Placenta	0.0	Colon cancer tissue	1.7
Uterus Pool	1.1	Colon ca. SW1116	1.5
Ovarian ca. OVCAR-3	4.7	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	82.4	Colon ca. SW-48	1.3
Ovarian ca. OVCAR-4	2.5	Colon Pool	1.5
Ovarian ca. OVCAR-5	29.5	Small Intestine Pool	17.3
Ovarian ca. IGROV-1	15.5	Stomach Pool	2.9
Ovarian ca. OVCAR-8	4.9	Bone Marrow Pool	4.1
Ovary	0.0	Fetal Heart	4.1
Breast ca. MCF-7	35.8	Heart Pool	4.1
Breast ca. MDA-	4.5	Lymph Node Pool	9.8
MB-231
Breast ca. BT 549	12.1	Fetal Skeletal Muscle	3.0
Breast ca. T47D	87.1	Skeletal Muscle Pool	4.9
Breast ca. MDA-N	10.2	Spleen Pool	4.2
Breast Pool	2.9	Thymus Pool	4.3
Trachea	2.7	CNS cancer (glio/astro)	2.4
		U87-MG
Lung	3.2	CNS cancer (glio/astro)	14.2
		U-118-MG
Fetal Lung	1.4	CNS cancer (neuro; met)	0.0
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	3.7
		539
Lung ca. LX-1	28.3	CNS cancer (astro)	18.9
		SNB-75
Lung ca. NCI-H146	3.6	CNS cancer (glio) SNB-	11.7
		19
Lung ca. SHP-77	4.3	CNS cancer (glio) SF-	15.0
		295
Lung ca. A549	2.5	Brain (Amygdala) Pool	3.5
Lung ca. NCI-H526	0.0	Brain (cerebellum)	33.7
Lung ca. NCI-H23	100.0	Brain (fetal)	8.9
Lung ca. NCI-H460	8.2	Brain (Hippocampus)	5.8
		Pool
Lung ca. HOP-62	3.8	Cerebral Cortex Pool	4.1
Lung ca. NCI-H522	26.2	Brain (Substantia nigra)	4.5
		Pool
Liver	0.0	Brain (Thalamus) Pool	5.0
Fetal Liver	3.4	Brain (whole)	4.8
Liver ca. HepG2	0.9	Spinal Cord Pool	0.0
Kidney Pool	7.3	Adrenal Gland	1.2
Fetal Kidney	6.7	Pituitary gland Pool	1.3
Renal ca. 786-0	9.6	Salivary Gland	0.9
Renal ca. A498	4.6	Thyroid (female)	1.1
Renal ca. ACHN	4.3	Pancreatic ca. CAPAN2	2.5
Renal ca. UO-31	11.2	Pancreas Pool	3.6

[1050]

TABLE ABD
Panel 2.2
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3536, Run		Ag3536, Run
Tissue Name	173761868	Tissue Name	173761868
Normal Colon	0.0	Kidney Margin	11.9
		(OD04348)
Colon cancer (OD06064)	0.0	Kidney malignant	36.6
		cancer (OD06204B)
Colon Margin	0.0	Kidney normal adjacent	0.0
(OD06064)		tissue (OD06204E)
Colon cancer (OD06159)	0.0	Kidney Cancer	10.5
		(OD04450-01)
Colon Margin	0.0	Kidney Margin	10.7
(OD06159)		(OD04450-03)
Colon cancer (OD06297-	0.0	Kidney Cancer 8120613	10.7
04)
Colon Margin	0.0	Kidney Margin 8120614	0.0
(OD06297-05)
CC Gr.2 ascend colon	0.0	Kidney Cancer 9010320	0.0
(ODO3921)
CC Margin (ODO3921)	0.0	Kidney Margin 9010321	0.0
Colon cancer metastasis	0.0	Kidney Cancer 8120607	0.0
(OD06104)
Lung Margin (OD06104)	0.0	Kidney Margin 8120608	0.0
Colon mets to lung	0.0	Normal Uterus	0.0
(OD04451-01)
Lung Margin (OD04451-	4.5	Uterine Cancer 064011	9.7
02)
Normal Prostate	23.3	Normal Thyroid	0.0
Prostate Cancer	0.0	Thyroid Cancer 064010	0.0
(OD04410)
Prostate Margin	32.1	Thyroid Cancer	0.0
(OD04410)		A302152
Normal Ovary	11.7	Thyroid Margin	0.0
		A302153
Ovarian cancer	9.3	Normal Breast	0.0
(OD06283-03)
Ovarian Margin	0.0	Breast Cancer	3.3
(OD06283-07)		(OD04566)
Ovarian Cancer 064008	6.4	Breast Cancer 1024	39.0
Ovarian cancer	0.0	Breast Cancer	50.3
(OD06145)		(OD04590-01)
Ovarian Margin	0.0	Breast Cancer Mets	42.9
(OD06145)		(OD04590-03)
Ovarian cancer	9.3	Breast Cancer	100.0
(OD06455-03)		Metastasis (OD04655-
		05)
Ovarian Margin	5.8	Breast Cancer 064006	11.8
(OD06455-07)
Normal Lung	0.0	Breast Cancer 9100266	3.9
Invasive poor diff. lung	0.0	Breast Margin 9100265	0.0
adeno (ODO4945-01
Lung Margin	0.0	Breast Cancer A209073	0.0
(ODO4945-03)
Lung Malignant Cancer	0.0	Breast Margin	59.5
(OD03126)		A2090734
Lung Margin (OD03126)	11.4	Breast cancer	25.3
		(OD06083)
Lung Cancer	8.4	Breast cancer node	76.8
(OD05014A)		metastasis (OD06083)
Lung Margin	0.0	Normal Liver	0.0
(OD05014B)
Lung cancer (OD06081)	0.0	Liver Cancer 1026	0.0
Lung Margin (OD06081)	0.0	Liver Cancer 1025	11.0
Lung Cancer (OD04237-	0.0	Liver Cancer 6004-T	18.8
01)
Lung Margin (OD04237-	0.0	Liver Tissue 6004-N	0.0
02)
Ocular Melanoma	7.3	Liver Cancer 6005-T	12.8
Metastasis
Ocular Melanoma	0.0	Liver Tissue 6005-N	0.0
Margin (Liver)
Melanoma Metastasis	0.0	Liver Cancer 064003	0.0
Melanoma Margin	0.0	Normal Bladder	0.0
(Lung)
Normal Kidney	0.0	Bladder Cancer 1023	0.0
Kidney Ca, Nuclear	0.0	Bladder Cancer	0.0
grade 2 (OD04338)		A302173
Kidney Margin	7.9	Normal Stomach	0.0
(OD04338)
Kidney Ca Nuclear grade	24.3	Gastric Cancer 9060397	0.0
1/2 (OD04339)
Kidney Margin	7.1	Stomach Margin	0.0
(OD04339)		9060396
Kidney Ca, Clear cell	0.0	Gastric Cancer 9060395	25.0
type (OD04340)
Kidney Margin	0.0	Stomach Margin	0.0
(OD04340)		9060394
Kidney Ca, Nuclear	0.0	Gastric Cancer 064005	11.5
grade 3 (OD04348)

[1051]

TABLE ABE
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3536, Run		Ag3536, Run
Tissue Name	166444751	Tissue Name	166444751
Secondary Th1 act	2.2	HUVEC IL-1 beta	0.0
Secondary Th2 act	0.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN	2.3
		gamma
Secondary Th1 rest	0.5	HUVEC TNF alpha + IL4	0.9
Secondary Th2 rest	0.0	HUVEC IL-11	2.8
Secondary Tr1 rest	3.7	Lung Microvascular EC	7.6
		none
Primary Th1 act	0.0	Lung Microvascular EC	1.9
		TNF alpha + IL-1 beta
Primary Th2 act	5.8	Microvascular Dermal EC	4.8
		none
Primary Tr1 act	0.8	Microvascular Dermal EC	1.0
		TNF alpha + IL-1 beta
Primary Th1 rest	5.1	Bronchial epithelium	9.7
		TNF alpha + IL1 beta
Primary Th2 rest	6.3	Small airway epithelium	1.2
		none
Primary Tr1 rest	4.8	Small airway epithelium	6.3
		TNF alpha + IL-1 beta
CD45RA CD4	0.0	Coronery artery SMC rest	1.1
lymphocyte act
CD45RO CD4	2.5	Coronery artery SMC	1.0
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	1.0	Astrocytes rest	5.1
Secondary CD8	0.0	Astrocytes TNF alpha + IL-	17.3
lymphocyte rest		1 beta
Secondary CD8	0.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	0.7	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	1.2	CCD1106 (Keratinocytes)	4.0
CD95 CH11		none
LAK cells rest	0.0	CCD1106 (Keratinocytes)	14.7
		TNF alpha + IL-1 beta
LAK cells IL-2	5.0	Liver cirrhosis	33.0
LAK cells IL-2 + IL-12	4.1	Lupus kidney	10.0
LAK cells IL-2 + IFN	8.4	NCI-H292 none	2.0
gamma
LAK cells IL-2 + IL-18	4.5	NCI-H292 IL-4	3.8
LAK cells	1.3	NCI-H292 IL-9	8.1
PMA/ionomycin
NK Cells IL-2 rest	3.8	NCI-H292 IL-13	10.3
Two Way MLR 3 day	2.0	NCI-H292 IFN gamma	5.0
Two Way MLR 5 day	1.2	HPAEC none	5.2
Two Way MLR 7 day	1.2	HPAEC TNF alpha + IL-1	3.6
		beta
PBMC rest	0.0	Lung fibroblast none	8.8
PBMC PWM	2.4	Lung fibroblast TNF	2.6
		alpha + IL-1 beta
PBMC PHA-L	0.0	Lung fibroblast IL-4	3.3
Ramos (B cell) none	0.0	Lung fibroblast IL-9	1.1
Ramos (B cell)	0.0	Lung fibroblast IL-13	0.0
ionomycin
B lymphocytes PWM	1.1	Lung fibroblast IFN	0.0
		gamma
B lymphocytes CD40L	2.7	Dermal fibroblast	3.4
and IL-4		CCD1070 rest
EOL-1 dbcAMP	0.0	Dermal fibroblast	9.7
		CCD1070 TNF alpha
EOL-1 dbcAMP	1.9	Dermal fibroblast	2.6
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	0.0	Dermal fibroblast IFN	3.1
		gamma
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-	0.8	IBD Colitis 2	1.0
CD40
Monocytes rest	0.0	IBD Crohn's	0.0
Monocytes LPS	1.8	Colon	100.0
Macrophages rest	1.9	Lung	23.8
Macrophages LPS	0.9	Thymus	4.6
HUVEC none	6.3	Kidney	12.7
HUVEC starved	4.5

[1052] CNS_neurodegeneration_v.1.0 Summary: Ag3536 This panel confirms the expression of the CG59301-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1053] General_screening_panel_v.1.4 Summary: Ag3536 Highest expression of the CG59301-01 gene is detected in one of the lung cancer cell line NCI-H23 (CT=30.8). In addition, high expression of this gene is also detected in a breast cancer cell line T47D and ovarian cancer cell line SK-OV-3 (CTs=31). Therefore, expression of this gene can be use to distinguish these samples from other samples used in this panel and as marker in detection of these cancer. Also, significant expression of this gene is seen in CNS cancer, colon cancer, gastric cancer, lung cancer, breast cancer, renal cancer and prostate cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancer.

[1054] Low expression of this gene is also observed in samples derived from prostate, kidney and bladder. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of disease associated with these tissues.

[1055] This gene is expressed at low to moderate levels in cerebellum, hippocampus, and fetal brain (CTs=32-35). Therefore, this gene may play a role in central nervous system disorders such as, Parkinson's disease, epilepsy, seizure, ataxia, autism, schizophrenia and depression.

[1056] Panel 2.2 Summary: Ag3536 Significant expression of the CG59301-01 gene is seen in two of the breast cancer metastasis samples in this panel (CTs=34-34.5). Therefore, expression of this gene may be used to distinguish breast cancers from the other samples on this panel. Furthermore, therapeutic modulation of the activity of this gene product may be beneficial in the treatment of breast cancer.

[1057] Panel 4D Summary: Ag3536 Highest expression of CG59301-01 is detected in colon (CT=30.83). Therefore, expression of this gene may be used to distinguish colon from the other tissues on this panel. Furthermore, expression of this gene is decreased in colon samples from patients with IBD colitis and Crohn's disease (CT>35) relative to normal colon. Therefore, therapeutic modulation of the this gene product may be useful in the treatment of inflammatory bowel disease.

[1058] Low to moderate expression of this gene is also seen samples derived from lung, activated and resting primary Th2, IL-2+IFN gamma treated LAK cells, HUVEC, lung microvascular EC, TNFalpha+IL1beta treated bronchial epithelium, TNFalpha+IL1beta treated small airway epithelium, TNFalpha+IL-1beta treated astrocytes, TNFalpha+IL-1beta treated CCF1106 (keratinocytes), lung fibroblast, TNF alpha treated dermal fibroblast CCD1070 cells and in liver cirrhosis samples. Therefore, therapeutic modulation of this gene or its protein product may be beneficial in the treatment of general autoimmunity, allergies, asthma, psoriasis and emphysema.

[1059] Panel CNS—1 Summary: Ag3536 Expression of this gene is low/undetectable (CTs>35) across all of the samples on this panel.

AC. NOV35a (CG59525-01: CARCINOEMBRYONIC ANTIGEN CGM1)

[1060] Expression of gene CG59525-01 was assessed using the primer-probe set Ag3457, described in Table ACA. Results of the RTQ-PCR runs are shown in Tables ACB, and ACC.

TABLE ACA
Probe Name Ag3457
			Start
Primers	Sequences	Length	Position
Forward	5′-tcccatctatgaggaattgcta-3′	(SEQ ID NO:335)	22	703
Probe	TET-5′-ccatgacacaaacatttactgctggg-3′-TAMRA	(SEQ ID NO:336)	26	727
Reverse	5′-aagaaaccacatctgctttgtg-3′	(SEQ ID NO:337)	22	758

[1061]

TABLE ACB
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3457,		Rel. Exp.(%) Ag3457,
Tissue Name	Run 217044328	Tissue Name	Run 217044328
Adipose	0.0	Renal ca. TK-10	0.0
Melanoma*	0.0	Bladder	0.0
Hs688(A).T
Melanoma*	0.0	Gastric ca. (liver met.)	0.0
Hs688(B).T		NCI-N87
Melanoma* M14	0.0	Gastric ca. KATO III	4.3
Melanoma*	0.0	Colon ca. SW-948	0.0
LOXIMVI
Melanoma* SK-	0.0	Colon ca. SW480	100.0
MEL-5
Squamous cell	0.0	Colon ca.* (SW480	11.7
carcinoma SCC-4		met) SW620
Testis Pool	5.6	Colon ca. HT29	0.0
Prostate ca.* (bone	0.0	Colon ca. HCT-116	0.0
met) PC-3
Prostate Pool	0.0	Colon ca. CaCo-2	0.0
Placenta	0.0	Colon cancer tissue	13.5
Uterus Pool	0.0	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	0.0	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	10.2
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	0.0
Ovarian ca. IGROV-1	0.0	Stomach Pool	0.0
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	4.8
Ovary	0.0	Fetal Heart	5.3
Breast ca. MCF-7	0.0	Heart Pool	0.0
Breast ca. MDA-	0.0	Lymph Node Pool	8.4
MB-231
Breast ca. BT 549	0.0	Fetal Skeletal Muscle	0.0
Breast ca. T47D	16.0	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	5.3	Spleen Pool	20.7
Breast Pool	21.3	Thymus Pool	6.5
Trachea	0.0	CNS cancer (glio/astro)	0.0
		U87-MG
Lung	6.1	CNS cancer (glio/astro)	4.8
		U-118-MG
Fetal Lung	15.5	CNS cancer (neuro;met)	0.0
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	0.0
		539
Lung ca. LX-1	24.0	CNS cancer (astro)	0.0
		SNB-75
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-	0.0
		19
Lung ca. SHP-77	5.1	CNS cancer (glio) SF-	0.0
		295
Lung ca. A549	0.0	Brain (Amygdala) Pool	0.0
Lung ca. NCI-H526	0.0	Brain (cerebellum)	0.0
Lung ca. NCI-H23	0.0	Brain (fetal)	3.4
Lung ca. NCI-H460	0.0	Brain (Hippocampus)	4.0
		Pool
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	17.3
Lung ca. NCI-H522	0.0	Brain (Substantia nigra)	0.0
		Pool
Liver	0.0	Brain (Thalamus) Pool	0.0
Fetal Liver	10.7	Brain (whole)	0.0
Liver ca. HepG2	0.0	Spinal Cord Pool	10.6
Kidney Pool	6.7	Adrenal Gland	0.0
Fetal Kidney	4.6	Pituitary gland Pool	0.0
Renal ca.786-0	0.0	Salivary Gland	0.0
Renal ca. A498	0.0	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.0	Pancreas Pool	18.3

[1062]

TABLE ACC
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3457, Run		Ag3457, Run
Tissue Name	166417095	Tissue Name	166417095
Secondary Th1 act	100.0	HUVEC IL-1 beta	0.0
Secondary Th2 act	24.0	HUVEC IFN gamma	0.0
Secondary Tr1 act	60.3	HUVEC TNF alpha + IFN	0.0
		gamma
Secondary Th1 rest	76.8	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	55.1	HUVEC IL-11	0.0
Secondary Tr1 rest	57.4	Lung Microvascular EC	8.7
		none
Primary Th1 act	11.3	Lung Microvascular EC	1.2
		TNF alpha + IL-1 beta
Primary Th2 act	28.1	Microvascular Dermal EC	6.0
		none
Primary Tr1 act	44.4	Microsvasular Dermal EC	1.4
		TNF alpha + IL-1 beta
Primary Th1 rest	96.6	Bronchial epithelium	0.0
		TNF alpha + IL1 beta
Primary Th2 rest	52.9	Small airway epithelium	0.0
		none
Primary Tr1 rest	26.6	Small airway epithelium	0.0
		TNF alpha + IL-1 beta
CD45RA CD4	6.6	Coronery artery SMC rest	0.0
lymphocyte act
CD45RO CD4	36.6	Coronery artery SMC	0.0
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	8.6	Astrocytes rest	0.0
Secondary CD8	10.7	Astrocytes TNF alpha + IL-	0.0
lymphocyte rest		1 beta
Secondary CD8	27.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	24.5	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	33.2	CCD1106 (Keratinocytes)	0.0
CD95 CH11		none
LAK cells rest	7.6	CCD1106 (Keratinocytes)	0.0
		TNF alpha + IL-1 beta
LAK cells IL-2	24.0	Liver cirrhosis	4.4
LAK cells IL-2 + IL-12	18.6	Lupus kidney	0.0
LAK cells IL-2 + IFN	22.2	NCI-H292 none	0.0
gamma
LAK cells IL-2 + IL-18	12.3	NCI-H292 IL-4	0.0
LAK cells	8.7	NCI-H292 IL-9	0.0
PMA/ionomycin
NK Cells IL-2 rest	12.8	NCI-H292 IL-13	0.0
Two Way MLR 3 day	11.8	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	1.0	HPAEC none	0.0
Two Way MLR 7 day	10.7	HPAEC TNF alpha + IL-1	0.0
		beta
PBMC rest	14.3	Lung fibroblast none	0.0
PBMC PWM	6.4	Lung fibroblast TNF	0.0
		alpha + IL-1 beta
PBMC PHA-L	1.0	Lung fibroblast IL-4	0.0
Ramos (B cell) none	7.3	Lung fibroblast IL-9	0.0
Ramos (B cell)	6.4	Lung fibroblast IL-13	0.0
ionomycin
B lymphocytes PWM	43.5	Lung fibroblast IFN	0.0
		gamma
B lymphocytes CD40L	52.9	Dermal fibroblast	0.0
and IL-4		CCD1070 rest
EOL-1 dbcAMP	28.9	Dermal fibroblast	54.3
		CCD1070 TNF alpha
EOL-1 dbcAMP	21.5	Dermal fibroblast	0.0
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	15.5	Dermal fibroblast IFN	0.0
		gamma
Dendritic cells LPS	4.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-	31.2	IBD Colitis 2	2.9
CD40
Monocytes rest	16.0	IBD Crohn's	0.0
Monocytes LPS	0.8	Colon	11.3
Macrophages rest	17.7	Lung	11.1
Macrophages LPS	8.5	Thymus	0.8
HUVEC none	0.0	Kidney	15.4
HUVEC starved	0.0

[1063] CNS_neurodegeneration_v1.0 Summary: Ag3457 Expression of CG59525-01 gene is low/undetectable (CTs>34.5) across all of the samples on this panel.

[1064] General_screening_panel_v1.4 Summary: Ag3457 Significant expression of CG59525-01 gene is seen exclusively in a colon cancer cell line (CT=34.02). Therefore, expression of this gene may be used to distinguish colon cancers from the other samples on this panel. Furthermore, therapeutic modulation of the activity of the protein encoded by this gene may be beneficial in the treatment of colon cancer.

[1065] Panel 4D Summary: Ag3457 Low to moderate expression of CG59525-01 gene is detected in both resting and activated, primary and secondary Th1, Th2, Tr1 samples, activated secondary CD8 lymphocyte and 2ry Th1/Th2/Tr1_anti-CD95 CH11. In addition, this gene is down-regulated in activated primary Th1 cells (CT=35) as compared to resting primary Th1 cells (CT=32). Therefore, this gene may be important in regulation of T cell activation or participate in the function(s) of these T cells. Therapeutics designed with the protein encoded for by this transcript could be important in regulating T cell function and treating T cell mediated diseases such as asthma, arthritis, psoriasis, IBD, and systemic lupus erythematosus.

[1066] CG59525-01 gene codes for a carcinoembryonic antigen-related cell adhesion molecule (CEACAM). CEACAM1, a related protein, has been shown to regulate early maturation and activation of dentritic cells, thereby facilitating priming and polarization of T cell responses (Ref. 1). Low to moderate expression of this gene is also detected in untreated dendritic cells (CT=34) and anti-CD40 treated cells (CT=33). Thus, the protein encoded by this transcript may be important in dendritic cell differentiation and activation and also, in priming and polarization of T cell responses. Therefore, therapeutics designed with the protein encoded by this transcript could be important for the treatment of asthma, emphysema, inflammatory bowel disease, arthritis and psoriasis.

[1067] Expression of this gene is stimulated in IL-2, IL-2+IL12, IL-2+IFN gamma treated LAK cells, PWM/CD40L and IL-4 treated B lymphocytes, anti-CD40 treated dendritic cells, and CCD1070 TNF alpha treated dermal fibroblast. Therefore, therapeutic modulation of this gene or its protein product may be beneficial in the treatment of general autoimmunity, psoriasis and emphysema.

[1068] References.

[1069] 1. Kammerer R, Stober D, Singer B B, Obrink B, Reimann J. (2001) Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation. J Immunol Jun. 1, 2001; 166(11 ):6537-44

AD. NOV36a (CG59484-01: TGF-BETA RESISTANCE-ASSOCIATED PROTEIN)

[1070] Expression of gene CG59484-01 was assessed using the primer-probe set Ag3448, described in Table ADA. Results of the RTQ-PCR runs are shown in Tables ADB, ADC and ADD.

TABLE ADA
Probe Name Ag3448
			Start
Primers	Sequences	Length	Position
Forward	5′-cagaacactccgtggtcatc-3′	(SEQ ID NO:338)	20	1390
Probe	TET-5′-tcacatgtttgctatatcctcatcagg-3′-TAMRA	(SEQ ID NO:339)	21	1419
Reverse	5′-tttgatxataxxgagxtgaga-3′	(SEQ ID NO:340)	21	1446

[1071]

TABLE ADB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3448,		Rel. Exp.(%) Ag3448,
Tissue Name	Run 210375137	Tissue Name	Run 210375137
AD 1 Hippo	8.1	Control (Path) 3	3.2
		Temporal Ctx
AD 2 Hippo	23.7	Control (Path) 4	23.0
		Temporal Ctx
AD 3 Hippo	4.4	AD 1 Occipital Ctx	9.2
AD 4 Hippo	3.8	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 Hippo	96.6	AD 3 Occipital Ctx	3.0
AD 6 Hippo	52.1	AD 4 Occipital Ctx	13.3
Control 2 Hippo	19.8	AD 5 Occipital Ctx	38.2
Control 4 Hippo	5.8	AD 6 Occipital Ctx	13.1
Control (Path) 3	4.3	Control 1 Occipital	1.5
Hippo		Ctx
AD 1 Temporal Ctx	9.9	Control 2 Occipital	66.0
		Ctx
AD 2 Temporal Ctx	25.2	Control 3 Occipital	9.2
		Ctx
AD 3 Temporal Ctx	3.8	Control 4 Occipital	4.6
		Ctx
AD 4 Temporal Ctx	1.3	Control (Path) 1	79.6
		Occipital Ctx
AD 5 Inf Temporal	100.0	Control (Path) 2	8.5
Ctx		Occipital Ctx
AD 5 Sup Temporal	41.8	Control (Path) 3	1.9
Ctx		Occipital Ctx
AD 6 Inf Temporal	54.3	Control (Path) 4	12.9
Ctx		Occipital Ctx
AD 6 Sup Temporal	50.0	Control 1 Parietal	3.6
Ctx		Ctx
Control 1 Temporal	3.3	Control 2 Parietal	36.3
Ctx		Ctx
Control 2 Temporal	45.1	Control 3 Parietal	14.9
Ctx		Ctx
Control 3 Temporal	7.6	Control (Path) 1	78.5
Ctx		Parietal Ctx
Control 3 Temporal	6.3	Control (Path) 2	18.3
Ctx		Parietal Ctx
Control (Path) 1	59.5	Control (Path) 3	2.1
Temporal Ctx		Parietal Ctx
Control (Path) 2	32.3	Control (Path) 4	35.1
Temporal Ctx		Parietal Ctx

[1072]

TABLE ADC
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3448,		Rel. Exp.(%) Ag3448,
Tissue Name	Run 217044206	Tissue Name	Run 217044206
Adipose	2.2	Renal ca.TK-10	3.1
Melanoma*	3.6	Bladder	5.2
Hs688(A).T
Melanoma*	4.6	Gastric ca. (liver met.)	3.5
Hs688(B).T		NCI-N87
Melanoma* M14	2.8	Gastric ca. KATO III	6.7
Melanoma*	2.7	Colon ca. SW-948	0.7
LOXIMVI
Melanoma* SK-	6.1	Colon ca. SW480	1.8
MEL-5
Squamous cell	1.3	Colon ca.* (SW480	2.1
carcinoma SCC-4		met) SW620
Testis Pool	2.6	Colon ca. HT29	1.4
Prostate ca.* (bone	9.0	Colon ca. HCT-116	5.5
met) PC-3
Prostate Pool	2.5	Colon ca. CaCo-2	2.0
Placenta	1.2	Colon cancer tissue	2.7
Uterus Pool	1.8	Colon ca. SW1116	0.7
Ovarian ca. OVCAR-3	4.9	Colon ca. Colo-205	0.5
Ovarian ca. SK-OV-3	5.8	Colon ca. SW-48	0.6
Ovarian ca. OVCAR-4	0.6	Colon Pool	100.0
Ovarian ca. OVCAR-5	2.6	Small Intestine Pool	5.1
Ovarian ca. IGROV-1	1.0	Stomach Pool	2.9
Ovarian ca. OVCAR-8	0.9	Bone Marrow Pool	2.7
Ovary	2.5	Fetal Heart	2.8
Breast ca. MCF-7	3.2	Heart Pool	2.3
Breast ca. MDA-	3.9	Lymph Node Pool	5.5
MB-231
Breast ca. BT 549	7.1	Fetal Skeletal Muscle	1.3
Breast ca. T47D	5.6	Skeletal Muscle Pool	3.0
Breast ca. MDA-N	1.4	Spleen Pool	5.8
Breast Pool	5.0	Thymus Pool	6.5
Trachea	3.8	CNS cancer (glio/astro)	3.0
		U87-MG
Lung	1.0	CNS cancer (glio/astro)	17.7
		U-118-MG
Fetal Lung	7.0	CNS cancer (neuro; met)	4.8
		SK-N-AS
Lung ca. NCI-N417	1.0	CNS cancer (astro) SF-	2.3
		539
Lung ca. LX-1	2.0	CNS cancer (astro)	9.2
		SNB-75
Lung ca. NCI-H146	4.1	CNS cancer (glio) SNB-	1.1
		19
Lung ca. SHP-77	7.8	CNS cancer (glio) SF-	10.4
		295
Lung ca. A549	4.5	Brain (Amygdala) Pool	8.0
Lung ca. NCI-H526	1.7	Brain (cerebellum)	5.4
Lung ca. NCI-H23	5.6	Brain (fetal)	10.5
Lung ca. NCI-H460	2.6	Brain (Hippocampus)	9.0
		Pool
Lung ca. HOP-62	1.5	Cerebral Cortex Pool	11.4
Lung ca. NCI-H522	4.7	Brain (Substantia nigra)	9.4
		Pool
Liver	0.5	Brain (Thalamus) Pool	15.4
Fetal Liver	5.6	Brain (whole)	14.5
Liver ca. HepG2	0.9	Spinal Cord Pool	4.8
Kidney Pool	8.6	Adrenal Gland	4.7
Fetal Kidney	3.3	Pituitary gland Pool	2.4
Renal ca. 786-0	3.2	Salivary Gland	1.4
Renal ca. A498	0.7	Thyroid (female)	1.5
Renal ca. ACHN	1.8	Pancreatic ca. CAPAN2	2.5
Renal ca. UO-31	3.7	Pancreas Pool	5.1

[1073]

TABLE ADD
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3448, Run		Ag3448, Run
Tissue Name	166397206	Tissue Name	166397206
Secondary Th1 act	29.9	HUVEC IL-1 beta	8.7
Secondary Th2 act	30.4	HUVEC IFN gamma	13.2
Secondary Tr1 act	48.6	HUVEC TNF alpha + IFN	7.1
		gamma
Secondary Th1 rest	39.8	HUVEC TNF alpha + IL4	8.1
Secondary Th2 rest	20.7	HUVEC IL-11	5.3
Secondary Tr1 rest	31.0	Lung Microvascular EC	10.8
		none
Primary Th1 act	15.0	Lung Microvascular EC	8.7
		TNFalpha + IL-1 beta
Primary Th2 act	40.9	Microvascular Dermal EC	19.8
		none
Primary Tr1 act	54.7	Microsvasular Dermal EC	7.6
		TNFalpha + IL-1 beta
Primary Th1 rest	100.0	Bronchial epithelium	5.2
		TNFalpha + IL1 beta
Primary Th2 rest	49.0	Small airway epithelium	3.6
		none
Primary Tr1 rest	37.6	Small airway epithelium	20.7
		TNFalpha + IL-1 beta
CD45RA CD4	15.3	Coronery artery SMC rest	6.8
lymphocyte act
CD45RO CD4	36.9	Coronery artery SMC	4.9
lymphocyte act		TNFalpha + IL-1 beta
CD8 lymphocyte act	21.3	Astrocytes rest	13.6
Secondary CD8	24.7	Astrocytes TNFalpha + IL-	15.2
lymphocyte rest		1 beta
Secondary CD8	25.3	KU-812 (Basophil) rest	6.1
lymphocyte act
CD4 lymphocyte none	18.8	KU-812 (Basophil)	23.2
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	48.6	CCD1106 (Keratinocytes)	4.8
CD95 CH11		none
LAK cells rest	21.3	CCD1106 (Keratinocytes)	21.6
		TNFalpha + IL-1 beta
LAK cells IL-2	61.1	Liver cirrhosis	8.5
LAK cells IL-2 + IL-12	44.4	Lupus kidney	11.9
LAK cells IL-2 + IFN	48.0	NCI-H292 none	14.6
gamma
LAK cells IL-2 + IL-18	40.3	NCI-H292 IL-4	18.2
LAK cells	11.8	NCI-H292 IL-9	17.9
PMA/ionomycin
NK Cells IL-2 rest	28.3	NCI-H292 IL-13	10.1
Two Way MLR 3 day	28.1	NCI-H292 IFN gamma	13.3
Two Way MLR 5 day	22.7	HPAEC none	6.1
Two Way MLR 7 day	25.5	HPAEC TNF alpha + IL-1	8.5
		beta
PBMC rest	12.5	Lung fibroblast none	13.1
PBMC PWM	28.7	Lung fibroblast TNF	14.9
		alpha + IL-1 beta
PBMC PHA-L	9.5	Lung fibroblast IL-4	14.7
Ramos (B cell) none	24.7	Lung fibroblast IL-9	7.6
Ramos (B cell)	18.0	Lung fibroblast IL-13	9.8
ionomycin
B lymphocytes PWM	18.0	Lung fibroblast IFN	15.4
		gamma
B lymphocytes CD40L	25.9	Dermal fibroblast	24.7
and IL-4		CCD1070 rest
EOL-1 dbcAMP	12.2	Dermal fibroblast	54.3
		CCD1070 TNF alpha
EOL-1 dbcAMP	10.1	Dermal fibroblast	8.8
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	40.1	Dermal fibroblast IFN	5.8
		gamma
Dendritic cells LPS	24.3	Dermal fibroblast IL-4	13.6
Dendritic cells anti-	38.7	IBD Colitis 2	3.4
CD40
Monocytes rest	28.3	IBD Crohn's	4.0
Monocytes LPS	11.8	Colon	46.0
Macrophages rest	40.1	Lung	12.2
Macrophages LPS	14.8	Thymus	19.2
HUVEC none	12.2	Kidney	41.5
HUVEC starved	16.6

[1074] CNS_neurodegeneration_v1.0 Summary: Ag3448 This panel confirms the expression of CG59484-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1075] General_screening_panel_v1.4 Summary: Ag3448 Highest expression of CG59484-01 gene is detected in colon (CT=24.9). Therefore, expression of this gene can used to distinguish this sample from other samples in the panel. Furthermore, expression of this gene is decreased in colon cancer tissue and the cell lines (Cts=30-32). Therefore, therapeutic modulation of the activity of the protein encoded by this gene may be useful in the treatment of colon related diseases such as colon cancers, Crohn's disease, and ulcerative colitis.

[1076] Among tissues with metabolic or endocrine function, this gene is expressed at moderate levels (CTs=29-30) in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[1077] This gene is expressed at significant (CTs=27-29) levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression. However, moderate levels of expression of this gene are detected in areas outside of the central nervous system, suggesting the possibility of a wider role in intercellular signaling.

[1078] Panel 4D Summary: Ag3448 Highest expression of CG59484-01 gene is detected in resting primary Th1 cells. Thus expression of this gene can be used to distinguish this sample from other samples used in this panel. However, moderate levels of expression of this gene are detected in large number of samples used in this panel, suggesting the possibility of a wider role in intercellular signaling.

[1079] Interestingly, expression of this gene is decreased in colon samples from patients with IBD colitis (CT=31.22) and Crohn's disease (CT=30.99) relative to normal colon (CT=27.45). Therefore, therapeutic modulation of the activity of the protein encoded by this gene may be useful in the treatment of inflammatory bowel disease.

AE. NOV38a (CG59454-01: BUTYROPHILIN)

[1080] Expression of gene CG59454-01 was assessed using the primer-probe set Ag3444, described in Table AEA. Results of the RTQ-PCR runs are shown in Tables AEB, and AEC.

TABLE ABA
Probe Name Ag3444
			Start
Primers	Sequences	Length	Position
Forward	5′-gccttccttctgctcaacttt-3′	(SEQ ID NO:341)	20	73
Probe	TET-5′-cttcagctgctcatgcctcactcag-3′-TAMRA	(SEQ ID NO:342)	25	112
Reverse	5′-agggtccaagcacagaaaac-3′	(SEQ ID NO:343)	20	141

[1081]

TABLE AEB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3444,		Rel. Exp.(%) Ag3444,
Tissue Name	Run 210374886	Tissue Name	Run 210374886
AD 1 Hippo	26.8	Control (Path) 3	17.3
		Temporal Ctx
AD 2 Hippo	50.7	Control (Path) 4	25.3
		Temporal Ctx
AD 3 Hippo	14.6	AD 1 Occipital Ctx	27.2
AD 4 Hippo	12.3	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	75.3	AD 3 Occipital Ctx	19.2
AD 6 Hippo	88.3	AD 4 Occipital Ctx	43.5
Control 2 Hippo	40.3	AD 5 Occipital Ctx	15.4
Control 4 Hippo	56.6	AD 6 Occipital Ctx	36.1
Control (Path) 3	10.4	Control 1 Occipital	14.9
Hippo		Ctx
AD 1 Temporal Ctx	39.2	Control 2 Occipital	74.7
		Ctx
AD 2 Temporal Ctx	37.4	Control 3 Occipital	14.6
		Ctx
AD 3 Temporal Ctx	11.0	Control 4 Occipital	27.7
		Ctx
AD 4 Temporal Ctx	34.2	Control (Path) 1	100.0
		Occipital Ctx
AD 5 Inf Temporal	72.2	Control (Path) 2	28.3
Ctx		Occipital Ctx
AD 5 Sup Temporal	69.3	Control (Path) 3	3.8
Ctx		Occipital Ctx
AD 6 Inf Temporal	33.2	Control (Path) 4	22.8
Ctx		Occipital Ctx
AD 6 Sup Temporal	50.7	Control 1 Parietal	27.7
Ctx		Ctx
Control 1 Temporal	24.7	Control 2 Parietal	27.5
Ctx		Ctx
Control 2 Temporal	45.1	Control 3 Parietal	21.6
Ctx		Ctx
Control 3 temporal	20.3	Control (Path) 1	66.0
Ctx		Parietal Ctx
Control 4 Temporal	12.2	Control (Path) 2	46.0
Ctx		Parietal Ctx
Control (Path) 1	60.3	Control (Path) 3	12.2
Temporal Ctx		Parietal Ctx
Control (Path) 2	58.6	Control (Path) 4	62.9
Temporal Ctx		Parietal Ctx

[1082]

TABLE AEC
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3444, Run		Ag3444, Run
Tissue Name	166397205	Tissue Name	166397205
Secondary Th1 act	11.5	HUVEC IL-1 beta	4.1
Secondary Th2 act	26.4	HUVEC IFN gamma	13.0
Secondary Tr1 act	22.1	HUVEC TNF alpha + IFN	20.2
		gamma
Secondary Th1 rest	43.8	HUVEC TNF alpha + IL4	9.4
Secondary Th2 rest	41.2	HUVEC IL-11	2.4
Secondary Tr1 rest	49.0	Lung Microvascular EC	3.8
		none
Primary Th1 act	6.7	Lung Microvascular EC	20.2
		TNFalpha + IL-1 beta
Primary Th2 act	17.6	Microvascular Dermal EC	5.8
		none
Primary Tr1 act	18.3	Microsvasular Dermal EC	18.8
		TNFalpha + IL-1 beta
Primary Th1 rest	98.6	Bronchial epithelium	4.4
		TNFalpha + IL1 beta
Primary Th2 rest	53.2	Small airway epithelium	1.5
		none
Primary Tr1 rest	29.1	Small airway epithelium	5.1
		TNFalpha + IL-1 beta
CD45RA CD4	12.5	Coronery artery SMC rest	6.2
lymphocyte act
CD45RO CD4	22.4	Coronery artery SMC	5.5
lymphocyte act		TNFalpha + IL-1 beta
CD8 lymphocyte act	18.0	Astrocytes rest	3.1
Secondary CD8	20.0	Astrocytes TNFalpha + IL-	15.3
lymphocyte rest		1 beta
Secondary CD8	9.7	KU-812 (Basophil) rest	3.1
lymphocyte act
CD4 lymphocyte none	36.3	KU-812 (Basophil)	8.2
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	43.2	CCD1106 (Keratinocytes)	1.6
CD95 CH11		none
LAK cells rest	29.3	CCD1106 (Keratinocytes)	25.0
		TNFalpha + IL-1 beta
LAK cells IL-2	76.8	Liver cirrhosis	10.2
LAK cells IL-2 + IL-12	59.5	Lupus kidney	6.0
LAK cells IL-2 + IFN	77.4	NCI-H292 none	10.5
gamma
LAK cells IL-2 + IL-18	61.1	NCI-H292 IL-4	13.3
LAK cells	8.0	NCI-H292 IL-9	11.0
PMA/ionomycin
NK Cells IL-2 rest	42.0	NCI-H292 IL-13	7.1
Two Way MLR 3 day	100.0	NCI-H292 IFN gamma	18.3
Two Way MLR 5 day	33.7	HPAEC none	3.1
Two Way MLR 7 day	13.7	HPAEC TNF alpha + IL-1	14.4
		beta
PBMC rest	35.8	Lung fibroblast none	10.7
PBMC PWM	20.9	Lung fibroblast TNF	60.7
		alpha + IL-1 beta
PBMC PHA-L	5.6	Lung fibroblast IL-1	5.7
Ramos (B cell) none	18.8	Lung fibroblast IL-9	4.3
Ramos (B cell)	10.4	Lung fibroblast IL-13	4.2
ionomycin
B lymphocytes PWM	16.7	Lung fibroblast IFN	18.2
		gamma
B lymphocytes CD40L	26.4	Dermal fibroblast	7.9
and IL-4		CCD1070 rest
EOL-1 dbcAMP	2.0	Dermal fibroblast	36.6
		CCD1070 TNF alpha
EOL-1 dbcAMP	0.6	Dermal fibroblast	10.2
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	19.2	Dermal fibroblast IFN	24.1
		gamma
Dendritic cells LPS	10.2	Dermal fibroblast IL-4	7.0
Dendritic cells anti-	8.1	IBD Colitis 2	3.9
CD40
Monocytes rest	30.8	IBD Crohn's	9.8
Monocytes LPS	16.7	Colon	92.7
Macrophages rest	22.7	Lung	16.5
Macrophages LPS	14.9	Thymus	8.9
HUVEC none	4.4	Kidney	30.1
HUVEC starved	8.5

[1083] CNS_neurodegeneration_v1.0 Summary: Ag3444 This panel confirms the expression of the CG59454-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment.

[1084] The CG59454-01 gene codes for butyrophilin protein (BTN), a milk protein. Recently it was demonstrated that active immunization of the dark Agouti rat with native BFN triggers an inflammatory response in the CNS characterized by the formation of scattered meningeal and perivascular infiltrates of T cells and microphages (see Ref. 1 in panel 4D).

[1085] General_screening_panel_v1.4 Summary: Ag3444 Results from one experiment with the CG59454-01 gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[1086] Panel 4D Summary: Ag3444 Highest expression of CG59454-01 is detected in samples derived from two way MLR 3 day and resting primary Th1 cells (CTs=25). Thus, expression of this gene can be used to distinguish these two samples from other samples in the panel. In addition, expression of this gene is down-regulated in activated primary Th1 cells (CT=29) as compared to resting primary Th1 cells (CT-=25). Thus, therapeutics designed with the protein encoded for by this transcript could be important in treating T-cell mediated diseases such as asthma, emphysema, psoriasis, IBD, systemic lupus erythematosus, autoimmune encephalomyelitis, and parasitic disease.

[1087] CG59454-01 gene codes for butyrophilin protein, a milk protein. Recently, butyrophilin has been shown to modulates the encephalitogenic T cell response to myelin oligodendrocytc glycoprotein in experimental autoimmune encephalomyelitis (Ref. 1).

[1088] References.

[1089] 1. Stefferl A, Schubart A, Storch2 M, Amini A, Mather I, Lassmann H, Linington C. (2000) Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. J Immunol 165(5):2859-65

AF. NOV39a (CG59307-01: KIAA1769)

[1090] Expression of gene CG59307-01 was assessed using the primer-probc set Ag3539, described in Table AFA. Results of the RTQ-PCR runs are shown in Tables AFB, AFC and AFD.

TABLE AFA
Probe Name Ag3539
			Start
Primers	Sequences	Length	Position
Forward	5′-ctactcatctatggcccctttg-3′	(SEQ ID NO:344)	22	2617
Probe	TET-5′-caagacctacacgctggccatgg-3′-TAMRA	(SEQ ID NO:345)	23	2646
Reverse	5′-agatgagcaccttggtttcag-3′	(SEQ ID NO:345)	21	2693

[1091]

TABLE AFB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3539,		Rel. Exp.(%) Ag3539,
Tissue Name	Run 210638376	Tissue Name	Run 210638376
AD 1 Hippo	24.7	Control (Path) 3	55.5
		Temporal Ctx
AD 2 Hippo	34.9	Control (Path) 4	34.6
		Temporal Ctx
AD 3 Hippo	39.5	AD 1 Occipital Ctx	27.0
AD 4 Hippo	48.6	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 Hippo	56.3	AD 3 Occipital Ctx	39.5
AD 6 Hippo	85.3	AD 4 Occipital Ctx	49.0
Control 2 Hippo	43.8	AD 5 Occipital Ctx	57.4
Control 4 Hippo	62.9	AD 6 Occipital Ctx	70.2
Control (Path) 3	24.7	Control 1 Occipital	79.6
Hippo		Ctx
AD 1 Temporal Ctx	59.9	Control 2 Occipital	53.6
		Ctx
AD 2 Temporal Ctx	29.1	Control 3 Occipital	25.3
		Ctx
AD 3 Temporal Ctx	26.8	Control 4 Occipital	48.6
		Ctx
AD 4 Temporal Ctx	50.3	Control (Path) 1	33.7
		Occipital Ctx
AD 5 Inf Temporal	82.9	Control (Path) 2	17.1
Ctx		Occipital Ctx
AD 5 Sup Temporal	58.2	Control (Path) 3	26.4
Ctx		Occipital Ctx
AD 6 Inf Temporal	98.6	Control (Path) 4	36.9
Ctx		Occipital Ctx
AD 6 Sup Temporal	100.0	Control 1 Parietal	16.7
Ctx		Ctx
Control 1 Temporal	31.2	Control 2 Parietal	76.3
Ctx		Ctx
Control 2 Temporal	41.2	Control 3 Parietal	15.5
Ctx		Ctx
Control 3 Temporal	22.2	Control (Path) 1	28.7
Ctx		Parietal Ctx
Control 3 Temporal	49.3	Control (Path) 2	23.0
Ctx		Parietal Ctx
Control (Path) 1	53.6	Control (Path) 3	27.0
Temporal Ctx		Parietal Ctx
Control (Path) 2	41.8	Control (Path) 4	52.9
Temporal Ctx		Parietal Ctx

[1092]

TABLE AFC
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3539,		Rel. Exp.(%) Ag3539,
Tissue Name	Run 217049118	Tissue Name	Run 217049118
Adipose	2.4	Renal ca. TK-10	3.6
Melanoma*	1.2	Bladder	12.5
Hs688(A).T
Melanoma*	0.9	Gastric ca. (liver met.)	100.0
Hs688(B).T		NCI-N87
Melanoma* M14	2.7	Gastric ca: KATO III	5.4
Melanoma*	2.2	Colon ca. SW-948	1.1
LOXIMVI
Melanoma* SK-	2.9	Colon ca. SW480	8.3
MEL-5
Squamous cell	1.6	Colon ca.* (SW480	1.8
carcinoma SCC-4		met) SW620
Testis Pool	0.4	Colon ca. HT29	2.6
Prostate ca.* (bone	3.3	Colon ca. HCT-116	3.4
met) PC-3
Prostate Pool	1.2	Colon ca. CaCo-2	4.4
Placenta	0.7	Colon cancer tissue	5.5
Uterus Pool	0.2	Colon ca. SW1116	0.6
Ovarian ca. OVCAR-3	3.3	Colon ca. Colo-205	0.4
Ovarian ca. SK-OV-3	1.8	Colon ca. SW-48	1.0
Ovarian ca. OVCAR-4	1.5	Colon Pool	0.9
Ovarian ca. OVCAR-5	9.3	Small Intestine Pool	0.8
Ovarian ca. IGROV-1	6.3	Stomach Pool	0.8
Ovarian ca. OVCAR-8	5.8	Bone Marrow Pool	0.4
Ovary	1.7	Fetal Heart	0.4
Breast ca. MCF-7	7.0	Heart Pool	0.6
Breast ca. MDA-	5.4	Lymph Node Pool	0.8
MB-231
Breast ca. BT 549	40.9	Fetal Skeletal Muscle	0.5
Breast ca. T47D	21.5	Skeletal Muscle Pool	1.7
Breast ca. MDA-N	2.8	Spleen Pool	5.9
Breast Pool	0.8	Thymus Pool	1.7
Trachea	1.2	CNS cancer (glio/astro)	4.1
		U87-MG
Lung	0.2	CNS cancer (glio/astro)	7.1
		U-118-MG
Fetal Lung	3.3	CNS cancer (neuro;met)	3.0
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	1.3
		539
Lung ca. LX-1	3.0	CNS cancer (astro)	6.8
		SNB-75
Lung ca. NCI-H146	0.2	CNS cancer (gilo) SNB-	5.7
		19
Lung ca. SHP-77	1.9	CNS cancer (glio) SF-	11.3
		295
Lung ca. A549	0.7	Brain (Amygdala) Pool	0.2
Lung ca. NCI-H526	0.2	Brain (cerebellum)	0.3
Lung ca. NCI-H23	6.7	Brain (fetal)	0.5
Lung ca. NCI-H460	0.6	Brain (Hippocampus)	0.2
		Pool
Lung ca. HOP-62	2.8	Cerebral Cortex Pool	0.3
Lung ca. NCI-H522	23	Brain (Substantia nigra)	0.5
		Pool
Liver	0.4	Brain (Thalamus) Pool	0.2
Fetal Liver	0.6	Brain (whole)	0.5
Liver ca. HepG2	0.7	Spinal Cord Pool	0.4
Kidney Pool	1.5	Adrenal Gland	1.4
Fetal Kidney	0.5	Pituitary gland Pool	0.3
Renal ca. 786-0	2.1	Salivary Gland	0.5
Renal ca. A498	1.4	Thyroid (female)	1.2
Renal ca. ACHN	2.4	Pancreatic ca. CAPAN2	4.0
Renal ca. UO-31	1.4	Pancreas Pool	1.3

[1093]

TABLE AFD
Panel 4D
	Rel Exp.(%)		Rel. Exp.(%)
	Ag3539, Run		Ag3539, Run
Tissue Name	166447031	Tissue Name	166447031
Secondary Th1 act	6.2	HUVEC IL-1 beta	3.4
Secondary Th2 act	57.0	HUVEC IFN gamma	18.6
Secondary Tr1 act	18.0	HUVEC TNF alpha + IFN	44.4
		gamma
Secondary Th1 rest	23.0	HUVEC TNF alpha + IL4	14.6
Secondary Th2 rest	7.3	HUVEC IL-11	3.3
Secondary Tr1 rest	13.6	Lung Microvascular EC	6.8
		none
Primary Th1 act	0.5	Lung Microvascular EC	14.8
		TNFalpha + IL-1 beta
Primary Th2 act	2.4	Microvascular Dermal EC	5.9
		none
Primary Tr1 act	2.1	Microsvasular Dermal EC	17.2
		TNFalpha + IL-1 beta
Primary Th1 rest	16.2	Bronchial epithelium	7.0
		TNFalpha + IL1 beta
Primary Th2 rest	3.6	Small airway epithelium	2.4
		none
Primary Tr1 rest	2.5	Small airway epithelium	16.5
		TNFalpha + IL-1 beta
CD45RA CD4	20.4	Coronery artery SMC rest	3.1
lymphocyte act
CD45RO CD4	12.2	Coronery artery SMC	3.3
lymphocyte act		TNFalpha + IL-1 beta
CD8 lymphocyte act	2.3	Astrocytes rest	3.5
Secondary CD8	17.8	Astrocytes TNFalpha + IL-	30.6
lymphocyte rest		1 beta
Secondary CD8	8.1	KU-812 (Basophil) rest	0.6
lymphocyte act
CD4 lymphocyte none	7.0	KU-812 (Basophil)	6.6
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	3.0	CCD1106 (Keratinocytes)	9.6
CD95 CH11		none
LAK cells rest	6.8	CCD1106 (Keratinocytes)	100.0
		TNFalpha + IL-1 beta
LAK cells IL-2	23.7	Liver cirrhosis	5.2
LAK cells IL-2 + IL-12	33.4	Lupus kidney	4.0
LAK cells IL-2 + IFN	48.6	NCI-H292 none	8.2
gamma
LAK cells IL-2 + IL-18	35.8	NCI-H292 IL-4	13.0
LAK cells	19.2	NCI-H292 IL-9	9.4
PMA/ionomycin
NK Cells IL-2 rest	17.0	NCI-H292 IL-13	10.2
Two Way MLR 3 day	38.4	NCI-H292 IFN gamma	37.1
Two Way MLR 5 day	19.2	HPAEC none	2.6
Two Way MLR 7 day	6.1	HPAEC TNF alpha + IL-1	29.9
		beta
PBMC rest	7.7	Lung fibroblast none	10.1
PBMC PWM	8.3	Lung fibroblast TNF	61.1
		alpha + IL-1 beta
PBMC PHA-L	1.8	Lung fibroblast IL-4	10.3
Ramos (B cell) none	0.8	Lung fibroblast IL-9	4.8
Ramos (B cell)	0.3	Lung fibroblast IL-13	5.0
ionomycin
B lymphocytes PWM	4.0	Lung fibroblast IFN	41.8
		gamma
B lymphocytes CD40L	7.8	Dermal fibroblast	4.2
and IL-4		CCD1070 rest
EOL-1 dbcAMP	5.4	Dermal fibroblast	10.9
		CCD1070 TNF alpha
EOL-1 dbcAMP	10.4	Dermal fibroblast	8.4
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	3.3	Dermal fibroblast IFN	23.7
		gamma
Dendritic cells LPS	41.8	Dermal fibroblast IL-4	10.2
Dendritic cells anti-	1.9	IBD Colitis 2	2.2
CD40
Monocytes rest	13.3	IBD Crohn's	2.7
Monocytes LPS	57.0	Colon	26.8
Macrophages rest	3.3	Lung	7.3
Macrophages LPS	60.7	Thymus	2.8
HUVEC none	3.6	Kidney	9.2
HUVEC starved	7.1

[1094] CNS_neurodegeneration_v1.0 Summary: Ag3539 This panel confirms the expression of the CG59307-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1095] General_screening_panel_v1.4 Summary: Ag3539 Highest expression of the CG59307-0l gene is detected in a sample derived from one of the gastric cancer cell line NCI-N87 (CT=23.9). Thus expression of this gene can be used to distinguish this sample from other samples in the panel. In addition low levels of expression of this gene is also associated with colon cancer, ovarian cancer, breast cancer, and CNS cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.

[1096] Among tissues with metabolic or endocrine function, this gene is expressed at moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract (CTs=27-31). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[1097] In addition, this gene is expressed at low to moderate levels (CTs=31-33) in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1098] Panel 4D Summary: Ag3539 Highest expression of the CG59307-01 gene is detected in a sample derived from TNFalpha+IL-1beta treated CCD1106 (Keratinocytes) (CT=26.45). Furthermore, expression of this gene is stimulated in activated secondary Th1 cells, LAK cells treated with IL-2/IL-2+IFN gamma/IL-2+IL-12/IL-2+IL-18, LPS treated dendritic cells, monocytes, and macrophages, TNF alpha+IFN gamma treated HUVEC, FNFalpha+IL-1beta treated astrocytes, CCD1106 (Keratinocytes), and lung fibroblasts. Therefore, therapeutics designed with the protein encoded for by this transcript could be important in regulating T cell function and treating T cell mediated diseases such as asthma, arthritis, psoriasis, IBD, cancer cell killing, improvement of host immunity to microbial and viral infections and systemic lupus erythematosus.

AG. NOV40a (CG59713-01: VAN GOGH)

[1099] Expression of gene CG59713-01 was assessed using the primer-probe set Ag3513, described in Table AGA. Results of the RTQ-PCR runs are shown in Tables AGB, AGC and AGD.

TABLE AGA
Probe Name Ag3513
			Start
Primers	Sequences	Length	Position
Forward	5′-gacttcagcctcgtagtcaatg-3′	(SEQ ID NO:347)	22	1474
Probe	TET-5′-tgaagaaaattccattcattcatactcttctg-3′-TAMRA	(SEQ ID NO:348)	30	1496
Reverse	5′-tttgtgagatttggggtctatg-3′	(SEQ ID NO:349)	22	1533

[1100]

TABLE AGB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3513,		Rel. Exp.(%) Ag3513,
Tissue Name	Run 210499622	Tissue Name	Run 210499622
AD 1 Hippo	32.3	Control (Path) 3	6.9
		Temporal Ctx
AD 2 Hippo	46.0	Control (Path) 4	73.2
		Temporal Ctx
AD 3 Hippo	12.3	AD 1 Occipital Ctx	12.1
AD 4 Hippo	12.1	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	82.4	AD 3 Occipital Ctx	19.6
AD 6 Hippo	92.7	AD 4 Occipital Ctx	22.1
Control 2 Hippo	20.6	AD 5 Occipital Ctx	10.0
Control 4 Hippo	28.1	AD 6 Occipital Ctx	25.5
Control (Path) 3	23.2	Control 1 Occipital	18.0
Hippo		Ctx
AD 1 Temporal Ctx	26.4	Control 2 Occipital	44.8
		Ctx
AD 2 Temporal Ctx	25.9	Control 3 Occipital	21.0
		Ctx
AD 3 Temporal Ctx	11.4	Control 4 Occipital	21.3
		Ctx
AD 4 Temporal Ctx	33.7	Control (Path) 1	100.0
		Occipital Ctx
AD 5 Inf Temporal	100.0	Control (Path) 2	16.6
Ctx		Occipital Ctx
AD 5 Sup Temporal	100.0	Control (Path) 3	5.9
Ctx		Occipital Ctx
AD 6 Inf Temporal	40.6	Control (Path) 4	21.0
Ctx		Occipital Ctx
AD 6 Sup Temporal	72.2	Control 1 Parietal	13.5
Ctx		Ctx
Control 1 Temporal	12.8	Control 2 Parietal	49.3
Ctx		Ctx
Control 2 Temporal	16.8	Control 3 Parietal	11.8
Ctx		Ctx
Control 3 Temporal	16.3	Control (Path) 1	50.0
Ctx		Parietal Ctx
Control 4 Temporal	10.6	Control (Path) 2	48.0
Ctx		Parietal Ctx
Control (Path) 1	78.5	Control (Path) 3	12.9
Temporal Ctx		Parietal Ctx
Control (Path) 2	22.2	Control (Path) 4	71.2
Temporal Ctx		Parietal Ctx

[1101]

TABLE AGC
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3513,		Rel. Exp.(%) Ag3513,
Tissue Name	Run 217240777	Tissue Name	Run 217240777
Adipose	5.6	Renal ca. TK-10	37.4
Melanoma*	25.7	Bladder	17.7
Hs688(A).T
Melanoma*	29.3	Gastric ca. (liver met.)	85.3
Hs688(B).T		NCI-N87
Melanoma* M14	68.8	Gastric ca. KATO III	78.5
Melanoma*	20.3	Colon ca. SW-948	19.3
LOXIMVI
Melanoma* SK-	31.0	Colon ca. SW480	84.1
MEL-5
Squamous cell	36.1	Colon ca.* (SW480	27.2
carcinoma SCC-4		met) SW620
Testis Pool	5.3	Colon ca. HT29	26.6
Prostate ca.* (bone	37.9	Colon ca. HCT-116	73.7
met) PC-3
Prostate Pool	8.4	Colon CaCo-2	18.4
Placenta	4.4	Colon cancer tissue	13.4
Uterus Pool	4.7	Colon ca. SW1116	7.9
Ovarian ca. OVCAR-3	48.0	Colon ca. Colo-205	17.0
Ovarian ca. SK-OV-3	100.0	Colon ca. SW-48	10.6
Ovarian ca. OVCAR-4	26.1	Colon Pool	18.2
Ovarian ca. OVCAR-5	37.1	Small Intestine Pool	8.8
Ovarian ca. IGROV-1	24.0	Stomach Pool	8.9
Ovarian ca. OVCAR-8	17.7	Bone Marrow Pool	9.2
Ovary	9.5	Fetal Heart	7.0
Breast ca. MCF-7	67.4	Heart Pool	8.5
Breast ca. MDA-	67.4	Lymph Node Pool	22.1
MB-231
Breast ca. BT 549	71.2	Fetal Skeletal Muscle	4.0
Breast ca. T47D	82.9	Skeletal Muscle Pool	2.7
Breast ca. MDA-N	29.7	Spleen Pool	5.2
Breast Pool	16.7	Thymus Pool	11.7
Trachea	14.1	CNS cancer (glio/astro)	49.3
		U87-MG
Lung	2.4	CNS cancer (glio/astro)	34.4
		U-118-MG
Fetal Lung	19.5	CNS cancer (neuro; met)	19.3
		SK-N-AS
Lung ca. NCI-N417	3.2	CNS cancer (astro) SF-	54.7
		539
Lung ca. LX-1	17.6	CNS cancer (astro)	62.9
		SNB-75
Lung ca. NCI-H146	9.5	CNS cancer (glio) SNB-19	21.9
		19
Lung ca. SHP-77	53.6	CNS cancer (glio) SF-	16.0
		295
Lung ca. A549	35.6	Brain (Amygdala) Pool	1.2
Lung ca. NCI-H526	6.8	Brain (cerebellum)	1.6
Lung ca. NCI-H23	33.4	Brain (fetal)	7.2
Lung ca. NCI-H460	41.2	Brain (Hippocampus)	1.3
		Pool
Lung ca. HOP-62	11.5	Cerebral Cortex Pool	1.4
Lung ca. NCI-H522	16.5	Brain (Substantia nigra)	1.4
		Pool
Liver	1.3	Brain (Thalamus) Pool	2.2
Fetal Liver	28.3	Brain (whole)	3.8
Liver ca. HepG2	21.3	Spinal Cord Pool	1.8
Kidney Pool	24.1	Adrenal Gland	16.8
Fetal Kidney	8.7	Pituitary gland Pool	0.5
Renal ca. 786-0	55.9	Salivary Gland	8.8
Renal ca. A498	14.6	Thyroid (female)	11.2
Renal ca. ACHN	17.2	Pancreatic ca. CAPAN2	35.8
Renal ca. UO-31	24.0	Pancreas Pool	22.8

[1102]

TABLE AGD
Panel 4D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3513, Run		Ag3513, Run
Tissue Name	166407114	Tissue Name	166407114
Secondary Th1 act	21.3	HUVEC IL-1 beta	17.9
Secondary Th2 act	26.4	HUVEC IFN gamma	18.8
Secondary Tr1 act	33.7	HUVEC TNF alpha + IFN	11.6
		gamma
Secondary Th1 rest	11.6	HUVEC TNF alpha + IL4	15.8
Secondary Th2 rest	8.7	HUVEC IL-11	7.3
Secondary Tr1 rest	10.2	Lung Microvascular EC	18.7
		none
Primary Th1 act	6.8	Lung Microvascular EC	14.4
		TNFalpha + IL-1 beta
Primary Th2 act	20.2	Microvascular Dermal EC	26.6
		none
Primary Tr1 act	23.2	Microsvasular Dermal EC	21.9
		TNFalpha + IL-1 beta
Primary Th1 rest	47.0	Bronchial epithelium	21.2
		TNFalpha + IL 1 beta
Primary Th2 rest	18.3	Small airway epithelium	13.8
		none
Primary Tr1 rest	16.4	Small airway epithelium	89.5
		TNFalpha + IL-1 beta
CD45RA CD4	10.2	Coronery artery SMC rest	10.5
lymphocyte act
CD45RO CD4	19.2	Coroncry artery SMC	8.4
lymphocyte act		TNFalpha + IL-1 beta
CD8 lymphocyte act	4.4	Astrocytes rest	15.3
Secondary CD8	6.9	Astrocytes TNFalpha + IL-	23.3
lympnocyte rest		1 beta
Secondary CD8	11.0	KU-812 (Basophil) rest	21.2
lymphocyte act
CD4 lymphocyte none	1.4	KU-812 (Basophil)	34.6
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	13.2	CCD1106 (Keratinocytes)	32.5
CD95 CH11		none
LAK cells rest	2.1	CCD1106 (Keratinocytes)	100.0
		TNFalpha + IL-1 beta
LAK cells IL-2	37.4	Liver cirrhosis	2.9
LAK cells IL-2 + IL-12	12.4	Lupus kidney	5.6
LAK cells IL-2 + IFN	18.7	NCI-H292 none	36.6
gamma
LAK cells IL-2 + IL-18	17.7	NCI-H292 IL-4	69.3
LAK cells	0.6	NCI-H292 IL-9	56.6
PMA/ionomycin
NK Cells IL-2 rest	21.5	NCI-H292 IL-13	35.4
Two Way MLR 3 day	3.8	NCI-H292 IFN gamma	29.3
Two Way MLR 5 day	5.6	HPAEC none	12.0
Two Way MLR 7 day	5.1	HPAEC TNF alpha + IL-1	10.8
		beta
PBMC rest	2.6	Lung fibroblast none	11.2
PBMC PWM	4.5	Lung fibroblast TNF	13.9
		alpha + IL-1 beta
PBMC PHA-L	4.1	Lung fibroblast IL-4	16.5
Ramos (B cell) none	0.2	Lung fibroblast IL-9	11.4
Ramos (B cell)	0.0	Lung fibroblast IL-13	8.6
ionomycin
B lymphocytes PWM	11.3	Lung fibroblast IFN	19.8
		gamma
B lymphocytes CD40L	4.9	Dermal fibroblast	44.8
and IL-4		CCD 1070 rest
EOL-1 dbcAMP	5.5	Dermal fibroblast	49.7
		CCD1070 TNF alpha
EOL-1 dbcAMP	3.5	Dermal fibroblast	19.6
PMA/ionomyein		CCD1070 IL-1 beta
Dendritic cells none	2.9	Dermal fibroblast IFN	11.7
		gamma
Dendritic cells LPS	1.7	Dermal fibroblast IL-4	21.5
Dendritic cell anti-	3.6	IBD Colitis 2	1.2
CD 40
Monocytes rest	1.1	IBD Crohn's	1.8
Monocytes LPS	0.4	Colon	23.0
Macrophages rest	5.6	Lung	9.4
Macrophages LPS	1.6	Thymus	16.2
HUVEC none	35.6	Kidney	16.2
HUVEC starved	40.3

[1103] CNS_neurodegeneration_v1.0 Summary: Ag3513 This panel confirms the expression of the CG59713-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1104] General_screening_panel_v1.4 Summary: Ag3513 Highest expression of the CG59713-01 is detected in sample derived from one of the ovarian cancer SK-OV-3(CT=28). Furthermore, significant expression of this gene is associated with number of cancer samples (pancreatic cancer, CNS cancer, colon cancer, gastric cancer, renal cancer, lung cancer, breast cancer, prostate cancer, melanoma cell lines) used in this panel. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, or antibodies, might be beneficial in the treatment of all these cancers.

[1105] Interestingly, this gene is expressed at much higher levels in fetal (CT=30) when compared to adult liver (CT=34). This observation suggests that expression of this gene can be used to distinguish fetal from adult liver. In addition, the relative overexpression of this gene in fetal liver suggests that the protein product may be required for growth and development of the liver in fetus and thus may also act in a regenerative capacity in the adult. Therefore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of liver related diseases.

[1106] Among tissues with metabolic or endocrine function, this gene is expressed at high to moderate levels (CTs=30-32) in pancreas, adipose, adrenal gland, thyroid, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[1107] In addition, this gene is expressed at low levels (CTs=32-34) in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1108] Panel 4D Summary: Ag3513 Highest expression of the CG59713-01 is detected in TNFalpha+IL-1beta treated keratinocytes (CT=27.9). Therefore, expression of this gene can be used to distinguish TNFalpha+IL-1beta treated keratinocytes from other samples used in this panel.

[1109] In addition, expression of this gene is stimulated in activated secondary Th1, Th2, and Tr1 cells, LAK cells treated with IL-2, TNFalpha+IL-1beta treated small airway epithelium and NCI-H292 treated with IL-4. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, or antibodies, might be beneficial in the treatment of psoriasis, asthma, emphysema, cancer, microbial and viral infections.

AH. NOV41a (CG59570-01: AQUAPORIN)

[1110] Expression of gene CG59570-01 was assessed using the primer-probe set Ag3475, described in Table AHA. Results of the RTQ-PCR runs are shown in Tables AHB, and AHC.

TABLE AHA
Probe Name Ag3475
			Start
Primers	Sequences	Length	Positon
Forward	5′-acaaaacatggttcaagcatct-3′	(SEQ ID NO:350)	22	2
Probe	TET-5′-ccaaaatggtctcctggtccgtgata-3′-TAMRA	(SEQ ID NO: 351)	26	49
Reverse	5′-accatatttcctggatctttgc-3′	(SEQ ID NO:352)	22	75

[1111]

TABLE AHB
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3475,		Rel. Exp.(%) Ag3475,
Tissue Name	Run 222691300	Tissue Name	Run 222691300
Adipose	100.0	Renal ca. TK-10	1.1
Melanoma*	0.0	Bladder	3.4
Hs688(A).T
Melanoma*	0.1	Gastric ca. (liver met.)	8.5
Hs688(B).T		NCI-N87
Melanoma* M14	0.2	Gastric ca. KATO III	0.2
Melanoma*	1.1	Colon ca. SW-948	1.2
LOXIMVI
Melanoma* SK-	0.0	Colon ca. SW480	0.0
MEL-5
Squamous cell	0.0	Colon ca.* (SW480	0.4
carcinoma SCC-4		met) SW620
Testis Pool	10.2	Colon ca. HT29	0.2
Prostate ca.* (bone	2.2	Colon HCT-116	0.6
met) PC-3
Prostate Pool	0.6	Colon ca. CaCo-2	0.0
Placenta	0.3	Colon cancer tissue	9.6
Uterus Pool	0.8	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.5	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	0.1	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.3	Colon Pool	1.5
Ovarian ca. OVCAR-5	0.3	Small Intestine Pool	0.6
Ovarian ca. IGROV-1	5.0	Stomach Pool	2.2
Ovarian ca. OVCAR-8	0.3	Bone Marrow Pool	0.8
Ovary	0.1	Fetal Heart	1.2
Breast ca. MCF-7	0.1	Heart Pool	20.6
Breast ca. MDA-	0.1	Lymph Node Pool	1.3
MB-231
Breast ca. BT 549	0.3	Fetal Skeletal Muscle	4.7
Breast ca. T47D	0.5	Skeletal Muscle Pool	14.3
Breast ca. MDA-N	0.5	Spleen Pool	1.9
Breast Pool	1.0	Thymus Pool	6.0
Trachea	4.0	CNS cancer (glio/astro)	0.7
		U87-MG
Lung	0.2	CNS cancer (glio/astro)	4.7
		U-118-MG
Fetal Lung	0.4	CNS cancer (neuro; met)	0.2
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	0.0
		539
Lung ca. LX-1	0.7	CNS cancer (astro)	2.8
		SNB-75
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-	3.8
		19
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-	0.2
		295
Lung ca. A549	0.2	Brain (Amygdala) Pool	0.7
Lung ca. NCI-H526	0.0	Brain (cerebellum)	13.2
Lung ca. NCI-H23	0.1	Brain (fetal)	0.1
Lung ca. NCI-H460	0.3	Brain (Hippocampus)	1.3
		Pool
Lung ca. HOP-62	0.3	Cerebral Cortex Pool	0.1
Lung ca. NCI-H522	1.7	Brain (Substantia nigra)	0.8
		Pool
Liver	0.0	Brain (Thalamus) Pool	0.1
Fetal Liver	0.0	Brain (whole)	0.2
Liver ca. HepG2	2.0	Spinal Cord Pool	1.3
Kidney Pool	3.6	Adrenal Gland	10.2
Fetal Kidney	0.9	Pituitary gland Pool	0.0
Renal ca.786-0	1.3	Salivary Gland	2.5
Renal ca. A498	0.5	Thyroid (female)	0.7
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.1	Pancreas Pool	1.1

[1112]

TABLE AHC
Panel 4D
	Rel. Exp. (%)		Rel. Exp. (%)
	Ag3475, Run		Ag3475, Run
Tissue Name	166420470	Tissue Name	166420470
Secondary Th1 act	1.9	HUVEC IL-1 beta	1.6
Secondary Th2 act	0.7	HUVEC IFN gamma	3.5
Secondary Tr1 act	0.9	HUVEC TNF alpha + IFN	0.5
		gamma
Secondary Th1 rest	1.5	HUVEC TNF alpha + IL4	2.0
Secondary Th2 rest	1.5	HUVEC IL-11	3.1
Secondary Tr1 rest	0.6	Lung Microvascular EC	50.3
		none
Primary Th1 act	0.0	Lung Microvascular EC	22.1
		TNFalpha + IL-1beta
Primary Th2 act	1.2	Microvascular Dermal EC	0.8
		none
Primary Tr1 act	1.0	Microvascular Dermal EC	1.3
		THFalpha + IL-1beta
Primary Th1 rest	3.3	Bronchial epithelium	0.6
		TNFalpha + IL1beta
Primary Th2 rest	2.2	Small airway epithelium	2.7
		none
Primary Tr1 rest	1.1	Small airway epithelium	17.8
		TNFalpha + IL-1beta
CD45RA CD4	0.0	Coronery artery SMC rest	1.7
lymphocyte act
CD45RO CD4	0.0	Coronery artery SMC	0.0
lymphocyte act		TNFalpha + IL-1beta
CD8 lymphocyte act	0.0	Astrocytes rest	2.6
Secondary CD8	1.4	Astrocytes TNFalpha + IL-	6.6
lymphocyte rest		1 beta
Secondary CD8	0.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	0.0	KU-812 (Basophil)	1.0
		PMA/ionomycin
2ry TH1/TH2/TR1_anti-	5.1	CCD1106 (Keratinocytes)	1.2
CD95 CH11		none
LAK cells rest	0.0	CCD1106 (Keratinocytes)	3.1
		TNFalpha + IL-1beta
LAK cells IL-2	0.0	Liver cirrhosis	4.5
LAK cells IL-2 + IL-12	0.5	Lupus kidney	13.4
LAK cells IL-2 + IFN	0.0	NCI-H292 none	3.0
gamma
LAK cells IL-2 + IL-18	0.3	NCI-H292 IL-4	0.8
LAK cells	0.7	NCI-H292 IL-9	4.3
PMA/ionomycin
NK Cells IL-2 rest	1.0	NCI-H292 IL-13	3.3
Two Way MLR 3 day	0.0	NCI-H292 IFN gamma	1.7
Two Way MLR 5 day	0.0	HPAEC none	100.0
Two Way MLR 7 day	0.6	HPAEC TNF alpha + IL-1	78.5
		beta
PBMC rest	0.6	Lung fibroblast none	5.8
PBMC PWM	0.0	Lung fibroblasts TNF	2.7
		alpha + IL-1 beta
PBMC PHA-L	0.0	Lung fibroblast IL-4	3.8
Ramos (B cell) none	0.2	Lung fibroblast IL-9	1.3
Ramos (B cell)	0.0	Lung fibroblast IL-13	0.3
ionomycin
B lymphocytes PWM	0.0	Lung fibroblast IFN	3.5
		gamma
B lymphocytes CD40L	0.0	Dermal fibroblast	3.1
and IL-4		CCD1070 rest
EOL-1 dbcAMP	0.0	Dermal fibroblast	2.0
		CCD1070 TNF alpha
EOL-1 dbcAMP	0.4	Dermal fibroblast	0.0
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	0.0	Dermal fibroblast IFN	0.0
		gamma
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-	1.8	IBD Colitis 2	2.5
CD40
Monocytes rest	0.0	IBD Crohn's	12.3
Monocytes LPS	0.0	Colon	25.7
Macrophages rest	0.0	Lung	1.3
Macrophages LPS	0.0	Thymus	38.4
HUVEC none	3.1	Kidney	20.9
HUVEC starved	4.5

[1113] CNS_neurodegeneration_v1.0 Summary: Ag3475 Expression of the CG59570-01 gene is low/undetectable (CTs>34.5) across all of the samples on this panel.

[1114] General_screening_panel_v1.4 Summary: Ag3475 High expression of the CG59570-01 gene is detected exclusively in adipose tissue sample (CT=27.73). Thus expression of this gene can be used to distinguish adipose sample from other samples in this panel. In addition to adipose tissue, low levels of expression of this gene is also seen in other tissues with metabolic or endocrine function such as pancreas, adrenal gland, thyroid, skeletal muscle, heart, and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[1115] CG59570-01 codes for protein similar to aquaporin 7. Aquaporins are water channels that are usually found in tissues where water movements are abundant and/or physiologically important. In a systematic analysis of genes expressed in human adipose tissue, Kuniyama et al. (Ref. 1) identified AQP7L, a predicted 342-amino acid protein. They showed that this aquaporin participates in glycerol transport in adipocytes. Thus, we predict that protein encoded by this transcript may also play a role in glycerol transport in adipocytes.

[1116] Interestingly, this gene is expressed at much higher levels in adult (CT=30) when compared to fetal heart (CT=34). This observation suggests that expression of this gene can be used to distinguish fetal from adult heart. Furthermore, therapeutic modulation of the protein encoded by this gene could be useful in treatment of heart related diseases.

[1117] In addition, this gene is expressed at significant levels in some regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, and cerebellum (CTs=30-34). Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, seizure, ataxia, autism, schizophrenia and depression.

[1118] Reference.

[1119] 1. Kuriyama, H.; Kawamoto, S.; Ishida, N.; Ohno, I.; Mita, S.; Matsuzawa, Y.; Matsubara, K.; Okubo, K. (1997) Molecular cloning and expression of a novel human aquaporin from adipose tissue with glycerol permeability. Biochem. Biophys. Res. Commun. 241: 53-58.

[1120] Panel 4D Summary: Ag3475 High expression of the CG59570-01 is detected untreated and TNF alpha+IL-1beta treated (CTs=30) HPAEC cells. Thus expression of this gene can be used to distinguish these two samples from other samples in this panel. In addition, low levels of expression of this gene is also detected in lung fibroblast, IFN-gamma treated lung fibroblast, IL-9 treated NCI-H292 cells, starved and IFN-gama treated HUVEC cells, anti-CD95 CH11 treated secondary Th1/Th2/Tr1 cells, and TNFalpha+IL-1beta treated small airway epithelium. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of lung related diseases such as asthma, allergies, emphysema, COPD.

[1121] Interestingly, this gene is expressed at much higher levels in TNFalpha+IL-1beta treated (CT=32) as compared to untreated small airway epithelium (CT=35). Thus, expression of this gene can be used to distinguish TNFalpha+IL-1beta treated from the untreated small airway epithelium cells.

[1122] Expression of this gene is detected at low levels (CT=34.5) in liver cirrhosis, but not in normal liver (no expression in normal liver is detected on Panel 1.4). The protein encoded for by this gene could potentially allow cells within the liver to respond to specific microenvironmental signals. Therefore, therapies designed with the protein encoded for by this gene may potentially modulate liver function and play a role in the identification and treatment of inflammatory or autoimmune diseases which effect the liver including liver cirrhosis and fibrosis.

[1123] In addition, moderate expression of this gene is also observed in kidney, thymus and colon. Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene may be important in the treatment of inflammatory or autoimmune diseases that affect these tissues.

AI. NOV42a (CG56162-02: LYSOPHOSPHOLIPASE-LIKE)

[1124] Expression of gene CG56162-02 was assessed using the primer-probe set Ag2042, described in Table AIA. Results of the RTQ-PCR runs are shown in Tables AIB and AIC. Please note that CG56162-02 represents a full-length physical clone.

TABLE AIA
Probe Name Ag2042
			Start
Primers	Sequences	Length	Position
Forward	5′-cataatggaaacaggacctgaa-3′	(SEQ ID NO:353)	22	32
Probe	TET-5′-ccttccagcatgccagaggaaagtt-3′-TAMRA	(SEQ ID NO:354)	25	57
Reverse	5′-aggtcctggtagggaatgct-3′	(SEQ ID NO:355)	20	102

[1125]

TABLE AIB
Panel 1.3D
	Rel. Exp. (%) Ag 2042,		Rel. Exp. (%) Ag2042,
Tissue Name	Run 165627321	Tissue Name	Run 165627321
Liver adenocarcinoma	5.8	Kidney (fetal)	6.4
Pancreas	0.8	Renal ca. 786-0	25.7
Pancreatic ca. CAPAN	8.5	Renal ca. A498	27.0
2
Adrenal gland	1.6	Renal ca. RXF 393	46.0
Thyroid	1.4	Renal ca. ACHN	14.7
Salivary gland	6.2	Renal ca. UO-31	41.8
Pituitary gland	1.6	Renal ca. TK-10	8.5
Brain (fetal)	33.7	Liver	3.5
Brain (whole)	92.0	Liver (fetal)	0.9
Brain (amygdala)	37.9	Liver ca.	0.0
		(hepatoblast) HepG2
Brain (cerebellum)	94.6	Lung	8.8
Brain (hippocampus)	50.7	Lung (fetal)	12.1
Brain (subtantia nigra)	11.6	Lung ca. (small cell)	2.1
		LX-1
Brain (thalamus)	51.1	Lung ca. (small cell)	6.1
		NCI-H69
Cerebral Cortex	76.3	Lung ca. (s.cell var.)	0.0
		SHP-77
Spinal cord	12.0	Lung ca. (large	1.6
		cell) NCI-H460
glio/astro U87-MG	28.3	Lung ca. (non-sm.	6.4
		cell) A549
glio/astro U-118-MG	100.0	Lung ca. (non-s.cell)	0.4
		NCI-H23
astrocytoma SW1783	3.2	Lung ca. (non-s.cell)	0.0
		HOP-62
neuro*; met SK-N-AS	0.3	Lung ca. (non-s.cl)	0.0
		NCI-H522
astrocytoma SF-539	40.9	Lung ca. (squam.)	12.6
		SW 900
astrocytoma SNB-75	12.3	Lung ca. (squam.)	9.0
		NCI-H596
glioma SNB-19	4.1	Mammary gland	9.5
glioma U251	1.5	Breast ca.* (pl.ef)	5.8
		MCF-7
glioma SF-295	1.4	Breast ca.* (pl.ef)	21.9
		MDA-MB-231
Heart (fetal)	6.0	Breast ca.* (pl.ef)	0.4
		T47D
Heart	12.8	Breast ca. BT-549	0.3
Skeletal muscle (fetal)	8.5	Breast ca. MDA-N	1.3
Skeletal muscle	6.2	Ovary	2.1
Bone marrow	2.3	Overian ca. OVCAR-	0.0
		3
Thymus	1.0	Ovarian ca. OVCAR-	7.6
		4
Spleen	13.3	Ovarian ca. OVCAR-	10.2
		5
Lymph node	5.7	Ovarian ca. OVCAR-	10.6
		8
Colorectal	10.5	Ovarian ca. IGROV-1	3.2
Stomach	5.5	Ovarian ca.* (ascites)	45.7
		SK-OV-3
Small intestine	10.2	Uterus	8.7
Colon ca. SW480	0.3	Placenta	4.3
Colon ca.*	0.0	Prostate	1.3
SW620 (SW480 met)
Colon ca. HT29	8.1	Prostate ca.* (bone	22.2
		met) PC-3
Colon ca. HCT-116	2.4	Testis	0.8
Colon ca. CaCo-2	0.8	Melanoma	1.4
		Hs688(A).T
Colon ca.	10.8	Melanoma* (met)	4.5
tissue (ODO3866)		Hs688(B).T
Colon ca. HCC-2998	2.2	Melanonma UACC-62	3.0
Gastric ca.* (liver met)	7.3	Melanoma M14	0.0
NCI-N87
Bladder	1.5	Melanoma LOX	1.4
		IMVI
Trachea	11.6	Melanoma* (met)	0.1
		SK-MEL-5
Kidney	5.1	Adipose	9.2

[1126]

TABLE AIC
Panel 4D
	Rel. Exp. (%)		Rel. Exp. (%)
	Ag2042, Run		Ag2042, Run
Tissue Name	161383006	Tissue Name	161383006
Secondary TH1 act	0.3	HUVEC IL-1beta	22.8
Secondary Th2 act	0.7	HUVEC IFN gamma	17.4
Secondary Tr1 act	1.0	HUVEC TNF alpha + IFN	59.0
		gamma
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	54.0
Secondary Th2 rest	1.5	HUVEC IL-11	14.1
Secondary Tr1 rest	0.9	Lung Microvascular EC	42.0
		none
Primary Th1 act	0.9	Lung Microvascular EC	79.6
		TNFalpha + IL-1beta
Primary Th2 act	1.9	Microvascular Dermal EC	54.3
		none
Primary Tr1 act	0.4	Microvascular Dermal EC	54.3
		TNFalpha + IL-1beta
Primary Th1 rest	1.2	Bronchial epithelium	7.8
		TNFalpha + IL1beta
Primary Th2 rest	1.5	Small airway epithelium	12.8
		none
Primary Tr1 rest	0.8	Small airway epithelium	41.5
		TNFalpha + IL-1beta
CD45RA CD4	15.3	Coronery artery SMC rest	0.0
lymphocyte act
CD45RO CD4	0.4	Coronery artery SMC	7.3
lymphocyte act		TNFalpha + IL-1beta
CD8 lymphocyte act	1.2	Astrocytes rest	0.7
Secondary CD8	0.2	Astrocytes TNFalpha + IL-	3.6
lymphocyte rest		1beta
Secondary CD8	3.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	0.1	KU-812 (Basophil)	0.3
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	1.3	CCD1106 (Keratinocytes)	18.0
CD95 CH11		none
LAK cells rest	3.3	CCD1106 (Keratinocytes)	1.0
		TNFalpha + IL-1beta
LAK cells IL-2	0.2	Liver cirrhosis	3.5
LAK cells IL-2 + IL-12	1.2	Lupus kidney	5.4
LAK cells IL-2 + IFN	3.2	NCI-H292 none	16.3
gamma
LAK cells IL-2 + IL-18	1.7	NCI-H292 IL-4	24.1
LAK cells	2.1	NCI-H292 IL-9	23.3
PMA/ionomycin
NK Cells IL-2 rest	0.0	NCI-H292 IL-13	11.9
Two Way MLR 3 day	7.3	NCI-H292 IFN gamma	21.9
Two Way MLR 5 day	2.5	HPAEC none	25.7
Two Way MLR 7 day	1.3	HPAEC TNF alpha + IL-1	64.6
		beta
PBMC rest	0.4	Lung fibroblast none	18.8
PBMC PWM	9.2	Lung fibroblast TNF	33.7
		alpha + IL-1 beta
PBMC PHA-L	2.4	Lung fibroblast IL-4	29.5
Ramos (B cell) none	0.0	Lung fibroblast IL-9	43.2
Ramos (B cell)	0.0	Lung fibroblast IL-13	18.7
ionomycin
B lymphocytes PWM	10.7	Lung fibroblast IFN	29.1
		gamma
B lymphocytes CD40L	8.3	Dermal fibroblast	64.6
and IL-4		CCD1070 rest
EOL-1 dbcAMP	0.0	Dermal fibroblast	100.0
		CCD1070 TNF alpha
EOL-1 dbcAMP	0.1	Dermal fibroblast	48.0
PMA/ionomycin		CCD1070 IL-1 beta
Dendritic cells none	7.3	Dermal fibroblast IFN	24.0
		gamma
Dendritic cells LPS	28.1	Dermal fibroblast IL-4	41.5
Dendritic cells anti-	13.0	IBD Colitis 2	0.4
CD40
Monocytes rest	0.1	IBD Crohn's	1.0
Monocytes LPS	16.5	Colon	18.4
Macrophages rest	51.4	Lung	44.1
Macrophages LPS	18.0	Thymus	17.2
HUVEC none	45.1	Kidney	5.4
HUVEC starved	54.7

[1127] Panel 1.3D Summary: Ag1906/Ag2042 The expression of CG56162-02 gene was assessed in two independent runs using 2 different probe/primer pairs, with good concordance between the runs. Highest expression in this panel is seen in brain derived tissue, including the cerebral cortex and a brain cancer (CTs=25-27). Thus, the expression of this gene could be used to distinguish these samples from other samples in the panel.

[1128] This gene encodes a lysophosphase homolog that also has high levels of expression in many of the endocrine/metabolic tissues found on this panel, including adipose, liver, pancreas, pituitary, skeletal muscle and small intestine. Lysophospholipids are detergent-like intermediates in phospholipid metabolism. Lysophospholipases are important enzymes in the regulation of hormone biosynthesis and metabolism, and have been shown to be important in the regulation of insulin secretion (see reference below). Increased lysophospholipids levels have been detected in a variety of diseases including atherosclerosis and hyperlipidemia. In some cases, increased levels of lysophospholipids are hypothesized to result from a dysfunction of lysophospholipids-regulating enzymes including lysophospholipases, which act on biologic membranes to regulate the level of lysophospholipids by hydrolysis. Thus, this gene product may be useful in the treatment of diseases associated with increased lysophospholipids.

[1129] This gene also shows high expression in the brain. Lysophospholipases are critical enzymes that regulate brain membrane phospholipids. Alterations in their activity have been associated with a host of neurological disorders, including schizophrenia, Parkinson's disease, and Alzheimer's disease. Thus, therapeutic modulation of the expression or function of this gene or gene product may be useful in the treatment of these diseases. Please note that results from a third experiment with the probe/primer set Ag1952 are not included. The amp plot indicates that there were experimental difficulties with this run.

[1130] References:

[1131] 1. Capito K, Reinsmark R, Thams P. Mechanism of fat-induced attenuation of glucose-induced insulin secretion from mouse pancreatic islets. Acta Diabetol December 1999;36(3): 119-25

[1132] 2. Ross B M, Turenne S, Moszczynska A, Warsh J J, Kish S J. Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia. Brain Res Mar. 13, 1999; 821 (2):407-13

[1133] 3. Ross B M, Moszczynska A, Erlich J, Kish S J. Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: possible implications for Parkinson's disease. Neuroscience April 1998;83(3):791-8

[1134] 4. Ross B M, Moszczynska A, Erlich J, Kish S J. Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem February 1998;70(2):786-93

[1135] Panel 4D Summary: Ag1906/Ag1952/Ag2042 The expression ofCG56162-02 gene was assessed in three independent runs using three different probe/primer pairs, with good concordance between the runs. This gene is expressed at moderate levels in a wide variety of cells including resting macrophages, TNF-alpha-activated dermal fibroblasts, LPS-stimulated dendritic cells, TN-alpha+IL-1-beta-activated pulmonary artery endothelial cells, TNF-alpha+IL-1-beta-activated lung microvascular cells, and TNF-alpha+IFN-gamma-activated umbilical vein endothelial cells (CTs=27-28). Thus, antibodies and small molecules that antagonize the function of the CG120803-01 geen product may be useful to reduce or eliminate the symptoms in patients with inflammatory and autoimmune diseases, such as lupus erythematosus, asthma, emphysema, Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, osteoarthritis, and psoriasis.

AJ. NOV45a and NOV45b (CG59859-01 and CG59859-02: TESTIS EXPRESSED PROTEIN 261 (TEG-261))

[1136] Expression of genes CG59859-01 and CG59859-02 was assessed using the primer-probe set Ag3623, described in Table AJA. Results of the RTQ-PCR runs arc shown in Tables AJB, AJC and AJD. Please note that CG59859-02 represents a full-length physical clone of the CG59859-01 gene, validating the prediction of the gene sequence.

TABLE AJA
Probe Name Ag3623
			Start
Primers	Sequences	Length	Position
Forward	5′-cgtctccaattatttcaccaaa-3′	(SEQ ID NO:356)	22	534
Probe	TET-5′-agggatccttggttgtcttctccttca-3′-TAMRA	(SEQ ID NO:357)	26	576
Reverse	5′-cttctgacgactgggtagaatg-3′	(SEQ ID NO:358)	22	612

[1137]

TABLE AJB
CNS_neurodegeneration_v1.0
	Rel. Exp. (%) Ag3623,		Rel. Exp. (%) Ag2623,
Tissue Name	Run 211005294	Tissue Name	Run 211005294
AD 1 Hippo	22.4	Control (Path) 3	12.2
		Temporal Ctx
AD 2 Hippo	42.9	Control (Path) 4	25.9
		Temporal Ctx
AD 3 Hippo	16.6	AD 1 Occipital Ctx	21.6
AD 4 Hippo	9.5	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	76.3	AD 3 Occipital Ctx	21.2
AD 6 Hippo	50.7	AD 4 Occipital Ctx	22.7
Control 2 Hippo	32.8	AD 5 Occipital Ctx	5.8
Control 4 Hippo	28.5	AD 6 Occipital Ctx	39.0
Control (Path) 3	9.8	Control 1 Occipital	14.3
Hippo		Ctx
AD 1 Temporal Ctx	27.7	Control 2 Occipital	80.1
		Ctx
AD 2 Temporal Ctx	48.0	Control 3 Occipital	18.8
		Ctx
AD 3 Temporal Ctx	15.4	Control 4 Occipital	13.9
		Ctx
AD 4 Temporal Ctx	13.9	Control (Path) 1	100.0
		Occipital Ctx
AD 5 Inf Temporal	86.5	Control (Path) 2	15.3
Ctx		Occipital Ctx
AD 5 Sup Temporal	64.6	Control (Path) 3	9.4
Ctx		Occipital Ctx
AD 6 Inf Temporal	62.4	Control (Path) 4	18.9
Ctx		Occipital Ctx
AD 6 Sup Temporal	63.7	Control 1 Parietal	17.8
Ctx		Ctx
Control 1 Temporal	14.1	Control 2 Parietal	40.1
Ctx		Ctx
Control 2 Temporal	40.1	Control 3 Parietal	16.2
Ctx		Ctx
Control 3 Temporal	21.9	Control (Path) 1	94.0
Ctx		Parietal Ctx
Control 4 Temporal	13.9	Control (Path) 2	36.3
Ctx		Parietal Ctx
Control (Path) 1	67.8	Control (Path) 3	11.7
Temporal Ctx		Parietal Ctx
Control (Path) 2	37.4	Control (Path) 4	36.1
Temporal Ctx		Parietal Ctx

[1138]

TABLE AJC
General_screening_panel_v1.4
	Rel. Exp. (%) Ag3623,		Rel. Exp. (%) Ag3623,
Tissue Name	Run 218211559	Tissue Name	Run 218211559
Adipose	3.9	Renal ca. TK-10	33.2
Melanoma*	22.8	Bladder	9.1
Hs688(A).T
Melanoma*	27.7	Gastric ca. (liver met.)	29.7
Hs688(B).T		NCI-N87
Melanoma* M14	29.1	Gastric ca. KATO III	100.0
Melanoma*	27.4	Colon ca. SW-948	15.0
LOXIMVI
Melanoma* SK-	14.8	Colon ca. SW480	45.4
MEL-5
Squamous cell	9.1	Colon ca.* (SW480	23.7
carcinoma SCC-4		met) SW620
Testis Pool	8.4	Colon ca. HT29	12.7
Prostate ca.* (bone	29.5	Colon ca. HCT-116	28.7
met) PC-3
Prostate Pool	3.2	Colon ca. CaCo-2	17.8
Placenta	16.0	Colon cancer tissue	13.8
Uterus Pool	1.8	Colon ca. SW1116	7.4
Ovarian ca. OVCAR-	13.1	Colon ca. Colo-205	11.5
3
Ovarian ca. SK-OV-	39.8	Colon ca. SW-48	13.5
3
Ovarian ca. OVCAR-	25.0	Colon Pool	8.0
4
Ovarian ca. OVCAR-	40.9	Small Intestine Pool	6.9
5
Ovarian ca. IGROV-	19.9	Stomach Pool	3.4
1
Ovarian ca. OVCAR-	14.5	Bone Marrow Pool	2.8
8
Ovary	6.7	Fetal Heart	9.2
Breast ca. MCF-7	23.3	Heart Pool	3.5
Breast ca. MDA-	40.3	Lymph Node Pool	8.7
MB-231
Breast ca. BT 549	11.8	Fetal Skeletal Muscle	3.7
Breast ca. T47D	69.7	Skeletal Muscle Pool	7.8
Breast ca. MDA-N	15.4	Spleen Pool	3.4
Breast Pool	7.3	Thymus Pool	6.8
Trachea	8.8	CNS cancer (glio/astro)	28.9
		U87-MG
Lung	1.0	CNS cancer (glio/astro)	52.9
		U-118-MG
Fetal Lung	6.7	CNS cancer (neuro; met)	20.2
		SK-N-AS
Lung ca. NCI-N417	7.2	CNS cancer (astro) SF-	12.8
		539
Lung ca. LX-1	19.2	CNS cancer (astro)	54.3
		SNB-75
Lung ca. NCI-H146	12.1	CNS cancer (glio) SNB-	21.8
		19
Lung ca. SHP-77	23.5	CNS cancer (glio) SF-	50.7
		295
Lung ca. A549	28.7	Brain (Amygdala) Pool	3.7
Lung ca. NCI-H526	13.8	Brain (cerebellum)	9.2
Lung ca. NCI-H23	26.6	Brain (fetal)	11.3
Lung ca. NCI-H460	7.6	Brain (Hippocampus)	3.6
		Pool
Lung ca. HOP-62	14.4	Cerebral Cortex Pool	4.0
Lung ca. MCI-H522	19.9	Brain (Substantia nigra)	5.6
		Pool
Liver	2.9	Brain (Thalamus) Pool	5.6
Fetal Liver	13.6	Brain (whole)	6.3
Liver ca. HepG2	12.8	Spinal Cord Pool	5.2
Kidney Pool	18.4	Adrenal Gland	12.7
Fetal Kidney	5.2	Pituitary gland Pool	2.5
Renal ca. 786-0	14.7	Salivary Gland	11.5
Renal ca. A498	7.3	Thyroid (female)	13.0
Renal ca. ACHN	7.6	Pancreatic ca. CAPAN2	20.9
Renal ca. UO-31	15.9	Pancreas Pool	12.7

[1139]

TABLE AJD
Panel 4.1D
	Rel. Exp. (%)		Rel. Exp. (%)
	Ag3623, Run		Ag3623, Run
Tissue Name	169944863	Tissue Name	169944863
Secondary Th1 act	73.7	HUVEC IL-1 beta	68.8
Secondary Th2 act	100.0	HUVEC IFN gamma	51.8
Secondary Tr1 act	84.7	HUVEC TNF alpha + IFN	49.0
		gamma
Secondary Th1 rest	16.4	HUVEC TNF alpha + IL4	53.6
Secondary Th2 rest	30.4	HUVEC IL-11	20.6
Secondary Tr1 rest	28.3	Lung Microvascular EC	79.0
		none
Primary Th1 act	88.3	Lung Microvascular EC	71.7
		TNFalpha + IL-1beta
Primary Th2 act	85.9	Microvascular Dermal EC	56.6
		none
Primary Tr1 act	97.9	Microvascular Dermal EC	36.6
		TNFalpha + IL-1beta
Primary Th1 rest	29.7	Bronchial epithelium	31.4
		TNFalpha + IL1beta
Primary Th2 rest	34.2	Small airway epithelium	32.3
		none
Primary Tr1 rest	39.5	Small airway epithelium	54.3
		TNFalpha + IL-1beta
CD45RA CD4	76.3	Coronery artery SMC rest	43.2
lymphocyte act
CD45RO CD4	74.2	Coronery artery SMC	47.3
lymphocyte act		TNFalpha + IL-1beta
CD8 lymphocyte act	81.8	Astrocytes rest	37.1
Secondary CD8	75.3	Astrocytes TNFalpha + IL-	37.4
lymphocyte rest		1beta
Secondary CD8	48.0	KU-812 (Basophil) rest	18.0
lymphocyte act
CD4 lymphocyte none	13.0	KU-812 (Basophil)	47.6
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	36.1	CCD1106 (Keratinocytes)	59.9
CD95 CH11		none
LAK cells rest	36.3	CCD1106 (Keratinocytes)	36.1
		TNFalpha + IL-1beta
LAK cells IL-2	51.4	Liver cirrhosis	6.1
LAK cells IL-2 + IL-12	62.4	NCI-H292 none	30.6
LAK cells IL-2 + IFN	67.8	NCI-H292 IL-4	54.7
gamma
LAK cells IL-2 + IL-18	62.4	NCI-H292 IL-9	74.7
LAK cells	31.6	NCI-H292 IL-13	61.1
PMA/ionomycin
NK Cells IL-2 rest	44.1	NCI-H292 IFN gamma	72.7
Two Way MLR 3 day	47.0	HPAEC none	42.3
Two Way MLR 5 day	49.3	HPAEC TNF alpha + IL-1	63.3
		beta
Two Way MLR 7 day	33.4	Lung fibroblast none	40.6
PBMC rest	15.3	Lung fibroblast TNF	27.5
		alpha + IL-1 beta
PBMC PWM	79.6	Lung fibroblast IL-4	67.4
PBMC PHA-L	62.4	Lung fibroblast IL-9	86.5
Ramos (B cell) none	97.9	Lung fibroblast IL-13	71.2
Ramos (B cell)	77.9	Lung fibroblast IFN	77.4
ionomycin		gamma
B lymphocytes PWM	67.8	Dermal fibroblast	77.9
		CCD1070 rest
B lymphocytes CD40L	39.8	Dermal fibroblast	87.1
and IL-4		CCD1070 TNF alpha
EOL-1 dbcAMP	33.2	Dermal fibroblast	47.0
		CCD1070 IL-1 beta
EOL-1 dbcAMP	38.7	Dermal fibroblast IFN	40.6
PMA/ionomycin		gamma
Dendritic cells none	48.3	Dermal fibroblast IL-4	75.3
Dendritic cells LPS	40.6	Dermal Fibroblasts rest	59.0
Dendritic cells anti-	59.5	Neutrophils TNFa + LPS	2.6
CD40
Monocytes rest	40.3	Neutrophils rest	9.1
Monocytes LPS	45.1	Colon	18.7
Macrophages rest	41.8	Lung	34.4
Macrophages LPS	24.3	Thymus	29.5
HUVEC none	41.2	Kidney	38.7
HUVEC starved	43.2

[1140] CNS_neurodegeneration_v1.0 Summary: Ag3623 This panel confirms the expression of the CG59859-01 gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1141] General_screening_panel_v1.4 Summary: Ag3623 Highest expression of the CG59859-01 gene is detected in samples derived from gastric cancer KATO III cell line (CT=25). Furthermore, high expression of this gene is seen in samples derived from CNS cancer, colon cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer and melanoma cells. Therefore, expression of this gene can be used to distinguish these samples from other samples in the panel and also as a marker in detection of these cancers. In addition, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of these cancers.

[1142] In addition, this gene is expressed at significant levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1143] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[1144] Panel 4.1D Summary: Ag3623 Highest expression of the CG59859-01 gene is detected in activated secondary Th2 cells (CT=28.8). In high expression of this gene is seen in activated primary and secondary—Th1, Th2 and Tr1 cells (CTs=29) as compared to corresponding resting cells (CTs=30-31). Therefore expression of this gene can be used to distinguish between these activated versus resting cells.

[1145] Also, this gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

[1146] Interestingly, expression of this gene is stimulated in PWM/PHA-L treated PBMC cells and PMA/ionomycin treated KU-812 cells (basophils) (CTs=29) as compared to the corresponding untreated/resting cells (CTs=31). Therefore, expression of this gene can be used to distinguish these treated versus untreated cells. In addition, antibody or small molecule therapies designed with the protein encoded for by this gene could block or inhibit inflammation or tissue damage due to basophil activation or PBMC activation in response to systemic lupus erythematosus, Crohn's disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, allergies, hypersensitivity reactions, psoriasis, and viral infections.

AK. NOV46a (CG59913-01: ATP-BINDING CASSETTE TRANSPORTER)

[1147] Expression of gene CG59913-01 was assessed using the primer-probe set Ag363 1, described in Table AKA. Results of the RTQ-PCR runs are shown in Tables AKB, AKC and AKD.

TABLE AKA
Probe Name Ag3631
			Start
Primers	Sequences	Length	Position
Forward	5′-cagttccaacatcaggttcagt-3′	(SEQ ID NO:359)	22	1614
Probe	TET-5′-aatcacacactttcaagaatggctga-3′-TAMRA	(SEQ ID NO:360)	26	1646
Reverse	5′-ttgtggacaaaatccagtgaa-3′	(SEQ ID NO:361)	21	1691

[1148]

TABLE AKB
CNS_neurodegeneration_v1.0
	Rel. Exp. (%) Ag3631,		Rel. Exp. (%) Ag3631,
Tissue Name	Run 211020526	Tissue Name	Run 211020526
AD 1 Hippo	6.8	Control (Path) 3	3.3
		Temporal Ctx
AD 2 Hippo	16.7	Control (Path) 4	37.6
		Temporal Ctx
AD 3 Hippo	4.2	AD 1 Occipital Ctx	11.9
AD 4 Hippo	3.3	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 Hippo	100.0	AD 3 Occipital Ctx	5.7
AD 6 Hippo	24.7	AD 4 Occipital Ctx	14.9
Control 2 Hippo	4.8	AD 5 Occipital Ctx	22.4
Control 4 Hippo	8.0	AD 6 Occipital Ctx	17.4
Control (Path) 3	6.1	Control 1 Occipital	3.3
Hippo		Ctx
AD 1 Temporal Ctx	14.7	Control 2 Occipital	33.2
		Ctx
AD 2 Temporal Ctx	16.0	Control 3 Occipital	9.9
		Ctx
AD 3 Temporal Ctx	5.0	Control 4 Occipital	1.6
		Ctx
AD 4 Temporal Ctx	13.2	Control (Path) 1	55.5
		Occipital Ctx
AD 5 Inf Temporal	61.1	Control (Path) 2	10.2
Ctx		Occipital Ctx
AD 5 Sup Temporal	27.7	Control (Path) 3	4.2
Ctx		Occipital Ctx
AD 6 Inf Temporal	35.6	Control (Path) 4	28.9
Ctx		Occipital Ctx
AD 6 Sup Temporal	31.6	Control 1 Parietal	5.6
Ctx		Ctx
Control 1 Temporal	6.5	Control 2 Parietal	31.4
Ctx		Ctx
Control 2 Temporal	10.6	Control 3 Parietal	7.0
Ctx		Ctx
Control 3 Temporal	9.5	Control (Path) 1	42.6
Ctx		Parietal Ctx
Control 3 Temporal	3.5	Control (Path) 2	27.4
Ctx		Parietal Ctx
Control (Path) 1	44.4	Control (Path) 3	3.8
Temporal Ctx		Parietal Ctx
Control (Path) 2	26.6	Control (Path) 4	44.8
Temporal Ctx		Parietal Ctx

[1149]

TABLE AKC
General_screening_panel_v1.4
	Rel. Exp. (%) Ag3631,		Rel. Exp. (%) Ag3631,
Tissue Name	Run 218233412	Tissue Name	Run 218233412
Adipose	36.1	Renal ca. TK-10	0.1
Melanoma*	3.0	Bladder	10.9
Hs688 (A).T
Melanoma*	2.0	Gastric ca. (liver met.)	0.0
Hs688 (B).T		NCI-N87
Melanoma* M14	0.4	Gastric ca. KATO III	0.0
Melanoma*	0.0	Colon ca. SW-948	0.1
LOXIMVI
Melanoma* SK-	0.5	Colon ca. SW480	0.0
MEL-5
Squamous cell	0.0	Colon ca.* (SW480	0.0
carcinoma SCC-4		met) SW620
Testis Pool	14.0	Colon ca. HT29	0.0
Prostate ca.* (bone	0.1	Colon ca. HCT-116	0.0
met) PC-3
Prostate Pool	2.9	Colon ca. CaCo-2	0.4
Placenta	0.2	Colon cancer tissue	2.1
Uterus Pool	20.4	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-	0.1	Colon ca. Colo-205	0.0
3
Ovarian ca. SK-OV-	0.7	Colon ca. SW-48	0.0
3
Ovarian ca. OVCAR-	0.0	Colon Pool	36.9
4
Ovarian ca. OVCAR-	0.4	Small Intestine Pool	28.5
5
Ovarian ca. IGROV-	0.3	Stomach Pool	14.5
1
Ovarian ca. OVCAR-	0.0	Bone Marrow Pool	9.5
8
Ovary	21.5	Fetal Heart	23.7
Breast ca. MCF-7	0.2	Heart Pool	21.9
Breast ca. MDA-	0.0	Lymph Node Pool	27.7
MB-231
Breast ca. BT 549	0.3	Fetal Skeletal Muscle	15.2
Breast ca. T47D	0.1	Skeletal Muscle Pool	21.2
Breast ca. MDA-N	3.4	Spleen Pool	5.8
Breast Pool	25.3	Thymus Pool	12.3
Trachea	16.5	CNS cancer (glio/astro)	0.0
		U87-MG
Lung	28.5	CNS cancer (glio/astro)	0.0
		U-118-MG
Fetal Lung	20.9	CNS cancer (neuro; met)	0.6
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	0.0
		539
Lung ca. LX-1	0.4	CNS cancer (astro)	0.0
		SNB-75
Lung ca. NCI-H146	0.2	CNS cancer (glio) SNB-	0.1
		19
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-	0.7
		295
Lung ca. A549	0.0	Brain (Amygdala) Pool	4.4
Lung ca. NCI-H526	0.0	Brain (cerebellum)	1.5
Lung ca. NCI-H23	0.5	Brain (fetal)	3.3
Lung ca. NCI-H460	0.4	Brain (Hippocampus)	4.3
		Pool
Lung ca. HOP-62	0.3	Cerebral Cortex Pool	5.6
Lung ca. NCI-H522	0.0	Brain (Substansia nigra)	4.4
		Pool
Liver	0.9	Brain (Thalamus) Pool	7.3
Fetal Liver	11.4	Brain (whole)	4.3
Liver ca. HepG2	0.2	Spinal Cord Pool	6.7
Kidney Pool	100.0	Adrenal Gland	5.7
Fetal Kidney	3.6	Pituitary gland Pool	2.8
Renal ca. 786-0	0.0	Salivary Gland	1.8
Renal ca. A498	0.0	Thyroid (female)	4.2
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	1.4	Pancreas Pool	20.9

[1150]

TABLE AKD
Panel 4.1D
	Rel. Exp. (%)		Rel. Exp. (%)
	Ag3631, Run		Ag3631, Run
Tissue Name	169960855	Tissue Name	169960855
Secondary Th1 act	0.0	HUVEC IL-1 beta	7.1
Secondary Th2 act	0.0	HUVEC IFN gamma	32.1
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN	1.2
		gamma
Secondary Th1 rest	0.8	HUVEC TNF alpha + IL4	3.8
Secondary Th2 rest	2.7	HUVEC IL-11	8.6
Secondary Tr1 rest	3.2	Lung Microvascular EC	14.8
		none
Primary Th1 act	0.0	Lung Microvascular EC	8.2
		TNFalpha + IL-1 beta
Primary Th2 act	0.5	Microvascular Dermal EC	14.7
		none
Primary Tr1 act	0.0	Microvascular Dermal EC	9.3
		TNFalpha + IL-1beta
Primary Th1 rest	0.9	Bronchial epithelium	9.6
		TNFalpha + IL1beta
Primary Th2 rest	9.3	Small airway epithelium	2.3
		none
Primary Tr1 rest	0.5	Small airway epithelium	3.0
		TNFalpha + IL-1beta
CD45RA CD4	0.8	Coronery artery SMC rest	96.6
lymphocyte act
CD45RO CD4	1.4	Coronery artery SMC	81.2
lymphocyte act		TNFalpha + IL-1beta
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8	0.0	Astrocytes TNFalpha + IL-	0.6
lymphocyte rest		1beta
Secondary CD8	0.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	0.4	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	3.8	CCD1106 (Keratinocytes)	0.0
CD95 CH11		none
LAK cells rest	1.6	CCD1106 (Keratinocytes)	0.6
		TNF-alpha + IL-1beta
LAK cells IL-2	0.0	Liver cirrhosis	33.0
LAK cells IL-2 + IL-12	1.3	NCI-H292 none	0.0
LAK cells IL-2 + IFN	1.0	NCI-H292 IL-4	0.0
gamma
LAK cells IL-2 + IL-18	0.3	NCI-H292 IL-9	0.0
LAK cells	1.4	NCI-H292 IL-13	0.0
PMA/ionomycin
NK Cells IL-2 rest	0.6	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	1.9	HPAEC none	94.0
Two Way MLR 5 day	1.6	HPAEC TNF alpha + IL-1	100.0
		beta
Two Way MLR 7 day	0.0	Lung fibroblast none	1.0
PBMC rest	0.0	Lung fibroblast TNF	0.6
		alpha + IL-1 beta
PBMC PWM	0.9	Lung fibroblast IL-4	0.5
PBMC PHA-L	0.0	Lung fibroblast IL-9	0.5
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.0
Ramos (B cell)	0.0	Lung fibroblast IFN	2.2
ionomycin		gamma
B lymphocytes PWM	0.0	Dermal fibroblast	0.5
		CCD1070 rest
B lymphocytes CD40L	1.0	Dermal fibroblast	0.0
and IL-4		CCD1070 TNF alpha
EOL-1 dbcAMP	0.9	Dermal fibroblast	0.4
		CCD1070 IL-1 beta
EOL-1 dbcAMP	0.5	Dermal fibroblast IFN	68.3
PMA/ionomycin		gamma
Dendritic cells none	0.9	Dermal fibroblast IL-4	24.1
Dendritic cells LPS	2.4	Dermal Fibroblasts rest	27.5
Dendritic cells anti-	1.9	Neutrophils TNFa + LPS	0.0
CD40
Monocytes rest	3.0	Neutrophils rest	0.0
Monocytes LPS	5.9	Colon	17.1
Macrophages rest	1.2	Lung	16.7
Macrophages LPS	0.7	Thymus	23.7
HUVEC none	4.7	Kidney	13.2
HUVEC starved	4.6

[1151] CNS_neurodegeneration_v1.0 Summary: Ag3631 This panel confirms the expression of the CG59913-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

[1152] General_screening_panel_v1.4 Summary: Ag3631 The expression of the CG59913-01 is highest in sample derived from kidney (CT=28.23). Furhtermore, expression of this gene is very low in fetal kidney (CT=33). Thus, expression of this gene can be used in distinguishing the adult kidney from fetal kidney and also from other samples in this panel.

[1153] Among tissues with metabolic or endocrine function, this gene is expressed at low to moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, fetal liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.

[1154] In addition, this gene is expressed at significant levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1155] CG59913-01 gene codes for a variant of ATP-binding casette A9 protein, an ATP-binding cassette (ABC) transporter belonging to ABCA sub-family. The ABC superfamily comprises of myriad transmembrane proteins involved in the transport of vitamins, peptides, steroid hormones, ions, sugars, and amino acids (ref. 1). Known genetic diseases resulting from dysfunctional ABC transporters are cystic fibrosis, Zellweger syndrome, adrenoleukodystrophy, multidrug resistance, Stargardt macular dystrophy, Tangier disease (TD) and familial HDL deficiency (FHA) (ref. 2, 3). Recently, it has been shown that functional loss of ABCA1, a transporter belonging to ABCA subfamily, in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis, as well as, high-density lipoprotein cholesterol deficiency (ref 3). CG59913-01 gene is expressed in large number of the normal tissue used in this panel. In analogy to ABCA1, this gene may also play a wider role in lipid metabolism, renal inflammation, and cardiovascular disease and CNS disorders.

[1156] References.

[1157] 1. Higgins C F. (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67-113

[1158] PMID: 1282354

[1159] 2. Decottignies A, Goffeau A. (1997) Complete inventory of the yeast ABC proteins. Nat Genet 15(2):137-45.

[1160] The complete sequence of the yeast genome predicts the existence of 29 proteins belonging to the ubiquitous ATP-binding cassette (ABC) superfamily. Using binary comparison, phylogenetic classification and detection of conserved amino acid residues, the yeast ABC proteins have been classified in a total of six clusters, including ten subclusters of distinct predicted topology and presumed distinct function. Study of the yeast ABC proteins provides insight into the physiological function and biochemical mechanisms of their human homologues, such as those involved in cystic fibrosis, adrenoleukodystrophy, Zellweger syndrome, multidrug resistance and the antiviral activity of interferons.

[1161] PMID: 9020838

[1162] 3. Christiansen-Weber T A, Voland J R, Wu Y, Ngo K, Roland B L, Nguyen S, Peterson P A, Fung-Leung W P. (2000) Functional loss of ABCA1 in mice causes severe placental malformation, aberrant lipid distribution, and kidney glomerulonephritis as well as high-density lipoprotein cholesterol deficiency. Am J Pathol September 2000;157(3):1017-29

[1163] Tangier disease (TD) and familial HDL deficiency (FHA) have recently been linked to mutations in the human ATP-binding cassette transporter 1 (hABCA1), a member of the ABC superfamily. Both diseases are characterized by the lowering or lack of high-density lipoprotein cholesterol (HDL-C) and low serum cholesterol. The murine ABCA1−/− phenotype corroborates the human TD linkage to ABCA1. Similar to TD in humans, HDL-C is virtually absent in ABCA1−/− mice accompanied by a reduction in serum cholesterol and lipid deposition in various tissues. In addition, the placenta of ABCA1−/− mice is malformed, resulting in severe embryo growth retardation, fetal loss, and neonatal death. The basis for these defects appears to be altered steroidogenesis, a direct result of the lack of HDL-C. By 6 months of age, ABCA1−/− animals develop membranoproliferative glomerulonephritis due to deposition of immunocomplexes followed by cardiomegaly with ventricular dilation and hypertrophy, ultimately succumbing to congestive heart failure. This murine model of TD will be very useful in the study of lipid metabolism, renal inflammation, and cardiovascular disease and may reveal previously unsuspected relationships between them.

[1164] PMID: 10980140

[1165] Panel 4.1D Summary: Ag3631 The expression of the CG59913-01 gene is high in sample derived from HPAEC and coronary artery SMC cell lines(CTs=30). Thus, expression of this gene can be used to distinguish these samples from other samples in this panel.

[1166] Interestingly, expression of this gene is stimulated on treatment of dermal fibroblast and HUVEC cells with IFN gama (CTs=31-32). Therefore, therapeutics designed with the protein encoded for by this transcript could be important treating diseases such as asthma, arthritis, psoriasis, IBD, and systemic lupus erythematosus.

[1167] Significant expression of this gene is also detected in a liver cirrhosis sample (CT=32). Furthermore, expression of this gene is low/undetectable in normal liver (CT=35)in Panel 1.4, suggesting that its expression is unique to liver cirrhosis. Therefore, antibodies or small molecule therapeutics could reduce or inhibit fibrosis that occurs in liver cirrhosis.

[1168] This gene is expressed at moderate levels in the normal colon, lung, thymus and kidney tissues (CTs=32-33). This ubiquitous pattern of expression in normal tissues suggests that this gene product may be involved in homeostatic processes for these tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.4 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.

AL. NOV47a (CG59909-01: ATP-BINDING CASSETTE TRANSPORTER)

[1169] Expression of gene CG59909-01 was assessed using the primer-probe set Ag3630, described in Table ALA. Results of the RTQ-PCR runs are shown in Tables ALB, ALC and ALD.

TABLE ALA
Probe Name Ag3630
			Start
Primers	Sequences	Length	Position
Forward	5′-ttccaacaccaaaggactaatg-3′	(SEQ ID NO:362)	22	1339
Probe	TET-5′-aaatcgatgctgagcatccctctgat-3′-TAMRA	(SEQ ID NO:363)	26	1379
Reverse	5′-ttcaggagctactggttcaaaa-3′	(SEQ ID NO:364)	22	1410

[1170]

TABLE ALB
CNS_neurodegeneration_v1.0
	Rel. Exp.(%)	Rel. Exp.(%)		Rel. Exp.(%)	Rel. Exp.(%)
	Ag3630, Run	Ag3630, Run	Tissue	Ag3630, Run	Ag3630, Run
Tissue Name	211020447	224079049	Name	211020447	224079049
AD 1 Hippo	10.7	10.7	Control	4.4	3.2
			(Path) 3
			Temporal
			Ctx
AD 2 Hippo	26.1	25.5	Control	21.6	22.4
			(Path) 4
			Temporal
			Ctx
AD 3 Hippo	6.5	8.4	AD 1	19.9	26.8
			Occipital
			Ctx
AD 4 Hippo	9.3	8.1	AD 2	0.0	0.0
			Occipital
			Ctx
			(Missing)
AD 5 hippo	77.9	79.0	AD 3	8.8	12.6
			Occipital
			Ctx
AD 6 Hippo	64.2	51.4	AD 4	20.4	24.3
			Occipital
			Ctx
Control 2 Hippo	10.8	11.4	AD 5	29.7	35.1
			Occipital
			Ctx
Control 4 Hippo	6.8	5.5	AD 6	18.7	22.1
			Occipital
			Ctx
Control (Path) 3	9.1	9.9	Control 1	1.9	3.3
Hippo			Occipital
			Ctx
AD 1 Temporal	26.1	29.7	Control 2	30.8	35.6
Ctx			Occipital
			Ctx
AD 2 Temporal	21.0	31.2	Control 3	19.5	23.5
Ctx			Occipital
			Ctx
AD 3 Temporal	8.0	8.7	Control 4	2.4	3.3
Ctx			Occipital
			Ctx
AD 4 Temporal	20.6	25.5	Control	53.2	81.2
Ctx			(Path) 1
			Occipital
			Ctx
AD 5 Inf	100.0	100.0	Control	10.9	14.0
Temporal Ctx			(Path) 2
			Occipital
			Ctx
AD 5	32.5	50.7	Control	5.4	5.4
SupTemporal			(Path) 3
Ctx			Occipital
			Ctx
AD 6 Inf	56.3	69.3	Control	17.0	23.7
Temporal Ctx			(Path) 4
			Occipital
			Ctx
AD 6 Sup	52.1	62.4	Control 1	4.4	4.9
Temporal Ctx			Parietal Ctx
Control 1	4.0	6.0	Control 2	57.4	54.3
Temporal Ctx			Parietal Ctx
Control 2	10.0	20.9	Control 3	18.4	20.9
Temporal Ctx			Parietal Ctx
Control 3	11.3	12.5	Control	29.3	48.0
Temporal Ctx			(Path) 1
			Parietal Ctx
Control 4	7.1	7.2	Control	19.8	24.0
Temporal Ctx			(Path) 2
			Parietal Ctx
Control (Path) 1	29.1	31.6	Control	4.8	5.5
Temporal Ctx			(Path) 3
			Parietal Ctx
Control (Path) 2	20.9	25.5	Control	38.2	45.4
Temporal Ctx			(Path) 4
			Parietal Ctx

[1171]

TABLE ALC
General_screening_panel_v1.4
	Rel. Exp. (%) Ag3630,		Rel. Exp. (%) Ag3630,
Tissue Name	Run 218212091	Tissue Name	Run 218212091
Adipose	0.9	Renal ca. TK-10	0.0
Melanoma*	3.6	Bladder	52.9
Hs688 (A).T
Melanoma*	1.7	Gastric ca. (liver met.)	0.7
Hs688 (B).T		NCI-N87
Melanoma* M14	0.4	Gastric ca. KATO III	0.0
Melanoma*	0.1	Colon ca. SW-948	0.0
LOXIMVI
Melanoma* SK-	0.5	Colon ca. SW480	0.0
MEL-5
Squamous cell	0.0	Colon ca.* (SW480	0.1
carcinoma SCC-4		met) SW620
Testis Pool	11.8	Colon ca. HT29	0.0
Prostate ca.* (bone	0.2	Colon ca. HCT-116	0.2
met) PC-3
Prostate Pool	6.4	Colon ca. CaCo-2	0.4
Placenta	0.2	Colon cancer tissue	5.7
Uterus Pool	20.7	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-	0.0	Colon ca. Colo-205	0.8
3
Ovarian ca. SK-OV-	0.9	Colon ca. SW-48	0.0
3
Ovarian ca. OVCAR-	0.0	Colon Pool	38.7
4
Ovarian ca. OVCAR-	0.8	Small Intestine Pool	41.8
5
Ovarian ca. IGROV-	0.2	Stomach Pool	31.4
1
Ovarian ca. OVCAR-	0.1	Bone Marrow Pool	13.0
8
Ovary	47.6	Fetal Heart	20.7
Breast ca. MCF-7	0.7	Heart Pool	18.4
Breast ca. MDA-	0.2	Lymph Node Pool	24.1
MB-231
Breast ca. BT 549	0.9	Fetal Skeletal Muscle	27.0
Breast ca. T47D	0.5	Skeletal Muscle Pool	29.5
Breast ca. MDA-N	0.0	Spleen Pool	21.5
Breast Pool	39.0	Thymus Pool	20.7
Trachea	24.1	CNS cancer (glio/astro)	0.1
		U87-MG
Lung	29.9	CNS cancer (glio/astro)	0.0
		U-118-MG
Fetal Lung	100.0	CNS cancer (neuro; met)	0.0
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	0.1
		539
Lung ca. LX-1	0.0	CNS cancer (astro)	0.1
		SNB-75
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-	0.2
		19
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-	5.3
		295
Lung ca. A549	0.0	Brain (Amygdala) Pool	7.6
Lung ca. NCI-H526	0.0	Brain (cerebellum)	5.0
Lung ca. NCI-H23	3.7	Brain (fetal)	2.5
Lung ca. NCI-H460	3.0	Brain (Hippocampus)	7.8
		Pool
Lung ca. HOP-62	2.5	Cerebral Cortex Pool	9.7
Lung ca. NCI-H522	0.0	Brain (Substantia nigra)	6.2
		Pool
Liver	5.8	Brain (Thalamus) Pool	15.3
Fetal Liver	80.1	Brain (whole)	11.7
Liver ca. HepG2	0.0	Spinal Cord Pool	21.2
Kidney Pool	79.0	Adrenal Gland	16.3
Fetal Kidney	5.2	Pituitary gland Pool	3.7
Renal ca. 786-0	0.0	Salivary Gland	4.6
Renal ca. A498	0.1	Thyroid (female)	3.2
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	0.0
Renal ca. UO-31	0.2	Pancreas Pool	25.5

[1172]

TABLE ALD
Panel 4.1D
	Rel. Exp.(%)		Rel. Exp.(%)
	Ag3630, Run		Ag3630, Run
Tissue Name	169960853	Tissue Name	169960853
Secondary Th1 act	0.4	HUVEC IL-1 beta	20.3
Secondary Th2 act	0.3	HUVEC IFN gamma	57.4
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN	8.5
		gamma
Secondary Th1 rest	0.3	HUVEC TNF alpha + IL4	8.0
Secondary Th2 rest	0.7	HUVEC IL-11	28.5
Secondary Tr1 rest	0.2	Lung Microvascular EC	10.4
		none
Primary Th1 act	0.2	Lung Microvascular EC	6.6
		TNF alpha + IL-1 beta
Primary Th2 act	0.0	Microvascular Dermal EC	24.3
		none
Primary Tr1 act	0.2	Microsvasular Dermal EC	16.7
		TNF alpha + IL-1 beta
Primary Th1 rest	0.5	Bronchial epithelium	3.0
		TNF alpha + IL1 beta
Primary Th2 rest	0.3	Small airway epithelium	3.5
		none
Primary Tr1 rest	0.7	Small airway epithelium	2.2
		TNF alpha + IL-1 beta
CD45RA CD4	1.0	Coronery artery SMC rest	68.3
lymphocyte act
CD45RO CD4	0.1	Coronery artery SMC	44.1
lymphocyte act		TNF alpha + IL-1 beta
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8	0.0	Astrocytes TNF alpha + IL-	0.1
lymphocyte rest		1 beta
Secondary CD8	0.0	KU-812 (Basophil) rest	0.0
lymphocyte act
CD4 lymphocyte none	1.7	KU-812 (Basophil)	0.0
		PMA/ionomycin
2ry Th1/Th2/Tr1_anti-	0.8	CCD1106 (Keratinocytes)	0.5
CD95 CH11		none
LAK cells rest	1.9	CCD1106 (Keratinocytes)	0.6
		TNF alpha + IL-1 beta
LAK cells IL-2	0.3	Liver cirrhosis	37.1
LAK cells IL-2 + IL-12	0.4	NCI-H292 none	0.2
LAK cells IL-2 + IFN	1.7	NCI-H292 IL-4	0.0
gamma
LAK cells IL-2 + IL-18	1.6	NCI-H292 IL-9	0.0
LAK cells	0.6	NCI-H292 IL-13	0.0
PMA/ionomycin
NK Cells IL-2 rest	0.4	NCI-H292 IFN gamma	0.0
Two Way MLR 3 day	1.1	HPAEC none	73.2
Two Way MLR 5 day	0.4	HPAEC TNF alpha + IL-1	100.0
		beta
Two Way MLR 7 day	0.0	Lung fibroblast none	1.8
PBMC rest	0.1	Lung fibroblast TNF	6.0
		alpha + IL-1 beta
PBMC PWM	0.2	Lung fibroblast IL-4	1.3
PBMC PHA-L	0.2	Lung fibroblast IL-9	1.6
Ramos (B cell) none	0.0	Lung fibroblast IL-13	1.3
Ramos (B cell)	0.0	Lung fibroblast IFN	2.0
ionomycin		gamma
B lymphocytes PWM	0.0	Dermal fibroblast	0.3
		CCD1070 rest
B lymphocytes CD40L	0.9	Dermal fibroblast	0.3
and IL-4		CCD1070 TNF alpha
EOL-1 dbcAMP	0.0	Dermal fibroblast	0.5
		CCD1070 IL-1 beta
EOL-1 dbcAMP	0.0	Dermal fibroblast IFN	53.6
PMA/ionomycin		gamma
Dendritic cells none	2.5	Dermal fibroblast IL-4	37.6
Dendritic cells LPS	2.8	Dermal Fibroblasts rest	25.2
Dendritic cells anti-	4.9	Neutrophils TNFa + LPS	0.0
CD40
Monocytes rest	0.4	Neutrophils rest	0.3
Monocytes LPS	5.9	Colon	11.3
Macrophages rest	0.9	Lung	27.4
Macrophages LPS	8.7	Thymus	24.7
HUVEC none	5.8	Kidney	19.8
HUVEC starved	9.8

[1173] CNS_neurodegeneration_v1.0 Summary: Ag3630,Two experiments with the same probe and primer set produce results that are in excellent agreement. This panel confirms the expression of this gene at low to moderate levels in the brains of an independent group of individuals. Expression of this gene is found to be up-regulated in the temporal cortex of Alzheimer's disease patients. Therefore, blockade of this protein product may be of use in reversing the dementia/memory loss associated with Alzheimer's disease and neuronal death.

[1174] General_screening_panel_v1.4 Summary: Ag3630 The CG59909-01 gene is expressed primarily in normal tissue samples, with highest expression in the fetal lung (CT=26.3).

[1175] This gene has low-to-moderate expression in adipose, liver, heart, skeletal muscle, adrenal, pituitary and pancreas. By homology, this gene product is a lipid or cholesterol transporter and can be expected to play a critical role in metabolic processes. Therapeutic modulation of ag3630 may be a treatment for endocrine or metabolic disease, including Types 1 and 2 diabetes and obesity.

[1176] Interestingly, this gene is expressed at much higher levels in fetal (CT=26.3) when compared to adult liver (CT=30.5). This observation suggests that expression of this gene can be used to distinguish fetal from adult liver.

[1177] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, schizophrenia and depression.

[1178] Panel 4.1D Summary: Ag3630 Highest expression of the CG59909-01 gene is detected in TNF alpha+IL-1beta treated HPAEC (CT=28.5). In addition, this gene is expressed in endothelium, smooth muscle cells and fibroblasts. It is also expressed in normal kidney, lung, colon, and thymus. The transcript was particularly induced by gamma interferon in HUVEC cells. HUVEC cells have been used in many in vitro models to examine leukocyte extravsation. Gamma interferon treatment induces the expression many proteins in HUVEC cells that induce leukocyte rolling and binding, necessary steps in the movement of leukocytes from the blood into the periphery. The putative transporter encoded for by this transcript could be important in endothelium mediated leukocyte recruitment and thus be an important target for the treatment of inflammation associated with asthma, emphysema, psoriasis, and arthritis.

[1179] Reference.

[1180] 1. Lidington E A, Moyes D L, McCormack A M, Rose M L. (1999) A comparison of primary endothelial cells and endothelial cell lines for studies of immune interactions. Transpl Immunol December 1999;7(4):239-46

AM. NOV48a (CG59945-01: STEROID HORMONE RECEPTOR)

[1181] Expression of gene CG59945-01 was assessed using the primer-probe sets Ag3632 and ag3666, described in Tables AMA and AMB. Results of the RTQ-PCR runs are shown in Tables AMC, and AMD.

TABLE AMA
Probe Name Ag3632
			Start
Primers	Sequences	Length	Position
Forward	5′-atggtggttgagcctgaga-3′	(SEQ ID NO:365)	19	904
Probe	TET-5′-agctctatgccttgcccgaccct-3′-TAMRA	(SEQ ID NO:366)	23	923
Reverse	5′-tcggtcaaagaggtcacaga-3′	(SEQ ID NO:367)	20	983

[1182]

TABLE AMB
Probe Name ag3666
			Start
Primers	Sequences	Length	Position
Forward	5′-gttcccttgatggaaaatgaag-3′	(SEQ ID NO:368)	21	14
Probe	TET-5′-cctcatctactgactctcccatccaa-3′-TAMRA	(SEQ ID NO:369)	26	35
Reverse	5′-gtgggaacttttgtcctcctt-3′	(SEQ ID NO:370)	21	76

[1183]

TABLE AMC
CNS_neurodegeneration_v1.0
	Rel. Exp.(%) Ag3632,		Rel. Exp.(%) Ag3632,
Tissue Name	Run 211020527	Tissue Name	Run 211020527
AD 1 Hippo	26.8	Control (Path) 3	0.0
		Temporal Ctx
AD 2 Hippo	40.9	Control (Path) 4	4.8
		Temporal Ctx
AD 3 Hippo	28.1	AD 1 Occipital Ctx	1.7
AD 4 Hippo	0.0	AD 2 Occipital Ctx	0.0
		(Missing)
AD 5 hippo	36.3	AD 3 Occipital Ctx	0.0
AD 6 Hippo	100.0	AD 4 Occipital Ctx	1.7
Control 2 Hippo	44.8	AD 5 Occipital Ctx	1.1
Control 4 Hippo	22.7	AD 6 Occipital Ctx	21.5
Control (Path) 3	50.3	Control 1 Occipital	0.0
Hippo		Ctx
AD 1 Temporal Ctx	0.0	Control 2 Occipital	7.4
		Ctx
AD 2 Temporal Ctx	1.1	Control 3 Occipital	1.4
		Ctx
AD 3 Temporal Ctx	0.0	Control 4 Occipital	1.5
		Ctx
AD 4 Temporal Ctx	36.3	Control (Path) 1	49.0
		Occipital Ctx
AD 5 Inf Temporal	13.2	Control (Path) 2	0.0
Ctx		Occipital Ctx
AD 5 SupTemporal	41.8	Control (Path) 3	1.2
Ctx		Occipital Ctx
AD 6 Inf Temporal	42.6	Control (Path) 4	17.8
Ctx		Occipital Ctx
AD 6 Sup Temporal	77.4	Control 1 Parietal	0.0
Ctx		Ctx
Control 1 Temporal	0.0	Control 2 Parietal	16.4
Ctx		Ctx
Control 2 Temporal	7.5	Control 3 Parietal	0.0
Ctx		Ctx
Control 3 Temporal	1.1	Control (Path) 1	14.6
Ctx		Parietal Ctx
Control 4 Temporal	1.9	Control (Path) 2	7.9
Ctx		Parietal Ctx
Control (Path) 1	6.3	Control (Path) 3	0.0
Temporal Ctx		Parietal Ctx
Control (Path) 2	7.6	Control (Path) 4	6.7
Temporal Ctx		Parietal Ctx

[1184]

TABLE AMD
General_screening_panel_v1.4
	Rel. Exp.(%) Ag3632,		Rel. Exp.(%) Ag3632,
Tissue Name	Run 218233723	Tissue Name	Run 218233723
Adipose	0.0	Renal ca. TK-10	0.0
Melanoma*	0.0	Bladder	0.0
Hs688(A).T
Melanoma*	0.0	Gastric ca. (liver met.)	0.0
Hs688(B).T		NCI-N87
Melanoma* M14	0.0	Gastric ca. KATO III	0.0
Melanoma*	0.0	Colon ca. SW-948	0.0
LOXIMVI
Melanoma*	0.0	Colon ca. SW480	0.0
SK-MEL-5
Squamous cell	0.0	Colon ca.* (SW480	0.0
carcinoma SCC-4		met) SW620
Testis Pool	100.0	Colon ca. HT29	3.3
Prostate ca.* (bone	0.0	Colon ca. HCT-116	0.0
met) PC-3
Prostate Pool	0.0	Colon ca. CaCo-2	0.0
Placenta	1.5	Colon cancer tissue	0.0
Uterus Pool	4.6	Colon ca. SW1116	0.0
Ovarian ca. OVCAR-3	0.0	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	2.4	Colon ca. SW-48	0.0
Ovarian ca. OVCAR-4	0.0	Colon Pool	0.0
Ovarian ca. OVCAR-5	0.0	Small Intestine Pool	0.0
Ovarian ca. IGROV-1	0.0	Stomach Pool	0.0
Ovarian ca. OVCAR-8	0.0	Bone Marrow Pool	0.0
Ovary	0.0	Fetal Heart	0.0
Breast ca. MCF-7	0.0	Heart Pool	0.0
Breast ca. MDA-	0.0	Lymph Node Pool	0.0
MB-231
Breast ca. BT 549	0.0	Fetal Skeletal Muscle	0.0
Breast ca. T47D	0.0	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	0.0	Spleen Pool	0.0
Breast Pool	0.0	Thymus Pool	0.0
Trachea	0.0	CNS cancer (glio/astro)	0.0
		U87-MG
Lung	0.0	CNS cancer (glio/astro)	0.0
		U-118-MG
Fetal Lung	0.0	CNS cancer (neuro; met)	0.0
		SK-N-AS
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-	0.0
		539
Lung ca. LX-1	0.0	CNS cancer (astro)	0.0
		SNB-75
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-	0.0
		19
Lung ca. SHP-77	0.0	CNS cancer (glio) SF-	0.0
		295
Lung ca. A549	0.0	Brain (Amygdala) Pool	0.0
Lung ca. NCI-H526	0.0	Brain (cerebellum)	0.0
Lung ca. NCI-H23	0.0	Brain (fetal)	0.0
Lung ca. NCI-H460	0.0	Brain (Hippocampus)	11.9
		Pool
Lung ca. HOP-62	0.0	Cerebral Cortex Pool	0.0
Lung ca. NCI-H522	0.0	Brain (Substantia nigra)	0.0
		Pool
Liver	0.0	Brain (Thalamus) Pool	2.9
Fetal Liver	0.0	Brain (whole)	0.0
Liver ca. HepG2	0.0	Spinal Cord Pool	0.0
Kidney Pool	1.6	Adrenal Gland	0.0
Fetal Kidney	1.9	Pituitary gland Pool	0.0
Renal ca. 786-0	0.0	Salivary Gland	0.0
Renal ca. A498	0.0	Thyroid (female)	0.0
Renal ca. ACHN	0.0	Pancreatic ca. CAPAN2	3.3
Renal ca. UO-31	0.0	Pancreas Pool	0.0

[1185] CNS_neurodegeneration_v1.0 Summary: Ag3632 This panel confirms the expression of The CG59945-01 gene at significant levels in the brain in an independent group of individuals. This gene is found to be upregulated in the temporal cortex of Alzheimer's disease patients. Blockade of this receptor may be of use in the treatment of this disease and decrease neuronal death.

[1186] The CG59945-01 gene, a steroid hormone receptor homolog. Steroid hormones play a role in brain development and modulating emotion, among other functions. Based on the expression of this gene in the brain and its homology to a steroid hormone receptor, this gene product may play a role in normal neurologic development and function.

[1187] Ag3666 Results from one experiment with this gene are not included. The amp plot indicates that there were experimental difficulties with this run.

[1188] References:

[1189] 1. Kawata M, Matsuda K, Nishi M, Ogawa H, Ochiai I. Intracellular dynamics of steroid hormone receptor. Neurosci Res July 2001;40(3):197-203

[1190] General_screening_panel_v1.4 Summary: Ag3632 Expression of the CG59945-01 gene is restricted to the testis (CT=33.9). Thus, expression of this gene could be used to differentiate between this sample and other samples on this panel and as a marker of testicular tissue. Furthermore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of male infertility or hypogonadism.

[1191] General_screening_panel_v1.5 Summary: Ag3666 Expression of the CG59945-01 gene is low/undetectable in all samples on this panel (CTs>35).

[1192] Panel 4.1D Summary: Ag3632/Ag3666 Expression of the CG59945-01 gene is low/undetectable in all samples on this panel (CTs>35).

[1193] Panel CNS—1 Summary: Ag3666 Expression of the CG59945-01 gene is low/undetectable in all samples on this panel (CTs>35).

Example D

[1194] Identification of Single Nucleotide Polymorphisms in NOVX Nucleic Acid Sequences

[1195] Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a “cSNP” to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.

[1196] SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.

[1197] Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation's human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools™ program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.

[1198] The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence (Alderborn et al., Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. Genome Research. 10 (8) 1249-1265, 2000).

[1199] Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.

RESULTS

NOV2a SNP Data

[1200] One polymorphic variant of NOV2a has been identified and is shown in Table 3A.

	TABLE 3A
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377213	69	T	C	15	Thr	Thr

NOV4a SNP Data

[1201] Four polymorphic variants of NOV5a have been identified and are shown in Table 3B.

	TABLE 3B
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377217	137	A	T	40	Gln	His
13377216	231	A	C	72	Ile	Leu
13377215	401	G	A	128	Val	Val
13377214	417	C	T	134	Gln	End

NOV5a SNP Data

[1202] Four polymorphic variants of NOV5a have been identified and are shown in Table 3C.

	TABLE 3C
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13375650	1871	A	G	616	Lys	Arg
13375649	1895	A	G	624	Asn	Ser
13375648	1900	A	G	626	Thr	Ala
13375647	1931	T	C	636	Val	Ala

NOV7a SNP Data

[1203] Two polymorphic variants of NOV7a have been identified and arc shown in Table 3D.

	TABLE 3D
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377218	90	C	T	0
13377219	185	T	C	29	Leu	Pro

NOV10s SNP Data

[1204] Two polymorphic variants of NOV10a have been identified and are shown in Table 3E.

	TABLE 3E
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377221	668	T	C	6	Leu	Leu
13377220	803	A	T	51	Leu	Leu

NOV11a SNP Data

[1205] Seven polymorphic variants of NOV11a have been identified and are shown in Table 3F.

	TABLE 3F
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13374741	856	A	G	271	Pro	Pro
13377222	994	C	T	317	Cys	Cys
13377223	1234	A	G	397	Pro	Pro
13377224	1417	C	T	458	Cys	Cys
13374755	1736	G	A	565	Gly	Ser
13377226	2012	G	T	657	Glu	End
13377227	2073	T	C	677	Leu	Pro

NOV15a SNP Data

[1206] One polymorphic variant of NOV15a has been identified and is shown in Table 3G.

	TABLE 3G
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377231	202	C	T	54	Asp	Asp

NOV19a SNP Data

[1207] Two polymorphic variants of NOV19a has been identified and are shown in Table 3H.

	TABLE 3H
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377233	348	C	T	86	His	His
13377232	516	T	C	142	His	His

NOV21a SNP Data

[1208] One polymorphic variant of NOV21 a has been identified and is shown in Table 3I.

	TABLE 3I
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377234	438	T	C	125	Phe	Phe

NOV23a SNP Data

[1209] Eight polymorphic variants of NOV23a have been identified and are shown in Table 3J.

	TABLE 3J
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13374631	498	A	G	142	Gln	Arg
13374630	643	G	T	190	Gln	His
13374633	672	A	G	200	Asp	Gly
13377237	715	C	T	214	Ser	Ser
13377238	903	C	T	277	Thr	Ile
13374632	983	A	G	304	Lys	Glu
13377240	1419	T	C	449	Val	Ala
13374629	1547	T	C	492	Ser	Pro

NOV24a SNP Data

[1210] Six polymorphic variants of NOV24a have been identified and are shown in Table 3K.

	TABLE 3K
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377245	596	C	T	0
13377246	779	A	C	42	Ser	Arg
13377244	1327	G	A	224	Pro	Pro
13377243	1586	G	A	311	Ala	Thr
13377242	1764	C	T	0
13377241	1825	A	G	0

NOV25a SNP Data

[1211] Eight polymorphic variants of NOV25a have been identified and are shown in Table 3L.

	TABLE 3L
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13375267	2963	A	G	925	Leu	Leu
13375266	3213	C	T	1009	Pro	Ser
13375265	3313	T	C	1042	Val	Ala
13375264	3981	G	A	1265	Val	Met
13375263	4023	A	G	1279	Thr	Ala
13375262	4051	G	T	1288	Gly	Val
13375261	4105	A	G	1306	Asn	Ser
13375260	4117	T	C	1310	Ile	Thr

NOV27a SNP Data

[1212] Three polymorphic variants of NOV27a have been identified and are shown in Table 3M.

	TABLE 3M
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377249	233	T	C	0
13377248	1714	C	T	419	Thr	Thr
13377247	2008	A	G	517	Gln	Gln

NOV29a SNP Data

[1213] Three polymorphic variants of NOV29a have been identified and are shown in Table 3N.

	TABLE 3N
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13375558	132	G	A	44	Leu	Leu
13375557	149	A	C	50	Lys	Thr
13375556	187	T	C	63	Ser	Pro

NOV30a SNP Data

[1214] Six polymorphic variants of NOV30a have been identified and are shown in Table 3O.

	TABLE XX
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13374752	1871	A	G	599	Met	Val
13374753	1970	A	G	632	Met	Val
13374754	2001	T	C	642	Phe	Ser
13377254	2249	C	T	725	Leu	Leu
13377253	3186	A	C	1037	Gln	Pro
13377252	3318	C	T	0

NOV31 a SNP Data

[1215] Fifteen polymorphic variants of NOV31a have been identified and are shown in Table 3P.

	TABLE 3P
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377256	1335	C	T	434	Asn	Asn
13377257	1415	A	G	461	Asp	Gly
13377258	1476	A	G	481	Ala	Ala
13377259	1526	T	C	498	Val	Ala
13377260	1613	G	A	527	Cys	Tyr
13377261	1630	A	G	533	Thr	Ala
13377262	1812	A	T	593	Ala	Ala
13377263	1929	G	A	632	Ala	Ala
13377264	1942	C	T	637	Arg	Trp
13377265	2343	T	C	770	Gly	Gly
13374745	2418	C	T	795	Ser	Ser
13374744	2535	C	T	834	Leu	Leu
13374743	2549	A	G	839	Asp	Gly
13377266	2642	T	C	870	Leu	Pro
13377267	2649	C	T	872	Asp	Asp

NOV33a SNP Data

[1216] Two polymorphic variants of NOV33a have been identified and are shown in Table 3Q.

	TABLE 3Q
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377270	79	T	C	17	Leu	Pro
13377269	400	T	C	124	Val	Ala

NOV36a SNP Data

[1217] Three polymorphic variants of NOV36a have been identified and are reported in Table 3R.

	TABLE 3R
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377273	91	C	G	24	Ala	Ala
13377272	230	T	C	71	Ser	Pro
13377271	4250	A	G	1411	Thr	Ala

NOV37a SNP Data

[1218] Two polymorphic variants of NOV37a have been identified and are reported in Table 3S.

	TABLE 3S
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377274	266	A	G	73	Arg	Arg
13377276	702	A	G	219	Ile	Val

NOV39a SNP Data

[1219] Two polymorphic variants of NOV39a have been identified and are shown in Table 3T.

	TABLE 3T
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377277	6369	T	C	2123	Ser	Ser
13377278	8094	G	A	2698	Pro	Pro

NOV40a SNP Data

[1220] One polymorphic variant of NOV40a has been identified and is shown in Table 3U.

	TABLE 3U
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377279	355	G	A	115	Ala	Thr

NOV42a SNP Data

[1221] One polymorphic variant of NOV42a has been identified and is shown in Table 3V.

	TABLE 3V
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377280	698	A	G	221	Leu	Leu

NOV43a SNP Data

[1222] One polymorphic variant of NOV43a has been identified and is shown in Table 3W.

	TABLE 3W
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377281	1371	T	C	433	His	His

NOV44a SNP Data

[1223] Four polymorphic variants of NOV44a have been identified and are shown in Table 3X.

	TABLE 3X
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377282	604	A	G	45	Asn	Ser
13377283	684	A	G	72	Thr	Ala
13377284	1123	G	A	218	Arg	His
13377285	1489	T	C	340	Val	Ala

NOV45a SNP Data

[1224] One polymorphic variant of NOV45a has been identified and is shown in Table 3Y.

	TABLE 3Y
	Nucleotides	Amino Acids
	Base			Base
Variant	Position of	Wild-		Position of	Wild-
No.	SNP	type	Variant	SNP	type	Variant
13377286	624	T	C	191	Ser	Ser

OTHER EMBODIMENTS

[1225] Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims.

Claims

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1-101; b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1-101, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; c) the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1-101; d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1-101, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and e) a fragment of any of a) through d).

2. The polypeptide of claim 1 that is a naturally occurring allelic variant of the sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1-101.

3. The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n−1, wherein n is an integer between 1-101.

4. The polypeptide of claim 1 that is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution.

5. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

6. A kit comprising in one or more containers, the pharmaceutical composition of claim 5.

7. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is the polypeptide of claim 1.

8. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising: (a) providing said sample; (b) introducing said sample to an antibody that binds immunospecifically to the polypeptide; and (c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.

9. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising: a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.

10. A method for modulating the activity of the polypeptide of claim 1, the method comprising introducing a cell sample expressing the polypeptide of said claim with an antibody that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

11. The method of claim 10, wherein said subject is a human.

12. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: a) a mature form of the amino acid sequence of SEQ ID NO:2n, wherein n is an integer between 1-101; b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1-101, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; c) the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1-101; d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1-101, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:2n, wherein n is an integer between 1-101, or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and f) the complement of any of said nucleic acid molecules.

13. The nucleic acid molecule of claim 12, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant.

14. The nucleic acid molecule of claim 12 that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant.

15. The nucleic acid molecule of claim 12, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NO:2n−1, wherein n is an integer between 1-101.

16. The nucleic acid molecule of claim 12, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of a) the nucleotide sequence selected from the group consisting of SEQ ID NO:2n−1, wherein n is an integer between 1-101; b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2n−1, wherein n is an integer between 1-101, is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO:2n−1, wherein n is an integer between 1-101; and d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO:2n−1, wherein n is an integer between 1-101, is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

17. The nucleic acid molecule of claim 12, wherein said nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO:2n−1, wherein n is an integer between 1-101, or a complement of said nucleotide sequence.

18. The nucleic acid molecule of claim 12, wherein the nucleic acid molecule comprises a nucleotide sequence in which any nucleotide specified in the coding sequence of the chosen nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides in the chosen coding sequence are so changed, an isolated second polynucleotide that is a complement of the first polynucleotide, or a fragment of any of them.

19. A vector comprising the nucleic acid molecule of claim 12.

20. The vector of claim 19, further comprising a promoter operably linked to said nucleic acid molecule.

21. A cell comprising the vector of claim 20.

22. A method for determining the presence or amount of the nucleic acid molecule of claim 12 in a sample, the method comprising: (a) providing said sample; (b) introducing said sample to a probe that binds to said nucleic acid molecule; and (c) determining the presence or amount of said probe bound to said nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in said sample.

23. The method of claim 22 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.

24. The method of claim 23 wherein the cell or tissue type is cancerous.

25. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 12 in a first mammalian subject, the method comprising: a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

26. An antibody that binds immunospecifically to the polypeptide of claim 1.

27. The antibody of claim 26, wherein said antibody is a monoclonal antibody.

28. The antibody of claim 26, wherein the antibody is a humanized antibody.

29. The antibody of claim 26, wherein the antibody is a fully human antibody

30. The antibody of claim 26, wherein the dissociation constant for the binding of the polypeptide to the antibody is less than 1×10−9 M.

31. The antibody of claim 26, wherein the antibody neutralizes an activity of the polypeptide.

32. A pharmaceutical composition comprising the antibody of claim 26 and a pharmaceutically acceptable carrier.

33. A kit comprising in one or more containers, the pharmaceutical composition of claim 29.

34. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is a NOVX antibody.

35. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the antibody of claim 26 in an amount sufficient to treat or prevent said NOVx-associated disorder in said subject.

36. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 26 in an amount sufficient to alleviate the pathological state.

37. A method of treating or preventing a pathology associated within the polypeptide of claim 1, said method comprising administering to a subject in which such treatment or prevention is desired a NOVX antibody in an amount sufficient to treat or prevent said pathology in said subject.

38. The method of claim 37, wherein the subject is a human.